<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialResultsOutput hits="500" offset="1500" totalResults="4191"><SearchResults><Trial Id="245575"><Indications><Indication>Rhinitis</Indication></Indications><CompaniesSponsor><Company>Laboratoire De La Mer</Company></CompaniesSponsor><Countries><Country>Czech Republic</Country></Countries><DateChangeLast>2018-01-27T00:00:00Z</DateChangeLast><DateEnd>2016-10-07T00:00:00Z</DateEnd><DateStart>2015-09-10T00:00:00Z</DateStart><Identifiers><Identifier>2015-002796-23</Identifier><Identifier>RHINO</Identifier><Identifier>RHINO-CZ-2015-01</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Olynth alone</Intervention><Intervention>Rhinaction alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>560</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>with contraindication to vasoactive treatment Known allergy to essential oils Use of other &lt;b&gt;cold&lt;/b&gt; medicine prior to inclusion (except topical vasoactives and/or topical antiseptics that...inclusion are forbidden Presence of chronic disease that may interfere with &lt;b&gt;cold&lt;/b&gt; treatment and/or symptoms reporting (such as chronic rhinosinusitis) Pregnant...written informed consent prior to performance of any study-related procedure Diagnosis of common &lt;b&gt;cold&lt;/b&gt;: Jackson score of two or higher; symptoms severity rated as 0 = absent</Teaser><TrialCategories><Category>Borderline product</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other respiratory disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>RHINO: Multicenter, parallel, randomized, single-blind trial comparing the efficacy and tolerability of Rhinaction, an osmotic decongestant nasal spray containing essential oils versus Olynth 0.1%, a vasoconstrictor, in the relief of acute rhinitis symptoms in adults</TitleDisplay><PrimaryCompletionDate/><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Managing Director</Name></ContactNames></Trial><Trial Id="243290"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Vanilloid VR1 agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Patch formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesCollaborator><Company>Astellas Pharma GmbH</Company></CompaniesCollaborator><CompaniesSponsor><Company>Medical University of Vienna</Company></CompaniesSponsor><Countries><Country>Austria</Country></Countries><DateChangeLast>2018-11-16T00:00:00Z</DateChangeLast><DateEnd>2015-09-30T00:00:00Z</DateEnd><DateStart>2015-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2013-002546-36</Identifier><Identifier>CAPS2</Identifier><Identifier>FA738B0401</Identifier><Identifier>NCT02570841</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>capsaicin dermal patch, NeurogesX/Astellas/Acorda/Grunenthal alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>heat pain threshold, HPT in degC) but also the temperature by which capsaicin does not yet trigger a &lt;b&gt;cold&lt;/b&gt; pain (&lt;b&gt;cold&lt;/b&gt; pain threshold, CPT in degC). Moreover the investigators want to find out the mechanical...high-dose topical capsaicin (Qutenza) for 60 min. The secondary objectives of the trial are: To determine &lt;b&gt;cold&lt;/b&gt;-painthreshold under exposition of high-dose capsaicin for 60 min. To determine mechanical-painthreshold under exposition of high-dose capsaicin</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Pain Thresholds Under High-dose Topical Capsaicin</TitleDisplay><PrimaryCompletionDate type="Actual">2015-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>7 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Erich Knolle, MD</Name></ContactNames></Trial><Trial Id="241745"><Indications><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>Northwestern University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2016-09-27T00:00:00Z</DateChangeLast><DateEnd>2016-11-30T00:00:00Z</DateEnd><DateStart>2015-04-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT02550093</Identifier><Identifier>STU86297</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>oxytocin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The objective of this randomized, double-blinded, crossover study is to evaluate the effect of intranasal oxytocin on pain sensitivity and threshold.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold</TitleDisplay><PrimaryCompletionDate type="Actual">2015-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>19 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>David R Walega, MD</Name></ContactNames></Trial><Trial Id="241299"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology></Technologies><CompaniesSponsor><Company>Pontificia Universidad Catolica De Chile</Company></CompaniesSponsor><Countries><Country>Chile</Country></Countries><DateChangeLast>2017-06-06T00:00:00Z</DateChangeLast><DateEnd>2017-03-31T00:00:00Z</DateEnd><DateStart>2016-01-31T00:00:00Z</DateStart><Identifiers><Identifier>15-001</Identifier><Identifier>NCT02557386</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>levobupivacaine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The investigators objective is to determine which volume of levobupivacaine 0.25% (Chirocaine) is necessary to produce analgesia and sensitive blockade while minimizing motor blockade in adductor canal nerve block in patients undergoing cruciate ligament reconstruction surgery.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Assessment of other outcomes associated with anesthetic use</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Musculoskeletal disease related outcomes</EndpointIndex><EndpointIndex>Pain - Clinical Assessments</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment of patient satisfaction</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Optimal Volume of Bupivacaine in Adductor Canal Nerve Block</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects in need of Procedural Analgesia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2016-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Andrea Araneda, MD</Name><Name>Fernando R Altermatt, MD</Name><Name>Fernando R Altermatt, MSc</Name><Name>Sebastian Paredes, MD</Name></ContactNames></Trial><Trial Id="240642"><Indications><Indication>Urticaria</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin E antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2019-02-21T00:00:00Z</DateChangeLast><DateEnd>2016-01-31T00:00:00Z</DateEnd><DateStart>2015-04-30T00:00:00Z</DateStart><Identifiers><Identifier>2014-005424-97</Identifier><Identifier>CIGE025EFR02</Identifier><Identifier>NCT02550106</Identifier><Identifier>SUNRISE</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>omalizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>136</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>within 30 days before enrollment Body weight&amp;lt; 40 kg Clearly defined underlying etiology for chronic urticaria other than CSU (main manifestation being physical urticaria). This includes the following urticaria types: acute, solar, cholinergic, heat, &lt;b&gt;cold&lt;/b&gt;, aquagenic, delayed pressure or contact urticaria, or skin disease that includes urticarial plaques (other than CSU) such as bullous pemphigoid, dermatitis herpetiformis The following diseases which may have symptoms of urticaria or angioedema: urticarial</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Urticaria - Assessment by Urticarial Scores - Assessment by Urticaria Activity Score (UAS)</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms - Assessment of angioedema</EndpointIndex><EndpointIndex>Urticaria - Other Protocol Specified Outcomes</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments - Angioedema activity score(AAS)</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments - Angioedema quality of life score(AE-Q2oL)</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Dermatology Life Quality Index (DLQI)</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments - Chronic Urticaria Quality of Life (CU-Q2oL) Scores</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>SUNRISE: Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistamine Treatment</TitleDisplay><PatientSegmentTerms><PatientSegment>Urticaria - Subjects with Chronic Urticaria - Patiets with chronic spontaneous urticaria</PatientSegment><PatientSegment>Urticaria - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>D-dimer</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>9 Months</TrialDuration><NumberOfSites>31</NumberOfSites><ContactNames><Name>ALAIN DUPUY</Name><Name>ANNICK BARBAUD</Name><Name>BRIGITTE MILPIED</Name><Name>CHRISTOPHE BEDANE</Name><Name>CLAIRE BERNIER TAUGOURDEAU</Name><Name>DELPHINE STAUMONT SALLE</Name><Name>EMMANUEL MAHE</Name><Name>EMMANUELLE AMSLER</Name><Name>EVELYNE COLLET</Name><Name>FABIEN PELLETIER</Name><Name>FRANCOISE GIORDANO LABADIE</Name><Name>FREDERIC CAMBAZARD</Name><Name>GERARD GUILLET</Name><Name>GERMAINE GABISON</Name><Name>Information&amp;Communication Médicales</Name><Name>JEAN-JACQUES GROB</Name><Name>JEAN-PHILIPPE LACOUR</Name><Name>JULIETTE JEGOU</Name><Name>LAURENCE BOUILLET</Name><Name>LAURENT MEUNIER</Name><Name>LILIANE LAROCHE</Name><Name>LUDOVIC MARTIN</Name><Name>MARIE CHRISTINE FERRIER LE BOUEDEC</Name><Name>MARIE SYLVIE DOUTRE</Name><Name>NADIA RAISON PEYRON</Name><Name>Novartis Pharmaceuticals</Name><Name>OLIVIER CHOSIDOW</Name><Name>PASCAL JOLY</Name><Name>PATRICE PLANTIN</Name><Name>PHILIPPE BERBIS</Name><Name>PHILIPPE MODIANO</Name><Name>SELIM ARACTINGI</Name><Name>THIERRY BOYE</Name><Name>VINCENT DESCAMPS</Name><Name>ZIAD REGUIAI</Name></ContactNames></Trial><Trial Id="240639"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Public Health England</Company></CompaniesCollaborator><CompaniesSponsor><Company>Imperial College London</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2019-06-14T00:00:00Z</DateChangeLast><DateEnd>2016-04-30T00:00:00Z</DateEnd><DateStart>2015-10-31T00:00:00Z</DateStart><Identifiers><Identifier>15SM2801</Identifier><Identifier>2015-003019-39</Identifier><Identifier>NCT02549365</Identifier><Identifier>SNIFFLE-3</Identifier></Identifiers><InterventionsControlDisplay><Intervention>surveillance (nasal swabbing) alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention><Intervention>surveillance (nasal swabbing) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>176</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study would enrol 200 children (and at least 200 unvaccinated household sibling controls), many with a history of asthma or recurrent wheezing, and allow an assessment of efficacy, safety and immune correlates in these children, and how this varies with prior administration of pandemic influenza vaccine and/or Live attenuated influenza vaccine (LAIV, Flumist ). Main objective of the trial: Is the intranasal LAIV influenza (flu) vaccine effective in children. Secondary objectives of the trial</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza Vaccine - Protocol Specified Other Endpoints - Antiviral efficacy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>SNIFFLE-3: Efficacy and Safety of Nasal Influenza Immunization in Children</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children - Children more than 5 years of age</PatientSegment><PatientSegment>Influenza Vaccine - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Immunoglobulin A</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>6 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Dr Paul Turner</Name><Name>Paul J Turner</Name></ContactNames></Trial><Trial Id="240157"><Indications><Indication>Cardiogenic shock</Indication></Indications><CompaniesSponsor><Company>Klinikum der Universitat Muenchen</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2019-03-31T00:00:00Z</DateEnd><DateStart>2015-11-30T00:00:00Z</DateStart><Identifiers><Identifier>ECLS-SHOCK</Identifier><Identifier>GE IDE MucM001-15</Identifier><Identifier>NCT02544594</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Standard treatment alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Extra-Corporal Life Support (ECLS) alone</Intervention><Intervention>Standard treatment alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>42</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>pressure&amp;lt; 90 mmHg &gt; 30 min or inotropes required to maintain pressure &gt; 90 mmHg during systole Signs of left heart insufficiency and pulmonary congestion Signs of impaired organ perfusion with at least one of the following: Altered mental status &lt;b&gt;Cold&lt;/b&gt;, clammy skin Urine output&amp;lt; 30 ml/h Serum lactate&gt; 2 mmol/l Informed consent</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiac Function - Assessment of ejection fraction</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiac Function - Functional capacity - subjective by NYHA class</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Area of infarction (percentage)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Exercise Capacity/Tolerance - Six-minute walk test (6MWT)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Laboratory/Diagnostic Measures - Serum lactate values</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Coronary artery disease - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex><EndpointIndex>Coronary artery disease - Protocol Specified Other Endpoints - MRI changes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ECLS-SHOCK: Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction</TitleDisplay><PatientSegmentTerms><PatientSegment>Coronary artery disease - Subjects Undergoing /Underwent Major Cardiac Intervention</PatientSegment><PatientSegment>Coronary artery disease - Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - Acute onset/new onset myocardial infarction (MI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - Non ST elevation myocardial infarction (NSTEMI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - ST elevation myocardial infarction (STEMI)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Ejection fraction </BiomarkerName><BiomarkerName> Lactic Acid </BiomarkerName><BiomarkerName> Left ventricular ejection fraction </BiomarkerName><BiomarkerName> Six-minute walk distance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>40 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Stefan Brunner, MD</Name><Name>Steffen Massberg, MD</Name></ContactNames></Trial><Trial Id="23999"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Rabin Medical Center</Company></CompaniesSponsor><Countries><Country>Israel</Country></Countries><DateChangeLast>2013-09-10T00:00:00Z</DateChangeLast><DateEnd>2013-08-31T00:00:00Z</DateEnd><DateStart>2008-08-31T00:00:00Z</DateStart><Identifiers><Identifier>ML21706</Identifier><Identifier>NCT00737659</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mycophenolate mofetil alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>138</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>infection requiring the continued use of antibiotics or evidence of an HIV infection, or the presence of a chronic active hepatitis B (HBs-Ag positive) or C Current or historic panel reactive antibody (PRA)&gt; 50% Positive crossmatch (irrespective of method) &lt;b&gt;Cold&lt;/b&gt; ischemia time of the graft of more than 30 h Patients who had received an investigational new drug within the last 3 months at the time of enrollment Multi-organ recipients (eg, kidney and pancreas) or previous transplant with any organ other than </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Dose Comparison</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Clinical Response - Assessment of time to treatment failure (TTF)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Composite Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>CellCept Dose Adjustment Versus Fixed Dose (Standard Care) in Renal Transplant Recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Renal re-transplant recipients</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2011-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>60 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Alexander Yussim, Dr.</Name><Name>Eitan Mor, Prof.</Name><Name>Eytan Mor</Name><Name>Eytan Mor, Prof.</Name><Name>Ravit Tvito, RC</Name><Name>Richard Nakache</Name><Name>Richard Nakache, MD</Name><Name>Richard Nakache, Prof.</Name></ContactNames></Trial><Trial Id="239685"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsControl><Action>Inactivated viral vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Injectable formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Bill &amp; Melinda Gates Foundation</Company></CompaniesCollaborator><CompaniesSponsor><Company>Liverpool School of Tropical Medicine</Company><Company>Royal Liverpool and Broadgreen University Hospitals NHS Trust</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2019-03-19T00:00:00Z</DateChangeLast><DateEnd>2017-04-30T00:00:00Z</DateEnd><DateStart>2015-05-20T00:00:00Z</DateStart><Identifiers><Identifier>10.1186/ISRCTN16993271</Identifier><Identifier>18994</Identifier><Identifier>2014-004634-26</Identifier><Identifier>4896</Identifier><Identifier>ISRCTN16993271</Identifier><Identifier>LAIV/EHPC</Identifier><Identifier>NCT03502291</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Fluarix alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>324</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study was to look at the effect of live attenuated inactivated influenza vaccine (LAIV) on pneumococcal carriage dynamics and compares it with the Quadrivalent Inactivated Influenza Vaccine (QIV). Main objectives of the trial were: To define the effect of LAIV on pneumococcal colonisation using the EHPC model in order to assess the potential effects of mass influenza vaccination. To measure colonisation acquisition, density and duration. Secondary objectives were: To evaluate changes in</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Influenza Vaccine - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>LAIV/EHPC: The effect of live attenuated inactivated influenza vaccine on experimental human pneumococcal carriage study</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2017-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Angela Wright</Name><Name>Jamie Rylance</Name></ContactNames></Trial><Trial Id="235016"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Daily dosing</Technology><Technology>Oral formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Chiesi Farmaceutici SpA</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2019-03-01T00:00:00Z</DateChangeLast><DateEnd>2016-06-30T00:00:00Z</DateEnd><DateStart>2015-07-31T00:00:00Z</DateStart><Identifiers><Identifier>2014-005572-28</Identifier><Identifier>CCD-06235AA1-02</Identifier><Identifier>NCT02500212</Identifier></Identifiers><InterventionsControlDisplay><Intervention>tacrolimus (oral sustained-release), Astellas alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>tacrolimus (improved tablet formulation), Veloxis/Chiesi/Paladin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>75</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Recipients with TGI (Taux de Greffons Incompatibles histories, ie, rate of graft incompatible among donors over the past five years) &gt; 85% and/or having pre-transplant donor-specific anti-HLA antibodies (DSA) Recipients of a kidney with an anticipated &lt;b&gt;cold&lt;/b&gt; ischemia time &gt;/= 24 h Recipients positive for hepatitis C virus (HCV-RNA positive) and/or hepatitis B virus (HBV-DNA or HBsAg positive) Recipients positive for Human Immunodeficiency Virus (HIV-Ab positive) Patients with a current malignancy or a </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - AUC (Area under the concentration curve) of drug/drug metabolites</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Plasma drug/drug metabolite concentration</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Vital Signs</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>European Ancestry</Term></TermsPatientSelection><TitleDisplay>Pharmacokinetic Study of Envarsus in Adult De-Novo Kidney Transplant Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - De Novo Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> QT interval</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>11 Months</TrialDuration><NumberOfSites>8</NumberOfSites><ContactNames><Name>Clinical Project Manager</Name></ContactNames></Trial><Trial Id="233637"><Indications><Indication>Cough</Indication></Indications><CompaniesSponsor><Company>Clalit Health Services</Company></CompaniesSponsor><Countries><Country>Israel</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2016-04-06T00:00:00Z</DateEnd><DateStart>2015-12-23T00:00:00Z</DateStart><Identifiers><Identifier>ABO-COUGH-2015</Identifier><Identifier>NCT02486835</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Poliflav M.A alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>150</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The intent of this study was to use a protective syrup (Poliflav M.V) which does not act as a sedative or as a potent mucolytic and measure its efficacy and safety versus placebo in subjects with moderate to severe night and daily cough.</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Tolerability of a Specific Plantain, Thyme and Honey Cough Syrup Versus Placebo in Child Cough Due to Common Cold</TitleDisplay><PrimaryCompletionDate type="Actual">2016-04-03T00:00:00Z</PrimaryCompletionDate><TrialDuration>3 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Herman A Cohen, Prof.</Name></ContactNames></Trial><Trial Id="232630"><Indications><Indication>Rhinitis</Indication></Indications><CompaniesSponsor><Company>Kyung Hee University Gangdong Hospital</Company><Company>Ministry of Health &amp; Welfare, Korea</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2018-01-26T00:00:00Z</DateChangeLast><DateEnd>2016-01-31T00:00:00Z</DateEnd><DateStart>2015-08-31T00:00:00Z</DateStart><Identifiers><Identifier>B120014</Identifier><Identifier>KCT0001544</Identifier><Identifier>KHNMCOH2015-04-009</Identifier><Identifier>NCT02477293</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Hyeonggaeyeongyo-tang alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to evaluate the safety and effectiveness of Hyeonggaeyeongyo-tang for chronic rhinitis according to pattern identification in Korean medicine.</Teaser><TrialCategories><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of eosinophil count</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of immunoglobulin levels</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Laboratory/Diagnostic Measures - Assessment of skin prick test response</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of other end points</EndpointIndex><EndpointIndex>Allergic rhinitis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Allergic rhinitis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Rhinoconjunctivitis Quality of life questionnaire(RQLQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>The Efficacy and Safety of Hyeonggaeyeongyo-tang for Chronic Rhinitis According to Pattern Identification in Korean Medicine</TitleDisplay><BiomarkerNames><BiomarkerName>Eosinophils </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Immunoglobulin E</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Seong-Kyu Ko, KMD, PhD</Name></ContactNames></Trial><Trial Id="23254"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Bacterial protein synthesis inhibitor</Action><Action>Macrolide antibiotic</Action><Action>Systemic dermatological antibacterial product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Odense University Hospital</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2014-01-07T00:00:00Z</DateChangeLast><DateEnd>2007-12-31T00:00:00Z</DateEnd><DateStart>2001-05-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT00132860</Identifier><Identifier>ProToCOL</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>azithromycin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>800</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>in whom the intervention is known to be inefficient Patients with pulmonary malignancy Patients with other pulmonary diseases than &lt;b&gt;COLD&lt;/b&gt; Patients with immunodeficiency. However, &lt;b&gt;COLD&lt;/b&gt; patients treated with steroids can be included Patients with... Patients &amp;gt; 50 years of age, with a current admission for exacerbation of &lt;b&gt;COLD&lt;/b&gt; or at least one admission within the previous two years Current or ex-smoker Postbronchodilator FEV1&amp;lt; 60% in stable condition (&amp;gt; 4 weeks after hospitalization) Bronchodilator</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change in post bronchodilator FEV1</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Mortality/Morbidity</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Therapy Related Outcomes - Assessment of treatment failure</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Health Economic Assessments - Assessment of direct cost</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment of quality of life</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Prophylactic ﻿Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease (COLD)</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Smokers</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Chitinase-3-like protein 1 </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>79 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Svend Pedersen</Name></ContactNames></Trial><Trial Id="22920"><Indications><Indication>Perennial allergic rhinitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Glucocorticoid receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Respiratory system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Microparticle formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Suspension</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-06-13T00:00:00Z</DateChangeLast><DateEnd>2011-02-28T00:00:00Z</DateEnd><DateStart>2008-06-30T00:00:00Z</DateStart><Identifiers><Identifier>2015-004891-31</Identifier><Identifier>FFR110537</Identifier><Identifier>NCT00682643</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>fluticasone furoate (nasal, allergic rhinitis), GSK alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>550</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> of Asthma - Expert Panel Report 3, National Institutes of Health, August 28, 2007. Note: subjects will be allowed to use short-acting inhaled beta2 agonists only on an as needed basis Rhinitis medicamentosa Bacterial or viral infection (eg, common &lt;b&gt;cold&lt;/b&gt;) of the eyes or upper respiratory tract within 2 weeks of visit 1 or during the screening period Documented evidence of acute or significant chronic sinusitis, as determined by the individual investigator Current or history of glaucoma and/or ocular</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Ocular/Non Nasal Symptoms - Assessment of Total ocular symptoms score (TOSS)</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Ocular/Non Nasal Symptoms - Assessment of individual ocular symptoms</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Assessment of reflective total nasal symptom score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of adverse events</EndpointIndex><EndpointIndex>Allergic rhinitis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-Round) Allergic Rhinitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Perennial Allergic Rhinitis</PatientSegment><PatientSegment>Allergic rhinitis - Subjects with Seasonal Allergic Rhinitis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Intraocular pressure </BiomarkerName><BiomarkerName> Lens </BiomarkerName><BiomarkerName> Optic cup </BiomarkerName><BiomarkerName> Optic disc</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>56</NumberOfSites><ContactNames><Name>GSK Clinical</Name><Name>GSK Clinical Support Help Desk</Name><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="228683"><Indications><Indication>Kidney transplant rejection</Indication><Indication>Liver transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Daily dosing</Technology><Technology>Oral formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2017-06-19T00:00:00Z</DateChangeLast><DateEnd>2013-05-31T00:00:00Z</DateEnd><DateStart>2012-03-31T00:00:00Z</DateStart><Identifiers><Identifier>AS/111/10</Identifier><Identifier>F506-CL-0894</Identifier><Identifier>NCT02432053</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tacrolimus (oral sustained-release), Astellas alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>92</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>non-registered medication within 28 days prior to entry in this study Pregnant women or breast-feeding mother Patients or respective donors known to be positive for human immunodeficiency virus (HIV) Unlikely to comply with the visits scheduled in the protocol &lt;b&gt;Cold&lt;/b&gt; ischemia time of the donor kidney&gt; 30 h High immunological risk, defined as a positive cross match or PRA grade 50% in the previous 6 months Liver cirrhosis Significant liver disease, defined as having either elevated serum glutamic pyruvic transaminase</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Steroid resistant AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Acute Graft Rejection (AGR) - Steroid resistant AGR</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Creatinine Clearance</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Graft Loss/Graft Failure - Incidence of graft loss</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Liver transplantation - Infections/Opportunistic Infections</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study to Demonstrate Safety and Efficacy of Advagraf in Patients Undergoing Kidney or Liver Transplantation in India</TitleDisplay><PatientSegmentTerms><PatientSegment>Liver transplantation - Subjects with History of/Currently on/Scheduled for Liver Transplant Therapy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Lipids</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>7</NumberOfSites><ContactNames><Name>Medical Director</Name></ContactNames></Trial><Trial Id="228677"><Indications><Indication>End stage renal disease</Indication><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Chiesi Farmaceutici SpA</Company></CompaniesSponsor><Countries><Country>Poland</Country><Country>Spain</Country><Country>Italy</Country><Country>Germany</Country><Country>Austria</Country><Country>Belgium</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2017-01-24T00:00:00Z</DateEnd><DateStart>2015-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2014-004314-29</Identifier><Identifier>CCD-06235AA1-01</Identifier><Identifier>NCT02432833</Identifier><Identifier>STEADY</Identifier></Identifiers><InterventionsControlDisplay><Intervention>tacrolimus (improved tablet formulation), Veloxis/Chiesi/Paladin alone</Intervention><Intervention>tacrolimus alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>tacrolimus (improved tablet formulation), Veloxis/Chiesi/Paladin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>428</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>levels higher than 30%. Whenever PRA, either complement-dependentcytotoxicity-PRA or calculated PRA , is not available, patients who arepositive on solid-phase screening assay for anti-HLA antibodies must not be enrolled Recipient of a kidney with a &lt;b&gt;cold&lt;/b&gt; ischemia time of &gt;/= 30 h White blood cells count&amp;lt;/= 2.8 x 10(9) cells/l unless ANC &gt; 1.0 x 10(9)/l Platelet count&amp;lt; 50 x 10(9) cells/l ALT or AST levels&gt; 3 times the normal upper limit during the 30 days prior transplant procedure Current abuse</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Clinical Response - Assessment of incidence/frequency of treatment failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Delayed Graft Function (DGF)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Dose-adjusted trough concentration (C0/Dose)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of use of Rescue Medication - Need of immunosuppressive medication</EndpointIndex><EndpointIndex>Kidney transplantation - Protocol Specified Other Endpoints - Assessment of Number of Patients Withdrawn From Immunosuppression</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>STEADY: Multicenter, Open-Label, Randomized, Two-Arm, Parallel-Group Study to Assess Efficacy and Safety of Envarsus Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Kidney Transplant Subjects</PatientSegment><PatientSegment>End stage renal disease - Subjects by disease severity - Subjects with stage 5 chronic kidney disease/end stage renal disease(ESRD)</PatientSegment><PatientSegment>Kidney transplantation - Antibody Compatible Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - De Novo Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Subjects with End Stage Renal Disease/Chronic Renal Failure</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2017-01-24T00:00:00Z</PrimaryCompletionDate><TrialDuration>19 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Gabriele Nicolini</Name><Name>Klemens Budde, MD</Name></ContactNames></Trial><Trial Id="227683"><Indications><Indication>Allergic rhinitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Glucocorticoid receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Respiratory system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Microparticle formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Suspension</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-02-09T00:00:00Z</DateChangeLast><DateEnd>2017-10-25T00:00:00Z</DateEnd><DateStart>2015-09-30T00:00:00Z</DateStart><Identifiers><Identifier>201492</Identifier><Identifier>NCT02424539</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>fluticasone furoate (nasal, allergic rhinitis), GSK alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>358</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>itraconazole, clarithromycin, etc); allergen immunotherapy for the treatment of allergies Use of followings medications are not allowed throughout the study: short-acting antihistamines, including ocular preparations and antihistamines contained in anti-&lt;b&gt;cold&lt;/b&gt; medicine, insomnia or antalgical; oral or inhaled anticholinergics; oral or intranasal decongestants; oral or intranasal antileukotrienes; oral or inhaled long-acting beta 2 agonists; Chinese traditional medicines that have potential effect to AR; </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Laboratory/Diagnostic Measures - Nasal lavage fluid and nasal secretions analysis</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of nasal congestion</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of nasal itching</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of rhinorrhoea</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of sneezing</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Ocular/Non Nasal Symptoms - Assessment of Total ocular symptoms score (TOSS)</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Therapy Related Outcomes - Assessment of other efficacy parameters</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Assessment of reflective total nasal symptom score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of use of Rescue Medication - Assessment of rescue medication free days</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Asian Ancestry</Term></TermsPatientSelection><TitleDisplay>A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 and 110 microg in Chinese Pediatric Subjects With Allergic Rhinitis (AR)</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Pediatric Allergic Rhinitis Subjects</PatientSegment><PatientSegment>Allergic rhinitis - Subjects with Intermittent Allergic Rhinitis</PatientSegment><PatientSegment>Allergic rhinitis - Subjects with Persistent Allergic rhinitis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Albumin </BiomarkerName><BiomarkerName> Alkaline phosphatase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Basophils </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Calcium </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Eosinophils </BiomarkerName><BiomarkerName> Erythrocytes </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hematocrit </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mean corpuscular hemoglobin </BiomarkerName><BiomarkerName> Mean corpuscular volume </BiomarkerName><BiomarkerName> Monocytes </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> Respiratory frequency </BiomarkerName><BiomarkerName> Sodium </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Total protein </BiomarkerName><BiomarkerName> Urea nitrogen </BiomarkerName><BiomarkerName> Urinary specific gravity</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-10-25T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>16</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="226394"><Indications><Indication>Nerve injury</Indication></Indications><CompaniesSponsor><Company>BERUFSGENOSSENSCHAFTLICHE UNFALLKLIN</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2018-09-30T00:00:00Z</DateEnd><DateStart>2015-03-31T00:00:00Z</DateStart><Identifiers><Identifier>BGU-LU-123</Identifier><Identifier>CNT</Identifier><Identifier>NCT02372669</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Chitosan nerve tube alone</Intervention><Intervention>Primary microsurgical repair alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The objective of this study is to evaluate whether the additional use of a nerve tube in primary microsurgical repair of traumatic sensory nerve lesions of the hand has an effect on convalescence and functional results. In this study, investigators want to test a Chitosan based nerve tube (already certified German medical product with European label [CE-label]) as an additional treatment for digital nerve injuries without a gap. The primary endpoint is tested in the per-protocol set (PPS) via an</Teaser><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>CNT: Chitosan Nerv Tube for Primary Repair of Traumatic Sensory Nerve Lesions of the Hand</TitleDisplay><BiomarkerNames><BiomarkerName>Finger motion </BiomarkerName><BiomarkerName> Muscle strength</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>42 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Adrien Daigeler, MD</Name><Name>Florian Neubrech, MD</Name><Name>Michael Sauerbier, MD</Name><Name>Thomas Kremer, MD</Name></ContactNames></Trial><Trial Id="225521"><Indications><Indication>Shock</Indication></Indications><CompaniesSponsor><Company>Austin &amp; Repatriation Medical Centre</Company><Company>University of Melbourne</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2018-04-12T00:00:00Z</DateChangeLast><DateStart>2015-02-16T00:00:00Z</DateStart><Identifiers><Identifier>ACTRN12615000100594</Identifier><Identifier>ANZCTR367737</Identifier><Identifier>HREC/14/Austin/458</Identifier><Identifier>U1111-1166-0487</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Plasma-Lyte 148 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>9</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Age:&amp;lt; 18 years or &gt; 45 years Pregnancy or have given birth within one year Hereditary hematological conditions (sickle cell anaemia and thalassemia) that are susceptible to anaemia Recent (within 10 days) history of &lt;b&gt;cold&lt;/b&gt;, fever, or upper or lower respiratory tract infection (this may theoretically increase risk of infection with venesected blood when it is being stored prior to re-infusion) Morbid obesity (BMI&gt; 35 kg/m2) Body weight&gt; 100 kg</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Dose Comparison</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>The Effects of Bolus and Slow Fluid Infusions in Healthy Volunteers with Shock</TitleDisplay><BiomarkerNames><BiomarkerName>Arterial oxygen saturation </BiomarkerName><BiomarkerName> Cardiac Index </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Lactic Acid </BiomarkerName><BiomarkerName> Mean arterial pressure </BiomarkerName><BiomarkerName> Natriuretic peptides A </BiomarkerName><BiomarkerName> Oxygen saturation </BiomarkerName><BiomarkerName> Partial pressure of carbon dioxide </BiomarkerName><BiomarkerName> Partial pressure of oxygen </BiomarkerName><BiomarkerName> Stroke volume </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Tumor necrosis factor </BiomarkerName><BiomarkerName> Vascular resistance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Laurence Weinberg</Name></ContactNames></Trial><Trial Id="22440"><Indications><Indication>Asthma</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>RTI International</Company></CompaniesCollaborator><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-14T00:00:00Z</DateChangeLast><DateEnd>2010-03-31T00:00:00Z</DateEnd><DateStart>2007-10-31T00:00:00Z</DateStart><Identifiers><Identifier>MI-MA175</Identifier><Identifier>NCT00626808</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>321697</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This is a retrospective cohort study of children included in a large medical insurance claims database. The purpose of this study is to evaluate the effectiveness of the risk minimization plan of FluMist among children.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Retrospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Asthma - Assessment of hospitalization</EndpointIndex><EndpointIndex>Asthma - Assessment of hospitalization - Assessment of number of emergency department visits</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex><EndpointIndex>Influenza Vaccine - Health Economic Assessments</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>A Post-Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment><PatientSegment>Asthma - Subjects with Symptomatic Disease</PatientSegment><PatientSegment>Influenza Vaccine - Children - Children less than 5 years of age</PatientSegment><PatientSegment>Influenza Vaccine - Subjects with comorbid conditions - Subjects with respiratory disorders</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment><PatientSegment>Influenza virus infection - Children - Children less than 5 years of age</PatientSegment><PatientSegment>Influenza virus infection - Subjects with comorbid conditions - Subjects with respiratory disorders</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>29 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chris Ambrose, M.D.</Name><Name>Holli Hamilton</Name></ContactNames></Trial><Trial Id="224132"><Indications><Indication>Anesthesia</Indication><Indication>Hypotension</Indication></Indications><CompaniesCollaborator><Company>Australian and New Zealand College of Anesthetists</Company></CompaniesCollaborator><CompaniesSponsor><Company>King Edward Memorial Hospital for Women</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2016-08-24T00:00:00Z</DateChangeLast><DateStart>2013-02-04T00:00:00Z</DateStart><Identifiers><Identifier>ACTRN12612000996864</Identifier><Identifier>ANZCTR362972</Identifier></Identifiers><InterventionsControlDisplay><Intervention>phenylephrine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>metaraminol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>180</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Contraindication to spinal or CSE anesthesia Diabetes mellitus Pre-eclampsia, pregnancy-induced hypertension or essential hypertension Cardiovascular or cerebrovascular disease Fetal abnormality or intrauterine growth restriction Failure to establish block to &lt;b&gt;cold&lt;/b&gt; to T4 Supplementary epidural anesthesia prior to delivery of the baby Conversion to general anesthesia Excessive shivering that makes blood pressure monitoring unreliable</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A randomized study to see if two drugs that increase blood pressure, namely phenylephrine and metaraminol, are equally effective to preventing blood pressure falls and in resulting in a healthy baby, at the time of spinal anesthesia for elective caesarean section</TitleDisplay><BiomarkerNames><BiomarkerName>Heart rate </BiomarkerName><BiomarkerName> Partial pressure of carbon dioxide </BiomarkerName><BiomarkerName> Partial pressure of oxygen </BiomarkerName><BiomarkerName> Systolic blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Michael Paech</Name><Name>Nolan McDonnell</Name></ContactNames></Trial><Trial Id="22378"><Indications><Indication>Asthma</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesCollaborator><Company>Medical Research Council</Company><Company>Medical Research Council of Canada</Company></CompaniesCollaborator><CompaniesSponsor><Company>McGill University Health Center</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2017-04-01T00:00:00Z</DateChangeLast><DateEnd>2005-09-30T00:00:00Z</DateEnd><DateStart>1999-11-30T00:00:00Z</DateStart><Identifiers><Identifier>FAP30006</Identifier><Identifier>MRC/PMAC program</Identifier><Identifier>NCT00238927</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>fluticasone propionate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>150</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> purpose of this study was to determine, in children aged 1 to 6 years with recurrent asthma induced by upper respiratory tract infections (URTI), whether the administration of high doses of inhaled fluticasone started at the onset of symptoms of a &lt;b&gt;cold&lt;/b&gt; would result in a reduced severity and shorter duration of asthma exacerbations and would not be associated with reduced growth velocity, osteopenia, and adrenal suppression.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Anthropometric Assessments - Assessment of anthropometric changes</EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score</EndpointIndex><EndpointIndex>Asthma - Assessment of Co-morbidity - Infection</EndpointIndex><EndpointIndex>Asthma - Assessment of Cortisol Levels</EndpointIndex><EndpointIndex>Asthma - Assessment of Cough</EndpointIndex><EndpointIndex>Asthma - Assessment of Dyspnea</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Asthma - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Asthma - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Asthma - Assessment of Wheeze</EndpointIndex><EndpointIndex>Asthma - Assessment of hospitalization</EndpointIndex><EndpointIndex>Asthma - Assessment of hospitalization - Assessment of number of emergency department visits</EndpointIndex><EndpointIndex>Asthma - Assessment of hospitalization - Hospitalization due to cardiovascular events</EndpointIndex><EndpointIndex>Asthma - Assessment of use of Rescue Medication - Beta agonist usage</EndpointIndex><EndpointIndex>Asthma - Assessment of use of Rescue Medication - Corticosteroid usage</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Bone - Assessment by Bone mineral density (BMD)</EndpointIndex><EndpointIndex>Osteoporosis - Assessment of Co-morbidity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Clinical Trial of Fluticasone Versus Placebo at the Onset of a Cold for Children With Asthma</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment><PatientSegment>Asthma - Subjects with Intermittent/Episodic Asthma</PatientSegment><PatientSegment>Osteoporosis - Subjects with Secondary Osteoporosis</PatientSegment><PatientSegment>Osteoporosis - Subjects with comorbid conditions</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Bone mineral density </BiomarkerName><BiomarkerName> Hydrocortisone</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2005-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>70 Months</TrialDuration><NumberOfSites>5</NumberOfSites><ContactNames><Name>Francine M. Ducharme, MD, MSc</Name></ContactNames></Trial><Trial Id="223408"><Indications><Indication>Paralysis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Alpha 1 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Hypertensive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>The Craig H. Neilsen Foundation</Company></CompaniesCollaborator><CompaniesSponsor><Company>James J. Peters Veterans Affairs Medical Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-06-03T00:00:00Z</DateChangeLast><DateEnd>2019-10-31T00:00:00Z</DateEnd><DateStart>2015-04-30T00:00:00Z</DateStart><Identifiers><Identifier>01589</Identifier><Identifier>315696</Identifier><Identifier>HAN-14-045</Identifier><Identifier>NCT02379156</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>cool temperature exposure alone</Intervention><Intervention>midodrine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>will wear minimal clothing during the study to maximize bare skin exposure to the cool temperature. Visit 1: &lt;b&gt;Cold&lt;/b&gt; Ambient Challenge Instrumentation: subjects are able-bodied controls matched for age and gender. Procedure is exposure to cool temperature...transferred to a warm room (81degF), covered with warming blankets, and given warm fluids. If symptoms continue, Dr. William Bauman will assess the subject and provide the appropriate care. Visit 2: &lt;b&gt;Cold&lt;/b&gt; Ambient Challenge with Midodrine : Subjects will administered a 10 </Teaser><TrialCategories><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia</TitleDisplay><BiomarkerNames><BiomarkerName>Body temperature </BiomarkerName><BiomarkerName> Brachial artery blood pressure </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hydrocortisone </BiomarkerName><BiomarkerName> Norepinephrine</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>54 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>John P Handrakis, PT, DPT, EdD</Name><Name>Oriana F Tascione, BS</Name></ContactNames></Trial><Trial Id="221843"><Indications><Indication>Anesthesia</Indication><Indication>Liver transplantation</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>General anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Inhalant formulation</Technology><Technology>Liquid formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Centre Hospitalier Universitaire de Liege</Company></CompaniesSponsor><Countries><Country>Belgium</Country></Countries><DateChangeLast>2015-07-03T00:00:00Z</DateChangeLast><DateEnd>2017-12-31T00:00:00Z</DateEnd><DateStart>2015-01-31T00:00:00Z</DateStart><Identifiers><Identifier>2014-26-06</Identifier><Identifier>NCT02341833</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>sevoflurane alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>240</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>sevoflurane during organs harvesting in brain dead donors. More particularly, the investigators will investigate whether sevoflurane preconditioning protects against ischemia-reperfusion of the liver and kidney allografts after a prolonged period of &lt;b&gt;cold&lt;/b&gt; ischemia and whether this protection translates in to a better clinical functional recovery of these allografts.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>Effects of Preconditioning With Sevoflurane During Organ Procurement From Brain Dead Donors: Impact on Early Function of Liver Allografts</TitleDisplay><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> International Normalized Ratio </BiomarkerName><BiomarkerName> Prothrombin time</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2017-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>35 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Gregory G Minguet, MD</Name><Name>Jean L Joris, MD, PhD</Name></ContactNames></Trial><Trial Id="22156"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Bronchodilator</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Drug combination</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2018-07-07T00:00:00Z</DateChangeLast><DateEnd>2008-10-31T00:00:00Z</DateEnd><DateStart>2005-06-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT00197106</Identifier><Identifier>SAM101667</Identifier></Identifiers><IndicationsAdverse><Indication>Candida infection</Indication><Indication>Common cold</Indication><Indication>Headache</Indication><Indication>Throat disease</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>fluticasone propionate alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>176</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>November 2010 showed that between fluticasone propionate and fluticasone propionate + salmeterol differences were not seen regarding adverse events (AEs) [ 1516349 ]. In 2012, results were published. The most frequently reported adverse events were common &lt;b&gt;cold&lt;/b&gt; (28 and 17%), headache (14 and 21%), sore throat (8 and 6%), oropharyngeal candidiasis (1 and 1%), in the fluticasone propionate + salmeterol and fluticasone propionate arms, respectively. Worsening of asthma, aggravated infection (worsening viral </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score - Symptom free period</EndpointIndex><EndpointIndex>Asthma - Assessment of Co-morbidity - Infection</EndpointIndex><EndpointIndex>Asthma - Assessment of Exacerbations</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of exhaled nitric oxide</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Asthma - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Asthma - Assessment of Pulmonary Function - Peak expiratory flow</EndpointIndex><EndpointIndex>Asthma - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Treatment Of Symptomatic Asthma In Children</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Peak expiratory flow rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>40 Months</TrialDuration><NumberOfSites>18</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="22021"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Bronchodilator</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Drug combination</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2008-07-31T00:00:00Z</DateEnd><DateStart>2007-10-31T00:00:00Z</DateStart><Identifiers><Identifier>HZA109895</Identifier><Identifier>NCT00503009</Identifier></Identifiers><IndicationsAdverse><Indication>Dyspepsia</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>fluticasone propionate alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>16</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Lack of Efficacy</Reason></ReasonForTrialDiscontinuation><Teaser>clinic visits would include a physical examination, lung function tests, inflammatory cell analysis from nasal secretions and/or sputum, and blood draws. Patients would inhale an FDA approved virus through their nose which is known to cause the common &lt;b&gt;cold&lt;/b&gt;. All study related medications and medical examinations would be provided at no cost to the patients. The drugs used in this study were approved for the age group under study.Patients were randomized to receive fluticasone propionate + salmeterol (</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1) - Assessment of morning/evening FEV1</EndpointIndex><EndpointIndex>Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of exhaled nitric oxide</EndpointIndex><EndpointIndex>Asthma - Assessment of Peak Expiratory Flow/Flow Rate (PEFR)</EndpointIndex><EndpointIndex>Asthma - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Study Of RV-39 In Patients Who Also Have Asthma</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced expiratory volume </BiomarkerName><BiomarkerName> Nitric oxide </BiomarkerName><BiomarkerName> Peak expiratory flow rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="219225"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>B-lymphocyte antigen CD20 inhibitor</Action><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action><Action>Somatostatin receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action><Action>Anticancer polyclonal antibody</Action><Action>Antiviral</Action><Action>Growth hormone release inhibitor</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody polyclonal</Technology><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Chimeric monoclonal antibody</Technology><Technology>Film coating</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology><Technology>Tablet formulation</Technology></Technologies><Countries><Country>Mexico</Country></Countries><DateChangeLast>2015-01-14T00:00:00Z</DateChangeLast><DateEnd>2011-06-30T00:00:00Z</DateEnd><DateStart>2010-06-30T00:00:00Z</DateStart><Identifiers><Identifier>ESWMEX001</Identifier><Identifier>NCT02328222</Identifier><Identifier>SWKT</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including Thymoglobulin , basiliximab , methylprednisolone , mycophenolate mofetil , prednisone , rituximab , tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>71</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>diagnosis of dyslipidemia, high systemic blood pressure, or post-transplantation diabetes mellitus (PTDM). Post-transplant assessments would be made at 3, 6, 9, and 12 months. Information collected would include the date of the transplant, type of donor, &lt;b&gt;cold&lt;/b&gt; and warm ischemic times, immunosuppressant-induction ( basiliximab ) and maintenance (TAC, MMF, PDN), date of AR diagnosis, and the anti-rejection treatment (methylprednisolone or thymoglobulin ). The number of AR events, their severity, and the presence</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Chronic Graft Rejection (CGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Dysfunction</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>ESWMEX001: Esteroid Withdrawal Study, Safety and Efficacy in Renal Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living related donor (LRD) - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living unrelated donor - renal transplant recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>ALFONSO M CUETO-MANZANO, PhD</Name></ContactNames></Trial><Trial Id="219133"><Indications><Indication>Cytomegalovirus infection</Indication><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Inosine monophosphate dehydrogenase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Novartis AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>University Hospital, Bordeaux</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2018-11-15T00:00:00Z</DateChangeLast><DateEnd>2018-10-10T00:00:00Z</DateEnd><DateStart>2014-05-02T00:00:00Z</DateStart><Identifiers><Identifier>2013-003195-12</Identifier><Identifier>CHUBX2012/29</Identifier><Identifier>EVERCMV</Identifier><Identifier>NCT02328963</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Variable regimens including enteric-coated mycophenolate sodium, Novartis</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including basiliximab , ciclosporin, Novartis , everolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>186</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The goal of this prospective, multicentric, randomized, controlled trial was to demonstrate that an immunosuppressive regimen associating everolimus and reduced dose of cyclosporine A can prevent acute rejection episodes as efficiently as standard regimen but can also efficiently reduce the incidence of Cytomegalovirus (CMV) infection at 6 months post-transplantation.</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Laboratory/Diagnostic Measures - Genetic analysis</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Laboratory/Diagnostic Measures - Renal function tests</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Survival - Assessment of Survival Rates</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Viral Load</EndpointIndex><EndpointIndex>Herpesvirus infection - Graft Assessments</EndpointIndex><EndpointIndex>Herpesvirus infection - Graft survival</EndpointIndex><EndpointIndex>Herpesvirus infection - Incidence/Prevalence of Herpes Infections/Diseases - Incidence/prevalence of CMV infection/disease</EndpointIndex><EndpointIndex>Herpesvirus infection - Protocol Specified Other Endpoints - Graft rejection/failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Bone Marrow - Anemia</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Bone Marrow - Neutropenia</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Bone Marrow - Thrombocytopenia</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Clinical Response - Assessment of incidence/frequency of treatment failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Delayed Graft Function (DGF) - Incidence/proportion of patients with DGF</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR) - GFR calculated using MDRD Study formula</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Dysfunction</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival - Graft survival rate at 12 months (1 year) post-transplant</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival - Graft survival rate at 6 months post-transplant</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Laboratory/Diagnostic Measures - Genetic analysis</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Hyperlipidemia/dyslipidemia</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Incidence of adverse events/Side Effects</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival - Patient survival at 1 year post-transplant</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections - Bk polyoma virus infection</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections - CMV infection</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications - New onset/post transplant diabetes mellitus</EndpointIndex><EndpointIndex>Kidney transplantation - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Kidney transplantation - Post Transplant Malignancies - Progression of neoplasia</EndpointIndex><EndpointIndex>Kidney transplantation - Protocol Specified Other Endpoints - Assessment of Number of Patients Withdrawn From Immunosuppression</EndpointIndex><EndpointIndex>Kidney transplantation - Protocol Specified Other Endpoints - Degree of inflammation and fibrosis in renal biopsies</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>EVERCMV: Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Cytomegalovirus Infections</PatientSegment><PatientSegment>Kidney transplantation - Others - Eligible renal donors</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients with Co-Morbid Infections - Renal transplant recipients with cytomegalovirus (CMV) infection</PatientSegment><PatientSegment>Kidney transplantation - Subjects with End Stage Renal Disease/Chronic Renal Failure</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Human cytomegalovirus DNA polymerase catalytic subunit </BiomarkerName><BiomarkerName> Human cytomegalovirus serine/threonine protein kinase UL97</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-10-10T00:00:00Z</PrimaryCompletionDate><TrialDuration>53 Months</TrialDuration><NumberOfSites>9</NumberOfSites><ContactNames><Name>Lionel COUZI, MD</Name><Name>Rodolphe THIEBAUT, MD, PhD</Name></ContactNames></Trial><Trial Id="219046"><Indications><Indication>Renal injury</Indication></Indications><CompaniesCollaborator><Company>Dr Franz Kohler Chemie GmbH</Company></CompaniesCollaborator><CompaniesSponsor><Company>Istituto Scientifico H San Raffaele</Company></CompaniesSponsor><Countries><Country>Italy</Country></Countries><DateChangeLast>2019-05-24T00:00:00Z</DateChangeLast><DateEnd>2018-01-17T00:00:00Z</DateEnd><DateStart>2015-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2014-003818-92</Identifier><Identifier>CURITIBA TRIAL</Identifier><Identifier>CURITIBA/9/OSR</Identifier><Identifier>NCT02327611</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Ringer's lactate solution alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Custodiol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>randomized into one of the two arms: Arm I: patients would undergo renal perfusion with Custodiol. Arm II: patients would undergo renal perfusion with &lt;b&gt;cold&lt;/b&gt; Ringer's lactate solution enriched with methylprednisolone 125 mg/l and mannitol 12.5 g/l....renal injury in patients undergoing thoracoabdominal aortic aneurysm (TAAA) open repair using Custodiol (&lt;b&gt;cold&lt;/b&gt; crystalloid solution enriched with histidine-tryptophan-ketoglutarate) renal perfusion versus an enriched Ringers lactate solution. The</Teaser><TrialCategories><Category>Hospital solutions</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>CURITIBA TRIAL: Custodiol Versus Ringer: What is the Best Agent?</TitleDisplay><PrimaryCompletionDate type="Actual">2018-01-17T00:00:00Z</PrimaryCompletionDate><TrialDuration>34 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Laura Pasin</Name><Name>Yamume Tshomba</Name><Name>Yamume tshomba</Name></ContactNames></Trial><Trial Id="21832"><Indications><Indication>Urticaria</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Histamine H1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Charite Universitaetsmedizin Berlin</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2013-12-02T00:00:00Z</DateChangeLast><DateEnd>2007-11-01T00:00:00Z</DateEnd><DateStart>2006-11-30T00:00:00Z</DateStart><Identifiers><Identifier>AUDACU</Identifier><Identifier>EudraCT-Number: 2005-006133-32</Identifier><Identifier>NCT00600847</Identifier><Identifier>P04685</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>desloratadine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>33</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> The aim of this study was to compare &lt;b&gt;cold&lt;/b&gt; urticaria lesions by thermography, volumetry and digital time lapse photography in acquired &lt;b&gt;cold&lt;/b&gt; urticaria (ACU) patients treated with placebo, 5 and 20 mg desloratadine . Hypothesis: The updosing of desloratadine (20 mg) is more effective in the treatment of ACU symptoms as compared to standard </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Dose Comparison</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms - Assessment by wheal and flare of lesions</EndpointIndex><EndpointIndex>Urticaria - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Urticaria - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Urticaria - Other Protocol Specified Outcomes - Assessment of critical stimulation time threshold(CSTT)after cold challenge</EndpointIndex><EndpointIndex>Urticaria - Other Protocol Specified Outcomes - Assessment of critical temperature threshold (CTT)after cold challenge</EndpointIndex><EndpointIndex>Urticaria - Other Protocol Specified Outcomes - Photographic assessment of lesions</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>AUDACU: A Study to Assess and Compare the Effects of 5 mg Versus 20 mg Desloratadine on the Development of Cold Urticaria Lesions</TitleDisplay><PatientSegmentTerms><PatientSegment>Urticaria - Subjects with Cold Contact Urticaria (CCU)</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>11 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Marcus Maurer, MD</Name></ContactNames></Trial><Trial Id="21727"><Indications><Indication>Urticaria</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Histamine H1 receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Histamine H1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>UCB SA</Company></CompaniesSponsor><Countries><Country>France</Country><Country>Malaysia</Country><Country>South Africa</Country><Country>Germany</Country><Country>Italy</Country><Country>UK</Country><Country>Romania</Country><Country>Spain</Country><Country>Belgium</Country></Countries><DateChangeLast>2018-01-21T00:00:00Z</DateChangeLast><DateEnd>2007-01-31T00:00:00Z</DateEnd><DateStart>2005-12-31T00:00:00Z</DateStart><Identifiers><Identifier>A00394</Identifier><Identifier>CUTE</Identifier><Identifier>EudraCT 2005-000358-65</Identifier><Identifier>NCT00264303</Identifier></Identifiers><InterventionsControlDisplay><Intervention>desloratadine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>levocetirizine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>886</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>that would interfere with the evaluation of the therapeutic response Be incapable of giving their written informed consent Pregnancy or breast feeding Have any of the following pathologies: senile pruritus; acute urticaria; cholinergic,solar, heat, &lt;b&gt;cold&lt;/b&gt;, water or drug-induced urticaria; isolated delayed pressure urticaria;contact urticaria; urticarial vasculitis; or hereditary angioneurotic oedema Have any dermatological disease that would interfere with evaluation of therapeutic response (e.g. generalized</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pruritus - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Pruritus - Assessment of Clinical Symptoms - Assessment of duration and severity of pruritus</EndpointIndex><EndpointIndex>Pruritus - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Urticaria - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Urticaria - Assessment by Urticarial Scores</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms - Assessment of pruritus(itch) severity</EndpointIndex><EndpointIndex>Urticaria - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>CUTE: Chronic Urticaria Treatment Evaluation</TitleDisplay><PatientSegmentTerms><PatientSegment>Pruritus - Subjects with Pruritus Associated with Dermatological Disorders - Subjects with urticaria</PatientSegment><PatientSegment>Urticaria - Subjects with Chronic Urticaria - Subjects with chronic idiopathic urticaria(CIU)</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>77</NumberOfSites><ContactNames><Name>Krassimir Mitchev</Name><Name>UCB Clinical Trial Call Center</Name></ContactNames></Trial><Trial Id="216511"><Indications><Indication>Topical anesthesia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor mu agonist</Action><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>5-HT uptake inhibitor</Action><Action>Analgesic</Action><Action>Local anesthetic</Action><Action>Norepinephrine uptake inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Injectable formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Antwerp University Hospital</Company></CompaniesSponsor><Countries><Country>Belgium</Country></Countries><DateChangeLast>2018-05-26T00:00:00Z</DateChangeLast><DateEnd>2016-11-30T00:00:00Z</DateEnd><DateStart>2014-11-30T00:00:00Z</DateStart><Identifiers><Identifier>14/38/393</Identifier><Identifier>NCT02293330</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including Taradyal , levobupivacaine , paracetamol , tramadol hydrochloride (once-daily, Contramid), Labopharm</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>71</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> tibial nerve as an initial bolus. After injection a would be advanced 4 cm beyond the needle tip. Correct catheter placement would be confirmed by ultrasound. The sensory block of the peroneal and tibial nerve would be separately tested by loss of &lt;b&gt;cold&lt;/b&gt; sensation before transfer to the operating room, at least 20 min after the initial injection of lidocaine. When no block would be detected it would be considered as a block failure and the patient would be excluded from the study. After performing </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Assessment of other outcomes associated with anesthetic use</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Numerical Analog Scale (NRS/NAS)</EndpointIndex><EndpointIndex>Pain - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Continuous Versus Automated Bolus Infusion in Sciatic Nerve Catheters</TitleDisplay><BiomarkerNames><BiomarkerName>Blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Margaretha Breebaart</Name></ContactNames></Trial><Trial Id="216221"><Indications><Indication>Lipid metabolism disorder</Indication><Indication>Obesity</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Dipeptidyl peptidase IV inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>DPP IV inhibitor antidiabetic product</Action><Action>Glucagon-like peptide 1 metabolism modulator</Action><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesCollaborator><CompaniesSponsor><Company>Leiden University Medical Center</Company><Company>Universiteit Leiden</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2016-12-31T00:00:00Z</DateEnd><DateStart>2014-03-31T00:00:00Z</DateStart><Identifiers><Identifier>2014-003532-39</Identifier><Identifier>NCT02294084</Identifier><Identifier>P14.242</Identifier><Identifier>Sita01</Identifier><Identifier>SitaBAT01</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>sitagliptin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>the investigators will determine BAT volume and total BAT activity via &lt;b&gt;cold&lt;/b&gt;-induced 18F-FDG PET-CT scans, resting energy expenditure via indirect calorimetry using...and two study days after treatment (day 84 and 85) on which a &lt;b&gt;cold&lt;/b&gt;-induced PET-CT scan as well as metabolic studies and skeletal muscle biopsies are performed...At t = 90 min, REE will be measured again. At t = 120 min, &lt;b&gt;cold&lt;/b&gt;-induced venous blood samples will be obtained followed by performance of the PET-CT scan (see Appendix</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Obesity - Assessment of C-peptide Levels</EndpointIndex><EndpointIndex>Obesity - Assessment of HbA1c levels</EndpointIndex><EndpointIndex>Obesity - Assessment of Insulin Levels</EndpointIndex><EndpointIndex>Obesity - Assessment of Metabolic Parameters - Assessment of energy expenditure</EndpointIndex><EndpointIndex>Obesity - Assessment of fat</EndpointIndex><EndpointIndex>Obesity - Assessment of lipid profiles - Assessment of HDL</EndpointIndex><EndpointIndex>Obesity - Assessment of lipid profiles - Assessment of LDL-C</EndpointIndex><EndpointIndex>Obesity - Assessment of lipid profiles - Assessment of Triglycerides</EndpointIndex><EndpointIndex>Obesity - Assessment of lipid profiles - Assessment of cholesterol</EndpointIndex><EndpointIndex>Obesity - Glycemic Control Analysis - Assessment of blood glucose</EndpointIndex><EndpointIndex>Obesity - Glycemic Control Analysis - Assessment of glucose metabolism</EndpointIndex><EndpointIndex>Obesity - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Obesity - Imaging/Radiological Assessments - Dual energy x-ray absorptiometry (DEXA) assessments</EndpointIndex><EndpointIndex>Obesity - Protocol Specified Other Endpoints - Signaling pathways in skeletal muscle</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>European Ancestry</Term></TermsPatientSelection><TitleDisplay>Sita01: Sitagliptin and Brown Adipose Tissue</TitleDisplay><PatientSegmentTerms><PatientSegment>Obesity - Overweight (pre-obese) Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Brown adipose tissue </BiomarkerName><BiomarkerName> C-peptide </BiomarkerName><BiomarkerName> Fat mass </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Insulin </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Nonesterified fatty acids </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides </BiomarkerName><BiomarkerName> Very low density lipoprotein cholesterol</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>33 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Clinical Trial Information</Name><Name>Patrick Rensen, PhD</Name></ContactNames></Trial><Trial Id="21574"><Indications><Indication>Hypertension</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>ACE inhibitor</Action><Action>Calcium channel inhibitor L-type</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Pfizer Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Montreal Heart Institute</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2008-03-31T00:00:00Z</DateEnd><DateStart>2006-04-30T00:00:00Z</DateStart><Identifiers><Identifier>(Investigator initiated study)</Identifier><Identifier>MHI 05740</Identifier><Identifier>NCT00313547</Identifier><Identifier>Pfizer NRA9060008</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>amlodipine plus quinapril hydrochloride</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Patient Enrollment Issues</Reason></ReasonForTrialDiscontinuation><Teaser>The purpose of this study was to compare the impact of two blood pressure lowering treatments (high dose quinapril versus low dose quinapril plus amlodipine ) on variations in heart rate over 24 h.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiac Markers</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Exercise Capacity/Tolerance</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Matrix metalloproteinase-9 (MMP-9) assessments</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Laboratory/Diagnostic Measures - Hormonal Assay</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Therapy Related Outcomes - Safety assessment</EndpointIndex><EndpointIndex>Coronary artery disease - Protocol Specified Other Endpoints - Pharmacogenomics/Proteomics Study</EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Pressure (BP) - BP control rate</EndpointIndex><EndpointIndex>Hypertension - Assessment of Heart/Pulse Rate - Heart rate variability</EndpointIndex><EndpointIndex>Hypertension - Assessment of Hormone Levels</EndpointIndex><EndpointIndex>Hypertension - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Hypertension - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of matrix metalloproteinases (MMP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Renin, Angiotensin, Aldosterone (RAS) Biomarkers - Aldosterone</EndpointIndex><EndpointIndex>Hypertension - Assessment of Renin, Angiotensin, Aldosterone (RAS) Biomarkers - Renin</EndpointIndex><EndpointIndex>Hypertension - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Hypertension - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Biomarkers - RAAS biomarkers</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hormone Levels - Plasma norepinephrine</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Inflammatory &amp; Oxidative Stress Markers - Matrix metalloproteinase-9 (MMP-9) assessments</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Vital Signs - Assessment of heart rate</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Protocol Specified Other Endpoints - Pharmacogenetic/Pharmacogenomic Study</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>High-Dose Quinapril Versus Low-Dose Quinapril Plus Amlodipine in the Treatment of High-Risk Hypertensive Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Coronary artery disease - Subjects with High Cardiovascular Risk Profile - Diabetes mellitus/impaired glucose tolerance</PatientSegment><PatientSegment>Coronary artery disease - Subjects with High Cardiovascular Risk Profile - Subjects with hypertension</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease</PatientSegment><PatientSegment>Hypertension - Subjects on Hypertensive Treatment</PatientSegment><PatientSegment>Hypertension - Subjects with Primary/Essential Hypertension</PatientSegment><PatientSegment>Hypertension - Subjects with Primary/Essential Hypertension - Subjects with stage 1 (JNC 6) hypertension</PatientSegment><PatientSegment>Hypertension - Subjects with comorbid conditions - Subjects co-morbid with coronary artery disease</PatientSegment><PatientSegment>Hypertension - Subjects with comorbid conditions - Subjects with type 2 diabetes mellitus</PatientSegment><PatientSegment>Hypertension - Treatment Naive Subjects</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with comorbid conditions - Subjects with heart disease</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with comorbid conditions - Subjects with hypertension</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with specific disease - Subjects with Prediabetes/Impaired Glucose Tolerance</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Aldosterone </BiomarkerName><BiomarkerName> Norepinephrine</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>23 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jacques Champlain</Name><Name>Michel White</Name><Name>Simon Denus</Name></ContactNames></Trial><Trial Id="215589"><Indications><Indication>Rhinitis</Indication></Indications><CompaniesSponsor><Company>Universitaire Ziekenhuizen Leuven</Company></CompaniesSponsor><Countries><Country>Belgium</Country></Countries><DateChangeLast>2015-12-05T00:00:00Z</DateChangeLast><DateEnd>2017-12-31T00:00:00Z</DateEnd><DateStart>2015-07-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02288156</Identifier><Identifier>TBM</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>capsaicin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>medication affecting nasal function like beta-blockers History of prolonged use or abuse of decongestant nasal spray like xylometazoline spray and/or use or abuse of decongestive oral medication Evidence of infectious rhinitis/rhinosinusitis or common &lt;b&gt;cold&lt;/b&gt; within 4 weeks prior to inclusion Pregnancy or lactation Any disorder of which might compromise the ability of a patient to give truly informed consent for participation in this study Enrollment in other investigational drug trial(s) or receiving other</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Elaboration of Patient-friendly Treatment Strategy With Capsaicin Nasal Spray in Patients With Idiopathic Rhinitis</TitleDisplay><PrimaryCompletionDate type="Anticipated">2017-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>29 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Emily Dekimpe, Msc</Name><Name>Hellings Peter, MD</Name><Name>Peter Hellings, Prof. Dr.</Name><Name>Sofie Mees</Name></ContactNames></Trial><Trial Id="21533"><Indications><Indication>Atopic dermatitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-10 receptor antagonist</Action><Action>IL-2 receptor antagonist</Action><Action>IL-4 receptor antagonist</Action><Action>Interferon gamma receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mast cell degranulation inhibitor</Action><Action>Topical antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Emulsion dermatological</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Switzerland</Country></Countries><DateChangeLast>2008-07-24T00:00:00Z</DateChangeLast><DateEnd>2005-09-30T00:00:00Z</DateEnd><DateStart>2004-09-30T00:00:00Z</DateStart><Identifiers><Identifier>CASM981C2314</Identifier><Identifier>NCT00139581</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>pimecrolimus alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Subjects with open skin infections (bacterial, viral or fungal) if at the application site Subjects with herpes simplex virus (common &lt;b&gt;cold&lt;/b&gt; sores) are allowed to participate in the study (if not at the application site) Subjects who have head lice or...the treatment of AD during the run-in period Subjects with active skin infections (bacterial, viral or fungal) except common &lt;b&gt;cold&lt;/b&gt; sores at the application site Subjects who failed to record study medication use (and non use) and dosing regimen during</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Dermatitis - Assessment of Clinical Response - Assessment of pruritus</EndpointIndex><EndpointIndex>Dermatitis - Assessment of Dermatitis Recurrence/Flares</EndpointIndex><EndpointIndex>Dermatitis - Investigator's Global Assessment (IGA)</EndpointIndex><EndpointIndex>Dermatitis - Treatment Response Assessed by Eczema Area and Severity Index (EASI) score</EndpointIndex><EndpointIndex>Pruritus - Investigator's Global Assessment (IGA)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects</TitleDisplay><PatientSegmentTerms><PatientSegment>Atopic Dermatitis - Patients enrolled based on Investigator global assessment [IGA] Scores - Score of 2 -3</PatientSegment><PatientSegment>Atopic Dermatitis - Patients enrolled based on Investigator global assessment [IGA] Scores - Score of 3-4</PatientSegment><PatientSegment>Atopic Dermatitis - Patients with Mild to Moderate Atopic Dermatitis</PatientSegment><PatientSegment>Atopic Dermatitis - Patients with Moderate to Severe Atopic Dermatitis</PatientSegment><PatientSegment>Dermatitis - Subjects with Atopic Dermatitis (AD) - Subjects with mild to moderate atopic dermatitis</PatientSegment><PatientSegment>Dermatitis - Subjects with Atopic Dermatitis (AD) - Subjects with moderate to severe atopic dermatitis</PatientSegment><PatientSegment>Pruritus - Subjects with Pruritus Associated with Dermatological Disorders - Subjects with dermatitis/eczema</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="215221"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Sociedad Andaluza de Trasplantes de Organos y Tejidos</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fundacion Publica Andaluza para la Investigacion de Malaga en Biomedicina y Salud</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2016-09-07T00:00:00Z</DateChangeLast><DateEnd>2017-12-31T00:00:00Z</DateEnd><DateStart>2015-02-28T00:00:00Z</DateStart><Identifiers><Identifier>EVITAESTEROIDE-12</Identifier><Identifier>NCT02284464</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including mycophenolate , prednisone , tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>230</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Patients who receive a multiorgan transplant Retransplants Presence of DSA before the transplant or at the time of randomization &lt;b&gt;Cold&lt;/b&gt; ischemia time&gt; 30 h Patients with serum creatinine&gt; 2 mg/dl or proteinuria &gt; 1 g/day at the time of randomization Prior episode of severe rejection (II-B-III in the Banff/13 classification) prior to randomization Presence of subclinical rejection or</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Cardiovascular Events - Hypertension</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Inflammatory &amp; Oxidative Stress Markers - Donor specific antibodies</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Hyperlipidemia/dyslipidemia</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Immunological Conversion Following Medication</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications - New onset/post transplant diabetes mellitus</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Steroid Withdrawal and Donor-specific Anti-HLA Antibodies in Renal Transplant Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2017-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>34 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Abelardo Caballero, PhD</Name><Name>Domingo Hernandez, PhD</Name><Name>Edisson Rudas, MD</Name><Name>Isabel Garcia, PhD</Name><Name>Joana Sellares, MD</Name><Name>Maria Angeles Cobo, PhD</Name><Name>Pedro Ruiz, MsC</Name><Name>Veronica Lopez, MD</Name></ContactNames></Trial><Trial Id="214963"><Indications><Indication>Anesthesia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Alpha 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anxiolytic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology></Technologies><CompaniesSponsor><Company>Antwerp University Hospital</Company></CompaniesSponsor><Countries><Country>Belgium</Country></Countries><DateChangeLast>2016-12-30T00:00:00Z</DateChangeLast><DateEnd>2017-12-31T00:00:00Z</DateEnd><DateStart>2014-10-31T00:00:00Z</DateStart><Identifiers><Identifier>13/35/334</Identifier><Identifier>NCT02282319</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>chloroprocaine alone</Intervention><Intervention>chloroprocaine plus dexmedetomidine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>150</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The primary objective of this double-blind, randomized study is to determine the effect of dexmedetomidine on onset and duration of the sensory and motor block and on the influence on bladder function after spinal anesthesia with chloroprocaine. The primary hypothesis of investigators is that sensory block will significantly be prolonged by dexmedetomidine administered by both the spinal and the intravenous route. The investigators do not expect a significant difference in motor block duration</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Spinal or Intravenous Dexmedetomidine in Ambulatory Surgery</TitleDisplay><BiomarkerNames><BiomarkerName>Blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2017-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>38 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Catherine Vandepitte, MD</Name><Name>Dimitri Dylst, MD</Name><Name>Marcel Vercauteren, MD, PHD</Name><Name>Margaretha Breebaart, MD</Name><Name>Veerle Verheyen, studynurse</Name><Name>margaretha breebaart, MD</Name><Name>veerle verheyen, nurse</Name></ContactNames></Trial><Trial Id="214505"><Indications><Indication>Obesity</Indication></Indications><CompaniesSponsor><Company>Mike O'Callaghan Federal Hospital</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-12-18T00:00:00Z</DateChangeLast><DateEnd>2016-12-31T00:00:00Z</DateEnd><DateStart>2015-02-28T00:00:00Z</DateStart><Identifiers><Identifier>AcupObesity</Identifier><Identifier>FWH20140089H</Identifier><Identifier>NCT02269371</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>auricular acupuncture alone</Intervention><Intervention>standard of care weight loss intervention alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>82</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>ear for 15 min. All subjects, regardless of randomization group, would be instructed to have no heavy meals, no excessive hot or &lt;b&gt;cold&lt;/b&gt; foods, no heavy exercise or intercourse, and no alcohol for 24 h after this visit. Visit 2 to 12 (week 2 to...measurements form class). All subjects, regardless of randomization group, would be instructed to have no heavy meals, no excessive hot or &lt;b&gt;cold&lt;/b&gt; foods, no heavy exercise or intercourse, and no alcohol for 24 h after this visit. Visit 13 (week 24/12 weeks</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of BMI</EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of height</EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of waist circumference</EndpointIndex><EndpointIndex>Obesity - Assessment of Vital Signs</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>AcupObesity: Auricular Acupuncture in the Treatment of Obesity</TitleDisplay><BiomarkerNames><BiomarkerName>Body Mass Index </BiomarkerName><BiomarkerName> Body height </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Waist circumference</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Clinton Borchardt, MD</Name></ContactNames></Trial><Trial Id="214490"><Indications><Indication>Anesthesia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Adrenergic receptor agonist</Action><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anti-inflammatory</Action><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Injectable formulation</Technology><Technology>Intrathecal formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Rectal formulation</Technology><Technology>Rectal formulation local</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology></Technologies><CompaniesSponsor><Company>Antwerp University Hospital</Company></CompaniesSponsor><Countries><Country>Belgium</Country></Countries><DateChangeLast>2015-04-23T00:00:00Z</DateChangeLast><DateEnd>2010-08-31T00:00:00Z</DateEnd><DateStart>2009-07-31T00:00:00Z</DateStart><Identifiers><Identifier>EC 9/25/113</Identifier><Identifier>NCT02271867</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>levobupivacaine alone</Intervention><Intervention>ropivacaine alone</Intervention><Intervention>epinephrine plus levobupivacaine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>45</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study aimed at investigating, in a quantitative way, the block characteristics of three different commonly used local anesthetics on peripheral nerves through the application of thermal QST by measuring changes in sensory detection thresholds. Furthermore, the investigators wanted to evaluate if QST could be of value for measuring gradual changes in block characteristics on the adjacent nerves at distance of the injection site in an US-ISB.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Thermal QST for Interscalene Block Evaluation</TitleDisplay><PrimaryCompletionDate type="Actual">2010-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="213956"><Indications><Indication>Hypothermia</Indication></Indications><CompaniesCollaborator><Company>Queensland University of Technology</Company></CompaniesCollaborator><CompaniesSponsor><Company>Mater Health Services' Adult Hospital, Brisbane, Qld</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2016-07-22T00:00:00Z</DateChangeLast><DateStart>2015-02-04T00:00:00Z</DateStart><Identifiers><Identifier>ACTRN12614001088639</Identifier><Identifier>ANZCTR367160</Identifier><Identifier>HREC/14/MHS/157</Identifier><Identifier>U1111-1162-2246</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Cocoon warm air heater alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The aim of this study is to test warming patients pre-operatively via a warming blanket (which utilises heated air) to reduce the amount of heat loss during surgery.</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A pre-operative warming regime versus no pre-operative warming for maintenance of normothermia in women receiving intrathecal morphine for cesarean section</TitleDisplay><BiomarkerNames><BiomarkerName>Body temperature</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Judy Munday</Name></ContactNames></Trial><Trial Id="213653"><Indications><Indication>Kidney transplantation</Indication></Indications><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-01-25T00:00:00Z</DateChangeLast><DateEnd>2015-12-31T00:00:00Z</DateEnd><DateStart>2012-07-31T00:00:00Z</DateStart><Identifiers><Identifier>ACN-ATG-KTX-12-1</Identifier><Identifier>NCT02267512</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>anti-T-lymphocyte immune globulin (ATG-F) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>280</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Subject has previously received or is receiving an organ transplant other than kidney Subject is receiving double-kidney transplant Subject is receiving an ABO incompatible or T-cells cross match positive transplant &lt;b&gt;Cold&lt;/b&gt; ischemia time of allograft is&gt; 24 h before kidney transplantation surgery Subject is receiving organ from a Human Leukocyte Antibody (HLA) identical donor Known contraindication to administration of ATG-F, including: Subject has known hypersensitivity</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Incidence/number of AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Delayed Graft Function (DGF) - Incidence/proportion of patients with DGF</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Incidence of adverse events/Side Effects</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in A new Kidney Transplant Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Antibody Compatible Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - De Novo Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Subjects with End Stage Renal Disease/Chronic Renal Failure</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>41 Months</TrialDuration><NumberOfSites>13</NumberOfSites><ContactNames><Name>Medical Director</Name></ContactNames></Trial><Trial Id="21341"><Indications><Indication>Otitis media</Indication></Indications><ActionsPrimaryInterventionsControl><Action>DNA gyrase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antibacterial</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Antibiotic</Technology><Technology>Biological therapeutic</Technology><Technology>Film coating</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Genentech Inc</Company><Company>University of Colorado at Denver and Health Sciences Center</Company></CompaniesCollaborator><Countries><Country>US</Country></Countries><DateChangeLast>2018-06-26T00:00:00Z</DateChangeLast><DateEnd>2011-05-31T00:00:00Z</DateEnd><DateStart>2007-01-31T00:00:00Z</DateStart><Identifiers><Identifier>06-0556</Identifier><Identifier>BB-IND Number: 100242</Identifier><Identifier>NCT00419380</Identifier><Identifier>Z3816s</Identifier></Identifiers><InterventionsControlDisplay><Intervention>ofloxacin alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>dornase alfa alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to evaluate dornase alfa (Pulmozyme) as compared to a standard ear drop ofloxacin (Floxin) to dissolve clogged tubes. This study would monitor the use of the new drug for any problems related to the medication.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Otitis media - Assessment of Clinical Response</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme)</TitleDisplay><PatientSegmentTerms><PatientSegment>Otitis media - Subjects with Prior Tympanostomy Tube Insertion</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>52 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Kenny Chan</Name></ContactNames></Trial><Trial Id="212347"><Indications><Indication>Anesthesia</Indication><Indication>Pain</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesCollaborator><Company>A.P. Møller foundation</Company></CompaniesCollaborator><CompaniesSponsor><Company>Aarhus University</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2018-04-10T00:00:00Z</DateChangeLast><DateEnd>2015-03-31T00:00:00Z</DateEnd><DateStart>2015-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2013-005346-10</Identifier><Identifier>AUH-TFB-SR</Identifier><Identifier>NCT02255591</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Lumbar Ultrasound Trident technique alone</Intervention><Intervention>Shamrock technique alone</Intervention><Intervention>Variable regimens including adrenaline , gadolinium , lidocaine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The main objective of the trial was to complete a double-blinded, randomized, controlled trial of a lumbar plexus block with the Shamrock technique versus the Lumbar Ultrasound Trident technique by estimating the time of performance of lumbar plexus blocks in healthy subjects. Secondary objectives included: Estimates of number and depth of needle injections, distance of injection site from the midline, minimal electric nerve stimulation totrigger muscular response and the type of response, and</Teaser><TrialCategories><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures - Imaging assessments</EndpointIndex><EndpointIndex>Pain - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Assessment of duration of block</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Level/Depth of block</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Pain - Health Economic Assessments</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Numerical Analog Scale (NRS/NAS)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Perceptions on Epidural Questionnaire (PEQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Shamrock Versus Lumbar Ultrasound Trident - Ultrasound Guided Block of the Lumbar Plexus</TitleDisplay><BiomarkerNames><BiomarkerName>Mean arterial pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>1 Month</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Clinical Trial Info - Shamrock</Name><Name>Thomas F Bendtsen, MD,PhD,Prof.</Name></ContactNames></Trial><Trial Id="211862"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Inactivated viral vaccine</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Suspension</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Centers for Disease Control and Prevention</Company><Company>University of Wisconsin-Madison</Company></CompaniesCollaborator><CompaniesSponsor><Company>Marshfield Clinic</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-07-20T00:00:00Z</DateChangeLast><DateEnd>2015-04-30T00:00:00Z</DateEnd><DateStart>2014-09-30T00:00:00Z</DateStart><Identifiers><Identifier>5U01IP000471-04</Identifier><Identifier>NCT02250274</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention><Intervention>Fluzone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>131</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to assess the serologic and cell-mediated immune response to licensed live attenuated influenza vaccine, LAIV ( FluMist ) and inactivated influenza vaccine,IIV ( Fluzone ) in children 5 to 17 years old. The effects of prior infection and or prior season vaccination were examined. Children were followed during the influenza season to identify laboratory-confirmed influenza (ie, vaccine failure).</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Influenza Vaccine - Incidence of Influenza/Influenza Like Illness</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children - Children more than 5 years of age</PatientSegment><PatientSegment>Influenza Vaccine - Subjects with Influenza</PatientSegment><PatientSegment>Influenza Vaccine - Subjects with Prior Other Vaccination - Subjects with Prior Influenza Vaccination</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Immunoglobulin A </BiomarkerName><BiomarkerName> Immunoglobulin G</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>7 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Edward A Belongia, MD</Name></ContactNames></Trial><Trial Id="211686"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>A.P. Møller foundation</Company></CompaniesCollaborator><CompaniesSponsor><Company>Aarhus University</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2015-09-01T00:00:00Z</DateEnd><DateStart>2015-03-31T00:00:00Z</DateStart><Identifiers><Identifier>2014-001702-18</Identifier><Identifier>NCT02248870</Identifier><Identifier>PROTOCOL1TDN</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including adrenaline , bupivacaine, AstraZeneca , dexamethasone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>7</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Other</Reason></ReasonForTrialDiscontinuation><Teaser>The aim of the study was to investigate if more patients with hip fracture experience lasting pre-operative analgesic until the time of operation or 20 h after a femoral nerve block with bupivacaine with adrenaline with the addition of dexamethasone compared to the same nerve block done without dexamethasone. Secondary objectives of the trial: Investigate the course of pain reduction until 30 min after the nerve block. Success rate of sufficient analgesia after femoral nerve block for pain in</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures - Imaging assessments</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Assessment of other outcomes associated with anesthetic use</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR) - Assessment of time to response</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of procedural outcomes</EndpointIndex><EndpointIndex>Pain - Protocol Specified Other Endpoints - Other post-operative outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Femoral Nerve Block With Bupivacaine and Adjuvant Dexamethasone in Patients With Hip Fracture</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with bone pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>5 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Dep. Anaesthesia and Intensive Care</Name><Name>Thomas F. Bendtsen, MD, Ph.d.</Name></ContactNames></Trial><Trial Id="211640"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>ORL1 receptor agonist</Action><Action>Opioid receptor mu partial agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Antidepressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Health and Medical Research Council</Company><Company>University of New South Wales</Company></CompaniesCollaborator><CompaniesSponsor><Company>South Eastern Sydney Area Health Service</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2016-08-10T00:00:00Z</DateChangeLast><DateStart>2014-10-22T00:00:00Z</DateStart><Identifiers><Identifier>141088 (HREC/14/POWH/208)</Identifier><Identifier>ACTRN12614001038684</Identifier><Identifier>ANZCTR367105</Identifier><Identifier>U1111-1161-8062</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>buprenorphine (sublingual, opioid dependence), Indivior plus naloxone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>9</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>usual daily dose of sublingual buprenorphine (range 4-16mg)(in the form of buprenorphine -naloxone) compared with 150% and 200% of the usual daily dose, in buprenorphine maintained participants on experimental pain threshold and tolerance using the &lt;b&gt;cold&lt;/b&gt; pressor test. Each dose condition will be tested once (single-dose only). Participants will have 3 wash out days in between each study session. To maintain the blind participants will receive a blinded dose of buprenorphine +naloxone film dose on the</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain tolerance</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Assessment of sedation level</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Pain by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Pain - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>A pilot study examining the analgesic effect of ascending buprenorphine doses in opioid dependent people</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Suzanne Nielsen</Name></ContactNames></Trial><Trial Id="211571"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Coordinacion de Investigacion en Salud</Company><Company>Instituto Mexicano del Seguro Social</Company></CompaniesCollaborator><Countries><Country>Mexico</Country></Countries><DateChangeLast>2017-05-09T00:00:00Z</DateChangeLast><DateEnd>2013-10-31T00:00:00Z</DateEnd><DateStart>2013-06-30T00:00:00Z</DateStart><Identifiers><Identifier>EBWL</Identifier><Identifier>NCT02244086</Identifier><Identifier>R-2013-2301-21</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>bupivacaine, AstraZeneca alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>114</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> of the epidural catheter. Sensory level as measured by thermal sensitivity this would be done with closed eyes of the patient, two test tubes filled, one with &lt;b&gt;cold&lt;/b&gt; 5 water use – 10degC, and one with hot water at 40 to 45deg C, the skin touched the bottom of the tube for more than 3 s and would be asked to identify the patient saying '&lt;b&gt;cold&lt;/b&gt;' or 'hot'. The region would be delimiting with sensory block from zone to zone without blocking lock. Blocking engine if there would be assessed using the modified</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Female</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>EBWL: Analgesic Efficacy of Two Concentrations of Bupivacaine in Women in Labor</TitleDisplay><BiomarkerNames><BiomarkerName>Activated Clotting Time </BiomarkerName><BiomarkerName> Blood cells </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Respiratory frequency </BiomarkerName><BiomarkerName> Urea</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>4 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Horacio Márquez González, MSc</Name><Name>Ilse C Iparrea Ramos, Dr.</Name><Name>Maria V Jiménez Báez, PhD</Name><Name>Ricardo Rodríguez Ramon, Dr.</Name></ContactNames></Trial><Trial Id="21136"><Indications><Indication>Heart transplantation</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Inosine monophosphate dehydrogenase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Argentina</Country><Country>Australia</Country><Country>US</Country><Country>Canada</Country></Countries><DateChangeLast>2017-04-03T00:00:00Z</DateChangeLast><DateEnd>2004-04-30T00:00:00Z</DateEnd><DateStart>2002-01-31T00:00:00Z</DateStart><Identifiers><Identifier>CERL080A2401</Identifier><Identifier>NCT00574743</Identifier></Identifiers><InterventionsControlDisplay><Intervention>mycophenolate mofetil alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>enteric-coated mycophenolate sodium, Novartis alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>162</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Patients with donor hearts greater than 60 years of age and/or with &lt;b&gt;cold&lt;/b&gt; ischemia time of more than 6 h and/or donor hearts which have obvious coronary disease or are known to have heart disease at time of transplant Patients on left ventricular assist device who have received any immunotherapy prior to transplantation or who are scheduled to receive immunotherapy thereafter Patients with panel reactive antibodies (PRA) 25% Patients with serum creatinine 3.0 mg/dl Females of childbearing potential</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR)</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR) - AGR associated with hemodynamic compromise (HDC)</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Therapy Related Outcomes - Assessment of treatment failure</EndpointIndex><EndpointIndex>Heart transplantation - Post Transplant Malignancies</EndpointIndex><EndpointIndex>Heart transplantation - Post Transplant Malignancies - Post transplant lymphoproliferative disorder (PTLD)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Heart transplantation - Heart Transplant Recipients</PatientSegment><PatientSegment>Heart transplantation - Heart Transplant Recipients - Primary (First) Heart Transplant Recipients</PatientSegment><PatientSegment>Heart transplantation - Subjects with History of/on Currently on Heart Transplant Therapy</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2004-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>27 Months</TrialDuration><NumberOfSites>9</NumberOfSites><ContactNames><Name>Novartis</Name></ContactNames></Trial><Trial Id="211168"><Indications><Indication>Common cold</Indication><Indication>Influenza virus infection</Indication></Indications><CompaniesCollaborator><Company>Sino-American Tianjin Smith Kline &amp; French Laboratories Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-01-04T00:00:00Z</DateChangeLast><DateEnd>2015-02-28T00:00:00Z</DateEnd><DateStart>2015-01-31T00:00:00Z</DateStart><Identifiers><Identifier>202271</Identifier><Identifier>NCT02246166</Identifier><Identifier>RH02565</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>paracetamol + pseudoephedrine + dextromethorphan + chlorpheniramine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>53</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>any medication or herbal remedies to treat &lt;b&gt;cold&lt;/b&gt; prior to screening (antibiotics in the last 7 days, antihistamines in the last 72 h, analgesics or antipyretics...Mandatory: nasal congestion At least one of catarrh symptoms: runny nose or sneezing Onset of first symptoms of &lt;b&gt;cold&lt;/b&gt; must have occurred within 48 h of screening...efficacy and tolerability of the active tablets (paracetamol, pseudoephedrine, chlorpheniramine and dextromethorphan) versus placebo in &lt;b&gt;cold&lt;/b&gt; and influenza patients.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Influenza virus infection - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex><EndpointIndex>Influenza virus infection - Patient Reported Outcomes/Quality of Life Assessments - Symptom score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>The Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets Compared to Placebo in Subjects Suffering From the Common Cold or Influenza</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza virus infection - Subjects with Influenza</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body temperature</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>1 Month</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="21110"><Indications><Indication>Cardiogenic shock</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>GP IIb IIIa antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Platelet aggregation inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody fragment</Technology><Technology>Biological therapeutic</Technology><Technology>Cell culture</Technology><Technology>Chimeric monoclonal antibody</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Eli Lilly &amp; Co</Company></CompaniesCollaborator><CompaniesSponsor><Company>Charles University</Company></CompaniesSponsor><Countries><Country>Czech Republic</Country></Countries><DateChangeLast>2018-12-20T00:00:00Z</DateChangeLast><DateEnd>2009-06-30T00:00:00Z</DateEnd><DateStart>2006-09-30T00:00:00Z</DateStart><Identifiers><Identifier>Charles University, Prague</Identifier><Identifier>MSM 0021620817</Identifier><Identifier>NCT00420030</Identifier><Identifier>PRAGUE-7</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>abciximab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> ECG) with indication to urgent coronary angiography Signs of cardiogenic shock including inclompletely developed shock (at least one of the following must be present):  Shock index &gt;1 Hypotension (BP&amp;lt; 90mmHg) and HR &gt; 90/min Organ hypoperfusion-&lt;b&gt;cold&lt;/b&gt; wett sweating skin and HR&gt; 90/min Need of catecholamine support to maintain BP&gt; 90/min Killip II-III + systolic BP below 120 mmHg Informed consent signed either by patient or his/her relative in case of diminished consciousness</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiac Function - Assessment of left ventricular ejection fraction (LVEF)</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiac Function - Changes in Left ventricular ejection fraction</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Coronary Angiographic Findings - Myocardial blush grade</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Coronary TIMI Flow</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Hemorrhagic Complications - TIMI major bleeding events</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Thrombotic/Thromboembolic Events - Ischemic stroke</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiac Function - Assessment of ejection fraction</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Global/Regional Myocardial Perfusion</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Hemorrhagic Complications - Major/minor bleeding</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Stenosis/Restenosis - Coronary stenosis</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Nonfatal cerebral infarction /Ischemic stroke</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PRAGUE-7: Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Cardiogenic Shock</TitleDisplay><PatientSegmentTerms><PatientSegment>Acute coronary syndrome - Subjects with Abnormal Echo/ECG findings - Left bundle branch block</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with Abnormal Echo/ECG findings - ST segment changes (elevation /depression)</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with Acute Myocardial Infarction (MI)</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with History of Cardiac Intervention - Coronary angiogram/catheterization</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with comorbid conditions - Subjects co-morbid with cardiogenic shock</PatientSegment><PatientSegment>Coronary artery disease - Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Abnormal Echo/ECG findings - ST segment abnormalities</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Arrhythmias and Conduction Disorders</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Complications of the Underlying IHD</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - Acute onset/new onset myocardial infarction (MI)</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>33 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Petr Tousek, MD,PhD</Name><Name>Petr Widimsky, Prof,MD,PhD</Name></ContactNames></Trial><Trial Id="210479"><Indications><Indication>Allergic rhinitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Histamine H1 receptor antagonist</Action><Action>Leukotriene C4 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Drug combination</Technology><Technology>Nasal formulation local</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Suspension</Technology></Technologies><CompaniesSponsor><Company>Universitaire Ziekenhuizen Leuven</Company></CompaniesSponsor><Countries><Country>Belgium</Country></Countries><DateChangeLast>2018-07-19T00:00:00Z</DateChangeLast><DateEnd>2015-12-31T00:00:00Z</DateEnd><DateStart>2014-10-31T00:00:00Z</DateStart><Identifiers><Identifier>AZELASTINE/FLUTICASONE AZE/FLU</Identifier><Identifier>NCT02238353</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>azelastine + fluticasone (nasal spray, allergic rhinitis), Meda/Cipla alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>45</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The objective of this study was to evaluate the effect MP-2902 (azelastine/fluticasone [137/50 microg]) nasal spray on symptom control, nasal mediators and nasal hyperresponsiveness in allergic rhinitis (AR).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of nasal inflammatory/ immunological markers</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Pulmonary Function - Assessment of Peak nasal inspiratory flow (PNIF)</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Rhinitis Visual-Analogue Score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score</EndpointIndex><EndpointIndex>Allergic rhinitis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Azelastine/fluticasone (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR)</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Moderate to Severe Allergic Rhinitis</PatientSegment><PatientSegment>Allergic rhinitis - Subjects with Persistent Allergic rhinitis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Eosinophil peroxidase </BiomarkerName><BiomarkerName> Hexosaminidase D </BiomarkerName><BiomarkerName> Histamine </BiomarkerName><BiomarkerName> Interleukin-5 </BiomarkerName><BiomarkerName> Peak nasal inspiratory flow </BiomarkerName><BiomarkerName> Protachykinin-1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2015-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>emily dekimpe, Msc</Name><Name>peter hellings, MD</Name><Name>peters hellings, MD</Name></ContactNames></Trial><Trial Id="210307"><Indications><Indication>Rhinorrhea</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor antagonist</Action><Action>Muscarinic receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Boehringer Ingelheim International GmbH</Company></CompaniesSponsor><DateChangeLast>2014-09-17T00:00:00Z</DateChangeLast><DateEnd>2003-05-31T00:00:00Z</DateEnd><DateStart>2002-12-31T00:00:00Z</DateStart><Identifiers><Identifier>244.2503</Identifier><Identifier>NCT02238210</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ipratropium bromide alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>230</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study would consist of two groups: Group 1: patients suffering from common &lt;b&gt;cold&lt;/b&gt; would receive Atrovent &amp;nbsp;tid for 4 days. Group 2: patients suffering from allergy would receive Atrovent &amp;nbsp;tid for 14 days....study was to determine the safety of Atrovent nasal spray 0.06% in pediatric patients (ages 2 to 5 years) with symptoms of rhinorrhea associated with a naturally occurring common &lt;b&gt;cold&lt;/b&gt; or from symptoms of rhinorrhea associated with allergies.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety Trial of Atrovent in Pediatric Patients With Rhinorrhea Associated With a Common Cold or Allergy</TitleDisplay><PrimaryCompletionDate type="Actual">2003-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>0</NumberOfSites></Trial><Trial Id="20932"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Erythropoietin ligand</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Hematopoietic stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Glycoprotein</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Leiden University Medical Center</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2018-06-02T00:00:00Z</DateChangeLast><DateEnd>2010-07-31T00:00:00Z</DateEnd><DateStart>2005-07-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT00157300</Identifier><Identifier>P05-026</Identifier><Identifier>PROTECT</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>epoetin beta, Roche alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>92</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Donor related factors: A prolonged warm ischemic time (&gt; 45 min) A &lt;b&gt;cold&lt;/b&gt; ischemic time of&gt; 24 h Serum creatinin of&gt; 150 micromol/l</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Incidence/number of AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Delayed Graft Function (DGF)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of dialysis</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients - Non heart beating donor - renal transplant recipients</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>60 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Ton Rabelink</Name></ContactNames></Trial><Trial Id="208745"><Indications><Indication>Anesthesia</Indication><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intrathecal formulation</Technology><Technology>Rectal formulation</Technology><Technology>Rectal formulation local</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>University of California San Diego</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-07-09T00:00:00Z</DateChangeLast><DateEnd>2014-12-31T00:00:00Z</DateEnd><DateStart>2014-08-31T00:00:00Z</DateStart><Identifiers><Identifier>ADDUCTOR CANAL BASAL VS BOLUS</Identifier><Identifier>NCT02219438</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ropivacaine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>24</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>catheters would be removed after 8 h. To check the perineural catheter placement accuracy, the adductor canal nerve block would be evaluated 8 h after local anesthetic initiation and considered successful when subjects experience a decreased sensation to &lt;b&gt;cold&lt;/b&gt; of the skin in the saphenous nerve distribution as compared with their ipsilateral upper extremity. Subjects would be deemed non-responders if both extremities failed to exhibit any increase in tolerance to cutaneous electrical current by 8 h. For </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Continuous Adductor Canal Nerve Blocks: Relative Effects of a Basal Infusion versus Hourly Bolus Doses</TitleDisplay><PrimaryCompletionDate type="Actual">2014-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>4 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="207108"><Indications><Indication>Pulpitis</Indication></Indications><CompaniesSponsor><Company>King's College London</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-01-21T00:00:00Z</DateChangeLast><DateEnd>2017-07-31T00:00:00Z</DateEnd><DateStart>2012-07-31T00:00:00Z</DateStart><Identifiers><Identifier>11-LO-1893</Identifier><Identifier>NCT02201641</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Fuji IX alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Biodentine alone</Intervention><Intervention>Cone Beam computed tomography (Morita Accuitomo) alone</Intervention><Intervention>periapical radiographs alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>53</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>This study aims to investigate the tooth nerve response to a recently introduced therapeutic filling material (calcium silicate cement) called Biodentine and to assess the quality of the overlying filling compared to another material (glass ionomer cement) called Fuji IX used more commonly. Also to compare the effectiveness of cone beam computed tomography x-rays compared to conventional periapical X-rays in detecting lesions around these teeth.</Teaser><TrialCategories><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy of Calcium Silicate Pulp-capping; a Randomized, Controlled, Clinical Trial</TitleDisplay><PrimaryCompletionDate type="Anticipated">2017-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>60 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Timothy F Watson, BDS,MSc,PhD</Name></ContactNames></Trial><Trial Id="206374"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action><Action>Beta 2 adrenoceptor antagonist</Action><Action>Beta adrenoceptor agonist</Action><Action>Muscarinic receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2014-07-30T00:00:00Z</DateChangeLast><DateEnd>2002-05-11T00:00:00Z</DateEnd><DateStart>2001-01-10T00:00:00Z</DateStart><Identifiers><Identifier>SMS40315</Identifier></Identifiers><IndicationsAdverse><Indication>Common cold</Indication><Indication>Headache</Indication><Indication>Insomnia</Indication><Indication>Tachycardia</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>ipratropium bromide alone</Intervention><Intervention>salmeterol alone</Intervention><Intervention>Variable regimens including ipratropium bromide , salmeterol , salmeterol+ ipratropium</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>735</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>September 2005, the results were published. AEs reported in 39, 43, 47 and 43% subjects in PBO, SALM, IP and SALM/IP group respectively. The most frequent AEs reported were headache, upper respiratory tract infection, sore throat, dry throat, common &lt;b&gt;cold&lt;/b&gt;, diarrhea, nausea, respiratory tract infection, bronchitis, cough, insomnia, tachycardia and leg cramps. Non-fatal SAEs were reported in 0, &amp;lt; 1, &amp;lt; 1 and 4% subjects in the PBO (n = 105), SALM (n = 211), IP (n = 206) and SALM/IP (n = 213) group</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Disease Progression - Severity of symptoms/symptom scores (SS)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 area under curve (AUC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Changes in St Georges Respiratory Questionnaire (SGRQ)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Transition Dyspnea Index (TDI) Score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Control, Parallel-Group, 8-Week Study in Subjects With COPD to Compare Salmeterol Xinafoate Versus Ipratropium Bromide Versus Salmeterol Xinafoate Plus Ipratropium Bromide Versus Placebo</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Smokers</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with History of Treatment</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>16 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="204833"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Bronchodilator</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Drug combination</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Norway</Country><Country>Sweden</Country><Country>Finland</Country></Countries><DateChangeLast>2014-09-05T00:00:00Z</DateChangeLast><DateEnd>2001-09-01T00:00:00Z</DateEnd><DateStart>2000-11-01T00:00:00Z</DateStart><Identifiers><Identifier>SAM40034</Identifier><Identifier>Seretide Nordic Jump-Up Study</Identifier></Identifiers><IndicationsAdverse><Indication>Bronchitis</Indication><Indication>Common cold</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Hoarseness</Indication><Indication>Influenza virus infection</Indication><Indication>Sinusitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>fluticasone propionate alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>180</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In September 2004, results were published. In the FSC 100/50 microg bid Diskus and FP 250 microg bid Diskus groups, adverse events were reported in 62 and 75% patients. The most common adverse events reported were common &lt;b&gt;cold&lt;/b&gt;, hoarseness, influenza, upper respiratory tract infection, sinusitis, sore throat, Candida, headache, fever, oral candidiasis, respiratory tract infection, bronchitis, nasal congestion, nausea and exacerbation of asthma. In the FSC 100/50 microg bid Diskus and FP 250 microg </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change from baseline in FEV1</EndpointIndex><EndpointIndex>Asthma - Assessment of Peak Expiratory Flow/Flow Rate (PEFR) - Assessment of morning/evening PEFR</EndpointIndex><EndpointIndex>Asthma - Assessment of Peak Expiratory Flow/Flow Rate (PEFR) - Change from baseline in PEFR</EndpointIndex><EndpointIndex>Asthma - Assessment of Therapy Related Outcomes - Asthma control</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Seretide Nordic Jump-Up Study: A Randomized, Double-Blind, Multicenter, Parallel-Group, Active-Comparison Study Of Fluticasone Propionate/Salmeterol Combination Diskus 100/50 microg bid With Fluticasone Propionate (FP) 250 microg bid As Initial Maintenance Treatment In Persistent Asthma (Seretide Nordic Jump-Up Study)</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment><PatientSegment>Asthma - Subjects with Symptomatic Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>10 Months</TrialDuration><NumberOfSites>3</NumberOfSites></Trial><Trial Id="204664"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action><Action>Beta adrenoceptor agonist</Action><Action>Leukotriene D4 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Buccal formulation systemic</Technology><Technology>Daily dosing</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2014-08-06T00:00:00Z</DateChangeLast><DateEnd>2003-05-29T00:00:00Z</DateEnd><DateStart>2001-10-29T00:00:00Z</DateStart><Identifiers><Identifier>SAS40037</Identifier></Identifiers><IndicationsAdverse><Indication>Back pain</Indication><Indication>Cough</Indication><Indication>Headache</Indication><Indication>Sinusitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline alone</Intervention><Intervention>fluticasone propionate alone</Intervention><Intervention>montelukast sodium alone</Intervention><Intervention>salmeterol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>641</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> respectively. The most common adverse events reported were common &lt;b&gt;cold&lt;/b&gt;, upper respiratory tract infection, headache, sore throat, &lt;b&gt;cold&lt;/b&gt; symptoms, couch, bronchitis, back pain, sinusitis, influenza, diarrhea and heartburn. In the respective groups, common &lt;b&gt;cold&lt;/b&gt; was reported in 6, 10, 5 and 5% patients, upper respiratory tract infection was reported in 5, 7, 6 and 6% patients, sore throat was reported in 4, 4, 2 and 2% patients, &lt;b&gt;cold&lt;/b&gt; symptoms was reported in 3, 3, 2 and 2% patients, bronchitis was reported</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score - Symptom free period</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1) - Assessment of morning/evening FEV1</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change from baseline in FEV1</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change in pre bronchodilator FEV1</EndpointIndex><EndpointIndex>Asthma - Assessment of Peak Expiratory Flow/Flow Rate (PEFR) - Change from baseline in PEFR</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments - Assessment of patient satisfaction</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, 16-Week Comparison Study of Asthma Control in Adolescents and Adults Receiving Either Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50 microg bid, Fluticasone Propionate DISKUS 100 microg bid, Salmeterol Xinafoate DISKUS 50 microg bid or Oral Montelukast 10 mg qd</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with mild persistent asthma</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with moderate persistent asthma</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with severe persistent asthma</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>19 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="204531"><Indications><Indication>Seasonal allergic rhinitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Histamine H1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action><Action>Systemic antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Buccal formulation systemic</Technology><Technology>Capsule formulation</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Oral controlled release formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2014-07-22T00:00:00Z</DateChangeLast><DateEnd>1998-01-19T00:00:00Z</DateEnd><Identifiers><Identifier>FLTA4004</Identifier></Identifiers><IndicationsAdverse><Indication>Back pain</Indication><Indication>Bronchitis</Indication><Indication>Constipation</Indication><Indication>Contact dermatitis</Indication><Indication>Cough</Indication><Indication>Diarrhea</Indication><Indication>Epistaxis</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Sunburn</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>fluticasone propionate alone</Intervention><Intervention>loratadine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>333</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In December 2005, results were published. The percentage of patients with adverse events in the PBO, FP and LOR groups was 24, 29 and 24%. The most common adverse events reported were epistaxis, common &lt;b&gt;cold&lt;/b&gt;, upper respiratory tract infection, sore throat, blood in nasal mucus, otitis media, sinusitis, pharyngitis, nasal irritation, nasal discomfort, nasal burning, exacerbation of pressure in sinus, thick feeling in throat, hoarseness, headache, dizziness, migraine, entrapment of nerve in neck, insomnia</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of nasal congestion</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of nasal itching</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of rhinorrhoea</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of sneezing</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Ocular/Non Nasal Symptoms</EndpointIndex><EndpointIndex>Allergic rhinitis - Physician Global Assessment of Disease Activity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>European Ancestry</Term></TermsPatientSelection><TitleDisplay>A Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Efficacy and Safety Outcomes of Fluticasone Propionate Aqueous Nasal Spray Versus Encapsulated Loratadine Tablets Versus Placebo for 4 Weeks in Subjects with Seasonal Allergic Rhinitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Seasonal Allergic Rhinitis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="204373"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Leukotriene D4 antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action><Action>Beta adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Daily dosing</Technology><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2014-08-25T00:00:00Z</DateChangeLast><DateEnd>1999-09-08T00:00:00Z</DateEnd><DateStart>1999-01-15T00:00:00Z</DateStart><Identifiers><Identifier>SMS40004</Identifier></Identifiers><IndicationsAdverse><Indication>Back pain</Indication><Indication>Bronchitis</Indication><Indication>Common cold</Indication><Indication>Cough</Indication><Indication>Diarrhea</Indication><Indication>Dizziness</Indication><Indication>Emesis</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Influenza virus infection</Indication><Indication>Nasal congestion</Indication><Indication>Sinusitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>montelukast sodium alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>salmeterol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>467</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>adverse events that were reported during the study in salmeterol xinafoate and montelukast groups were, headache (11 and 9%), upper respiratory tract infection (9 and 11%), sore throat (7 and 9%), cough (4 and 5%), diarrhea (4 and 1%), common &lt;b&gt;cold&lt;/b&gt; (3 and 6%), &lt;b&gt;cold&lt;/b&gt; symptoms (3 and 4%), back pain (3 and 2%), nasal sinus infection (3 and 2%), influenza (2 and 3%), sinusitis (2 and 2%), fever (2 and 1%), nasal congestion (2 and 1%), gastric upset (2 and 2%), vomiting (2 and 2%), bronchitis (1 and 3%), dizziness</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score - Daytime asthma symptom score</EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score - Nighttime asthma symptom score</EndpointIndex><EndpointIndex>Asthma - Assessment of Peak Expiratory Flow/Flow Rate (PEFR) - Assessment of morning/evening PEFR</EndpointIndex><EndpointIndex>Asthma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Asthma - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments - Assessment of patient satisfaction</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Randomized, Double-Blind, Double-Dummy, Parallel Group Comparison of Salmeterol Xinafoate Inhalation Powder (50 mcg BID) With Oral Montelukast (10 mg QD) in Subjects With Persistent Asthma Symptomatic on Concomitant Inhaled Corticosteroid Therapy</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with moderate persistent asthma</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with severe persistent asthma</PatientSegment><PatientSegment>Asthma - Subjects with Symptomatic Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Peak expiratory flow rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>7 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="204060"><Indications><Indication>Cardiopulmonary bypass surgery</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anxiolytic</Action><Action>General anesthetic</Action><Action>Hypnotic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Injectable emulsion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>National Institute for Health Research (NIHR)</Company></CompaniesCollaborator><CompaniesSponsor><Company>University Hospitals Bristol NHS Foundation Trust</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2019-05-04T00:00:00Z</DateChangeLast><DateEnd>2016-12-31T00:00:00Z</DateEnd><DateStart>2010-02-15T00:00:00Z</DateStart><Identifiers><Identifier>2009-015779-28</Identifier><Identifier>CS/2008/3029</Identifier><Identifier>ISRCTN84968882</Identifier><Identifier>ProMPT</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>propofol, AstraZeneca/Fresenius alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>96</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>allocated to either: Control: cardioplegia with placebo (intralipid) supplementation. Warm blood cardioplegia would be used for CABG participants and &lt;b&gt;cold&lt;/b&gt; blood cardioplegia for patients having AVR. Intervention: cardioplegia with propofol supplementation (6 microg/ml). Warm blood cardioplegia would be used for patients having isolated CABG and &lt;b&gt;cold&lt;/b&gt; blood cardioplegia for participants having AVR. Method of administration would be through either antegrade or retrograde cardioplegia delivery according</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Adverse Events - Renal dysfunction/Complications/Requirement for dialysis</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiac Markers - Troponin T (TnT) elevation</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Fatal MI/Non-fatal MI</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - 8-isoprostane (8-iso-prostaglandin (PG)f2a)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of interleukins</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of serum cytokines</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates - Assessment of all cause mortality</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Renal Function</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Fatal /Non-fatal stroke</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Coronary artery disease - Hematological Assessments</EndpointIndex><EndpointIndex>Coronary artery disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment of European Quality of Life Questionnaire (EuroQol: EQ-5D)</EndpointIndex><EndpointIndex>Coronary artery disease - Patient Reported Outcomes/Quality of Life Assessments - Minnesota living with heart failure questionnaire</EndpointIndex><EndpointIndex>Coronary artery disease - Protocol Specified Other Endpoints - Pharmacogenomics/Proteomics Study</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ProMPT: Propofol Cardioplegia for Myocardial Protection Trial</TitleDisplay><PatientSegmentTerms><PatientSegment>Coronary artery disease - Subjects Undergoing /Underwent Major Cardiac Intervention - Cardiac valve surgery</PatientSegment><PatientSegment>Coronary artery disease - Subjects Undergoing /Underwent Major Cardiac Intervention - On pump coronary artery bypass grafting (CABG)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>8-Epi-prostaglandin F2 alpha </BiomarkerName><BiomarkerName> Complement C3a </BiomarkerName><BiomarkerName> Complement C5a </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Interleukin-10 </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Lactic Acid </BiomarkerName><BiomarkerName> Neutrophil gelatinase-associated lipocalin </BiomarkerName><BiomarkerName> Troponin T, cardiac muscle </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>82 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Alan Bryan</Name></ContactNames></Trial><Trial Id="201913"><Indications><Indication>Topical anesthesia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Adrenergic receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Injectable formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Albert Einstein Healthcare Network</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2014-08-01T00:00:00Z</DateEnd><DateStart>2012-08-31T00:00:00Z</DateStart><Identifiers><Identifier>HN 4405</Identifier><Identifier>NCT01673061</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>vapocoolant alone</Intervention><Intervention>epinephrine plus lidocaine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>21</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Lack of Efficacy</Reason></ReasonForTrialDiscontinuation><Teaser> Age&amp;lt; 18 years Unable to consent Pregnant or breastfeeding Prisoner or in police custody Known sensitivity to vapocoolant or lidocaine &lt;b&gt;Cold&lt;/b&gt; hypersensitivity Chronic steroid use Peripheral neuropathy Diabetes HIV Malignancy Immunosuppressive state Sickle cell disease Sarcoidosis Abscess &gt; 2 cm in any dimension Abscess requiring procedural sedation and analgesia for incision and drainage</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bacterial skin infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment of acceptability of therapy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage</TitleDisplay><PatientSegmentTerms><PatientSegment>Bacterial skin infection - Subjects with Uncomplicated Skin and Skin Structure Infections - Subjects with uncomplicated/superficial skin abscess</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with pain associated with infections</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with pain due to dermatological conditions</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2014-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Joseph D'Orazio, MD</Name><Name>Kathia Damiron</Name></ContactNames></Trial><Trial Id="201148"><ActionsPrimaryInterventionsPrimary><Action>Benzodiazepine receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anxiolytic</Action><Action>General anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Injectable formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fred Hutchinson Cancer Research Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-04-18T00:00:00Z</DateChangeLast><DateEnd>2008-08-31T00:00:00Z</DateEnd><DateStart>2006-11-30T00:00:00Z</DateStart><Identifiers><Identifier>2040.00</Identifier><Identifier>CDR0000551927</Identifier><Identifier>IR-6130</Identifier><Identifier>NCT00499460</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>oxycodone hydrochloride alone</Intervention><Intervention>Variable regimens including digoxin , garlic , midazolam hydrochloride , oxycodone hydrochloride</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>15</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>concentrations of oxycodone and its metabolites would be measured by LC-MS. Response to experimentally induced pain by the &lt;b&gt;Cold&lt;/b&gt; Pressor Test (CPT) would be assessed at baseline and periodically after oxycodone treatment. Subjective ratings of opioid...50 beats per min No abnormal cardiac rhythm by EKG No unusually sensitive response or resistance to pain stimulation (&lt;b&gt;Cold&lt;/b&gt;&amp;nbsp;Pressor&amp;nbsp;Test) Must be right handed No color blindness No history of learning disabilities or dyslexia Must be literate</Teaser><TrialCategories><Category>Herbal preparation</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Effects of Garlic Supplements on Opioids in Healthy Volunteers</TitleDisplay><BiomarkerNames><BiomarkerName>Cytochrome P450 3A4 </BiomarkerName><BiomarkerName> Multidrug resistance protein 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Danny D Shen, PhD</Name></ContactNames></Trial><Trial Id="200642"><Indications><Indication>Hypothermia</Indication></Indications><CompaniesSponsor><Company>Medical University of Vienna</Company></CompaniesSponsor><Countries><Country>Austria</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2011-01-31T00:00:00Z</DateEnd><DateStart>2008-05-31T00:00:00Z</DateStart><Identifiers><Identifier>FAEWPP</Identifier><Identifier>NCT00555126</Identifier><Identifier>POLYTRAUMA-007</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Forced Air Warming alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Warming with endovascular catheter + forced air warming alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Suspended</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Patient Enrollment Issues</Reason></ReasonForTrialDiscontinuation><Teaser>The purpose of the study was to test the hypothesis that fast, perioperative warming with an endovascular catheter versus forced air warming may improve patient outcome (primary outcome: combined perioperative morbidity, secondary outcome: bleeding, infection).</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Factorial Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>FAEWPP: Forced Air Versus Endovascular Warming in Polytrauma Patients</TitleDisplay><PrimaryCompletionDate type="Anticipated">2011-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Oliver Kimberger, M.D.</Name></ContactNames></Trial><Trial Id="199925"><Indications><Indication>Allergic rhinitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Alpha 1 adrenoceptor agonist</Action><Action>Histamine H1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Decongestant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Oral controlled release formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Sanofi SA</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2018-05-11T00:00:00Z</DateChangeLast><DateEnd>2014-06-30T00:00:00Z</DateEnd><DateStart>2014-06-30T00:00:00Z</DateStart><Identifiers><Identifier>FEXHYL06934</Identifier><Identifier>NCT02175485</Identifier><Identifier>U1111-1152-0373</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>fexofenadine + pseudoephedrine (once-daily, ProSlo II), aaiPharma/sanofi-aventis alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>24</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>inflammation (acute rhinitis, chronic rhinitis, congestive rhinitis, atrophic rhinitis, purulent nasal discharge, sinusitis in the presence of &lt;b&gt;cold&lt;/b&gt;-like, etc) on the day of treatment exposure Patients who have taken any of the following medications that may...drops, eye drops, injection, and topical use), anticholinergic agents, vasoconstrictor nose drops, antihistamine-containing &lt;b&gt;cold&lt;/b&gt; remedies, agents that can be expected to have an antiallergic/antihistaminic effect (including Chinese medicines and</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of nasal congestion</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of nasal itching</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of sneezing</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Therapy Related Outcomes - Assessment of other efficacy parameters</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>Evaluation of Efficacy of Dellegra in Exposure Unit</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Seasonal Allergic Rhinitis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-06-30T00:00:00Z</PrimaryCompletionDate><NumberOfSites>1</NumberOfSites><ContactNames><Name>Clinical Sciences &amp; Operations</Name></ContactNames></Trial><Trial Id="199336"><Indications><Indication>Common cold</Indication></Indications><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2014-07-07T00:00:00Z</DateChangeLast><DateEnd>2011-04-30T00:00:00Z</DateEnd><DateStart>2011-02-28T00:00:00Z</DateStart><Identifiers><Identifier>C6930943</Identifier><Identifier>NCT01466348</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>paracetamol alone</Intervention><Intervention>caffeine plus paracetamol</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>49</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>lactation Hypersensitivity to drugs Have taken caffeine in the last 12 h or treated their &lt;b&gt;cold&lt;/b&gt;... Present with symptoms of the common &lt;b&gt;cold&lt;/b&gt; of no &amp;gt; 96 h duration Score of &amp;gt;/= 2 on a self-rating for malaise and at least 4 other &lt;b&gt;cold&lt;/b&gt; symptoms...cognitive function and mood assessment in subjects suffering from the common &lt;b&gt;cold&lt;/b&gt;, when taking a novel paracetamol and caffeine combination verses paracetamol alone</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effects of a Common Cold Treatment on Cognitive Function</TitleDisplay><PrimaryCompletionDate type="Actual">2011-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>2 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="199254"><Indications><Indication>Pain</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Rigshospitalet, Denmark</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2018-07-05T00:00:00Z</DateChangeLast><DateEnd>2014-07-31T00:00:00Z</DateEnd><DateStart>2014-06-30T00:00:00Z</DateStart><Identifiers><Identifier>2014-001752-31</Identifier><Identifier>NCT02172729</Identifier><Identifier>SM1-PJ-14</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lidocaine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>14</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The objective of the study was to investigate whether increased dose of local anesthetic ( lidocaine ) increases duration of peripheral nerve block (adductor canal block) and to develop a model for assessing duration of peripheral nerve blockades. The study hypothesis was that increasing the dose of lidocaine (by increased concentration) would increase the duration of an adductor canal block. The study was a follow up on an identical study (SM1-PJ-13, EudraCT number: 2013-001822-24 [ 150472</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Assessment of duration of block</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>The Effect of Different Doses (Mass) of Local Anesthetic on Duration of Adductor Canal Block in Healthy Subjects-Part 2</TitleDisplay><PrimaryCompletionDate type="Actual">2014-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>1 Month</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jørgen B Dahl, Professor</Name><Name>Pia Jæger, MD</Name></ContactNames></Trial><Trial Id="199134"><Indications><Indication>Rhinitis</Indication></Indications><CompaniesSponsor><Company>Universitaire Ziekenhuizen Leuven</Company></CompaniesSponsor><Countries><Country>Belgium</Country></Countries><DateChangeLast>2018-06-30T00:00:00Z</DateChangeLast><DateEnd>2011-09-30T00:00:00Z</DateEnd><DateStart>2011-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01223820</Identifier><Identifier>Nasal Capsaicin treatment</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>capsaicin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>36</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to evaluate the neuro-immunological analysis of both idiopathic rhinitis and healthy control subjects treated with capsaicin. The hypothesis was that nasal capsaicin treatment had reduced neurogenic inflammation, which inturn reduced the nasal symptoms.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Neuro-immunological Analysis of Idiopathic Rhinitis Subjects and Controls Treated With Capsaicin</TitleDisplay><PrimaryCompletionDate type="Actual">2011-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Laura H Van Gerven, MD</Name><Name>Peter W Hellings, MD, PhD</Name></ContactNames></Trial><Trial Id="198493"><Indications><Indication>Atelectasis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Duke University</Company></CompaniesSponsor><DateChangeLast>2015-03-06T00:00:00Z</DateChangeLast><DateEnd>2012-07-31T00:00:00Z</DateEnd><DateStart>2010-12-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02168387</Identifier><Identifier>PRO00026503</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Continuous high frequency oscillator (CHFO) alone</Intervention><Intervention>acetylcysteine alone</Intervention><Intervention>dornase alfa alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>39</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to evaluate whether a therapy that uses a machine called a continuous high frequency oscillator (CHFO) is more successful at removing mucus than medications that thin out the mucus. The aim of this research study was to test whether children with atelectasis on a ventilator were more likely to improve with mechanical removal of their mucus with the CHFO as compared with medications that thin out the mucus.</Teaser><TrialCategories><Category>Biological</Category><Category>Medical device</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy of Percussive Ventilation Therapy (MetaNeb) Compared With Mucolytic Agents for Atelectasis in the Mechanically Ventilated Pediatric Patient</TitleDisplay><BiomarkerNames><BiomarkerName>Lung</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>19 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Ira Cheifetz, MD</Name></ContactNames></Trial><Trial Id="197758"><Indications><Indication>Hypersensitivity</Indication></Indications><CompaniesSponsor><Company>Korean Society of Ginseng</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2018-01-30T00:00:00Z</DateChangeLast><DateEnd>2014-03-31T00:00:00Z</DateEnd><DateStart>2012-10-31T00:00:00Z</DateStart><Identifiers><Identifier>KHNMC-OH-IRB 2012-004</Identifier><Identifier>NCT01664156</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Korean red ginseng alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Female aged 16 to 60 years Women complaining &lt;b&gt;cold&lt;/b&gt; hypersensitivity on hands and feet Thermal deviation between the palm and the upper arm is &amp;gt; 0.3degC...on &lt;b&gt;cold&lt;/b&gt; hypersensitivity of hands and feet in women. To establish scientific evidence for the use of Korean red ginseng by investigating changes of infrared thermography. The hypothesis was that Korean red ginseng would reduce &lt;b&gt;cold&lt;/b&gt; hypersensitivity</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Female</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Effect of Korean Red Ginseng on Women With Cold Hypersensitivity of Hands and Feet</TitleDisplay><BiomarkerNames><BiomarkerName>Heart rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>JIN-MOO LEE, Ph. D</Name></ContactNames></Trial><Trial Id="19761"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-15T00:00:00Z</DateChangeLast><DateEnd>2011-06-30T00:00:00Z</DateEnd><DateStart>2007-10-31T00:00:00Z</DateStart><Identifiers><Identifier>MI-MA162</Identifier><Identifier>NCT00569894</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>29296</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to assess the safety of FluMist vaccination.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>A Postmarketing Study to Evaluate the Safety of FluMist in Children</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children - Children less than 5 years of age</PatientSegment><PatientSegment>Influenza virus infection - Children - Children less than 5 years of age</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>44 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Seth Toback, M.D.</Name></ContactNames></Trial><Trial Id="196306"><Indications><Indication>Hypothermia</Indication></Indications><CompaniesSponsor><Company>University of Leipzig</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2017-05-17T00:00:00Z</DateChangeLast><DateEnd>2010-01-31T00:00:00Z</DateEnd><DateStart>2008-04-30T00:00:00Z</DateStart><Identifiers><Identifier>COOL</Identifier><Identifier>COOL-TRIAL</Identifier><Identifier>NCT00843297</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Arctic Sun alone</Intervention><Intervention>CoolGard alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Consecutive patients with restoration of spontaneous circulation (ROSC) after resuscitation due to out-of-hospital SCA, admitted to our intensive care unit, underwent MIH. Hypothermia was induced by infusion of &lt;b&gt;cold&lt;/b&gt; saline and whole-body-cooling methods (electronic randomization: invasive CoolGard or non-invasive Arctic Sun). The core body temperature was operated at 32 to 34degC over a period of 24 h followed by active rewarming. Neurological status was evaluated at hospital discharge and 6 months</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>COOL: COOL-Trial: Outcome With Invasive and Non-invasive Cooling After Cardiac Arrest</TitleDisplay><BiomarkerNames><BiomarkerName>Gamma enolase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Holger Thiele, Associate Professor</Name><Name>Undine Pittl, MD</Name></ContactNames></Trial><Trial Id="195799"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Daily dosing</Technology><Technology>Oral formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>Taiwan</Country><Country>South Korea</Country></Countries><DateChangeLast>2019-03-06T00:00:00Z</DateChangeLast><DateEnd>2016-12-22T00:00:00Z</DateEnd><DateStart>2014-06-26T00:00:00Z</DateStart><Identifiers><Identifier>506-MA-1001</Identifier><Identifier>NCT02161237</Identifier><Identifier>OPTIMIZE</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tacrolimus (oral sustained-release), Astellas alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>73</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Receiving or having previously received an organ transplant other than a kidney &lt;b&gt;Cold&lt;/b&gt; ischemia time of the donor kidney&gt; 24 h Receiving a graft from a non-heart-beating donor other than of Maastricht category 3 Significant liver disease Receiving a graft from a hepatitis C or B positive donor Requiring on-going dosing with a systemic</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Glomerular Filtration Rate (GFR) - Assessment of Estimated Glomerular Filtration Rate(eGFR)/Creatinine Clearance(CCr/CrCl/CLcr)</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Survival</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Transplantation</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Vital Signs</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>OPTIMIZE: Asian Study to Investigate Safety and Efficacy of Optimized Dosing of Advagraf in Kidney Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Kidney Transplant Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-12-22T00:00:00Z</PrimaryCompletionDate><TrialDuration>29 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Medical Director</Name></ContactNames></Trial><Trial Id="195579"><Indications><Indication>Allergic conjunctivitis</Indication></Indications><CompaniesCollaborator><Company>University of Worcester</Company></CompaniesCollaborator><CompaniesSponsor><Company>The University of Aston In Birmingham</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2017-05-03T00:00:00Z</DateChangeLast><DateEnd>2013-02-28T00:00:00Z</DateEnd><DateStart>2012-03-31T00:00:00Z</DateStart><Identifiers><Identifier>ALLERGY12</Identifier><Identifier>NCT01569191</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Non-pharmaceutical tear supplement (hypromellose) alone</Intervention><Intervention>cold compresses (CC) alone</Intervention><Intervention> Elestat (epinastine HCl ophthalmic solution) 0.05% alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>18</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Subjects would receive artificial tear supplement (hypromellose) or &lt;b&gt;cold&lt;/b&gt; compresses (CC) in which eye gel mask blue placed over the closed eyes or &amp;nbsp;Elestat (epinastine...with &lt;b&gt;cold&lt;/b&gt; compress combined with ATs or EH (p &amp;lt; 0.05). a similar cooling effect was reported with &lt;b&gt;cold&lt;/b&gt; compress combined with ATs or EH (p... Investigators aimed to examine the efficacy of artificial tear supplements (ATS) and &lt;b&gt;cold&lt;/b&gt; compresses (CC) alone, in comparison to anti-allergic</Teaser><TrialCategories><Category>Hospital solutions</Category><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic conjunctivitis - Assessment of Conjunctivitis Symptoms</EndpointIndex><EndpointIndex>Allergic conjunctivitis - Assessment of ocular function - Assessment of biomicroscopy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic conjunctivitis - Subjects with Acute Allergic Conjunctivitis</PatientSegment><PatientSegment>Allergic conjunctivitis - Subjects with Allergic Rhinoconjunctivitis</PatientSegment><PatientSegment>Allergic conjunctivitis - Subjects with Asymptomatic Allergic Conjunctivitis</PatientSegment><PatientSegment>Allergic conjunctivitis - Subjects with Seasonal Allergic Conjunctivitis(SAC)</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>11 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>James Wolffsohn</Name><Name>Louise Robertson</Name><Name>Paramdeep Bilkhu</Name><Name>Roy Kennedy</Name></ContactNames></Trial><Trial Id="195175"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Northwestern University</Company><Company>US Department of Defense</Company></CompaniesCollaborator><CompaniesSponsor><Company>Rehabilitation Institute Of Chicago</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-06-30T00:00:00Z</DateChangeLast><DateEnd>2014-12-31T00:00:00Z</DateEnd><DateStart>2012-05-31T00:00:00Z</DateStart><Identifiers><Identifier>DOD_PAP 12</Identifier><Identifier>NCT01632709</Identifier><Identifier>PPAP</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>bupivacaine, AstraZeneca alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>16</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>sensory stimulation tests (such as vibration and pinprick tests), some questionnaires about health and pain history, hot and &lt;b&gt;cold&lt;/b&gt; sensory tests, and thermal pictures of body would be taken before and after receiving a quick electrical stimulus. Subjects...4 weeks after your second visit. Subjects would have the same questionnaires as during the first and second visits, sensory tests, hot and &lt;b&gt;cold&lt;/b&gt; temperature testing and thermal pictures would be taken before and after a quick electrical stimulus.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures - Imaging assessments</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Quantitative sensory testing</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by diary scores</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PPAP: Pathophysiology of Post Amputation Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>31 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Amy Kirsling</Name><Name>Norman Harden, M.D.</Name></ContactNames></Trial><Trial Id="194997"><Indications><Indication>Common cold</Indication><Indication>Influenza virus infection</Indication></Indications><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-11-26T00:00:00Z</DateChangeLast><DateEnd>2011-06-30T00:00:00Z</DateEnd><DateStart>2011-05-31T00:00:00Z</DateStart><Identifiers><Identifier>C7591227</Identifier><Identifier>NCT01332578</Identifier></Identifiers><IndicationsAdverse><Indication>Blepharospasm</Indication><Indication>Headache</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>paracetamol + hot drink alone</Intervention><Intervention>paracetamol alone</Intervention><Intervention>Variable regimens including ascorbic acid , paracetamol , phenylephrine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>25</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> The study was designed to investigate whether paracetamol from a hot remedy reaches the plasma faster than standard paracetamol tablets. The study would also assess the gastrointestinal transit of two oral &lt;b&gt;cold&lt;/b&gt; and influenza ('flu') formulations using gamma scintigraphy.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza virus infection - Elderly Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>1 Month</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Cheri Hudson</Name><Name>GSK Clinical Trials</Name><Name>Howard Stevens</Name></ContactNames></Trial><Trial Id="192945"><Indications><Indication>Diabetic peripheral neuropathy</Indication></Indications><CompaniesSponsor><Company>Lorenz Biotech S.P.A</Company></CompaniesSponsor><Countries><Country>France</Country><Country>Italy</Country><Country>Germany</Country></Countries><DateChangeLast>2018-12-16T00:00:00Z</DateChangeLast><DateEnd>2010-04-30T00:00:00Z</DateEnd><DateStart>2006-05-31T00:00:00Z</DateStart><Identifiers><Identifier>EuropeanFREMS</Identifier><Identifier>NCT01628627</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Aptiva device alone</Intervention><Intervention>Frequency Modulated Neural Stimulation alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>164</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> m/s) and sural (0.80 +/- 1.08 versus -0.91 +/- 1.13 m/s). Day and night pain was significantly reduced by FREMS however it was measurable by VAS only immediately after each treatment but not form 3 months after treatment.Significant improvement in &lt;b&gt;cold&lt;/b&gt; sensation threshold and non-significant differences in vibration and warm sensation thresholds were observed in the FREMS group when compared to the placebo [ 1565920 ].</Teaser><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Pain - Assessment of Pain Intensity</EndpointIndex><EndpointIndex>Diabetic complication - Neurological Assessments</EndpointIndex><EndpointIndex>Diabetic complication - Neurological Assessments - Nerve conduction assessments</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Diabetic complication - Protocol Specified Other Endpoints - Assessment of prescription changes/rescue medication uses</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Safety and Tolerability - Assessment of adverse effects</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Neurological Assessments</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Neurological Assessments - Nerve conduction assessments</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropathic Pain - Based on Michigan Diabetic Neuropathy Scale</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Electrodiagnostic testing</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Quantitative sensory testing</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Frequency Modulated Neural Stimulation (FREMS) in Symptomatic Diabetic Neuropathy</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy</PatientSegment><PatientSegment>Insulin dependent diabetes - Subjects with Good Glycemic Control</PatientSegment><PatientSegment>Insulin dependent diabetes - Subjects with Moderate Glycemic Control</PatientSegment><PatientSegment>Insulin dependent diabetes - Subjects with Poor/Inadequate Glycemic Control</PatientSegment><PatientSegment>Insulin dependent diabetes - Subjects with Specified Duration of Disease - Subjects with more than 1 year of diabetes mellitus</PatientSegment><PatientSegment>Insulin dependent diabetes - Subjects with diabetic neuropathy</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Good Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic neuropathy</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain - Subjects with diabetic neuropathy</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>47 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Emanuele Bosi</Name></ContactNames></Trial><Trial Id="192021"><Indications><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>Catholic University of Korea</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2018-08-11T00:00:00Z</DateChangeLast><DateEnd>2011-08-31T00:00:00Z</DateEnd><DateStart>2011-07-31T00:00:00Z</DateStart><Identifiers><Identifier>MOMO0910</Identifier><Identifier>NCT01606046</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Emla (lidocaine and prilocaine) alone</Intervention><Intervention>vapocoolant spray alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>99</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Those who refused to participate in the experiment Those who were unable to understand a VAS and Likert scale Those with a history of allergic reaction to vapocoolant spray or lidocaine Those with a history of &lt;b&gt;cold&lt;/b&gt; intolerance (Raynaud's syndrome, etc) Those who took oral pain medications or used topical anesthetics within 24 h of the experiment Those who exhibited abnormal lower extremity sensation during the physical examination or who showed pain on gastrocnemius</Teaser><TrialCategories><Category>Medical device</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Comparison of the Effects of Vapocoolant Spray and EMLA Cream on Pain During Needle Electromyography</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects in need of Procedural Analgesia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>1 Month</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>SangHyun Kim, Professor</Name></ContactNames></Trial><Trial Id="191459"><Indications><Indication>Common cold</Indication></Indications><CompaniesSponsor><Company>Bayer AG</Company></CompaniesSponsor><Countries><Country>Italy</Country></Countries><DateChangeLast>2019-01-29T00:00:00Z</DateChangeLast><DateEnd>2007-06-30T00:00:00Z</DateEnd><DateStart>2005-10-31T00:00:00Z</DateStart><Identifiers><Identifier>11756</Identifier><Identifier>EUDRACT: 2004-004683-71</Identifier><Identifier>NCT01033526</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>acetylsalicylic acid plus ascorbic acid</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>388</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Age between 18 and 65 years Onset of &lt;b&gt;cold&lt;/b&gt; symptoms within 48 h before screening Objective symptoms of common &lt;b&gt;cold&lt;/b&gt; Subjective symptoms of common &lt;b&gt;cold&lt;/b&gt;...dose, placebo-controlled parallel groups study evaluating efficacy and tolerability of 800 mg acetylsalicylic acid in adult patients with a common &lt;b&gt;cold&lt;/b&gt; during a 2 h in patient phase; and a follow-up period of 5 days of home treatment as required</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Symptomatic Treatment of Common Cold Symptoms</TitleDisplay><PrimaryCompletionDate/><TrialDuration>20 Months</TrialDuration><NumberOfSites>28</NumberOfSites><ContactNames><Name>Bayer Study Director</Name></ContactNames></Trial><Trial Id="19054"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Genentech Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-03-07T00:00:00Z</DateChangeLast><DateEnd>2008-11-30T00:00:00Z</DateEnd><DateStart>2008-02-20T00:00:00Z</DateStart><Identifiers><Identifier>NCT00434278</Identifier><Identifier>TOPIC</Identifier><Identifier>Z3877g</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dornase alfa alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>27</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>A multicenter, randomized, double-blind, placebo-controlled study of subjects with stable CF who would be randomized to continue treatment with Pulmozyme or be withdrawn for 2 weeks. Subjects whose CF symptoms are stable without any change in therapy for 2 weeks prior to enrollment would be eligible for participation.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Volume in One Second (FEV1) - Assessment of change from baseline in FEV1</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Vital Capacity (FVC) - Assessment of change from baseline in FVC</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Functional Disability/Physical Function - Assessment of physical activity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TOPIC: A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Cystic Fibrosis Subjects with Lung Manifestation - Subjects with abnormal FEV1 Values</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with H/O or Scheduled For Treatment of Cystic Fibrosis - Subjects on/Scheduled for rehabilitation therapy</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with H/O or Scheduled For Treatment of Cystic Fibrosis - Subjects on/Scheduled for treatment with Medications</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with gene variants - CFTR_HUMAN_Mutation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Actins </BiomarkerName><BiomarkerName> Elastase-1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>40</NumberOfSites><ContactNames><Name>Michelle Freemer, M.D.</Name></ContactNames></Trial><Trial Id="189828"><Indications><Indication>Upper respiratory tract infection</Indication></Indications><CompaniesCollaborator><Company>Research Fund for the Control of Infectious Disease</Company></CompaniesCollaborator><CompaniesSponsor><Company>The University of Hong Kong</Company></CompaniesSponsor><Countries><Country>Hong Kong</Country></Countries><DateChangeLast>2017-11-17T00:00:00Z</DateChangeLast><DateEnd>2007-06-30T00:00:00Z</DateEnd><DateStart>2005-06-30T00:00:00Z</DateStart><Identifiers><Identifier>HKUCTR-6</Identifier><Identifier>NCT00887172</Identifier><Identifier>UW 05-026 T/689</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Jing Fang Bai Du san alone</Intervention><Intervention>Ying Qiao san alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>327</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Patients would be ramdomized into: group A (Wind-&lt;b&gt;cold&lt;/b&gt; syndrome) and group B (Wind-heat syndrome). Patients in group A (Wind-&lt;b&gt;cold&lt;/b&gt; syndrome) would be randomized to receive the Jing Fan Bai Du san or placebo. Patients in group B (Wind-heat syndrome) would be randomized to receive Ying Qiao san or placebo. Both group A and B treatments and placebo would be given in sachets of granules that are identical in appearance. Each patient would be required to return to the clinic for follow-up assessment by </Teaser><TrialCategories><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Trial of Chinese Herbal Medicine in the Treatment of Upper Respiratory Tract Infections (URTIs)</TitleDisplay><BiomarkerNames><BiomarkerName>Body temperature</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>24 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>HKUCTR Administrator</Name><Name>Prof. Cindy Lo-kuen Lam</Name></ContactNames></Trial><Trial Id="189628"><Indications><Indication>Sinusitis</Indication></Indications><CompaniesSponsor><Company>Montavit</Company></CompaniesSponsor><Countries><Country>Poland</Country><Country>Austria</Country></Countries><DateChangeLast>2018-01-22T00:00:00Z</DateChangeLast><DateEnd>2016-12-24T00:00:00Z</DateEnd><DateStart>2013-12-13T00:00:00Z</DateStart><Identifiers><Identifier>2013-002977-23</Identifier><Identifier>Tav02-13</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Tavipec alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>320</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>drug abuse likely to lead to uncooperative behavior History of psychiatric and/or neurological illness likely to lead to uncooperative behavior Participation in another clinical trial within 1 month Patients using medication for treatment of common &lt;b&gt;cold&lt;/b&gt; like symptoms (excluding nasal douche)</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of Tavipec versus Placebo in Patients with Acute Rhinosinusitis</TitleDisplay><PrimaryCompletionDate/><TrialDuration>36 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>clinical trial manager</Name></ContactNames></Trial><Trial Id="18952"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease modulator</Action><Action>Unspecified enzyme modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Recombinant enzyme</Technology></Technologies><CompaniesSponsor><Company>Hospital for Sick Children</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2018-06-30T00:00:00Z</DateChangeLast><DateEnd>2009-06-30T00:00:00Z</DateEnd><DateStart>2008-01-31T00:00:00Z</DateStart><Identifiers><Identifier>1000010903</Identifier><Identifier>NCT00557089</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dornase alpha (inhaled, AERx), Aradigm/Genentech alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>17</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study would assess whether rhDNase treatment improves ventilation inhomogeneity as assessed by lung clearance index (LCI) in patients with cystic fibrosis (CF).</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Flow (FEF) - Forced expiratory flow 25-75%</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Expiratory Volume in One Second (FEV1) - Assessment of FEV1 % predicted</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Forced Vital Capacity (FVC) - Assessment of FVC % predicted</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of exhaled nitric oxide</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function - Assessment by lung clearance index</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Safety and Tolerability - Assessment of adverse events/treatment emergent adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>The Effect of rhDNase on Ventilation Inhomogeneity in Patients With Cystic Fibrosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Cystic Fibrosis Subjects with Lung Manifestation</PatientSegment><PatientSegment>Cystic fibrosis - Pediatric Cystic Fibrosis Subjects</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis - Subjects with abnormal sweat test (sweat chloride &gt;60 mEq/liter)</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis - Subjects with mutation in the gene for CFTR protein</PatientSegment><PatientSegment>Cystic fibrosis - Subjects with gene variants - CFTR_HUMAN_Mutation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory flow </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Felix Ratjen, MD</Name></ContactNames></Trial><Trial Id="18883"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Genentech Inc</Company></CompaniesSponsor><DateChangeLast>2019-03-07T00:00:00Z</DateChangeLast><DateEnd>2009-05-01T00:00:00Z</DateEnd><DateStart>2008-06-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT00680316</Identifier><Identifier>Z4240g</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dornase alfa alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>3</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>This is a phase IV, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the effect of pulmozyme on pulmonary function, health-related quality of life (HRQOL), and respiratory symptoms in 3 to 5 year-old children with cystic fibrosis (CF). Approximately 40 patients were planned to be enrolled in this study. However, only three patients were eligible for random allocation and received treatment: one patient in the pulmozyme group and two patients in the placebo group</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function - Assessment of effort dependent lung function</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by CF_questionnaire_revised(CFQ_R)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study of Pulmozyme in 3 to 5 Year-Old Patients With Cystic Fibrosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Pediatric Cystic Fibrosis Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Michelle Freemer, M.D.</Name></ContactNames></Trial><Trial Id="188662"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Inactivated viral vaccine</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Intradermal formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Suspension</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>National Institute of Allergy and Infectious Diseases</Company></CompaniesCollaborator><CompaniesSponsor><Company>Stanford University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2014-12-31T00:00:00Z</DateEnd><DateStart>2011-08-31T00:00:00Z</DateStart><Identifiers><Identifier>1U19AI090019-01</Identifier><Identifier>NCT02141581</Identifier><Identifier>SLVP021 2011-2014</Identifier><Identifier>SU-21987- 2011</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention><Intervention>Fluzone alone</Intervention><Intervention>Intanza alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>86</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study is to investigate the responses to licensed trivalent, inactivated influenza vaccine (TIV) delivered by different routes: intramuscular (IM) Fluzone and intradermal (ID) Intanza and to the live, attenuated influenza vaccine (LAIV) FluMist administered intranasally -- all given to generally healthy male and female adult volunteers.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Plasmablast Trafficking and Antibody Response in Influenza Vaccination</TitleDisplay><BiomarkerNames><BiomarkerName>Plasma cells</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>40 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Cornelia L Dekker</Name><Name>Cornelia L Dekker, MD</Name><Name>Harry B Greenberg, MD</Name><Name>Mark M Davis</Name><Name>Xiaosong He</Name><Name>Xiaosong He, PhD</Name></ContactNames></Trial><Trial Id="186445"><Indications><Indication>Common cold</Indication></Indications><CompaniesSponsor><Company>McNeil AB</Company></CompaniesSponsor><Countries><Country>Belgium</Country></Countries><DateChangeLast>2018-01-22T00:00:00Z</DateChangeLast><DateEnd>2008-03-31T00:00:00Z</DateEnd><DateStart>2007-01-31T00:00:00Z</DateStart><Identifiers><Identifier>2006-000058-35</Identifier><Identifier>A7801002</Identifier><Identifier>NCT00378144</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Sinutab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>469</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Age &gt;/= 18 years Reported &lt;b&gt;cold&lt;/b&gt; symptoms beginning&amp;lt;/= 48 h prior to visit 1 Scored &gt;/= 2 for each of nasal congestion and headache using the Modified Jackson Subject Evaluation Scale Willing and able to comply with scheduled visits, treatment plan, and other study procedures Evidence</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR) - Assessment of time to response</EndpointIndex><EndpointIndex>Pain - Assessment of Social and Occupational Functioning</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of Sinutab on Subjects in the Setting of a Common Cold</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with other types of headache</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2008-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Elisabeth A Kruse, PhD</Name></ContactNames></Trial><Trial Id="185880"><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Inactivated viral vaccine</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Suspension</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>National Institute of Allergy and Infectious Diseases</Company></CompaniesCollaborator><CompaniesSponsor><Company>Stanford University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-09T00:00:00Z</DateChangeLast><DateEnd>2009-12-31T00:00:00Z</DateEnd><DateStart>2009-07-31T00:00:00Z</DateStart><Identifiers><Identifier>2U19AI057229-06</Identifier><Identifier>NCT02133781</Identifier><Identifier>SU-17218- 2009</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention><Intervention>Fluzone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This is an exploratory study using a strategy that has not been previously employed to investigate the effects of age and vaccine type on specific kinds of immune responses to licensed, 2009 to 2010 influenza vaccine in children and adults.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>Influenza virus infection - Patient Reported Outcomes/Quality of Life Assessments - Self-efficacy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>B-cell Immunity to Influenza (SLVP017)- Year 1, 2009</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza virus infection - Children</PatientSegment><PatientSegment>Influenza virus infection - Elderly Subjects</PatientSegment><PatientSegment>Influenza virus infection - Vaccination Naive Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Cornelia L Dekker, MD</Name><Name>Harry B Greenberg, MD</Name><Name>Mark M Davis, PhD</Name><Name>Xiaosong He, PhD</Name></ContactNames></Trial><Trial Id="185216"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>Cytotoxic T-lymphocyte protein-4 modulator</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>Somatostatin receptor agonist</Action><Action>T cell surface glycoprotein CD28 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer polyclonal antibody</Action><Action>Growth hormone release inhibitor</Action><Action>Immunosuppressant</Action><Action>Lymphocyte inhibitor</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody polyclonal</Technology><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Protein fusion</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Bristol-Myers Squibb Co</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of Wisconsin-Madison</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-06-19T00:00:00Z</DateChangeLast><DateEnd>2022-04-30T00:00:00Z</DateEnd><DateStart>2014-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2013-0672</Identifier><Identifier>BelatPilot</Identifier><Identifier>IM103-327</Identifier><Identifier>NCT02130817</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including Thymoglobulin , belatacept , dexamethasone , enteric-coated mycophenolate sodium, Novartis , immunoglobulin G , prednisone , tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>with a donor specific antibody (DSA) as deemed by the local PI to be associated with significant risk of rejection Patient has received an ABO incompatible donor kidney Recipients will be receiving a dual or en bloc kidney transplant Donor anticipated &lt;b&gt;cold&lt;/b&gt; ischemia is &gt; 30 h Recipient or donor is known to be seropositive for hepatitis C virus (HCV) or B virus (HBV) except for hepatitis B surface antibody positive. HCV seropositive patients with a negative HCV viral load testing may be included Recipient</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Assessment of risk of acute rejection</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival - Graft survival rate at 12 months (1 year) post-transplant</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Inflammatory &amp; Oxidative Stress Markers - Donor specific antibodies</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival - Patient survival at 1 year post-transplant</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections - Bk polyoma virus infection</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections - CMV infection</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications - New onset/post transplant diabetes mellitus</EndpointIndex><EndpointIndex>Kidney transplantation - Post Transplant Malignancies - Incidence of malignancy</EndpointIndex><EndpointIndex>Kidney transplantation - Post Transplant Malignancies - Post transplant lymphoproliferative disorder (PTLD)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>BelatPilot: Belatacept in Kidney Transplantation of Moderately Sensitized Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Expanded Criteria Donor (ECD) Renal Transplant Recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>95 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Arjang Djamali, M.D.</Name><Name>Lynn Jacobson, M.S.</Name></ContactNames></Trial><Trial Id="182649"><Indications><Indication>Common cold</Indication><Indication>Throat disease</Indication></Indications><CompaniesSponsor><Company>Bayer AG</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2014-12-19T00:00:00Z</DateChangeLast><DateEnd>2005-03-31T00:00:00Z</DateEnd><DateStart>2003-11-30T00:00:00Z</DateStart><Identifiers><Identifier>11381</Identifier><Identifier>NCT01465009</Identifier></Identifiers><InterventionsControlDisplay><Intervention>paracetamol alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>aspirin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>508</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Male and female patients Onset of common &lt;b&gt;cold&lt;/b&gt; within the past 5 days Current sore throat Confirmed presence of a tonsillo-pharyngitis...in treating the symptoms of sore throat associated with a common &lt;b&gt;cold&lt;/b&gt;. The study was designed to develop a treatment method against sore throat associated with a common &lt;b&gt;cold&lt;/b&gt; which would have more advantages for patients than the methods</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Respiratory disease related outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Placebo and Active-controlled Study to Compare the Efficacy of Aspirin and Paracetamol in Treatment of Sore Throat Associated With a Common Cold</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with pain associated with infections</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>16 Months</TrialDuration><NumberOfSites>8</NumberOfSites><ContactNames><Name>Bayer Study Director</Name></ContactNames></Trial><Trial Id="181776"><Indications><Indication>Pain</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticonvulsant agent</Action><Action>GABA modulator</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Canterbury District Health Board</Company><Company>University of Otago</Company></CompaniesSponsor><Countries><Country>New Zealand</Country></Countries><DateChangeLast>2016-08-08T00:00:00Z</DateChangeLast><DateStart>2014-04-09T00:00:00Z</DateStart><Identifiers><Identifier>14/CEN/41</Identifier><Identifier>ACTRN12614000379617</Identifier><Identifier>ANZCTR365581</Identifier><Identifier>U1111-1151-9675</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>gabapentin plus nortriptyline</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>150</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>This study aims to assess pre-operative factors which may contribute to the development of chronic post-surgical pain. In addition, two medications will be trialled to determine their efficacy in the prevention of chronic post-surgical pain.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Post-operative Pain</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>The Transition From Acute to Chronic Post-surgical Pain - A Prospective, Randomized, Controlled Trial of Two Medications (Nortriptyline and Gabapentin) in 150 Participants Undergoing Hip or Knee Replacement Surgery</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Acute Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Campbell MacLachlan</Name><Name>Edward Shipton</Name></ContactNames></Trial><Trial Id="181565"><Indications><Indication>Anesthesia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor mu agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>5-HT uptake inhibitor</Action><Action>Analgesic</Action><Action>Norepinephrine uptake inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug coating</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Universidad Autonoma de San Luis Potosi</Company></CompaniesSponsor><Countries><Country>Mexico</Country></Countries><DateChangeLast>2018-07-02T00:00:00Z</DateChangeLast><DateEnd>2014-10-31T00:00:00Z</DateEnd><DateStart>2014-04-30T00:00:00Z</DateStart><Identifiers><Identifier>CEIFE-008-014</Identifier><Identifier>NCT02110966</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including epinephrine , mepivacaine , tramadol hydrochloride</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>56</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Patients will be diagnosed with the &lt;b&gt;cold&lt;/b&gt; test and they will indicate their pain scores using numerical rating scale, this is a 11 point scale where the ends points are the extremes of no pain and the worst pain. Accordingly, no pain corresponded...min, the anesthetic blockade will be assessed by a three step examination: lip numbess, positive/negative response to &lt;b&gt;cold&lt;/b&gt; testing and clinical discomfort during endodontic access. Inferior alveolar nerve block success will be defined as the absence</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Assessment of duration of block</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Assessment of hospitalization - Assessment of number of emergency department visits</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Mepivacaine-Tramadol on the Success of Inferior Alveolar Nerve Block in Symptomatic Irreversible Pulpitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects in need of Procedural Analgesia</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with dental pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>6 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Amaury Pozos, MSc, PhD</Name><Name>Daniel Chavarria, MSc, PhD</Name><Name>Laura Rodríguez, DDS</Name></ContactNames></Trial><Trial Id="181444"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><CompaniesSponsor><Company>Assistance Publique Hopitaux de Paris</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2014-04-24T00:00:00Z</DateChangeLast><DateEnd>2006-10-31T00:00:00Z</DateEnd><DateStart>2003-08-31T00:00:00Z</DateStart><Identifiers><Identifier>ANTEAB</Identifier><Identifier>AOM01075</Identifier><Identifier>NCT00190437</Identifier><Identifier>P010310</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>amoxicillin + clavulanic acid alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>520</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> are those with documented or suspected &lt;b&gt;COLD&lt;/b&gt;, exclusive of other bronchial or lung disease, and admitted for acute exacerbation, in the absence of overt sepsis or broncho-pneumonia, and having no other organ...objective of this study was to evaluate the effectiveness of the precocious antibiotic therapy on the length of the respiratory symptoms with the admitted patients in polyvalent medical intensive care of chronic obstructive lung disease (&lt;b&gt;COLD&lt;/b&gt;).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation requiring medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>ANTEAB: A Study of Early Antibiotherapy in the ICU Management of Acute Exacerbations of COPD</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with disease related complications - Subjects with acute exacerbation of COPD/Infections</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2006-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>38 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Christian BRUN-BUISSON, Pr,MD,PhD</Name></ContactNames></Trial><Trial Id="180839"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Inactivated viral vaccine</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Suspension</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>University of Rochester</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2012-05-31T00:00:00Z</DateEnd><DateStart>2010-08-31T00:00:00Z</DateStart><Identifiers><Identifier>25914</Identifier><Identifier>NCT01194297</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention><Intervention>Fluzone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>3</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Patient Enrollment Issues</Reason></ReasonForTrialDiscontinuation><Teaser>The specific aim of this project was to compare the immune response and reactions of trivalent, inactivated influenza vaccine ( Fluzone ) and live, attenuated, intranasal influenza vaccine ( FluMist ) in groups of former premature, very low birth weight and former full-term infants (FT) aged 24 to 35 months. Investigators hypothesized that the immune response in FT infants would be greater with FluMist than Fluzone , and that wheezing episodes would be no more than twice as frequent in FluMist as</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term Infants</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children - Children less than 5 years of age</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment><PatientSegment>Influenza virus infection - Children - Children less than 5 years of age</PatientSegment><PatientSegment>Influenza virus infection - Subjects with Prior Other Vaccination - Subjects with Prior Influenza Vaccination</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>B-lymphocytes </BiomarkerName><BiomarkerName> Immunoglobulin A </BiomarkerName><BiomarkerName> Interferon gamma </BiomarkerName><BiomarkerName> Interleukin-2 </BiomarkerName><BiomarkerName> Interleukin-4 </BiomarkerName><BiomarkerName> T-Lymphocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Carl T. D'Angio, MD</Name><Name>Elizabeth Werner</Name></ContactNames></Trial><Trial Id="180835"><Indications><Indication>Influenza virus infection</Indication></Indications><CompaniesSponsor><Company>National Cheng-Kung University Hospital</Company></CompaniesSponsor><Countries><Country>Taiwan</Country></Countries><DateChangeLast>2017-07-16T00:00:00Z</DateChangeLast><DateEnd>2014-06-30T00:00:00Z</DateEnd><DateStart>2013-10-31T00:00:00Z</DateStart><Identifiers><Identifier>A-BR-101-139</Identifier><Identifier>NCT02105519</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>AdimFlu-S alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> to eggs or egg protein or similar pharmacological effects to study medication Personal or family history of Guillain-Barre syndrome An acute febrile illness within 1 week prior to vaccination Current upper respiratory illness, including the common &lt;b&gt;cold&lt;/b&gt; or nasal congestion within 72 h Subjects with influenza-like illness as defined by the presence of fever (temperature &gt;/= 38degC) and at least two of the following four symptoms: headache, muscle/joint aches and pains (eg, myalgia/arthralgia), sore</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD)</PatientSegment><PatientSegment>Influenza Vaccine - Elderly Subjects</PatientSegment><PatientSegment>Influenza Vaccine - Subjects with Prior Other Vaccination - Subjects with Prior Influenza Vaccination</PatientSegment><PatientSegment>Influenza Vaccine - Subjects with comorbid conditions - Subjects with renal disorders/diseases/dysfunction</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2014-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>An-Bang Wu</Name><Name>Chin-Chung Tseng</Name><Name>Junne-Ming Sung</Name><Name>Ming-Cheng Wang</Name><Name>Wei-Hung Lin</Name><Name>Yu-Tzu Chang</Name></ContactNames></Trial><Trial Id="178385"><Indications><Indication>Asthma</Indication><Indication>Respiratory tract infection</Indication></Indications><CompaniesSponsor><Company>Kecioren Education and Training Hospital</Company></CompaniesSponsor><Countries><Country>Turkey</Country></Countries><DateChangeLast>2018-01-18T00:00:00Z</DateChangeLast><DateEnd>2008-10-31T00:00:00Z</DateEnd><DateStart>2007-08-31T00:00:00Z</DateStart><Identifiers><Identifier>B100İEG0110001 - 2860</Identifier><Identifier>NCT00733226</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Broncho-Vaxom alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to determine whether OM-85 BV (Broncho-Vaxom) has any effect on respiratory infections, infection related wheezing attacks, beta-2 agonist use, duration of attacks and effect on serum cytokine levels.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Co-morbidity - Infection</EndpointIndex><EndpointIndex>Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Serum cytokines/interleukins/chemokines</EndpointIndex><EndpointIndex>Asthma - Assessment of Wheeze</EndpointIndex><EndpointIndex>Asthma - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex><EndpointIndex>Asthma - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Asthma - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Asthma - Assessment of use of Rescue Medication - Beta agonist usage</EndpointIndex><EndpointIndex>Asthma - Assessment of use of Rescue Medication - Duration of medication use</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Effect of OM-85 BV on Wheezing Related Morbidity in Children With Recurrent Wheezing</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with Symptomatic Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cytokines</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>C H RAZI, MD</Name><Name>C H Razi, MD</Name><Name>G Yilmaz</Name></ContactNames></Trial><Trial Id="177521"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>Somatostatin receptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>Somatostatin receptor agonist</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer polyclonal antibody</Action><Action>Growth hormone release inhibitor</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer polyclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Growth hormone release inhibitor</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody polyclonal</Technology><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Novartis AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Geral de Fortaleza</Company></CompaniesSponsor><Countries><Country>Brazil</Country></Countries><DateChangeLast>2019-02-25T00:00:00Z</DateChangeLast><DateEnd>2017-07-31T00:00:00Z</DateEnd><DateStart>2012-12-31T00:00:00Z</DateStart><Identifiers><Identifier>CRAD001ABR25T</Identifier><Identifier>NCT02084446</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Variable regimens including Prednisone , Thymoglobulin , enteric-coated mycophenolate sodium, Novartis , methylprednisolone , tacrolimus</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including Prednisone , Thymoglobulin , everolimus , methylprednisolone , tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Donor organ with a &lt;b&gt;cold&lt;/b&gt; ischemic time&amp;gt; 30 h Patients who produce&amp;lt; 300 ml of urine in the first 24 h post-transplantation Patients who are recipients of multiple organ transplants Patients who are recipients of ABO incompatible transplants...donor (including expanded criteria donor organs), living unrelated or non-HLA identical living related donor kidney Recipient of a kidney with a &lt;b&gt;cold&lt;/b&gt; ischemia time&amp;lt; 30 h Graft must be functional (producing &amp;gt;/= 300 ml of urine within 24 h after transplantation</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Laboratory/Diagnostic Measures - Renal function tests</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Mortality/Death Rates - Transplant related mortality</EndpointIndex><EndpointIndex>Herpesvirus infection - Graft Assessments</EndpointIndex><EndpointIndex>Herpesvirus infection - Hematological Assessments</EndpointIndex><EndpointIndex>Herpesvirus infection - Incidence/Prevalence of Herpes Infections/Diseases - Incidence/prevalence of CMV infection/disease</EndpointIndex><EndpointIndex>Herpesvirus infection - Protocol Specified Other Endpoints - Graft rejection/failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Bone Marrow</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Creatinine Clearance - Creatinine clearance using Cockcroft-Gault formula</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Gastrointestinal adverse events</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Hyperlipidemia/dyslipidemia</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Urinary Protein Excretion/Proteinuria</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections - Bk polyoma virus infection</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections - CMV infection</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications - New onset/post transplant diabetes mellitus</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Everolimus + Very Low Tacrolimus versus Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects at risk of developing disease</PatientSegment><PatientSegment>Kidney transplantation - Antibody Incompatible Renal Transplant (AiT) Recipients - HLA antibody incompatible (HLAi) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - De Novo Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living unrelated donor - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>55 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Maria Oliveira</Name><Name>Petrucia Pinheiro</Name><Name>Ronaldo M Esmeraldo, MD</Name></ContactNames></Trial><Trial Id="176717"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action><Action>Somatostatin receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer polyclonal antibody</Action><Action>Antiviral</Action><Action>Growth hormone release inhibitor</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody polyclonal</Technology><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Daily dosing</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Astellas Pharma GmbH</Company><Company>Roche Pharma (Schweiz) AG</Company><Company>Sanofi Genzyme</Company></CompaniesCollaborator><CompaniesSponsor><Company>Klinikum der Albert-Ludwigs Universitaet Freiburg</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2018-11-27T00:00:00Z</DateChangeLast><DateEnd>2014-07-31T00:00:00Z</DateEnd><DateStart>2008-06-30T00:00:00Z</DateStart><Identifiers><Identifier>087/08</Identifier><Identifier>4033996</Identifier><Identifier>DRKS00000452</Identifier><Identifier>EUDRACT NO. 2007-006516-31</Identifier><Identifier>Harmony</Identifier><Identifier>IT1850071</Identifier><Identifier>NCT00724022</Identifier><Identifier>UKF001600</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including Decortin H , Thymoglobulin , basiliximab , mycophenolate mofetil , prednisolon , tacrolimus (oral sustained-release), Astellas</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>600</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> with signs of drug abuse or alcohol abuse Patients taking additional medicines with known interactions with the immune suppressive substances (MMF [ CellCept ] and tacrolimus [ Advagraf ]) that preclude an adequate control of the immunosuppression &lt;b&gt;Cold&lt;/b&gt; ischemia time of donor kidney&gt; 30 h Pregnant or nursing patients</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cataract - Assessment of Co-morbidity</EndpointIndex><EndpointIndex>Cataract - Assessment of Lens Opacity</EndpointIndex><EndpointIndex>Cataract - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Harmony: Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Cataract - Subjects at risk of developing disease - Subjects with history of other systemic disorders</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Renal re-transplant recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Cystatin C </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>73 Months</TrialDuration><NumberOfSites>28</NumberOfSites><ContactNames><Name>Christian Hugo, Prof. Dr.</Name><Name>Oliver Thomusch, Prof. Dr.</Name><Name>Ulrich Hopt, Prof.Dr.Dr.</Name></ContactNames></Trial><Trial Id="175873"><Indications><Indication>Cough</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Elastase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antioxidant agent</Action><Action>Expectorant</Action><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Edmond Pharma</Company></CompaniesCollaborator><CompaniesSponsor><Company>Careggi Hospital</Company></CompaniesSponsor><Countries><Country>Italy</Country></Countries><DateChangeLast>2014-03-21T00:00:00Z</DateChangeLast><DateStart>2011-12-22T00:00:00Z</DateStart><Identifiers><Identifier>Cough/1/2010</Identifier><Identifier>EudraCT 2011-000620-14</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>erdosteine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The main objective of the study is to evaluate the anti-tussive activity of erdosteine and the secondary objectives are to determine the effect of erdosteine on response to a cough challenge with citric acid and to determine the effects of short term erdosteine treatment on chronic cough on bronchitis phenotypes of COPD.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Mean change in the Leicester Cough Questionnaire (LCQ) scores</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effects of Short Term Erdosteine Treatment on Chronic Cough on Bronchitis Phenotypes of COPD</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Chronic Bronchitis</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Symptomatic Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="175805"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action><Action>Beta 2 adrenoceptor antagonist</Action><Action>Beta adrenoceptor agonist</Action><Action>Muscarinic receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2014-03-04T00:00:00Z</DateChangeLast><DateEnd>2002-09-03T00:00:00Z</DateEnd><DateStart>2001-01-18T00:00:00Z</DateStart><Identifiers><Identifier>SMS40314</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Headache</Indication><Indication>Lower respiratory tract infection</Indication><Indication>Nasal congestion</Indication><Indication>Nausea</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>ipratropium bromide alone</Intervention><Intervention>salmeterol alone</Intervention><Intervention>Variable regimens including ipratropium bromide , salmeterol , salmeterol + ipratropium</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>731</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In September 2005, results were published. The most frequently observed on therapy adverse events were, headache, upper respiratory tract infection, lower respiratory tract infection, diarrhea, nausea, insomnia, vomiting, common &lt;b&gt;cold&lt;/b&gt;, sore throat, nasal congestion, exacerbation of COPD and fatigue. The serious adverse events observed were pneumonia, exacerbation of COPD, cardiomegaly, deep vein thrombosis, inferior myocardial infarction, pulmonary embolism, transient ischemic attack, etc. None of</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Disease Progression - Severity of symptoms/symptom scores (SS)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 area under curve (AUC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Changes in St Georges Respiratory Questionnaire (SGRQ)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Transition Dyspnea Index (TDI) Score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, 8-Week Comparison of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Salmeterol Xinafoate Plus Ipratropium Bromide Versus Placebo in Subjects With Chronic Obstructive Pulmonary Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Smokers</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with History of Treatment</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>19 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="174006"><Indications><Indication>Cardiogenic shock</Indication><Indication>Myocardial infarction</Indication></Indications><CompaniesSponsor><Company>University of Leipzig</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2018-11-05T00:00:00Z</DateChangeLast><DateEnd>2016-10-31T00:00:00Z</DateEnd><DateStart>2009-06-30T00:00:00Z</DateStart><Identifiers><Identifier>342</Identifier><Identifier>IABP-SHOCK II</Identifier><Identifier>NCT00491036</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Bare-metal stents alone</Intervention><Intervention>Drug-eluting stents alone</Intervention><Intervention>Intraaortic balloon pump alone</Intervention><Intervention>Percutaneous coronary intervention alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>600</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>(PCI or CABG) Systolic blood pressure&amp;lt; 90 mmHg &gt; 30 min or inotropes required to maintain pressure &gt; 90 mmHg during systole Signs of pulmonary congestion Signs of impaired organ perfusion with at least one of the following: Altered mental status &lt;b&gt;Cold&lt;/b&gt;, clammy skin Urine output&amp;lt; 30 ml/h Serum lactate&gt; 2 mmol/l Informed consent</Teaser><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Co-morbidity</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Mortality/Death Rates - Assessment of in-hospital mortality</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Renal Function</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Acute coronary syndrome - Hematological Assessments - Leukocyte count</EndpointIndex><EndpointIndex>Acute coronary syndrome - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex><EndpointIndex>Acute coronary syndrome - Protocol Specified Other Endpoints - Assessment of other inflammatory biomarkers</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates - Assessment of in-hospital mortality</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Renal Function</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Coronary artery disease - Detection of Coronary Artery Disease (CAD)</EndpointIndex><EndpointIndex>Coronary artery disease - Hematological Assessments</EndpointIndex><EndpointIndex>Coronary artery disease - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex><EndpointIndex>Renal failure - Assessment of Glomerular Filtration Rate (GFR) - Assessment of estimated glomerular filtration rate(eGFR)/creatinine clearance(CCr/CrCl/CLcr)</EndpointIndex><EndpointIndex>Renal failure - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C reactive protein (CRP)</EndpointIndex><EndpointIndex>Renal failure - Assessment of Medication Use</EndpointIndex><EndpointIndex>Renal failure - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Renal failure - Assessment of Organ Function - Cardiac assessment</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Replacement Therapy(RRT) - Assessment of filtration/dialysis</EndpointIndex><EndpointIndex>Renal failure - Patient Reported Outcomes/Quality of Life Assessments - Quality of Life(QOL)</EndpointIndex><EndpointIndex>Renal failure - Protocol Specified Other Endpoints - Length of stay in hospital /ICU</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>IABP-SHOCK II: Intraaortic Balloon Pump in Cardiogenic Shock II</TitleDisplay><PatientSegmentTerms><PatientSegment>Acute coronary syndrome - Non-ST Segment Elevation Myocardial Infarction(NSTEMI) Subjects</PatientSegment><PatientSegment>Acute coronary syndrome - ST Segment Elevation Myocardial Infarction(STEMI) Subjects</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with Acute Myocardial Infarction (MI) - Killip class III subjects</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with History of Cardiac Intervention - Coronary angiogram/catheterization</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with comorbid conditions</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with comorbid conditions - Subjects co-morbid with cardiogenic shock</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with comorbid conditions - Subjects with renal disorders/diseases/dysfunction</PatientSegment><PatientSegment>Coronary artery disease - Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Complications of the Underlying IHD</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - Acute onset/new onset myocardial infarction (MI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - Non ST elevation myocardial infarction (NSTEMI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - ST elevation myocardial infarction (STEMI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with comorbid conditions</PatientSegment><PatientSegment>Coronary artery disease - Subjects with comorbid conditions - Subjects with renal disorders/diseases/dysfunction</PatientSegment><PatientSegment>Renal failure - Subjects with Prerenal Causes for Acute Renal Failure(ARF) - Subjects with cardiopulmonary disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Catecholamines </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Cystatin C </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Hepatitis A virus cellular receptor 1 </BiomarkerName><BiomarkerName> Lactic Acid </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Neutrophil gelatinase-associated lipocalin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>88 Months</TrialDuration><NumberOfSites>20</NumberOfSites><ContactNames><Name>Holger Thiele, MD</Name></ContactNames></Trial><Trial Id="173944"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intrathecal formulation</Technology><Technology>Rectal formulation</Technology><Technology>Rectal formulation local</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Glostrup University Hospital</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2018-12-11T00:00:00Z</DateChangeLast><DateEnd>2012-05-31T00:00:00Z</DateEnd><DateStart>2011-01-31T00:00:00Z</DateStart><Identifiers><Identifier>2011-005118-13</Identifier><Identifier>NCT01577940</Identifier><Identifier>SM1-PLP-11</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ropivacaine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>8</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>mean number of dermatomes anesthetized at 24 h post block assessed with pinprick was found to be 1.5 on the active side, when compared with 0 on the placebo (p = 0.039). The mean number of dermatomes anesthetized at 24 h post block assessed with heat/&lt;b&gt;cold&lt;/b&gt; was found to be 2 on the active side, when compared with 0 on the placebo (p = 0.034). The levels of HPDT scores were not significantly different between groups at 24 h [ 1526327 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Pulmonary Function</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Method Study: Bilateral TAP Block With 24 h Infusion</TitleDisplay><PrimaryCompletionDate type="Actual">2012-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>16 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Pernille L Petersen, MD</Name></ContactNames></Trial><Trial Id="173410"><Indications><Indication>Cough</Indication></Indications><CompaniesSponsor><Company>Montefiore Medical Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2014-06-30T00:00:00Z</DateEnd><DateStart>2014-01-31T00:00:00Z</DateStart><Identifiers><Identifier>MMC-IRB-13-10-170</Identifier><Identifier>NCT02062710</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dextromethorphan alone</Intervention><Intervention>diphenhydramine plus phenylephrine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>22</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Healthy adult nonsmokers Onset of acute, viral upper respiratory tract infection (common &lt;b&gt;cold&lt;/b&gt;) within 72 h of enrollment</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Antitussive Effect of A Naturally Flavored Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo</TitleDisplay><PrimaryCompletionDate type="Actual">2014-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Peter Dicpinigaitis</Name></ContactNames></Trial><Trial Id="173172"><Indications><Indication>Anesthesia</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Analgesic</Action><Action>Local anesthetic</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intrathecal formulation</Technology><Technology>Rectal formulation</Technology><Technology>Rectal formulation local</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Australia and New Zealand College of Anaesthetists</Company></CompaniesCollaborator><CompaniesSponsor><Company>Royal Prince Alfred Hospital</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2016-08-11T00:00:00Z</DateChangeLast><DateStart>2010-10-04T00:00:00Z</DateStart><Identifiers><Identifier>ACTRN12612000401853</Identifier><Identifier>ANZCTR335874</Identifier></Identifiers><InterventionsControlDisplay><Intervention>ropivacaine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>hyaluronidase plus ropivacaine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>This phase IV, randomized, parallel-group study aims to investigate the effect of the drug hyaluronidase on the efficacy of ultrasound-guided fascia iliaca compartment block (FICB). The investigators hypothesise that adding hyaluronidase to a plain 0.5% ropivacaine local anesthetic solution will increase the success of FICB - chiefly the proportion of patients achieving obturator nerve anesthesia (weakness of thigh adduction). The effects on the speed of onset and blood levels of co-administered</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of procedural outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>In patients undergoing ultrasound-guided fascia iliaca compartment blockade before knee replacement surgery, does the addition of hyaluronidase to the local anesthetic solution improve the success rate and hasten the onset of the nerve blockade?</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects in need of Procedural Analgesia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>2</NumberOfSites><ContactNames><Name>Andrew Lansdown</Name></ContactNames></Trial><Trial Id="172529"><Indications><Indication>Renal injury</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Vasopressin V1 receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Vasoconstrictor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Injectable emulsion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>National Liver Institute, Egypt</Company></CompaniesSponsor><Countries><Country>Egypt</Country></Countries><DateChangeLast>2017-06-12T00:00:00Z</DateChangeLast><DateEnd>2016-12-31T00:00:00Z</DateEnd><DateStart>2013-05-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02059460</Identifier><Identifier>TERLI-NGAL-111</Identifier><Identifier>Terli-NGAL</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>liver transplantation alone</Intervention><Intervention>Variable regimens including methylprednisolone , rocronium , terlipressin acetate</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>25</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> (CVP), cardiac output (COP), stroke volume (SV), corrected flow time (FTc), systemic vascular resistance (SVR) would be recorded after induction of anesthesia, then every h during the operation. Other parameters like anhepatic phase time, warm and &lt;b&gt;cold&lt;/b&gt; ischemia time; graft weight , recipient graft body weight ratio; fluid, blood product transfusion; blood glucose level, postoperative complication; ICU stay, length of hospital stay and 30 days mortality (the need for postoperative renal replacement</Teaser><TrialCategories><Category>Biological</Category><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Blood Glucose Levels</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Post Transplant Complications</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Renal Function - Urine output</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Liver transplantation - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Liver transplantation - Protocol Specified Other Endpoints - Graft weight/standard liver volume</EndpointIndex><EndpointIndex>Renal failure - Assessment of Acute Renal Failure</EndpointIndex><EndpointIndex>Renal failure - Assessment of Biomarkers - Assessment of neutrophil gelatinase-associated lipocalin(NGAL)</EndpointIndex><EndpointIndex>Renal failure - Assessment of Fluid Balance</EndpointIndex><EndpointIndex>Renal failure - Assessment of Glomerular Filtration Rate (GFR) - Assessment of estimated glomerular filtration rate(eGFR)/creatinine clearance(CCr/CrCl/CLcr)</EndpointIndex><EndpointIndex>Renal failure - Assessment of Medication Use</EndpointIndex><EndpointIndex>Renal failure - Assessment of Organ Function - Cardiac assessment</EndpointIndex><EndpointIndex>Renal failure - Assessment of Organ Function - Metabolic/endocrinal assessment</EndpointIndex><EndpointIndex>Renal failure - Assessment of Postoperative Status</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Function - Assessment of creatinine level</EndpointIndex><EndpointIndex>Renal failure - Assessment of adverse events</EndpointIndex><EndpointIndex>Renal failure - Protocol Specified Other Endpoints - Length of stay in hospital /ICU</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Terli-NGAL: Perioperative Evaluation of Terlipressin Infusion During Living Donor Liver Transplantation on Incidence of Acute Kidney</TitleDisplay><PatientSegmentTerms><PatientSegment>Liver transplantation - Liver Transplant Recipients</PatientSegment><PatientSegment>Liver transplantation - Living Donor Liver Transplant (LDLTx) Recipients</PatientSegment><PatientSegment>Renal failure - Subjects with Prerenal Causes for Acute Renal Failure(ARF) - Subjects with/at risk of blood loss</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Cardiac Output </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Mean arterial pressure </BiomarkerName><BiomarkerName> Neutrophil gelatinase-associated lipocalin </BiomarkerName><BiomarkerName> Stroke volume </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Vascular resistance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>43 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Hanaa S Rashed, MSc</Name></ContactNames></Trial><Trial Id="172310"><Indications><Indication>Hypotension</Indication><Indication>Hypothermia</Indication></Indications><CompaniesSponsor><Company>Inonu University</Company></CompaniesSponsor><DateChangeLast>2014-05-29T00:00:00Z</DateChangeLast><IndicationsAdverse><Indication>Emesis</Indication><Indication>Nausea</Indication><Indication>Pain</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>ephedrine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>110</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>The purpose of this phase IV, randomized, single-center, parallel-group and double-blind study was to evaluate the effect of bolus or the combination of bolus and infusion of ephedrine on maternal hypothermia and maternal hypotension during cesarean section under spinal anesthesia in pregnant women presenting for scheduled cesarean delivery [ 1523420 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>A phase IV, randomized, single-center, parallel-group and double-blind study to evaluate the effect of bolus or the combination of bolus and infusion of ephedrine on maternal hypothermia and maternal hypotension during cesarean section under spinal anesthesia in pregnant women presenting for scheduled cesarean delivery</TitleDisplay><BiomarkerNames><BiomarkerName>Blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="172150"><Indications><Indication>Acne vulgaris</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Retinoic acid receptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Topical anti-acne product</Action></ActionsSecondaryInterventionsControl><Technologies><Technology>Dermatological formulation</Technology><Technology>Dermatological gel formulation</Technology><Technology>Emulsion dermatological</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Actavis Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Actavis LLC</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2018-03-24T00:00:00Z</DateChangeLast><DateEnd>2009-12-31T00:00:00Z</DateEnd><DateStart>2009-03-31T00:00:00Z</DateStart><Identifiers><Identifier>ADAP-0.3/2008</Identifier><Identifier>NCT01095640</Identifier></Identifiers><InterventionsControlDisplay><Intervention>adapalene alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Adapalene Topical Gel (Actavis Mid Atlantic LLC) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1159</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>have performed wax epilation of the face within 14 days prior to baseline will also be excluded from study participation Patients who engage in activities that involve excessive or prolonged exposure to sunlight or weather extremes, such as wind or &lt;b&gt;cold&lt;/b&gt;, will be excluded from study participation Patients who consume excessive amounts of alcohol (&gt; 2 drinks per day) or use drugs of abuse (including, but not limited to, cannabinoids, cocaine and barbiturates) as judged by history will be excluded from</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Bioequivalence</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Acne vulgaris - Assessment of Lesion Count and Characteristics - Change in inflammatory lesion counts</EndpointIndex><EndpointIndex>Acne vulgaris - Assessment of Lesion Count and Characteristics - Change in noninflammatory lesion counts</EndpointIndex><EndpointIndex>Acne vulgaris - Assessment of Therapy Related Outcomes - Assessment of overall treatment success</EndpointIndex><EndpointIndex>Acne vulgaris - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Study Comparing 0.3% Adapalene Topical Gel to Differin 0.3% Adapalene Topical Gel</TitleDisplay><PatientSegmentTerms><PatientSegment>Acne vulgaris - Subjects by disease severity - Subjects with Mild Acne Vulgaris</PatientSegment><PatientSegment>Acne vulgaris - Subjects by disease severity - Subjects with Moderate Acne Vulgaris</PatientSegment><PatientSegment>Acne vulgaris - Subjects with Inflammatory Lesions - Subjects with nodules/nodulocystic lesions</PatientSegment><PatientSegment>Acne vulgaris - Subjects with specific disease - Subjects with Facial Acne Vulgaris</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Alur S. Kumar, MD</Name><Name>Anilkumar Malik, MD</Name><Name>Bela J. Shah, MD</Name><Name>D. N. Balraj, PI</Name><Name>Hemanji R. Jerajani, MD</Name><Name>Jayadev Betkerur, MD</Name><Name>Jayesh Kothari, MD</Name><Name>Kailash Bhatia, MD</Name><Name>Karigi Siddalingappa, MD</Name><Name>Leelavathy B., MD</Name><Name>Mahendra M. Kura, MD</Name><Name>Manjunath S. M., MD</Name><Name>Manoj K. Parekh, MD</Name><Name>Mhaske, MD</Name><Name>Mukta Sachdev, MD</Name><Name>Nataraja, MD</Name><Name>P. V. Patalay, MD</Name><Name>P. V. S. Prasad, MD</Name><Name>Putta Srinivas, MD</Name><Name>Rachita Dhurat, MD</Name><Name>Rajitha K., MD</Name><Name>Rajkumar V., MD</Name><Name>Ramesh M., MD</Name><Name>Ranjan C. Raval, MD</Name><Name>Ravi M. Rathod, MD</Name><Name>Sailaja K. Surapaneni, MD</Name><Name>V. K. Somani, MD</Name><Name>V. R. Sardesai, MD</Name><Name>Vijaykumar Garg, MD</Name><Name>Vishal B., MD</Name><Name>Yogesh Marfatia, MD</Name></ContactNames></Trial><Trial Id="171641"><Indications><Indication>Urticaria</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin E antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>University of Toronto</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2014-02-06T00:00:00Z</DateChangeLast><InterventionsPrimaryDisplay><Intervention>omalizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>68</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>mean UAS-7 decreased from 24.4 to 2.2 and the quantitative medication score decreased from 13.3 to 3.0 in Quebec City.  The most common maintenance dosing intervals were 1 to 3 months. A total of 6 patients with &lt;b&gt;cold&lt;/b&gt; urticaria became symptom free, with a significant decrease of their &lt;b&gt;cold&lt;/b&gt; stimulation tolerance test [ 1522006 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Urticaria - Assessment by Urticarial Scores - Assessment by Urticaria Activity Score (UAS)</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Urticaria - Assessment of adverse events</EndpointIndex><EndpointIndex>Urticaria - Assessment of use of Rescue Medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Prospective, Open-label Study of Real-life Experiences With Omalizumab for the Treatment of Chronic Urticaria</TitleDisplay><PatientSegmentTerms><PatientSegment>Urticaria - Subjects with Chronic Urticaria</PatientSegment><PatientSegment>Urticaria - Subjects with Severe Urticaria</PatientSegment><PatientSegment>Urticaria - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>2</NumberOfSites></Trial><Trial Id="170423"><ActionsPrimaryInterventionsPrimary><Action>Insulin ligand</Action><Action>Insulin receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Human insulin fast acting product</Action><Action>Human insulin intermediate acting product</Action><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Peptide</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Centre Hospitalier Universitaire Dijon</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2015-09-11T00:00:00Z</DateChangeLast><DateEnd>2014-01-30T00:00:00Z</DateEnd><DateStart>2012-03-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT02048189</Identifier><Identifier>RUDONI PARI 2011</Identifier><Identifier>TRICIDIA</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>insulin detemir alone</Intervention><Intervention>insulin glulisine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> MRI ) Pacemaker (CI MRI) Pregnancy, breast feeding Medically significant physical or psychiatric inability, patients under guardianship or wards of court The practice of violent sports Poor conditions of hygiene Professional environment of extreme &lt;b&gt;cold&lt;/b&gt; or heat</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Insulin resistance - Glycemic Control Analysis - Assessment of blood glucose</EndpointIndex><EndpointIndex>Insulin resistance - Glycemic Control Analysis - Assessment of insulin resistance</EndpointIndex><EndpointIndex>Insulin resistance - Glycemic Control Analysis - Assessment of insulin secretion</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Beta Cell Function - Insulin secretion rate</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of insulin resistance</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of postprandial glucose</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TRICIDIA: Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes</TitleDisplay><PatientSegmentTerms><PatientSegment>Insulin resistance - Subjects with comorbid conditions - Subjects with diabetes mellitus</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects on Treatment/Requiring &gt;1 Antidiabetic Agent</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects on Treatment/Requiring Insulin</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Poor/Inadequate Glycemic Control</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Insulin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2015-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Alfred PENFORMIS</Name><Name>Isabelle SIMONEAU-ROBIN</Name><Name>Sabine BAILLOT-RUDONI</Name></ContactNames></Trial><Trial Id="169515"><Indications><Indication>Neuropathic pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Albumin modulator</Action><Action>Alpha 1 acid glycoprotein modulator</Action><Action>Lanosterol-14 demethylase inhibitor</Action><Action>Opioid receptor mu agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>5-HT uptake inhibitor</Action><Action>Analgesic</Action><Action>Ergosterol synthesis inhibitor</Action><Action>Fungicide</Action><Action>Lipoprotein modulator</Action><Action>Norepinephrine uptake inhibitor</Action><Action>Platelet aggregation inhibitor</Action><Action>Systemic dermatological antifungal product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Turku University Hospital</Company></CompaniesSponsor><Countries><Country>Finland</Country></Countries><DateChangeLast>2018-09-08T00:00:00Z</DateChangeLast><DateEnd>2010-12-31T00:00:00Z</DateEnd><DateStart>2010-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2010-020617-82</Identifier><Identifier>54/180/2010</Identifier><Identifier>NCT01214941</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ticlopidine alone</Intervention><Intervention>itraconazole plus tramadol hydrochloride</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>12</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The objective of the study was to investigate the possible interaction of oral tramadol with itraconazole and ticlopidine , which are inhibitors of CYP3A4 and 2B6. Primary endpoints of the study are plasma concentrations of tramadol and its metabolites.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Verbal Rating Scale [VRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures - Assessment of biochemical parameters</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol</TitleDisplay><PrimaryCompletionDate type="Actual">2010-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>3 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Klaus T Olkkola, MD, PhD, Prof</Name></ContactNames></Trial><Trial Id="168657"><Indications><Indication>Lower back pain</Indication></Indications><CompaniesSponsor><Company>Avanos Medical Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2015-04-30T00:00:00Z</DateEnd><DateStart>2010-12-31T00:00:00Z</DateStart><Identifiers><Identifier>100-10-0001</Identifier><Identifier>COLD</Identifier><Identifier>NCT01263054</Identifier></Identifiers><InterventionsControlDisplay><Intervention>standard medical management alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>TransDiscal System alone</Intervention><Intervention>standard medical management alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>67</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of this randomized controlled trial was to evaluate the safety and efficacy of the TransDiscal System (TDS) in treating discogenic pain of the lumbar spine using a modified disc biacuplasty procedure. The primary efficacy measure would be the Visual Analog Scale (VAS) at 6 months post treatment/randomization and the TransDiscal System would be compared against medical management (standard of care).</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function - Assessment by Oswestry Disability Index (ODI)</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Oswestry Disability Index (ODI)</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Euro Quality of Life (EQ-5D) Questionnaire</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>COLD: Safety and Efficacy of the TransDiscal System Versus Medical Management in Treating Chronic Discogenic Low Back Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with back pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>52 Months</TrialDuration><NumberOfSites>10</NumberOfSites><ContactNames><Name>David Curd, MS</Name></ContactNames></Trial><Trial Id="166963"><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Antimicrobial</Action><Action>Bacterial cell wall synthesis inhibitor</Action><Action>Tetracycline</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Buccal formulation systemic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Richmond Pharmacology</Company></CompaniesCollaborator><CompaniesSponsor><Company>Helperby Therapeutics Ltd</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2014-01-13T00:00:00Z</DateChangeLast><DateEnd>2013-12-31T00:00:00Z</DateEnd><DateStart>2009-12-31T00:00:00Z</DateStart><Identifiers><Identifier>ANTIRESDEV</Identifier><Identifier>C09040</Identifier><Identifier>NCT02030912</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>amoxicillin alone</Intervention><Intervention>minocycline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>42</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>investigational drug within the 3 months preceding the study Present or residual gastrointestinal, renal insufficiency or hepatic disorder Abnormal pathology of nasal passages Any clinically significant allergy or drug intolerance Active hay fever, on-going &lt;b&gt;cold&lt;/b&gt;/flu symptoms, including rhinitis at baseline (visit 2) Any medical history of renal insufficiency or hepatic disorder or other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs History of hypersensitivity</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>ANTIRESDEV: Effect of Minocycline and Amoxicillin on Antibiotic Resistant Bacteria and Indigenous Microbiotas</TitleDisplay><PrimaryCompletionDate type="Actual">2012-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jorg Taubel, MD</Name></ContactNames></Trial><Trial Id="166075"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus novel</Technology></Technologies><CompaniesSponsor><Company>Cleveland Clinic Foundation</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-07-12T00:00:00Z</DateChangeLast><DateEnd>2003-04-01T00:00:00Z</DateEnd><DateStart>2002-10-31T00:00:00Z</DateStart><Identifiers><Identifier>4675</Identifier><Identifier>NCT00419224</Identifier><Identifier>RPC 6817</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>live attenuated influenza vaccine (CoVaccine adjuvant), BioDiem/ Serum Institute of India alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>36</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to determine whether influenza vaccination protects patients who receive a certain type of bone marrow transplantation.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Antibodies</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Therapy Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Influenza Vaccination in Bone Marrow Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Elderly Subjects</PatientSegment><PatientSegment>Influenza Vaccine - Immunocompromised Subjects - Subjects receiving transplant</PatientSegment><PatientSegment>Influenza virus infection - Elderly Subjects</PatientSegment><PatientSegment>Influenza virus infection - Health Care Workers</PatientSegment><PatientSegment>Influenza virus infection - Immunocompromised Subjects - Subjects receiving transplant</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Allogenic Stem Cell Transplantation(SCT)</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Bone Marrow Transplantation(BMT)</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Hematopoietic Stem Cell Transplantation(HSCT)</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>5 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Sherif B Mossad, MD</Name></ContactNames></Trial><Trial Id="165612"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Leukotriene C4 antagonist</Action><Action>Leukotriene D4 antagonist</Action><Action>Leukotriene E4 antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action><Action>Beta adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Film coating</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2016-08-20T00:00:00Z</DateChangeLast><DateEnd>1997-12-19T00:00:00Z</DateEnd><DateStart>1997-10-31T00:00:00Z</DateStart><Identifiers><Identifier>SLGA5025 (RM1998/00157/00)</Identifier></Identifiers><IndicationsAdverse><Indication>Common cold</Indication><Indication>Headache</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>zafirlukast alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>salmeterol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>268</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In October 1997, results were published. Non-serious adverse events were found to be in 35% and 36% subjects in the salmeterol (SAL) and zafirlukast (ZAF) groups, respectively. Upper respiratory tract infection, common &lt;b&gt;cold&lt;/b&gt; and headache were found to be most frequently reported AEs in both groups. One SAE was not treatment related in salmeterol (SAL) group. No SAEs reported in zafirlukast (ZAF) group. No deaths were reported in both groups [ 1512464 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score</EndpointIndex><EndpointIndex>Asthma - Assessment of Exacerbations</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1) - Assessment of morning/evening FEV1</EndpointIndex><EndpointIndex>Asthma - Assessment of Peak Expiratory Flow/Flow Rate (PEFR) - Assessment of morning/evening PEFR</EndpointIndex><EndpointIndex>Asthma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Asthma - Assessment of Sleep</EndpointIndex><EndpointIndex>Asthma - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma Quality of Life Questionnaire (AQLQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Randomized, Double-blind, Parallel-Group, Comparison of Inhaled Salmeterol Xinafoate (42 microg bid) with Oral Zafirlukast (20 mg bid) in Subjects with Mild to Moderate Asthma</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with moderate persistent asthma</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with severe persistent asthma</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>1 Month</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="165325"><Indications><Indication>Influenza virus A infection</Indication><Indication>Influenza virus B infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Exo-alpha sialidase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>Viral replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2014-01-31T00:00:00Z</DateChangeLast><DateEnd>2005-04-01T00:00:00Z</DateEnd><DateStart>2001-12-01T00:00:00Z</DateStart><Identifiers><Identifier>112311</Identifier><Identifier>OTH112311</Identifier></Identifiers><IndicationsAdverse><Indication>Dizziness</Indication><Indication>Hypothermia</Indication><Indication>Insomnia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>zanamivir alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>405</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The objectives of the study were to: Detect whether zanamivir -resistant influenza virus would appear among patients who were treated with zanamivir .</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Vital Signs</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>Special Drug Use Investigation for Relenza (Resistant appearance)</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza virus infection - Subjects with Influenza</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>40 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="165132"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Drug combination</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Denmark</Country><Country>Iceland</Country><Country>Ireland</Country><Country>Italy</Country><Country>Canada</Country><Country>UK</Country></Countries><DateChangeLast>2014-01-08T00:00:00Z</DateChangeLast><DateEnd>1996-12-17T00:00:00Z</DateEnd><DateStart>1995-01-16T00:00:00Z</DateStart><Identifiers><Identifier>SLGQ97 (SLGB4010)</Identifier></Identifiers><IndicationsAdverse><Indication>Asthma</Indication><Indication>Bronchitis</Indication><Indication>Common cold</Indication><Indication>Headache</Indication><Indication>Influenza virus infection</Indication><Indication>Lower respiratory tract infection</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline alone</Intervention><Intervention>fluticasone propionate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>859</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In August 2005 results were published. The most common AEs in all three treatment groups were exacerbation of asthma, upper respiratory tract infection , influenza, common &lt;b&gt;cold&lt;/b&gt;, headache, lower respiratory tract infection, bronchitis, sore throat, hoarseness, back pain, nasal congestion and diarrhea . The most common SAE in the fluticasone propionate + salmeterol xinafoate treatment group was chest pain and in the fluticasone propionate 500 treatment group was exacerbation of asthma. In subjects </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score - Daytime asthma symptom score</EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score - Nighttime asthma symptom score</EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score - Symptom free period</EndpointIndex><EndpointIndex>Asthma - Assessment of Exacerbations - Number/rate/frequency/duration of exacerbation</EndpointIndex><EndpointIndex>Asthma - Assessment of Exacerbations - Severity of exacerbation</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Asthma - Assessment of Peak Expiratory Flow/Flow Rate (PEFR) - Assessment of morning/evening PEFR</EndpointIndex><EndpointIndex>Asthma - Assessment of use of Rescue Medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Multicenter, Double-Blind, Parallel-Group Study to Evaluate the Relative Clinical Benefits of Three Treatment Interventions: Salmeterol Xinafoate 50 microg bid Plus Fluticasone Propionate 250 microg bid; Fluticasone Propionate 500 microg bid; Fluticasone Propionate 250 microg bid, in Adult Asthmatic Subjects Poorly Controlled on Current Inhaled Corticosteroids</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment><PatientSegment>Asthma - Subjects with Levels of Asthma Control - Subjects with poorly controlled/not well controlled asthma</PatientSegment><PatientSegment>Asthma - Subjects with Symptomatic Disease - Subjects with acute/exacerbation of asthma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>23 Months</TrialDuration><NumberOfSites>6</NumberOfSites></Trial><Trial Id="165126"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action><Action>Beta adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2014-01-03T00:00:00Z</DateChangeLast><DateEnd>1993-06-01T00:00:00Z</DateEnd><DateStart>1992-01-01T00:00:00Z</DateStart><Identifiers><Identifier>SLGL17</Identifier></Identifiers><IndicationsAdverse><Indication>Bronchitis</Indication><Indication>Cough</Indication><Indication>Fever</Indication><Indication>Influenza virus infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>salbutamol, GlaxoSmithKline alone</Intervention><Intervention>salmeterol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>66</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>(2 and 3% respectively), fever (2 and 3% respectively), phlegm production (2 and 2 % respectively) and influenza (2 and 2% respectively). Sore throat was the only adverse event which was reported in salmeterol group whereas dizziness, palpitations, &lt;b&gt;cold&lt;/b&gt; sweat, vertigo, pneumonia and expectoration were the adverse events which were reported only in subjects who received placebo. Exacerbation of bronchitis was the only non fatal serious adverse event (SAE) which was reported in placebo group. Fatal </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Disease Progression - Severity of symptoms/symptom scores (SS)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Laboratory/Diagnostic Measures - Methacholine PC20/PC20 Adenosine Monophosphate Challenge (AMP) Challenge test</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessments of Airway Status/Obstruction - Assessment of bronchial hyperresponsiveness</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Peak Expiratory Flow Rate/Expiratory Flow Measurements</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Single-Center, Randomized, Double-Blind, Cross-Over Study to Compare the Efficacy of Inhaled Salmeterol Xinafoate Dry Powder 50 microg bid via the Diskhaler with Placebo Dry Powder bid via the Diskhaler in the Treatment of Non-Reversible COPD Patients and to Provoke with Histamine and Methacholine Before and After Treatment to Investigate Whether Salmeterol Can Reduce the Bronchial Hyperreactivity</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Smokers</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 4/Very Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Symptomatic Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>17 Months</TrialDuration><NumberOfSites>2</NumberOfSites></Trial><Trial Id="164117"><Indications><Indication>Heart transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Complement C5 factor inhibitor</Action><Action>Somatostatin receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer polyclonal antibody</Action><Action>Growth hormone release inhibitor</Action><Action>Immunomodulator</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody polyclonal</Technology><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Alexion Pharmaceuticals Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Cedars-Sinai Medical Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2019-12-31T00:00:00Z</DateEnd><DateStart>2012-11-30T00:00:00Z</DateStart><Identifiers><Identifier>CSR 205237</Identifier><Identifier>DUET</Identifier><Identifier>NCT02013037</Identifier><Identifier>PRO00028970</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Thymoglobulin plus eculizumab</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Donor or recipient age is&amp;lt; 18 or &gt; 75 years &lt;b&gt;Cold&lt;/b&gt; ischemia time is&gt; 6 h Current clinical, radiographic, or laboratory evidence of active or latent tuberculosis (TB), as determined by local standard of care History of active TB within the last two years, even if treated History of active TB greater</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR) - Acute antibody mediated/humoral rejection</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR) - Acute cellular rejection</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Cardiac Allograft Vasculopathy (CAV)/Chronic Rejection</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Cardiovascular Events - Assessment of left ventricular dysfunction</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Cardiovascular Events - Hemodynamic compromise/low output syndrome</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Inflammatory &amp; Oxidative Stress Markers - Complement factors (C3, C4, Factor B (FB))</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Inflammatory &amp; Oxidative Stress Markers - Panel reactive antibodies (PRA) levels</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Safety and Tolerability - Withdrawal/discontinuation of the drug due to toxicity</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Survival - Patient survival rate at 1 year</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of hospitalization</EndpointIndex><EndpointIndex>Heart transplantation - Health Economic Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>DUET: The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Heart transplantation - Heart Transplant Recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Left ventricular ejection fraction</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>85 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jignesh Patel, M.D., Ph.D.</Name></ContactNames></Trial><Trial Id="161703"><ActionsPrimaryInterventionsPrimary><Action>IL-6 receptor antagonist</Action><Action>IL-6 receptor modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action><Action>Antihypertensive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Roche Holding AG</Company></CompaniesSponsor><Countries><Country>Switzerland</Country><Country>UK</Country></Countries><DateChangeLast>2018-11-15T00:00:00Z</DateChangeLast><DateEnd>2014-12-31T00:00:00Z</DateEnd><DateStart>2014-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2013-002341-11</Identifier><Identifier>NCT01991990</Identifier><Identifier>WA29049</Identifier></Identifiers><IndicationsAdverse><Indication>Eosinophilia</Indication><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Skin rash</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>tocilizumab (intravenous), Roche/Chugai alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>18</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This phase IV, single-blind, randomized, two-arm study would explore the pharmacodynamics effects of tocilizumab (RoActemra/Actemra) on neutrophil redistribution, function and survival in healthy subjects.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-dose RoActemra/Actemra (Tocilizumab) in Healthy Volunteers</TitleDisplay><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Eosinophils </BiomarkerName><BiomarkerName> Low affinity immunoglobulin gamma Fc region receptor III-A </BiomarkerName><BiomarkerName> Neutrophils</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>7 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Clinical Trials</Name><Name>Trial Information Support Line-TISL</Name></ContactNames></Trial><Trial Id="161634"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Inactivated viral vaccine</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Suspension</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>National Institute of Allergy and Infectious Diseases</Company></CompaniesCollaborator><CompaniesSponsor><Company>Stanford University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-16T00:00:00Z</DateChangeLast><DateEnd>2010-01-31T00:00:00Z</DateEnd><DateStart>2009-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2U19AI057229-06</Identifier><Identifier>5U19AI057229-07</Identifier><Identifier>NCT01987349</Identifier><Identifier>SLVP-018</Identifier><Identifier>SU-17219</Identifier><Identifier>SU-17219-2009</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention><Intervention>Fluzone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>72</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The investigators plan was to study the response to different influenza vaccines much more broadly and deeply across different age groups and with different vaccine modalities and to probe the influence of genetics on these responses using monozygotic and dizygotic twins.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza Vaccine - Hematological Assessments</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza virus infection - Hematological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP-018) - Year 1, 2009</TitleDisplay><BiomarkerNames><BiomarkerName>Cytokines </BiomarkerName><BiomarkerName> Lymphocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>4 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ann Arvin, MD</Name><Name>Cornelia L Dekker, MD</Name><Name>Garry Nolan, PhD</Name><Name>Mark M Davis, PhD</Name><Name>Stephen Quake, PhD</Name></ContactNames></Trial><Trial Id="161462"><Indications><Indication>Kidney transplantation</Indication><Indication>Non-insulin dependent diabetes</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>Cytotoxic T-lymphocyte protein-4 modulator</Action><Action>T cell surface glycoprotein CD28 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>Lymphocyte inhibitor</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Protein fusion</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Hospital Vall D'Hebron</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2015-02-17T00:00:00Z</DateChangeLast><DateStart>2013-05-28T00:00:00Z</DateStart><Identifiers><Identifier>ES</Identifier><Identifier>EudraCT 2011-006162-40</Identifier><Identifier>NODAT-BELATAC</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>belatacept alone</Intervention><Intervention>tacrolimus alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>polyoma virus-associated nephropathy, which is mostly due to BK virus infection Receiving or having previously received an organ transplant other than a kidney Recipient of dual kidney transplantation Recipient of a graft from a non-heart-beating donor &lt;b&gt;Cold&lt;/b&gt; ischemia time of the donor kidney&gt; 30 h PRA&gt;30% Significant liver disease Diabetes Mellitus diagnose prior to transplantation positive serology for hepatitis B and C virus Seronegative or unknown EBV serostatus</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Laboratory/Diagnostic Measures - Renal function tests</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Survival - Assessment of Survival Rates</EndpointIndex><EndpointIndex>Herpesvirus infection - Graft survival</EndpointIndex><EndpointIndex>Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex><EndpointIndex>Herpesvirus infection - Protocol Specified Other Endpoints - Graft rejection/failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR) - GFR calculated using MDRD Study formula</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>New-Onset Diabetes Mellitus After Renal Transplantation. A Multicenter, Prospective, Randomized, Open-Study to Evaluate Belatacept-Based Versus Tacrolimus-Based Immunosuppression</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Epstein-Barr Virus Infections</PatientSegment><PatientSegment>Kidney transplantation - Antibody Incompatible Renal Transplant (AiT) Recipients</PatientSegment><PatientSegment>Kidney transplantation - Antibody Incompatible Renal Transplant (AiT) Recipients - HLA antibody incompatible (HLAi) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Subjects with End Stage Renal Disease/Chronic Renal Failure</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="161287"><Indications><Indication>Hypothermia</Indication><Indication>Seizure disorder</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesCollaborator><Company>Estonian Science Foundation</Company></CompaniesCollaborator><CompaniesSponsor><Company>Tartu University</Company></CompaniesSponsor><Countries><Country>Estonia</Country></Countries><DateChangeLast>2013-11-22T00:00:00Z</DateChangeLast><DateStart>2012-08-14T00:00:00Z</DateStart><Identifiers><Identifier>1</Identifier><Identifier>EudraCT 2010-020103-70</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lidocaine plus phenobarbital</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The main objective of this study was to describe pharmacokinetic (PK) profile of phenobarbital in term neonates with seizures in therapeutic hypothermia and to describe PK parameters of lidocaine in term neonates with seizures in therapeutic hypothermia. Secondary objectives: To correlate plasma PK profiles of lidocaine and/or phenobarbital with clinical efficacy (cessation of clinical and/or subclinical seizures) in term neonates in therapeutic hypothermia. To assess the safety profiles of</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Epilepsy - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Epilepsy - Assessment of Seizure Activity - Assessment of seizure frequency</EndpointIndex><EndpointIndex>Epilepsy - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term></TermsPatientSelection><TitleDisplay>Pharmacokinetics of Intravenous Phenobarbital and Lidocaine in the Treatment of Neonatal Seizures of Term Neonates Requireing Therapeutic Hypothermia</TitleDisplay><PatientSegmentTerms><PatientSegment>Epilepsy - Subjects with Neonatal Seizures</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="160677"><Indications><Indication>Hypertension</Indication><Indication>Vascular disease</Indication></Indications><CompaniesSponsor><Company>Third Military Medical University of the Chinese PLA</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2016-01-16T00:00:00Z</DateChangeLast><DateEnd>2013-12-31T00:00:00Z</DateEnd><DateStart>2013-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2012CB517805</Identifier><Identifier>NCT01982669</Identifier><Identifier>SATIETY-1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>spicy food intake alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>606</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>system disease or oral and digestive disease Capsaicin allergy and poor compliance Recently oral diuretics and participate in other pharmacological experiment in 3 months Acute infection, cancer, serious arrhythmias, drug or alcohol abuse Currently have &lt;b&gt;cold&lt;/b&gt;, fever, acidosis, dehydration, diarrhea, vomiting during the study Unwilling or unable to communication due to the dysnomia and language disorders Severe neural or psychiatric diseases that would preclude fully understand and corporation in the study</Teaser><TermsDesign><Term>Observational</Term><Term>Cross-sectional</Term><Term>Defined Population</Term></TermsDesign><EndpointIndex><EndpointIndex>Obesity - Assessment of Dietary Intake</EndpointIndex><EndpointIndex>Obesity - Patient Reported Outcomes/Quality of Life Assessments - Diet history questionnaire</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Spicy Diet on Salty Taste and Salt Intake</TitleDisplay><BiomarkerNames><BiomarkerName>Body Mass Index </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Sodium </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Waist circumference</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="160296"><Indications><Indication>Anesthesia</Indication><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Liposome formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Suspension</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>St Lukes Roosevelt Hospital Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateStart>2015-05-31T00:00:00Z</DateStart><Identifiers><Identifier>13-0060</Identifier><Identifier>NCT01977339</Identifier></Identifiers><InterventionsControlDisplay><Intervention>bupivacaine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>bupivacaine (extended release/DepoFoam, postoperative pain), Pacira BioSciences/Nuance Biotech alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Other</Reason></ReasonForTrialDiscontinuation><Teaser> age Scheduled to undergo primary unilateral TKA under general anesthesia American Society of Anesthesiology (ASA) Physical Status1 to 3 Able to demonstrate motor function by performing a 20 m walk, and sensory function by exhibiting sensitivity to &lt;b&gt;cold&lt;/b&gt; Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy of Single Injection Femoral Nerve Block With Liposomal Bupivacaine for Total Knee Arthroplasty</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects in need of Procedural Analgesia</PatientSegment><PatientSegment>Pain - Subjects with Acute Pain</PatientSegment><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2016-07-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ali Shariat, MD</Name></ContactNames></Trial><Trial Id="159050"><Indications><Indication>Osteoarthritis</Indication></Indications><CompaniesSponsor><Company>Tianjin University of Traditional Chinese Medicine</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-01-26T00:00:00Z</DateChangeLast><DateEnd>2016-08-22T00:00:00Z</DateEnd><DateStart>2013-08-22T00:00:00Z</DateStart><Identifiers><Identifier>ChiCTR-TRC-13003713</Identifier><Identifier>TYLL2013[Y]021</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Bitongning alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Yaotongning alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>360</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser> Conforms to the diagnosis standard of Lumbar osteoarthritis Conforms to the TCM syndromes of &lt;b&gt;Cold&lt;/b&gt; dampness and blood stasis At the age of 18 to 65 years old Quiescent VAS &amp;gt;/= 3 points Subjects agreed, and signed the informed consent form...The aim of this study was to evaluate of the analgesic effect of Yaotongning capsules treatment on lumbar osteoarthritis (&lt;b&gt;cold&lt;/b&gt; dampness and blood stasis) and to evaluate of the safety of Yaotongning capsules in clinical application [ 1492616 </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Functional Disability/Physical Function - Assessment of functional disability by Oswestry Disability Index (ODI)</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Joint Stiffness - Assessment of joint stiffness by VAS score</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Pain</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Osteoarthritis - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Pain by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function - Assessment by Functional Assessment Screening Questionnaire</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>The Clinical Studies Yaotongning Capsules Listed after the Evaluation</TitleDisplay><PatientSegmentTerms><PatientSegment>Osteoarthritis - Subjects With Disc Degeneration (Spinal Osteoarthritis) - Subjects with lumbosacral osteoarthritis</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with arthritic pain</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with back pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chunmin Wang</Name><Name>Jinjia Guo</Name></ContactNames></Trial><Trial Id="158935"><Indications><Indication>Cough</Indication></Indications><CompaniesCollaborator><Company>Aboca Spa</Company></CompaniesCollaborator><CompaniesSponsor><Company>Clalit Health Services</Company></CompaniesSponsor><Countries><Country>Israel</Country></Countries><DateChangeLast>2018-11-05T00:00:00Z</DateChangeLast><DateEnd>2014-04-30T00:00:00Z</DateEnd><DateStart>2013-12-31T00:00:00Z</DateStart><Identifiers><Identifier>COM-13-00</Identifier><Identifier>NCT01968434</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Mucolit alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Grintuss alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>150</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Cough attributed to URTI such as the common &lt;b&gt;cold&lt;/b&gt; Age 2 to 5 years Moderate to severe day cough according to questionnaire (score at least three on all three questions relating to day cough) considering the day prior to enrollment Moderate to...syrup (Grintuss) from natural ingredients in children's cough due to upper respiratory tract infections (URTI) such as the common &lt;b&gt;cold&lt;/b&gt;. The hypothesis was that protecting the throat is very useful in decreasing cough severity, both day and night, without</Teaser><TrialCategories><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Comparison of Efficacy and Tolerability of Two Cough Syrups in Cough Due to Cold in Children</TitleDisplay><PrimaryCompletionDate type="Actual">2014-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>4 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Herman Avner Cohen, Professor</Name></ContactNames></Trial><Trial Id="156345"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Somatostatin receptor agonist</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer polyclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Growth hormone release inhibitor</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody polyclonal</Technology><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company><Company>Novartis Farma SpA</Company><Company>Novartis Pharma Services AG</Company></CompaniesSponsor><Countries><Country>Poland</Country><Country>Croatia</Country><Country>Lebanon</Country><Country>Australia</Country><Country>Greece</Country><Country>Brazil</Country><Country>Thailand</Country><Country>Saudi Arabia</Country><Country>Chile</Country><Country>Netherlands</Country><Country>Turkey</Country><Country>Japan</Country><Country>Slovenia</Country><Country>Italy</Country><Country>Germany</Country><Country>Russian Federation</Country><Country>Slovakia</Country><Country>Czech Republic</Country><Country>Spain</Country><Country>Taiwan</Country><Country>France</Country><Country>Bulgaria</Country><Country>Sweden</Country><Country>Serbia</Country><Country>Portugal</Country><Country>Singapore</Country><Country>Belgium</Country><Country>Austria</Country><Country>Kuwait</Country><Country>Egypt</Country><Country>Mexico</Country><Country>Philippines</Country><Country>Argentina</Country><Country>South Africa</Country><Country>Switzerland</Country><Country>Colombia</Country><Country>Malaysia</Country><Country>Norway</Country><Country>US</Country><Country>Israel</Country><Country>South Korea</Country><Country>India</Country></Countries><DateChangeLast>2019-05-27T00:00:00Z</DateChangeLast><DateEnd>2018-01-17T00:00:00Z</DateEnd><DateStart>2013-12-03T00:00:00Z</DateStart><Identifiers><Identifier>2013-000322-66</Identifier><Identifier>2013-CT0162</Identifier><Identifier>CRAD001A2433</Identifier><Identifier>CRAD001AAU13</Identifier><Identifier>DRKS00006458</Identifier><Identifier>JapicCTI-142416</Identifier><Identifier>NCT01950819</Identifier><Identifier>NCT02316938</Identifier><Identifier>NMRR-13-1371-18609</Identifier><Identifier>PHRR140804-000215</Identifier><Identifier>TRANSFORM</Identifier></Identifiers><IndicationsAdverse><Indication>BK virus infection</Indication><Indication>Bacterial infection</Indication><Indication>Cytomegalovirus infection</Indication><Indication>Epstein Barr virus infection</Indication><Indication>Hematoma</Indication><Indication>Lymphocele</Indication><Indication>Pain</Indication><Indication>Viral infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>corticosteroid therapy alone</Intervention><Intervention>Variable regimens including arm B , ciclosporin, Novartis , enteric-coated mycophenolate sodium, Novartis , methylprednisolone , methylprednisone , mycophenolate mofetil , prednisone , tacrolimus</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>corticosteroid therapy alone</Intervention><Intervention>Variable regimens including Thymoglobulin , arm A , basiliximab , ciclosporin, Novartis , everolimus , methylprednisolone , methylprednisone , prednisone , tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2037</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Written informed consent obtained Male or female subject &gt; 18 years old Subject randomized within 24 h of completion of transplant surgery Recipient of a kidney with a &lt;b&gt;cold&lt;/b&gt; ischemia time&amp;lt; 30 h Recipient of a primary (or secondary, if first graft is not lost due to immunological reasons) renal transplant from a deceased heart beating, living unrelated, living related non-human leukocyte antigen identical or an expanded</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Biomarkers - Assessment of cystatin</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Glomerular Filtration Rate (GFR) - Assessment of Estimated Glomerular Filtration Rate(eGFR)/Creatinine Clearance(CCr/CrCl/CLcr)</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of adverse events</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Incidence/number of AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Time to AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Cardiac Function - Incidence of cardiovascular events/diseases</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Creatinine Clearance</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Liver Functions - Serum albumin</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function - Fractional albumin clearance</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function - Serum cystatin C levels</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function - Urinary albumin to creatinine ratio (UACR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Urinary Protein Excretion/Proteinuria</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections - Bk polyoma virus infection</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections - CMV infection</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications - New onset/post transplant diabetes mellitus</EndpointIndex><EndpointIndex>Kidney transplantation - Post Transplant Malignancies - Incidence of malignancy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TRANSFORM: Advancing Renal Transplant Efficacy and Safety Outcomes With an Everolimus-Based Regimen</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Kidney Transplant Subjects</PatientSegment><PatientSegment>End stage renal disease - Subjects at risk of developing disease</PatientSegment><PatientSegment>Kidney transplantation - De Novo Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients - Heart beating donor - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Expanded Criteria Donor (ECD) Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living related donor (LRD) - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living unrelated donor - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Renal re-transplant recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Albumin </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Cystatin C </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Urinary albumin to creatinine ratio </BiomarkerName><BiomarkerName> Urinary protein </BiomarkerName><BiomarkerName> Urinary protein/Creatinine ratio</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-02-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>49 Months</TrialDuration><NumberOfSites>184</NumberOfSites><ContactNames><Name>Clinical Trial Information Desk</Name><Name>Dr. Angel Joaquin Amante</Name><Name>Dr. Romina Danguilan</Name><Name>Lee Chen Neng, Alvin</Name><Name>Novartis Pharma K.K.</Name><Name>Novartis Pharmaceuticals</Name><Name>intan azura binti rizal edgar</Name></ContactNames></Trial><Trial Id="155026"><Indications><Indication>Common cold</Indication></Indications><CompaniesSponsor><Company>Boehringer Ingelheim International GmbH</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-03-31T00:00:00Z</DateChangeLast><DateEnd>2014-03-31T00:00:00Z</DateEnd><DateStart>2013-09-30T00:00:00Z</DateStart><Identifiers><Identifier>1326.1</Identifier><Identifier>NCT01944631</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Iota-Carrageenan (Bisolviral) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Common &lt;b&gt;cold&lt;/b&gt; or flu like symptoms for &amp;gt; 48 h Recent (within the previous 2 days) intake of a common &lt;b&gt;cold&lt;/b&gt; medicine that in... Patients consider that they are in an early stage of common &lt;b&gt;cold&lt;/b&gt; with symptoms of no more than 48 h duration Symptom score of &amp;gt;/= 1 for for at least one...on &lt;b&gt;cold&lt;/b&gt; symptoms. The effect of treatment on the duration of the &lt;b&gt;cold&lt;/b&gt; and the patients viral load plus cytokine level indicating the inflammatory</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Iota-Carrageenan Nasal Spray in Common Cold</TitleDisplay><BiomarkerNames><BiomarkerName>Cytokines</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>6 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Boehringer Ingelheim</Name></ContactNames></Trial><Trial Id="154691"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intrathecal formulation</Technology><Technology>Rectal formulation</Technology><Technology>Rectal formulation local</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>University of New Mexico</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2015-03-31T00:00:00Z</DateEnd><DateStart>2014-03-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01943240</Identifier><Identifier>PEC BLOCK</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ropivacaine alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Patient Enrollment Issues</Reason></ReasonForTrialDiscontinuation><Teaser>admission and when the patient has met PACU discharge criteria would be recorded. Any supplementary local anesthetics or analgesia would also be noted. Prior to PACU discharge, a blinded assessor would assess the patient for any reduced sensation to &lt;b&gt;cold&lt;/b&gt; in the distribution of the radial, ulnar, median nerves in the hand and musculocutaneous nerve in the arm as well as the motor integrity of the four said nerves. Patient grip strength would be measured on the surgical and contralateral sides with a</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Breast tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by IVRS 11-Point Numeric Rating Scale (NRS) pain score</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Nausea and Vomiting</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Pain</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Cancer supportive care - Protocol Specified Other Endpoints - Assessment of Other Treatment or Procedure Related Outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Pectoral Nerve Blockade in Mastectomy</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Cancer/Treatment-related Pain</PatientSegment><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment><PatientSegment>Pain - Subjects with Acute Pain</PatientSegment><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Muscle strength</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Nicholas Lam, MD</Name></ContactNames></Trial><Trial Id="154404"><Indications><Indication>Urticaria</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Histamine H1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Ophthalmological agent</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Freeze drying</Technology><Technology>Ophthalmic formulation</Technology><Technology>Ophthalmic liquid formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Grupo de Alergologia Clinica y Experimental</Company></CompaniesSponsor><Countries><Country>Colombia</Country></Countries><DateChangeLast>2018-05-26T00:00:00Z</DateChangeLast><DateEnd>2014-01-31T00:00:00Z</DateEnd><DateStart>2013-08-31T00:00:00Z</DateStart><Identifiers><Identifier>GACE-01</Identifier><Identifier>NCT01940393</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>bilastine alone</Intervention><Intervention>cetirizine alone</Intervention><Intervention>desloratadine alone</Intervention><Intervention>ebastine alone</Intervention><Intervention>fexofenadine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>150</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of the study was to evaluate if skin test inhibition correlates with the clinical effect of five anti-histamines.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Dermatology Life Quality Index (DLQI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria</TitleDisplay><PatientSegmentTerms><PatientSegment>Urticaria - Subjects with Chronic Urticaria</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jorge Sánchez, M.D</Name></ContactNames></Trial><Trial Id="153989"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD52 antagonist</Action><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Apoptosis stimulator</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Novartis AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of Toledo</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-04-18T00:00:00Z</DateChangeLast><DateEnd>2020-12-31T00:00:00Z</DateEnd><DateStart>2013-07-03T00:00:00Z</DateStart><Identifiers><Identifier>Everolimus</Identifier><Identifier>NCT01935128</Identifier><Identifier>UTHSC-16</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>alemtuzumab alone</Intervention><Intervention>Variable regimens including enteric-coated mycophenolate sodium, Novartis , everolimus , tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>55</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness Patient who has received a kidney transplant from a deceased or living unrelated-/related donor Recipient of a kidney allograft with a &lt;b&gt;cold&lt;/b&gt; ischemia time (CIT)&amp;lt; 36 h Female patients must have a negative pregnancy test prior to study enrollment Patients on calcineurin inhibitor(s) (CNI) ( tacrolimus and myfortic ) without steroid maintenance following Campath induction Patients with </Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Immune Response - Immunogenic response against other antigens</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Laboratory/Diagnostic Measures - Renal function tests</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Survival - Assessment of Survival Rates</EndpointIndex><EndpointIndex>Herpesvirus infection - Graft survival</EndpointIndex><EndpointIndex>Herpesvirus infection - Hematological Assessments</EndpointIndex><EndpointIndex>Herpesvirus infection - Incidence/Prevalence of Herpes Infections/Diseases - Incidence/prevalence of CMV infection/disease</EndpointIndex><EndpointIndex>Herpesvirus infection - Protocol Specified Other Endpoints - Graft rejection/failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Inflammatory &amp; Oxidative Stress Markers - Donor specific antibodies</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Assessment of nephrotoxicity</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Gastrointestinal adverse events</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Mucosal ulcers</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Urinary Protein Excretion/Proteinuria</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications - Glucose intolerance/impaired glucose tolerance</EndpointIndex><EndpointIndex>Kidney transplantation - Other Post Transplant Complications</EndpointIndex><EndpointIndex>Kidney transplantation - Post Transplant Malignancies</EndpointIndex><EndpointIndex>Renal failure - Assessment of Glomerular Filtration Rate (GFR) - Assessment of estimated glomerular filtration rate(eGFR)/creatinine clearance(CCr/CrCl/CLcr)</EndpointIndex><EndpointIndex>Renal failure - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Renal failure - Assessment of Organ Function - Metabolic/endocrinal assessment</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Function - Assessment of creatinine level</EndpointIndex><EndpointIndex>Renal failure - Assessment of Safety and Tolerability - Assessment of infections</EndpointIndex><EndpointIndex>Renal failure - Assessment of Survival - Assessment of patient survival</EndpointIndex><EndpointIndex>Renal failure - Assessment of Urinary Protein Excretion/Proteinuria</EndpointIndex><EndpointIndex>Renal failure - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath Induction</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects at risk of developing disease</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients</PatientSegment><PatientSegment>Renal failure - Subjects with History/Scheduled for Renal Replacement Therapy - Subjects with history/scheduled for renal transplantation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood platelets </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Granulocytes </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> Total protein </BiomarkerName><BiomarkerName> Urinary protein</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>89 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Michael Rees, MD, PhD</Name></ContactNames></Trial><Trial Id="153633"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>Uniformed Services University of the Health Sciences</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-12T00:00:00Z</DateChangeLast><DateEnd>2013-10-31T00:00:00Z</DateEnd><DateStart>2012-09-30T00:00:00Z</DateStart><Identifiers><Identifier>IDCRP-070</Identifier><Identifier>NCT01933048</Identifier><Identifier>SNIF</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1100</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this prospective, open-label clinical trial was to evaluate the immunogenicity of self-administered (SA) live, attenuated influenza vaccine (LAIV, FluMist ) in comparison with healthcare worker administered (HCWA) FluMist and to evaluate the feasibility of group self-administration of LAIV.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Influenza Vaccine - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Influenza virus infection - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>SNIF: Self-Administered Nasal Influenza Feasibility Study</TitleDisplay><PrimaryCompletionDate type="Actual">2013-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Jessica Rosas</Name><Name>Michelande Ridore</Name><Name>Timothy Burgess, MD, MPH, Capt, MC, USN</Name></ContactNames></Trial><Trial Id="153430"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>F Hoffmann-La Roche AG</Company><Company>Roche Holding AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Westmead Hospital</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2018-06-27T00:00:00Z</DateChangeLast><DateStart>2000-01-01T00:00:00Z</DateStart><Identifiers><Identifier>ACTRN12611001041943</Identifier><Identifier>ANZCTR347525</Identifier><Identifier>HREC98/9/4.8 (695)</Identifier><Identifier>U1111-1124-8603</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dornase alfa alone</Intervention><Intervention>physiotherapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this trial was to provide information for each individual patient as to whether they benefit more with Pulmozyme before or Pulmozyme after their physiotherapy technique [ 1474249 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Exercise Capacity/Tolerance</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Pulmonary Function - FEV1/FVC ratio</EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of Sputum - Assessment of sputum production/composition</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Is the Effectiveness of Pulmozyme Related to Timing? Pre or Post Physiotherapy?</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>FEV / FVC ratio </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Maximal oxygen uptake</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>43</NumberOfSites><ContactNames><Name>Anne Drury</Name><Name>Peter Middleton</Name></ContactNames></Trial><Trial Id="152279"><Indications><Indication>Cardiogenic shock</Indication></Indications><CompaniesCollaborator><Company>Deutsche Stiftung für Herzforschung</Company><Company>European Commission</Company><Company>German Centre for Cardiovascular Research</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of Lubeck</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2017-10-31T00:00:00Z</DateEnd><DateStart>2013-04-30T00:00:00Z</DateStart><Identifiers><Identifier>CULPRIT-SHOCK</Identifier><Identifier>CULPRIT-SHOCK1.2</Identifier><Identifier>NCT01927549</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Percutaneous coronary intervention alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>706</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Systolic blood pressure &gt; 90 mmHg for &gt; 30 min or Catecholamines required to maintain pressure &gt; 90 mmHg during systole and Signs of pulmonary congestion Signs of impaired organ perfusion with at least one of the following criteria Altered mental status &lt;b&gt;Cold&lt;/b&gt;, clammy skin and extremities Oliguria with urine output&amp;lt; 30 ml/h Serum-lactate &gt; 2.0 mmol/l Informed consent</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiac Markers - Creatine kinase (CK)</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiac Markers - Creatine kinase MB isoenzyme (CK-MB)</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiac Markers - Troponin I</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Cardiovascular Events - Recurrent ischemic events/Recurrent MI</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Hemorrhagic Complications</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Renal Function - Impaired renal function</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Reperfusion/Revascularization</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of hospitalization</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiac Markers - Creatine kinase (CK) levels</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiac Markers - Creatine kinase MB isoenzyme (CK-MB) level</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiac Markers - Troponin I (TnI) elevation</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiovascular Events - Recurrent MI</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Hemorrhagic Complications</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Renal Function</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Reperfusion/Revascularization</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of hospitalization</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>CULPRIT-SHOCK: Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock</TitleDisplay><PatientSegmentTerms><PatientSegment>Acute coronary syndrome - Non-ST Segment Elevation Myocardial Infarction(NSTEMI) Subjects</PatientSegment><PatientSegment>Acute coronary syndrome - ST Segment Elevation Myocardial Infarction(STEMI) Subjects</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with Acute Myocardial Infarction (MI)</PatientSegment><PatientSegment>Acute coronary syndrome - Subjects with comorbid conditions - Subjects co-morbid with cardiogenic shock</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Complications of the Underlying IHD</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - Acute onset/new onset myocardial infarction (MI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - Non ST elevation myocardial infarction (NSTEMI)</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Unstable Coronary Artery Disease - ST elevation myocardial infarction (STEMI)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatine Kinase, MB Form </BiomarkerName><BiomarkerName> Creatine kinase </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Troponin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>54 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Holger Thiele, MD</Name></ContactNames></Trial><Trial Id="152208"><Indications><Indication>Perennial allergic rhinitis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-09-24T00:00:00Z</DateChangeLast><DateEnd>1996-02-02T00:00:00Z</DateEnd><DateStart>1994-07-29T00:00:00Z</DateStart><Identifiers><Identifier>FLN-403</Identifier></Identifiers><IndicationsAdverse><Indication>Common cold</Indication><Indication>Cough</Indication><Indication>Headache</Indication><Indication>Influenza virus infection</Indication><Indication>Nasal congestion</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>fluticasone propionate alone</Intervention><Intervention>pseudoephedrine alone</Intervention><Intervention>terfenadine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>75</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>results were published. The mean number of days on rescue medication (pseudoephedrine) was 126.2 and 174.4 for fluticasone and terfenadine groups, respectively. In fluticasone versus terfenadine groups, painful surgical wounds (24 versus 28%), common &lt;b&gt;cold&lt;/b&gt; (21 versus 20%), nasal congestion following procedure (16 versus 10%), headache (5 versus 10%), influenza (5 versus 6%), and cough (3 versus 5%) were the most frequent adverse events (AEs). Serious adverse events were not reported in both the groups</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of eosinophil count</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of adverse events</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Allergic rhinitis - Patient Reported Outcomes/Quality of Life Assessments - Patient's global evaluation of allergic rhinitis</EndpointIndex><EndpointIndex>Allergic rhinitis - Physician Global Assessment of Disease Activity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>The Effects of Fluticasone Propionate Aqueous Nasal Spray versus Terfenadine Tablets on the Nasal Mucosa: A One-Year Nasal Biopsy Study in Patients With Perennial Allergic Rhinitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Perennial Allergic Rhinitis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>CD3 Antigens </BiomarkerName><BiomarkerName> Eosinophils </BiomarkerName><BiomarkerName> Interleukin-2 receptor alpha chain </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain </BiomarkerName><BiomarkerName> Tryptase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>18 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="151370"><Indications><Indication>Chronic fatigue syndrome</Indication></Indications><CompaniesSponsor><Company>Yonsei University</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2013-08-23T00:00:00Z</DateChangeLast><DateEnd>2013-10-31T00:00:00Z</DateEnd><DateStart>2013-08-31T00:00:00Z</DateStart><Identifiers><Identifier>3-2012-0154</Identifier><Identifier>NCT01926132</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ascorbic acid alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Pregnancy and lactation Acute common &lt;b&gt;cold&lt;/b&gt;, acute gastroenteritis, uncontrolled diabetes, uncontrolled hypertension, liver disease or renal disease Previous medical history, affectable by high-dose ascorbic acid (gout, renal calculi and glucose-6-phosphate dehydrogenase deficiency) Hypersensitivity</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>High-dose Ascorbic Acid Intravenous Injection Decreases Mitochondrial DNA Damage In Chronic Fatigue Patients: Randomized, Controlled Study</TitleDisplay><PrimaryCompletionDate type="Anticipated">2013-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>2 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jae Yong Shim, MD</Name></ContactNames></Trial><Trial Id="150998"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Bronchodilator</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Drug combination</Technology><Technology>Inhalant formulation</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2013-08-23T00:00:00Z</DateChangeLast><DateStart>1999-08-31T00:00:00Z</DateStart><Identifiers><Identifier>SAS40019</Identifier><Identifier>SER9806</Identifier></Identifiers><IndicationsAdverse><Indication>Common cold</Indication><Indication>Cough</Indication><Indication>Dyspnea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>In April 2007, results were published. Most frequent adverse events occurred in 43 and 57% patients of fluticasone propionate + salmeterol and placebo arms, respectively. Common &lt;b&gt;cold&lt;/b&gt; (14 versus 21%), dyspnea (7 versus 14%), cough (7 versus 21%), flu/fever (0 versus 14%) were reported in fluticasone propionate + salmeterol versus placebo arms, respectively. No serious adverse events were reported in both the groups [ 1466802 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>A phase IIIb/IV, safety, single-center, randomized, double-blind, parallel-group comparison of the effect of the salmeterol/fluticasone propionate combination product (50/250 microg) bid via the Diskus inhaler with placebo bid via the Diskus inhaler in young adults who are in clinical remission of allergic asthma</TitleDisplay><BiomarkerNames><BiomarkerName>Adenosine Monophosphate </BiomarkerName><BiomarkerName> Eosinophils </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Nitric oxide</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="150530"><Indications><Indication>Opiate dependence</Indication><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>ORL1 receptor agonist</Action><Action>Opioid receptor mu partial agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Antidepressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Turku University Hospital</Company></CompaniesSponsor><Countries><Country>Finland</Country></Countries><DateChangeLast>2018-08-30T00:00:00Z</DateChangeLast><DateStart>2012-08-28T00:00:00Z</DateStart><Identifiers><Identifier>2012-002871-32</Identifier><Identifier>EUCTR2012-002871-32-FI</Identifier><Identifier>FI::Rifabupre</Identifier><Identifier>Rifabupre</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>buprenorphine (sublingual, opioid dependence), Indivior plus rifampicin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>12</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The main objective of this trial was to examine the possible interactions of sublingual and iv buprenorphine with rifampicin [ 1465822 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Quantitative sensory testing</EndpointIndex><EndpointIndex>Pain - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Clinical Assessments - Assessment of hematological function</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Rifabupre: Effects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous Buprenorphine: A Four-Phase, Crossover Study in Healthy Subjects</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>mari fihlman</Name></ContactNames></Trial><Trial Id="150472"><Indications><Indication>Pain</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Rigshospitalet, Denmark</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2016-08-10T00:00:00Z</DateChangeLast><DateEnd>2013-08-01T00:00:00Z</DateEnd><DateStart>2013-05-28T00:00:00Z</DateStart><Identifiers><Identifier>2013-001822-24</Identifier><Identifier>EUCTR2013-001822-24-DK</Identifier><Identifier>SM1-PJ-13</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lidocaine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>16</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The main objective of this trial was to investigate whether increased dose of local anesthetic ( lidocain ) would increase duration of peripheral nerve block (adductor canal block). The secondary objective was to develop a model for assessing duration of peripheral nerve blockades. The effect of different doses (mass) of local anesthetic on duration of adductor canal block in healthy volunteers [ 1465747 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Quantitative sensory testing</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Assessment of duration of block</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Level/Depth of block</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>The effect of different doses of local anesthetic on duration of a nerve blockade</TitleDisplay><PrimaryCompletionDate/><TrialDuration>2 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jorgen Dahl</Name></ContactNames></Trial><Trial Id="150231"><Indications><Indication>Anesthesia</Indication></Indications><CompaniesSponsor><Company>Austin Health</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2017-07-08T00:00:00Z</DateChangeLast><DateStart>2008-10-01T00:00:00Z</DateStart><Identifiers><Identifier>ACTRN12608000414314</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lignocaine alone</Intervention><Intervention>vapocoolant cold spray (butane, propane and pentane blend) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>220</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Refusal to provide consentInability to provide informed consent (Non-English speaking, altered mental state, significant illness, urgent need for IV cannulation) Moderate to severe discomfort or painDiseases of the skin associated with &lt;b&gt;cold&lt;/b&gt; intolerance (eg: Raynaud's) Known allergy to spray contents or lignocaine Peripheral neuropathy Parenteral analgesia in the previous 4 h Use of other local anesthetics</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Topical Alkane Vapocoolant Spray versus Subcutaneous Lignocaine Injection For Reducing The Pain Of Intravenous Cannulation: A Randomized, Controlled, Clinical Trial</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects in need of Procedural Analgesia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>David Taylor</Name></ContactNames></Trial><Trial Id="150199"><CompaniesSponsor><Company>Medical University of Vienna</Company></CompaniesSponsor><Countries><Country>Austria</Country></Countries><DateChangeLast>2013-08-22T00:00:00Z</DateChangeLast><DateStart>2005-10-03T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT 2005-002159-41</Identifier><Identifier>Mo_top_Sb_100505</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>buprenorphine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>16</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>induced hyperalgesia of the skin compared to vehicle. This effect was dose dependent in a dose range between 0.01 and 0.04 % buprenorphine cream. The secondary objectives of this study were: To test the study drug concerning secondary outcome variables: &lt;b&gt;Cold&lt;/b&gt; pain perception threshold (CPPT) in the inflamed area and in normal skin. Stimulus response to different moving innocuous stimuli (Q-tip, cotton wisp, soft brush) in the inflamed area and in normal skin. Heat pain tolerance threshold (HPTT) in the </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Investigation of the Antihyperalgesic Effect of Topical Buprenorphine in an UV-B Induced Inflammatory Skin Pain Model in Healthy Volunteers - Topical Buprenorphine in Sunburn</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="14997"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-12T00:00:00Z</DateChangeLast><DateEnd>2009-03-31T00:00:00Z</DateEnd><DateStart>2008-06-30T00:00:00Z</DateStart><Identifiers><Identifier>MI-MA182</Identifier><Identifier>MI-MA182</Identifier><Identifier>NCT00677820</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>300</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>divided into two arms: Arm 1: In this arm, FluMist vaccine would be supplied in intranasal sprayers containing a total volume of 0.5 ml of sucrose-phosphate buffer, egg allantoic fluid, and approximately 107 FFU (fluorescent focus units) of each of three &lt;b&gt;cold&lt;/b&gt;-adapted, attenuated, 6:2 reassortant influenza strains A/South Dakota/6/07 (H1N1), A/Uruguay/716/07 (H3N2), and B/Florida/4/2006. Arm 2: Placebo would be supplied in intranasal sprayers containing 0.5 ml of sucrose-phosphate buffer.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>MI-MA182: A Prospective Study to Evaluate the Safety of a Trivalent Vaccine of New 6 : 2 Influenza Virus Reassortants</TitleDisplay><PrimaryCompletionDate type="Actual">2008-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Maria Allende</Name><Name>Raburn Mallory, MD</Name><Name>Raymond Mallory</Name></ContactNames></Trial><Trial Id="148997"><Indications><Indication>Seasonal allergic rhinitis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Histamine H1 receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Capsule formulation</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-06-26T00:00:00Z</DateChangeLast><DateEnd>2013-10-17T00:00:00Z</DateEnd><DateStart>2013-08-01T00:00:00Z</DateStart><Identifiers><Identifier>IND IDE 109805</Identifier><Identifier>NCT01916226</Identifier><Identifier>Study 200165</Identifier></Identifiers><InterventionsControlDisplay><Intervention>cetirizine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>fluticasone propionate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>682</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>or nasal septal perforation that could affect the deposition of intranasal study drug Nasal (eg, nasal septum), ocular, or throat injury, or surgery to these areas in the last 3 months Rhinitis medicamentosa. Bacterial or viral infection (eg, common &lt;b&gt;cold&lt;/b&gt;) of the eyes or upper respiratory tract within 2 weeks of visit 1 or during the screening period Documented evidence of acute or significant chronic sinusitis, as determined by the individual investigator Current or history of glaucoma and/or cataracts</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Ocular/Non Nasal Symptoms - Assessment of Total ocular symptoms score (TOSS)</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Assessment of AM/PM instantaneous total nasal symptom score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Assessment of AM/PM reflective total nasal symptom score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Assessment of reflective total nasal symptom score</EndpointIndex><EndpointIndex>Allergic rhinitis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Rhinoconjunctivitis Quality of life questionnaire(RQLQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Comparator Study of Fluticasone Propionate Nasal Spray Versus (versus) Cetirizine in the Treatment of Seasonal Allergic Rhinitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Moderate to Severe Allergic Rhinitis</PatientSegment><PatientSegment>Allergic rhinitis - Subjects with Seasonal Allergic Rhinitis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>2 Months</TrialDuration><NumberOfSites>31</NumberOfSites><ContactNames><Name>Cheri Hudson</Name><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="14890"><Indications><Indication>Cardiac failure</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>BNP agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action><Action>Cardiac agent</Action><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Protein recombinant</Technology></Technologies><CompaniesSponsor><Company>University of Texas System</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2013-12-02T00:00:00Z</DateChangeLast><DateEnd>2005-04-30T00:00:00Z</DateEnd><DateStart>2003-12-31T00:00:00Z</DateStart><Identifiers><Identifier>IRB0603-412</Identifier><Identifier>NCT00559338</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>nesiritide alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>104</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Systolic blood pressure of less than 90 mm Hg Frank or impending cardiogenic shock Cardiopulmonary arrest Evidence of low cardiac output (&lt;b&gt;cold&lt;/b&gt; clammy extremities Mental status changes) New onset congestive heart failure Suspected acute coronary syndrome (elevated troponin New electrocardiographic changes, or history consistent with cardiac ischemia High clinical suspicion of pulmonary embolism</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of Renal Function</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of hospitalization</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of hospitalization - Assessment of number of emergency department visits</EndpointIndex><EndpointIndex>Cardiac failure - Assessment of hospitalization - Assessment of rehospitalizations</EndpointIndex><EndpointIndex>Myocardial disease - Assessment of hospitalization</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department</TitleDisplay><PatientSegmentTerms><PatientSegment>Cardiac failure - Subjects with NYHA Functional Class - Severe/NYHA Functional Class IV Heart Failure Subjects</PatientSegment><PatientSegment>Myocardial disease - Subjects with comorbid conditions - Subjects co-morbid with heart failure</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>16 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Adam H Miller</Name></ContactNames></Trial><Trial Id="148511"><Indications><Indication>Pain</Indication><Indication>Pulpitis</Indication><Indication>Topical anesthesia</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Adrenergic receptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Adrenergic receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Injectable formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesCollaborator><Company>Fundacao de Amparo a Pesquisa do Estado Sao Paulo</Company></CompaniesCollaborator><CompaniesSponsor><Company>Universidade Estadual de Campina</Company></CompaniesSponsor><Countries><Country>Brazil</Country></Countries><DateChangeLast>2018-09-08T00:00:00Z</DateChangeLast><DateEnd>2011-01-31T00:00:00Z</DateEnd><DateStart>2010-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2009-10834-4</Identifier><Identifier>NCT01912755</Identifier></Identifiers><InterventionsControlDisplay><Intervention>epinephrine plus lidocaine</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>articaine plus epinephrine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Long-lasting moderate to severe pain during &lt;b&gt;cold&lt;/b&gt; test Absence of periapical radiolucency except for a widened periodontal ligament (evaluated in periapical radiographs) Vital coronal pulp on access opening</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures - Imaging assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Anesthetic Efficacy Of Articaine And Lidocaine In Lower Molars With Irreversible Pulpits</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects in need of Procedural Analgesia</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>11 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>José FA Almeida, DDS, PhD</Name><Name>Maria RF Monteiro, DDS, MSc</Name></ContactNames></Trial><Trial Id="145471"><Indications><Indication>Parturition</Indication></Indications><CompaniesCollaborator><Company>Academy of Finland</Company></CompaniesCollaborator><CompaniesSponsor><Company>National Institute for Health and Welfare, Finland</Company></CompaniesSponsor><Countries><Country>Mozambique</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2016-05-31T00:00:00Z</DateEnd><DateStart>2007-05-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT00488579</Identifier><Identifier>PROFEG</Identifier><Identifier>PROFEG</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ferrous sulphate plus folic acid</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>4326</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of the study was to compare two policies of iron administration during pregnancy in regard to health of the mother and infant and program feasibility. The two groups compared were routine iron prophylaxis and screening of anemia and therapy with iron.</Teaser><TrialCategories><Category>Dietary supplement</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anemia - Anthropometric Assessments</EndpointIndex><EndpointIndex>Anemia - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Anemia - Assessment of Safety and Tolerability - Assessment of side-effects/complications</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PROFEG: Routine Iron Prophylaxis During Pregnancy</TitleDisplay><PatientSegmentTerms><PatientSegment>Anemia - Subjects at risk of developing disease - Subjects with pregnancy as a risk factor</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Birth weight </BiomarkerName><BiomarkerName> Hemoglobin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2007-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>108 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Baltazar Chilundo</Name><Name>Elina Hemminki, PhD, MD</Name></ContactNames></Trial><Trial Id="144021"><Indications><Indication>Heart transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Belgium</Country></Countries><DateChangeLast>2013-12-23T00:00:00Z</DateChangeLast><DateEnd>2003-06-17T00:00:00Z</DateEnd><DateStart>2000-09-16T00:00:00Z</DateStart><Identifiers><Identifier>CCHI621ABE01</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including ATG (rabbit anti-lymphocyte immunoglobulin) , basiliximab , ciclosporin, Novartis , mycophenolate mofetil</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>56</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Male or female cardiac patients aged 18 to 70 years of age undergoing primary heart transplantation with a donor heart &lt;b&gt;cold&lt;/b&gt; ischemia time of time&amp;lt; 6 h Females capable of becoming pregnant must have a negative pregnancy test prior to randomization and are required to practice a medically approved method of birth control for the duration of the study The patient has given</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of hospitalization - Assessment of rehospitalizations</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of hospitalization - Duration and average total days of hospitalisation</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Basiliximab Versus Antithymocyte Globulin in “De Novo” Heart Transplantation: Open Randomized Pilot Trial</TitleDisplay><BiomarkerNames><BiomarkerName>Lymphocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>33 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="143799"><Indications><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>Medizinische Universität Innsbruck</Company></CompaniesSponsor><Countries><Country>Austria</Country></Countries><DateChangeLast>2016-07-11T00:00:00Z</DateChangeLast><DateStart>2010-05-26T00:00:00Z</DateStart><Identifiers><Identifier>13814</Identifier><Identifier>EudraCT 2010-019354-40</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>levodopa + benserazide (oral, Parkinson's disease), Roche alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>19</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to examine of the influence of STN stimulation on the pain threshold of patients with idiopathic Parkinsons disease. Change in pain threshold before and after levodopa administration (OFF/OFF OFF/ON). Difference in the pain threshold at STN-DBS (OFF/OFF ON/OFF) in comparison to the difference in the pain threshold with levodopa (OFF/OFF OFF/ON) [ 1446902 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Quantitative sensory testing</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Non-Motor Symptoms of Parkinson's Disease - Assessment of sensory function</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Parkinson's Disease ON-OFF States</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Examination of the Influence of STN Stimulation on the Pain Threshold of Patients With Idiopathic Parkinsons Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain</PatientSegment><PatientSegment>Parkinsons disease - Subjects with Non-Motor Symptoms of Parkinson's Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="143797"><Indications><Indication>Non-insulin dependent diabetes</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Insulin ligand</Action><Action>Insulin receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Human insulin fast acting product</Action><Action>Human insulin intermediate acting product</Action><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Peptide</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Centre Hospitalier Universitaire Dijon</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2017-04-12T00:00:00Z</DateChangeLast><DateEnd>2015-09-30T00:00:00Z</DateEnd><DateStart>2012-01-31T00:00:00Z</DateStart><Identifiers><Identifier>2011-004602-19</Identifier><Identifier>NCT01889914</Identifier><Identifier>TRICIDIA2</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>insulin glulisine alone</Intervention><Intervention>insulin detemir plus insulin glulisine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> an untreated by the laser proliferative ischemic retinopathy BMI (body mass index)&amp;lt; 28.5 kg/m2 Pacemaker (CI IRM) Presence of implantable material (CI IRM) Pregnancy, breastfeeding Practices of violent sports Professional extreme environment of &lt;b&gt;cold&lt;/b&gt; or heat Serious psychiatric diseases physical and/or psychiatric Incapacitated medically significant Poor sanitation</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Insulin resistance - Anthropometric Assessments - Assessment of body weight</EndpointIndex><EndpointIndex>Insulin resistance - Assessment of HbA1c Levels</EndpointIndex><EndpointIndex>Insulin resistance - Glycemic Control Analysis - Assessment of blood glucose</EndpointIndex><EndpointIndex>Insulin resistance - Glycemic Control Analysis - Assessment of insulin resistance</EndpointIndex><EndpointIndex>Insulin resistance - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Insulin Sensitivity - Hyperinsulinemic euglycemic clamp</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of insulin resistance</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Hyperglycemic events/episodes</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Obesity, Body Weight &amp; Fat Tissue Assessment</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TRICIDIA2: Treatment By Insulin Continuous Infusion In Type 2 Diabetes</TitleDisplay><PatientSegmentTerms><PatientSegment>Insulin resistance - Insulin Resistance in Metabolic Diseases Subjects - Subjects with obesity</PatientSegment><PatientSegment>Insulin resistance - Subjects with comorbid conditions - Subjects with diabetes mellitus</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects on Monotherapy - Subjects only on metformin</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects on Treatment/Requiring Insulin</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with comorbid conditions - Subjects with obesity</PatientSegment><PatientSegment>Obesity - Obese Class I Subjects</PatientSegment><PatientSegment>Obesity - Obese Class II Subjects</PatientSegment><PatientSegment>Obesity - Overweight (pre-obese) Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2015-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>44 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Sabine RUDONI, MD</Name></ContactNames></Trial><Trial Id="143285"><Indications><Indication>Neuropathic pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor mu agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Patch formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Mundipharma International Corp Ltd</Company></CompaniesSponsor><Countries><Country>New Zealand</Country><Country>Australia</Country></Countries><DateChangeLast>2017-03-31T00:00:00Z</DateChangeLast><DateStart>2010-03-05T00:00:00Z</DateStart><Identifiers><Identifier>ACTRN12609000647235</Identifier><Identifier>ANZCTR308284</Identifier><Identifier>ASSET DPNP</Identifier><Identifier>BUP3029</Identifier></Identifiers><IndicationsAdverse><Indication>Emesis</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>buprenorphine (transdermal patch, pain), Grunenthal/ Mundipharma alone</Intervention><Intervention>paracetamol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>186</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> or lower extremity pain which may confound assessment of DPNP Patient has clinical evidence of active infection at the site of DPNP Patient has undergone prior neurolytic treatment (nerve destructive procedures by application of chemicals, heat or &lt;b&gt;cold&lt;/b&gt;), intrathecal pump insertion, or spinal cord stimulation for DPNP or other lower limb symptomatology, or has had somatic or sympathetic nerve blocks within the last 6 months for DPNP or other lower limb symptomatology Patient has symptomatic Peripheral</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Co-morbidity - Assessment of depression</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Depression Severity by Specific Criteria - Assessment by Beck Depression Inventory (BDI)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Pain - Assessment by Neuropathic Pain Symptom Inventory (NPSI)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Pain - Assessment of Pain Intensity</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Sleep - Sleep Interference Scores</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Brief Pain Inventory (BPI)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Numeric Rating Scale for Pain</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Patient Global Impression of Change (PGIC)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - McGill questionnaire</EndpointIndex><EndpointIndex>Diabetic complication - Protocol Specified Other Endpoints - Assessment of prescription changes/rescue medication uses</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Depression Severity by Specific Criteria - Assessment by Beck Depression Inventory (BDI)</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of pain - Assessment by Neuropathic Pain Symptom Inventory (NPSI)</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Brief Pain Inventory (BPI)</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Numeric Rating Scale for Pain</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Patient Global Impression of Change (PGIC)</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - McGill questionnaire</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Depression Severity by Specific Criteria - Assessment by Beck Depression Inventory (BDI)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Pain - Assessment by Neuropathic Pain Symptom Inventory (NPSI)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Brief Pain Inventory (BPI)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Numeric Rating Scale for Pain</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Patient Global Impression of Change (PGIC)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - McGill questionnaire</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Brief Pain Inventory[BPI]</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on McGill Pain Questionnaire</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment by Neuropathic Pain Symptom Inventory (NPSI)</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR) - Rate of &gt;/=30% response</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR) - Rate of &gt;/=50% response</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ASSET DPNP: A Multicenter, Randomized, Double-Blind, Parallel-Group Comparison of the Efficacy and Safety of Transdermal Buprenorphine (Norspa, Buprenorphine transdermal system [BTDS]) And Placebo in Patients With Diabetic Peripheral Neuropathic Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy</PatientSegment><PatientSegment>Insulin dependent diabetes - Subjects with diabetic neuropathy</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Good Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic neuropathy</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>2</NumberOfSites><ContactNames><Name>Christine Smith</Name><Name>Dennis Yue</Name><Name>Eric Meyer</Name><Name>Madonna Kava</Name></ContactNames></Trial><Trial Id="142989"><Indications><Indication>Respiratory disorder</Indication></Indications><CompaniesCollaborator><Company>Society for Pediatric Anesthesia in New Zealand and Australia</Company><Company>University of Western Australia</Company></CompaniesCollaborator><CompaniesSponsor><Company>The Princess Margaret Hospital for Children</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2018-07-17T00:00:00Z</DateChangeLast><DateStart>2012-05-28T00:00:00Z</DateStart><Identifiers><Identifier>ACTRN12612000608864</Identifier><Identifier>HREC 1933EP</Identifier><Identifier>SAFA</Identifier></Identifiers><PatientCountEnrollment>280</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Children, aged 4 to 16 years, male or female undergoing elective minor surgery Healthy children (n = 100) with no risk factors Children (n = 180) with 2 or more risk factors for developing PRAE: &lt;b&gt;Cold&lt;/b&gt; or flu currently or in the last 2 weeks Eczema at present or in the past Wheezing in the last 12 months Asthma in the past (if wheezing in the last 12 months is negative) Dry nocturnal cough Wheezing at exercise Family history of asthma (mother, father</Teaser><TrialCategories><Category>Biomarker identification</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Asthma - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>SAFA: Safer Anesthesia for Children With Asthma (SAFA Trial): Can Exhaled Nitric Oxide (NO) Levels Predict Children at Risk for Respiratory Complications? – A Pilot Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects at risk of developing disease</PatientSegment><PatientSegment>Asthma - Subjects with Symptomatic Disease</PatientSegment><PatientSegment>Asthma - Subjects with comorbid conditions</PatientSegment><PatientSegment>Asthma - Subjects with comorbid conditions - Subjects co-morbid with atopic dermatitis/eczema</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Nitric oxide</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>2</NumberOfSites><ContactNames><Name>Britta Ungern</Name><Name>Britta Ungern-sternberg</Name></ContactNames></Trial><Trial Id="142364"><Indications><Indication>Rheumatoid arthritis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cytotoxic T-lymphocyte protein-4 stimulator</Action><Action>T cell surface glycoprotein CD28 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody fragment</Technology><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Protein conjugated</Technology><Technology>Protein fusion</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Bristol-Myers Squibb Co</Company></CompaniesCollaborator><CompaniesSponsor><Company>School of Medicine, Keio University</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2017-07-06T00:00:00Z</DateChangeLast><DateEnd>2012-01-01T00:00:00Z</DateEnd><DateStart>2010-09-01T00:00:00Z</DateStart><Identifiers><Identifier>JPRN-UMIN000004137</Identifier><Identifier>ORION</Identifier></Identifiers><IndicationsAdverse><Indication>Acute bronchitis</Indication><Indication>Common cold</Indication><Indication>Constipation</Indication><Indication>Cystitis</Indication><Indication>Lower back pain</Indication><Indication>Periarthritis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>abatacept (continuation group) alone</Intervention><Intervention>abatacept (discontinuation group) alone</Intervention><Intervention>abatacept alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>51</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>patients being excluded for varied reasons [ 1353083 ]. In July 2013, results were presented. Serious adverse events were not reported. Patients in the continuation group experienced acute bronchitis (5.9%) and lower back pain/cystitis/constipation/common &lt;b&gt;cold&lt;/b&gt;/left scapulohumeral periarthritis (5.9%) [ 1440986 ]. Results were published in April 2015. A total of three patients who continued or resumed abatacept reported non-serious adverse events [ 1667056 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C-reactive protein (CRP)/high sensitivity C-reactive protein (hs-CRP)</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Remission</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Remission - DAS28 remission rate</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Imaging/Radiological Assessments - Van der Heijde-modified total Sharp Score (mTSS)/Modified Sharp Total Radiographic Score</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Patient Reported Outcomes/Quality of Life Assessments - Health Assessment Questionnaire (HAQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>ORION: Orencia Remission Induction And Outcome Navigation Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Rheumatoid arthritis - Active Rheumatoid Arthritis</PatientSegment><PatientSegment>Rheumatoid arthritis - Subjects on Rheumatoid Arthritis Therapy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Rheumatoid factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>16 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Kikuchi Kayoko</Name><Name>Tsutomu Takeuchi</Name></ContactNames></Trial><Trial Id="141408"><Indications><Indication>Essential hypertension</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcium channel inhibitor</Action><Action>Calcium channel inhibitor L-type</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>Hong Kong</Country><Country>Italy</Country></Countries><DateChangeLast>2019-03-07T00:00:00Z</DateChangeLast><DateStart>2008-02-19T00:00:00Z</DateStart><Identifiers><Identifier>00-MEP-04</Identifier><Identifier>EudraCT 2007-004938-16</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>amlodipine alone</Intervention><Intervention>barnidipine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>malignancy including leukaemia and lymphoma within the past five years (skin cancer other than melanoma is an exception) is reported Use of drugs known to affect blood pressure (such as tricyclic anti-depressants, carbenoxolone, phenothiazines, some common &lt;b&gt;cold&lt;/b&gt; medications and amphetamines) after the first dose of single-blind placebo medication is reported/detected A history of drug, medication or alcohol abuse is known Hypersensitivity or intolerance to either barnidipine or amlodipine or to other calcium</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Catecholamines Levels - Norepinephrine levels</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Randomized, Double-blind Study to Compare the Effect on Sympathetic Activity and Hemodynamic Profile of Barnidipine and Amlodipine in Patients With Mild to Moderate Essential Hypertension</TitleDisplay><PatientSegmentTerms><PatientSegment>Hypertension - Subjects with Primary/Essential Hypertension - Subjects with stage 1 (JNC 6) hypertension</PatientSegment><PatientSegment>Hypertension - Subjects with Primary/Essential Hypertension - Subjects with stage 2 (JNC 6) hypertension</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Norepinephrine</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>2</NumberOfSites><ContactNames><Name>Karen Kar Loen Chan</Name></ContactNames></Trial><Trial Id="141321"><Indications><Indication>Pain</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>5-HT uptake inhibitor</Action><Action>Analgesic</Action><Action>Antidepressant</Action><Action>Anxiolytic</Action><Action>Norepinephrine uptake inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Daily dosing</Technology><Technology>Enteric coated formulation</Technology><Technology>Oral controlled release formulation</Technology><Technology>Oral formulation</Technology><Technology>Pellet</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Danish Pain Research Center</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2019-03-07T00:00:00Z</DateChangeLast><DateStart>2007-03-05T00:00:00Z</DateStart><Identifiers><Identifier>Dulo2006</Identifier><Identifier>EudraCT 2006-005506-32</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>duloxetine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>86</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>The purpose of this study was to analyze chronic pain patients with and without neuropathic pain with respect to: effect of a balanced serotonergic and noradrenergic reuptake inhibitor ( duloxetine ) on pain, anxiety and depression measures; relation between character and quality of pain, depression and anxiety; time course for changes in pain, anxiety and depression following treatment [ 1441325 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Depression - Assessment of Co-morbidity</EndpointIndex><EndpointIndex>Depression - Assessment of Co-morbidity - Assessment of anxiety disorder</EndpointIndex><EndpointIndex>Depression - Assessment of Depression Severity by Specific Criteria</EndpointIndex><EndpointIndex>Depression - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Depression - Assessment of Sleep</EndpointIndex><EndpointIndex>Depression - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on McGill Pain Questionnaire</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Central nervous system disease outcomes</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Pain, Anxiety and Depression in Neuropathic and Non-neuropathic Pain: Effect of Monoamine Modulation</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with fibromyalgia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="14098"><Indications><Indication>Allergic rhinitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Histamine H1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>UCB Pharma Inc</Company></CompaniesSponsor><Countries><Country>Italy</Country><Country>Germany</Country></Countries><DateChangeLast>2018-01-22T00:00:00Z</DateChangeLast><DateEnd>2005-09-30T00:00:00Z</DateEnd><DateStart>2005-04-30T00:00:00Z</DateStart><Identifiers><Identifier>2004-002823-42</Identifier><Identifier>A00401</Identifier><Identifier>EudraCT2004-002823-42</Identifier><Identifier>LEADER</Identifier><Identifier>LEADER</Identifier><Identifier>NCT00160589</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>desloratadine alone</Intervention><Intervention>levocetirizine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>729</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> To enter study at Visit 1, subjects should not: Be pregnant (positive urinary pregnancy test) or lactating Have an ear, nose, throat (ENT) infection during the 2 weeks preceding Visit 1 (eg, sinusitis, purulent rhinorrhea, common &lt;b&gt;cold&lt;/b&gt;) Have an associated asthma requiring corticosteroid treatment Have an atopic dermatitis or an urticaria requiring an antihistamine treatment or theadministration of oral or topical corticosteroids Have an associated ENT disease such as vasomotor rhinitis</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Change from baseline in total nasal symptom score</EndpointIndex><EndpointIndex>Pruritus - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Pruritus - Assessment of Therapy Related Outcomes - Assessment of treatment effectiveness</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>LEADER: Levocetirizine And Desloratadine in Allergic Rhinitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Seasonal Allergic Rhinitis</PatientSegment><PatientSegment>Pruritus - Subjects with Pruritus Associated with Systemic Disorders - Subjects with allergic disorders</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2005-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Krassimir Mitchev</Name><Name>UCB Clinical Trial Call Center</Name></ContactNames></Trial><Trial Id="14042"><Indications><Indication>Allergic rhinitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Histamine H1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Sanofi SA</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2013-12-02T00:00:00Z</DateChangeLast><DateEnd>2003-07-31T00:00:00Z</DateEnd><DateStart>2002-12-31T00:00:00Z</DateStart><Identifiers><Identifier>M016455A_4145</Identifier><Identifier>NCT00637585</Identifier></Identifiers><IndicationsAdverse><Indication>Cellulitis</Indication><Indication>Common cold</Indication><Indication>Diarrhea</Indication><Indication>Drowsiness</Indication><Indication>Gastroenteritis</Indication><Indication>Insomnia</Indication><Indication>Lactose intolerance</Indication><Indication>Syncope</Indication><Indication>Urinary tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>desloratadine alone</Intervention><Intervention>fexofenadine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>42</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>experienced six AEs and included injured finger (sequence 1), diarrhea (n = 1; sequence 3), gastroenteritis (n = 1; sequence 3), fainting (sequence 4), infected gland (sequence 6) and head &lt;b&gt;cold&lt;/b&gt; (sequence 6). A total of three placebo-treated patients experienced four AEs and included conjunctivitis (n = 1; sequence 4), &lt;b&gt;cold&lt;/b&gt; sore (n = 1; sequence 4), headache (sequences 5 and 6). None of the reported events were found to be related to the study treatments. Of 16 events, 12 were treated with counteractive </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Laboratory/Diagnostic Measures - Assessment of skin prick test response</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine</TitleDisplay><PrimaryCompletionDate/><TrialDuration>7 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Dr Eli Meltzer</Name><Name>Dr Sherwin A Gillman</Name><Name>Phyllis Diener</Name></ContactNames></Trial><Trial Id="13885"><Indications><Indication>Allergic rhinitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Glucocorticoid receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Respiratory system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Microparticle formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Suspension</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Russian Federation</Country><Country>Hungary</Country><Country>Germany</Country><Country>US</Country><Country>Slovakia</Country><Country>Estonia</Country><Country>Canada</Country></Countries><DateChangeLast>2018-11-27T00:00:00Z</DateChangeLast><DateEnd>2008-06-30T00:00:00Z</DateEnd><DateStart>2008-01-31T00:00:00Z</DateStart><Identifiers><Identifier>2007-006562-15</Identifier><Identifier>FFU111439</Identifier><Identifier>NCT00609674</Identifier></Identifiers><IndicationsAdverse><Indication>Arthralgia</Indication><Indication>Bronchitis</Indication><Indication>Cough</Indication><Indication>Epistaxis</Indication><Indication>Headache</Indication><Indication>Rhinopharyngitis</Indication><Indication>Sneezing</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>fluticasone furoate (nasal, allergic rhinitis), GSK alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>315</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>intermittent asthma [NAEPP, 2007; GINA, 2006], or very mild asthma (Canada) [Lemiere, 2004] Subjects will be allowed to use short-acting inhaled beta2 agonists only on an as needed basis Rhinitis medicamentosa Bacterial or viral infection (eg, common &lt;b&gt;cold&lt;/b&gt;) of the eyes or upper respiratory tract within 2 weeks of visit 1 or during the screening period Documented evidence of acute or significant chronic sinusitis, as determined by the individual investigator Current or history of glaucoma and/or ocular</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Ocular/Non Nasal Symptoms - Assessment of Total ocular symptoms score (TOSS)</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Ocular/Non Nasal Symptoms - Assessment of individual ocular symptoms</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Pulmonary Function - Assessment of Peak nasal inspiratory flow (PNIF)</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Assessment of AM/PM instantaneous total nasal symptom score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Assessment of AM/PM reflective total nasal symptom score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Assessment of instantaneous total nasal symptom score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Assessment of reflective total nasal symptom score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of adverse events</EndpointIndex><EndpointIndex>Allergic rhinitis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Rhinoconjunctivitis Quality of life questionnaire(RQLQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-Round) Allergic Rhinitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Perennial Allergic Rhinitis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Peak nasal inspiratory flow</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>37</NumberOfSites><ContactNames><Name>Cheri Hudson</Name><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="135047"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsControl><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Chinese Ministry of Science and Technology</Company></CompaniesCollaborator><CompaniesSponsor><Company>Tianjin University of Traditional Chinese Medicine</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2014-01-02T00:00:00Z</DateChangeLast><DateStart>2007-09-01T00:00:00Z</DateStart><Identifiers><Identifier>ChiCTR-TRC-00000464</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Variable regimens including fluticasone propionate , salbutamol, GlaxoSmithKline , theophylline</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Traditional Chinese Medicine plus salbutamol, GlaxoSmithKline</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>396</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>would receive theophylline sustained release, twice daily for 10 days; Flixotide aerosol 125 microg/inhaled bid for 10 days and Ventolin aerosol if needed. Arm 3: patients with hot wheezing would receive Qinlong Zhixiao decoction granules bid 10 days; &lt;b&gt;cold&lt;/b&gt; wheezing: Suma Wenfei Pingxiao decoction granules bid 10 days; windy wheezing: Masu Zhixiao Decoction Granules twice daily for 10 days and Ventolin aerosol if needed [ 1429033 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score</EndpointIndex><EndpointIndex>Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Serum cytokines/interleukins/chemokines</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures - Assessment of hematology/biochemistry</EndpointIndex><EndpointIndex>Asthma - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Asthma - Assessment of Physical Examination - Cardiac evaluation</EndpointIndex><EndpointIndex>Asthma - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Asthma - Assessment of Sleep</EndpointIndex><EndpointIndex>Asthma - Assessment of Sputum - Eosinophilic cationic protein (ECP) in sputum</EndpointIndex><EndpointIndex>Asthma - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Asthma - Assessment of use of Rescue Medication - Frequency/rate of medication use</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Research on Comprehensive Therapy With Traditional Chinese Medicine for Acute Attack of Bronchial Asthmas</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with Intermittent/Episodic Asthma</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with mild persistent asthma</PatientSegment><PatientSegment>Asthma - Subjects with Symptomatic Disease - Subjects with acute/exacerbation of asthma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Eosinophil cationic protein </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Interleukin-8</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Qiang Wang</Name><Name>Zengtao Sun</Name></ContactNames></Trial><Trial Id="134587"><Indications><Indication>Osteoarthritis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cyclooxygenase 2 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Non-steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Merck &amp; Co Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Curtin University</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2016-08-08T00:00:00Z</DateChangeLast><DateStart>2009-08-03T00:00:00Z</DateStart><Identifiers><Identifier>ACTRN12609000524291</Identifier><Identifier>ANZCTR308104</Identifier><Identifier>HR47-2009</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>etoricoxib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The purpose of this trial was to evaluate whether people with painful knee osteoarthritis have greater pain sensitivity than similar aged healthy people, and can this pain sensitivity be altered by a 2-week course of the anti-inflammatory Arcoxia ( etoricoxib ) [ 1428104 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Functional Disability/Physical Function - Assessment of neurological function</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Functional Disability/Physical Function - Assessment of physical function by WOMAC Score</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Joint Stiffness - Assessment joint stiffness by WOMAC Score</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Pain</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Pain - Assessment of Pain Intensity</EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Pain - Assessment of Pain by WOMAC Score</EndpointIndex><EndpointIndex>Osteoarthritis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by SF-36/SF-12</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function - Assessment of physical activity</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on WOMAC scale</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropathic Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Other Measures of Pain Quality</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Do People With Painful Knee Osteoarthritis Have Greater Pain Sensitivity Than Similar Aged Healthy People, and Can This Pain Sensitivity Be Altered by a 2-Week Course of the Anti-Inflammatory Arcoxia?</TitleDisplay><PatientSegmentTerms><PatientSegment>Osteoarthritis - Subjects Enrolled Based on WOMAC Scores - Subjects enrolled based on WOMAC pain score</PatientSegment><PatientSegment>Osteoarthritis - Subjects with Osteoarthritis of Knee</PatientSegment><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with arthritic pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Penny Moss</Name><Name>Tony Wright</Name></ContactNames></Trial><Trial Id="134332"><Indications><Indication>Pain</Indication></Indications><CompaniesCollaborator><Company>Victoria University of Wellington</Company></CompaniesCollaborator><CompaniesSponsor><Company>Sunshine Hospital</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2018-06-14T00:00:00Z</DateChangeLast><DateEnd>2010-12-30T00:00:00Z</DateEnd><DateStart>2009-02-01T00:00:00Z</DateStart><Identifiers><Identifier>ACTRN12609000006246</Identifier><Identifier>PCIF</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>fentanyl alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>abnormalities Non-singleton pregnancy Allergy to opioid analgesia Bronchial asthma Myasthenia gravis Opioid Tolerance including regular use of methadone, buprenorphine, heroin, morphine, oxycodone Chronic nasal problems ie, hay-fever, sinusitis, common &lt;b&gt;cold&lt;/b&gt; Inability to self administer patient-controlled Intranasal Fentanyl (PCIF)</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PCIF: Self-administered Fentanyl for Birthing Women</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects in need of Procedural Analgesia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>22 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Debra Kerr</Name></ContactNames></Trial><Trial Id="133615"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Public Health England</Company><Company>University Hospital Southampton NHS Foundation Trust</Company></CompaniesCollaborator><CompaniesSponsor><Company>Imperial College London</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2019-06-28T00:00:00Z</DateChangeLast><DateEnd>2014-02-28T00:00:00Z</DateEnd><DateStart>2013-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2013-002031-26</Identifier><Identifier>NCT01859039</Identifier><Identifier>RHM CHI 0659</Identifier><Identifier>RHMCHI065</Identifier><Identifier>SNIFFLE</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>282</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The objective of this multicenter study was to assess the safety of intranasal live attenuated influenza vaccine (LAIV), FluMist in egg-allergic subjects, in order to demonstrate that these subjects can safely be given the new live attenuated influenza vaccine within a primary care health environment. The secondary objective of this study was to assess weather the administration of the intranasal LAIV influenza ('flu) vaccine safe in children who have experienced a previous severe allergic reaction</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Clinical Symptoms</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>SNIFFLE: Safety of Nasal Influenza Immunization in Egg Allergic Children</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>12</NumberOfSites><ContactNames><Name>Gary Stiefel</Name><Name>Huw Thomas</Name><Name>Jurgen Schwarze</Name><Name>Matthew Snape</Name><Name>Mich Erlewyn-Lajeunesse, DM FRCPCH</Name><Name>Paul J Turner, FRACP PhD</Name><Name>Paul Turner</Name></ContactNames></Trial><Trial Id="133611"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>AstraZeneca plc</Company></CompaniesCollaborator><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-12T00:00:00Z</DateChangeLast><DateEnd>2013-12-31T00:00:00Z</DateEnd><DateStart>2013-05-31T00:00:00Z</DateStart><Identifiers><Identifier>MED-VA-FLUMIST-1156</Identifier><Identifier>NCT01859143</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>300</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This prospective annual release study was designed to evaluate the safety on new influenza virus vaccine strains to be included in FluMist for the 2013 to 2014 influenza season.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of Three New 6 : 2 Influenza Virus Reassortants in Adults</TitleDisplay><PrimaryCompletionDate type="Actual">2013-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>7 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Naomi Veney</Name><Name>Raburn Mallory, MD</Name></ContactNames></Trial><Trial Id="13266"><Indications><Indication>Hepatitis C virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Interferon alpha 2 ligand</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>PEGylated formulation</Technology><Technology>Peptide</Technology><Technology>Protein conjugation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesCollaborator><Company>Hoffmann-La Roche Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Mayo Clinic Foundation</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-07-17T00:00:00Z</DateChangeLast><DateEnd>2009-04-30T00:00:00Z</DateEnd><DateStart>2004-07-31T00:00:00Z</DateStart><Identifiers><Identifier>1404-04</Identifier><Identifier>NCT00275548</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>peginterferon alfa-2a alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>12</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Multi-organ or retransplant recipient Patients with HCC who do not meet inclusion criteria or require systemic chemotherapy -Recipient of ABO incompatible organ Donor &lt;b&gt;cold&lt;/b&gt; ischemia time &gt; 20 h Anti-HBc positive donor Histological evidence of unresolved rejection Episode of steroid resistant rejection or use of OKT3 Evidence of current hepatitis B (sAg, cAb, IgM) Seropositivity for HIV infection Serum creatinine &gt; 2 x</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Early Virologic Response (EVR)</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Post Liver Transplantation Events - Acute/chronic rejection</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR)</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Viral Breakthrough/Relapse</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Liver Transplantation</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with comorbid conditions - Subjects with cirrhosis</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with comorbid conditions - Subjects with hepatocellular carcinoma</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>57 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Michael Charlton</Name></ContactNames></Trial><Trial Id="131068"><Indications><Indication>Opiate dependence</Indication><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>ORL1 receptor agonist</Action><Action>Opioid receptor mu partial agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Antidepressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Turku University Hospital</Company></CompaniesSponsor><Countries><Country>Finland</Country></Countries><DateChangeLast>2016-01-06T00:00:00Z</DateChangeLast><DateEnd>2014-11-30T00:00:00Z</DateEnd><DateStart>2013-04-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT01854489</Identifier><Identifier>RIFABUPRE</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>buprenorphine (sublingual, opioid dependence), Indivior alone</Intervention><Intervention>rifampicin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>12</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this study was to examine the possible interactions of sublingual buprenorphine and intravenous buprenorphine with rifampicin.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain tolerance</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Quantitative sensory testing</EndpointIndex><EndpointIndex>Pain - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Pain - Protocol Specified Other Endpoints - Assessment of pupil size</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Effects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous Buprenorphine</TitleDisplay><PrimaryCompletionDate type="Actual">2014-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>19 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="130696"><Indications><Indication>Herpesvirus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>HSV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Johnson &amp; Johnson</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2013-11-26T00:00:00Z</DateChangeLast><DateEnd>2007-03-15T00:00:00Z</DateEnd><DateStart>2006-08-31T00:00:00Z</DateStart><Identifiers><Identifier>CA-P-3978-01</Identifier><Identifier>EudraCT 2006-004015-21</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Compeed Total Care Cold Sore Patch alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>aciclovir alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>300</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Patients would receive either Compeed &lt;b&gt;cold&lt;/b&gt; sore patch or Zovirax cream 5% [ 1421352 ]....s) that in the judgment of the investigator may affect the course of the &lt;b&gt;cold&lt;/b&gt; sore lesion or interfere with the actions of the study treatment or confound the...within past 30 days Known allergy to any of the ingredients in the Compeed &lt;b&gt;cold&lt;/b&gt; sore patch or Zovirax Cream Known alcohol or drug abuse Participation in any other</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Randomized Clinical Study Comparing Compeed Cold Sore Patch to Zovirax Cream 5% in the Treatment of Herpes Labialis</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>6 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="129483"><Indications><Indication>Respiratory tract infection</Indication></Indications><CompaniesSponsor><Company>Swedish Herbal Institute</Company></CompaniesSponsor><Countries><Country>Finland</Country></Countries><DateChangeLast>2018-01-29T00:00:00Z</DateChangeLast><DateStart>2009-12-10T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT 2009-012640-17</Identifier><Identifier>KJos/FIN</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Kan Jang alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>108</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Who were ill &amp;gt; 3 days with a common &lt;b&gt;cold&lt;/b&gt; With the fever &amp;gt; 38.5degC Suffering from accompanying illnesses such as bronchiolitis, pneumonia, pleuritis, septic...Subjects predominantly suffering from two or more symptoms of common &lt;b&gt;cold&lt;/b&gt; (cough expectoration, running nose, headache, fever, sore throat, earache, malaise /fatigue...assess the efficacy of Kan Jang oral solution in non complicated respiratory tract infections (common &lt;b&gt;cold&lt;/b&gt;) when it was used in the daily dose of 60 ml (30 ml bid) [ 1418319</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Migraine/Other Headaches</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Randomized, Controlled, Parallel-Group, Double-Blind Study of the Proprietary Kan Jang Oral Solution Versus Placebo in Patients With Non Complicated Respiratory Tract Infections (Common Cold)</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with pain associated with infections</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="129124"><Indications><Indication>Neuropathic pain</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Grunenthal GmbH</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2018-11-20T00:00:00Z</DateChangeLast><DateEnd>2014-03-14T00:00:00Z</DateEnd><DateStart>2012-08-13T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT 2012-003077-26</Identifier><Identifier>IMIVER</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lidocaine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>46</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The main objective of this study was to determine if the response to topical lidocaine in focal peripheral neuropathic pain depends on pain phenotype (irritable versus non-irritable nociceptor) [ 1418366 ]. The secondary objectives were: To test the effect of topical lidocaine on different pain phenomena in peripheral neuropathic pain. To test if the effect of topical lidocaine depends on presence of pain paraxysms. To test if the effect of topical lidocaine dependes on pain characteristics as</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Post Herpetic Neuralgia</EndpointIndex><EndpointIndex>Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - Numeric rating scale</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Quantitative sensory testing</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Topical Lidocaine for the Treatment of Focal Peripheral Neuropathic Pain: Response in Relation to Pain Phenotype</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Varicella Zoster Virus Infections - Subjects with shingles/herpes zoster</PatientSegment><PatientSegment>Pain - Subjects with Mild to Moderate Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain - Subjects with post herpetic neuralgia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>19 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Soren Sindrup</Name></ContactNames></Trial><Trial Id="128680"><Indications><Indication>Lateral epicondylitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Glucocorticoid receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Local anesthetic</Action><Action>Steroidal anti-inflammatory</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesSponsor><Company>Griffith University</Company><Company>National Health and Medical Research Council</Company><Company>University of Queensland</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2017-07-03T00:00:00Z</DateChangeLast><DateStart>2008-08-01T00:00:00Z</DateStart><Identifiers><Identifier>2007001703</Identifier><Identifier>ACTRN12609000051246</Identifier><Identifier>ANZCTR82438</Identifier><Identifier>PINTe</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lidocaine (endometriosis), Isifer plus triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>132</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this study was to evaluate the efficacy of combining physiotherapy and corticosteroid injection ( Lignocaine or triamcinolone ) in the treatment of tennis elbow. The hypotheses to be tested in this study were: Addition of physiotherapy to an injection when compared to injection alone will: improve long term efficacy, and reduce the recurrence rate. The benefits gained by adding physiotherapy to injection outweighs the cost associated with injection alone. The combined corticosteroid</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Factorial Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Pain During Activity</EndpointIndex><EndpointIndex>Pain - Assessment of Pain at Rest</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Pain - Clinical Assessments</EndpointIndex><EndpointIndex>Pain - Health Economic Assessments</EndpointIndex><EndpointIndex>Pain - Health Economic Assessments - Assessment of direct cost</EndpointIndex><EndpointIndex>Pain - Health Economic Assessments - Assessment of indirect cost</EndpointIndex><EndpointIndex>Pain - Health Economic Assessments - Burden/Cost-of-Illness Analysis (BOI/COI)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Euro Quality of Life (EQ-5D) Questionnaire</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>PINTe: Optimizating corticosteroid injection for lateral epicondylalgia with the addition of physiotherapy: A randomized control trial with placebo comparison</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Acute Pain</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with arthritic pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Muscle strength</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Bill Vicenzino</Name></ContactNames></Trial><Trial Id="12844"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor mu agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral absorption enhancer</Technology><Technology>Oral controlled release formulation</Technology><Technology>Oral formulation</Technology><Technology>Pellet</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>King Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>Puerto Rico</Country><Country>US</Country></Countries><DateChangeLast>2018-07-12T00:00:00Z</DateChangeLast><DateEnd>2008-12-31T00:00:00Z</DateEnd><DateStart>2008-03-31T00:00:00Z</DateStart><Identifiers><Identifier>ACCESS 2008</Identifier><Identifier>K284-07-4001</Identifier><Identifier>NCT00640042</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>morphine (rapid-onset, extended-release, SODAS), Pfizer alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1570</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to provide information on a broad, 'real-world' population of chronic pain patients assessing both pain control with Avinza (morphine sulfate) as well as the potential risk for misuse and abuse.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability - Assessment of dependency potential</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ACCESS 2008: Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2008-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>385</NumberOfSites><ContactNames><Name>Sherry Siegel</Name><Name>Sherry Siegel, MD</Name></ContactNames></Trial><Trial Id="12811"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Synaptic vesicle glycoprotein 2A modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticonvulsant agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Odense University Hospital</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2013-12-02T00:00:00Z</DateChangeLast><DateEnd>2009-01-01T00:00:00Z</DateEnd><DateStart>2007-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT00423527</Identifier><Identifier>keppra3</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>levetiracetam (oral), UCB alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a randomized, double-blind, placebo-controlled, crossover trial on the effect of levetiracetam 3000 mg daily on pain in multiple sclerosis (MS).</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of Functional Disability/Physical Function - Change in muscle stiffness</EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of Pain</EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of Pain - Assessment of Pain Intensity</EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of Pain - Pain related sleep disturbance</EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of Therapy Related Outcomes - Efficacy</EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Multiple sclerosis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function - Assessment of muscle tone</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropathic Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Pain During Activity</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Levetiracetam in Central Pain in Multiple Sclerosis (MS)</TitleDisplay><PatientSegmentTerms><PatientSegment>Multiple sclerosis - Subjects with Symptomatic Disease</PatientSegment><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Søren H Sindrup, MD</Name></ContactNames></Trial><Trial Id="12752"><ActionsPrimaryInterventionsPrimary><Action>Cyclooxygenase 2 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Non-steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>National Institutes of Health</Company></CompaniesCollaborator><CompaniesSponsor><Company>Pennsylvania State University</Company><Company>Pfizer Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2006-04-30T00:00:00Z</DateEnd><DateStart>2004-08-31T00:00:00Z</DateStart><Identifiers><Identifier>70,328-01</Identifier><Identifier>IIG Pfizer(PJK)</Identifier><Identifier>ISRCTN05282752</Identifier><Identifier>MOIRR10732</Identifier><Identifier>NCT00260325</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>valdecoxib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Patients would receive administration of single-dose of 40 mg valdecoxib or placebo po. Measurement of heat/&lt;b&gt;cold&lt;/b&gt; pain threshold and area of heat/capsaicin-induced hyperalgesia would be carried out....2006. There were no significantly relevant differences when volunteers were treated with valdecoxib or placebo in relation to either &lt;b&gt;cold&lt;/b&gt;- or hot pain threshold or the intensity of pain after supra-threshold, thermal pain stimulation. The area of</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effect of Valdecoxib Pretreatment on Pain and Secondary Hyperalgesia in Healthy Volunteers</TitleDisplay><PrimaryCompletionDate type="Actual">2006-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>20 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Piotr K Janicki, MD, PhD</Name></ContactNames></Trial><Trial Id="12704"><Indications><Indication>Hyperalgesia</Indication><Indication>Neuropathic pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CACNA2D calcium channel subunit modulator</Action><Action>GABA A receptor alpha-2 subunit stimulator</Action><Action>GABA A receptor delta subunit stimulator</Action><Action>GABA receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticonvulsant agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>German Government</Company></CompaniesCollaborator><CompaniesSponsor><Company>Ruhr Universitat Bochum</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2013-12-02T00:00:00Z</DateChangeLast><DateEnd>2008-04-30T00:00:00Z</DateEnd><DateStart>2006-07-31T00:00:00Z</DateStart><Identifiers><Identifier>2005-000411-10</Identifier><Identifier>4478944789</Identifier><Identifier>BfArM61-3910-4030984</Identifier><Identifier>EPOM</Identifier><Identifier>EV2005-2509</Identifier><Identifier>NCT00310583</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>pregabalin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of this randomized placebo-controlled study is to evaluate the effects of pregabalin on on mechanical hyperalgesia. The number of responders and non-responders to pregabalin will be evaluated in respect to mechanical hyperalgesia (stimulus-response-function on static punctual stimuli evoking pain determined via pinprick). The hypothesis is that in the placebo group, the amount of non-responders will increase.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment by Neuropathic Pain Symptom Inventory (NPSI)</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Quantitative sensory testing</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Neuropathic pain scale score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>EPOM: Effects of Pregabalin on Mechanical Hyperalgesia</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>21 Months</TrialDuration><NumberOfSites>17</NumberOfSites><ContactNames><Name>Achim Berthele, PD MD</Name><Name>Andrea Scherens, MD</Name><Name>Andrea Schmitz, MD</Name><Name>Andreas Binder, MD</Name><Name>Bernhard G. Landwehrmeyer, Prof. MD</Name><Name>Christhop Maier, Prof. MD</Name><Name>Christian Gerber, MD</Name><Name>Christian Maihöfner, MD</Name><Name>Christoph Bach, MD</Name><Name>Christoph Maier, Prof. MD</Name><Name>Christoph Maier, Prof. MD.</Name><Name>Christoph Stippich, PD MD</Name><Name>Claudia Sommer, Prof. MD</Name><Name>Dorothee Nietzsche, MD</Name><Name>Esther Pogatzki-Zahn, PD MD</Name><Name>Frank Birklein, Prof. MD</Name><Name>Frank Petzke, MD</Name><Name>Frank Petzke, PD MD</Name><Name>Ingolf C Bötefür, MD</Name><Name>J Schattschneider, MD</Name><Name>Janne Ludwig, MD</Name><Name>Klaus Unertl, Prof. MD</Name><Name>Meike Lauchert, MD</Name><Name>Michael Valet, MD</Name><Name>Nurcan Uceler, MD</Name><Name>Peter Busche, MD</Name><Name>Rainer Freynhagen, MD</Name><Name>Ralf Baron, Prof. MD</Name><Name>Roland Klug, MD</Name><Name>Roman Rolke, MD</Name><Name>Sabine Bredanger, MD</Name><Name>Shanhaz C Azad, PD MD</Name><Name>Shanhnaz C Azad, PD MD</Name><Name>Susann Seddigh, MD</Name><Name>Thomas R Toelle, Prof. MD</Name><Name>Thorsten Giesecke, MD</Name><Name>Till Sprenger, MD</Name><Name>Ulrike Friess, MD</Name><Name>Volker Huge, MD</Name><Name>Wolfgang Koppert, PD MD</Name></ContactNames></Trial><Trial Id="126414"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Chong Kun Dang Pharmaceutical Corp</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2017-06-12T00:00:00Z</DateChangeLast><DateEnd>2015-04-30T00:00:00Z</DateEnd><DateStart>2013-01-31T00:00:00Z</DateStart><Identifiers><Identifier>223KTP12003</Identifier><Identifier>My-Rept_KT_P4</Identifier><Identifier>NCT01842269</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mycophenolate mofetil plus tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>156</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> &lt;b&gt;Cold&lt;/b&gt; ischemia time&gt; 30 h Patient who receive Human lymphocyte antigen (HLA)-identical donor Patient with dual kidney transplantation recipient or have history of other organ transplantation in past or current Patient who receive extra-renal solid organ </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Incidence of adverse events/Side Effects</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Vital Signs</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>My-Rept_KT_P4: Evaluate the Efficacy and Safety of My-Rept Tablet Versus My-Rept Capsule in Combination With Tacrolimus in Kidney Transplant Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Renal re-transplant recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>27 Months</TrialDuration><NumberOfSites>10</NumberOfSites><ContactNames><Name>Yu Seun Kim, Ph. D</Name></ContactNames></Trial><Trial Id="125405"><Indications><Indication>Poliovirus infection</Indication><Indication>Rotavirus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Inactivated vaccine</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture</Technology><Technology>Freeze drying</Technology><Technology>Intramuscular formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Bill &amp; Melinda Gates Foundation</Company><Company>Pharma Services Holding Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of Chile</Company></CompaniesSponsor><Countries><Country>Chile</Country></Countries><DateChangeLast>2018-12-29T00:00:00Z</DateChangeLast><DateEnd>2014-06-30T00:00:00Z</DateEnd><DateStart>2013-04-30T00:00:00Z</DateStart><Identifiers><Identifier>IPV002ABMG</Identifier><Identifier>NCT01841671</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Rotarix alone</Intervention><Intervention>bOPV alone</Intervention><Intervention>mOPV type 2 alone</Intervention><Intervention>polio vaccine, Sanofi Pasteur alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>570</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>collected at five times for each subject, using WHO approved protocols and kits, and transported and stored following the WHO procedures for detection of polioviruses. Fresh stools would be collected unmixed with urine in a screw-top container, placed in a &lt;b&gt;cold&lt;/b&gt; box with frozen ice packs, and transported to the designated laboratory for storage in a freezer at -20degC. A log book of collected and stored samples would be kept by the study personnel. Stool samples would be used later to determine the excretion</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Polio Vaccine - Assessment of Immune Response - Assessment of anti-polio antibody concentration</EndpointIndex><EndpointIndex>Polio Vaccine - Assessment of Immune Response - Assessment of seropositivity/seroconversion rate</EndpointIndex><EndpointIndex>Polio Vaccine - Assessment of Immune Response - Immunogenic response to other antigens</EndpointIndex><EndpointIndex>Polio Vaccine - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Polio Vaccine - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Rotavirus Vaccine - Assessment of Immune Response - Assessment of anti-rotavirus antibodies</EndpointIndex><EndpointIndex>Rotavirus Vaccine - Assessment of Immune Response - Assessment of seropositivity/seroconversion rate</EndpointIndex><EndpointIndex>Rotavirus Vaccine - Assessment of Immune Response - Immunogenic response to other vaccine/infectious agent</EndpointIndex><EndpointIndex>Rotavirus Vaccine - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Rotavirus Vaccine - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Newborn Infants (up to 5 months)</Term></TermsPatientSelection><TitleDisplay>Immunogenicity of one or two Doses of bOPV in Chilean Infants Primed With IPV Vaccine</TitleDisplay><BiomarkerNames><BiomarkerName>B-cell antigen receptor complex-associated protein alpha chain </BiomarkerName><BiomarkerName> Immunoglobulin A</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2014-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Miguel L O'Ryan, MD</Name><Name>Monica Espinoza</Name></ContactNames></Trial><Trial Id="12472"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Kaiser Permanente</Company></CompaniesCollaborator><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-16T00:00:00Z</DateChangeLast><DateEnd>2011-06-30T00:00:00Z</DateEnd><DateStart>2003-10-31T00:00:00Z</DateStart><Identifiers><Identifier>FM025</Identifier><Identifier>NCT00113880</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>63061</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this trial was to assess the safety of FluMist vaccination, the rates of medically attended events (MAEs) in FluMist recipients (including serious adverse events [SAEs], anaphylaxis, urticaria, asthma, wheezing, pre-specified grouped diagnoses and rare events potentially related to wild-type influenza would be compared to rates in multiple non-randomized control groups).</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Longitudinal</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate the Safety of FluMist in Healthy Children and Healthy Adults</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2008-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>92 Months</TrialDuration><NumberOfSites>75</NumberOfSites><ContactNames><Name>Christopher Ambrose, M.D.</Name></ContactNames></Trial><Trial Id="124606"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2013-11-07T00:00:00Z</DateChangeLast><DateEnd>2013-06-01T00:00:00Z</DateEnd><DateStart>2011-03-17T00:00:00Z</DateStart><Identifiers><Identifier>CERL080AIN04T</Identifier><Identifier>CTRI/2012/02/002441</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including enteric-coated mycophenolate sodium, Novartis , mycophenolate mofetil , tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>cell cross match positive transplant Patients with platelet count 100,000/mm at the evaluation before randomization before surgery or white blood cell count of 4500/mm3, or leukocytopenia (2500/mm3), or hemoglobin 6 g/dl prior to randomization Renal &lt;b&gt;cold&lt;/b&gt; ischemic time (CIT) 30 h Patients with a known hypersensitivity to either study drugs or their class, or to any of excipients Patients with clinically significant systemic infection at time of transplant or within 2 weeks of transplant Patients who</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Blood Glucose Levels</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Cardiac Function - Assessment of blood pressure</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Glomerular Filtration Rate (GFR) - Assessment of Estimated Glomerular Filtration Rate(eGFR)/Creatinine Clearance(CCr/CrCl/CLcr)</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Immune Response</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Renal Biopsy</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Survival</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Transplantation</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of adverse events</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of dialysis - Assessment of dialytic complications</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of lipid profiles</EndpointIndex><EndpointIndex>End stage renal disease - Glycemic Control Analysis - Assessment of glucose level</EndpointIndex><EndpointIndex>End stage renal disease - Hematological Assessments - Assessment of hemoglobin levels</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Cardiovascular Risk Factors</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Protocol Specified Other Endpoints - Other Laboratory Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>To Evaluate the Effect and Safety of Two Immunosuppresant Drugs (Tacrolimus With Enteric Coated Mycophenolate Sodium or Mycophenolate Mofetil) in New Renal Transplant Recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Kidney Transplant Subjects</PatientSegment><PatientSegment>End stage renal disease - Subjects with Liver Disorder/Associated Nephropathy</PatientSegment><PatientSegment>Kidney transplantation - De Novo Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>1-Pentadecanoyl-2-(octadecenoyl)-3-(octadecenoyl)-glycerol </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Total cholesterol</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>26 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Sameer Guliani</Name><Name>Sanjeev Jasuja</Name></ContactNames></Trial><Trial Id="12377"><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-07-02T00:00:00Z</DateChangeLast><DateEnd>2005-01-31T00:00:00Z</DateEnd><DateStart>2004-06-30T00:00:00Z</DateStart><Identifiers><Identifier>FM026</Identifier><Identifier>NCT00192140</Identifier></Identifiers><IndicationsAdverse><Indication>Cough</Indication><Indication>Emesis</Indication><Indication>Fever</Indication><Indication>Myalgia</Indication><Indication>Nasal congestion</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>345</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to evaluate the viral shedding, genotypic and phenotypic stability of shed vaccine viruses, immunogenicity, and safety of FluMist when administered to healthy individuals between 5 and 49 years of age.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Viral Load/Viral Shedding</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Viral Load/Viral Shedding</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Trial to assess the shedding, immunogenicity, and safety of FluMist administered to healthy individuals 5 to 49 years of age</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children - Children more than 5 years of age</PatientSegment><PatientSegment>Influenza Vaccine - Elderly Subjects</PatientSegment><PatientSegment>Influenza virus infection - Children - Children more than 5 years of age</PatientSegment><PatientSegment>Influenza virus infection - Elderly Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Kunitz-type protease inhibitor 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>7 Months</TrialDuration><NumberOfSites>11</NumberOfSites><ContactNames><Name>Robert Walker</Name></ContactNames></Trial><Trial Id="12374"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Inactivated viral vaccine</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Suspension</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>National Institute of Allergy and Infectious Diseases</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-16T00:00:00Z</DateChangeLast><DateEnd>2007-06-01T00:00:00Z</DateEnd><DateStart>2005-08-31T00:00:00Z</DateStart><Identifiers><Identifier>04-079</Identifier><Identifier>NCT00138385</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention><Intervention>Fluzone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a phase IV, single-center, randomized study of the immune responses of children given one of two licensed influenza vaccines Fluzone or FluMist (inactivated vaccine given intramuscularly, or live, attenuated vaccine given intranasally).</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Comparison of Inactivated and Live, Attenuated Influenza Vaccine in Children 5 to 9 Years of Age- Year 3 Amendment</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children - Children more than 5 years of age</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment><PatientSegment>Influenza virus infection - Children - Children more than 5 years of age</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>21 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="123272"><Indications><Indication>Kidney transplantation</Indication><Indication>Liver transplantation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Daily dosing</Technology><Technology>Oral formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2019-05-31T00:00:00Z</DateChangeLast><DateStart>2012-01-31T00:00:00Z</DateStart><Identifiers><Identifier>AS/111/10/Version 3/1-Aug-2011</Identifier><Identifier>CTRI/2012/01/002361</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tacrolimus (oral sustained-release), Astellas alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>Pregnant women or breast-feeding mother Patients or respective donors known to be positive for human immunodeficiency virus (HIV) Unlikely to comply with the visits scheduled in the protocol Exclusion criteria (specifically for kidney transplant patients) &lt;b&gt;Cold&lt;/b&gt; ischemia time of the donor kidney 30 h High immunological risk, defined as a positive cross match or PRA grade 50% in the previous 6 months Liver cirrhosis Significant liver disease, defined as having either elevated serum glutamic pyruvic transaminase</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Incidence/number of AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Severity of AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Steroid resistant AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Time to AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Acute Graft Rejection (AGR) - Incidence/number of AGR episodes</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Acute Graft Rejection (AGR) - Severity of acute rejection</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Acute Graft Rejection (AGR) - Steroid resistant AGR</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Acute Graft Rejection (AGR) - Steroid sensitive AGR</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Acute Graft Rejection (AGR) - Time to AGR episodes</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Liver transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Liver transplantation - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Clinical Trial to Study the Safety and Efficacy of Once Daily Advagraf in Patients Who are Undergoing Kidney or Liver Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Subjects Awaiting Renal Transplant</PatientSegment><PatientSegment>Kidney transplantation - Subjects with End Stage Renal Disease/Chronic Renal Failure</PatientSegment><PatientSegment>Liver transplantation - Subjects Awaiting Liver Transplantation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anti-lymphocytes antibodies</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>10</NumberOfSites><ContactNames><Name>Alan Almeida</Name><Name>Anand Khakhar</Name><Name>Dinesh Khullar</Name><Name>Georgi Abraham</Name><Name>M. Bahadur</Name><Name>M. Rela</Name><Name>Pratik Shah</Name><Name>R. Sharma</Name><Name>Subba Budithi</Name><Name>Subhash Gupta</Name><Name>V. Tamilarasi</Name><Name>Vikranht Reddy</Name></ContactNames></Trial><Trial Id="12309"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>National Institute of Allergy and Infectious Diseases</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-16T00:00:00Z</DateChangeLast><DateEnd>2007-04-30T00:00:00Z</DateEnd><DateStart>2006-10-31T00:00:00Z</DateStart><Identifiers><Identifier>06-0041</Identifier><Identifier>NCT00385281</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>50</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to look at changes that occur in blood and nasal swab samples after a person’s immune system responds to receiving a flu vaccine ( FluMist ). The investigators would look at the immune response in 50 healthy volunteers, between 21 and 49 years of age, after they had been vaccinated with one dose of a flu vaccine ( FluMist ) sprayed into the nose. A blood sample and nasal swab of each nostril would be collected from volunteers before they receive the flu vaccination. After</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Laboratory/Diagnostic Measures</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Proteomic Profiling for Influenza Vaccination - FluMist</TitleDisplay><PrimaryCompletionDate type="Actual">2007-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>6 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="122767"><Indications><Indication>Xerophthalmia</Indication></Indications><CompaniesSponsor><Company>Alcon Pharmaceuticals Ltd</Company><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2018-01-10T00:00:00Z</DateChangeLast><DateStart>2010-05-25T00:00:00Z</DateStart><Identifiers><Identifier>CTRI/2010/091/000497</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Refresh Tears alone</Intervention><Intervention>Systane alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>78</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>contribute to dry eye if the dosing regimen has not been stable for at least 30 days prior to Visit 1 Additionally, the dosing regimen must remain stable throughout the study period Medications known to contribute to dry eye include, but are not limited to, &lt;b&gt;cold&lt;/b&gt; and allergy treatments, tricyclic antidepressants, and hormone replacement therapies Presence of ocular conditions such as active acute blepharitis, conjunctival infections, iritis, or any other ocular condition that may preclude the safe administration</Teaser><TrialCategories><Category>Borderline product</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Xerophthalmia - Assessment of Tear Dynamics - Assessment of ocular surface staining</EndpointIndex><EndpointIndex>Xerophthalmia - Assessment of Tear Dynamics - Assessment of tear film breakup time(TBUT)</EndpointIndex><EndpointIndex>Xerophthalmia - Patient Reported Outcomes/Quality of Life Assessments - Assessment of treatment satisfaction</EndpointIndex><EndpointIndex>Xerophthalmia - Patient Reported Outcomes/Quality of Life Assessments - Subjective assessment of dry eye syndrome</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>To Evaluate the Physical Effects of Systane in Subjects with Moderate to Severe Dry Eye</TitleDisplay><PatientSegmentTerms><PatientSegment>Xerophthalmia - Subjects with Mild Dry Eye</PatientSegment><PatientSegment>Xerophthalmia - Subjects with Moderate Dry Eye</PatientSegment><PatientSegment>Xerophthalmia - Subjects with Severe Dry Eye</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>4</NumberOfSites><ContactNames><Name>Anand Parthasarathy</Name><Name>Prema Padmanabhan</Name><Name>Rishi Mohan</Name><Name>Salman Anzer</Name><Name>Samar Basak</Name></ContactNames></Trial><Trial Id="12224"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Inactivated viral vaccine</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Suspension</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>National Institute of Allergy and Infectious Diseases</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-07-02T00:00:00Z</DateChangeLast><DateEnd>2006-01-01T00:00:00Z</DateEnd><DateStart>2005-08-26T00:00:00Z</DateStart><Identifiers><Identifier>03-183</Identifier><Identifier>NCT00138281</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention><Intervention>Fluzone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Sixty adults, aged 18 to 49 would be randomly assigned to receive either FluMist or Fluzone . Some of the subjects would have participated in previous studies for these two vaccines. The study would last 4 months with subject participation being 28 days. The purpose of this study was to measure immune response to the vaccinations.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Influenza Immunity Against Pandemic Respiratory Virus</TitleDisplay><PrimaryCompletionDate type="Actual">2005-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>4 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="121783"><Indications><Indication>Streptococcus pneumoniae infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Prophylactic vaccine</Action><Action>Subunit vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Protein conjugated</Technology><Technology>Suspension</Technology></Technologies><CompaniesCollaborator><Company>Dutch Ministry of Health, Welfare and Sport</Company></CompaniesCollaborator><CompaniesSponsor><Company>National Institute for Public Health and the Environment</Company><Company>Rijksinstituut voor Volksgezondheid en Milieu</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2018-09-05T00:00:00Z</DateChangeLast><DateEnd>2012-12-01T00:00:00Z</DateEnd><DateStart>2011-09-07T00:00:00Z</DateStart><Identifiers><Identifier>2011-002103-15</Identifier><Identifier>NTR3069</Identifier><Identifier>PIEN</Identifier><Identifier>VAC-259</Identifier><Identifier>VAC-259 Vaccinology</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Prevnar 13 alone</Intervention><Intervention>Synflorix alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>160</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> The subjects have to be of normal health (same health criteria apply as used in well-baby clinics when a child receives a vaccination, eg, also children with small increases in temperature (&amp;lt; 38.5DegC) or &lt;b&gt;cold&lt;/b&gt; are seen as children with normal health) The parents/legally representatives have to be willing and able to allow their child to participate in the trial according to the described procedures Presence of a signed informed consent (the parents/legally</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Booster Response - Assessment of anti-pneumococcal booster response</EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Immune Response - Assessment of anti-diphtheria antibody concentration</EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Immune Response - Assessment of anti-pertussis antibody concentration (PT)</EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Immune Response - Assessment of anti-pneumococcal antibody concentration</EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Immune Response - Assessment of anti-polyribosyl-ribitol-phosphate antibody concentration (PRP)</EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Immune Response - Assessment of anti-tetanus antibody concentration</EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Immune Response - Assessment of cell-mediated immunity</EndpointIndex><EndpointIndex>Haemophilus Influenzae Type B Vaccine - Assessment of Immune Response - Assessment of anti-diphtheria antibody concentration</EndpointIndex><EndpointIndex>Haemophilus Influenzae Type B Vaccine - Assessment of Immune Response - Assessment of anti-pertussis antibody concentration (PT)</EndpointIndex><EndpointIndex>Haemophilus Influenzae Type B Vaccine - Assessment of Immune Response - Assessment of anti-pneumococcal antibody concentration</EndpointIndex><EndpointIndex>Haemophilus Influenzae Type B Vaccine - Assessment of Immune Response - Assessment of anti-polyribosyl-ribitol-phosphate antibody concentration (PRP)</EndpointIndex><EndpointIndex>Haemophilus Influenzae Type B Vaccine - Assessment of Immune Response - Assessment of anti-tetanus antibody concentration</EndpointIndex><EndpointIndex>Haemophilus Influenzae Type B Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>Hepatitis B Vaccine - Assessment of Immune Response - Cell mediated immunity</EndpointIndex><EndpointIndex>Pneumococcal Vaccine - Assessment of Booster Response</EndpointIndex><EndpointIndex>Pneumococcal Vaccine - Assessment of Immune Response - Assessment of anti-pneumococcal antibody concentration</EndpointIndex><EndpointIndex>Pneumococcal Vaccine - Assessment of Immune Response - Assessment of cell-mediated immunity</EndpointIndex><EndpointIndex>Pneumococcal Vaccine - Assessment of Immune Response - Immunogenic response to other vaccine/infectious agent</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Immune Response - Anti-pneumococcal antibodies</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Immune Response - Cell-mediated immunity</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Immune Response - Immunogenic response to other vaccine/infectious agent</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Polio Vaccine - Assessment of Booster Response</EndpointIndex><EndpointIndex>Polio Vaccine - Assessment of Immune Response - Assessment of cell-mediated immunity</EndpointIndex><EndpointIndex>Polio Vaccine - Assessment of Immune Response - Immunogenic response to other antigens</EndpointIndex><EndpointIndex>Polio Vaccine - Assessment of Laboratory/Diagnostic Measures</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term></TermsPatientSelection><TitleDisplay>PIEN: Pneumococcal Immune Response to Synflorix or Prevenar-13 in Infants</TitleDisplay><PatientSegmentTerms><PatientSegment>DTP Vaccine - Subjects Naive to Other Vaccines - Subjects Naive to DTP Vaccine</PatientSegment><PatientSegment>DTP Vaccine - Subjects Naive to Other Vaccines - Subjects naive to haemophilus influenzae B vaccine</PatientSegment><PatientSegment>DTP Vaccine - Subjects Naive to Other Vaccines - Subjects naive to hepatitis B vaccine</PatientSegment><PatientSegment>DTP Vaccine - Subjects Naive to Other Vaccines - Subjects naive to pneumococcal vaccine</PatientSegment><PatientSegment>DTP Vaccine - Subjects Naive to Other Vaccines - Subjects naive to polio vaccine</PatientSegment><PatientSegment>DTP Vaccine - Subjects with Prior Other Vaccination - Subjects with Prior DTP Vaccination</PatientSegment><PatientSegment>DTP Vaccine - Subjects with Prior Other Vaccination - Subjects with prior haemophilus influenzae B vaccination(HIB)</PatientSegment><PatientSegment>DTP Vaccine - Subjects with Prior Other Vaccination - Subjects with prior hepatitis B vaccination(HBV)</PatientSegment><PatientSegment>DTP Vaccine - Subjects with Prior Other Vaccination - Subjects with prior pneumococcal vaccination(PCV/PPSV)</PatientSegment><PatientSegment>DTP Vaccine - Subjects with Prior Other Vaccination - Subjects with prior polio vaccination(IPV/OPV)</PatientSegment><PatientSegment>Haemophilus Influenzae Type B Vaccine - Subjects Naive to Vaccines - Subjects Naive to H.Influenzae Type B(HIB) Vaccine</PatientSegment><PatientSegment>Haemophilus Influenzae Type B Vaccine - Subjects with Prior Other Vaccination - Subjects with Prior H.Influenzae Type B(HIB) Vaccination</PatientSegment><PatientSegment>Haemophilus Influenzae Type B Vaccine - Subjects with Prior Other Vaccination - Subjects with prior DTP vaccination</PatientSegment><PatientSegment>Haemophilus Influenzae Type B Vaccine - Subjects with Prior Other Vaccination - Subjects with prior hepatitis vaccination</PatientSegment><PatientSegment>Haemophilus Influenzae Type B Vaccine - Subjects with Prior Other Vaccination - Subjects with prior pneumococcal vaccination</PatientSegment><PatientSegment>Haemophilus Influenzae Type B Vaccine - Subjects with Prior Other Vaccination - Subjects with prior polio vaccination</PatientSegment><PatientSegment>Hepatitis B Vaccine - Subjects with Prior Other Vaccination</PatientSegment><PatientSegment>Pneumococcal Vaccine - Subjects Naive to Other Vaccines - Subjects naive to DTP vaccine</PatientSegment><PatientSegment>Pneumococcal Vaccine - Subjects Naive to Other Vaccines - Subjects naive to hepatitis B vaccine</PatientSegment><PatientSegment>Pneumococcal Vaccine - Subjects Naive to Other Vaccines - Subjects naive to pneumococcal conjugated vaccine(PCV)</PatientSegment><PatientSegment>Pneumococcal Vaccine - Subjects Naive to Other Vaccines - Subjects naive to polio vaccine</PatientSegment><PatientSegment>Pneumococcal Vaccine - Subjects with Prior Other Vaccination - Subjects with prior DTP vaccination</PatientSegment><PatientSegment>Pneumococcal Vaccine - Subjects with Prior Other Vaccination - Subjects with prior haemophilus influenzae B vaccination(HIB)</PatientSegment><PatientSegment>Pneumococcal Vaccine - Subjects with Prior Other Vaccination - Subjects with prior hepatitis B vaccination(HBV)</PatientSegment><PatientSegment>Pneumococcal Vaccine - Subjects with Prior Other Vaccination - Subjects with prior pneumococcal conjugated vaccine(PCV)</PatientSegment><PatientSegment>Polio Vaccine - Subjects Naive to Vaccines</PatientSegment><PatientSegment>Polio Vaccine - Subjects Naive to Vaccines - Subjects Naive to Polio Vaccine</PatientSegment><PatientSegment>Polio Vaccine - Subjects with Prior Other Vaccination</PatientSegment><PatientSegment>Polio Vaccine - Subjects with Prior Other Vaccination - Subjects with Prior Polio Vaccination</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>B-lymphocytes </BiomarkerName><BiomarkerName> Immunoglobulin G </BiomarkerName><BiomarkerName> Memory B-Lymphocytes </BiomarkerName><BiomarkerName> Plasma cells</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>14 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Alienke Wijmenga-monsuur</Name><Name>Riet Jongerius</Name></ContactNames></Trial><Trial Id="12174"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>National Institute of Allergy and Infectious Diseases</Company><Company>Novartis AG</Company><Company>Sanofi Pasteur MSD</Company><Company>Scott and White Hospital &amp; Clinic</Company></CompaniesCollaborator><CompaniesSponsor><Company>Baylor College of Medicine</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-16T00:00:00Z</DateChangeLast><DateEnd>2010-06-30T00:00:00Z</DateEnd><DateStart>1998-10-31T00:00:00Z</DateStart><Identifiers><Identifier>BCM H-21853</Identifier><Identifier>BCM H-21853</Identifier><Identifier>CEI</Identifier><Identifier>Flu-035-09</Identifier><Identifier>NCT00138294</Identifier><Identifier>R01 AI041050 (ended 31Jan2009)</Identifier><Identifier>R01AI041050</Identifier><Identifier>SW070912</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>29255</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purposes of this study were: To learn if the vaccine FluMist , when given to school aged children 5 to 18 years of age, can stop or lessen the influenza outbreak in the community To show that vaccination of these children would significantly reduce breathing problems (in the vaccinated children and unvaccinated people they come in contact with in the community) that require a visit to the doctor for treatment To continue to collect safety and flu protection information on FluMist given to</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza Vaccine - Incidence of Influenza/Influenza Like Illness</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Incidence of Influenza/Influenza Like Illness</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>CEI: Control of Epidemic Influenza Through a School-based Influenza Vaccination Program</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>140 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Pedro A Piedra, MD</Name></ContactNames></Trial><Trial Id="12092"><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Inactivated viral vaccine</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Suspension</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>National Institute of Allergy and Infectious Diseases</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-17T00:00:00Z</DateChangeLast><DateEnd>2007-07-31T00:00:00Z</DateEnd><DateStart>2004-10-31T00:00:00Z</DateStart><Identifiers><Identifier>04-060</Identifier><Identifier>IRBMed# 2004-03</Identifier><Identifier>IRBMed# 2004-0334</Identifier><Identifier>NCT00133523</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention><Intervention>Fluvirin alone</Intervention><Intervention>Fluzone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2349</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this randomized, double-blinded, placebo-controlled, experimental epidemiological study was to compare two licensed flu vaccines ( FluMist and Fluzone or Fluvirin ) to each other and to placebo. The study would be conducted among healthy adult participants aged 18 to 49 years, and was expected to last three years. During year one, participants would be randomized to receive one of the two licensed flu vaccines or placebo, given as either nasal spray (live-attenuated vaccine or</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Incidence of Laboratory Confirmed Influenza</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Incidence of Laboratory Confirmed Influenza</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>FLU-VACS Comparative Study in Adults</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Elderly Subjects</PatientSegment><PatientSegment>Influenza virus infection - Elderly Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>33 Months</TrialDuration><NumberOfSites>6</NumberOfSites></Trial><Trial Id="120173"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Erythropoietin ligand</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Hematopoietic stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Glycoprotein</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Roche Holding AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Central Manchester Healthcare NHS Trust</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2017-06-19T00:00:00Z</DateChangeLast><DateStart>2007-09-01T00:00:00Z</DateStart><Identifiers><Identifier>10322</Identifier><Identifier>EPO and DGF</Identifier><Identifier>EPOTRIAL</Identifier><Identifier>EudraCT: 2006-005373-22</Identifier><Identifier>ISRCTN85447324</Identifier><Identifier>MREC N: 07/Q1407/94</Identifier><Identifier>UKCRN ID: 6784</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>epoetin beta, Roche alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>from either of the below cases: Donor: Aged &gt; 50 years with: cerebrovascular accident (CVA) + hypertension (HTN) + serum creatinine (SCr) &gt; 1.5; CVA + HTN; CVA + SCr &gt; 1.5; HTN + SCr &gt; 1.5 Aged &gt; 60 years with: CVA; HTN; SCr &gt; 1.5 Additional criteria: &lt;b&gt;Cold&lt;/b&gt; ischemia time (CIT) &gt;/= 24 h Donor with cardiac death</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Delayed Graft Function (DGF) - Incidence/proportion of patients with DGF</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Inflammatory &amp; Oxidative Stress Markers - Serum interleukins</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>EPOTRIAL: Erythopoietin and delayed graft function in renal allografts from extended criteria donors</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Expanded Criteria Donor (ECD) Renal Transplant Recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Interleukin-18 </BiomarkerName><BiomarkerName> Neutrophil gelatinase-associated lipocalin </BiomarkerName><BiomarkerName> Son of sevenless homolog 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>2</NumberOfSites><ContactNames><Name>Michael Picton</Name></ContactNames></Trial><Trial Id="119479"><Indications><Indication>Rheumatoid arthritis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>TNF antagonist</Action><Action>TNF binding agent</Action><Action>Type II TNF receptor modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Liquid formulation</Technology><Technology>Protein fusion</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Pfizer Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Charite Universitaetsmedizin Berlin</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2016-10-31T00:00:00Z</DateChangeLast><DateEnd>2009-07-31T00:00:00Z</DateEnd><DateStart>2007-01-24T00:00:00Z</DateStart><Identifiers><Identifier>0881A1-102134</Identifier><Identifier>DRKS00000150</Identifier><Identifier>EA1/098/06</Identifier><Identifier>Schlafprojekt</Identifier><Identifier>U1111-1111-2826</Identifier></Identifiers><InterventionsControlDisplay><Intervention>methotrexate alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>etanercept alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>hypertension, severe lung disease, history of HIV-infection, immunodeficiency syndromes, other rheumatological disorders than RA, demyelinating CNS disease, multiple sklerosis or psychiatric disorders patients with other reasons for sleeping disorders (&lt;b&gt;COLD&lt;/b&gt;, sleep apnea, allergic rhinitis etc) Patients who received live vaccination within 4 weeks of screening Patients receiving intraarticular injections with glucocorticoids within 4 weeks of screening Patients receiving intramuscular or iv injections </Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Insomnia - Assessment of Co-morbidity</EndpointIndex><EndpointIndex>Insomnia - Assessment of Fatigue</EndpointIndex><EndpointIndex>Insomnia - Assessment of Laboratory/Diagnostic Measures - Assessment of Inflammatory/Immunological Markers</EndpointIndex><EndpointIndex>Insomnia - Assessment of Laboratory/Diagnostic Measures - Assessment of electrophysiological recordings</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of sleep efficiency</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of sleep quality</EndpointIndex><EndpointIndex>Rheumatoid arthritis - American College of Rheumatology (ACR) 20 Response</EndpointIndex><EndpointIndex>Rheumatoid arthritis - American College of Rheumatology (ACR) 50 Response</EndpointIndex><EndpointIndex>Rheumatoid arthritis - American College of Rheumatology (ACR) 70 Response</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Fatigue</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Immune Response</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Remission</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Sleep - Assessment of sleep quality</EndpointIndex><EndpointIndex>Rheumatoid arthritis - Assessment of Treatment Response by ACR Criteria</EndpointIndex><EndpointIndex>Rheumatoid arthritis - DAS-28 (Disease Activity Score) Response</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Schlafprojekt: Effects of Treatment With Etanercept on Fatigue, Sleepiness, Well Being, Sleep Quality and Selected Immune Parameters in Patients With Rheumatoid Arthritis</TitleDisplay><PatientSegmentTerms><PatientSegment>Insomnia - Subjects with comorbid conditions</PatientSegment><PatientSegment>Rheumatoid arthritis - Active Rheumatoid Arthritis</PatientSegment><PatientSegment>Rheumatoid arthritis - Subjects on Rheumatoid Arthritis Therapy</PatientSegment><PatientSegment>Rheumatoid arthritis - Treatment Naive Subjects</PatientSegment><PatientSegment>Rheumatoid arthritis - Treatment Naive Subjects - Corticosteroid-naive subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>30 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Frank Buttgereit</Name><Name>Rene Dziurla</Name><Name>Thomas Meng</Name></ContactNames></Trial><Trial Id="118759"><Indications><Indication>Hypothermia</Indication><Indication>Mild cognitive impairment</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Alpha 1 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Hypertensive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>James J. Peters Veterans Affairs Medical Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-06-09T00:00:00Z</DateChangeLast><DateEnd>2015-10-31T00:00:00Z</DateEnd><DateStart>2011-07-31T00:00:00Z</DateStart><Identifiers><Identifier>01374</Identifier><Identifier>NCT01822535</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>midodrine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>they would be asked to empty their bladders prior to arrival and again upon arrival, if needed. Visit 1: &lt;b&gt;Cold&lt;/b&gt; ambient challenge: instrumentation: during visit 1, all subjects would be transferred to a padded table for instrumentation, after which...of &lt;b&gt;cold&lt;/b&gt; exposure (in both groups) on visits 1 and 2. Visit 2: &lt;b&gt;Cold&lt;/b&gt; ambient challenge with midodrine: visit 2 would be completed in subjects with tetraplegia who participated in visit 1 and who had an impaired</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Factorial Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Body Temperature in Persons With Tetraplegia When Exposed to Cold</TitleDisplay><BiomarkerNames><BiomarkerName>Basal metabolic rate </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hydrocortisone </BiomarkerName><BiomarkerName> Maximal oxygen uptake </BiomarkerName><BiomarkerName> Norepinephrine </BiomarkerName><BiomarkerName> Oxygen saturation</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>51 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>John P Handrakis, PT, DPT, EdD</Name></ContactNames></Trial><Trial Id="118515"><Indications><Indication>Asthma</Indication></Indications><CompaniesCollaborator><Company>Ministry of Health, Spain</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fundació Sant Joan de Déu</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-07-03T00:00:00Z</DateChangeLast><DateStart>2012-07-23T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT 2012-000372-42</Identifier><Identifier>FSJD-ALINO-2011</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>budesonide alone</Intervention><Intervention>salbutamol alone</Intervention><Intervention>terbutaline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>114</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Patients who do not fulfil the criteria defined in the GEMA guidelines for uncontrolled mild persistent bronchial asthma Patients with an obstructive pattern on spirometry explained by another disease: &lt;b&gt;COLD&lt;/b&gt;, sequelae of tuberculosis, bronchiolitis, etc Patients who are clinically unstable at the time of inclusion or who have worsened in the 3 months prior to study inclusion Patients who cannot correctly take treatment via the inhaled route Patients with</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score</EndpointIndex><EndpointIndex>Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of exhaled nitric oxide</EndpointIndex><EndpointIndex>Asthma - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma control questionnaire (ACQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Phase IV, Open-Label, Prospective, Randomized Clinical Trial to Evaluate the Usefulness of Measuring Nitric Oxide in Exhaled Air in the Therapeutic Management of Adult Patients With Mild Asthma</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with Atopic Asthma</PatientSegment><PatientSegment>Asthma - Subjects with Levels of Asthma Control - Subjects with controlled asthma</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with mild persistent asthma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Nitric oxide</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites><ContactNames><Name>Rosa Palau</Name></ContactNames></Trial><Trial Id="118184"><Indications><Indication>Autism</Indication></Indications><CompaniesSponsor><Company>University Medical Center Groningen</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2016-02-04T00:00:00Z</DateChangeLast><DateStart>2011-08-25T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT 2010-018740-13</Identifier><Identifier>acareoxt01</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>oxytocin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>78</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Participants may not have a nasal congestion due to &lt;b&gt;cold&lt;/b&gt; or allergies All participants must be free of psychotropic medication or neuroleptics and stimulant medication. They may not have a history of alcohol or drug dependence For the empathy experiment, all participants are required to abstain from stimulants, XTC, soft drugs and alcohol for about 20 h, from caffeine for about 4 h and from cigarette smoking and taking food for 2 </Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Autism - Assessment of Functional Disability/Physical Function - Assessment by Social Responsiveness Scale (SRS)</EndpointIndex><EndpointIndex>Autism - Assessment of the Symptoms of Autism - Assessment of deficits in social interaction</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Short- and Long-term Effects of Oxytocin on Empathy and Social Behaviour in Autistic and Antisocial Male Adults</TitleDisplay><PatientSegmentTerms><PatientSegment>Autism - Subjects with Asperger's Syndrome</PatientSegment><PatientSegment>Autism - Subjects with Autistic Disorder</PatientSegment><PatientSegment>Autism - Subjects with Pervasive Developmental Disorders (NOS)</PatientSegment><PatientSegment>Autism - Subjects with comorbid conditions</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="11816"><Indications><Indication>Salmonella typhi infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Polysaccharide subunit vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Centers for Disease Control and Prevention</Company><Company>The Center for Tropical Diseases</Company><Company>University of Western Ontario</Company><Company>Wellcome Trust</Company></CompaniesCollaborator><CompaniesSponsor><Company>International Vaccine Institute</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2017-07-01T00:00:00Z</DateChangeLast><DateEnd>2006-11-30T00:00:00Z</DateEnd><DateStart>2001-10-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT00131833</Identifier><Identifier>T3</Identifier></Identifiers><InterventionsControlDisplay><Intervention>meningococcal A alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Typhim Vi alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>96468</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>immunizations for a mean duration of 23 days. The vaccination rate was 90% in those aged &amp;lt;/= 15 years (90%) compared to 70% in adolescents and young adults. Planned mop-up activities increased the coverage by 17%. The overall vaccine wastage was 11%. The &lt;b&gt;cold&lt;/b&gt; chain was maintained and documented [ 991220 ].</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Meningococcal Vaccine - Assessment of Behavioral Parameters</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Assessment of Immune Response</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Assessment of adverse events</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Health Economic Assessments - Assessment of cost effectiveness</EndpointIndex><EndpointIndex>Typhoid Vaccine - Assessment of Behavioral Parameters</EndpointIndex><EndpointIndex>Typhoid Vaccine - Assessment of Immune Response</EndpointIndex><EndpointIndex>Typhoid Vaccine - Assessment of Immune Response - Assessment of anti-Vi antibodies</EndpointIndex><EndpointIndex>Typhoid Vaccine - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Typhoid Vaccine - Assessment of Therapy Related Outcomes - Assessment of Feasibility</EndpointIndex><EndpointIndex>Typhoid Vaccine - Health Economic Assessments - Assessment of cost effectiveness</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Asian Ancestry</Term></TermsPatientSelection><TitleDisplay>Typhoid Vi vaccine effectiveness in Hechi, Guangxi, China</TitleDisplay><PatientSegmentTerms><PatientSegment>Typhoid Vaccine - Subjects at risk of developing disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>61 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dong Baiqing</Name></ContactNames></Trial><Trial Id="11793"><Indications><Indication>Allergic rhinitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Histamine H1 receptor antagonist</Action><Action>Leukotriene D4 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Capsule formulation</Technology><Technology>Daily dosing</Technology><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Sanofi SA</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2013-12-02T00:00:00Z</DateChangeLast><DateEnd>2003-05-31T00:00:00Z</DateEnd><DateStart>2003-02-28T00:00:00Z</DateStart><Identifiers><Identifier>M016455A_4146</Identifier><Identifier>NCT00638118</Identifier></Identifiers><IndicationsAdverse><Indication>Back pain</Indication><Indication>Hyperthyroidism</Indication><Indication>Nausea</Indication><Indication>Skin rash</Indication><Indication>Viral infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>fexofenadine alone</Intervention><Intervention>montelukast sodium alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>48</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Other short-acting antihistamines such as chlorpheniramine or drugs with antihistaminic activity 3 days OTC oral antihistamines, decongestants (includes pseudoephedrine and other decongestants), or antihistamines/decongestant combinations including all &lt;b&gt;cold&lt;/b&gt;, cough, and sleep aids 3 days OTC ophthalmic decongestant,antihistamine, or decongestant/antihistamine combinations 3 days Other anticholinergic agents 3 days Immunotherapy injection 1 day Other drugs should only be permitted if they are not expected</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Laboratory/Diagnostic Measures - Assessment of skin prick test response</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Seasonal Allergic Rhinitis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>3 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Phyllis Diener</Name></ContactNames></Trial><Trial Id="11790"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-07-01T00:00:00Z</DateChangeLast><DateEnd>2005-04-01T00:00:00Z</DateEnd><DateStart>2004-10-31T00:00:00Z</DateStart><Identifiers><Identifier>MI-MA004</Identifier><Identifier>NCT00192218</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>3022</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study was designed to measure the effectiveness of influenza vaccination FluMist in school children by comparing, between target (ie, children offered FluMist ) and control (ie, children not offered FluMist ) school families.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children - Children more than 5 years of age</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment><PatientSegment>Influenza virus infection - Children - Children more than 5 years of age</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate>2005-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Robert Walker</Name></ContactNames></Trial><Trial Id="117799"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2015-03-02T00:00:00Z</DateChangeLast><DateStart>2005-10-11T00:00:00Z</DateStart><Identifiers><Identifier>2005-002372-16</Identifier><Identifier>CRAD001B351</Identifier><Identifier>EudraCT 2005-002372-16</Identifier><Identifier>RAD351</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including basiliximab , ciclosporin, Novartis , everolimus , mycophenolate mofetil , prednsione</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> &lt;b&gt;Cold&lt;/b&gt; ischemia time&gt; 40 h Patients who are recipients of multiple solid organ transplants, including dual and en bloc kidneys, or who have previously received transplanted organs Patients with non-diarrhea associated hemolytic-uremic syndrome Recipients of donor specific transfusions Patients with panel reactive T cell antibodies of 50% or higher at the last assessment before transplantation Patients unable</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Chronic Graft Rejection (CGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Dysfunction - Chronic graft dysfunction</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>RAD351: A Multicenter, Open-Label, Single-Arm, Safety, Tolerability, Efficacy and Pharmacokinetic Study of RAD-001 in Pediatric De Novo Renal Transplant Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Antibody Incompatible Renal Transplant (AiT) Recipients - HLA antibody incompatible (HLAi) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living related donor (LRD) - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living unrelated donor - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Subjects Awaiting Renal Transplant</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Total protein/Creatinine ratio</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="117735"><Indications><Indication>Upper respiratory tract infection</Indication></Indications><CompaniesSponsor><Company>Reckitt Benckiser Healthcare (UK) Ltd</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-08-16T00:00:00Z</DateChangeLast><DateEnd>2011-04-01T00:00:00Z</DateEnd><DateStart>2011-01-11T00:00:00Z</DateStart><Identifiers><Identifier>2010-024045-69</Identifier><Identifier>TH1017</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Strepsils Extra alone</Intervention><Intervention>Strepsils Plus alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>180</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>mouth ulcers, cough) Those with a history of alcohol abuse or consume alcohol in excess of the recommended amounts (excessive alcohol &gt; 21 units per week for females and &gt; 28 units per week for males) Those who have used an analgesic, antipyretic or &lt;b&gt;cold&lt;/b&gt; medication (eg, decongestant, antihistamine, antitussive or throat lozenge/spray) within the previous 8 h Those who have used a longer acting or slow release analgesic during the previous 24 h eg, piroxicam and naproxen Those who have taken any medicated</Teaser><TrialCategories><Category>Medical device</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A multicenter, randomized, double-blind, single-dose parallel-group, placebo-controlled study to investigate the efficacy of Strepsils Plus and Strepsils Extra in the treatment of sore throat due to upper respiratory tract infection</TitleDisplay><PrimaryCompletionDate/><TrialDuration>2 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="117725"><Indications><Indication>Common cold</Indication></Indications><CompaniesSponsor><Company>Pfizer Consumer Healthcare</Company></CompaniesSponsor><Countries><Country>Belgium</Country></Countries><DateChangeLast>2017-07-28T00:00:00Z</DateChangeLast><DateStart>2005-07-26T00:00:00Z</DateStart><Identifiers><Identifier>A7801001</Identifier><Identifier>EudraCT 2004-001637-41</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Sinutab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>500</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>pregnancy Are unwilling or unable to abstain from the use of antihistamines or &lt;b&gt;cold&lt;/b&gt;/cough/pain preparations during the treatment period Use of concomitant drugs that could... Age 18 years or more Reported &lt;b&gt;cold&lt;/b&gt; symptoms begin&amp;lt;/= 48 h prior to visit 1 Scored &amp;gt;/= 2 for each of nasal congestion and headache using the Modified Jackson...common &lt;b&gt;cold&lt;/b&gt; which consists of four signs/symptoms: nasal congestion, headache, sore throat, and pressure around the eyes. To assess the</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Migraine/Other Headaches</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Social and Occupational Functioning</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Respiratory disease related outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Community Pharmacy Based Investigation in the Self-Medication area: Efficacy and Safety of Sinutab (Paracetamol [500 mg]/Pseudoephedrine [30 mg]) on Subjects With Nasal Congestion Accompanied by Headache And/or Fever in the Setting of a Common Cold</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with other types of headache</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="117600"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>ORL1 receptor agonist</Action><Action>Opioid receptor mu partial agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticonvulsant agent</Action><Action>Antidepressant</Action><Action>GABA modulator</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Mental Health Drug and Alcohol Office (MHDAO)</Company></CompaniesCollaborator><CompaniesSponsor><Company>Health Sydney Local Health District</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2016-08-12T00:00:00Z</DateChangeLast><DateStart>2010-03-05T00:00:00Z</DateStart><Identifiers><Identifier>ACTRN12612000288820</Identifier><Identifier>ANZCTR362195</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including buprenorphine (sublingual, opioid dependence), Indivior , gabapentin , methadone , naltrexone , oxycodone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>36</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>the study laboratory for three 3-h study sessions, each separated by at least 5 days. At each session, the &lt;b&gt;cold&lt;/b&gt; pressor test would be conducted 2 h after baseline. In random order each participant would receive: Placebo (either matched placebo...severe pain within 4 weeks prior to the study Currently participating in another research project that may interfere with the present study Medications with significant pharmacokinetic/dynamic interaction with study medications &lt;b&gt;Cold&lt;/b&gt; urticaria</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain tolerance</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Pain by Visual Analog Scale (VAS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Optimizing Management of Acute Pain in Opioid Substitution Therapy Patients: A Pilot Laboratory Randomized Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Specific Therapy Naive Subjects</PatientSegment><PatientSegment>Pain - Subjects with Acute Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Respiratory frequency</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>3</NumberOfSites><ContactNames><Name>Bridin Murnion</Name><Name>Suzanne Nielsen</Name></ContactNames></Trial><Trial Id="117463"><Indications><Indication>Upper respiratory tract infection</Indication></Indications><CompaniesSponsor><Company>Deutsche Homoopathie Union</Company></CompaniesSponsor><Countries><Country>Russian Federation</Country><Country>Germany</Country><Country>Ukraine</Country></Countries><DateChangeLast>2018-03-31T00:00:00Z</DateChangeLast><DateEnd>2011-04-30T00:00:00Z</DateEnd><DateStart>2010-11-15T00:00:00Z</DateStart><Identifiers><Identifier>09-NI-EP-001</Identifier><Identifier>2010-021422-35</Identifier><Identifier>INFI</Identifier><Identifier>ISRCTN60440500</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Influcid alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>520</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>weeks prior to or at enrolment as well as current indication requiring these drugs during the trial Indication for administration of or treatment with antiviral drugs Treatment with any antipyretics, nasal decongestants, expectorants and/or any other &lt;b&gt;cold&lt;/b&gt; medication or measure for relief of URTI eg, local anesthetics, anti-inflammatory drugs, antitussiva, homeopathic drugs, nutritional supplements or drugs containing zinc, echinacea, garlic or vitamin C (100 mg/day), during the past 7 days prior to </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>INFI: Influcid in Feverish Infections</TitleDisplay><PrimaryCompletionDate/><TrialDuration>5 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Manuela Thinesse-mallwitz</Name></ContactNames></Trial><Trial Id="11734"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Inactivated viral vaccine</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Suspension</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Sanofi Pasteur Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of Michigan</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2008-05-31T00:00:00Z</DateEnd><DateStart>2007-09-30T00:00:00Z</DateStart><Identifiers><Identifier>FLUVACS</Identifier><Identifier>FLUVACS</Identifier><Identifier>NCT00538512</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention><Intervention>Fluzone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1952</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>To purpose of this study was to evaluate the absolute (versus placebo) and relative (one vaccine compared to the other) efficacies of the live attenuated Flumist and inactivated Fluzone influenza vaccines, in preventing laboratory confirmed symptomatic influenza caused by circulating strains whether similar or dissimilar to strains included in the vaccines.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza Vaccine - Incidence of Laboratory Confirmed Influenza</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza virus infection - Incidence of Laboratory Confirmed Influenza</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>FLUVACS: Comparative Study of Influenza Vaccines in Adults, Fluvacs-Year 4</TitleDisplay><PrimaryCompletionDate type="Actual">2008-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Arnold S. Monto, MD</Name></ContactNames></Trial><Trial Id="117168"><Indications><Indication>Upper respiratory tract infection</Indication></Indications><CompaniesSponsor><Company>Reckitt Benckiser plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-01-19T00:00:00Z</DateChangeLast><DateEnd>2008-02-19T00:00:00Z</DateEnd><DateStart>2007-10-26T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT 2007-004375-19</Identifier><Identifier>Strepsils Original Efficacy Study</Identifier><Identifier>TH0705</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Strepsils Original alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>350</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>pastille, spray, or any products with demulcent properties such as boiled sweets, within the previous 2 h Those who have used any sore throat medication containing a local anesthetic within the past 4 h Those who have used any analgesic, antipyretic or '&lt;b&gt;cold&lt;/b&gt;' medication (eg, decongestant, antihistamine, antitussive, or throat lozenge) within the previous 8 h Those who have used a longer acting or slow release analgesic during the previous 24 h eg, proxicam Those taking antibiotics during the previous 14</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Strepsils Original Efficacy Study: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multiple-dose Study of the Efficacy of Strepsils Original Throat Lozenges in the Relief of Sore Throat Due to Upper Respiratory Tract Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Acute Pain</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with pain associated with infections</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>3 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="117012"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>IL-2 receptor antagonist</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action><Action>Immunosuppressant</Action><Action>Lymphocyte inhibitor</Action><Action>Protein synthesis inhibitor</Action><Action>Systemic antipsoriatic product</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Drug coating</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Barts and The London NHS Trust</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2017-06-20T00:00:00Z</DateChangeLast><DateStart>2005-08-01T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT 2004-005055-33</Identifier><Identifier>ML17443</Identifier><Identifier>UK ELiTE</Identifier></Identifiers><InterventionsControlDisplay><Intervention>mycophenolate mofetil plus tacrolimus</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>daclizumab (intravenous, transplant rejection), PDL/Roche plus sirolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>180</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Known hypersensitivity or absolute contraindications to any of the medications administered in the context of the study or any other substances present in the study medications Panel Reactive Antibody (PRA)&gt; 50% within 6 months prior to enrollment &lt;b&gt;Cold&lt;/b&gt; ischemia time of the graft of &gt; 30 h Patients who had received an investigational new drug within the last 3 months Patients previously treated with daclizumab or basiliximab</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Bone - Assessment by Bone mineral density (BMD)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Cardiovascular Events - Hypertension</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR) - Calculated GFR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival - Graft survival rate at 12 months (1 year) post-transplant</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Hyperlipidemia/dyslipidemia</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of use of Rescue Medication - Need of immunosuppressive medication</EndpointIndex><EndpointIndex>Kidney transplantation - Imaging/Radiological Assessments - Assessment by imaging/radiology</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>UK ELiTE: Evaluating the Safety and Efficacy of Mycophenolate Mofetil, Daclizumab and a Single, Initial Week of Corticosteroids in Combination With Tacrolimus or Sirolimus With Continued Steroid as Mainstay Immunosuppression in Comparison to Current Standard Immunosuppression (Mycophenolate Mofetil, Tacrolimus and Continued Corticosteroids) in Renal Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Subjects Awaiting Renal Transplant</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="116801"><Indications><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>Centre for Human Drug Research</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2015-11-24T00:00:00Z</DateChangeLast><DateStart>2011-11-22T00:00:00Z</DateStart><Identifiers><Identifier>CHDR1117</Identifier><Identifier>EudraCT 2011-005086-20</Identifier><Identifier>NL38626.000.11</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>paracetamol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>12</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>disease as determined by medical history taking Clinically significant findings as determined by medical history taking Any current, clinically significant, known medical condition, in particular any existing conditions that would affect sensitivity to &lt;b&gt;cold&lt;/b&gt; (such as atherosclerosis, Raynaud’s disease, urticaria, hypothyroidism) or pain (paraesthesia, etc) Medical history of fainting or syncope eci Previous allergic reaction to paracetamol Pregnancy and/or breast feeding in females Subjects indicating </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain tolerance</EndpointIndex><EndpointIndex>Pain - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Effects of Paracetamol on Nociception in Adolescents</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="116499"><Indications><Indication>Herpes simplex virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action><Action>HSV replication inhibitor</Action><Action>Unspecified drug target</Action><Action>Virus uptake inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Dermatological formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hadassah Medical Organization</Company></CompaniesSponsor><DateChangeLast>2017-06-30T00:00:00Z</DateChangeLast><DateStart>2007-04-17T00:00:00Z</DateStart><Identifiers><Identifier>376.HMO-CTIL</Identifier><Identifier>NCT00467662</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Superlysine alone</Intervention><Intervention>aciclovir alone</Intervention><Intervention>docosanol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>75</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The purpose of this double-blinded, non-inferiority, prospective, parallel-group, intend to treat trial is to check the safety, efficacy and convenience of use of the natural agent 'superlysin gel' as treatment for Herpes labialis in comparison to acyclovir 5% and docozanole 10%.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Duration</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Healing</EndpointIndex><EndpointIndex>Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Comparison of Topical Antiviral Agents for Labial Cold Sores (Herpes Labialis)</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites><ContactNames><Name>Doron Aframian, DMD,PhD</Name><Name>Doron J Aframian, DMD, PhD</Name></ContactNames></Trial><Trial Id="115894"><Indications><Indication>Lung embolism</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Tissue plasminogen activator stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Fibrinolysis stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Protein recombinant</Technology></Technologies><CompaniesSponsor><Company>Ekos Corp</Company></CompaniesSponsor><Countries><Country>Switzerland</Country><Country>Germany</Country></Countries><DateChangeLast>2018-11-16T00:00:00Z</DateChangeLast><DateEnd>2013-05-31T00:00:00Z</DateEnd><DateStart>2010-07-31T00:00:00Z</DateStart><Identifiers><Identifier>2010-022468-11</Identifier><Identifier>EKOS Protocol Number 08</Identifier><Identifier>NCT01166997</Identifier><Identifier>ULTIMA</Identifier><Identifier>ULTIMA08</Identifier></Identifiers><InterventionsControlDisplay><Intervention>unfractionated heparin alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>EkoSonic Endovascular System alone</Intervention><Intervention>alteplase plus unfractionated heparin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>59</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>collapse at presentation defined as: need for cardiopulmonary resuscitation; or systolic blood pressure&amp;lt; 90 mmHg for at least 15 min, or drop of systolic blood pressure by at least 40 mmHg for at least 15 min with signs of end organ hypoperfusion (&lt;b&gt;cold&lt;/b&gt; extremities or low urinary output &amp;lt; 30 ml/h or mental confusion); or need for catecholamine administration to maintain adequate organ perfusion and a systolic blood pressure of &gt; 90 mmHg Severe hypertension on repeated readings (systolic&gt; 180 mmHg</Teaser><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Thrombosis - Assessment of Thrombotic/Thromboembolic Events - Assessment of pulmonary embolism(PE)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ULTIMA: Ultrasound Accelerated Thrombolysis of Pulmonary Embolism</TitleDisplay><PatientSegmentTerms><PatientSegment>Thrombosis - Subjects with comorbid conditions - Subjects with cardiovascular diseases/disorders</PatientSegment><PatientSegment>Thrombosis - Subjects with disease related complications - Subjects with pulmonary embolism</PatientSegment><PatientSegment>Thrombosis - Subjects with disease related complications - Subjects with venous thrombus complications</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Hemoglobin </BiomarkerName><BiomarkerName> Right ventricle/Left ventricle ratio </BiomarkerName><BiomarkerName> Six-minute walk distance </BiomarkerName><BiomarkerName> Systolic blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>34 Months</TrialDuration><NumberOfSites>10</NumberOfSites><ContactNames><Name>Hans-Joachim Lau</Name><Name>Nils Kucher, Prof Dr med</Name></ContactNames></Trial><Trial Id="11559"><Indications><Indication>Allergic rhinitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Glucocorticoid receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Respiratory system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Microparticle formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Suspension</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2016-12-30T00:00:00Z</DateChangeLast><DateEnd>2007-11-30T00:00:00Z</DateEnd><DateStart>2007-08-31T00:00:00Z</DateStart><Identifiers><Identifier>FFU105927</Identifier><Identifier>NCT00519636</Identifier></Identifiers><InterventionsControlDisplay><Intervention>fluticasone propionate alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>fluticasone furoate (nasal, allergic rhinitis), GSK alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>360</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> nasal septum) injury or surgery in the last 3 months asthma, with the exception of mild intermittent asthma [National Asthma Education and Prevention Program (NARPP) Guidelines, 2002] Rhinitis medicamentosa bacterial or viral infection (eg, common &lt;b&gt;cold&lt;/b&gt;) of the eyes or upper respiratory tract within 2 weeks of visit one or during the screening period documented evidence of acute or significant chronic sinusitis as determined by the individual investigator, current or history of glaucoma and/or cataracts</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Assessment of reflective total nasal symptom score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of compliance/adherence</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Comparator Study Evaluating Patient Experience And Preference Of FFNS versus FPNS</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Perennial Allergic Rhinitis</PatientSegment><PatientSegment>Allergic rhinitis - Subjects with Seasonal Allergic Rhinitis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>3 Months</TrialDuration><NumberOfSites>28</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="11556"><Indications><Indication>Herpesvirus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>HSV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><DateChangeLast>2018-12-18T00:00:00Z</DateChangeLast><DateEnd>2007-07-01T00:00:00Z</DateEnd><DateStart>2003-10-31T00:00:00Z</DateStart><Identifiers><Identifier>CFAM810A2403</Identifier><Identifier>NCT00248144</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>famciclovir alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>701</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> 18 years or older A history typical for recurrent Herpes labialis. The subject must have experienced three or more episodes of &lt;b&gt;cold&lt;/b&gt; sores in the last 12 months, and have a history of prodromal symptoms, as defined by the patient, preceding at least 50% of these &lt;b&gt;cold&lt;/b&gt; sores, and must also have a history of vesicular lesions in at least 50% of the recurrent episodes of &lt;b&gt;cold&lt;/b&gt; sores General good health, without other serious medical conditions and specifically with normal renal and hepatic function, as</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Development in aborted lesion</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Healing</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Post Herpetic Neuralgia</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study To Evaluate The Safety And Efficacy Of Single Day Or Single Dose Famciclovir For The Treatment Of Recurrent Herpes Labialis</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with pain associated with infections</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>44 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Novartis Pharmaceuticals Japan</Name></ContactNames></Trial><Trial Id="115230"><Indications><Indication>Perennial allergic rhinitis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2014-03-06T00:00:00Z</DateChangeLast><DateEnd>2001-10-02T00:00:00Z</DateEnd><DateStart>1999-08-15T00:00:00Z</DateStart><Identifiers><Identifier>FNM40017</Identifier></Identifiers><IndicationsAdverse><Indication>Common cold</Indication><Indication>Cough</Indication><Indication>Emesis</Indication><Indication>Epistaxis</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Pain</Indication><Indication>Pharyngitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>fluticasone propionate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>150</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>groups [ 1390730 ]. Results were published in May 2005. The most commonly observed adverse events in both groups were cough, fever, headache, upper respiratory tract infection, sore throat, streptococcal pharyngitis, gastric pain, epistaxis, common &lt;b&gt;cold&lt;/b&gt;, vomiting and earache. There were no drug-related serious adverse events during the study [ 1390726 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Organ Function</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Therapy Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>A phase IV, multicenter, double-blind, randomized, parallel-group study to evaluate the potential growth effects of a one-year course of fluticasone propionate aqueous nasal spray versus placebo in prepubescent, pediatric subjects with perennial allergic rhinitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Pediatric Allergic Rhinitis Subjects</PatientSegment><PatientSegment>Allergic rhinitis - Subjects with Perennial Allergic Rhinitis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Bone mineral density</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>25 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="114455"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Leukotriene D4 antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Bronchodilator</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Buccal formulation systemic</Technology><Technology>Daily dosing</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Israel</Country><Country>Turkey</Country><Country>Italy</Country><Country>Croatia</Country><Country>Bulgaria</Country><Country>Estonia</Country><Country>Czech Republic</Country><Country>Canada</Country><Country>UK</Country><Country>Ukraine</Country><Country>Slovakia</Country><Country>Norway</Country><Country>Germany</Country><Country>Sweden</Country><Country>Spain</Country><Country>South Africa</Country><Country>Slovenia</Country><Country>Netherlands</Country><Country>Greece</Country></Countries><DateChangeLast>2013-03-07T00:00:00Z</DateChangeLast><DateStart>1999-03-24T00:00:00Z</DateStart><Identifiers><Identifier>SAS40015</Identifier></Identifiers><IndicationsAdverse><Indication>Common cold</Indication><Indication>Headache</Indication><Indication>Influenza virus infection</Indication><Indication>Pharyngitis</Indication><Indication>Rhinitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Variable regimens including fluticasone propionate , fluticasone propionate + montelukast , montelukast sodium</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>806</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>Results were published in March 2003. Both treatments were equally well tolerated [ 1381821 ]. Results were published in April 2007. The most commonly observed adverse events in both groups were exacerbation of asthma, common &lt;b&gt;cold&lt;/b&gt;, upper respiratory tract infection, headache, sore throat, influenza, rhinitis and pharyngitis 6 (1%) 2 (&amp;lt;1%). There were no fatal or non-fatal drug-related serious adverse events during the study [ 1389340 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A phase IV, randomized, multicenter, 12-week, double-blind, double-dummy, parallel group, active-controlled study to compare the safety and efficacy of salmeterol/fluticasone propionate via the diskus/accuhaler inhaler with fluticasone propionate via the diskus/accuhaler inhaler plus oral montelukast in adolescents and adults with reversible airways obstruction</TitleDisplay><BiomarkerNames><BiomarkerName>Peak expiratory flow rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>18</NumberOfSites></Trial><Trial Id="11295"><Indications><Indication>Allergic rhinitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Glucocorticoid receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Respiratory system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Microparticle formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Suspension</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-26T00:00:00Z</DateChangeLast><DateEnd>2007-11-30T00:00:00Z</DateEnd><DateStart>2007-08-31T00:00:00Z</DateStart><Identifiers><Identifier>FFU105924</Identifier><Identifier>NCT00539006</Identifier></Identifiers><InterventionsControlDisplay><Intervention>fluticasone propionate alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>fluticasone furoate (nasal, allergic rhinitis), GSK alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>377</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> nasal septum) injury or surgery in the last 3 months asthma, with the exception of mild intermittent asthma [National Asthma Education and Prevention Program (NARPP) Guidelines, 2002] Rhinitis medicamentosa bacterial or viral infection (eg, common &lt;b&gt;cold&lt;/b&gt;) of the eyes or upper respiratory tract within 2 weeks of visit one or during the screening period documented evidence of acute or significant chronic sinusitis as determined by the individual investigator,current or history of glaucoma and/or cataracts</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Assessment of reflective total nasal symptom score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of compliance/adherence</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Comparator Study Evaluating Patient Preference Of FFNS versus FPNS</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Perennial Allergic Rhinitis</PatientSegment><PatientSegment>Allergic rhinitis - Subjects with Seasonal Allergic Rhinitis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>3 Months</TrialDuration><NumberOfSites>24</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="11002"><Indications><Indication>Acute sinusitis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Bacterial cell wall synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Buccal formulation systemic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Institute of Allergy and Infectious Diseases</Company></CompaniesCollaborator><CompaniesSponsor><Company>Washington University in St Louis</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-12-21T00:00:00Z</DateChangeLast><DateEnd>2010-08-31T00:00:00Z</DateEnd><DateStart>2006-10-31T00:00:00Z</DateStart><Identifiers><Identifier>05-0140</Identifier><Identifier>NCT00377403</Identifier><Identifier>U01AI064655-01A1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>amoxicillin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>172</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> The purpose of this trial was to compare the symptom relief provided by five &lt;b&gt;cold&lt;/b&gt; medicines versus the symptom relief provided by the same five &lt;b&gt;cold&lt;/b&gt; medicines plus the antibiotic, amoxicillin , in people who had sinus infections.The enrollment for the study was 200 adult volunteers, aged 18 to 70 years old, with sinus infections for 28 days. Subjects would receive</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Treatment of Acute Sinusitis</TitleDisplay><PrimaryCompletionDate type="Actual">2009-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>46 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jane Garbutt, MB, ChB</Name></ContactNames></Trial><Trial Id="109918"><Indications><Indication>Osteoarthritis</Indication></Indications><CompaniesSponsor><Company>Coolsystems Inc</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Australia</Country></Countries><DateChangeLast>2018-07-14T00:00:00Z</DateChangeLast><DateEnd>2012-05-31T00:00:00Z</DateEnd><DateStart>2008-07-31T00:00:00Z</DateStart><Identifiers><Identifier>2007-02</Identifier><Identifier>NCT00712816</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Ice with compressive bandages alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Game Ready Injury Treatment System (cryopneumatic device) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>224</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> The purpose of the study was to evaluate the effectiveness of a device that delivers &lt;b&gt;cold&lt;/b&gt; and intermittent compression as compared to ice and compressive wraps on patients who had undergone knee replacement.</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Osteoarthritis - Assessment of Functional Disability/Physical Function</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Use of Cold and Compression Therapy With Total Knee Replacement Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Osteoarthritis - Subjects With History of /Scheduled For Surgical Procedures - Subjects with history of/scheduled for total knee arthroplasty</PatientSegment><PatientSegment>Osteoarthritis - Subjects with Osteoarthritis of Knee</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>46 Months</TrialDuration><NumberOfSites>11</NumberOfSites></Trial><Trial Id="107209"><Indications><Indication>Synovitis</Indication></Indications><CompaniesSponsor><Company>Shuguang Hospital Shanghai University Of Traditional Chinese Medicine</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-01-10T00:00:00Z</DateChangeLast><DateEnd>2013-12-31T00:00:00Z</DateEnd><DateStart>2012-10-18T00:00:00Z</DateStart><Identifiers><Identifier>ChiCTR-TRC-13003025</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Huamoyan granules alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>480</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Diagnosed as dampness and rheumatism or deficiency &lt;b&gt;cold&lt;/b&gt; of spleen and stomach Ready to be pregnant, pregnancy or breast feeding woman Diabetic patients Patients with allergical constitution or allergical to ingredients of test drug Accompanied with knee osteoarthritis without swelling; blood stagnation </Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Musculoskeletal Pain</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Clinical Study of Huamoyan Granules in Treating Acute and Chronic Knee Joint Synovitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Somatic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>14 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jinxue Wang</Name><Name>Xiaoying  Song</Name></ContactNames></Trial><Trial Id="10707"><Indications><Indication>Chlamydia trachomatis infection</Indication><Indication>Trachoma</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Bacterial protein synthesis inhibitor</Action><Action>Macrolide antibiotic</Action><Action>Systemic dermatological antibacterial product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Institute of Allergy and Infectious Diseases</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of California San Francisco</Company></CompaniesSponsor><Countries><Country>Niger</Country><Country>US</Country></Countries><DateChangeLast>2013-12-02T00:00:00Z</DateChangeLast><DateEnd>2009-08-31T00:00:00Z</DateEnd><DateStart>2008-01-31T00:00:00Z</DateStart><Identifiers><Identifier>5R01AI048789</Identifier><Identifier>H1079-31932</Identifier><Identifier>NCT00618449</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>azithromycin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1139</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>lab technician can also not touch anything other than the swab and the vial. Once the swab has been taken, it is inserted in an open NUC vial, broken off, and the NUC vial is closed. The sealed vial is labeled with a pre-printed label and placed in a &lt;b&gt;cold&lt;/b&gt; box with ice packs while in the field. The scribe will record that the specimen has been taken, or any reason why it was not taken. 5. At this point, the sample person is eligible for azithromycin, which is administered at 20mg/kg. A height stick will</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bacterial Conjunctivitis - Assessment of Active Infection</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TitleDisplay>Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger</TitleDisplay><PatientSegmentTerms><PatientSegment>Bacterial Conjunctivitis - Subjects at risk of developing disease</PatientSegment><PatientSegment>Bacterial Conjunctivitis - Subjects with Chronic Bacterial Conjunctivitis - Subjects with trachoma</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>19 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Abdou Amza</Name><Name>Julius Schachter</Name></ContactNames></Trial><Trial Id="106705"><Indications><Indication>Coronary artery disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Adenosine A2a receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>CNS diagnostic agent</Action><Action>Cardiovascular diagnostic agent</Action><Action>Endocrine diagnostic agent</Action><Action>Gastrointestinal diagnostic agent</Action><Action>Imaging agent</Action><Action>MRI imaging agent</Action><Action>Neoplasm diagnostic agent</Action><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Imaging</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Astellas Pharma US Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Washington University in St Louis</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2015-06-30T00:00:00Z</DateEnd><DateStart>2013-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01779869</Identifier><Identifier>PET/MR-P</Identifier><Identifier>PET/MR-Perfusion</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including 13N-ammonia , gadobenic acid , regadenoson</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>16</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>to gadolinium-based MR contrast agent Second or third degree atrioventricular (AV) block Active asthma Seizures Current hypotension (&amp;lt; 100/60) Current hypertension (&gt; 160/90) Pregnancy Breast feeding Use of caffeine, nicotine or over the counter &lt;b&gt;cold&lt;/b&gt; medicines within 12 h of the cardiac PET-MRI examination Use of the medication dipyridamole within 48 h of the cardiac PET-MRI examination</Teaser><TrialCategories><Category>Diagnostic</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Diagnosis</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Therapy Related Outcomes - Efficacy/feasibility Assessment</EndpointIndex><EndpointIndex>Coronary artery disease - Detection of Coronary Artery Disease (CAD)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PET/MR-P: Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson</TitleDisplay><PatientSegmentTerms><PatientSegment>Coronary artery disease - Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Myocardial blood perfusion</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>29 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Pamela K Woodard, MD, BA</Name></ContactNames></Trial><Trial Id="106308"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action><Action>Beta adrenoceptor agonist</Action><Action>Leukotriene C4 antagonist</Action><Action>Leukotriene D4 antagonist</Action><Action>Leukotriene E4 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>University of Wisconsin-Madison</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2016-08-20T00:00:00Z</DateChangeLast><DateStart>1999-06-30T00:00:00Z</DateStart><Identifiers><Identifier>CMS-1253</Identifier></Identifiers><IndicationsAdverse><Indication>Common cold</Indication><Indication>Headache</Indication><Indication>Influenza virus infection</Indication><Indication>Insomnia</Indication><Indication>Nausea</Indication><Indication>Sinusitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>salmeterol alone</Intervention><Intervention>zafirlukast alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>289</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Due to therapy most frequent adverse events reported across salmeterol and zafirlukast were common &lt;b&gt;cold&lt;/b&gt; (6, 8%), headache (5,8%), upper respiratory tract infection (3, 6%), sinusitis (4, &amp;lt;1%), nausea (3, &amp;lt;1%), insomnia (3, 1%), cough (&amp;lt;1, 2%), influenza (2, 0%), tension headache (1, 0%), nasal sinus infection (1, 1%).  Subject with non-fatal serious adverse events was seen in one patient with SAL.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score</EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score - Daytime asthma symptom score</EndpointIndex><EndpointIndex>Asthma - Assessment of Exacerbations</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1) - Assessment of morning/evening FEV1</EndpointIndex><EndpointIndex>Asthma - Assessment of Peak Expiratory Flow/Flow Rate (PEFR) - Assessment of morning/evening PEFR</EndpointIndex><EndpointIndex>Asthma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Asthma - Assessment of Sleep - Nighttime sleep score</EndpointIndex><EndpointIndex>Asthma - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma Quality of Life Questionnaire (AQLQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Randomized, Double-blind, Multicenter Study to Compare Salmeterol Versus Zafirlukast in Asthma Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with mild persistent asthma</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with moderate persistent asthma</PatientSegment><PatientSegment>Asthma - Subjects with Symptomatic Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="105541"><Indications><Indication>Cough</Indication></Indications><CompaniesSponsor><Company>Universidade Federal de Pernambuco</Company></CompaniesSponsor><Countries><Country>Brazil</Country></Countries><DateChangeLast>2018-01-11T00:00:00Z</DateChangeLast><DateEnd>2012-03-31T00:00:00Z</DateEnd><DateStart>2011-06-30T00:00:00Z</DateStart><Identifiers><Identifier>BROMETOSS</Identifier><Identifier>Brom1</Identifier><Identifier>NCT01356693</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Bromelin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>102</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Cough for&amp;lt; 24 h Common &lt;b&gt;cold&lt;/b&gt; symptoms: nasal obstruction, headache, myalgias, runny nose...of the study is to compare the phytotherapic 'Bromelin', a compound preparation of honey from the bee apis mellifera with the extract of the pineapple (Ananas comosus) with placebo in reducing cough episodes in patients with the common &lt;b&gt;cold&lt;/b&gt;.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>BROMETOSS: Bromelin, a Compound Prepared With Ananas Comocus Extract and Honey, for Acute Cough</TitleDisplay><PrimaryCompletionDate type="Anticipated">2011-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Almerinda R silva, MD, MsC</Name><Name>Decio M Peixoto, MD, PhD</Name><Name>Dinaldo C Oliveira, MD, PhD</Name><Name>Emanuel S Sarinho, MD, PhD</Name><Name>Emanuel SC Sarinho, MD, PhD</Name><Name>Jose A Rizzo, MD, PhD</Name></ContactNames></Trial><Trial Id="104657"><Indications><Indication>Xerophthalmia</Indication></Indications><CompaniesSponsor><Company>Southern California College of Optometry</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-09-05T00:00:00Z</DateChangeLast><DateEnd>2007-04-30T00:00:00Z</DateEnd><DateStart>2006-10-31T00:00:00Z</DateStart><Identifiers><Identifier>05-S4507</Identifier><Identifier>NCT00388791</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Saline alone</Intervention><Intervention>Systane alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>and/or conjunctiva and/or eyelids; mycobacterial infection of the eye; and/or fungal disease of the eye Use of topical ocular medications during the study period Subjects using systemic steroids, immunosuppressive agents and/or anti-cholinergics (eg, &lt;b&gt;cold&lt;/b&gt; and allergy medications, tricyclic antidepressants) for treatment of autoimmune connective tissue disease may not be enrolled in the study if they have not been on a stable dosing regimen for a minimum of 30 days prior to the eligibility visit. In </Teaser><TrialCategories><Category>Borderline product</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Xerophthalmia - Assessment of Tear Dynamics - Assessment of ocular surface staining</EndpointIndex><EndpointIndex>Xerophthalmia - Assessment of Tear Dynamics - Assessment of tear film breakup time(TBUT)</EndpointIndex><EndpointIndex>Xerophthalmia - Assessment of ocular function</EndpointIndex><EndpointIndex>Xerophthalmia - Patient Reported Outcomes/Quality of Life Assessments - Subjective assessment of dry eye syndrome</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Comparison of Systane Free versus Saline in the Treatment of Dry Eye</TitleDisplay><PatientSegmentTerms><PatientSegment>Xerophthalmia - Subjects with Mild Dry Eye</PatientSegment><PatientSegment>Xerophthalmia - Subjects with Moderate Dry Eye</PatientSegment><PatientSegment>Xerophthalmia - Subjects with Severe Dry Eye</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Tear break-up time</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>6 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jerry R Paugh</Name></ContactNames></Trial><Trial Id="104654"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Somatostatin receptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsSecondaryInterventionsControl><Action>Anticancer</Action><Action>Anticancer polyclonal antibody</Action><Action>Growth hormone release inhibitor</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsControl><Technologies><Technology>Antibody polyclonal</Technology><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>University Hospital Basel</Company></CompaniesSponsor><Countries><Country>Switzerland</Country></Countries><DateChangeLast>2018-01-10T00:00:00Z</DateChangeLast><DateEnd>2015-02-28T00:00:00Z</DateEnd><DateStart>2009-01-31T00:00:00Z</DateStart><Identifiers><Identifier>82/06</Identifier><Identifier>NCT00861536</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Thymoglobulin alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>ATG Fresenius S alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>immunological risk constellation, defined by receiving a kidney from a HLA-identical related living donor Patient and donor have a positive T-cell crossmatch Patient and donor are ABO incompatible Patient with combined transplantation Age of donor&gt; 75 years &lt;b&gt;Cold&lt;/b&gt; ischemia time&gt; 40 h Patient has leucopenia, defined as having at transplantation&amp;lt; 3000/mm3 leukocytes Patient has thrombocytopenia, defined as having at transplantation&amp;lt; 75000/mm3 thrombocytes Patient is allergic or intolerant to ATG-Fresenius</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Chronic Graft Rejection (CGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Comparison of ATG to Thymoglobuline in Renal Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Antibody Incompatible Renal Transplant (AiT) Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2015-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>73 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Juerg Steiger, MD,Prof</Name></ContactNames></Trial><Trial Id="104648"><Indications><Indication>Transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Angiotensin II AT-1 receptor antagonist</Action><Action>Angiotensin II receptor antagonist</Action><Action>Benzodiazepine receptor agonist</Action><Action>Cytotoxic T-lymphocyte protein-4 modulator</Action><Action>H+ K+ ATPase inhibitor</Action><Action>T cell surface glycoprotein CD28 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Acid pump inhibitor antiulcerant product</Action><Action>Anti-inflammatory</Action><Action>Antibacterial</Action><Action>Anticancer</Action><Action>Antihypertensive</Action><Action>Antitussive</Action><Action>Anxiolytic</Action><Action>Gastric secretion inhibitor</Action><Action>General anesthetic</Action><Action>Immunosuppressant</Action><Action>Lymphocyte inhibitor</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Granule</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Injectable formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Protein fusion</Technology><Technology>Small molecule therapeutic</Technology><Technology>Stereochemistry</Technology><Technology>Sustained release formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Bristol-Myers Squibb Co</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-09-08T00:00:00Z</DateChangeLast><DateEnd>2013-04-30T00:00:00Z</DateEnd><DateStart>2013-01-31T00:00:00Z</DateStart><Identifiers><Identifier>IM103-151</Identifier><Identifier>NCT01766050</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including belatacept , caffeine , dextromethorphan hydrobromide (sustained release) , losartan , midazolam hydrochloride , omeprazole</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>45</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to determine the effects of belatacept on the pharmacokinetics of caffeine, losartan , omeprazole , dextromethorphan and midazolam .</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Pharmacokinetics</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers</TitleDisplay><PrimaryCompletionDate type="Actual">2013-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>3 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Bristol-Myers Squibb</Name></ContactNames></Trial><Trial Id="104552"><Indications><Indication>Neisseria meningitidis meningitis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Polysaccharide subunit vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Freeze drying</Technology><Technology>Intramuscular formulation</Technology><Technology>Liquid formulation</Technology><Technology>Oligosaccharide</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline Biologicals</Company><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2018-10-12T00:00:00Z</DateChangeLast><DateEnd>2018-01-22T00:00:00Z</DateEnd><DateStart>2013-03-15T00:00:00Z</DateStart><Identifiers><Identifier>2017-000166-30</Identifier><Identifier>205341</Identifier><Identifier>MENACWY CONJ-025</Identifier><Identifier>NCT01766206</Identifier><Identifier>V59_62</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Menveo alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>3948</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>has ever had: An allergic reaction to the active substances or any of the other ingredients of the study vaccine; an allergic reaction to diphtheria toxoid An illness with high fever; however, a mild fever or upper respiratory infection (for example &lt;b&gt;cold&lt;/b&gt;) itself is not a reason to delay vaccination. Special care should be taken for subjects having hemophilia or any other problem that may stop your blood from clotting properly, such as persons receiving blood thinners (anticoagulants) Infants who were</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Meningitis - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Meningitis - Assessment of Safety and Tolerability - Reactogenicity(local/systemic reactions)</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Assessment of Safety and Tolerability - Assessment of local reactions</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Assessment of Safety and Tolerability - Assessment of systemic reactions</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Asian Ancestry</Term></TermsPatientSelection><TitleDisplay>MENACWY CONJ-025: Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea</TitleDisplay><PrimaryCompletionDate type="Actual">2018-01-22T00:00:00Z</PrimaryCompletionDate><TrialDuration>58 Months</TrialDuration><NumberOfSites>53</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="103647"><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation aerosol</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Stereochemistry</Technology></Technologies><CompaniesCollaborator><Company>Sumitomo Chemical Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Johns Hopkins University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2013-01-10T00:00:00Z</DateChangeLast><DateStart>2004-05-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT00325767</Identifier><Identifier>RPN 04-03-19-11</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>albuterol alone</Intervention><Intervention>levalbuterol (inhalation solution), Akorn alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>10</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> History of heart disease, irregular heartbeat, hypertension History of diabetes, hyperthyroid History of pneumonia, tuberculosis History of seizure disorder, depression, hospitalization in the last month for non-elective purposes, &lt;b&gt;cold&lt;/b&gt; or flu in the previous 3 months</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol</TitleDisplay><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Beth L Laube, Ph.D.</Name><Name>Jeffrey C Cleary, M.D.</Name></ContactNames></Trial><Trial Id="103547"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Injectable formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Cork University Hospital</Company></CompaniesSponsor><Countries><Country>Ireland</Country></Countries><DateChangeLast>2017-04-11T00:00:00Z</DateChangeLast><DateEnd>2013-01-31T00:00:00Z</DateEnd><DateStart>2011-10-31T00:00:00Z</DateStart><Identifiers><Identifier>JR-786-GS</Identifier><Identifier>NCT01759524</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>bupivacaine, AstraZeneca alone</Intervention><Intervention>clonidine plus lidocaine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this study was to compare lidocaine 2% + 1.5 microg/kg clonidine with 0.5% bupivacaine alone in terms of block selectivity for combined sciatic-saphenous nerve block in patients under going semi elective foot/ankle procedures.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Assessment of duration of block</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Level/Depth of block</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>To Compare lidocaine 2%/Clonidine in Combination, With Bupivacaine 0.5% Alone in Equal Volumes for Combined Sciatic-saphenous Nerve Block in Terms of Selectivity of Blockade</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects in need of Procedural Analgesia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>George Shorten, FCARCSI PhD</Name><Name>Jassim Rauf</Name></ContactNames></Trial><Trial Id="103170"><Indications><Indication>Cardiac arrest</Indication><Indication>Hypothermia</Indication></Indications><CompaniesSponsor><Company>University of Leipzig</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2013-01-03T00:00:00Z</DateChangeLast><DateEnd>2010-01-31T00:00:00Z</DateEnd><DateStart>2008-04-30T00:00:00Z</DateStart><Identifiers><Identifier>COOL-NSE</Identifier><Identifier>NCT01102153</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ArcticSun alone</Intervention><Intervention>Coolgard alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>108</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The objective of the study was to assess the efficiency of different cooling methods and further improve these methods, the investigators would collect blood samples to measure the neuron specific enolase (NSE) in patients treated with invasive cooling as compared to patients treated with non-invasive cooling.</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Neuron Specific Enolase (NSE) as Outcome Parameter of Cooling Therapy After Survived Sudden Cardiac Death</TitleDisplay><BiomarkerNames><BiomarkerName>Gamma enolase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Alexandra Schratter, MD</Name><Name>Holger Thiele, Associate Professor</Name><Name>Undine Pittl, MD</Name></ContactNames></Trial><Trial Id="102812"><Indications><Indication>Hypothermia</Indication></Indications><CompaniesSponsor><Company>University of Wisconsin-Madison</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2014-12-31T00:00:00Z</DateEnd><DateStart>2012-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2011-0823</Identifier><Identifier>NCT01626690</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Bair hugger warming device alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Bair paws warming device alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Other</Reason></ReasonForTrialDiscontinuation><Teaser>The purpose of this study was to determine if placement of a forced-air warming device prior to institution of regional anesthesia improves peri-operative temperature control in patients undergoing total hip arthroplasty.</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Prospective Trial of the Effect of Pre-operative Forced-air Warming on Peri-operative Body Temperature Following Neuraxial Anesthesia in Total Hip Arthroplasty Patients</TitleDisplay><BiomarkerNames><BiomarkerName>Body temperature</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>31 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="101931"><CompaniesSponsor><Company>Odense University Hospital</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2019-04-02T00:00:00Z</DateChangeLast><DateEnd>2007-01-31T00:00:00Z</DateEnd><DateStart>2006-02-28T00:00:00Z</DateStart><Identifiers><Identifier>EudraCT 2005-004082-42</Identifier><Identifier>NCT00271973</Identifier><Identifier>OXY-2</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>oxycodone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>32</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>compared with extensive metabolizers (EM). Compared to EM, &amp;nbsp;there was less reduction in pain AUC on oxycodone for PM in the &lt;b&gt;cold&lt;/b&gt; pressor test. The plasma oxymorphone/oxycodone ratio was significantly lower in PM compared with EM (p &amp;lt; 0.001) [ 1533038...time AUC) and were associated with less adverse drug reactions. The combined wild-type genotype 3435CC-2677GG was associated with less antinociceptive effect of oxycodone in the discomfort rating of the &lt;b&gt;cold&lt;/b&gt; pressor test (13% reduction versus 23%, p = 0.019) and more severe adverse drug reactions</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain tolerance</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Quantitative sensory testing</EndpointIndex><EndpointIndex>Pain - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Pain - Gene variants involved in outcome measures - ABCB1_HUMAN_rs1045642(C)</EndpointIndex><EndpointIndex>Pain - Gene variants involved in outcome measures - ABCB1_HUMAN_rs2032582(A)</EndpointIndex><EndpointIndex>Pain - Gene variants involved in outcome measures - ABCB1_HUMAN_rs2032582(T)</EndpointIndex><EndpointIndex>Pain - Gene variants involved in outcome measures - CYP2D6_HUMAN_Mutation</EndpointIndex><EndpointIndex>Pain - Gene variants involved in outcome measures - OPRM1_HUMAN_rs1799971(G)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>OXY-2: The Pharmacogenetics of Oxycodone Analgesia in Human Experimental Pain Models</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cytochrome P450 2D6 </BiomarkerName><BiomarkerName> Mu-Type opioid receptor </BiomarkerName><BiomarkerName> Multidrug resistance protein 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>11 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Stine T. Zwisler, Dr.</Name></ContactNames></Trial><Trial Id="100989"><Indications><Indication>Heart transplantation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospices Civils De Lyon</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2019-01-03T00:00:00Z</DateChangeLast><DateStart>2004-03-31T00:00:00Z</DateStart><Identifiers><Identifier>2003.325</Identifier><Identifier>LOW CYCLO</Identifier><Identifier>NCT00159159</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ciclosporine plus mycophenolate mofetil</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>106</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>Recipient: Males or females, ages&gt; 18 to &amp;lt; 65 years First cardiac transplant Negative pregnancy test for females of childbearing potential, at screening. Efficient method of contraception must be used during the study Written informed consent Donor: &lt;b&gt;Cold&lt;/b&gt; ischemia duration&amp;lt; 6 h</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR)</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR) - AGR &gt;/= to prespecified ISHLT grades</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Blood Pressure (BP) - Diastolic blood pressure (DBP)</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Blood Pressure (BP) - Systolic blood pressure</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Cardiac Function - Assessment of left ventricular ejection fraction (LVEF)</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Cardiac Function - Assessment of left ventricular fractional shortening</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Creatinine Clearance</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Renal Function - Area under curve of creatinine</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Renal Function - Serum cystatin C levels</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Urinary Protein Excretion/Proteinuria</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of lipid profiles - Assessment of Total Cholesterol</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of lipid profiles - HDL-C (high-density lipoprotein cholesterol)</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of lipid profiles - LDL-C (low-density lipoprotein cholesterol)</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of lipid profiles - Triglyceride levels (TG)</EndpointIndex><EndpointIndex>Heart transplantation - Glycemic Control Analysis - Assessment of blood glucose</EndpointIndex><EndpointIndex>Heart transplantation - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Heart transplantation - Protocol Specified Other Endpoints - Efficacy parameters - unspecified</EndpointIndex><EndpointIndex>Renal failure - Assessment of Glomerular Filtration Rate (GFR) - Assessment of estimated glomerular filtration rate(eGFR)/creatinine clearance(CCr/CrCl/CLcr)</EndpointIndex><EndpointIndex>Renal failure - Assessment of Organ Function - Cardiac assessment</EndpointIndex><EndpointIndex>Renal failure - Assessment of Organ Function - Metabolic/endocrinal assessment</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Function - Assessment of creatinine level</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Function - Serum cystatin C levels</EndpointIndex><EndpointIndex>Renal failure - Assessment of Urinary Protein Excretion/Proteinuria</EndpointIndex><EndpointIndex>Renal failure - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>LOW CYCLO: Study Evaluating the Benefit of Two Doses of Ciclosporine in de Novo Cardiac Transplant</TitleDisplay><PatientSegmentTerms><PatientSegment>Heart transplantation - Heart Transplant Recipients</PatientSegment><PatientSegment>Heart transplantation - Heart Transplant Recipients - Primary (First) Heart Transplant Recipients</PatientSegment><PatientSegment>Renal failure - Subjects with History/Scheduled for Other Transplantations</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Cystatin C </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Left ventricular ejection fraction </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Pascale BOISSONNAT, MD</Name></ContactNames></Trial><Trial Id="100134"><Indications><Indication>Measles virus infection</Indication><Indication>Mumps virus infection</Indication><Indication>Rubella virus infection</Indication><Indication>Varicella zoster virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateStart>2013-08-31T00:00:00Z</DateStart><Identifiers><Identifier>114229</Identifier><Identifier>NCT01738841</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Priorix-Tetra alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Sponsor/Business Decision</Reason></ReasonForTrialDiscontinuation><Teaser> Child in care Any contraindications to vaccination as stated in the Prescribing Information Acute, severe febrile illness at the time of enrollment. The presence of a minor infection, such as a &lt;b&gt;cold&lt;/b&gt;, will not exclude the subject from the study Previous receipt of a measles, mumps, rubella and/or varicella-virus containing vaccine&amp;lt; 3 months prior to study entry Previous enrollment in this trial Subjects with impaired immune function, including</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Herpes Virus Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>MMR Vaccine - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra in Children Living in the Philippines</TitleDisplay><PrimaryCompletionDate type="Anticipated">2016-03-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>0</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="88421"><Indications><Indication>Non-insulin dependent diabetes</Indication><Indication>Renal failure</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Glucagon-like peptide 1 receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiarteriosclerotic</Action><Action>Antiparkinsonian</Action><Action>Hypoglycemic agent</Action><Action>Neuroprotectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Peptide</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novo Nordisk A/S</Company></CompaniesSponsor><Countries><Country>France</Country><Country>Ukraine</Country><Country>US</Country><Country>Poland</Country><Country>Russian Federation</Country><Country>UK</Country></Countries><DateChangeLast>2019-05-09T00:00:00Z</DateChangeLast><DateEnd>2013-08-20T00:00:00Z</DateEnd><DateStart>2012-06-14T00:00:00Z</DateStart><Identifiers><Identifier>12029</Identifier><Identifier>2011-002968-24</Identifier><Identifier>LIRA-RENAL</Identifier><Identifier>NCT01620489</Identifier><Identifier>NN2211-3916</Identifier><Identifier>U1111-1122-3303</Identifier></Identifiers><IndicationsAdverse><Indication>Constipation</Indication><Indication>Diarrhea</Indication><Indication>Emesis</Indication><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Renal failure</Indication><Indication>Rhinopharyngitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>insulin regimen alone</Intervention><Intervention>liraglutide alone</Intervention><Intervention>oral antidiabetic drug alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>279</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> liraglutide versus 4.4% placebo), vomiting (12.1 versus 2.2%), diarrhea (7.1 versus 2.9%) and constipation (5.7 versus 1.5%). Additional frequent AEs were renal impairment (5 versus 5.8% placebo), nasopharyngitis, usually referred to as the common &lt;b&gt;cold&lt;/b&gt; (5 versus 11.7%), headache (5 versus 2.9%), increased lipase (15 versus 8.8%) and decreased glomerular filtration rate (6.4 versus 5.1%) [ 1569335 ]. In November 2014, results of a subgroup analysis were presented. The proportion of patients with hypoglycemic</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Anthropometric Assessments</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Nutritional Status</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Renal Function</EndpointIndex><EndpointIndex>End stage renal disease - Glycemic Control Analysis - Assessment of glucose level</EndpointIndex><EndpointIndex>End stage renal disease - Glycemic Control Analysis - Assessment of glycosylated hemoglobin (HbA1c)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of BMI</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Blood Glucose Levels - Self monitoring of blood glucose (SMBG)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - HbA1c response rates</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Renal Function</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Hyperglycemic events/episodes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>LIRA-RENAL: Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 3 chronic kidney disease</PatientSegment><PatientSegment>End stage renal disease - Subjects with Other Chronic Disorders/Associated Nephropathy</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects on Monotherapy</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects on Treatment/Requiring &gt;1 Antidiabetic Agent</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Good Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Poor/Inadequate Glycemic Control</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alpha-amylase 1 </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Lipase </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Urinary albumin to creatinine ratio</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-08-20T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>98</NumberOfSites><ContactNames><Name>Global Clinical Registry (GCR, 1452)</Name><Name>Helle Rau</Name></ContactNames></Trial><Trial Id="87952"><Indications><Indication>Migraine</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>5-HT 1b receptor agonist</Action><Action>5-HT 1d receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Nasal systemic formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral quick release formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Norway</Country><Country>Netherlands</Country><Country>Spain</Country><Country>UK</Country><Country>Italy</Country><Country>Greece</Country><Country>Denmark</Country><Country>Finland</Country><Country>Belgium</Country><Country>Germany</Country><Country>France</Country><Country>Switzerland</Country></Countries><DateChangeLast>2012-06-01T00:00:00Z</DateChangeLast><DateEnd>2003-03-21T00:00:00Z</DateEnd><DateStart>2002-10-10T00:00:00Z</DateStart><Identifiers><Identifier>SUM-30046</Identifier></Identifiers><IndicationsAdverse><Indication>Atrophy</Indication><Indication>Cough</Indication><Indication>Diarrhea</Indication><Indication>Dizziness</Indication><Indication>Emesis</Indication><Indication>Headache</Indication><Indication>Hypotension</Indication><Indication>Musculoskeletal pain</Indication><Indication>Nausea</Indication><Indication>Paresthesia</Indication><Indication>Phlebitis</Indication><Indication>Tremor</Indication><Indication>Vertigo</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>sumatriptan alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>481</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>, cognitive function disorders, lower respiratory infections and nasal inflammation each in &amp;lt; 1% of patients were the AEs reported in sumatriptan (50 mg group). Abdominal discomfort and pain, colitis ,cough, dyspeptic symptoms, flushing, hot and &lt;b&gt;cold&lt;/b&gt; sensations, hyposalivation, hypoesthesia, hypotension, muscle atrophy, weakness and tiredness, muscle pain, palpitations, phlebitis and vertigo each in &amp;lt; 1% of patients, chest symptoms and malaise and fatigue in 3% of patients were the AEs reported</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A phase IIIb, randomized, double-blind, placebo-controlled, parallel-group, single-attack, outpatient study to evaluate the efficacy, safety and tolerability of sumatriptan fast disintegrating tablets (FDT) 50 and 100 mg versus placebo during the mild pain phase of a migraine attack</TitleDisplay><PrimaryCompletionDate/><TrialDuration>5 Months</TrialDuration><NumberOfSites>11</NumberOfSites></Trial><Trial Id="87947"><Indications><Indication>Irritable bowel syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>5-HT 3 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antipsychotic</Action><Action>Anxiolytic</Action><Action>Gastrointestinal system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Austria</Country><Country>Switzerland</Country><Country>Germany</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateStart>2000-04-06T00:00:00Z</DateStart><Identifiers><Identifier>S3B30026</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Colic</Indication><Indication>Common cold</Indication><Indication>Constipation</Indication><Indication>Depression</Indication><Indication>Diarrhea</Indication><Indication>Diverticulitis</Indication><Indication>Dizziness</Indication><Indication>Flatulence</Indication><Indication>Headache</Indication><Indication>Migraine</Indication><Indication>Nausea</Indication><Indication>Pharyngitis</Indication><Indication>Upper respiratory tract infection</Indication><Indication>Urinary tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>alosetron alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>957</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Patient Enrollment Issues</Reason></ReasonForTrialDiscontinuation><Teaser>diverticulitis (n = 1) in 2 mg qd group. During the extension phase (1 mg bid only), AEs were observed in 29% patients in alosetron 1 mg bid group; and the most frequent AEs included constipation (4%), colic (3%), flatulence (1%), gastric pain (1%), common &lt;b&gt;cold&lt;/b&gt; (1%), pharyngitis (1%), upper respiratory tract infection (1%) and diarrhea (1%). There were no treatment-related non-fatal SAEs reported. None of the patients reported fatal SAEs in core study and extension phase. There were no deaths reported [ 1296626</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>An 8-week, randomized, double-blind, multicenter, phase IIIb study to compare the safety and efficacy of alosetron 1 mg bid with 2 mg qd for the treatment of irritable bowel syndrome in non-constipated female patients</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>3</NumberOfSites></Trial><Trial Id="83985"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>PDE 4 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antipsychotic</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>AstraZeneca plc</Company><Company>Takeda Development Centre Europe Ltd</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>Sweden</Country><Country>Denmark</Country><Country>Poland</Country><Country>UK</Country></Countries><DateChangeLast>2019-06-10T00:00:00Z</DateChangeLast><DateEnd>2016-02-29T00:00:00Z</DateEnd><DateStart>2012-02-29T00:00:00Z</DateStart><Identifiers><Identifier>2011-000582-13</Identifier><Identifier>D7120C00003</Identifier><Identifier>NCT01509677</Identifier><Identifier>RO-2455-402-RD</Identifier><Identifier>ROBERT</Identifier><Identifier>U1111-1155-8767</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>roflumilast alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>158</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>instability, defined as experiencing a COPD exacerbation 6 months prior to V0, as indicated by treatment with a systemically administered glucocorticosteroid and/or antibiotics and/or hospitalization  An upper/lower respiratory tract infection eg, common &lt;b&gt;cold&lt;/b&gt;, sinus symptoms, pneumonia which has not resolved 4 weeks prior to V0 Diagnosis of asthma and/or other relevant lung disease (eg, history of primary or clinically significant bronchiectases, cystic fibrosis, bronchiolitis, lung resection, lung cancer</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Bronchial Biopsy/Bronchoalveolar Lavage (BAL) Markers</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of FEV1/FVC Ratio</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Sputum</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ROBERT: Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Ex-smokers</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Smokers</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 1/Mild COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 4/Very Severe COPD</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cytotoxic T-Lymphocytes </BiomarkerName><BiomarkerName> Eosinophils </BiomarkerName><BiomarkerName> FEV / FVC ratio </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Leukocyte common antigen </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Macrophages </BiomarkerName><BiomarkerName> Macrosialin </BiomarkerName><BiomarkerName> Mucin-5AC </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-02-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>22</NumberOfSites><ContactNames><Name>AstraZeneca AstraZeneca</Name><Name>Clinical Trial Operations</Name></ContactNames></Trial><Trial Id="78516"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Beta 2 adrenoceptor agonist</Action><Action>Beta adrenoceptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Bronchodilator</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Drug combination</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Australia</Country></Countries><DateChangeLast>2011-07-01T00:00:00Z</DateChangeLast><DateStart>1999-08-31T00:00:00Z</DateStart><Identifiers><Identifier>SAM30003</Identifier></Identifiers><IndicationsAdverse><Indication>Allergic rhinitis</Indication><Indication>Asthma</Indication><Indication>Bronchitis</Indication><Indication>Candida infection</Indication><Indication>Common cold</Indication><Indication>Headache</Indication><Indication>Influenza virus infection</Indication><Indication>Lower respiratory tract infection</Indication><Indication>Otorhinolaryngological disease</Indication><Indication>Pneumonia</Indication><Indication>Sinusitis</Indication><Indication>Throat disease</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Variable regimens including fluticasone propionate , fluticasone propionate + salmeterol , salmeterol</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>382</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>The most frequently reported adverse events in the Seretide and fluticasone + salmeterol groups, respectively, were exacerbation of asthma (21 and 18%), upper respiratory tract infection (14 and 18%), common &lt;b&gt;cold&lt;/b&gt; (8 and 6%), headache (8 and 5%), lower respiratory tract infection (5 and 7%), sore throat (5 and 6%), oral candidiasis (5 and 6%), asthma (5 and 5%), sinusitis (4 and 5%), hay fever (4 and 1%), influenza (4 and 1%) and bronchitis (3 and 5%). The serious adverse events related to Seretide</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A phase IIIb, 24-week, multicenter, randomized, open-label, parallel-group trial to assess the safety and efficacy of Seretide compared to salmeterol and fluticasone propionate (250 or 500 microg) in patients with asthma</TitleDisplay><BiomarkerNames><BiomarkerName>Forced expiratory volume </BiomarkerName><BiomarkerName> Peak expiratory flow rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="66043"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Spain</Country><Country>Netherlands</Country><Country>Estonia</Country><Country>Russian Federation</Country><Country>Mexico</Country><Country>Australia</Country><Country>Argentina</Country><Country>Lithuania</Country><Country>Romania</Country><Country>Portugal</Country><Country>France</Country><Country>India</Country><Country>Greece</Country><Country>Turkey</Country><Country>Latvia</Country><Country>Belgium</Country><Country>Germany</Country><Country>Norway</Country><Country>Austria</Country><Country>Italy</Country><Country>Thailand</Country></Countries><DateChangeLast>2018-10-23T00:00:00Z</DateChangeLast><DateEnd>2014-10-30T00:00:00Z</DateEnd><DateStart>2010-08-09T00:00:00Z</DateStart><Identifiers><Identifier>2009-015918-22</Identifier><Identifier>CRAD001A2429</Identifier><Identifier>CTRI/2010/091/000679</Identifier><Identifier>ELEVATE</Identifier><Identifier>NCT01114529</Identifier></Identifiers><IndicationsAdverse><Indication>Cardiac failure</Indication><Indication>Diabetes mellitus</Indication><Indication>Heart arrhythmia</Indication><Indication>Hypercholesterolemia</Indication><Indication>Hyperlipidemia</Indication><Indication>Hypertriglyceridemia</Indication><Indication>Ischemic heart disease</Indication><Indication>Lipid metabolism disorder</Indication><Indication>Renal disease</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Variable regimens including ciclosporin, Novartis , enteric-coated mycophenolate sodium, Novartis , group 2 , tacrolimus</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including basiliximab , enteric-coated mycophenolate sodium, Novartis , everolimus , group 1</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>828</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>consent. If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness Patient receiving a primary or secondary kidney transplant from a cadaveric or living unrelated-/related donor &lt;b&gt;Cold&lt;/b&gt; ischemia time (CIT)&amp;lt; 24 h Negative pregnancy test for female patients At randomization: Patients on CNI ( Prograf or Neoral ) + Myfortic + steroids Serum creatinine&amp;lt; 2.8 mg/dl (250 micromol/l) and an actual eGFR (MDRD4) &gt;/= 25 ml/min/1.73 m2 </Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Cardiac Function - Assessment of Left ventricular function</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Procedure and Procedure Related Events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Renal Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Acute antibody mediated/humoral rejection</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Presumptive AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Sub-clinical AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Untreated AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR) - Calculated GFR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Incidence of adverse events/Side Effects</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>ELEVATE: Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living related donor (LRD) - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Renal re-transplant recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Arterial stiffness </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Left ventricle </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Pulse wave velocity </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides </BiomarkerName><BiomarkerName> Urinary protein</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-10-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>50 Months</TrialDuration><NumberOfSites>81</NumberOfSites><ContactNames><Name>Drug Regulatory Affairs</Name><Name>Medical Competence Center</Name><Name>Novartis Pharmaceuticals</Name><Name>S. S.sundar</Name><Name>dinesh Khullar</Name></ContactNames></Trial><Trial Id="62693"><Indications><Indication>Hypertension</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Angiotensin II receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Angiotensin II receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Antihypertensive</Action><Action>Diuretic agent</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action><Action>Diuretic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Takeda Development Center Americas, Inc</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Canada</Country></Countries><DateChangeLast>2019-01-11T00:00:00Z</DateChangeLast><DateEnd>2010-11-30T00:00:00Z</DateEnd><DateStart>2010-01-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01033071</Identifier><Identifier>TAK-491CLD_303</Identifier><Identifier>U1111-1112-4298</Identifier></Identifiers><InterventionsControlDisplay><Intervention>olmesartan medoxomil + hydrochlorothiazide (hypertension), Sankyo alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>azilsartan medoxomil potassium + chlorthalidone (hypertension), Takeda/ Arbor alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1071</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Tricyclic antidepressants Monoamine oxidase inhibitors Central nervous system stimulants Amphetamines or their derivatives Dopamine agonists Atypical antipsychotic agents Trazodone Lithium Diet medications (except orlistat) Nitrates Chronically used common &lt;b&gt;cold&lt;/b&gt; medications with pseudoephedrine or phenylephrine, or nonsteroidal anti-inflammatory drugs, including aspirin more than 325 mg/day or cyclooxygenase-2 inhibitors Systemic use of corticosteroids (topical or inhaled is acceptable) Thiazolidinediones </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - 12-hour mean ADBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - 12-hour mean ASBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - 24-hour mean ADBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - 24-hour mean ASBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Ambulatory diastolic blood pressure (ADBP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Ambulatory systolic blood pressure (ASBP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Day-time mean ADBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Day-time mean ASBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Night-time mean ADBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Night-time mean ASBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Trough ADBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ambulatory Blood Pressure (ABP) - Trough ASBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Pressure (BP) - BP control rate</EndpointIndex><EndpointIndex>Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Clinic/office DBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Diastolic Blood Pressure (DBP) - DBP control rate</EndpointIndex><EndpointIndex>Hypertension - Assessment of Diastolic Blood Pressure (DBP) - Seated DBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Systolic Blood Pressure (SBP) - Clinic/office SBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of Systolic Blood Pressure (SBP) - SBP control rate</EndpointIndex><EndpointIndex>Hypertension - Assessment of Systolic Blood Pressure (SBP) - Seated SBP</EndpointIndex><EndpointIndex>Hypertension - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil And Hydrochlorothiazide in Participants With Moderate to Severe Hypertension</TitleDisplay><PatientSegmentTerms><PatientSegment>Hypertension - Subjects with Primary/Essential Hypertension - Subjects with stage 2 (JNC 6) hypertension</PatientSegment><PatientSegment>Hypertension - Subjects with Primary/Essential Hypertension - Subjects with stage 3 (JNC 6) hypertension</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Systolic blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>95</NumberOfSites><ContactNames><Name>Sr VP Clinical Science</Name></ContactNames></Trial><Trial Id="62424"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody polyclonal</Technology><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>US</Country></Countries><DateChangeLast>2018-08-01T00:00:00Z</DateChangeLast><DateEnd>2013-03-31T00:00:00Z</DateEnd><DateStart>2010-01-31T00:00:00Z</DateStart><Identifiers><Identifier>CRAD001AUS92</Identifier><Identifier>NCT01025817</Identifier><Identifier>US92</Identifier></Identifiers><IndicationsAdverse><Indication>Infectious disease</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Variable regimens including mycophenolate mofetil , mycophenolate mofetil + tacrolimus , tacrolimus</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including everolimus , everolimus + tacrolimus , tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>613</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Donor organ with a &lt;b&gt;cold&lt;/b&gt; ischemic time&gt; 30 h Patients who produce&amp;lt; 100 ml of urine in the first 24 h post-transplantation Patients who are recipients of ABO incompatible transplants, or T-cell, or B-cell crossmatch positive transplant Patients with severe total hypercholesterolemia</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Clinical Response - Assessment of incidence/frequency of treatment failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Incidence of adverse events/Side Effects</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Urinary Protein Excretion/Proteinuria</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections - Bk polyoma virus infection</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections - CMV infection</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications - New onset/post transplant diabetes mellitus</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Non-Inferiority Study of the Safety and Efficacy of Everolimus With Low-Dose Tacrolimus to Mycophenolate Mofetil With Standard-Dose Tacrolimus in Kidney Transplant Recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Antibody Incompatible Renal Transplant (AiT) Recipients - HLA antibody incompatible (HLAi) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients - Non heart beating donor - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living related donor (LRD) - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living unrelated donor - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Renal re-transplant recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>38 Months</TrialDuration><NumberOfSites>50</NumberOfSites><ContactNames><Name>Adrian Cotterell</Name><Name>Ari Cohen</Name><Name>Azemi Barama</Name><Name>Charles Buren</Name><Name>David Buren</Name><Name>Kenneth Brayman</Name><Name>Kenneth Chavin</Name><Name>Mary Baldecchi</Name><Name>Matthew Cooper</Name><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="4233"><Indications><Indication>Diabetic neuropathy</Indication><Indication>Neuropathic pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CACNA2D calcium channel subunit modulator</Action><Action>GABA A receptor alpha-2 subunit stimulator</Action><Action>GABA A receptor delta subunit stimulator</Action><Action>GABA receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticonvulsant agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Pfizer Inc</Company></CompaniesSponsor><Countries><Country>Puerto Rico</Country><Country>US</Country></Countries><DateChangeLast>2018-12-14T00:00:00Z</DateChangeLast><DateEnd>2007-05-31T00:00:00Z</DateEnd><DateStart>2005-03-31T00:00:00Z</DateStart><Identifiers><Identifier>A0081071</Identifier><Identifier>NCT00143156</Identifier></Identifiers><IndicationsAdverse><Indication>Constipation</Indication><Indication>Diarrhea</Indication><Indication>Dizziness</Indication><Indication>Drowsiness</Indication><Indication>Edema</Indication><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Vision disorder</Indication><Indication>Weight gain</Indication><Indication>Xerostomia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>pregabalin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>450</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> placebo for any items of the QANeP (static mechanical allodynia, dynamic mechanical allodynia, punctate hyperalgesia testing area, punctate hyperalgesia reference area, temporal summation to tactile stimuli, &lt;b&gt;cold&lt;/b&gt; hyperalgesia testing area and &lt;b&gt;cold&lt;/b&gt; hyperalgesia reference area) except for &lt;b&gt;cold&lt;/b&gt; allodynia for which the pregabalin 600 mg group was significantly better than placebo (p = 0.0202) [ 1291143 ]. In November 2018, pooled results from ten studies ( NCT00156078 , NCT00159679 , NCT00143156 and </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Co-morbidity - Assessment of depression</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Pain - Assessment of Pain Intensity</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Sleep - Medical Outcomes Study (MOS) - Sleep Scale</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Brief Pain Inventory (BPI)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Hospital Anxiety and Depression Scale (HADS)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Patient Global Impression of Change (PGIC)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Co-morbidity - Assessment of depression</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Neurological Assessments</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Neurological Assessments - Sleep architecture</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Brief Pain Inventory (BPI)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Hospital Anxiety and Depression Scale (HADS)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Patient Global Impression of Change (PGIC)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Brief Pain Inventory[BPI]</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment by Neuropathic Pain Symptom Inventory (NPSI)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic neuropathy</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain - Subjects with diabetic neuropathy</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>26 Months</TrialDuration><NumberOfSites>54</NumberOfSites><ContactNames><Name>Pfizer CT.gov Call Center</Name><Name>Pfizer Call Center</Name></ContactNames></Trial><Trial Id="39497"><Indications><Indication>Obesity</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>5-HT uptake inhibitor</Action><Action>Appetite suppressant</Action><Action>Norepinephrine uptake inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Abbott Laboratories</Company></CompaniesSponsor><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2003-01-01T00:00:00Z</DateEnd><DateStart>1998-09-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT00645255</Identifier><Identifier>SB118</Identifier></Identifiers><IndicationsAdverse><Indication>Cardiovascular disease</Indication><Indication>Central nervous system disease</Indication><Indication>Death</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>sibutramine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>466</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Sponsor/Business Decision</Reason></ReasonForTrialDiscontinuation><Teaser>pose harm to the subject, obscure the effects of study medication or interfere with the process of drug absorption, distribution, metabolism, or excretion (ie, enzyme inducers or enzyme inhibitors). The regular use of sympathomimetics (eg, cough and &lt;b&gt;cold&lt;/b&gt; remedies, asthma medication) is contraindicated during the study. Study medication should be discontinued for 3 days before the use of opioids. The subject should not be taken off antidepressants in order to be placed in the study The subject must </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of BMI</EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of Body Weight</EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of waist-hip circumference</EndpointIndex><EndpointIndex>Obesity - Anthropometric Assessments - Assessment of weight loss</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese Subjects</TitleDisplay><PatientSegmentTerms><PatientSegment>Obesity - Obese Class I Subjects</PatientSegment><PatientSegment>Obesity - Obese Class II Subjects</PatientSegment><PatientSegment>Obesity - Overweight (pre-obese) Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>51 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>James Anderson</Name></ContactNames></Trial><Trial Id="350060"><Indications><Indication>Peanut hypersensitivity</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Allergen</Action><Action>Anti-inflammatory</Action><Action>Immunomodulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Peptide</Technology></Technologies><CompaniesSponsor><Company>Aimmune Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>Ireland</Country><Country>France</Country><Country>Spain</Country><Country>Sweden</Country><Country>UK</Country><Country>Netherlands</Country></Countries><DateChangeLast>2018-12-28T00:00:00Z</DateChangeLast><DateEnd>2018-11-23T00:00:00Z</DateEnd><DateStart>2018-10-24T00:00:00Z</DateStart><Identifiers><Identifier>2018-000326-58</Identifier><Identifier>ARC009</Identifier><Identifier>NCT03703791</Identifier></Identifiers><InterventionsControlDisplay><Intervention>standard of care alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>AR-101, Aimmune Therapeutics alone</Intervention><Intervention>standard of care alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Lack of Efficacy</Reason></ReasonForTrialDiscontinuation><Teaser>difficulty swallowing, food 'getting stuck'); or recurrent GI symptoms of any etiology History of a mast cell disorder including systemic mastocytosis, urticaria pigmentosa, chronic idiopathic or chronic physical urticaria beyond simple dermatographism (eg, &lt;b&gt;cold&lt;/b&gt; urticaria, cholinergic urticaria), and hereditary or idiopathic angioedema Severe persistent asthma or uncontrolled mild or moderate asthma Mild or moderate asthma (criteria steps 1 to 4; NHLBI, 2007) that is uncontrolled or difficult to control History</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other immune disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other immune disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other immune disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Real-World, Open-Label, QOL Assessment of Peanut Immunotherapy AR-101 in Children and Adolescents</TitleDisplay><PatientSegmentTerms><PatientSegment>Other immune disease - Subjects with specific disease - Subjects with food allergy</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2018-11-23T00:00:00Z</PrimaryCompletionDate><TrialDuration>1 Month</TrialDuration><NumberOfSites>18</NumberOfSites><ContactNames><Name>Regulatory Affairs</Name><Name>Ruth Bateson</Name></ContactNames></Trial><Trial Id="336553"><Indications><Indication>Fabry disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Alpha-galactosidase modulator</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Protein folding</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Amicus Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Spain</Country></Countries><DateChangeLast>2019-06-28T00:00:00Z</DateChangeLast><DateEnd>2020-09-01T00:00:00Z</DateEnd><DateStart>2018-10-11T00:00:00Z</DateStart><Identifiers><Identifier>2017-000146-21</Identifier><Identifier>AT1001-020</Identifier><Identifier>NCT03500094</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>migalastat alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This is an open-label study to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of migalastat treatment in pediatric subjects 12 to &amp;lt; 18 years of age with Fabry disease and amenable GLA variants.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Fabry disease - Anthropometric Assessments</EndpointIndex><EndpointIndex>Fabry disease - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Fabry disease - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Fabry disease - Assessment of Laboratory/Diagnostic Measures - Assessment of hematologic parameters</EndpointIndex><EndpointIndex>Fabry disease - Assessment of Laboratory/Diagnostic Measures - Assessment of urinary analysis</EndpointIndex><EndpointIndex>Fabry disease - Assessment of Laboratory/Diagnostic Measures - Assessment using electrophysiologic modalities</EndpointIndex><EndpointIndex>Fabry disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Fabry disease - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Fabry disease - Assessment of Renal Function</EndpointIndex><EndpointIndex>Fabry disease - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Fabry disease - Assessment of Therapy Related Outcomes - Assessment of treatment discontinuation</EndpointIndex><EndpointIndex>Fabry disease - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Fabry disease - Assessment of adverse events</EndpointIndex><EndpointIndex>Fabry disease - Assessment of pain</EndpointIndex><EndpointIndex>Fabry disease - Clinical Assessments</EndpointIndex><EndpointIndex>Fabry disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Fabry disease - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Fabry disease - Protocol Specified Other Endpoints - Assessment of concurrent medication requirements</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to &lt; 18 Years)</TitleDisplay><PatientSegmentTerms><PatientSegment>Fabry disease - Subjects with Genetically Confirmed Fabry Disease</PatientSegment><PatientSegment>Fabry disease - Subjects with gene variants - GLA_HUMAN_Mutation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Albumin </BiomarkerName><BiomarkerName> Alpha-galactosidase A </BiomarkerName><BiomarkerName> Body height </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Globotriaosyl lysosphingolipid </BiomarkerName><BiomarkerName> Heart </BiomarkerName><BiomarkerName> Membrane protein MLC1 </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Urinary protein</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-09-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>8</NumberOfSites><ContactNames><Name>Amicus Therapeutics Patient Advocacy</Name><Name>Clinical Research</Name></ContactNames></Trial><Trial Id="327912"><Indications><Indication>Glioblastoma</Indication><Indication>Gliosarcoma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Epidermal growth factor receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer alkylating agent</Action><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Immunotoxin</Action><Action>Microtubule inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody conjugated</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Oral formulation</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>AbbVie Deutschland GmbH &amp; Co KG</Company><Company>AbbVie Inc</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>Denmark</Country><Country>Germany</Country><Country>France</Country><Country>Australia</Country><Country>Netherlands</Country><Country>US</Country></Countries><DateChangeLast>2019-05-29T00:00:00Z</DateChangeLast><DateEnd>2020-02-16T00:00:00Z</DateEnd><DateStart>2018-07-30T00:00:00Z</DateStart><Identifiers><Identifier>2017-003171-64</Identifier><Identifier>M16-534</Identifier><Identifier>NCT03419403</Identifier><Identifier>UNITE</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>cold compress alone</Intervention><Intervention>ophthalmic steroid ointment therapy alone</Intervention><Intervention>radiation alone</Intervention><Intervention>steroid eye drop therapy alone</Intervention><Intervention>vasoconstrictor eye drop therapy alone</Intervention><Intervention>depatuxizumab mafodotin plus temozolomide</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>groups: Group 1: participants would receive steroid eye drop plus vasoconstrictor eye drop and &lt;b&gt;cold&lt;/b&gt; compress plus depatuxizumab mafodotin during both the chemoradiation therapy (RT and TMZ) and the adjuvant therapy (TMZ) periods of...Group 3: participants would receive steroid Eye Drop plus ophthalmic steroid ointment plus vasoconstrictor eye drop and &lt;b&gt;cold&lt;/b&gt; compresses plus depatuxizumab mafodotin during both the chemoradiation therapy (RT and TMZ) and the adjuvant therapy (TMZ</Teaser><TrialCategories><Category>Biological</Category><Category>Radiation therapy</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Central nervous system tumor - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Central nervous system tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Central nervous system tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Central nervous system tumor - Clinical Assessments</EndpointIndex><EndpointIndex>Glioblastoma - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Glioblastoma - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Glioblastoma - Assessment of adverse events</EndpointIndex><EndpointIndex>Glioblastoma - Clinical Assessments</EndpointIndex><EndpointIndex>Glioblastoma - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Glioblastoma - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>UNITE: Understanding New Interventions With GBM Therapy</TitleDisplay><PatientSegmentTerms><PatientSegment>Central nervous system tumor - Subjects with Astrocytomas - Subjects with glioblastoma (WHO Grade IV)</PatientSegment><PatientSegment>Central nervous system tumor - Subjects with Astrocytomas - Subjects with gliosarcoma (WHO Grade IV)</PatientSegment><PatientSegment>Central nervous system tumor - Subjects with gene variants - EGFR_HUMAN_Amplification</PatientSegment><PatientSegment>Glioblastoma - Subjects with De Novo Glioblastoma Multiforme</PatientSegment><PatientSegment>Glioblastoma - Subjects with gene variants - EGFR_HUMAN_Amplification</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Epidermal growth factor receptor </BiomarkerName><BiomarkerName> Visual acuity</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-09-16T00:00:00Z</PrimaryCompletionDate><TrialDuration>18 Months</TrialDuration><NumberOfSites>32</NumberOfSites><ContactNames><Name>AbbVie Inc.</Name><Name>EU Clinical Trials Helpdesk</Name></ContactNames></Trial><Trial Id="29005"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Italy</Country><Country>Sweden</Country><Country>UK</Country><Country>Slovakia</Country><Country>Hong Kong</Country><Country>US</Country></Countries><DateChangeLast>2018-06-08T00:00:00Z</DateChangeLast><DateEnd>2009-10-31T00:00:00Z</DateEnd><DateStart>2005-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2005-002854-22</Identifier><Identifier>A2309</Identifier><Identifier>CRAD001A2309</Identifier><Identifier>HKCTR-330</Identifier><Identifier>HKUCTR-330</Identifier><Identifier>KC/KE 05-0166/FR-3</Identifier><Identifier>NCT00251004</Identifier></Identifiers><InterventionsControlDisplay><Intervention>ciclosporin, Novartis plus enteric-coated mycophenolate sodium, Novartis</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including basiliximab , ciclosporin, Novartis , everolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>833</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Donor organ with a &lt;b&gt;cold&lt;/b&gt; ischemia time &gt; 40 h Received kidney from a non-heart beating donor Donor age &gt; 65 years Patients with platelet count&amp;lt;100,000/mm at the evaluation before randomization Patients with an absolute neutrophil count of&amp;lt; 1,500/mm³ at baseline before</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Untreated AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety Study of Everolimus Plus Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Subjects Awaiting Renal Transplant</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>48 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Novartis</Name></ContactNames></Trial><Trial Id="207540"><Indications><Indication>Migraine</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>5-HT 1b receptor agonist</Action><Action>5-HT 1d receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Nasal systemic formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral quick release formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2017-07-19T00:00:00Z</DateChangeLast><DateEnd>1990-12-10T00:00:00Z</DateEnd><DateStart>1990-01-16T00:00:00Z</DateStart><Identifiers><Identifier>GL/MIG/002</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Dizziness</Indication><Indication>Headache</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Migraleve alone</Intervention><Intervention>sumatriptan alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>864</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> of drunkenness and heaviness, hallucinations, neck stiffness, numbness in body and tongue, paraesthesia, pregnancy, shivers, sickness, slurred speech, soreness of neck, surgery, tingling of fingers, tremors, twisting sensation in head, chest pain, &lt;b&gt;cold&lt;/b&gt; sweats, facial and neck pain, otalgia, pain in arms and jaw, vertigo and vomiting. No fatal major adverse events were reported [ 1583105 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Migraine/Other Headaches</EndpointIndex><EndpointIndex>Pain - Assessment of Migraine/Other Headaches - Assessment of headache relief</EndpointIndex><EndpointIndex>Pain - Assessment of Migraine/Other Headaches - Assessment of other migraine-associated symptoms</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Phase IIIB, Double-Blind, Multicenter, Parallel-Group, General Practice Study to Compare Sumatriptan With Migraleve (Pfizer) in the Acute Treatment of Migraine</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Migraine - Subjects with migraine with aura</PatientSegment><PatientSegment>Pain - Subjects with Migraine - Subjects with migraine without aura</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with specific disease - Subjects with chronic migraine</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>10 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="195688"><Indications><Indication>Urticaria</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin E antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Dominican Republic</Country><Country>Brazil</Country><Country>Guatemala</Country><Country>Panama</Country><Country>Chile</Country><Country>Argentina</Country><Country>Canada</Country><Country>Mexico</Country></Countries><DateChangeLast>2018-11-20T00:00:00Z</DateChangeLast><DateEnd>2016-11-03T00:00:00Z</DateEnd><DateStart>2014-08-01T00:00:00Z</DateStart><Identifiers><Identifier>CIGE025ECA01</Identifier><Identifier>NCT02161562</Identifier><Identifier>OPTIMA</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>omalizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>314</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Patients having a clearly defined underlying etiology for chronic urticaria other than CSU including the following urticarias: acute, solar, cholinergic, heat, &lt;b&gt;cold&lt;/b&gt;, aquagenic, delayed pressure or contact Patients with other skin disease associated with itch that could interfere with study outcomes and/or compromise the safety of the patient Patients with evidence of parasitic infection Patients with a history</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Urticaria - Assessment by Urticarial Scores - Assessment by Urticaria Activity Score (UAS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Urticaria - Subjects with Chronic Urticaria - Patiets with chronic spontaneous urticaria</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2016-11-03T00:00:00Z</PrimaryCompletionDate><TrialDuration>27 Months</TrialDuration><NumberOfSites>35</NumberOfSites></Trial><Trial Id="165163"><Indications><Indication>Compensated liver cirrhosis</Indication><Indication>Hepatitis C virus infection</Indication><Indication>Liver cirrhosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Hepatitis C virus NS5B polymerase inhibitor</Action><Action>Hepatitis C virus protein NS5A inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Gilead Sciences Inc</Company></CompaniesSponsor><Countries><Country>Taiwan</Country><Country>South Korea</Country><Country>China</Country></Countries><DateChangeLast>2019-03-06T00:00:00Z</DateChangeLast><DateEnd>2017-09-29T00:00:00Z</DateEnd><DateStart>2013-12-10T00:00:00Z</DateStart><Identifiers><Identifier>GS-US-337-0131</Identifier><Identifier>NCT02021656</Identifier></Identifiers><IndicationsAdverse><Indication>Headache</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>sofosbuvir + ledipasvir (fixed-combination/oral, HCV/HBV), Gilead alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>384</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>such as  nasopharyngitis, headache, upper respiratory tract infection and pruritus were observed in 18, 9, 5 and 2% of patients, respectively with no cirrhosis (n = 282); 12, 10, 1 and 6% of patients, respectively with cirrhosis (n = 67); 17 (common &lt;b&gt;cold&lt;/b&gt; [n = 58] and acute nasopharyngitis [n = 1]), 9, 4 and 3% of patients, respectively with and without cirrhosis (n = 349). Most of the AEs were found to be mild and moderate in severity. AE, grade &gt;/= 2 AE, grade &gt;/= 3 AE, serious AE, treatment-related</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR)</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Viral Breakthrough/Relapse</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Asian Ancestry</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatitis C virus infection - Subjects Infected with HCV Genotype 1</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Prior Hepatitis C Therapy</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Hepatitis C virus infection - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Hepatitis C virus RNA</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-07-08T00:00:00Z</PrimaryCompletionDate><TrialDuration>45 Months</TrialDuration><NumberOfSites>45</NumberOfSites><ContactNames><Name>Gilead Study Director</Name></ContactNames></Trial><Trial Id="163884"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><CompaniesSponsor><Company>Boehringer Ingelheim AB</Company><Company>Boehringer Ingelheim Ellas AE</Company><Company>Boehringer Ingelheim GmbH</Company><Company>Boehringer Ingelheim International GmbH</Company></CompaniesSponsor><Countries><Country>Greece</Country><Country>US</Country><Country>New Zealand</Country><Country>Sweden</Country><Country>Ukraine</Country><Country>South Africa</Country><Country>Germany</Country><Country>Austria</Country><Country>Italy</Country><Country>Slovakia</Country><Country>Australia</Country><Country>Norway</Country><Country>Portugal</Country><Country>Canada</Country></Countries><DateChangeLast>2017-07-11T00:00:00Z</DateChangeLast><DateEnd>2014-11-30T00:00:00Z</DateEnd><DateStart>2013-11-30T00:00:00Z</DateStart><Identifiers><Identifier>1237.26</Identifier><Identifier>2013-002264-24</Identifier><Identifier>NCT02006732</Identifier><Identifier>OTEMTO 2</Identifier></Identifiers><InterventionsControlDisplay><Intervention>tiotropium alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>olodaterol + tiotropium bromide (inhaled, COPD) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>809</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>or placebo. Nasopharyngitis, COPD and cough were the most common adverse reactions in both the studies [ 1706819 ]. Further in October 2015, new post-hoc analysis were presented from two studies (NCT01431274 and NCT01431287). Nasopharyngitis (common &lt;b&gt;cold&lt;/b&gt;), cough and back pain were the most common adverse events in both the studies [ 1707342 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change from baseline in FEV1</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 area under curve (AUC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 trough response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - FVC area under curve (AUC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - Trough FVC response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Changes in St Georges Respiratory Questionnaire (SGRQ)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Transition Dyspnea Index (TDI) Score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>OTEMTO 2: Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Smokers</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Stable COPD</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>12 Months</TrialDuration><NumberOfSites>84</NumberOfSites><ContactNames><Name>Boehringer Ingelheim</Name><Name>Boehringer Ingelheim Call Center</Name><Name>Dave Singh</Name><Name>QRPE PSC CT Information Disclosure</Name></ContactNames></Trial><Trial Id="163600"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-17 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company><Company>Novartis Farma SpA</Company><Company>Novartis Pharma Services AG</Company></CompaniesSponsor><Countries><Country>Russian Federation</Country><Country>Spain</Country><Country>Italy</Country><Country>Belgium</Country><Country>Germany</Country><Country>France</Country><Country>Poland</Country><Country>Austria</Country><Country>UK</Country><Country>Sweden</Country></Countries><DateChangeLast>2019-05-07T00:00:00Z</DateChangeLast><DateEnd>2017-05-31T00:00:00Z</DateEnd><DateStart>2013-12-26T00:00:00Z</DateStart><Identifiers><Identifier>2013-003086-34</Identifier><Identifier>CAIN457A3301</Identifier><Identifier>NCT02008890</Identifier><Identifier>PRECISE</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>secukinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>237</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>computerized tomography (CT scan), or MRI with evidence of ongoing infectious or malignant process, obtained within 12 weeks prior to randomization, and evaluated by a qualified physician Active systemic infections during the last two weeks (exception: common &lt;b&gt;cold&lt;/b&gt;) prior to randomization or any infection that reoccurs on a regular basis History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection as defined by a positive QuantiFERON TB-Gold test (QFT) at screening. Patients</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by Other Scales - Palmoplantar pustular psoriasis area and severity indices (PPPASI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PRECISE: Palmoplantar Pustular Psoriasis Efficacy And Safety With Secukinumab</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with History of/Scheduled for Therapy</PatientSegment><PatientSegment>Psoriasis - Subjects with Localized Psoriasis - Subjects with palmoplantar psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Moderate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Severe Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-11-24T00:00:00Z</PrimaryCompletionDate><TrialDuration>41 Months</TrialDuration><NumberOfSites>82</NumberOfSites><ContactNames><Name>Clinical Trial Information Desk</Name><Name>Departamento Médico (HOR-MK)</Name><Name>Drug Regulatory Affairs</Name><Name>Medical Information Services</Name><Name>Medizinischer Infoservice (MCC)</Name><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="160278"><Indications><Indication>Hepatitis C virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Hepatitis C virus NS5B polymerase inhibitor</Action><Action>Hepatitis C virus protein NS5A inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>RNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug combination</Technology><Technology>Film coating</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Gilead Sciences Inc</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2018-11-19T00:00:00Z</DateChangeLast><DateEnd>2014-08-31T00:00:00Z</DateEnd><DateStart>2013-10-31T00:00:00Z</DateStart><Identifiers><Identifier>GS-US-337-0113</Identifier><Identifier>NCT01975675</Identifier></Identifiers><IndicationsAdverse><Indication>Anemia</Indication><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Pruritus</Indication><Indication>Rhinopharyngitis</Indication><Indication>Skin rash</Indication><Indication>Stomatitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>sofosbuvir + ledipasvir (fixed-combination/oral, HCV/HBV), Gilead alone</Intervention><Intervention>Variable regimens including ribavirin , sofosbuvir + ledipasvir (fixed-combination, HCV), Gilead + ribavirin , sofosbuvir + ledipasvir (fixed-combination/oral, HCV/HBV), Gilead</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>341</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>such as nasopharyngitis, headache, upper respiratory tract infection and pruritus were observed in 18, 9, 5 and 2% of patients, respectively with no cirrhosis (n = 282); 12, 10, 1 and 6% of patients, respectively with cirrhosis (n = 67); 17 (common &lt;b&gt;cold&lt;/b&gt; [n = 58] and acute nasopharyngitis [n = 1]), 9, 4 and 3% of patients, respectively with and without cirrhosis (n = 349). Most of the AEs were found to be mild and moderate in severity. AE, grade &gt;/= 2 AE, grade &gt;/= 3 AE, serious AE, treatment-related</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Safety and Tolerability - Treatment-emergent adverse events</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Sustained Virologic Response (SVR)</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Viral Breakthrough/Relapse</EndpointIndex><EndpointIndex>Hepatitis C virus infection - Assessment of Viral Load/Viral Kinetics</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Asian Ancestry</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of Sofosbuvir/Ledipasvir +/- Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatitis C virus infection - Subjects Infected with HCV Genotype 1</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Chronic Hepatitis C Infection</PatientSegment><PatientSegment>Hepatitis C virus infection - Subjects with Prior Hepatitis C Therapy</PatientSegment><PatientSegment>Hepatitis C virus infection - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Hemoglobin </BiomarkerName><BiomarkerName> Hepatitis C virus RNA</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>19</NumberOfSites><ContactNames><Name>Fusao Ikeda</Name><Name>Hirayuki Enomoto</Name><Name>Hiroshi Matsumura</Name><Name>Juan Betular</Name><Name>Masashi Mizokami</Name><Name>Namiki Izumi</Name><Name>Steven Knox</Name><Name>Takafumi Ichida</Name><Name>Tatsuya Ide</Name></ContactNames></Trial><Trial Id="158127"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Muscarinic M1 receptor antagonist</Action><Action>Muscarinic M3 receptor antagonist</Action><Action>Muscarinic receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action><Action>Muscarinic M1 receptor antagonist</Action><Action>Muscarinic M3 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Synergist</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Respiratory system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Aerosol formulation inhalant</Technology><Technology>Capsule formulation</Technology><Technology>Daily dosing</Technology><Technology>Dermatological formulation</Technology><Technology>Drug combination</Technology><Technology>Formulation powder</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Sustained release formulation</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Boehringer Ingelheim International GmbH</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Canada</Country><Country>UK</Country><Country>Finland</Country><Country>Germany</Country><Country>Czech Republic</Country><Country>Denmark</Country><Country>South Africa</Country><Country>Netherlands</Country><Country>Spain</Country><Country>Belgium</Country><Country>Ukraine</Country></Countries><DateChangeLast>2017-03-28T00:00:00Z</DateChangeLast><DateEnd>2014-11-30T00:00:00Z</DateEnd><DateStart>2013-11-30T00:00:00Z</DateStart><Identifiers><Identifier>1237.25</Identifier><Identifier>2013-002243-29</Identifier><Identifier>CCRN 2198 (COPD)</Identifier><Identifier>NCT01964352</Identifier><Identifier>OTEMTO 1</Identifier><Identifier>UKCRN 15256</Identifier></Identifiers><InterventionsControlDisplay><Intervention>tiotropium bromide alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>olodaterol hydrochloride + tiotropium bromide monohydrate l (Respimat Soft Mist/inhaled, COPD), Boehringer Ingelheim alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>813</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> placebo. Nasopharyngitis, COPD and cough were the most common adverse reactions in both the studies [ 1706819 ]. Further in October 2015, new post-hoc analysis were presented from two studies (NCT01964352 and NCT02006732 ). Nasopharyngitis (common &lt;b&gt;cold&lt;/b&gt;), cough and back pain were the most common adverse events in both the studies [ 1707342 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change from baseline in FEV1</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 area under curve (AUC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 trough response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - FVC area under curve (AUC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - Trough FVC response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Changes in St Georges Respiratory Questionnaire (SGRQ)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Transition Dyspnea Index (TDI) Score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>OTEMTO 1: Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Smokers</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Stable COPD</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>12 Months</TrialDuration><NumberOfSites>83</NumberOfSites><ContactNames><Name>Boehringer Ingelheim</Name><Name>Dave Singh</Name><Name>QRPE PSC CT Information Disclosure</Name></ContactNames></Trial><Trial Id="78583"><Indications><Indication>Non-insulin dependent diabetes</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>AMP activated protein kinase stimulator</Action><Action>Insulin sensitizer</Action><Action>PPAR gamma agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Biguanide antidiabetic product</Action><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Italy</Country><Country>Ukraine</Country></Countries><DateChangeLast>2014-02-26T00:00:00Z</DateChangeLast><DateEnd>2001-03-21T00:00:00Z</DateEnd><DateStart>1997-04-21T00:00:00Z</DateStart><Identifiers><Identifier>49653/025</Identifier></Identifiers><IndicationsAdverse><Indication>Anemia</Indication><Indication>Diabetes mellitus</Indication><Indication>Headache</Indication><Indication>Hypercholesterolemia</Indication><Indication>Hyperglycemia</Indication><Indication>Pain</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>metformin hydrochloride alone</Intervention><Intervention>rosiglitazone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 3a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this phase IIIa, multicentre, double-blind, parallel-group, placebo-controlled comparative study was to determine the effects of rosiglitazone on insulin sensitivity, endothelial function and vascular reactivity in comparison with metformin and placebo for the treatment of patients with non-insulin dependent diabetes mellitus (NIDDM) [ 1203253 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Insulin resistance - Assessment of Cardiac Function - Assessment of blood pressure</EndpointIndex><EndpointIndex>Insulin resistance - Assessment of Cardiac Function - Assessment of heart rate variability</EndpointIndex><EndpointIndex>Insulin resistance - Assessment of HbA1c Levels</EndpointIndex><EndpointIndex>Insulin resistance - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Insulin resistance - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C reactive protein (CRP)</EndpointIndex><EndpointIndex>Insulin resistance - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of TNF</EndpointIndex><EndpointIndex>Insulin resistance - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of plasminogen activator inhibitor-1</EndpointIndex><EndpointIndex>Insulin resistance - Assessment of Insulin Levels - Assessment of fasting insulin</EndpointIndex><EndpointIndex>Insulin resistance - Assessment of Insulin Sensitivity</EndpointIndex><EndpointIndex>Insulin resistance - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Insulin resistance - Assessment of Laboratory/Diagnostic Measures - Assessment of fibrinogen levels</EndpointIndex><EndpointIndex>Insulin resistance - Assessment of Liver Functions - Assessment of hepatic glucose production</EndpointIndex><EndpointIndex>Insulin resistance - Assessment of Vascular Endothelial Function - Assessment of vascular reactivity</EndpointIndex><EndpointIndex>Insulin resistance - Glycemic Control Analysis</EndpointIndex><EndpointIndex>Insulin resistance - Glycemic Control Analysis - Assessment of fasting blood glucose</EndpointIndex><EndpointIndex>Insulin resistance - Glycemic Control Analysis - Assessment of glucose disposal</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Diabetic Complications &amp; Events - Lactic acidosis</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C reactive protein (CRP)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Inflammatory &amp; Oxidative Stress Markers - Plasminogen activator inhibitor-1 (PAI-1)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Inflammatory &amp; Oxidative Stress Markers - Tissue plasminogen activator (t-PA) activity</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Insulin Levels - Assessment of fasting insulin</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Insulin Sensitivity</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Liver Functions - Assessment of hepatic glucose production</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Renal Function - Urinary albumin excretion/albuminuria</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Vital Signs - Assessment of heart rate</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A phase IIIa, multicentre, double-blind, parallel-group, placebo-controlled comparative study to determine the effects of rosiglitazone on insulin sensitivity, endothelial function and vascular reactivity in comparison with metformin and placebo for the treatment of patients with non-insulin dependent diabetes mellitus (NIDDM)</TitleDisplay><PatientSegmentTerms><PatientSegment>Insulin resistance - Subjects with comorbid conditions - Subjects with diabetes mellitus</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Good Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Fibrinogen </BiomarkerName><BiomarkerName> Fibronectin </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Insulin </BiomarkerName><BiomarkerName> Lactic Acid </BiomarkerName><BiomarkerName> Thrombomodulin </BiomarkerName><BiomarkerName> Tissue-type plasminogen activator </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>47 Months</TrialDuration><NumberOfSites>2</NumberOfSites></Trial><Trial Id="220556"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action><Action>Muscarinic receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Bronchodilator</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Daily dosing</Technology><Technology>Drug combination</Technology><Technology>Inhalant formulation</Technology><Technology>Microparticle formulation</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>China</Country><Country>Romania</Country><Country>Greece</Country><Country>Mexico</Country><Country>Hungary</Country><Country>Bulgaria</Country><Country>Estonia</Country><Country>Italy</Country><Country>Slovakia</Country><Country>Russian Federation</Country><Country>Poland</Country><Country>Ukraine</Country><Country>Germany</Country><Country>South Korea</Country></Countries><DateChangeLast>2018-11-09T00:00:00Z</DateChangeLast><DateEnd>2016-04-07T00:00:00Z</DateEnd><DateStart>2015-01-23T00:00:00Z</DateStart><Identifiers><Identifier>116853</Identifier><Identifier>CTR20150595</Identifier><Identifier>FULFIL</Identifier><Identifier>GSK study CTT116853</Identifier><Identifier>NCT02345161</Identifier></Identifiers><IndicationsAdverse><Indication>Chronic obstructive pulmonary disease</Indication><Indication>Headache</Indication><Indication>Heart disease</Indication><Indication>Pneumonia</Indication><Indication>Rhinopharyngitis</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>budesonide + formoterol fumarate, AstraZeneca alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Ellipta alone</Intervention><Intervention>Nebules alone</Intervention><Intervention>fluticasone furoate + umeclidinium + vilanterol (dry powder inhaled, COPD), GlaxoSmithKline/Theravance alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1811</PatientCountEnrollment><Phase>Phase 3a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a phase IIIa, randomized, double-blind, double-dummy, parallel-group, multicenter study evaluating once-daily fluticasone furoate/umeclidinium/vilanterol trifenatate ( FF/UMEC/VI 100/62.5/25 microg) inhalation powder versus twice-daily budesonide/formoterol. The primary purpose of this study was to demonstrate improvements in lung function and health status for patients treated with FF/UMEC/VI compared with budesonide/formoterol fumarate for 24 weeks [ 1632394 ], [ 1769051 ] , [ 1959379</Teaser><TrialCategories><Category>Medical device</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Cough</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Dyspnea - Assessment of intensity/severity of dyspnea</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation duration</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation rate/frequency/number</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation severity - moderate</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation severity - severe</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change from baseline in FEV1</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 trough response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Sputum</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Baseline Dyspnea Index (BDI) score</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Changes in St Georges Respiratory Questionnaire (SGRQ)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - EXACT-PRO score</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Transition Dyspnea Index (TDI) Score</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>FULFIL: A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/Umeclidinium/Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Ex-smokers</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Smokers</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 4/Very Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with History of Treatment</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Symptomatic Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Albumin </BiomarkerName><BiomarkerName> Alkaline phosphatase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Basophils </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Calcium </BiomarkerName><BiomarkerName> Carbon dioxide </BiomarkerName><BiomarkerName> Chlorides </BiomarkerName><BiomarkerName> Creatine kinase </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Eosinophils </BiomarkerName><BiomarkerName> Erythrocytes </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hematocrit </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Lung </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Magnesium </BiomarkerName><BiomarkerName> Monocytes </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> Oxyhemoglobins </BiomarkerName><BiomarkerName> PR interval </BiomarkerName><BiomarkerName> Phosphate </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> QT interval </BiomarkerName><BiomarkerName> Sodium </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Urea </BiomarkerName><BiomarkerName> Uric acid </BiomarkerName><BiomarkerName> gamma-Glutamyltransferase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-04-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>147</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="11455"><Indications><Indication>Herpes simplex virus infection</Indication></Indications><ActionsSecondaryInterventionsControl><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Prophylactic vaccine</Action><Action>Protein subunit vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Denmark</Country><Country>US</Country><Country>Sweden</Country><Country>Scandinavia</Country><Country>France</Country><Country>UK</Country><Country>Estonia</Country><Country>Hungary</Country><Country>Romania</Country><Country>New Zealand</Country><Country>Netherlands</Country><Country>Canada</Country><Country>Spain</Country><Country>Belgium</Country><Country>Greece</Country><Country>Norway</Country><Country>Australia</Country><Country>Iceland</Country><Country>Lithuania</Country></Countries><DateChangeLast>2019-01-08T00:00:00Z</DateChangeLast><DateEnd>2007-07-24T00:00:00Z</DateEnd><DateStart>2004-04-07T00:00:00Z</DateStart><Identifiers><Identifier>208141/040</Identifier><Identifier>HSV-040</Identifier><Identifier>NCT00224484</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Emesis</Indication><Indication>Nausea</Indication><Indication>Pharyngitis</Indication><Indication>Pruritus</Indication><Indication>Rhinopharyngitis</Indication><Indication>Spontaneous abortion</Indication><Indication>Suicidal ideation</Indication><Indication>Tachycardia</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Havrix alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Simplirix alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>5960</PatientCountEnrollment><Phase>Phase 3a Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Female planning to become pregnant or likely to become pregnant (as determined by the investigator) during the first 8 months of the study (months 0 to 8) Any previous confirmed history of, or current clinical signs or symptoms of, oro labial herpes (&lt;b&gt;cold&lt;/b&gt; sores), herpetic whitlow or genital herpes disease, such as swelling, papules, vesicles, pustules, ulcers, crusts, fissures, erythema, discharge, dysuria or pain, burning, itching, tingling in the ano-genital area History of previous or planned vaccination</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatitis A Vaccine - Assessment of Immune Response - Immunogenic response to other vaccine/infectious agent</EndpointIndex><EndpointIndex>Hepatitis A Vaccine - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Hepatitis A Vaccine - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Hepatitis A Vaccine - Assessment of Safety and Tolerability - Reactogenicity(local/systemic reactions)</EndpointIndex><EndpointIndex>Hepatitis A Vaccine - Incidence/prevalence of other infections/diseases</EndpointIndex><EndpointIndex>Herpes Virus Vaccine - Assessment of Immune Response - Anti-HSV antibodies</EndpointIndex><EndpointIndex>Herpes Virus Vaccine - Assessment of Immune Response - Immunogenic response against other antigens</EndpointIndex><EndpointIndex>Herpes Virus Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Herpes Virus Vaccine - Hematological Assessments</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Immune Response - Anti-HSV antibodies</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Immune Response - Immunogenic response against other antigens</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Herpesvirus infection - Hematological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety Study Of Herpes Simplex Vaccine In HSV Seronegative And Seropositive Females Between 10 And 17 Years Old</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatitis A Vaccine - Subjects with comorbid conditions</PatientSegment><PatientSegment>Herpes Virus Vaccine - Subjects with Prior/Current Herpes Virus Infections - Subjects with prior/current herpes simplex virus infection</PatientSegment><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Erythrocytes </BiomarkerName><BiomarkerName> Hematocrit </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Urea</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2007-07-24T00:00:00Z</PrimaryCompletionDate><TrialDuration>39 Months</TrialDuration><NumberOfSites>153</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="97796"><Indications><Indication>Chronic lymphocytic leukemia</Indication><Indication>Lymphoma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Btk tyrosine kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action><Action>B-lymphocyte adhesion inhibitor</Action><Action>B-lymphocyte migration inhibitor</Action><Action>Cell cycle inhibitor</Action><Action>Chemotaxis inhibitor</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Daily dosing</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology></Technologies><CompaniesCollaborator><Company>Janssen Research &amp; Development LLC</Company></CompaniesCollaborator><CompaniesSponsor><Company>Pharmacyclics Inc</Company></CompaniesSponsor><Countries><Country>Italy</Country><Country>US</Country><Country>Australia</Country><Country>Ukraine</Country><Country>Spain</Country><Country>Canada</Country><Country>Belgium</Country><Country>Germany</Country><Country>Turkey</Country><Country>Ireland</Country><Country>China</Country><Country>New Zealand</Country><Country>Israel</Country><Country>Poland</Country><Country>Russian Federation</Country><Country>UK</Country><Country>Czech Republic</Country></Countries><DateChangeLast>2019-06-20T00:00:00Z</DateChangeLast><DateEnd>2015-05-31T00:00:00Z</DateEnd><DateStart>2013-03-31T00:00:00Z</DateStart><Identifiers><Identifier>2012-003967-23</Identifier><Identifier>NCT01722487</Identifier><Identifier>PCYC-1115</Identifier><Identifier>PCYC-1115-CA</Identifier><Identifier>RESONATE-2</Identifier></Identifiers><IndicationsAdverse><Indication>Anemia</Indication><Indication>Atrial fibrillation</Indication><Indication>Bleeding</Indication><Indication>Cough</Indication><Indication>Death</Indication><Indication>Diarrhea</Indication><Indication>Emesis</Indication><Indication>Fatigue</Indication><Indication>Hematoma</Indication><Indication>Hypertension</Indication><Indication>Musculoskeletal pain</Indication><Indication>Nausea</Indication><Indication>Neutropenia</Indication><Indication>Pneumonia</Indication><Indication>Skin rash</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>chlorambucil alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>ibrutinib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>269</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>without alternative etiology, or increased absolute reticulocytosis (above ULN) or bone marrow erythropoiesis in the absence of bleeding) and at least one marker of direct or indirect autoimmune mechanism (positive direct antiglobulin for IgG or C3d, &lt;b&gt;cold&lt;/b&gt; agglutinins) (Ding 2007); Immune thrombocytopenia is defined by platelets&amp;lt;/= 100,000/microl and increased megakaryocytes on the bone marrow exam Eastern Cooperative Oncology Group (ECOG) performance score = 1 or 2 Diagnosis of CLL/SLL that meets</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anemia - Assessment of Biomarkers - Assessment of other biomarkers</EndpointIndex><EndpointIndex>Anemia - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Anemia - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Anemia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Anemia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Anemia - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Anemia - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Anemia - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Anemia - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Anemia - Assessment of Response Rates (RR) - Assessment of hematologic improvement</EndpointIndex><EndpointIndex>Anemia - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)</EndpointIndex><EndpointIndex>Anemia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Anemia - Assessment of Survival - Assessment of event free survival (EFS)</EndpointIndex><EndpointIndex>Anemia - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Anemia - Assessment of Therapy Related Outcomes - Assessment of treatment utilization/alterations</EndpointIndex><EndpointIndex>Anemia - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Anemia - Assessment of adverse events</EndpointIndex><EndpointIndex>Anemia - Assessment of hospitalization</EndpointIndex><EndpointIndex>Anemia - Hematological Assessments</EndpointIndex><EndpointIndex>Anemia - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Anthropometric Assessments - Assessment of anthropometric changes</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Biomarkers - Assessment of other biomarkers</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Bone Marrow</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Co-morbidity - Assessment of hematologic diseases/disorders</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Co-morbidity - Assessment of premalignant/malignant diseases/disorders</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Laboratory/Diagnostic Measures - Assessment using imaging modalities</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Metabolic Parameters</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Platelet Count</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Survival - Assessment of event free survival (EFS)</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Transfusions</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of adverse events</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of hospitalization</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of hospitalization - Assessment of number of emergency department visits</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Hematological Assessments</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Patient Reported Outcomes/Quality of Life Assessments - Assessment of symptom control</EndpointIndex><EndpointIndex>Leukemia - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Leukemia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Leukemia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Leukemia - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Leukemia - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Leukemia - Assessment of Response Rates (RR) - Assessment of hematologic/bone marrow response</EndpointIndex><EndpointIndex>Leukemia - Assessment of Survival - Assessment of event free survival (EFS)</EndpointIndex><EndpointIndex>Leukemia - Assessment of adverse events</EndpointIndex><EndpointIndex>Leukemia - Health Economic Assessments - Health care resource utilization</EndpointIndex><EndpointIndex>Leukemia - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Leukemia - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-C30</EndpointIndex><EndpointIndex>Leukemia - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EQ-5D (EuroQoL)</EndpointIndex><EndpointIndex>Leukemia - Patient Reported Outcomes/Quality of Life Assessments - Assessment by FACIT-F TOI</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Lymphoma - Assessment of Survival - Assessment of event free survival (EFS)</EndpointIndex><EndpointIndex>Lymphoma - Assessment of adverse events</EndpointIndex><EndpointIndex>Lymphoma - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Lymphoma - Hematological Assessments - Assessment of hematologic reconstitution</EndpointIndex><EndpointIndex>Lymphoma - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-C30</EndpointIndex><EndpointIndex>Lymphoma - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EQ-5D (EuroQoL)</EndpointIndex><EndpointIndex>Lymphoma - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EuroQol EQ-5D-5L Questionnaire</EndpointIndex><EndpointIndex>Lymphoma - Protocol Specified Other Endpoints - Assessment of Efficacy</EndpointIndex><EndpointIndex>Thrombocytopenia - Anthropometric Assessments - Assessment of anthropometric changes</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Bone Marrow</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Laboratory/Diagnostic Measures - Assessment using imaging modalities</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Metabolic Parameters</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Morbidity Rates</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Platelet Count</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Survival - Assessment of event free survival (EFS)</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Transfusions</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of adverse events</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of hospitalization</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of hospitalization - Assessment of number of emergency department visits</EndpointIndex><EndpointIndex>Thrombocytopenia - Clinical Assessments</EndpointIndex><EndpointIndex>Thrombocytopenia - Hematological Assessments</EndpointIndex><EndpointIndex>Thrombocytopenia - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Thrombocytopenia - Patient Reported Outcomes/Quality of Life Assessments - Assessment of symptom control</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>RESONATE-2: Open-label, Phase III BTK Inhibitor Ibrutinib Versus Chlorambucil Patients &gt;/= 65 Years or Older With Treatment-naive CLL or SLL</TitleDisplay><PatientSegmentTerms><PatientSegment>Anemia - Subjects with Hemolytic Anemia - Subjects with autoimmune hemolytic anemia</PatientSegment><PatientSegment>Anemia - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Anemia - Subjects with specific disease - Subjects with Cancer/Cancer Chemotherapy Induced Anemia</PatientSegment><PatientSegment>Idiopathic thrombocytopenic purpura - Subjects with comorbid conditions</PatientSegment><PatientSegment>Leukemia - Subjects with Chronic Lymphocytic Leukemia (CLL)</PatientSegment><PatientSegment>Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with small lymphocytic/prolymphocytic lymphoma</PatientSegment><PatientSegment>Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Indolent (slow-growing, low grade) Lymphoma</PatientSegment><PatientSegment>Thrombocytopenia - Subjects with Cancer/Chemotherapy Induced Thrombocytopenia</PatientSegment><PatientSegment>Thrombocytopenia - Subjects with Immune (Idiopathic) Thrombocytopenia</PatientSegment><PatientSegment>Thrombocytopenia - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>1-Phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2 </BiomarkerName><BiomarkerName> ADP-ribosyl cyclase 1 </BiomarkerName><BiomarkerName> B-lymphocyte antigen CD19 </BiomarkerName><BiomarkerName> B-lymphocytes </BiomarkerName><BiomarkerName> Beta-2-microglobulin </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> C-C chemokine receptor type 7 </BiomarkerName><BiomarkerName> CD27 antigen </BiomarkerName><BiomarkerName> CD3 Antigens </BiomarkerName><BiomarkerName> CD8-Positive T-Lymphocytes </BiomarkerName><BiomarkerName> Cellular tumor antigen p53 </BiomarkerName><BiomarkerName> Deoxyribonucleic acid </BiomarkerName><BiomarkerName> HLA-DR Antigens </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Immunoglobulin heavy locus </BiomarkerName><BiomarkerName> Interleukin-2 receptor alpha chain </BiomarkerName><BiomarkerName> Interleukin-7 receptor subunit alpha </BiomarkerName><BiomarkerName> Leukocyte common antigen </BiomarkerName><BiomarkerName> Low affinity immunoglobulin gamma Fc region receptor III </BiomarkerName><BiomarkerName> Lymph node </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Memory T-Lymphocytes </BiomarkerName><BiomarkerName> Monocyte differentiation antigen CD14 </BiomarkerName><BiomarkerName> Monocytes </BiomarkerName><BiomarkerName> Myeloid-derived suppressor cells </BiomarkerName><BiomarkerName> Natural killer T-cells </BiomarkerName><BiomarkerName> Natural killer cells </BiomarkerName><BiomarkerName> Neural cell adhesion molecule 1 </BiomarkerName><BiomarkerName> Programmed cell death protein 1 </BiomarkerName><BiomarkerName> Regulatory T-Lymphocytes </BiomarkerName><BiomarkerName> Spleen </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain </BiomarkerName><BiomarkerName> Thyroid-stimulating hormone </BiomarkerName><BiomarkerName> Thyroxine </BiomarkerName><BiomarkerName> Tumor necrosis factor receptor superfamily member 6 </BiomarkerName><BiomarkerName> Tyrosine-protein kinase BTK</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>225</NumberOfSites><ContactNames><Name>Alessandra Tedeschi</Name><Name>Deepali Suri</Name><Name>Jan Burger</Name><Name>Lori Styles, MD</Name><Name>Medical Monitor</Name><Name>Peter Hillmen</Name></ContactNames></Trial><Trial Id="96618"><Indications><Indication>Empyema</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Tissue plasminogen activator stimulator</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action><Action>Tissue plasminogen activator stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Fibrinolysis stimulator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Fibrinolysis stimulator</Action><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Inhalant formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>BC Children's Hospital</Company><Company>CHU de Quebec-Universite Laval</Company><Company>Canadian Institutes of Health Research</Company><Company>Childrens Hospital of Eastern Ontario (CHEO)</Company><Company>McMaster Children's Hospital</Company><Company>Physicians' Services Incorporated Foundation</Company><Company>St Michaels Hospital</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital for Sick Children</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2017-12-31T00:00:00Z</DateEnd><DateStart>2012-12-31T00:00:00Z</DateStart><Identifiers><Identifier>1000033767</Identifier><Identifier>DTPA trial</Identifier><Identifier>NCT01717742</Identifier></Identifiers><InterventionsControlDisplay><Intervention>alteplase alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>alteplase plus dornase alfa</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>96</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this multicenter, randomized, controlled trial was to compare the time to discharge from hospital after chest drain insertion in previously well children who present with pleural empyema, treated with intrapleural DNase (dornase alfa) ( Pulmozyme ) and tissue plasminogen activator (tPA) (alteplase) ( Cathflo ) by chest drain for three doses over 48 h compared with three doses over 48 h of alteplase alone. Other outcomes related to effectiveness, safety and cost would be assessed as</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pneumonia - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Pneumonia - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Pneumonia - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Pneumonia - Requirement of Ventilatory Support/Intervention</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>DTPA trial: Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema</TitleDisplay><PatientSegmentTerms><PatientSegment>Pneumonia - Subjects with Severe/Very Severe Pneumonia</PatientSegment><PatientSegment>Pneumonia - Subjects with disease related complications - Subjects with empyema</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body temperature </BiomarkerName><BiomarkerName> Hemoglobin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>60 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Eyal Cohen, MD, MSc</Name></ContactNames></Trial><Trial Id="9651"><Indications><Indication>Herpes simplex virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action><Action>Thymidine kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Viral replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Emulsion dermatological</Technology><Technology>Local formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Transport Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2013-12-04T00:00:00Z</DateChangeLast><DateEnd>2006-03-31T00:00:00Z</DateEnd><DateStart>2005-04-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT00230867</Identifier><Identifier>TPI-203</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>aciclovir (transdermal, iontophoretic), Transport Pharmaceuticals alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1800</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>by &lt;b&gt;cold&lt;/b&gt; sores which might affect the normal course of &lt;b&gt;cold&lt;/b&gt; sores (eg, eczema, psoriasis, albinism, or chronic vesiculobullous disorders) Subject is currently enrolled in another clinical trial or has used...multi-centered, double-blind, placebo-controlled trial to evaluate the safety and efficacy of acyclovir (SoloVir), delivered via a novel iontophoretic device, for the treatment of &lt;b&gt;cold&lt;/b&gt; sores in patients with recurrent herpes labialis lesions [ 604945 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Development in aborted lesion</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Duration</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Healing</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>11 Months</TrialDuration><NumberOfSites>26</NumberOfSites><ContactNames><Name>Christopher M Hull, MD</Name></ContactNames></Trial><Trial Id="96131"><Indications><Indication>Colonoscopy</Indication></Indications><CompaniesSponsor><Company>Ferring Pharmaceuticals SA</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-04-27T00:00:00Z</DateChangeLast><DateEnd>2010-10-31T00:00:00Z</DateEnd><DateStart>2010-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2009-01</Identifier><Identifier>NCT01073930</Identifier><Identifier>SEE CLEAR I</Identifier></Identifiers><IndicationsAdverse><Indication>Emesis</Indication><Indication>Headache</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Variable regimens including HalfLytely , HalfLytely + bisacodyl , bisacodyl</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>PicoPrep alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>608</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day, during the morning prior to the colonoscopy). Each PicoPrep pouch would be reconstituted by mixing the contents in a cup with 5 oz of &lt;b&gt;cold&lt;/b&gt; water. The first pouch would be taken between 5:00 PM and 9:00 PM the evening prior to the colonoscopy procedure. Subjects would consume five 8 oz glasses of clear liquids over the next few hours. The second pouch would be taken approximately 5 h before</Teaser><TrialCategories><Category>Borderline product</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SEE CLEAR I: Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep</TitleDisplay><PrimaryCompletionDate type="Actual">2010-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>9</NumberOfSites><ContactNames><Name>Clinical Development Support</Name></ContactNames></Trial><Trial Id="96017"><Indications><Indication>Colonoscopy</Indication></Indications><CompaniesSponsor><Company>Ferring Pharmaceuticals SA</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-04-27T00:00:00Z</DateChangeLast><DateEnd>2010-10-31T00:00:00Z</DateEnd><DateStart>2010-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2009-02</Identifier><Identifier>NCT01073943</Identifier><Identifier>SEE CLEAR II</Identifier></Identifiers><IndicationsAdverse><Indication>Emesis</Indication><Indication>Headache</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Variable regimens including HalfLytely , HalfLytely + bisacodyl , bisacodyl</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>PicoPrep alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>603</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>would receive PicoPrep (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of two pouches of powder administered in a divided dose. Each PicoPrep pouch was reconstituted by mixing the contents in a cup with 5 oz of &lt;b&gt;cold&lt;/b&gt; water. Subjects randomized to the PicoPrep group will begin treatment (first sachet) one day before colonoscopy between 4:00 and 6:00 PM, and will complete the treatment (second sachet) at least 6 h later, between 10:00 PM and 12:00 AM. Subjects would</Teaser><TrialCategories><Category>Borderline product</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Therapy Related Outcomes - Assessment of colon cleansing/bowel preparation</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Satisfaction Questionnaire (PSQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SEE CLEAR II: Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep</TitleDisplay><PrimaryCompletionDate type="Actual">2010-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>11</NumberOfSites><ContactNames><Name>Clinical Development Support</Name></ContactNames></Trial><Trial Id="95693"><Indications><Indication>Hypothermia</Indication></Indications><CompaniesSponsor><Company>Medical University of Vienna</Company></CompaniesSponsor><Countries><Country>Austria</Country></Countries><DateChangeLast>2012-10-26T00:00:00Z</DateChangeLast><DateEnd>2009-06-30T00:00:00Z</DateEnd><DateStart>2008-10-31T00:00:00Z</DateStart><Identifiers><Identifier>HotDogVienna</Identifier><Identifier>NCT00772460</Identifier></Identifiers><InterventionsControlDisplay><Intervention>BairHugger alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>HotDog alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of the study was to compare two patient warming systems with 40 patients each in a convective warming group (BairHugger, Arizant) and in a conductive warming group (HotDog, Augustine Biomedical). The patients would undergo small to medium trauma surgery and would be warmed with the randomized device. The study hypothesize that the area under the standardized core temperature/time curve would be significantly greater in the conductive warming group. Secondary outcome would be the mean</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Comparison of a New Patient Warming System Using Polymer Conductive Warming With Forced Air Warming During Surgery</TitleDisplay><PrimaryCompletionDate type="Actual">2009-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Oliver Kimberger, M.D.</Name></ContactNames></Trial><Trial Id="95165"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>IL-12 receptor antagonist</Action><Action>IL-23 antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Interleukin receptor 17A antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Amgen Inc</Company></CompaniesSponsor><Countries><Country>Portugal</Country><Country>Austria</Country><Country>Spain</Country><Country>France</Country><Country>Canada</Country><Country>Australia</Country><Country>Hungary</Country><Country>Poland</Country><Country>Netherlands</Country><Country>Czech Republic</Country><Country>US</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateStart>2012-08-31T00:00:00Z</DateStart><Identifiers><Identifier>2012-000656-34</Identifier><Identifier>20120103</Identifier><Identifier>AMAGINE-2</Identifier><Identifier>NCT01708603</Identifier></Identifiers><IndicationsAdverse><Indication>Arthralgia</Indication><Indication>Common cold</Indication><Indication>Headache</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>ustekinumab alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>brodalumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1831</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Sponsor/Business Decision</Reason></ReasonForTrialDiscontinuation><Teaser>In November 2014, results were published. Common &lt;b&gt;cold&lt;/b&gt;, upper respiratory tract infection, headache and joint pain were the most common adverse events that occurred in the brodalumab arms (more than 5 percent of subjects in either group). In 1% of subjects in the 210 mg group, 1.2% of subjects in the weight-based group, and 2.1% of subjects in the 140 mg group compared with 1.3% for ustekinumab and 2.6% for placebo, serious adverse events occurred during the placebo-controlled period. In the brodalumab</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment of Laboratory/Diagnostic Measures - Assessment of anti-drug antibodies</EndpointIndex><EndpointIndex>Psoriasis - Assessment of adverse events</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Psoriasis - Physician Global Assessment of Disease Activity - Assessment by Investigator/Physician Global Assessment (PGA) Scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>AMAGINE-2: Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with Moderate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment><PatientSegment>Psoriasis - Subjects with Severe Psoriasis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Antigen KI-67 </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> CD3 Antigens </BiomarkerName><BiomarkerName> Dendritic cells </BiomarkerName><BiomarkerName> Epidermis </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Integrin alpha-X </BiomarkerName><BiomarkerName> Interleukin-17A </BiomarkerName><BiomarkerName> Interleukin-17C </BiomarkerName><BiomarkerName> Interleukin-17F </BiomarkerName><BiomarkerName> Interleukin-23 subunit alpha </BiomarkerName><BiomarkerName> Keratin, type I cytoskeletal 16 </BiomarkerName><BiomarkerName> Keratinocytes </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Lysosome-associated membrane glycoprotein 3 </BiomarkerName><BiomarkerName> T-Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-09-30T00:00:00Z</PrimaryCompletionDate><NumberOfSites>159</NumberOfSites><ContactNames><Name>IHQ Medical Info - Clinical Trials</Name><Name>MD</Name></ContactNames></Trial><Trial Id="95140"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>IL-12 receptor antagonist</Action><Action>IL-23 antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Interleukin receptor 17A antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Amgen Inc</Company><Company>MedDerm Associates</Company></CompaniesSponsor><Countries><Country>France</Country><Country>Australia</Country><Country>Greece</Country><Country>Hungary</Country><Country>Latvia</Country><Country>US</Country><Country>Canada</Country><Country>Russian Federation</Country><Country>Belgium</Country><Country>Italy</Country><Country>Poland</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2015-10-31T00:00:00Z</DateEnd><DateStart>2012-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2012-000667-24</Identifier><Identifier>20120104</Identifier><Identifier>AMAGINE-3</Identifier><Identifier>NCT01708629</Identifier><Identifier>NCT02786732</Identifier></Identifiers><IndicationsAdverse><Indication>Arthralgia</Indication><Indication>Candida infection</Indication><Indication>Cerebrovascular trauma</Indication><Indication>Common cold</Indication><Indication>Depression</Indication><Indication>Headache</Indication><Indication>Ischemic heart disease</Indication><Indication>Neutropenia</Indication><Indication>Rhinopharyngitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>ustekinumab alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>brodalumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1881</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Sponsor/Business Decision</Reason></ReasonForTrialDiscontinuation><Teaser>In November 2014, results were presented. In the brodalumab arms (&gt; 5% of patients in either group) the most common adverse events that occurred were common &lt;b&gt;cold&lt;/b&gt;, joint pain, upper respiratory tract infection and headache. In 1.4%, 1.6%, 0.6%, 1.0% of patients, in 210, 140 mg, ustekinumab and placebo group serious adverse events occurred respectively [ 1611190 ]. In March 2015, results were presented. In placebo, ustekinumab, brodalumab 140 and 210 mg groups, 48.6, 53.7, 52.6 and 56.8% of any grade</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment of Laboratory/Diagnostic Measures - Assessment of anti-drug antibodies</EndpointIndex><EndpointIndex>Psoriasis - Assessment of adverse events</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Psoriasis - Physician Global Assessment of Disease Activity - Assessment by Investigator/Physician Global Assessment (PGA) Scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>AMAGINE-3: Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with Moderate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment><PatientSegment>Psoriasis - Subjects with Severe Psoriasis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Antigen KI-67 </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> CD3 Antigens </BiomarkerName><BiomarkerName> Dendritic cells </BiomarkerName><BiomarkerName> Epidermis </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Integrin alpha-X </BiomarkerName><BiomarkerName> Interleukin-17A </BiomarkerName><BiomarkerName> Interleukin-17C </BiomarkerName><BiomarkerName> Interleukin-17F </BiomarkerName><BiomarkerName> Interleukin-23 subunit alpha </BiomarkerName><BiomarkerName> Keratin, type I cytoskeletal 16 </BiomarkerName><BiomarkerName> Keratinocytes </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Lysosome-associated membrane glycoprotein 3 </BiomarkerName><BiomarkerName> T-Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>37 Months</TrialDuration><NumberOfSites>170</NumberOfSites><ContactNames><Name>Dip. Regolatorio</Name><Name>IHQ Medical Info - Clinical Trials</Name><Name>MD</Name></ContactNames></Trial><Trial Id="94794"><Indications><Indication>Chronic sinusitis</Indication></Indications><CompaniesSponsor><Company>Bionorica SE</Company></CompaniesSponsor><Countries><Country>Poland</Country><Country>Germany</Country><Country>Belgium</Country><Country>Czech Republic</Country></Countries><DateChangeLast>2017-10-25T00:00:00Z</DateChangeLast><DateEnd>2014-07-14T00:00:00Z</DateEnd><DateStart>2012-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2011-003623-35</Identifier><Identifier>CRS-02</Identifier><Identifier>NCT01706484</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>BNO-1016 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>927</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>decongestant preparations (alpha-sympathomimetics), analgesics (including systemic non-steroidal anti inflammatory drugs [NSAIDs], except paracetamol), mucolytics/secretolytics, antihistamines, or alternative medicine preparations for treatment of common &lt;b&gt;cold&lt;/b&gt; like symptoms or with immunomodulating properties within the last 7 days prior to V1 Patients with gastric or duodenal ulcer Other diseases within five years prior to V1, which in the opinion of the investigator disqualifies the patient for trial enrollment</Teaser><TrialCategories><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy And Safety Of Two Dosages Of A Herbal Medicinal Product (Dry Extract BNO-1016) in Chronic Rhinosinusitis</TitleDisplay><PrimaryCompletionDate type="Actual">2014-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Claus Bachert, Prof. Dr.</Name><Name>Senior Clinical Research Manager</Name></ContactNames></Trial><Trial Id="93607"><Indications><Indication>Sleep apnea</Indication></Indications><CompaniesSponsor><Company>Stanford University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-16T00:00:00Z</DateChangeLast><DateEnd>2014-06-30T00:00:00Z</DateEnd><DateStart>2011-12-31T00:00:00Z</DateStart><Identifiers><Identifier>1R01 HS019738-01</Identifier><Identifier>COMET</Identifier><Identifier>NCT01461473</Identifier><Identifier>SU-10182011-8536</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>oral appliance alone</Intervention><Intervention>positive airway pressure therapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>131</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>need for treatment for hypertension) which is currently untreated or taking medication for the treatment of hypertension Stable medication regimen for 2 months prior to the baseline testing visit. As-needed medications such as those used for allergy, &lt;b&gt;cold&lt;/b&gt;, or minor pain symptoms may be used at the discretion of the Clinical Center physician</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hypertension - Assessment of Blood Pressure (BP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Diastolic Blood Pressure (DBP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of tumor necrosis factor alpha (TNFa)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Inflammatory &amp; Oxidative Stress Markers - High-sensitivity C-reactive protein (hsCRP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Inflammatory &amp; Oxidative Stress Markers - Interleukin-6 (IL-6)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Systolic Blood Pressure (SBP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Vascular Endothelial Function - Flow-mediated dilatation (FMD)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Ventricular Structure/Dimension/Function</EndpointIndex><EndpointIndex>Hypertension - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Hypertension - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Hypertension - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Clinical Symptoms - Assessment of daytime fatigue</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Functional Disability/Physical Function - Assessment by Functional Outcomes of Sleep Questionnaire</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Laboratory/Diagnostic Measures - Assessment of Inflammatory/Immunological Markers</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Neuropsychological Function - Assessment of attention/concentration</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Psychiatric Symptoms - Assessment of mood symptoms</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Sleep - Assessment of day-time sleepiness</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Vascular Indices or Parameters - Assessment of endothelial function</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Sleep apnea - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Quality of Well-Being Self-Administered Scale (QWB-SA)</EndpointIndex><EndpointIndex>Sleep apnea - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Sleep apnea - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Sleep Apnea Quality of Life Index (SAQLI) questionaire</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>COMET: Comparative Outcomes Management With Electronic Data Technology (COMET) Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Hypertension - Subjects on Hypertensive Treatment</PatientSegment><PatientSegment>Hypertension - Subjects with Primary/Essential Hypertension</PatientSegment><PatientSegment>Hypertension - Subjects with comorbid conditions - Subjects with obesity</PatientSegment><PatientSegment>Hypertension - Subjects with comorbid conditions - Subjects with obstructive sleep apnea</PatientSegment><PatientSegment>Sleep apnea - Subjects with Moderate Sleep Apnea</PatientSegment><PatientSegment>Sleep apnea - Subjects with Obstructive Sleep Apnea</PatientSegment><PatientSegment>Sleep apnea - Subjects with Severe Sleep Apnea</PatientSegment><PatientSegment>Sleep apnea - Subjects with comorbid conditions - Subjects co-morbid with hypertension</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Brachial artery </BiomarkerName><BiomarkerName> Mean arterial pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Allan Pack, MD</Name><Name>Clete A Kushida, MD, PhD</Name><Name>Ruth Benca, MD</Name><Name>Susan Redline, MD</Name></ContactNames></Trial><Trial Id="92782"><Indications><Indication>Herpesvirus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Emulsion dermatological</Technology><Technology>Nanoparticle formulation dermatological</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>BlueWillow Biologics</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-05-19T00:00:00Z</DateChangeLast><DateEnd>2013-07-31T00:00:00Z</DateEnd><DateStart>2012-10-31T00:00:00Z</DateStart><Identifiers><Identifier>NB-001-010</Identifier><Identifier>NCT01695187</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>NB-001 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>362</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>more &lt;b&gt;cold&lt;/b&gt; sore recurrences on the lips and/or skin surrounding the lips in the previous year. The majority of their &lt;b&gt;cold&lt;/b&gt; sore recurrences proceeded by a...the duration of the &lt;b&gt;cold&lt;/b&gt; sore recurrence Be willing to refrain from participation in another clinical trial Be willing and able to use phone or internet to obtain... The purpose of this phase III study is to test the hypothesis that time to healing of a &lt;b&gt;cold&lt;/b&gt; sore will be lower </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Healing</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>NB-001 Treatment of Recurrent Herpes Labialis</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>12</NumberOfSites></Trial><Trial Id="92762"><Indications><Indication>Bleeding</Indication></Indications><CompaniesSponsor><Company>Massachusetts Eye &amp; Ear Infirmary</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2011-11-30T00:00:00Z</DateEnd><DateStart>2010-07-31T00:00:00Z</DateStart><Identifiers><Identifier>10-03-016</Identifier><Identifier>NCT01415583</Identifier></Identifiers><IndicationsAdverse><Indication>Bleeding</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>dexamethasone alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>314</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> family history of any bleeding disorder will be excluded Subjects currently on oral corticosteroids for other medical conditions or have recently taken any oral corticosteroid within 2 weeks of surgery Patients with tonsillectomy performed using a &lt;b&gt;cold&lt;/b&gt; knife technique, microdebrider, coblation or plasma knife due to surgeon or parent preference Where appropriate subjects who do not have informed consent or child assent signed will be excluded Children&amp;lt; 3 years old will be excluded due to the fact</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Morbidity</EndpointIndex><EndpointIndex>Sleep apnea - Assessment of Therapy Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Evaluating Perioperative Dexamethasone and the Risk of Bleeding in Tonsillectomy</TitleDisplay><PrimaryCompletionDate type="Actual">2011-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>16 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Christopher Hartnick, MD</Name></ContactNames></Trial><Trial Id="92245"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-5 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline Research &amp; Development Ltd</Company><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>US</Country><Country>France</Country><Country>Australia</Country><Country>UK</Country><Country>Mexico</Country><Country>Czech Republic</Country><Country>Netherlands</Country><Country>Poland</Country><Country>Germany</Country><Country>Canada</Country></Countries><DateChangeLast>2019-05-22T00:00:00Z</DateChangeLast><DateEnd>2013-12-31T00:00:00Z</DateEnd><DateStart>2012-10-31T00:00:00Z</DateStart><Identifiers><Identifier>115575</Identifier><Identifier>2012-001497-29</Identifier><Identifier>MEA115575</Identifier><Identifier>NCT01691508</Identifier><Identifier>SIRIUS</Identifier></Identifiers><IndicationsAdverse><Indication>Asthma</Indication><Indication>Bronchitis</Indication><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Rhinopharyngitis</Indication><Indication>Sinusitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>mepolizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>135</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Among the corticosteroid-dependent severe eosinophilic asthma (n = 45) subjects who previously used omalizumab for a median duration of 8 months, 82% of subjects discontinued use due to lack of efficacy. The primary exacerbation cause was allergy and &lt;b&gt;cold&lt;/b&gt; air in the prior omalizumab group and was respiratory infection in the no prior omalizumab group. Similar po corticosteroid reduction and exacerbation rate reduction (33 versus 29%) was observed in subjects previously treated with omalizumab when compared</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Anthropometric Assessments - Assessment of anthropometric changes</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures - Assessment of hematology/biochemistry</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures - Glucose evaluations</EndpointIndex><EndpointIndex>Asthma - Assessment of Physical Examination - Cardiac evaluation</EndpointIndex><EndpointIndex>Asthma - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Asthma - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Asthma - Assessment of use of Rescue Medication - Change in rescue medication use</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SIRIUS: Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment><PatientSegment>Asthma - Subjects with Levels of Asthma Control - Subjects with poorly controlled/not well controlled asthma</PatientSegment><PatientSegment>Asthma - Subjects with Levels of Asthma Control - Subjects with uncontrolled asthma</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with severe persistent asthma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Eosinophils </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>47</NumberOfSites><ContactNames><Name>Alfredo Gazca-Aguilar</Name><Name>Amal Assa'ad</Name><Name>Andrea Ludwig-Sengpiel</Name><Name>Anneke Brinke</Name><Name>Antoine Magnan</Name><Name>Arnaud Bourdin</Name><Name>Bronislava Novotna</Name><Name>Catherine Lemiere</Name><Name>Catherine Weiler</Name><Name>Charles Fogarty</Name><Name>Cheri Hudson</Name><Name>Dagmar Kindlova</Name><Name>Dante Hernandez-Colin</Name><Name>David Spencer</Name><Name>Dimitar Sajkov</Name><Name>Ekkehard Beck</Name><Name>Elisabeth Bel</Name><Name>Frederic Blay</Name><Name>GSK Clinical Trials</Name><Name>Geoffrey Chupp</Name><Name>Gert-Jan Braunstahl</Name><Name>Grazyna Pulka</Name><Name>Ian Pavord</Name><Name>James Martin</Name><Name>Jan Chlumsky</Name><Name>Jaromir Bystron</Name><Name>Jo Douglass</Name><Name>Kevin Mortimer</Name><Name>Mario Castro</Name><Name>Martin Hoffmann</Name><Name>Mathias Rolke</Name><Name>Michel Laviolette</Name><Name>Michel Aubier</Name><Name>Norbert Pauk</Name><Name>Oliver Kornmann</Name><Name>Parameswaran Nair</Name><Name>Peter Gibson</Name><Name>Peter Howarth</Name><Name>Philip Thompson</Name><Name>Piotr Kuna</Name><Name>Robert Mroz</Name><Name>Rohit Katial</Name><Name>Sabine Ballenberger</Name><Name>Sally Wenzel</Name><Name>Siegrid Hofmann</Name><Name>Stephanie Korn</Name><Name>Steven Meltzer</Name><Name>Vitezslav Kolek</Name><Name>Winfried Schroeder-Babo</Name><Name>Yves Donazzolo</Name><Name>Zenon Siergiejko</Name></ContactNames></Trial><Trial Id="91764"><Indications><Indication>Common cold</Indication></Indications><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-06-26T00:00:00Z</DateChangeLast><DateEnd>2012-11-30T00:00:00Z</DateEnd><DateStart>2011-11-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT01686646</Identifier><Identifier>RH01361</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>caffeine alone</Intervention><Intervention>paracetamol alone</Intervention><Intervention>caffeine plus paracetamol</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>240</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>of &lt;b&gt;cold&lt;/b&gt; for&amp;lt; 96 h, rating of at least '2' on malaise at least 4 other symptoms of &lt;b&gt;cold&lt;/b&gt; No history of clinically significant perennial rhinitis, no recent antibiotic, anti-histamine or &lt;b&gt;cold&lt;/b&gt; treatment, no caffeine in the previous...This study would investigate any improvement in alertness and performance based on cognitive function and mood assessment in subjects suffering from common &lt;b&gt;cold&lt;/b&gt;, when taking a novel paracetamol and caffeine combination versus paracetamol alone.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effects of Two Doses of a Common Cold Treatment on Alertness</TitleDisplay><PrimaryCompletionDate type="Actual">2012-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="91028"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Somatostatin receptor agonist</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer polyclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Growth hormone release inhibitor</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody polyclonal</Technology><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>University of Miami</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-12-06T00:00:00Z</DateChangeLast><DateEnd>2014-12-31T00:00:00Z</DateEnd><DateStart>2012-11-30T00:00:00Z</DateStart><Identifiers><Identifier>20110126</Identifier><Identifier>NCT01680861</Identifier></Identifiers><InterventionsControlDisplay><Intervention>enteric-coated mycophenolate sodium, Novartis plus tacrolimus</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Thymoglobulin alone</Intervention><Intervention>basiliximab alone</Intervention><Intervention>everolimus plus tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>32</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Previously received or is receiving an organ transplant other than a kidney Donor organ with a &lt;b&gt;cold&lt;/b&gt; ischemic time&gt; 48 h ABO incompatible donor kidney Recipients of T cell, or B cell cross-match positive transplant Panel reactive antibody (PRA)&gt; 30% HIV or hepatitis C virus, or hepatitis B virus anti-genemia Current malignancy or a history of malignancy</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Tacrolimus/Everolimus Versus Tacrolimus/Enteric Coated Mycophenolate Sodium</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Kidney Transplant Subjects</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>25 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Gaetano Ciancio, M.D.</Name></ContactNames></Trial><Trial Id="89855"><Indications><Indication>Cough</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Respiratory system agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Respicopea Limited</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-06-30T00:00:00Z</DateChangeLast><DateEnd>2013-08-31T00:00:00Z</DateEnd><DateStart>2012-07-31T00:00:00Z</DateStart><Identifiers><Identifier>BC1036-001</Identifier><Identifier>NCT01656668</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>AG-1321001 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>288</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to investigate the effect of BC-1036 (theobromine) on cough-related quality of life and cough severity following 2 weeks treatment.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of the Safety and Effectiveness of BC-1036 Capsules to Treat Frequent Long-Term Cough</TitleDisplay><PrimaryCompletionDate type="Actual">2013-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>13</NumberOfSites><ContactNames><Name>Alan Jackson, MB, BS</Name><Name>Alun George, MA MBBS, DRCOG, DCH, MRCGP</Name><Name>Alyn Morice, BA(Hons) MB.B.Chir MA FRCP</Name><Name>Bernard Higgins, MB ChB, MRCP, MD</Name><Name>Chris Strang, MB BS, D. Obst, RCOG M</Name><Name>Damien McNally, MB,BCh,BAO,DRCOG,DMH,MRCGP</Name><Name>Fan Chung, MB, BS, MD, FRCP, DSc (PI)</Name><Name>Ian Pavord, MB BS, MRCP, FRCP, DM</Name><Name>Lorcan McGarvey, MBBCh,BAOHons,MRCP,MD,CCST(PI)</Name><Name>Philip Marazzi, MB, BS</Name><Name>Richard Oliver, MB ChB, MRCGP</Name><Name>Surinder Birring, BSc,MBChB(Hons),MRCP,MD(PI)</Name><Name>Warwick Coulson, BSc, MBBS, DipRCOG, MRCGP</Name></ContactNames></Trial><Trial Id="89313"><Indications><Indication>Hypercholesterolemia</Indication></Indications><ActionsPrimaryInterventionsControl><Action>HMG CoA reductase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>HMG CoA reductase inhibitor</Action><Action>Proprotein convertase PC9 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Antiarteriosclerotic</Action><Action>Antihypercholesterolemic agent</Action><Action>Antihyperlipidemic agent</Action><Action>Antihypertriglyceridemic agent</Action><Action>Cardioprotectant</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Antiarteriosclerotic</Action><Action>Antihypercholesterolemic agent</Action><Action>Antihyperlipidemic agent</Action><Action>Antihypertriglyceridemic agent</Action><Action>Cardioprotectant</Action><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Buccal formulation systemic</Technology><Technology>Cell culture technique</Technology><Technology>Film coating</Technology><Technology>Immunoglobulin-G</Technology><Technology>Monoclonal antibody human</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Regeneron Pharmaceuticals Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Sanofi SA</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-31T00:00:00Z</DateChangeLast><DateEnd>2014-04-30T00:00:00Z</DateEnd><DateStart>2012-07-31T00:00:00Z</DateStart><Identifiers><Identifier>EFC11568</Identifier><Identifier>NCT01644175</Identifier><Identifier>ODYSSEY Combo I</Identifier><Identifier>U1111-1121-4356</Identifier></Identifiers><IndicationsAdverse><Indication>Dizziness</Indication><Indication>Rhinopharyngitis</Indication><Indication>Sinusitis</Indication><Indication>Upper respiratory tract infection</Indication><Indication>Urinary tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>atorvastatin alone</Intervention><Intervention>lipid modifying therapy alone</Intervention><Intervention>rosuvastatin alone</Intervention><Intervention>simvastatin alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>lipid modifying therapy alone</Intervention><Intervention>Variable regimens including alirocumab , atorvastatin , rosuvastatin , simvastatin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>316</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Greater number of injection site reactions were observed in patients receiving alirocumab. These patients had more reports of associated symptoms. Also, these patients had reactions of longer average duration than patients receiving placebo. Common &lt;b&gt;cold&lt;/b&gt; and flu or flu-like symptoms are the other common adverse events occurring more frequently in patients with alirocumab than placebo [ 1680323 ]. In September 2015, pooled analysis of ten phase III trials in the ODYSSEY program ( LONG TERM , FH I , </Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of lipid profiles - Low-density lipoprotein cholesterol (LDL-C) levels</EndpointIndex><EndpointIndex>Hypercholesterolemia - Assessment of Low-Density Lipoprotein (LDL)</EndpointIndex><EndpointIndex>Hypercholesterolemia - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Assessment of Low-Density Lipoprotein (LDL)</EndpointIndex><EndpointIndex>Lipid metabolism disorder - Assessment of lipid profiles</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ODYSSEY Combo I: Efficacy and Safety of Alirocumab (SAR-236553/REGN-727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia</TitleDisplay><PatientSegmentTerms><PatientSegment>Coronary artery disease - Subjects with High Cardiovascular Risk Profile - Hyperlipidemia/dyslipidemia</PatientSegment><PatientSegment>Coronary artery disease - Subjects with Stable Coronary Artery Disease</PatientSegment><PatientSegment>Hypercholesterolemia - Subjects with Primary Hypercholesterolemia</PatientSegment><PatientSegment>Hypercholesterolemia - Subjects with Risk Factors for Coronary Heart Disease</PatientSegment><PatientSegment>Hypercholesterolemia - Subjects with Risk Factors for Coronary Heart Disease - Subjects with past or present history of coronary heart disease</PatientSegment><PatientSegment>Lipid metabolism disorder - Subjects with Primary Hypercholesterolemia</PatientSegment><PatientSegment>Lipid metabolism disorder - Subjects with Risk Factors for Coronary Heart Disease(CHD)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Apolipoprotein A-I </BiomarkerName><BiomarkerName> Apolipoprotein B-100 </BiomarkerName><BiomarkerName> Apolipoprotein(a) </BiomarkerName><BiomarkerName> Conserved oligomeric Golgi complex subunit 2 </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Lipoproteins </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Non-high density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides </BiomarkerName><BiomarkerName> Urea nitrogen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>75</NumberOfSites><ContactNames><Name>Clinical Sciences &amp; Operations</Name></ContactNames></Trial><Trial Id="89149"><Indications><Indication>Perennial allergic rhinitis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Leukotriene D4 antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Histamine H1 receptor antagonist</Action><Action>Leukotriene D4 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Daily dosing</Technology><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hanmi Pharmaceutical Co Ltd</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2018-07-13T00:00:00Z</DateChangeLast><DateEnd>2013-02-28T00:00:00Z</DateEnd><DateStart>2012-06-30T00:00:00Z</DateStart><Identifiers><Identifier>HM-MOLZ-301</Identifier><Identifier>KCT0000484</Identifier><Identifier>MOLZ</Identifier><Identifier>NCT01640535</Identifier></Identifiers><InterventionsControlDisplay><Intervention>levocetrizine alone</Intervention><Intervention>montelukast sodium alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>levocetirizine plus montelukast sodium</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>283</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>anomaly History of acute, chronic sinusitis within 30 days of visit 1 History of intranasal/eye surgeries within 3 months of visit 1 Initiation of immunotherapy or dose modification within 1 month prior to visit 1 Upper respiratory infections including &lt;b&gt;cold&lt;/b&gt; and systemic infections within 3 weeks of visit 1 Chronic use of tricyclic antidepressants, beta agonists, bronchodilators, etc, that may affect the efficacy of study drug At visit 2, patients who recorded Daytime Nasal Symptom Scores for fewer than</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Assessment of daytime symptom score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Assessment of night time symptom score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>MOLZ: Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Perennial Allergic Rhinitis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Kyungmi Park</Name><Name>Minsook Jung</Name><Name>Yoan Park</Name></ContactNames></Trial><Trial Id="88355"><Indications><Indication>Idiopathic pulmonary fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CSF-1 antagonist</Action><Action>FGF receptor antagonist</Action><Action>FGF1 receptor antagonist</Action><Action>FGF2 receptor antagonist</Action><Action>FGF3 receptor antagonist</Action><Action>Flt3 tyrosine kinase inhibitor</Action><Action>Lck tyrosine kinase inhibitor</Action><Action>Lyn tyrosine kinase inhibitor</Action><Action>PDGF receptor alpha antagonist</Action><Action>PDGF receptor antagonist</Action><Action>PDGF receptor beta antagonist</Action><Action>Src tyrosine kinase inhibitor</Action><Action>VEGF receptor antagonist</Action><Action>VEGF-1 receptor antagonist</Action><Action>VEGF-2 receptor antagonist</Action><Action>VEGF-3 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Fibrosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Immuno-oncology</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Boehringer Ingelheim International GmbH</Company></CompaniesSponsor><Countries><Country>Czech Republic</Country><Country>UK</Country><Country>Israel</Country><Country>Spain</Country><Country>China</Country><Country>Ireland</Country><Country>Germany</Country><Country>South Korea</Country><Country>Turkey</Country><Country>Australia</Country><Country>Canada</Country><Country>Russian Federation</Country><Country>Chile</Country><Country>Italy</Country><Country>Portugal</Country><Country>France</Country><Country>US</Country><Country>Belgium</Country><Country>Netherlands</Country><Country>Mexico</Country><Country>India</Country><Country>Greece</Country><Country>Japan</Country><Country>Finland</Country></Countries><DateChangeLast>2019-05-21T00:00:00Z</DateChangeLast><DateEnd>2019-07-31T00:00:00Z</DateEnd><DateStart>2012-06-06T00:00:00Z</DateStart><Identifiers><Identifier>1199.33</Identifier><Identifier>2011-002766-21</Identifier><Identifier>CTRI/2013/01/003290</Identifier><Identifier>INPULSIS-ON</Identifier><Identifier>JapicCTI-121989</Identifier><Identifier>NCT01619085</Identifier><Identifier>UKCRN 12148</Identifier></Identifiers><IndicationsAdverse><Indication>Appetite loss</Indication><Indication>Bronchitis</Indication><Indication>Cough</Indication><Indication>Diarrhea</Indication><Indication>Dyspnea</Indication><Indication>Emesis</Indication><Indication>Nausea</Indication><Indication>Rhinopharyngitis</Indication><Indication>Weight loss</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>nintedanib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>752</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>-1120 were the most frequent AEs and leading to drug discontinuation in 5% (2.3 and 9.5% of patients continuing or initiating therapy, respectively) [ 1698764 ], [ 1700118 ]. In November 2015, results were presented. Diarrhea, nausea, cough, common &lt;b&gt;cold&lt;/b&gt; (nasopharyngitis), bronchitis, difficult or labored breathing (dyspnea), IPF disease progression, decreased appetite, weight decreased and vomiting were the most common adverse events. IPF was the most frequent serious adverse event reported which </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Laboratory/Diagnostic Measures - Assessment of blood biochemistry</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of Renal Function</EndpointIndex><EndpointIndex>Interstitial lung disease - Assessment of adverse events</EndpointIndex><EndpointIndex>Interstitial lung disease - Clinical Assessments - Assessment of liver function</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>INPULSIS-ON: Extension Trial of the Long-term Safety of BIBF-1120 in Patients With Idiopathic Pulmonary Fibrosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Interstitial lung disease - Subjects with Idiopathic Interstitial Lung Disease - Subjects with Idiopathic Pulmonary Fibrosis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Pancreatic alpha-amylase </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-07-05T00:00:00Z</PrimaryCompletionDate><TrialDuration>85 Months</TrialDuration><NumberOfSites>192</NumberOfSites><ContactNames><Name>Aloke Ghosal</Name><Name>Anand Pendse</Name><Name>Ashish Kumar</Name><Name>Boehringer Ingelheim</Name><Name>Mahendra Kawedia</Name><Name>Parag Khatavkar</Name><Name>Partha Gokhale</Name><Name>Parthiv Mehta</Name><Name>QRPE PSC CT Information Disclosure</Name><Name>Sathish Shivappa</Name><Name>Virendra Singh</Name></ContactNames></Trial><Trial Id="88056"><Indications><Indication>Multiple sclerosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cannabinoid CB1 receptor modulator</Action><Action>Cannabinoid CB2 receptor modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticancer</Action><Action>Muscle relaxant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Drug combination</Technology><Technology>Formulation aerosol</Technology><Technology>Natural product</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>GW Pharmaceuticals plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2014-03-05T00:00:00Z</DateChangeLast><DateEnd>2005-02-28T00:00:00Z</DateEnd><DateStart>2001-07-31T00:00:00Z</DateStart><Identifiers><Identifier>GWMS0001 EXT</Identifier><Identifier>NCT01610687</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Dizziness</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>nabiximols, GW Pharmaceuticals alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>137</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>improvements recorded and dosage taken remained stable. In 25 patients (of 62 approached) planned, sudden interruption of CBM for two weeks did not cause a consistent withdrawal syndrome, although at least one of--tiredness, interrupted sleep, hot and &lt;b&gt;cold&lt;/b&gt; flushes, mood alteration, reduced appetite, emotional lability, intoxication or vivid dreams was reported by11 (46%) patients [ 1531549 ]</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of Pain - Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of Spasticity</EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of Urodynamics</EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of adverse events</EndpointIndex><EndpointIndex>Multiple sclerosis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Multiple sclerosis - Subjects with Primary Progressive Multiple Sclerosis (PPMS)</PatientSegment><PatientSegment>Multiple sclerosis - Subjects with Progressive Relapsing Multiple Sclerosis (PRMS)</PatientSegment><PatientSegment>Multiple sclerosis - Subjects with Relapsing Remitting Multiple Sclerosis (RRMS)</PatientSegment><PatientSegment>Multiple sclerosis - Subjects with Secondary Progressive Multiple Sclerosis (SPMS)</PatientSegment><PatientSegment>Multiple sclerosis - Subjects with Symptomatic Disease</PatientSegment><PatientSegment>Multiple sclerosis - Subjects with Symptomatic Disease - Subjects with spasticity</PatientSegment><PatientSegment>Multiple sclerosis - Subjects with Symptomatic Disease - Subjects with urinary bladder dysfunction</PatientSegment><PatientSegment>Pain - Subjects with Acute Pain</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2005-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>43 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Derick Wade, FRCP MD</Name></ContactNames></Trial><Trial Id="87326"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Novartis AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Centre Hospitalier Universitaire D Amiens</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2018-06-09T00:00:00Z</DateChangeLast><DateEnd>2017-05-31T00:00:00Z</DateEnd><DateStart>2012-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2011-001385-18</Identifier><Identifier>CIME</Identifier><Identifier>NCT01595984</Identifier><Identifier>PI10-PR-CHOUKROUN</Identifier></Identifiers><InterventionsControlDisplay><Intervention>ciclosporin, Novartis plus enteric-coated mycophenolate sodium, Novartis</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>enteric-coated mycophenolate sodium, Novartis plus everolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Patient receiving a kidney from a heart attack donor, or an ABO incompatible donor or a donor with a positive T-cross match Patient with a maximum PRA&gt; 20% twice &lt;b&gt;Cold&lt;/b&gt; ischemic time&gt; 36 h Patients with thrombocytopenia (&amp;lt; 75,000/mm3), neutropenia (&amp;lt; 1500/mm3), leukopenia (&amp;lt; 2500/mm3) or a hemoglobin concentration &amp;lt; 8 g/dl, at inclusion visit Patient with severe hyperlipidemia: total cholesterol &gt;/= 9 mmol/l (&gt;/= 3.50</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>CIME: Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI) Versus a CNI-free Treatment in Renal Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living related donor (LRD) - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living unrelated donor - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2017-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>60 Months</TrialDuration><NumberOfSites>2</NumberOfSites></Trial><Trial Id="87068"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Bronchodilator</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Drug combination</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Italy</Country><Country>Poland</Country></Countries><DateChangeLast>2012-05-07T00:00:00Z</DateChangeLast><DateStart>2001-01-15T00:00:00Z</DateStart><Identifiers><Identifier>SCO30002</Identifier><Identifier>SFCT01</Identifier></Identifiers><IndicationsAdverse><Indication>Bronchitis</Indication><Indication>Candida infection</Indication><Indication>Common cold</Indication><Indication>Influenza virus infection</Indication><Indication>Rhinitis</Indication><Indication>Sinusitis</Indication><Indication>Tracheitis</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>fluticasone propionate alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>387</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>Safety results showed that adverse events (AEs) were reported in 55, 56 and 48% of patients from the SFC, FP and placebo groups, respectively. The most commonly reported AEs were COPD exacerbation (79, 72 and 59%), influenzal syndrome (3, 2 and 2%), &lt;b&gt;cold&lt;/b&gt; (3, 2 and 2%), rhinitis (2, 3 and &amp;lt; 1%), bronchitis (2, 2 and 2%), tracheitis (2, 0 and 0%), oral candidiasis (2, &amp;lt; 1 and &amp;lt; 1%), and sinusitis (2, 0 and 2%), in the respective groups. Treatment-related non-fatal or fatal serious AEs (SAEs)</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A phase III, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to assess the safety and efficacy of fluticasone propionate/salmeterol combination 500/50 microg bid compared to fluticasone propionate 500 microg bid in the treatment of chronic obstructive pulmonary disease (COPD)</TitleDisplay><BiomarkerNames><BiomarkerName>Forced expiratory volume </BiomarkerName><BiomarkerName> Peak expiratory flow rate </BiomarkerName><BiomarkerName> Vital capacity</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>2</NumberOfSites></Trial><Trial Id="86988"><ActionsSecondaryInterventionsPrimary><Action>Inactivated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Subunit vaccine</Action><Action>Toxoid vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Injectable emulsion</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><CompaniesSponsor><Company>Merck &amp; Co Inc</Company></CompaniesSponsor><Countries><Country>Taiwan</Country></Countries><DateChangeLast>2017-08-09T00:00:00Z</DateChangeLast><DateEnd>2003-08-31T00:00:00Z</DateEnd><DateStart>2002-03-31T00:00:00Z</DateStart><Identifiers><Identifier>001-02</Identifier><Identifier>2004_079</Identifier><Identifier>NCT00092469</Identifier><Identifier>V441-001</Identifier></Identifiers><IndicationsAdverse><Indication>Candida infection</Indication><Indication>Common cold</Indication><Indication>Fever</Indication><Indication>Gastroenteritis</Indication><Indication>Pediatric varicella zoster virus infection</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Hexavac alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>151</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> of all systemic AEs was mostly mild and transient with the most prevalent AE being fever, followed by the second most prevalent AE of infections. Upper respiratory tract infection was the most common event observed with other events such as common &lt;b&gt;cold&lt;/b&gt;, chicken pox, and candidiasis. The most affected system in all reported AEs was body as a whole (fever and infection) followed by digestive system (gastroenteritis). Approximately 48% of the reported systemic AEs (89/184 events) were diagnosed as drug-related</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Seroprotection Status - Subjects with anti-diphtheria antibody seroprotection</EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Seroprotection Status - Subjects with anti-hepatitis B antibody seroprotection</EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Seroprotection Status - Subjects with anti-pertussis antibody seroprotection (PT)</EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Seroprotection Status - Subjects with anti-polio virus antibody seroprotection</EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Seroprotection Status - Subjects with anti-polyribosyl-ribitol-phosphate antibody seroprotection (PRP)</EndpointIndex><EndpointIndex>DTP Vaccine - Assessment of Seroprotection Status - Subjects with anti-tetanus antibody seroprotection</EndpointIndex><EndpointIndex>Hepatitis B Vaccine - Assessment of Immune Response - Anti-hepatitis B antibody titers</EndpointIndex><EndpointIndex>Hepatitis B Vaccine - Assessment of Immune Response - Immunogenic response to other antigens</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Immune Response - Anti-hepatitis B antibody titers</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Immune Response - Immunogenic response to other antigens</EndpointIndex><EndpointIndex>Polio Vaccine - Assessment of Immune Response - Assessment of anti-polio antibody concentration</EndpointIndex><EndpointIndex>Polio Vaccine - Assessment of Immune Response - Immunogenic response to other antigens</EndpointIndex><EndpointIndex>Polio Vaccine - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Newborn Infants (up to 5 months)</Term></TermsPatientSelection><TitleDisplay>Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)</TitleDisplay><PatientSegmentTerms><PatientSegment>DTP Vaccine - Subjects with Prior Other Vaccination - Subjects with prior hepatitis B vaccination(HBV)</PatientSegment><PatientSegment>Polio Vaccine - Subjects with Prior Other Vaccination</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2003-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Medical Monitor</Name></ContactNames></Trial><Trial Id="86920"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Isotechnika Pharma Inc</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-03-07T00:00:00Z</DateChangeLast><DateStart>2013-03-31T00:00:00Z</DateStart><Identifiers><Identifier>CTR20130372</Identifier><Identifier>INSPIRE</Identifier><Identifier>ISA10-12</Identifier><Identifier>NCT01586845</Identifier></Identifiers><InterventionsControlDisplay><Intervention>tacrolimus alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>voclosporin alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>, HBV, HCV or tuberculosis Subjects receiving a a kidney from a non-heart beating donor Subjects receiving paired (en bloc or paired) kidney transplants Transplantation of multiple grafts (eg, kidney and pancreas) Subjects receiving a kidney with a &lt;b&gt;cold&lt;/b&gt; ischemia time&gt; 30 h Subjects receiving any transplanted organ other than a kidney Recipients of a bone marrow or stem cell transplant Any systemic infections requiring continued therapy at the time of entry into this study (prophylaxis against CMV </Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>INSPIRE: Safety and Efficacy Study of Voclosporin and Tacrolimus in Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2015-12-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chen</Name></ContactNames></Trial><Trial Id="86462"><Indications><Indication>Cryopyrin associated periodic syndrome</Indication><Indication>Familial cold autoinflammatory syndrome</Indication><Indication>Muckle Wells syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin G1 agonist</Action><Action>Interleukin-1 beta ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action><Action>Cardioprotectant</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>DNA technology</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intra-articular formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>France</Country><Country>Germany</Country><Country>Spain</Country><Country>Belgium</Country><Country>Switzerland</Country><Country>UK</Country></Countries><DateChangeLast>2019-06-18T00:00:00Z</DateChangeLast><DateEnd>2015-10-13T00:00:00Z</DateEnd><DateStart>2012-01-16T00:00:00Z</DateStart><Identifiers><Identifier>2011-005154-57</Identifier><Identifier>CACZ885D2307E1</Identifier><Identifier>D2307E1</Identifier><Identifier>NCT01576367</Identifier></Identifiers><IndicationsAdverse><Indication>Bronchitis</Indication><Indication>Cough</Indication><Indication>Dermatological disease</Indication><Indication>Diarrhea</Indication><Indication>Ear disease</Indication><Indication>Emesis</Indication><Indication>Fever</Indication><Indication>Gastroenteritis</Indication><Indication>Gastrointestinal disease</Indication><Indication>Headache</Indication><Indication>Infectious disease</Indication><Indication>Injury</Indication><Indication>Molluscum contagiosum infection</Indication><Indication>Ocular disease</Indication><Indication>Pneumonia</Indication><Indication>Poison intoxication</Indication><Indication>Respiratory disorder</Indication><Indication>Rhinitis</Indication><Indication>Rhinopharyngitis</Indication><Indication>Upper respiratory tract infection</Indication><Indication>Vascular disease</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>canakinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>17</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> In June 2016, results were presented. Out of 17 patients included, 12, 4, and 1 were found to be of muckle-wells syndrome (MWS), neonatal-onset multisystem inflammatory disease (NOMID), and familial &lt;b&gt;cold&lt;/b&gt; auto-inflammatory syndrome (FCAS) phenotypes, respectively. A total of 14 patients completed the study. Due to lack of therapeutic effect, two patients discontinued. By end of study (EOS), a total of 15 attained complete response (88.2%) at week 80</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other genetic disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other genetic disease - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Immune Response</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other neurological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other neurological disease - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Urticaria - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Urticaria - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Urticaria - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Urticaria - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Urticaria - Assessment of Therapy Related Outcomes - Assessment of change in the overall condition of urticaria</EndpointIndex><EndpointIndex>Urticaria - Assessment of Therapy Related Outcomes - Assessment of other efficacy parameters</EndpointIndex><EndpointIndex>Urticaria - Assessment of Therapy Related Outcomes - Overall therapeutic response</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy, Safety and Tolerability of ACZ-885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Other genetic disease - Subjects with specific disease</PatientSegment><PatientSegment>Other neurological disease - Others - Children and adolescents</PatientSegment><PatientSegment>Urticaria - Subjects with Cold Contact Urticaria (CCU)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Serum amyloid A protein 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-10-13T00:00:00Z</PrimaryCompletionDate><TrialDuration>44 Months</TrialDuration><NumberOfSites>17</NumberOfSites><ContactNames><Name>Clinical Trial Information Desk</Name><Name>Information&amp;Communication Médicale</Name><Name>Inma Bosch</Name><Name>Medical Information Services</Name><Name>Medizinischer Infoservice</Name><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="86381"><Indications><Indication>Herpes simplex virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action><Action>Glucocorticoid receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>HSV replication inhibitor</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Drug combination</Technology><Technology>Emulsion dermatological</Technology><Technology>Nucleoside synthesis</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesCollaborator><Company>TKL Research Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Meda Pharmaceuticals Ltd</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-04-10T00:00:00Z</DateChangeLast><DateEnd>2013-02-01T00:00:00Z</DateEnd><DateStart>2012-03-31T00:00:00Z</DateStart><Identifiers><Identifier>MP 800</Identifier><Identifier>NCT01574612</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>aciclovir + hydrocortisone (dermatological), Medivir alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>54</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> The purpose of this study was to test the safety of Xerese (acyclovir + hydrocortisone) cream 5/1% for the treatment of recurrent &lt;b&gt;cold&lt;/b&gt; sores in children ages 6 to 11 years after 5 days of treatment.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>An Open-label, Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6 to 11 Years Old</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>10</NumberOfSites><ContactNames><Name>Caroline Giullo</Name><Name>Claudia Cisneros</Name><Name>David Ginsburg, D.O.</Name><Name>Ellen Frankel</Name><Name>James Borders</Name><Name>Karen Hanna</Name><Name>Matthew Davis</Name><Name>Pierre Blemur</Name><Name>Robert Ford</Name><Name>Theresa Dayton</Name></ContactNames></Trial><Trial Id="8620"><Indications><Indication>Adult varicella zoster virus infection</Indication><Indication>Diabetic neuropathy</Indication><Indication>Neuropathic pain</Indication><Indication>Postherpetic neuralgia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Patch formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Grunenthal GmbH</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-07-03T00:00:00Z</DateChangeLast><DateEnd>2008-03-31T00:00:00Z</DateEnd><DateStart>2006-12-31T00:00:00Z</DateStart><Identifiers><Identifier>796838</Identifier><Identifier>NCT00414349</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lidocaine transdermal patch (PHN/pain), Endo/Teikoku/Grunenthal alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>350</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>sensomotor polyneurpathy of the lower extremities for&gt;/= 3 months (below the knees on both extremities) with at least 2 of the following symptoms present: burning, sensation, tingling or prickling, numbness from time to time, painful heat or &lt;b&gt;cold&lt;/b&gt; sensation (eg, warm or &lt;b&gt;cold&lt;/b&gt; water) Subjects with PHN and neuropathic pain present for&gt;/= 3 months after healing of the herpes zoster skin rash Without neurolytic neurosurgical therapy for their condition</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Pain - Assessment of Pain Intensity</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Post Herpetic Neuralgia</EndpointIndex><EndpointIndex>Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy and safety of topical versus systemic treatment in post-herpetic neuralgia and diabetic poly-neuropathic pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy - Subjects with diabetic neuropathic pain</PatientSegment><PatientSegment>Herpesvirus infection - Subjects with Varicella Zoster Virus Infections - Subjects with shingles/herpes zoster</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Good Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with Poor/Inadequate Glycemic Control</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic neuropathy</PatientSegment><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain - Subjects with diabetic neuropathy</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain - Subjects with post herpetic neuralgia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2008-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ralf Baron</Name><Name>Ralf Baron, Prof. Dr.</Name></ContactNames></Trial><Trial Id="85802"><Indications><Indication>Fibromyalgia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Histamine H1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Ocular antihistamine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Controlled release formulation</Technology><Technology>Ophthalmic formulation</Technology><Technology>Ophthalmic liquid formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Indiana University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2016-12-21T00:00:00Z</DateChangeLast><DateEnd>2012-12-31T00:00:00Z</DateEnd><DateStart>2012-03-31T00:00:00Z</DateStart><Identifiers><Identifier>1106005839 (1106-01)</Identifier><Identifier>KetoforFMS</Identifier><Identifier>NCT01553318</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ketotifen alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>51</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>medication that effects the central nervous system, eg, benzodiazepines, sedative/hypnotic, etc) during the 10-week study period unless medically necessary Must report all medication including herbal supplements and over-the-counter medications, eg, &lt;b&gt;cold&lt;/b&gt; medication, eye drops, etc, that he/she is currently taking to a member of the research team Must be willing to maintain a medication diary provided to him/her during the 10-week study period Must be willing to abstain any fibromyalgia related medication</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function - Assessment by Fibromyalgia Impact Questionnaire (FIQ)</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Musculoskeletal Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment of pain threshold</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>KetoforFMS: Novel Use of (Oral) Ketotifen for the Treatment of Fibromyalgia: A Pilot Study</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with fibromyalgia</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-C motif chemokine 2 </BiomarkerName><BiomarkerName> Eotaxin </BiomarkerName><BiomarkerName> Interleukin-8</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dennis C. Ang, MD</Name><Name>Janna Hilligoss</Name><Name>Melody Strickling</Name></ContactNames></Trial><Trial Id="8552"><Indications><Indication>Peripheral vascular disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Albumin modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Cardiovascular diagnostic agent</Action><Action>Endocrine diagnostic agent</Action><Action>MRI imaging agent</Action><Action>Neoplasm diagnostic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Imaging</Technology><Technology>Intravenous formulation</Technology></Technologies><CompaniesCollaborator><Company>Bayer Schering Pharma AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>EPIX Pharmaceuticals Inc</Company></CompaniesSponsor><DateChangeLast>2008-03-18T00:00:00Z</DateChangeLast><DateEnd>2003-07-10T00:00:00Z</DateEnd><DateStart>2002-07-25T00:00:00Z</DateStart><IndicationsAdverse><Indication>Paresthesia</Indication><Indication>Taste disorder</Indication><Indication>Temperature disorder</Indication><Indication>Xerostomia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>gadofosveset alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>96</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Adverse events possibly or probably related to gadofosveset were generally mild and transient. The most common adverse events were paresthesia (7.3%), taste perversion (4.2%) and flushing, dry mouth, and feeling &lt;b&gt;cold&lt;/b&gt;, (each 2.1%) [ 496607 ].</Teaser><TrialCategories><Category>Diagnostic</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Diagnosis</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A phase III study of gadofosveset for the detection of vascular disease in the pedal arteries</TitleDisplay><PrimaryCompletionDate/><TrialDuration>11 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Gregory Sorenson</Name></ContactNames></Trial><Trial Id="85409"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company><Company>Novartis Farmaceutica SA</Company><Company>Novartis Pharma Services AG</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>Norway</Country><Country>Brazil</Country><Country>Turkey</Country><Country>Argentina</Country><Country>Germany</Country><Country>France</Country><Country>Poland</Country><Country>Hungary</Country><Country>Sweden</Country><Country>US</Country><Country>Italy</Country><Country>Spain</Country><Country>Belgium</Country></Countries><DateChangeLast>2019-06-03T00:00:00Z</DateChangeLast><DateEnd>2018-09-24T00:00:00Z</DateEnd><DateStart>2012-08-17T00:00:00Z</DateStart><Identifiers><Identifier>2010-024381-21</Identifier><Identifier>CRAD001A2314</Identifier><Identifier>NCT01544491</Identifier><Identifier>P/006/2012</Identifier><Identifier>P/105/2011</Identifier><Identifier>P/105/2014</Identifier><Identifier>P/207/2010</Identifier></Identifiers><IndicationsAdverse><Indication>Infectious disease</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>steroid therapy alone</Intervention><Intervention>mycophenolate mofetil plus tacrolimus</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>everolimus plus tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>106</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> At baseline: Recipients of kidneys from donors with known renal disease (such as diabetes nephropathy, nephrosclerosis), at the time of transplant Recipients of a kidney with a &lt;b&gt;cold&lt;/b&gt; ischemia time&gt; 24 h History of hypersensitivity or contraindications to any of the study drugs or to drugs of similar chemical classes, or to any of the excipients History of malignancy of any organ system treated or untreated, carrying possible risk</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Incidence/number of AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Time to AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy, tolerability and safety of early introduction of everolimus, reduced calcineurin inhibitors and early steroid elimination compared to standard CNI, mycophenolate mofetil and steroid regimen in pediatric renal transplant recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Subjects Awaiting Renal Transplant</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body Mass Index </BiomarkerName><BiomarkerName> Body height </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Estradiol </BiomarkerName><BiomarkerName> Follicle-stimulating hormone </BiomarkerName><BiomarkerName> Inhibin B </BiomarkerName><BiomarkerName> Luteinizing Hormone </BiomarkerName><BiomarkerName> Testosterone </BiomarkerName><BiomarkerName> Thyroid-stimulating hormone </BiomarkerName><BiomarkerName> Thyroxine </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Triiodothyronine </BiomarkerName><BiomarkerName> Urinary protein </BiomarkerName><BiomarkerName> Urinary protein/Creatinine ratio</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-10-03T00:00:00Z</PrimaryCompletionDate><TrialDuration>73 Months</TrialDuration><NumberOfSites>40</NumberOfSites><ContactNames><Name>Departamento médico (ICRO)</Name><Name>Drug Regulatory Affairs</Name><Name>Information&amp;Communication Médicales</Name><Name>Medical Competence Center</Name><Name>Medical Information Servcies</Name><Name>Medical information</Name><Name>Medisinsk Informasjon</Name><Name>Novartis Pharmaceuticals</Name><Name>Public Information Desk</Name><Name>clinical Trial Information Desk</Name></ContactNames></Trial><Trial Id="85047"><Indications><Indication>Male hypogonadism</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Androgen receptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Estrogen receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Repros Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-06-30T00:00:00Z</DateChangeLast><DateEnd>2013-10-31T00:00:00Z</DateEnd><DateStart>2012-05-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT01534208</Identifier><Identifier>ZA-300</Identifier></Identifiers><IndicationsAdverse><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Muscle spasm</Indication><Indication>Thromboembolism</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>testosterone (MD-lotion), Eli Lilly/Acrux alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>enclomifene citrate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>499</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In September 2013, results showed that thromboembolism was the only SAE reported in one subject. As the study was conducted during the &lt;b&gt;cold&lt;/b&gt;, flu and allergy season the most common AEs were those related to the upper respiratory tract infections (11.6%). Headache (6.6%), muscle spasms (4%), and fatigue (2.8%) were the other AEs reported. Only 0.2% of men experienced changes in visual acuity but 1.4% of men experienced transient blurred vision. The drug was well-tolerated and there were no dose response</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hypogonadism - Anthropometric Assessments - Assessment of body weight</EndpointIndex><EndpointIndex>Hypogonadism - Assessment of FSH and/or LH Levels</EndpointIndex><EndpointIndex>Hypogonadism - Assessment of Hormone Levels - Assessment of testosterone levels</EndpointIndex><EndpointIndex>Hypogonadism - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Hypogonadism - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Hypogonadism - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Hypogonadism - Glycemic Control Analysis - Assessment of fasting blood glucose</EndpointIndex><EndpointIndex>Hypogonadism - Hematological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism</TitleDisplay><PatientSegmentTerms><PatientSegment>Hypogonadism - Subjects with Secondary Hypogonadism</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body Mass Index </BiomarkerName><BiomarkerName> Follicle-stimulating hormone </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Luteinizing Hormone </BiomarkerName><BiomarkerName> Testosterone</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>31</NumberOfSites><ContactNames><Name>Joseph S Podolski</Name><Name>Michele Rosner</Name></ContactNames></Trial><Trial Id="85018"><Indications><Indication>Premature labor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcium channel inhibitor L-type</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action><Action>Class IV antiarrhythmic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>MemorialCare Health System</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-03-07T00:00:00Z</DateChangeLast><DateEnd>2012-03-31T00:00:00Z</DateEnd><DateStart>2008-03-31T00:00:00Z</DateStart><Identifiers><Identifier>464-07</Identifier><Identifier>NCT00641784</Identifier></Identifiers><InterventionsControlDisplay><Intervention>magnesium sulfate alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>nifedipine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>This study was designed to contemporarily assess the efficacy of oral nifedipine versus iv magnesium sulfate in the acute management of preterm labor in women with singleton gestations, in terms of defined early and late neonatal measures.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Tocolytics Trial: intravenous (IV) Magnesium Versus Oral Nifedpine in Fetal Fibronectin (FFN) Postive Population</TitleDisplay><BiomarkerNames><BiomarkerName>Fibronectin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2012-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Kenneth Chan, MD</Name><Name>Vineet K Shrivastava, MD</Name></ContactNames></Trial><Trial Id="84951"><ActionsSecondaryInterventionsControl><Action>Anticancer</Action><Action>Cell cycle inhibitor</Action><Action>Microtubule inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action><Action>Cell cycle inhibitor</Action><Action>DNA synthesis inhibitor</Action><Action>Microtubule inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Natural product</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Danish Cancer Society</Company><Company>Eli Lilly &amp; Co</Company><Company>Herlev Hospital Region Hovedstaden</Company><Company>Sanofi SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>Danish Breast Cancer Cooperative Group</Company></CompaniesSponsor><DateChangeLast>2015-09-09T00:00:00Z</DateChangeLast><DateStart>2010-11-29T00:00:00Z</DateStart><IndicationsAdverse><Indication>Infectious disease</Indication><Indication>Neutropenia</Indication><Indication>Peripheral neuropathy</Indication><Indication>Thrombocytopenia</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>docetaxel alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including docetaxel , docetaxel + gemcitabine , gemcitabine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>337</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>This was a phase III, randomized study to compare safety and efficacy of gemcitabine plus docetaxel (GD) versus docetaxel in patients with predominantly human epidermal growth factor receptor (HER) 2-negative locally advanced or metastatic breast cancer [ 1262490 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Active Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A phase III, randomized study to compare safety and efficacy of gemcitabine plus docetaxel (GD) versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer</TitleDisplay><BiomarkerNames><BiomarkerName>Metalloproteinase inhibitor 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="84925"><Indications><Indication>Diabetic peripheral neuropathy</Indication><Indication>Neuropathic pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Vanilloid VR1 agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Patch formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-12-03T00:00:00Z</DateChangeLast><DateEnd>2014-02-28T00:00:00Z</DateEnd><DateStart>2012-02-29T00:00:00Z</DateStart><Identifiers><Identifier>E05-CL-3004</Identifier><Identifier>NCT01533428</Identifier><Identifier>STEP</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>capsaicin dermal patch, NeurogesX/Astellas/Acorda/Grunenthal alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>369</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>discontinuations due to drug-related TEAEs were reported [ 1694723 ]. In January 2017, results were published. Comparing two groups, except application site reactions all other treatment -emergent adverse events were similar. Sensory perception of sharp, &lt;b&gt;cold&lt;/b&gt;, warm, or vibration stimuli showed no indications of deterioration among groups [ 1900363 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Brief Pain Inventory (BPI)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Hospital Anxiety and Depression Scale (HADS)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Numeric Rating Scale for Pain</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Patient Global Impression of Change (PGIC)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - European quality of life instrument(EuroQol)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropathic Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Daily Pain Rating Scale (DPRS)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Euro Quality of Life (EQ-5D) Questionnaire</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Neuropathic pain scale score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>STEP: A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8% Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy - Subjects with diabetic polyneuropathy</PatientSegment><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>33</NumberOfSites><ContactNames><Name>Clinical Study Manager</Name></ContactNames></Trial><Trial Id="84352"><Indications><Indication>Asthma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-5 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>GlaxoSmithKline plc</Company><Company>The Netherlands Asthma Foundation</Company></CompaniesCollaborator><CompaniesSponsor><Company>Academic Medical Center, University of Amsterdam</Company></CompaniesSponsor><Countries><Country>Netherlands</Country></Countries><DateChangeLast>2019-03-14T00:00:00Z</DateChangeLast><DateEnd>2014-03-31T00:00:00Z</DateEnd><DateStart>2012-01-31T00:00:00Z</DateStart><Identifiers><Identifier>MATERIAL</Identifier><Identifier>MATERIAL</Identifier><Identifier>NCT01520051</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mepolizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>48</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aims of this mepolizumab study were to: To investigate whether interleukin(IL)-5 neutralization reduces the inflammatory response to viral airway infections in allergic asthma patients. To investigate whether IL-5 neutralization prevents or reduces asthma symptoms during virus-induced asthma exacerbations. To investigate whether IL-5 neutralization affects the cellular immune response to viral airway infections in allergic asthma patients. The hypothesis was that neutralization of IL-5 during</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Bronchial Biopsy/Bronchoalveolar Lavage (BAL) Markers - BAL fluid cell count</EndpointIndex><EndpointIndex>Asthma - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change in pre bronchodilator FEV1</EndpointIndex><EndpointIndex>Asthma - Assessment of Inflammatory &amp; Oxidative Stress Markers - Serum cytokines/interleukins/chemokines</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Asthma - Assessment of Laboratory/Diagnostic Measures - Antibody assays</EndpointIndex><EndpointIndex>Asthma - Patient Reported Outcomes/Quality of Life Assessments - Asthma control questionnaire (ACQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>MATERIAL: Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects at risk of developing disease - Ex-Smokers</PatientSegment><PatientSegment>Asthma - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for asthma drugs</PatientSegment><PatientSegment>Asthma - Subjects with Intermittent/Episodic Asthma</PatientSegment><PatientSegment>Asthma - Subjects with Persistent Asthma - Subjects with mild persistent asthma</PatientSegment><PatientSegment>Asthma - Subjects with Stable Asthma</PatientSegment><PatientSegment>Asthma - Subjects with Symptomatic Disease</PatientSegment><PatientSegment>Asthma - Subjects without Asthma Therapy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>B-lymphocytes </BiomarkerName><BiomarkerName> C-C motif chemokine 20 </BiomarkerName><BiomarkerName> Cytokines </BiomarkerName><BiomarkerName> Eosinophils </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Fractional concentration of exhaled nitric oxide </BiomarkerName><BiomarkerName> Immunoglobulin A </BiomarkerName><BiomarkerName> Interferon gamma </BiomarkerName><BiomarkerName> Interleukin-1 receptor antagonist protein </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Interleukin-8 </BiomarkerName><BiomarkerName> Macrophages </BiomarkerName><BiomarkerName> Monocytes </BiomarkerName><BiomarkerName> Natural killer cells </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> T-lymphocytes </BiomarkerName><BiomarkerName> Tryptase </BiomarkerName><BiomarkerName> Vascular endothelial growth factor A</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2013-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Elisabeth H Bel, MD, PhD</Name><Name>Koenraad F van der Sluijs, PhD</Name><Name>Peter J Sterk, PhD</Name><Name>René Lutter, PhD</Name><Name>Suzanne M Bal, PhD</Name></ContactNames></Trial><Trial Id="83614"><Indications><Indication>Chemotherapy induced nausea and vomiting</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>5-HT 3 receptor antagonist</Action><Action>NK1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-emetic</Action><Action>Antidepressant</Action><Action>Antitussive</Action><Action>Anxiolytic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>TESARO Inc</Company></CompaniesSponsor><Countries><Country>Italy</Country><Country>Ecuador</Country><Country>Hungary</Country><Country>South Africa</Country><Country>Malaysia</Country><Country>Mexico</Country><Country>South Korea</Country><Country>Georgia</Country><Country>Ukraine</Country><Country>Czech Republic</Country><Country>Brazil</Country><Country>Slovakia</Country><Country>Poland</Country><Country>Taiwan</Country><Country>Spain</Country><Country>US</Country></Countries><DateChangeLast>2018-03-21T00:00:00Z</DateChangeLast><DateEnd>2014-03-31T00:00:00Z</DateEnd><DateStart>2012-02-29T00:00:00Z</DateStart><Identifiers><Identifier>2010-022743-37</Identifier><Identifier>HEC2</Identifier><Identifier>NCT01500213</Identifier><Identifier>TS-P04833</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Anemia</Indication><Indication>Constipation</Indication><Indication>Dyspepsia</Indication><Indication>Febrile neutropenia</Indication><Indication>Headache</Indication><Indication>Leukopenia</Indication><Indication>Neutropenia</Indication><Indication>Thrombocytopenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Variable regimens including dexamethasone , granisetron , placebo + granisetron + dexamethasone , rolapitant (oral), TESARO , rolapitant + granisetron + dexamethasone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>555</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a phase III, multicenter, randomized, parallel-group, double-blind, active-controlled study of rolapitant in patient receiving highly emetogenic chemotherapy (HEC) [ 1745904 ]. Main objective of the trial was to determine whether administration of rolapitant with granisetron and dexamethasone improves CINV in the delayed phase (&gt; 24 to 120 h) of CINV compared with administration of placebo with granisetron and dexamethasone in patients receiving HEC. The primary outcome would be based on</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Nausea and Vomiting</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of adverse events</EndpointIndex><EndpointIndex>Cancer supportive care - Protocol Specified Other Endpoints - Assessment of Other Treatment or Procedure Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>HEC2: Phase III, Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Nausea and Vomiting</PatientSegment><PatientSegment>Cancer supportive care - Nausea and Vomiting - Highly emetic chemotherapy</PatientSegment><PatientSegment>Cancer supportive care - Other Chemotherapy Induced Adverse Events</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Urea nitrogen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>25 Months</TrialDuration><NumberOfSites>17</NumberOfSites><ContactNames><Name>Dennis Vargo, MD</Name><Name>Heidi Pryor</Name><Name>Ira Oliff</Name><Name>Joy Jardincino</Name><Name>Lorraine Hughes</Name><Name>Project Manager</Name><Name>Rupal Kalapanda</Name></ContactNames></Trial><Trial Id="83613"><Indications><Indication>Chemotherapy induced nausea and vomiting</Indication></Indications><ActionsPrimaryInterventionsControl><Action>5-HT 3 receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>5-HT 3 receptor antagonist</Action><Action>NK1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-emetic</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-emetic</Action><Action>Antidepressant</Action><Action>Antitussive</Action><Action>Anxiolytic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>TESARO Inc</Company></CompaniesSponsor><Countries><Country>Ukraine</Country><Country>Belarus</Country><Country>Spain</Country><Country>Portugal</Country><Country>Italy</Country><Country>Ecuador</Country><Country>Czech Republic</Country><Country>Mexico</Country><Country>Puerto Rico</Country><Country>South Korea</Country><Country>Taiwan</Country><Country>Bulgaria</Country><Country>Hong Kong</Country><Country>Argentina</Country><Country>Romania</Country><Country>Russian Federation</Country><Country>Brazil</Country><Country>Hungary</Country><Country>Belgium</Country><Country>Peru</Country><Country>Latvia</Country><Country>South Africa</Country><Country>France</Country><Country>US</Country><Country>Poland</Country><Country>Slovakia</Country><Country>Chile</Country><Country>Georgia</Country></Countries><DateChangeLast>2019-01-23T00:00:00Z</DateChangeLast><DateEnd>2014-02-28T00:00:00Z</DateEnd><DateStart>2012-02-29T00:00:00Z</DateStart><Identifiers><Identifier>2010-022746-24</Identifier><Identifier>NCT01500226</Identifier><Identifier>TS-P04834</Identifier></Identifiers><IndicationsAdverse><Indication>Anemia</Indication><Indication>Appetite loss</Indication><Indication>Constipation</Indication><Indication>Dizziness</Indication><Indication>Dyspepsia</Indication><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Neutropenia</Indication><Indication>Stomatitis</Indication><Indication>Urinary tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>dexamethasone plus granisetron</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including dexamethasone , granisetron , rolapitant (oral), TESARO</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1369</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a phase III, multicenter, randomized, parallel-group, double-blind, active-controlled study of rolapitant in patients receiving moderately emetogenic chemotherapy (MEC). Rolapitant or placebo would be administered orally 1 to 2 h prior to the initiation of chemotherapy on day 1 [ 1279872 ], [ 1745904 ]. The primary objective of the study was: To determine whether administration of rolapitant with granisetron and dexamethasone improves CINV in the delayed phase (&gt; 24 to 120 h) of CINV</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Nausea and Vomiting</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of adverse events</EndpointIndex><EndpointIndex>Cancer supportive care - Protocol Specified Other Endpoints - Assessment of Other Treatment or Procedure Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Phase III, Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Nausea and Vomiting</PatientSegment><PatientSegment>Cancer supportive care - Other Chemotherapy Induced Adverse Events</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> Urea nitrogen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>29</NumberOfSites><ContactNames><Name>Dennis Vargo, MD</Name><Name>Heidi Pryor</Name><Name>Ira Oliff</Name><Name>Joy Jardincino</Name><Name>Lorraine Hughes</Name><Name>Project Manager</Name><Name>Project Manger</Name><Name>Rupal Kalapanda</Name></ContactNames></Trial><Trial Id="83578"><Indications><Indication>Chemotherapy induced nausea and vomiting</Indication></Indications><ActionsPrimaryInterventionsControl><Action>5-HT 3 receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>5-HT 3 receptor antagonist</Action><Action>NK1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-emetic</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-emetic</Action><Action>Antidepressant</Action><Action>Antitussive</Action><Action>Anxiolytic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Pharm Olam de México, S. de R.L. de C.V.</Company></CompaniesCollaborator><CompaniesSponsor><Company>TESARO Inc</Company></CompaniesSponsor><Countries><Country>Hong Kong</Country><Country>Chile</Country><Country>Thailand</Country><Country>Puerto Rico</Country><Country>Philippines</Country><Country>Canada</Country><Country>Portugal</Country><Country>Bulgaria</Country><Country>Argentina</Country><Country>Italy</Country><Country>Spain</Country><Country>Romania</Country><Country>Peru</Country><Country>Latvia</Country><Country>Belgium</Country><Country>Russian Federation</Country><Country>US</Country><Country>Hungary</Country><Country>Mexico</Country><Country>Belarus</Country><Country>France</Country><Country>Guatemala</Country></Countries><DateChangeLast>2018-03-21T00:00:00Z</DateChangeLast><DateEnd>2014-05-31T00:00:00Z</DateEnd><DateStart>2012-02-29T00:00:00Z</DateStart><Identifiers><Identifier>2010-022742-25</Identifier><Identifier>HEC1</Identifier><Identifier>NCT01499849</Identifier><Identifier>TS-P04832</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Anemia</Indication><Indication>Constipation</Indication><Indication>Dyspepsia</Indication><Indication>Headache</Indication><Indication>Leukopenia</Indication><Indication>Neutropenia</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>dexamethasone plus granisetron</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including dexamethasone , granisetron , placebo + granisetron + dexamethasone , rolapitant (oral), TESARO , rolapitant + granisetron + dexamethasone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>532</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a phase III, multicenter, randomized, parallel-group, double-blind, active-controlled study of rolapitant in patients receiving HEC. Rolapitant or placebo would be administered prior to initiation of chemotherapy on day 1 with granisetron and dexamethasone. Patients would record all events of emesis and use of rescue medication for established nausea and/or vomiting, and would indicate the severity of nausea they experienced in each of the previous 24 h in the Nausea and Vomiting (NV</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Nausea and Vomiting</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of adverse events</EndpointIndex><EndpointIndex>Cancer supportive care - Protocol Specified Other Endpoints - Assessment of Other Treatment or Procedure Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>HEC1: Phase III, Safety and Efficacy Study of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy</TitleDisplay><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Urea nitrogen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>27 Months</TrialDuration><NumberOfSites>44</NumberOfSites><ContactNames><Name>Dennis Vargo, MD</Name><Name>Heidi Pryor</Name><Name>Lorraine Hughes</Name><Name>Lynnann Waggoner</Name><Name>Project Manager</Name><Name>Ricardo Uribe</Name><Name>Rupal Kalapanda</Name></ContactNames></Trial><Trial Id="8286"><Indications><Indication>Seizure disorder</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticonvulsant agent</Action><Action>Antidepressant</Action><Action>Glutamate release inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Europe</Country><Country>Australia</Country><Country>US</Country></Countries><DateChangeLast>2014-01-17T00:00:00Z</DateChangeLast><DateStart>1997-12-31T00:00:00Z</DateStart><Identifiers><Identifier>105-123</Identifier></Identifiers><IndicationsAdverse><Indication>Common cold</Indication><Indication>Viral infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>lamotrigine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>169</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This was a randomized, double-blind, placebo-controlled study of lamotrigine in children and young adults with Lennox-Gastaut syndrome [ 438112 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Epilepsy - Assessment of Epilepsy Syndromes</EndpointIndex><EndpointIndex>Epilepsy - Assessment of Generalized Seizures</EndpointIndex><EndpointIndex>Epilepsy - Assessment of Response Rates (RR) - Assessment of response rate</EndpointIndex><EndpointIndex>Epilepsy - Assessment of Seizure Activity</EndpointIndex><EndpointIndex>Epilepsy - Assessment of Seizure Activity - Assessment of seizure frequency</EndpointIndex><EndpointIndex>Epilepsy - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Epilepsy - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Lennox-Gastaut Quality of Life Questionnaire</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>A randomized, double-blind, placebo-controlled study of lamotrigine in children and young adults with Lennox-Gastaut syndrome</TitleDisplay><PatientSegmentTerms><PatientSegment>Epilepsy - Subjects with Lennox-Gastaut Syndrome</PatientSegment><PatientSegment>Epilepsy - Subjects with Primarily Generalized Seizures - Subjects with absence seizures</PatientSegment><PatientSegment>Epilepsy - Subjects with Primarily Generalized Seizures - Subjects with tonic-clonic seizures</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>2</NumberOfSites></Trial><Trial Id="82638"><Indications><Indication>Neuropathic pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Vanilloid VR1 agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Patch formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>Czech Republic</Country><Country>Ukraine</Country><Country>UK</Country><Country>Belgium</Country><Country>Italy</Country><Country>Russian Federation</Country><Country>Poland</Country><Country>Germany</Country><Country>Spain</Country><Country>Europe</Country><Country>Netherlands</Country><Country>France</Country></Countries><DateChangeLast>2019-06-25T00:00:00Z</DateChangeLast><DateEnd>2014-02-27T00:00:00Z</DateEnd><DateStart>2011-11-30T00:00:00Z</DateStart><Identifiers><Identifier>2009-016458-42</Identifier><Identifier>E05-CL-3002</Identifier><Identifier>NCT01478607</Identifier><Identifier>PACE</Identifier></Identifiers><IndicationsAdverse><Indication>Edema</Indication><Indication>Erythema</Indication><Indication>Fatigue</Indication><Indication>Influenza virus infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>standard of Care alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>capsaicin dermal patch, NeurogesX/Astellas/Acorda/Grunenthal alone</Intervention><Intervention>standard of Care alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>468</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> for majority of tests at EoS across all treatment arms. Numerically greater improvements were observed in the reporting of ‘normal' sharp (on ball of foot), warm and &lt;b&gt;cold&lt;/b&gt; sensation in arms 1 and 2 versus arm 3. In all arms, there was a reduction in the percentage of patients experiencing ‘absence' sharp (on ball of foot) warm, &lt;b&gt;cold&lt;/b&gt; and vibration by EoS. Arm 2 had greatest numerical change in the ‘absent' category with these tests. At EoS, only fewer patients in all three arms had ‘absent' or ‘markedly</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Hemoglobin A1c (HbA1c) Levels</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Liver Functions - Alanine aminotransferase (ALT)/Serum glutamic-pyruvic transaminase (SGPT)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Liver Functions - Aspartate aminotransferase (AST)/Serum glutamic oxaloacetic transaminase (SGOT)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Renal Function - Assessment of Blood Urea Nitrogen (BUN)</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Diabetic complication - Neurological Assessments</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Numeric Rating Scale for Pain</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Patient Global Impression of Change (PGIC)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment of patient satisfaction</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - European quality of life instrument(EuroQol)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Diabetic Complications &amp; Events - Diabetic neuropathy</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Liver Functions - Alanine aminotransferase (ALT)/Serum glutamic-pyruvic transaminase (SGPT)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Liver Functions - Aspartate aminotransferase (AST)/Serum glutamic oxaloacetic transaminase (SGOT)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Renal Function - Assessment of Blood Urea Nitrogen (BUN)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Neurological Assessments</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Numeric Rating Scale for Pain</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Patient Global Impression of Change (PGIC)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment of patient satisfaction</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - European quality of life instrument(EuroQol)</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Brief Pain Inventory[BPI]</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropathic Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Euro Quality of Life (EQ-5D) Questionnaire</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Neuropathic pain scale score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PACE: A Study to Evaluate the Long-Term Safety of Repeated Qutenza Administration for Treatment of Pain Caused by Nerve Damage in Diabetic Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy</PatientSegment><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy - Subjects with diabetic neuropathic pain</PatientSegment><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy - Subjects with diabetic polyneuropathy</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic neuropathy</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain - Subjects with diabetic neuropathy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Alkaline phosphatase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Basophils </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Eosinophils </BiomarkerName><BiomarkerName> Erythrocytes </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hematocrit </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Monocytes </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> Potassium </BiomarkerName><BiomarkerName> Sodium </BiomarkerName><BiomarkerName> Urea nitrogen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>27 Months</TrialDuration><NumberOfSites>86</NumberOfSites><ContactNames><Name>Senior Clinical Study Manager</Name><Name>Service Desk</Name></ContactNames></Trial><Trial Id="82247"><Indications><Indication>Bone disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Parathyroid hormone ligand</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Bone metabolism modulator</Action><Action>Bone synthesis stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Protein fusion</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Aarhus University Hospital</Company></CompaniesCollaborator><CompaniesSponsor><Company>Aarhus University</Company><Company>Takeda Pharmaceutical Co Ltd</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2018-05-25T00:00:00Z</DateChangeLast><DateEnd>2014-03-31T00:00:00Z</DateEnd><DateStart>2012-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2011-004465-32</Identifier><Identifier>2011/386</Identifier><Identifier>NCT01466829</Identifier><Identifier>PAATH</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>recombinant human parathyroid hormone (PTH) 1-84 (sc, osteoporosis), NPS/Shire alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this study was to compare healing time and quality of newly formed bone in cardiac surgery patients treated with parathyroid hormone (PTH) post-surgically and a control group treated with saline.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Male</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PAATH: Treatment With PTH After Sternotomy in Cardiac Surgery Patients</TitleDisplay><PrimaryCompletionDate type="Actual">2014-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Per Nielsen, MD</Name></ContactNames></Trial><Trial Id="82176"><Indications><Indication>Factor IX deficiency</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Factor IX agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Coagulation stimulator</Action><Action>Vulnerary agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Glycoprotein</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>PEGylated formulation</Technology><Technology>Protein recombinant</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>Novo Nordisk A/S</Company></CompaniesSponsor><Countries><Country>Japan</Country><Country>South America</Country><Country>US</Country><Country>Europe</Country><Country>Taiwan</Country><Country>UK</Country><Country>France</Country><Country>Croatia</Country><Country>Canada</Country><Country>Asia</Country><Country>Malaysia</Country><Country>Brazil</Country><Country>North America</Country><Country>Italy</Country><Country>Germany</Country></Countries><DateChangeLast>2019-02-09T00:00:00Z</DateChangeLast><DateEnd>2023-11-30T00:00:00Z</DateEnd><DateStart>2012-05-16T00:00:00Z</DateStart><Identifiers><Identifier>11093</Identifier><Identifier>2011-000826-31</Identifier><Identifier>JapicCTI-121877</Identifier><Identifier>NCT01467427</Identifier><Identifier>NMRR-12-109-11093</Identifier><Identifier>NN7999-3774</Identifier><Identifier>P/292/2010</Identifier><Identifier>U1111-1119-5013</Identifier><Identifier>UKCRN 12600</Identifier><Identifier>paradigm 5</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Contusion</Indication><Indication>Cough</Indication><Indication>Diarrhea</Indication><Indication>Eosinophilia</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Rhinopharyngitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>nonacog beta pegol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>25</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The aim of the trial was to evaluate safety, efficacy and pharmacokinetics of NNC-0156-0000-0009 (nonacog beta pegol, N9-GP) in previously treated patient with hemophilia B. This trial was conducted in Asia, Europe and North America [ 1497246 ], [ 1725602 ], [ 2021695 ]. The primary objective was to evaluate immunogenicity of glycopegylated recombinant coagulation factor IX (NNC-0156-0000-0009; N9-GP). The secondary objectives were: To evaluate safety other than immunogenicity of N9-GP. To evaluate</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hemophilia - Assessment of Hemostatic Efficacy</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Inhibitor Antibody Development - Assessment of development of factor IX inhibitor</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Laboratory/Diagnostic Measures - Assessment of hematologic parameters</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Hemophilia - Assessment of blood loss - Assessment of number of bleeding episodes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>paradigm 5: Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Hemophilia B</TitleDisplay><PatientSegmentTerms><PatientSegment>Hemophilia - Subjects with Hemophilia B</PatientSegment><PatientSegment>Hemophilia - Subjects with Moderate Hemophilia</PatientSegment><PatientSegment>Hemophilia - Subjects with Severe Hemophilia</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anti-Coagulation factor IX antibodies </BiomarkerName><BiomarkerName> Coagulation factor IX</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-03-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>138 Months</TrialDuration><NumberOfSites>39</NumberOfSites><ContactNames><Name>Clinical Disclosure (1452)</Name><Name>Faraizah Abdul Karim</Name><Name>Lene  Hasselriis</Name><Name>Marianne  Fridberg</Name><Name>Miss Teh Huiping</Name><Name>Ms Tan Enn Swan</Name><Name>Novo Nordisk</Name><Name>Paula  Persson</Name></ContactNames></Trial><Trial Id="81688"><Indications><Indication>Factor VIII deficiency</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Factor VIII agonist</Action><Action>Factor VIII modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Blood clotting modulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibody fragment</Technology><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Protein fusion</Technology><Technology>Protein recombinant</Technology></Technologies><CompaniesSponsor><Company>Biogen Idec Research Ltd</Company><Company>Bioverativ Inc</Company></CompaniesSponsor><Countries><Country>Spain</Country><Country>Ireland</Country><Country>South Africa</Country><Country>Germany</Country><Country>US</Country><Country>Hong Kong</Country><Country>Italy</Country><Country>India</Country><Country>Austria</Country><Country>Poland</Country><Country>Australia</Country><Country>Israel</Country><Country>China</Country><Country>Japan</Country><Country>Russian Federation</Country><Country>Brazil</Country><Country>France</Country><Country>Turkey</Country><Country>Portugal</Country><Country>Chile</Country><Country>Belgium</Country><Country>Switzerland</Country><Country>Sweden</Country><Country>UK</Country><Country>Netherlands</Country><Country>New Zealand</Country><Country>Canada</Country></Countries><DateChangeLast>2019-06-03T00:00:00Z</DateChangeLast><DateEnd>2017-10-31T00:00:00Z</DateEnd><DateStart>2011-12-31T00:00:00Z</DateStart><Identifiers><Identifier>2011-003072-37</Identifier><Identifier>8HA01EXT</Identifier><Identifier>ASPIRE</Identifier><Identifier>CCRN 767</Identifier><Identifier>CTRI/2012/07/002772</Identifier><Identifier>NCT01454739</Identifier><Identifier>P/077/2014</Identifier><Identifier>UKCRN 11705</Identifier></Identifiers><IndicationsAdverse><Indication>Arthralgia</Indication><Indication>Cough</Indication><Indication>Dental caries</Indication><Indication>Diarrhea</Indication><Indication>Headache</Indication><Indication>Hernia</Indication><Indication>Hot flashes</Indication><Indication>Influenza virus infection</Indication><Indication>Joint disease</Indication><Indication>Rhinopharyngitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>efmoroctocog alfa alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>240</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>to rFVIIIFc [ 1635451 ]. In August 2015, results were published. Safety results were consistent with the general hemophilia A population across the age groups. Serious allergic reactions and vascular clots were not observed. Nasopharyngitis (common &lt;b&gt;cold&lt;/b&gt;), arthralgia (joint pain) and upper respiratory infection with an incidence of &gt;/= 5% were the most commonly observed adverse events [ 1685091 ]. In December 2015, pooled results from NCT01027377 and NCT01454739 studies were presented. In patients </Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hemophilia - Assessment of Inhibitor Antibody Development</EndpointIndex><EndpointIndex>Hemophilia - Assessment of blood loss - Assessment of annualised bleeding episodes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term></TermsPatientSelection><TitleDisplay>ASPIRE: Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A</TitleDisplay><PatientSegmentTerms><PatientSegment>Hemophilia - Subjects with Hemophilia A</PatientSegment><PatientSegment>Hemophilia - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2017-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>70 Months</TrialDuration><NumberOfSites>108</NumberOfSites><ContactNames><Name>Alok Srivastava</Name><Name>Anjali Nagpal</Name><Name>Cecil Ross</Name><Name>Joseph John</Name><Name>Medical Director</Name><Name>Naresh Gupta</Name><Name>Non Disponibile</Name><Name>Not available</Name><Name>Ritika Bajaj</Name><Name>Shashikant Apte</Name><Name>non disponibile</Name></ContactNames></Trial><Trial Id="81180"><Indications><Indication>Chemotherapy induced nausea and vomiting</Indication></Indications><ActionsPrimaryInterventionsControl><Action>5-HT 3 receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>5-HT 3 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-emetic</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-emetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Helsinn Healthcare SA</Company></CompaniesSponsor><Countries><Country>Austria</Country><Country>Estonia</Country><Country>Chile</Country><Country>Germany</Country><Country>Czech Republic</Country><Country>France</Country><Country>Argentina</Country><Country>Romania</Country><Country>UK</Country><Country>Peru</Country><Country>Serbia</Country><Country>Poland</Country><Country>Ukraine</Country><Country>Hungary</Country><Country>US</Country><Country>Bulgaria</Country><Country>Russian Federation</Country></Countries><DateChangeLast>2018-04-05T00:00:00Z</DateChangeLast><DateEnd>2012-11-30T00:00:00Z</DateEnd><DateStart>2011-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2010-022872-30</Identifier><Identifier>DRKS00003925</Identifier><Identifier>NCT01442376</Identifier><Identifier>PALO-10-20</Identifier></Identifiers><IndicationsAdverse><Indication>Headache</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>ondansetron alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>palanosetron hydrochloride alone</Intervention><Intervention>palonosetron (high dose) alone</Intervention><Intervention>palonosetron (low dose) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>502</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>practice and if deemed appropriate by the investigator Dimenhydrinate; hydroxyzine; domperidone; lorazepam; cyclizine; cannabinoids;  scopolamine; trimetobenzamide Hcl; meclizine hydrochloride; pseudoephedrine Hcl Over the counter (OTC) antiemetics, OTC &lt;b&gt;cold&lt;/b&gt; or OTC allergy medications Herbal preparations containing ephedra or ginger Patient aged&amp;lt;/= 6 years who received any investigational drug (defined as a medication with no marketing authorization granted for any age group and any indication) within</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Nausea and Vomiting</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>QT interval</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>68</NumberOfSites><ContactNames><Name>Adriana Berretta</Name><Name>Alexander Moskalenko</Name><Name>Alicja Chybicka</Name><Name>Ana Guerra</Name><Name>Anca Colita</Name><Name>Angelina Stoyanova</Name><Name>Anna Balcerska</Name><Name>Antonio Aptowitzer</Name><Name>Armando Picon</Name><Name>Bohumir Blazek</Name><Name>Christopher Frantz</Name><Name>Clarke Anderson</Name><Name>Claudio Chamorro</Name><Name>Claudio Sandoval</Name><Name>Cristian La Rosa</Name><Name>Danuse Dembicka</Name><Name>Danuta Perek</Name><Name>Dragan Bobev</Name><Name>Edita Kabickova</Name><Name>Elena Basharova</Name><Name>Emilia Mihut</Name><Name>Francisco Cifuentes</Name><Name>Gabor Kovacs</Name><Name>Georgy Mentkevich</Name><Name>Hryhorii Klymniuk</Name><Name>Ingrith Miron</Name><Name>Irene Cherrick</Name><Name>Irene Slavc</Name><Name>Ivan Zhurylo</Name><Name>J. Johnston</Name><Name>Jacqueline Kraveka</Name><Name>Janic Dragana</Name><Name>Jeffrey Schwartz</Name><Name>Jerzy Kowalczyk</Name><Name>Jochen Roessler</Name><Name>John Geil</Name><Name>Juan Bustos</Name><Name>Juan Leon</Name><Name>Kadri Saks</Name><Name>Kateryna Vilchevska</Name><Name>Lauren Akers</Name><Name>Ljiljana Pejcic</Name><Name>Manisha Bansal</Name><Name>Margaret Macy</Name><Name>Margarita Belogurova</Name><Name>Mariusz Wysockl</Name><Name>Mark Ranalli</Name><Name>Miklos Garami</Name><Name>Milena Cickovic</Name><Name>Monica Dragomir</Name><Name>Monica Makiya</Name><Name>Nicolas Sirvent</Name><Name>Oleksandr Dudnichenko</Name><Name>Ramamoorthy Nagasubramanian</Name><Name>Rinat Galiulin</Name><Name>Robert Saylors</Name><Name>Ruth Ladenstein</Name><Name>Sandor Turi</Name><Name>Sirje Mikkel</Name><Name>Svetlana Gorbatykh</Name><Name>Thorsten Simon</Name><Name>Tomas Votava</Name><Name>Valerya Kaleva</Name><Name>Vladimir Lebedev</Name><Name>Wojciech Mlynarski</Name></ContactNames></Trial><Trial Id="81133"><Indications><Indication>Factor IX deficiency</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Factor IX agonist</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Antibody fragment</Technology><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Protein fusion</Technology></Technologies><CompaniesCollaborator><Company>Swedish Orphan Biovitrum AB</Company></CompaniesCollaborator><CompaniesSponsor><Company>Biogen Idec Research Ltd</Company><Company>Biogen Inc</Company><Company>Bioverativ Inc</Company></CompaniesSponsor><Countries><Country>Australia</Country><Country>UK</Country><Country>US</Country><Country>Netherlands</Country><Country>South Africa</Country><Country>Ireland</Country></Countries><DateChangeLast>2019-05-15T00:00:00Z</DateChangeLast><DateEnd>2014-11-30T00:00:00Z</DateEnd><DateStart>2012-06-30T00:00:00Z</DateStart><Identifiers><Identifier>2011-003076-36</Identifier><Identifier>9HB02PED</Identifier><Identifier>Kids B-LONG</Identifier><Identifier>NCT01440946</Identifier><Identifier>P/123/2011</Identifier></Identifiers><IndicationsAdverse><Indication>Common cold</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Factor IX plus eftrenonacog alfa</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> the study due to an adverse event [ 1637201 ]. In February 2017, results were presented. rFIXFc was well tolerated and adverse events (AEs) observed were typical of the pediatric hemophilia B population. The most common AEs were found to be common &lt;b&gt;cold&lt;/b&gt; (23%) and fall (20%).  Four participants experienced serious AEs, all of which were assessed as unrelated to rFIXFc by the investigators. There were no reports of anaphylaxis or serious hypersensitivity reactions to rFIXFc, no vascular thrombotic events</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hemophilia - Assessment of Inhibitor Antibody Development</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Hemophilia - Assessment of blood loss - Assessment of annualised bleeding episodes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Kids B-LONG: Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB-029, in Previously Treated Pediatric Participants With Hemophilia B</TitleDisplay><PatientSegmentTerms><PatientSegment>Hemophilia - Subjects with Hemophilia B</PatientSegment><PatientSegment>Hemophilia - Subjects with Severe Hemophilia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>29 Months</TrialDuration><NumberOfSites>18</NumberOfSites><ContactNames><Name>Medical Director</Name><Name>Roshni Kulkarni</Name><Name>not available</Name></ContactNames></Trial><Trial Id="81011"><Indications><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>Mundipharma Research GmbH &amp; Co. KG</Company></CompaniesSponsor><Countries><Country>Romania</Country><Country>UK</Country><Country>Czech Republic</Country><Country>Poland</Country><Country>Hungary</Country><Country>Spain</Country><Country>Germany</Country></Countries><DateChangeLast>2018-05-19T00:00:00Z</DateChangeLast><DateEnd>2013-10-31T00:00:00Z</DateEnd><DateStart>2011-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2011-002901-31</Identifier><Identifier>NCT01439100</Identifier><Identifier>OXN2504</Identifier></Identifiers><IndicationsAdverse><Indication>Constipation</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>oxycodone + naloxone (prolonged release tablet, pain), Mundipharma alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>172</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>benefit from WHO step III opioid therapy for the duration of the study Subjects must not have received opioid containing medication in the last 6 months on a regular basis (ie, prescribed medication or more than occasional self medication use for cough, &lt;b&gt;cold&lt;/b&gt; etc.)  Receiving stable treatment for Parkinson's disease for at least 4 weeks prior to randomization, the dose of which is expected to remain consistent throughout the double-blind phase  In the Investigator's opinion, the subject does not have visual</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Central nervous system disease outcomes</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Quality of Life (Unspecified)</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Non-Motor Symptoms of Parkinson's Disease - Assessment of sensory function</EndpointIndex><EndpointIndex>Parkinsons disease - Patient Reported Outcomes/Quality of Life Assessments - Quality of Life (QOL) questionnaire</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Randomized, Placebo-Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Psychogenic Pain</PatientSegment><PatientSegment>Parkinsons disease - Subjects with Advanced/Late Stage Parkinson's Disease</PatientSegment><PatientSegment>Parkinsons disease - Subjects with History of Treatment</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2013-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>31</NumberOfSites><ContactNames><Name>Attila Csanyi</Name><Name>Bernard Boothman</Name><Name>Ernest Balaguer</Name><Name>Joseph Classen</Name><Name>Julia Lajtos</Name><Name>Kallol Chaudhuri</Name><Name>Karis Eggert</Name><Name>Reinhard Ehret</Name><Name>Simon Ellis</Name><Name>Valeria Albu</Name></ContactNames></Trial><Trial Id="80946"><Indications><Indication>Pain</Indication></Indications><CompaniesSponsor><Company>Pfizer Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-08-08T00:00:00Z</DateChangeLast><DateEnd>2012-05-31T00:00:00Z</DateEnd><DateStart>2010-12-31T00:00:00Z</DateStart><Identifiers><Identifier>ALO-02-10-3001</Identifier><Identifier>B4531001</Identifier><Identifier>NCT01428583</Identifier></Identifiers><IndicationsAdverse><Indication>Constipation</Indication><Indication>Dizziness</Indication><Indication>Drowsiness</Indication><Indication>Emesis</Indication><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Myocardial infarction</Indication><Indication>Nausea</Indication><Indication>Pneumonia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>oxycodone + naltrexone (abuse-resistant), Pfizer alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>395</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The study was designed to provide information to assess the benefits versus risks of extended exposure to oxycodone HCl and naltrexone HCl extended-release capsules ( ALO-02 ) in a chronic non-cancer pain population.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability - Assessment of dependency potential</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Non-Cancer Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>67</NumberOfSites><ContactNames><Name>Pfizer CT.gov Call Center</Name></ContactNames></Trial><Trial Id="80828"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Beta 2 adrenoceptor agonist</Action><Action>Muscarinic M1 receptor antagonist</Action><Action>Muscarinic M3 receptor antagonist</Action><Action>Muscarinic receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action><Action>Muscarinic M1 receptor antagonist</Action><Action>Muscarinic M3 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Respiratory system agent</Action><Action>Synergist</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Respiratory system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Aerosol formulation inhalant</Technology><Technology>Capsule formulation</Technology><Technology>Daily dosing</Technology><Technology>Dermatological formulation</Technology><Technology>Drug combination</Technology><Technology>Formulation powder</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Sustained release formulation</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Boehringer Ingelheim International GmbH</Company></CompaniesSponsor><Countries><Country>Argentina</Country><Country>France</Country><Country>Finland</Country><Country>Czech Republic</Country><Country>Denmark</Country><Country>China</Country><Country>India</Country><Country>Australia</Country><Country>Hungary</Country><Country>Netherlands</Country><Country>New Zealand</Country><Country>Japan</Country><Country>Bulgaria</Country><Country>Slovenia</Country><Country>Germany</Country><Country>Guatemala</Country><Country>Canada</Country><Country>South Korea</Country><Country>Turkey</Country><Country>Portugal</Country><Country>Mexico</Country><Country>US</Country><Country>Estonia</Country><Country>Italy</Country><Country>Russian Federation</Country></Countries><DateChangeLast>2018-11-26T00:00:00Z</DateChangeLast><DateEnd>2013-09-30T00:00:00Z</DateEnd><DateStart>2011-09-30T00:00:00Z</DateStart><Identifiers><Identifier>1237.5</Identifier><Identifier>2009-010668-40</Identifier><Identifier>CTRI/2012/04/002557</Identifier><Identifier>JapicCTI-111687</Identifier><Identifier>NCT01431274</Identifier><Identifier>TONADO 1</Identifier></Identifiers><IndicationsAdverse><Indication>Cardiovascular disease</Indication><Indication>Cerebrovascular disease</Indication><Indication>Chronic obstructive pulmonary disease</Indication><Indication>Pneumonia</Indication><Indication>Respiratory disease</Indication><Indication>Stroke</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>olodaterol alone</Intervention><Intervention>tiotropium bromide alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>olodaterol hydrochloride + tiotropium bromide monohydrate l (Respimat Soft Mist/inhaled, COPD), Boehringer Ingelheim alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2624</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>5 microg: 74.7%; tiotropium 5 microg: 73.3%; tiotropium 2.5 microg: 73.4%; olodaterol 5 microg: 76.6% [ 1706819 ]. Further in October 2015, new post-hoc analysis were presented from two studies (NCT01431274 and NCT01431287). Nasopharyngitis (common &lt;b&gt;cold&lt;/b&gt;), cough and back pain were the most common adverse events in both the studies [ 1707342 ]. In January 2017, pooled results were published from two 52-week phase III trials (NCT01431274 and  NCT01431287 ). In the total population as well as in patient</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change in post bronchodilator FEV1</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 area under curve (AUC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 peak response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 trough response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - FVC area under curve (AUC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - FVC peak response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - Trough FVC response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Changes in St Georges Respiratory Questionnaire (SGRQ)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Transition Dyspnea Index (TDI) Score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TONADO 1: Tiotropium plus Olodaterol Fixed-Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects at risk of developing disease - Ex-smokers</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Stable COPD</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>24 Months</TrialDuration><NumberOfSites>197</NumberOfSites><ContactNames><Name>Boehringer Ingelheim</Name><Name>George Dsouza</Name><Name>Jenny Gullberg</Name><Name>Mahesh</Name><Name>Manuel Quaresma</Name><Name>Pradyut Waghray</Name><Name>QRPE PSC CT Information Disclosure</Name><Name>Raj Bhagat</Name><Name>Satish</Name><Name>Sharad Thikkiwal</Name><Name>Shoma Das</Name><Name>Sundeep Salvi</Name><Name>Virendra Singh</Name><Name>V Pattabhiraman</Name></ContactNames></Trial><Trial Id="80827"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Beta 2 adrenoceptor agonist</Action><Action>Muscarinic M1 receptor antagonist</Action><Action>Muscarinic M3 receptor antagonist</Action><Action>Muscarinic receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action><Action>Muscarinic M1 receptor antagonist</Action><Action>Muscarinic M3 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Respiratory system agent</Action><Action>Synergist</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action><Action>Respiratory system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Aerosol formulation inhalant</Technology><Technology>Capsule formulation</Technology><Technology>Daily dosing</Technology><Technology>Dermatological formulation</Technology><Technology>Drug combination</Technology><Technology>Formulation powder</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Sustained release formulation</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Boehringer Ingelheim AB</Company><Company>Boehringer Ingelheim GmbH</Company><Company>Boehringer Ingelheim International GmbH</Company><Company>Boehringer Ingelheim Ltd</Company><Company>SCS Boehringer Ingelheim Comm.V</Company></CompaniesSponsor><Countries><Country>Slovakia</Country><Country>China</Country><Country>US</Country><Country>Spain</Country><Country>Canada</Country><Country>Hungary</Country><Country>South Africa</Country><Country>Austria</Country><Country>Norway</Country><Country>Russian Federation</Country><Country>Turkey</Country><Country>Belgium</Country><Country>Serbia</Country><Country>Taiwan</Country><Country>Brazil</Country><Country>India</Country><Country>Romania</Country><Country>Sweden</Country><Country>Colombia</Country><Country>Germany</Country><Country>Japan</Country><Country>Croatia</Country><Country>Ireland</Country><Country>UK</Country><Country>Peru</Country></Countries><DateChangeLast>2018-11-27T00:00:00Z</DateChangeLast><DateEnd>2013-11-30T00:00:00Z</DateEnd><DateStart>2011-09-30T00:00:00Z</DateStart><Identifiers><Identifier>111688</Identifier><Identifier>1237.6</Identifier><Identifier>2009-010669-22</Identifier><Identifier>CCRN 438</Identifier><Identifier>CTRI/2012/04/002554</Identifier><Identifier>NCT01431287</Identifier><Identifier>TONADO 2</Identifier><Identifier>TONADO TM 2</Identifier><Identifier>UKCRN 11670</Identifier></Identifiers><IndicationsAdverse><Indication>Cardiovascular disease</Indication><Indication>Cerebrovascular disease</Indication><Indication>Chronic obstructive pulmonary disease</Indication><Indication>Pneumonia</Indication><Indication>Respiratory disease</Indication><Indication>Stroke</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>olodaterol alone</Intervention><Intervention>tiotropium bromide alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>olodaterol hydrochloride + tiotropium bromide monohydrate l (Respimat Soft Mist/inhaled, COPD), Boehringer Ingelheim alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2539</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> microg: 74.7%; tiotropium 5 microg: 73.3%; tiotropium 2.5 microg: 73.4%; olodaterol 5 microg: 76.6% [ 1706819 ]. Further in October 2015, new post-hoc analysis were presented from two studies ( NCT01431274 and NCT01431287). Nasopharyngitis (common &lt;b&gt;cold&lt;/b&gt;), cough and back pain were the most common adverse events in both the studies [ 1707342 ]. In January 2017, pooled results were published from two 52-week phase III trials ( NCT01431274 and NCT01431287). In the total population as well as in patient</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change in post bronchodilator FEV1</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 area under curve (AUC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 peak response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - FEV1 trough response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - FVC post bronchodilator administration</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - FVC area under curve (AUC)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - FVC peak response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Vital Capacity (FVC) - Trough FVC response</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Changes in St Georges Respiratory Questionnaire (SGRQ)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Transition Dyspnea Index (TDI) Score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TONADO TM 2: Tiotropium + Olodaterol Fixed-Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Stable COPD</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>223</NumberOfSites><ContactNames><Name>Aloke Ghosal</Name><Name>B. Mutha</Name><Name>Boehringer Ingelheim</Name><Name>Jenny Gullberg</Name><Name>Manish Jain</Name><Name>Parag Khatavkar</Name><Name>QRPE PSC CT Information Disclosure</Name><Name>Rajesh Swaranakar</Name><Name>Roland Buh</Name><Name>S. Balamurugan</Name><Name>Shoma Das</Name><Name>Sujeet Rajan</Name><Name>Tushar Sahastrabuddhe</Name></ContactNames></Trial><Trial Id="80695"><Indications><Indication>Factor IX deficiency</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Factor IX agonist</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Antibody fragment</Technology><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Injectable controlled release formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Protein fusion</Technology></Technologies><CompaniesCollaborator><Company>Swedish Orphan Biovitrum AB</Company></CompaniesCollaborator><CompaniesSponsor><Company>Biogen Idec Research Ltd</Company><Company>Bioverativ Inc</Company></CompaniesSponsor><Countries><Country>Netherlands</Country><Country>Italy</Country><Country>France</Country><Country>Panama</Country><Country>Brazil</Country><Country>Australia</Country><Country>Sweden</Country><Country>Belgium</Country><Country>Canada</Country><Country>UK</Country><Country>Russian Federation</Country><Country>Poland</Country><Country>Japan</Country><Country>Germany</Country><Country>Hong Kong</Country><Country>India</Country><Country>China</Country><Country>Ireland</Country><Country>South Africa</Country><Country>US</Country></Countries><DateChangeLast>2019-06-03T00:00:00Z</DateChangeLast><DateEnd>2017-10-31T00:00:00Z</DateEnd><DateStart>2011-12-08T00:00:00Z</DateStart><Identifiers><Identifier>2011-003075-11</Identifier><Identifier>9HB01EXT</Identifier><Identifier>B-YOND</Identifier><Identifier>CTRI/2012/05/002708l</Identifier><Identifier>NCT01425723</Identifier><Identifier>P/303/2014</Identifier><Identifier>UKCRN 11703</Identifier></Identifiers><IndicationsAdverse><Indication>Allergy</Indication><Indication>Common cold</Indication><Indication>Emesis</Indication><Indication>Headache</Indication><Indication>Hematuria</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>eftrenonacog alfa alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>common &lt;b&gt;cold&lt;/b&gt; and vomiting were the most common adverse events (incidence of &amp;gt;/= 5%) for adults and adolescents. Whereas, falls, common &lt;b&gt;cold&lt;/b&gt; and seasonal allergy were the most common adverse events for &amp;nbsp;children aged &amp;lt; 12 years [ 1686917...2017 [ 1899444 ]. In March 2017, interim&amp;nbsp;results were presented. rFIXFc was found to be well-tolerated and headache (12.1%), common &lt;b&gt;cold&lt;/b&gt; (11.2%) were the most common AEs unrelated to rFIXFc. A total of 39 serious AEs (SAEs) were reported in 23 patients</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hemophilia - Assessment of Inhibitor Antibody Development</EndpointIndex><EndpointIndex>Hemophilia - Assessment of blood loss - Assessment of number of bleeding episodes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term></TermsPatientSelection><TitleDisplay>B-YOND: Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B</TitleDisplay><PatientSegmentTerms><PatientSegment>Hemophilia - Subjects with Hemophilia B</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2017-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>70 Months</TrialDuration><NumberOfSites>65</NumberOfSites><ContactNames><Name>Alok Srivastava</Name><Name>Anjali Nagpal</Name><Name>Cecil Ross</Name><Name>John Pasi, MD, PhD</Name><Name>Medical Director</Name><Name>ND</Name><Name>Not available</Name><Name>Ritika Bajaj</Name><Name>Shashikant Apte</Name></ContactNames></Trial><Trial Id="80267"><Indications><Indication>Asthma</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2017-08-08T00:00:00Z</DateChangeLast><DateStart>1994-01-13T00:00:00Z</DateStart><Identifiers><Identifier>FLUTI/AH92/N114</Identifier></Identifiers><IndicationsAdverse><Indication>Asthma</Indication><Indication>Common cold</Indication><Indication>Cough</Indication><Indication>Headache</Indication><Indication>Hoarseness</Indication><Indication>Infectious disease</Indication><Indication>Influenza virus infection</Indication><Indication>Rhinopharyngitis</Indication><Indication>Throat disease</Indication><Indication>Tooth disease</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>fluticasone propionate (fixed) alone</Intervention><Intervention>fluticasone propionate (step-down) alone</Intervention><Intervention>fluticasone propionate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>332</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>Across treatment periods, the most frequent adverse events (AEs) reported in the fluticasone propionate step-down and fluticasone propionate fixed groups were headache, acute nasopharyngitis, sore throat, influenza, chest infection, asthma, hoarseness, &lt;b&gt;cold&lt;/b&gt; symptoms, exacerbation of asthma, toothache, cough and upper respiratory tract infection [ 1217186 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A phase III, randomized, multicenter, double-blind, parallel-group study to compare the efficacy, safety and tolerability of a high-dose treatment regimen of fluticasone propionate (2.0 mg reducing to 0.5 mg daily) with a fixed-dose of fluticasone propionate (0.5 mg daily) in maintaining the control attained following oral corticosteroid therapy for an acute severe exacerbation of asthma in adult patients</TitleDisplay><BiomarkerNames><BiomarkerName>Peak expiratory flow rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="80072"><Indications><Indication>Cough</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Respiratory system agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Ahn-Gook Pharmaceuticals Co Ltd</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2017-04-09T00:00:00Z</DateChangeLast><DateEnd>2011-05-31T00:00:00Z</DateEnd><DateStart>2010-05-31T00:00:00Z</DateStart><Identifiers><Identifier>AG1321001_ACP3</Identifier><Identifier>NCT01416480</Identifier></Identifiers><InterventionsControlDisplay><Intervention>levodropropizine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>AG-1321001 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>332</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this clinical trial was to evaluate the antitussive effect of theobromine capsule 300 mg in patients with acute bronchitis.</Teaser><TrialCategories><Category>Borderline product</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Clinical Trial to Evaluate the Safety and Efficacy of 'Theobromine Capsule' as an Antitussive in Acute Cougher</TitleDisplay><PrimaryCompletionDate type="Actual">2011-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jae Yeol Kim, M.D.</Name><Name>Jung Hyun chang, M.D.</Name><Name>Ki-Suck Jung, M.D.</Name><Name>Kwan Ho Lee, M.D.</Name><Name>Soo-Taek Uh, M.D.</Name><Name>Sung Soon Lee, M.D.</Name><Name>Yong Bum Park, M.D.</Name><Name>Young Kyoon Kim, M.D.</Name></ContactNames></Trial><Trial Id="80017"><Indications><Indication>Essential hypertension</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Alpha adrenoceptor antagonist</Action><Action>Beta adrenoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action><Action>Antioxidant agent</Action><Action>Cardiac agent</Action><Action>Class II antiarrhythmic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2011-08-16T00:00:00Z</DateChangeLast><DateStart>1989-03-31T00:00:00Z</DateStart><Identifiers><Identifier>105517/132</Identifier><Identifier>CAR-UK-104</Identifier></Identifiers><IndicationsAdverse><Indication>Bradycardia</Indication><Indication>Common cold</Indication><Indication>Diarrhea</Indication><Indication>Dizziness</Indication><Indication>Emesis</Indication><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Influenza virus infection</Indication><Indication>Migraine</Indication><Indication>Nausea</Indication><Indication>Orthostatic hypotension</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>carvedilol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>232</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>Results were published in September 2005. The most commonly observed adverse events (AEs) were relating to dizziness and/or postural hypotension, fatigue, headache/migraine, shortness of breath, nausea/vomiting, &lt;b&gt;cold&lt;/b&gt;/influenza, and malaise. The serious AEs observed were relating to dizziness and/or postural hypotension, bradycardia, nausea, vomiting and diarrhea, raised liver function tests and glucose [ 1215236 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A phase III, randomized, double-blind, multicenter, parallel group study to evaluate the efficacy and safety of carvedilol in the elderly patients with mild to moderate essential hypertension</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="79174"><Indications><Indication>Psoriatic arthritis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-17 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Israel</Country><Country>Australia</Country><Country>Italy</Country><Country>Bulgaria</Country><Country>Germany</Country><Country>Canada</Country><Country>US</Country><Country>UK</Country><Country>Belgium</Country><Country>Brazil</Country><Country>Slovakia</Country><Country>Poland</Country><Country>Czech Republic</Country><Country>Russian Federation</Country><Country>Singapore</Country><Country>Argentina</Country><Country>Philippines</Country><Country>Thailand</Country><Country>Romania</Country></Countries><DateChangeLast>2019-06-27T00:00:00Z</DateChangeLast><DateEnd>2014-10-31T00:00:00Z</DateEnd><DateStart>2011-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2011-000276-34</Identifier><Identifier>CAIN457F2306</Identifier><Identifier>F2306</Identifier><Identifier>FUTURE 1</Identifier><Identifier>NCT01392326</Identifier><Identifier>UKCRN ID: 11416</Identifier></Identifiers><IndicationsAdverse><Indication>Back pain</Indication><Indication>Candida infection</Indication><Indication>Crohns disease</Indication><Indication>Headache</Indication><Indication>Hypercholesterolemia</Indication><Indication>Infectious disease</Indication><Indication>Nausea</Indication><Indication>Rhinopharyngitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>secukinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>606</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>a stroke (0.6/100 patient-years), and two had a myocardial infarction (0.3/100 patient-years), throughout the study as compared with no patients in the placebo group [ 1699501 ]. In November 2015, results were presented. Nasopharyngitis (the common &lt;b&gt;cold&lt;/b&gt;, 19.6%), upper respiratory tract infection (19.1%) and back pain (8.9%) were the most common adverse events (AEs) for either secukinumab dose. Serious adverse event (SAE) rates were and 11.0% for secukinumab 150 and 75 mg, respectively [ 1710928 ],</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriatic arthritis - Assessment of Clinical Response by ACR Criteria - Assessment of ACR 20 response</EndpointIndex><EndpointIndex>Psoriatic arthritis - Assessment of Clinical Response by ACR Criteria - Assessment of ACR 70 response</EndpointIndex><EndpointIndex>Psoriatic arthritis - Assessment of Joint Disease Progression</EndpointIndex><EndpointIndex>Psoriatic arthritis - Imaging/Radiological Assessments - Van der Heijde modified sharp score (vdHS)</EndpointIndex><EndpointIndex>Psoriatic arthritis - Patient Reported Outcomes/Quality of Life Assessments - Disability index of the health assessment questionnaire (HAQDI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>FUTURE 1: Efficacy at 24 Weeks and Long-term Safety, Tolerability and Efficacy up to Two Years of Secukinumab (AIN-457) in Patients With Active Psoriatic Arthritis (PsA)</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriatic arthritis - Subjects with Active Psoriatic Arthritis - Subjects with moderate psoriatic arthritis</PatientSegment><PatientSegment>Psoriatic arthritis - Subjects with Active Psoriatic Arthritis - Subjects with severe psoriatic arthritis</PatientSegment><PatientSegment>Psoriatic arthritis - Subjects with Diagnosis of Psoriasis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anti-cyclic citrullinated peptides antibodies </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Erythrocyte sedimentation rate </BiomarkerName><BiomarkerName> Joint swelling </BiomarkerName><BiomarkerName> Joint tenderness </BiomarkerName><BiomarkerName> Lipids</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>37 Months</TrialDuration><NumberOfSites>119</NumberOfSites><ContactNames><Name>Clinical Trial Information Desk</Name><Name>DRA dept.</Name><Name>Dr Anita Lim Yee Nah</Name><Name>Dr Leung Ying Ying</Name><Name>Dr Yoon Kam Hon</Name><Name>Dr. Proton Rahman</Name><Name>Drug Regulatory Affairs</Name><Name>Informační služba - klin. hodnocení</Name><Name>Medical Dept - Desislava Uzunova</Name><Name>Medical information services</Name><Name>Medizinischer Infoservice</Name><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="79144"><Indications><Indication>Hepatitis B virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action><Action>HIV-1 reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action><Action>RNA DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>HIV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2014-03-03T00:00:00Z</DateChangeLast><DateEnd>2001-02-18T00:00:00Z</DateEnd><DateStart>1995-09-08T00:00:00Z</DateStart><Identifiers><Identifier>LB-04</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Acute sinusitis</Indication><Indication>Arthralgia</Indication><Indication>Cough</Indication><Indication>Eczema</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Insomnia</Indication><Indication>Jaundice</Indication><Indication>Pharyngitis</Indication><Indication>Pneumonia</Indication><Indication>Pruritus</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>lamivudine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In August 2005, results were published. Insomnia (10%), cough (10%), headache (15%), asthenopia, buzzing, dull headache, upper abdominal pain, lower abdominal pain on left side, &lt;b&gt;cold&lt;/b&gt;-like symptoms, joint pain, lassitude, listlessness of the lower limbs, generalized pruritus, pneumonia, jaundice, eczema of external auditory meatus, acute pharyngitis, acute sinusitis, occipital headache left side, fever, and sputum each in 5% of patients were the commonly observed adverse events up to week 260 in the</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of HBV Viral Response - Assessment of HBV viral load</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Histological Changes in Liver</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Liver Functions - Alanine transaminase (ALT) levels</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Viral Antigens - Assessment of HBeAg changes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>A phase III, single-center, open-label, study to evaluate the safety and efficacy of long-term treatment of lamivudine in patients with chronic hepatitis B</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatitis B virus infection - Subjects with Hepatitis B Infection - Subjects with Chronic Hepatitis B Infection</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>65 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="79117"><Indications><Indication>Hepatitis B virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action><Action>HIV-1 reverse transcriptase inhibitor</Action><Action>Nucleoside reverse transcriptase inhibitor</Action><Action>RNA DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>HIV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2014-03-04T00:00:00Z</DateChangeLast><DateEnd>1997-01-31T00:00:00Z</DateEnd><DateStart>1995-05-31T00:00:00Z</DateStart><Identifiers><Identifier>LB-03</Identifier></Identifiers><IndicationsAdverse><Indication>Appetite loss</Indication><Indication>Ascites</Indication><Indication>Chill</Indication><Indication>Common cold</Indication><Indication>Drowsiness</Indication><Indication>Drug eruption</Indication><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Liver failure</Indication><Indication>Liver tumor</Indication><Indication>Skin rash</Indication><Indication>Thyroid tumor</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>lamivudine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>results from a safety population of 133 patients were published. The most commonly observed adverse events in the study were headache (12.8, 13.5, and 0.8%), sleepiness (12.0, 12.0, and 0%), dull headache (3.8, 3.8, and 0%), rash (3.8, 4.5, and 0%), &lt;b&gt;cold&lt;/b&gt;-like symptoms (2.3, 5.3, and 1.5%), malaise (2.3, 4.5, and 1.5%), light headedness (1.5, 1.5, and 0%), chills (1.5, 1.5, and 0%), tension of neck muscle (0.8, 0.8, and 0%), anorexia (0, 0.8, and 1.5%), ascites (0, 0.8, and 1.5%), and eruption (0, 0.8</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of HBV Viral Response - Assessment of HBV viral load</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Liver Functions - Alanine transaminase (ALT) levels</EndpointIndex><EndpointIndex>Hepatitis B virus infection - Assessment of Viral Antigens - Assessment of HBeAg changes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A phase III, multicenter, open-label study to evaluate the long-term safety and efficacy of lamivudine in patients with chronic hepatitis B</TitleDisplay><PatientSegmentTerms><PatientSegment>Hepatitis B virus infection - Subjects with Hepatitis B Infection - Subjects with Chronic Hepatitis B Infection</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>20 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="78613"><Indications><Indication>Common cold</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><DateChangeLast>2011-12-29T00:00:00Z</DateChangeLast><DateStart>1994-11-30T00:00:00Z</DateStart><Identifiers><Identifier>FLNL39</Identifier><Identifier>FNM40137</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>fluticasone propionate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>after onset of the common &lt;b&gt;cold&lt;/b&gt; for 6 days [ 1203654 ].... Results were published in June 1998. The duration of common &lt;b&gt;cold&lt;/b&gt; symptoms was equal in both...common &lt;b&gt;cold&lt;/b&gt; were significantly more severe during days 1 to 10 (p &amp;lt; 0.05) in subjects found to have positive cultures for S pneumoniae, H influenzae</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TitleDisplay>A phase III, randomized, double-blind, placebo-controlled trial to study the effect of fluticasone propionate (FP) in subjects with common cold</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="78537"><Indications><Indication>Asthma</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Corticosteroid agonist</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2012-04-27T00:00:00Z</DateChangeLast><DateStart>1990-06-30T00:00:00Z</DateStart><Identifiers><Identifier>FLUTI/AH89/J78</Identifier></Identifiers><IndicationsAdverse><Indication>Back pain</Indication><Indication>Common cold</Indication><Indication>Cough</Indication><Indication>Dyspnea</Indication><Indication>Flatulence</Indication><Indication>Headache</Indication><Indication>Infectious disease</Indication><Indication>Nausea</Indication><Indication>Throat disease</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>budesonide alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>fluticasone propionate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>197</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>reported in the fluticasone propionate group were sore throat (22.9% of patients), headache (17.7%), cough (17.7%), and &lt;b&gt;cold&lt;/b&gt; (9.4%). A total of 68 patients receiving budesonide had AEs throughout treatment. The most common AEs reported in the budesonide...dyspnea, dry throat, flatulence and worsening of asthma were some of the SAEs observed in patients. Headache, cough, &lt;b&gt;cold&lt;/b&gt;, back ache, chest infection, wheeziness, sputum production and nausea were some of the AEs occurred frequently in patients [ 1202924</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A phase III, randomized, multicenter, open-label, parallel-group study to compare the efficacy, safety and tolerability of fluticasone propionate and budesonide administered via a metered dose inhaler in adult patients with moderate to severe symptomatic asthma</TitleDisplay><BiomarkerNames><BiomarkerName>Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Peak expiratory flow rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="78418"><Indications><Indication>Dengue virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>Sanofi Pasteur</Company><Company>Sanofi SA</Company></CompaniesSponsor><Countries><Country>Malaysia</Country><Country>Vietnam</Country><Country>Thailand</Country><Country>Indonesia</Country><Country>Philippines</Country></Countries><DateChangeLast>2018-12-18T00:00:00Z</DateChangeLast><DateEnd>2017-11-21T00:00:00Z</DateEnd><DateStart>2011-06-03T00:00:00Z</DateStart><Identifiers><Identifier>2014-001708-24</Identifier><Identifier>6463</Identifier><Identifier>CYD14</Identifier><Identifier>NCT01373281</Identifier><Identifier>NMRR-10-672-6463</Identifier><Identifier>PHRR121114-000015</Identifier><Identifier>U1111-1116-4957</Identifier><Identifier>UTN: U1111-1116-4957</Identifier></Identifiers><IndicationsAdverse><Indication>Infectious disease</Indication><Indication>Injury</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Dengvaxia alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>10275</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> the manifestations of Grade I participants, usually in the form of skin and/or other hemorrhages; Grade III: Circulatory failure manifested by rapid and weak pulse, narrowing of pulse pressure (20 mmHg or less) or hypotension, with the presence of &lt;b&gt;cold&lt;/b&gt; clammy skin and restlessness; and Grade IV: Profound shock with undetectable blood pressure and pulse. Independent Data Monitoring Committee (IDMC) severity criteria. The severity of VCD cases was assessed by an Independent IDMC using pre-defined standardized</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Dengue Vaccine - Assessment of Disease Incidence</EndpointIndex><EndpointIndex>Dengue Vaccine - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Dengue virus infection - Assessment of Disease Incidence</EndpointIndex><EndpointIndex>Dengue virus infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Asian Ancestry</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia</TitleDisplay><PatientSegmentTerms><PatientSegment>Dengue Vaccine - Subjects with Dengue Fever - People living in endemic areas</PatientSegment><PatientSegment>Dengue virus infection - Subjects at Risk of Dengue Fever - People living in endemic areas</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anti Dengue virus antibodies </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Immunoglobulin G </BiomarkerName><BiomarkerName> Immunoglobulin M</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-08-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>77 Months</TrialDuration><NumberOfSites>13</NumberOfSites><ContactNames><Name>Dr. Maria Rosario Capeding</Name><Name>Evon Chew Yeah Yoong</Name><Name>Hussain Imam B MD Ismail</Name><Name>Mary Noreen CHUA</Name><Name>Medical Director</Name><Name>Revathy Nallusamy</Name></ContactNames></Trial><Trial Id="78238"><Indications><Indication>Dengue virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Sanofi SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>Sanofi Pasteur Inc</Company></CompaniesSponsor><Countries><Country>Brazil</Country><Country>Colombia</Country><Country>Mexico</Country><Country>Puerto Rico</Country><Country>Honduras</Country></Countries><DateChangeLast>2019-04-18T00:00:00Z</DateChangeLast><DateEnd>2018-03-05T00:00:00Z</DateEnd><DateStart>2011-06-08T00:00:00Z</DateStart><Identifiers><Identifier>2014-001716-19</Identifier><Identifier>CYD15</Identifier><Identifier>NCT01374516</Identifier><Identifier>UTN: U1111-1116-4986</Identifier></Identifiers><IndicationsAdverse><Indication>Asthma</Indication><Indication>Polyneuropathy</Indication><Indication>Urticaria</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Dengvaxia alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20869</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of the study was to assess the efficacy of sanofi pasteur's CYD dengue vaccine ( Dengvaxia ) in preventing symptomatic virologically-confirmed dengue cases for dengue-endemic areas of Latin America. The primary objective of this study was to assess the efficacy of CYD dengue vaccine after three vaccinations at 0, 6 and 12 months in preventing symptomatic virologically-confirmed dengue cases, regardless of the severity, due to any of the four serotypes in children and adolescents aged 9 to</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Dengue Vaccine - Assessment of Disease Incidence</EndpointIndex><EndpointIndex>Dengue Vaccine - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Dengue virus infection - Assessment of Disease Incidence</EndpointIndex><EndpointIndex>Dengue virus infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America</TitleDisplay><PatientSegmentTerms><PatientSegment>Dengue Vaccine - Subjects with Dengue Fever - People living in endemic areas</PatientSegment><PatientSegment>Dengue virus infection - Subjects at Risk of Dengue Fever - People living in endemic areas</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anti Dengue virus antibodies </BiomarkerName><BiomarkerName> Anti-Yellow fever virus antibodies </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Immunoglobulin G </BiomarkerName><BiomarkerName> Immunoglobulin M</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>80 Months</TrialDuration><NumberOfSites>21</NumberOfSites><ContactNames><Name>Medical Director</Name></ContactNames></Trial><Trial Id="77559"><Indications><Indication>Ankylosing spondylitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-17 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>Mexico</Country><Country>US</Country><Country>Peru</Country><Country>Netherlands</Country><Country>UK</Country><Country>France</Country><Country>Taiwan</Country><Country>Belgium</Country><Country>Italy</Country><Country>Turkey</Country><Country>Russian Federation</Country><Country>Bulgaria</Country><Country>Canada</Country></Countries><DateChangeLast>2019-05-15T00:00:00Z</DateChangeLast><DateEnd>2014-12-31T00:00:00Z</DateEnd><DateStart>2011-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2010-024529-18</Identifier><Identifier>CAIN457F2305</Identifier><Identifier>CCRN 620</Identifier><Identifier>F2305</Identifier><Identifier>MEASURE 1</Identifier><Identifier>NCT01358175</Identifier><Identifier>UKCRN ID: 11043</Identifier></Identifiers><IndicationsAdverse><Indication>Candida infection</Indication><Indication>Diarrhea</Indication><Indication>Headache</Indication><Indication>Lipid metabolism disorder</Indication><Indication>Neutropenia</Indication><Indication>Pharyngitis</Indication><Indication>Rhinopharyngitis</Indication><Indication>Solid tumor</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>secukinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>371</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>adverse events. Improvements with secukinumab were sustained regardless of the anti-TNF status. Overall, secukinumab was well-tolerated with a safety profile through two years [ 1709789 ]. In November 2015, results were presented. Nasopharyngitis (common &lt;b&gt;cold&lt;/b&gt;; 24.3%), diarrhea (13.8%), headache (12.2%) and pharyngitis (sore throat; 11.6%) were the most common adverse events (AEs) observed in patients treated with secukinumab 150 mg at Week 104. Patiwnts (86.7%) experienced an AE and 12.2% experienced a </Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Spinal Mobility - Bath ankylosing spondylitis metrology index (BASMI)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Pharmacoeconomic Assessments</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Response to Therapy (ASAS criteria) - Assessments in Ankylosing Spondylitis (ASAS) 20</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Response to Therapy (ASAS criteria) - Assessments in Ankylosing Spondylitis (ASAS) 40</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>MEASURE 1: A 16-Week Efficacy and Two-Year Long-Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Ankylosing spondylitis - Active Ankylosing Spondylitis</PatientSegment><PatientSegment>Ankylosing spondylitis - Moderate Ankylosing Spondylitis (AS)</PatientSegment><PatientSegment>Ankylosing spondylitis - Severe Ankylosing Spondylitis (AS)</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with History of Use of Ankylosing Spondylitis Medications - Anti-TNF therapy</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with History of Use of Ankylosing Spondylitis Medications - NSAIDs</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with Treatment Resistant Disease - Subjects with NSAID resistant disease</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with Treatment Resistant Disease - Subjects with anti-TNF therapy resistant disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alkaline phosphatase, bone specific </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> C-terminal telopeptide of collagen type I </BiomarkerName><BiomarkerName> Joint swelling </BiomarkerName><BiomarkerName> Joint tenderness </BiomarkerName><BiomarkerName> Osteocalcin </BiomarkerName><BiomarkerName> Procollagen Type I N-terminal peptide </BiomarkerName><BiomarkerName> Procollagen type I carboxy terminal peptide </BiomarkerName><BiomarkerName> Sclerostin </BiomarkerName><BiomarkerName> Tumor necrosis factor </BiomarkerName><BiomarkerName> Tumor necrosis factor receptor superfamily member 11B</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>38 Months</TrialDuration><NumberOfSites>85</NumberOfSites><ContactNames><Name>Clinical Trial Information Desk</Name><Name>Dr. Atul Deodhar</Name><Name>Dr. Proton Rahman</Name><Name>Drug Regulatory Affairs</Name><Name>Medical Information Services</Name><Name>Medizinischer Infoservice</Name><Name>Novartis Pharma Services AG</Name><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="77484"><Indications><Indication>Gout</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Glucocorticoid receptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin G1 agonist</Action><Action>Interleukin-1 beta ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action><Action>Cardioprotectant</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Biological therapeutic</Technology><Technology>DNA technology</Technology><Technology>Dermatological formulation</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intra-articular formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Nasal formulation local</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>Hungary</Country><Country>Lithuania</Country><Country>Canada</Country><Country>US</Country></Countries><DateChangeLast>2018-11-09T00:00:00Z</DateChangeLast><DateEnd>2012-03-31T00:00:00Z</DateEnd><DateStart>2011-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2010-024173-39</Identifier><Identifier>CACZ885H2361</Identifier><Identifier>NCT01356602</Identifier></Identifiers><IndicationsAdverse><Indication>Aortitis</Indication><Indication>Cardiac failure</Indication><Indication>Constipation</Indication><Indication>Delirium</Indication><Indication>Migraine</Indication><Indication>Muscle injury</Indication><Indication>Pain</Indication><Indication>Staphylococcus infection</Indication><Indication>Unstable angina</Indication><Indication>Viral respiratory tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>canakinumab alone</Intervention><Intervention>canakinumab-LYO alone</Intervention><Intervention>canakinumab-PFS alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>397</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Use of the following therapies (within varying protocol defined timeframes): corticosteroids, narcotics, topical ice/&lt;b&gt;cold&lt;/b&gt; packs, chronic opiate treatment, NSAID (such as aspirin), colchicine Hemodialysis Live vaccine within 3 months before first dose Donation or loss of &gt;/= 400 ml within 3 months before first dose Gout brought on by other factors such as chemotherapy,</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Gout - Assessment of disease flare</EndpointIndex><EndpointIndex>Gout - Assessment of disease flare - Proportion of subjects requiring treatment for gout flares</EndpointIndex><EndpointIndex>Gout - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Gout - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Pain by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Gout - Patient Reported Outcomes/Quality of Life Assessments - Physician patient questionnaire(PPQ)</EndpointIndex><EndpointIndex>Gout - Physician Global Assessment of Disease Activity</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Musculoskeletal disease related outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Gout - Hyperuricemic Subjects with Gout</PatientSegment><PatientSegment>Gout - Subjects with Acute Gout - Subjects with acute gout flares</PatientSegment><PatientSegment>Gout - Subjects with Treatment Resistant Disease - Subjects with NSAID resistant disease</PatientSegment><PatientSegment>Gout - Subjects with Treatment Resistant Disease - Subjects with colchicine resistant disease</PatientSegment><PatientSegment>Gout - Subjects with Use of Anti-Gout Medications</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with arthritic pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>99</NumberOfSites><ContactNames><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="77110"><Indications><Indication>Raynauds disease</Indication><Indication>Scleroderma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>PDE 5 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>5-HETE modulator</Action><Action>Antihypertensive</Action><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Fundacao de Amparo a Pesquisa do Estado Sao Paulo</Company></CompaniesCollaborator><CompaniesSponsor><Company>Federal University of Sao Paulo</Company></CompaniesSponsor><Countries><Country>Brazil</Country></Countries><DateChangeLast>2018-11-15T00:00:00Z</DateChangeLast><DateEnd>2013-01-31T00:00:00Z</DateEnd><DateStart>2011-04-30T00:00:00Z</DateStart><Identifiers><Identifier>FAPESP 2011/00012-3</Identifier><Identifier>NCT01347008</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>sildenafil citrate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>41</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>results were published in October 2017 [ 2013083 ]. In October 2017, further results were published. Patients in sildenafil compared to placebo group reported a significantly higher mean percentage change from baseline in FBF before &lt;b&gt;cold&lt;/b&gt; stimulus (p = 0.026) and after &lt;b&gt;cold&lt;/b&gt; stimulus (p = 0.028) at 8 weeks, respectively. Patients in sildenafil group compared to placebo showed significant improvement in the percentage change from baseline to week 8 in the RP VAS score. No changes were seen in VEGF levels</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Functional Disability/Physical Function - Assessment by Raynaud Condition Score (RCS)</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of vascular endothelial growth factor (VEGF)</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Laboratory/Diagnostic Measures - Assessment of endothelial progenitor cells</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Wound Healing - Assessment of ulcer healing</EndpointIndex><EndpointIndex>Peripheral vascular disease - Imaging/Radiological Assessments - doppler</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - Subjects with raynaud's disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood flow </BiomarkerName><BiomarkerName> Endothelial progenitor cells </BiomarkerName><BiomarkerName> Hematopoietic progenitor cell antigen CD34 </BiomarkerName><BiomarkerName> Prominin-1 </BiomarkerName><BiomarkerName> Vascular endothelial growth factors</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Fernando V Andrigueti, MD</Name></ContactNames></Trial><Trial Id="77013"><Indications><Indication>Rhinovirus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Leukotriene C4 antagonist</Action><Action>Leukotriene D4 antagonist</Action><Action>Leukotriene E4 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>AstraZeneca plc</Company></CompaniesSponsor><DateChangeLast>2011-05-02T00:00:00Z</DateChangeLast><DateStart>1999-05-11T00:00:00Z</DateStart><Identifiers><Identifier>9188US/0020</Identifier></Identifiers><IndicationsAdverse><Indication>Insomnia</Indication><Indication>Xerostomia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>zafirlukast alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>55</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>The purpose of this phase III, double-blind, placebo-controlled trial was to evaluate the safety and efficacy of zafirlukast for the treatment of symptoms associated with rhinovirus infection [ 1187565 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>A phase III, double-blind, placebo-controlled trial to evaluate the safety and efficacy of zafirlukast for the treatment of symptoms associated with rhinovirus infection</TitleDisplay><BiomarkerNames><BiomarkerName>Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="76298"><Indications><Indication>Factor IX deficiency</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Factor IX agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Coagulation stimulator</Action><Action>Vulnerary agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Glycoprotein</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>PEGylated formulation</Technology><Technology>Protein recombinant</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>Novo Nordisk A/S</Company></CompaniesSponsor><Countries><Country>Italy</Country><Country>France</Country><Country>US</Country><Country>Malaysia</Country><Country>Russian Federation</Country><Country>Hungary</Country><Country>Germany</Country><Country>Thailand</Country><Country>Macedonia, The Former Yugoslav Republic of</Country><Country>Japan</Country><Country>UK</Country><Country>Canada</Country><Country>Netherlands</Country><Country>South Africa</Country><Country>Turkey</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2013-03-31T00:00:00Z</DateEnd><DateStart>2011-04-27T00:00:00Z</DateStart><Identifiers><Identifier>2010-023069-24</Identifier><Identifier>JapicCTI-111644</Identifier><Identifier>NCT01333111</Identifier><Identifier>NMRR-11-493-9528</Identifier><Identifier>NN7999-3747</Identifier><Identifier>Paradigm 2</Identifier><Identifier>U1111-1119-6415</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>nonacog beta pegol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>74</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this 52-week, single-blinded, randomized trial was to evaluate the safety and efficacy, including pharmacokinetics, of NNC-0156-0000-0009 (nonacog beta pegol) when used for treatment and prophylaxis of bleeding episodes in patients with hemophilia B [ 1427308 ], [ 1496839 ], [ 1725602 ], [ 2021695 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hemophilia - Assessment of Clinical Symptoms - Assessment of bleeding episodes</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Hemophilia - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Paradigm 2: Safety and Efficacy of NNC-0156-0000-0009 in Hemophilia B Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Hemophilia - Subjects with Hemophilia B</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Coagulation factor IX</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>45</NumberOfSites><ContactNames><Name>Chua Swee Choo @ Justine Chua</Name><Name>Global Clinical Registry (GCR, 1452)</Name><Name>Novo Nordisk</Name><Name>Shantini Evelyn Chelliah</Name></ContactNames></Trial><Trial Id="76048"><Indications><Indication>Varicella zoster virus infection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Antiviral</Action><Action>HSV replication inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>HSV replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Nucleoside synthesis</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>EMS SA</Company></CompaniesSponsor><Countries><Country>Brazil</Country></Countries><DateChangeLast>2019-04-21T00:00:00Z</DateChangeLast><DateEnd>2017-07-31T00:00:00Z</DateEnd><DateStart>2012-06-30T00:00:00Z</DateStart><Identifiers><Identifier>F500EMS1010</Identifier><Identifier>NCT01327144</Identifier></Identifiers><IndicationsAdverse><Indication>Back pain</Indication><Indication>Common cold</Indication><Indication>Diarrhea</Indication><Indication>Drowsiness</Indication><Indication>Headache</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>aciclovir alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>famciclovir alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>177</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>In July 2018, results were published. Headache, diarrhea, nausea, back pain, &lt;b&gt;cold&lt;/b&gt;, and drowsiness were the most common adverse events in both the groups, but were reported to be clinically insignificant [ 2060920 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Post Herpetic Neuralgia</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Herpesvirus infection - Patient Reported Outcomes/Quality of Life Assessments - Other patient reported outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With Herpes Zoster</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Varicella Zoster Virus Infections - Subjects with shingles/herpes zoster</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with pain associated with infections</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2017-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>61 Months</TrialDuration><NumberOfSites>5</NumberOfSites><ContactNames><Name>Felipe Pinho</Name><Name>Joyce Silva</Name></ContactNames></Trial><Trial Id="75744"><Indications><Indication>Herpesvirus infection</Indication></Indications><CompaniesSponsor><Company>BlueWillow Biologics</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-06-30T00:00:00Z</DateChangeLast><DateEnd>2012-01-31T00:00:00Z</DateEnd><DateStart>2011-04-30T00:00:00Z</DateStart><Identifiers><Identifier>NB-001-004</Identifier><Identifier>NCT01321359</Identifier><Identifier>SHaRCS</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>NB-001 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>907</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>eligibility criteria would be randomized in the study. Subjects would begin treatment as soon as they experience the onset of &lt;b&gt;cold&lt;/b&gt; sore symptoms. Treatment would be applied five times daily, approximately 3 to 4 h apart while awake. Treatment would...by a history of three or more &lt;b&gt;cold&lt;/b&gt; sore recurrences on the lips and/or skin surrounding the lips in the previous 12 months Have the majority of their &lt;b&gt;cold&lt;/b&gt; sore recurrences proceeded by a well defined history of prodromal symptoms</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Development in aborted lesion</EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Healing</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SHaRCS: A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections</PatientSegment><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections - Subjects with orofacial herpes</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>35</NumberOfSites><ContactNames><Name>Ginger Callison</Name><Name>Helen Chao</Name><Name>Janis Caldwell</Name><Name>Karen Breisinger</Name><Name>Kim Cruz</Name><Name>Michele Abernethy</Name><Name>Randi Derner</Name><Name>Roberto Aguirre</Name><Name>Sherri Chatham</Name><Name>Sue Denson</Name></ContactNames></Trial><Trial Id="74997"><Indications><Indication>Cryopyrin associated periodic syndrome</Indication><Indication>Familial cold autoinflammatory syndrome</Indication><Indication>Muckle Wells syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin G1 agonist</Action><Action>Interleukin-1 beta ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action><Action>Cardioprotectant</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>DNA technology</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intra-articular formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company><Company>Novartis Oncology</Company><Company>Novartis Pharma Services AG</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>Switzerland</Country><Country>UK</Country><Country>Ireland</Country><Country>Spain</Country><Country>France</Country><Country>Belgium</Country><Country>Germany</Country></Countries><DateChangeLast>2019-07-02T00:00:00Z</DateChangeLast><DateEnd>2014-11-30T00:00:00Z</DateEnd><DateStart>2010-11-30T00:00:00Z</DateStart><Identifiers><Identifier>2009-016859-22</Identifier><Identifier>CACZ885D2307</Identifier><Identifier>D2307</Identifier><Identifier>NCT01302860</Identifier><Identifier>P/208/2011</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>canakinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>17</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>months of age at the time of the screening visit Body weight&gt;/= 2.5 Kg Parent or legal guardian's written informed consent is required before any assessment is performed for patients At study entry, patients should have a clinical diagnosis of familial &lt;b&gt;cold&lt;/b&gt; autoinflammatory syndrome (FCAS), muckle-wells syndrome (MWS), or neonatal onset multisystem inflammatory disease (NOMID) and symptoms requiring pharmacological intervention. Prior agreement between the investigator and Novartis for study eligibility</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Immune Response</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Morbidity</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Safety and Tolerability - Assessment of serious/treatment emergent adverse events</EndpointIndex><EndpointIndex>Other neurological disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other neurological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other neurological disease - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Urticaria - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Urticaria - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Urticaria - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Urticaria - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Urticaria - Assessment of Therapy Related Outcomes - Overall therapeutic response</EndpointIndex><EndpointIndex>Urticaria - Assessment of adverse events</EndpointIndex><EndpointIndex>Urticaria - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Urticaria - Clinical Assessments</EndpointIndex><EndpointIndex>Urticaria - Investigator's Global Assessment (IGA)</EndpointIndex><EndpointIndex>Urticaria - Other Protocol Specified Outcomes</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy, Safety and Tolerability of ACZ-885 in Pediatric Patients With the Following Cryopyrin-Associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Other neurological disease - Others - Children and adolescents</PatientSegment><PatientSegment>Other neurological disease - Others - Neonates</PatientSegment><PatientSegment>Other neurological disease - Subjects with specific disease</PatientSegment><PatientSegment>Urticaria - Subjects with gene variants - NLRP3_HUMAN_Mutation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> NACHT, LRR and PYD domains-containing protein 3 </BiomarkerName><BiomarkerName> Serum amyloid A protein 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>18</NumberOfSites><ContactNames><Name>Chief Scientific Officer</Name><Name>Medical Information Services</Name><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="74356"><Indications><Indication>Parkinsons disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcium channel modulator</Action><Action>Dopamine receptor agonist</Action><Action>MAO B inhibitor</Action><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticonvulsant agent</Action><Action>Antiparkinsonian</Action><Action>Dopamine uptake inhibitor</Action><Action>Glutamate release inhibitor</Action><Action>Neuroprotectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Newron Pharmaceuticals SpA</Company></CompaniesSponsor><DateChangeLast>2018-12-04T00:00:00Z</DateChangeLast><DateEnd>2010-08-31T00:00:00Z</DateEnd><DateStart>2007-08-31T00:00:00Z</DateStart><Identifiers><Identifier>2006-005861-21</Identifier><Identifier>NCT01286935</Identifier><Identifier>NW-1015/018/III/2006</Identifier></Identifiers><IndicationsAdverse><Indication>Depression</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>safinamide alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>544</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> chronic pain and to confirm the positive effects observed after 6 months of treatment. When compared to placebo, safinamide showed significant improvements in the PDQ-39 items 37 ('painful cramps or spasm'; p = 0.0074) and 39 ('unpleasantly hot or &lt;b&gt;cold&lt;/b&gt;'; p = 0.0209) and reductions in the number of concomitant pain treatments by 26.2% (p = 0.005). After two years of treatment, significantly greater proportion of patients treated in the safinamide group were not using pain drugs (p = 0.0478) [ 2042299</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Disability Measured by Unified Parkinson’s Disease Rating Scale (UPDRS) - Assessment of UPDRS Part II scale/score</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Disability Measured by Unified Parkinson’s Disease Rating Scale (UPDRS) - Assessment of UPDRS Part III scale/score</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Disability Measured by Unified Parkinson’s Disease Rating Scale (UPDRS) - Assessment of UPDRS Part IV scale/score</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Dyskinesia</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Parkinson's Disease ON-OFF States - Assessment of OFF state of Parkinson's disease</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Parkinson's Disease ON-OFF States - Assessment of ON state of Parkinson's disease</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Sleep - Assessment of sleep parameters</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Therapy Related Outcomes - Assessment of drop-out rate/withdrawal rate</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Parkinsons disease - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A 18-Month Study of Long-Term Efficacy and Safety of Safinamide as Add-On Therapy in Patients With Mid-Late Stage PD</TitleDisplay><PatientSegmentTerms><PatientSegment>Parkinsons disease - Subjects with Advanced/Late Stage Parkinson's Disease</PatientSegment><PatientSegment>Parkinsons disease - Subjects with Motor Symptoms of Parkinson's Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>See Study 016 for details</Name></ContactNames></Trial><Trial Id="7435"><Indications><Indication>Heart transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Switzerland</Country><Country>Italy</Country><Country>Germany</Country><Country>Spain</Country></Countries><DateChangeLast>2016-11-22T00:00:00Z</DateChangeLast><DateEnd>2007-05-31T00:00:00Z</DateEnd><DateStart>2004-12-31T00:00:00Z</DateStart><Identifiers><Identifier>2004-001052-36</Identifier><Identifier>CRAD001A2411</Identifier><Identifier>NCT00150046</Identifier><Identifier>RAD2411</Identifier></Identifiers><InterventionsControlDisplay><Intervention>ciclosporin, Novartis plus mycophenolate mofetil</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>ciclosporin, Novartis plus everolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>176</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> or treatment within 1 month prior to randomization Patients receiving induction therapy which is not standard per local practice Patients with donor &gt; 60 years and/or with known donor coronary or heart disease at the time of transplant Donor heart &lt;b&gt;cold&lt;/b&gt; ischemic time &gt; 6 h Patients with panel reactive antibodies &gt; 20% Patients who are recipients of ABO incompatible transplants Patients with platelet count&amp;lt; 50,000/mm3 at the evaluation before randomization Presence of severe hypercholesterolemia</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR)</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Heart transplantation - Protocol Specified Other Endpoints - Efficacy parameters - unspecified</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Function</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Replacement Therapy(RRT) - Assessment of transplant</EndpointIndex><EndpointIndex>Renal failure - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>Heart transplantation - Heart Transplant Recipients</PatientSegment><PatientSegment>Heart transplantation - Heart Transplant Recipients - Primary (First) Heart Transplant Recipients</PatientSegment><PatientSegment>Renal failure - Subjects with History/Scheduled for Other Transplantations</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2007-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>29 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Basel Novartis Pharma AG</Name></ContactNames></Trial><Trial Id="73782"><Indications><Indication>Bronchitis</Indication><Indication>Upper respiratory tract infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antitussive</Action><Action>Antiviral</Action><Action>Expectorant</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Ewha Womans University</Company><Company>Hanyang University</Company><Company>Inha University</Company><Company>Konkuk University</Company><Company>Kyung Hee University</Company></CompaniesCollaborator><CompaniesSponsor><Company>Ahn-Gook Pharmaceuticals Co Ltd</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2017-01-23T00:00:00Z</DateChangeLast><DateEnd>2010-06-30T00:00:00Z</DateEnd><DateStart>2010-02-28T00:00:00Z</DateStart><Identifiers><Identifier>AG NPP_P3</Identifier><Identifier>EudraCT: 2007-003272-19</Identifier><Identifier>NCT01151202</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>AG-NPP709 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>236</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to assess therapeutic confirmation of AG-NPP709 syrup to evaluate the safety and efficacy in patients with acute upper respiratory tract infection and chronic inflammatory bronchitis.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exercise Capacity/Tolerance</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Therapy Related Outcomes - Cure rates/success rates</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG-NPP709 Syrup</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Chronic Bronchitis</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Symptomatic Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>4 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Dae-Hyun Lim</Name><Name>Ho-Joo Yoon</Name><Name>Jung Han</Name><Name>Sun-Hee Choi</Name><Name>Young-ho Na, PhD, MD</Name></ContactNames></Trial><Trial Id="73266"><Indications><Indication>Urticaria</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin E antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Genentech Inc</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>Australia</Country><Country>US</Country><Country>New Zealand</Country><Country>Singapore</Country><Country>Switzerland</Country><Country>Germany</Country><Country>Poland</Country></Countries><DateChangeLast>2018-04-20T00:00:00Z</DateChangeLast><DateEnd>2012-11-30T00:00:00Z</DateEnd><DateStart>2011-02-28T00:00:00Z</DateStart><Identifiers><Identifier>2010-022784-35</Identifier><Identifier>GA00889</Identifier><Identifier>GLACIAL</Identifier><Identifier>NCT01264939</Identifier><Identifier>Q4883g</Identifier><Identifier>UKCRN ID: 10115</Identifier></Identifiers><IndicationsAdverse><Indication>Cough</Indication><Indication>Diarrhea</Indication><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Rhinopharyngitis</Indication><Indication>Sinusitis</Indication><Indication>Upper respiratory tract inflammation</Indication><Indication>Urticaria</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>omalizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>336</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>agent within 30 days of day-14 Weight&amp;lt; 20 kg (44 lbs) Clearly defined underlying etiology for chronic urticarias other than CIU (main manifestation being physical urticaria). This includes the following urticarias: acute, solar, cholinergic, heat, &lt;b&gt;cold&lt;/b&gt;, aquagenic, delayed pressure or contact and as well as the following diseases as these diseases may have symptoms of urticaria or angioedema: urrticarial vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary or acquired angioedema</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms - Assessment of pruritus(itch) severity</EndpointIndex><EndpointIndex>Urticaria - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Urticaria - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>GLACIAL: A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1-Antihistamines, H2-Blockers, and/or Leukotriene Receptor Antagonists</TitleDisplay><PatientSegmentTerms><PatientSegment>Urticaria - Subjects with Chronic Urticaria - Subjects with chronic idiopathic urticaria(CIU)</PatientSegment><PatientSegment>Urticaria - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Basophils </BiomarkerName><BiomarkerName> Histamine</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>73</NumberOfSites><ContactNames><Name>Dr Derrick Aw Chen Wee</Name><Name>Dr Tay Yong Kwang</Name><Name>Edward R. Conner, M.D.</Name></ContactNames></Trial><Trial Id="71013"><ActionsSecondaryInterventionsControl><Action>Inactivated viral vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Prophylactic vaccine</Action><Action>Protein subunit vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Injectable formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Italy</Country><Country>Finland</Country><Country>Germany</Country></Countries><DateChangeLast>2017-08-07T00:00:00Z</DateChangeLast><DateEnd>2010-08-31T00:00:00Z</DateEnd><DateStart>2007-11-30T00:00:00Z</DateStart><Identifiers><Identifier>Eudract number 2007-003786-41</Identifier><Identifier>NCT00644059</Identifier><Identifier>NCT01015885</Identifier><Identifier>V70P5</Identifier><Identifier>V70P5TER</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Agrippal S1 alone</Intervention><Intervention>Fluarix alone</Intervention><Intervention>meningococcal C conjugate vaccine alone</Intervention><Intervention>tick-borne encephalitis vaccine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Fluad alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>4902</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>and participation in another clinical trial during the present study Experience of a severe acute infectious disease in the month prior to study start or experience of a mild acute infection disease in the week prior the study start (untreated common &lt;b&gt;cold&lt;/b&gt; is acceptable). The severity of the infectious disease occurred will be based on the investigator's judgment Any severe acute respiratory disease and infection requiring systemic antibiotic or antiviral therapy ongoing or resolved within 2 days prior</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Influenza Vaccine - Incidence of Influenza/Influenza Like Illness</EndpointIndex><EndpointIndex>Influenza Vaccine - Incidence of Laboratory Confirmed Influenza</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of cellular immunity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Influenza virus infection - Incidence of Influenza/Influenza Like Illness</EndpointIndex><EndpointIndex>Influenza virus infection - Incidence of Laboratory Confirmed Influenza</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Assessment of Immune Response - Assessment of anti-polyribosyl-ribitol-phosphate antibody concentration (PRP)</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Assessment of Safety and Tolerability - Assessment of local reactions</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Assessment of Safety and Tolerability - Assessment of systemic reactions</EndpointIndex><EndpointIndex>Meningococcal Vaccine - Protocol Specified Other Endpoints - Unspecified efficacy assessment</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subject (Aged 6 to &lt; 72 Months) Versus Control Vaccines</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>33 Months</TrialDuration><NumberOfSites>102</NumberOfSites><ContactNames><Name>Novartis Vacccines and Diagnostics</Name></ContactNames></Trial><Trial Id="7011"><Indications><Indication>Carpal tunnel syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Controlled release formulation</Technology><Technology>Local formulation unspecified</Technology><Technology>Patch formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Endo Health Solutions Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2007-01-01T00:00:00Z</DateEnd><DateStart>2005-11-30T00:00:00Z</DateStart><Identifiers><Identifier>EN3272-301</Identifier><Identifier>NCT00266214</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lidocaine patch, Immune Pharmaceuticals alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>210</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Sponsor/Business Decision</Reason></ReasonForTrialDiscontinuation><Teaser>severe CTS as defined by electrodiagnostic findings Have had steroid injections for CTS in the previous 3 months Have used diuretics (except a stable dose for hypertension) or Vitamin B6 or topical treatments for CTS (eg, ultrasound, iontophoresis, &lt;b&gt;cold&lt;/b&gt; laser) in the past 2 weeks Require sleep medications Are using a lidocaine-containing product that cannot be discontinued during the study Have a known sensitivity or allergy to an amide-type local anesthetic agent para-aminobenzoic (PABA) derivatives</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>PPD</Name></ContactNames></Trial><Trial Id="6983"><Indications><Indication>Insomnia</Indication></Indications><ActionsPrimaryInterventionsControl><Action>GABA A receptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsSecondaryInterventionsControl><Action>Hypnotic</Action></ActionsSecondaryInterventionsControl><Technologies><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2017-08-06T00:00:00Z</DateChangeLast><DateEnd>2007-06-27T00:00:00Z</DateEnd><DateStart>2006-02-28T00:00:00Z</DateStart><Identifiers><Identifier>6199-CL-0007</Identifier><Identifier>JapicCTI-060278</Identifier><Identifier>NCT00283946</Identifier></Identifiers><IndicationsAdverse><Indication>Anemia</Indication><Indication>Diarrhea</Indication><Indication>Dizziness</Indication><Indication>Drowsiness</Indication><Indication>Emesis</Indication><Indication>Headache</Indication><Indication>Hypertension</Indication><Indication>Nausea</Indication><Indication>Palpitation</Indication><Indication>Rhinopharyngitis</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>zolpidem (immediate-release, insomnia), Sanofi alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>zolpidem (controlled-release, insomnia), Sanofi alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>876</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> &gt;/= 45 min per night within 4 weeks before the start of the run-in period according to the health check sheet Patients who had a washout period before the start of the run-in period, when given antihistamine (H1 blocker only, including combination &lt;b&gt;cold&lt;/b&gt; remedy, except for eye-drops, nose drops or external medicine), hypnotics, or anxiolytic or antidepressant drugs for sleep Patients aged between 20 and 65 when their informed consent was obtained Patients who had an ability to fill in the sleep diary</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Insomnia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of early morning awakening</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of number of awakenings</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of sleep onset latency (SOL)</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of total sleep time (TST)</EndpointIndex><EndpointIndex>Insomnia - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>A Double-Blind, Group-Comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With Insomnia</TitleDisplay><PatientSegmentTerms><PatientSegment>Insomnia - Subjects with comorbid conditions</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>16 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Astellas Pharma Inc.</Name><Name>Central Contact</Name></ContactNames></Trial><Trial Id="69746"><Indications><Indication>Schizoaffective disorder</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>5-HT receptor antagonist</Action><Action>Dopamine D2 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antipsychotic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intramuscular formulation</Technology><Technology>Nanoparticle formulation injectable</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesCollaborator><Company>Quintiles Malaysia Sdn Bhd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Janssen Scientific Affairs</Company><Company>Ortho-McNeil Janssen Scientific Affairs, LLC</Company></CompaniesSponsor><Countries><Country>US</Country><Country>South Africa</Country><Country>Malaysia</Country><Country>Romania</Country><Country>India</Country><Country>Philippines</Country><Country>Ukraine</Country><Country>Bulgaria</Country></Countries><DateChangeLast>2018-04-27T00:00:00Z</DateChangeLast><DateEnd>2013-10-31T00:00:00Z</DateEnd><DateStart>2010-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2009-017271-17</Identifier><Identifier>6795</Identifier><Identifier>CR016618</Identifier><Identifier>CTRI/2011/091/000008</Identifier><Identifier>NCT01193153</Identifier><Identifier>NMRR-10-753-6795</Identifier><Identifier>R092670SCA3004</Identifier></Identifiers><IndicationsAdverse><Indication>Akathesia</Indication><Indication>Headache</Indication><Indication>Insomnia</Indication><Indication>Pain</Indication><Indication>Rhinopharyngitis</Indication><Indication>Tremor</Indication><Indication>Weight gain</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>paliperidone (open-label period) alone</Intervention><Intervention>paliperidone palmitate alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>667</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>were published in May 2014. Weight gain (8.5% in paliperidone palmitate versus 4.7% in placebo), insomnia (4.9 versus 7.1%), worsening of schizoaffective disorder (3.1 versus. 5.9%), headache (5.5 versus 3.5%) and nasopharyngitis, which is the common &lt;b&gt;cold&lt;/b&gt; (5.5 versus 3.5%) were the adverse events observed in &gt; 5% of patients. Akathisia (3.0% in paliperidone palmitate  versus 1.8% in placebo) and tremor (1.2 versus 2.4%) were the most common movement disorders observed. Increase in body weight (&gt;/= 7%</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Co-morbidity - Assessment of depression</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Functional Disability/Physical Function - Assessment of subjects by Personal and Social Performance Scale (PSP)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Psychiatric Symptoms - Assessment of subjects by PANSS (Positive And Negative Syndrome Scale)</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Symptoms of Schizophrenia - Assessment of negative symptoms</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Therapy Related Outcomes - Assessment of relapse/exacerbation</EndpointIndex><EndpointIndex>Schizophrenia - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Medication Satisfaction Questionnaire (MSQ)</EndpointIndex><EndpointIndex>Schizophrenia - Patient Reported Outcomes/Quality of Life Assessments - Assessment of subjects by CGI-S scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder</TitleDisplay><PatientSegmentTerms><PatientSegment>Schizophrenia - Subjects at risk of developing disease - Subjects with schizophrenia spectrum disorder</PatientSegment><PatientSegment>Schizophrenia - Subjects with Other Neuro-psychiatric Diseases/Disorders - Subjects with other psychotic disorders</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Prolactin </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>37 Months</TrialDuration><NumberOfSites>81</NumberOfSites><ContactNames><Name>Anil Nischal</Name><Name>Dong-Jing Fu, M.D., PhD</Name><Name>Hitendra Gandhi</Name><Name>Janssen Scientific Affairs, LLC Clinical Trial</Name><Name>Sangha Mitra Patnaik</Name><Name>Shoibal Mukherjee</Name><Name>Suarn Singh</Name><Name>Venu Jhanwar</Name><Name>Vinay Barhale</Name><Name>Vishal Indla</Name><Name>Yeoh Sin Yee</Name></ContactNames></Trial><Trial Id="69435"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Veloxis Pharmaceuticals A/S</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>Italy</Country><Country>Brazil</Country><Country>Poland</Country><Country>Spain</Country><Country>Sweden</Country><Country>Argentina</Country><Country>New Zealand</Country><Country>Mexico</Country><Country>Serbia</Country><Country>France</Country><Country>US</Country><Country>Australia</Country><Country>Singapore</Country><Country>South Korea</Country></Countries><DateChangeLast>2019-01-03T00:00:00Z</DateChangeLast><DateEnd>2014-03-31T00:00:00Z</DateEnd><DateStart>2010-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2008-003241-89</Identifier><Identifier>DRKS00006514</Identifier><Identifier>LCP-Tacro-3002</Identifier><Identifier>LCPTacro3002</Identifier><Identifier>NCT01187953</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Edema</Indication><Indication>Headache</Indication><Indication>Insomnia</Indication><Indication>Nausea</Indication><Indication>Tremor</Indication><Indication>Urinary tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Variable regimens including basiliximab , mycophenolate mofetil , tacrolimus</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including basiliximab , mycophenolate mofetil , tacrolimus (improved tablet formulation), Veloxis/Chiesi/Paladin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>543</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>positive serological test result for HIV-1, HBV or HCV Donor with history of malignant disease (current or historical) Centers for disease control and prevention high-risk donor Patients with mental dysfunction or inability to cooperate with the study &lt;b&gt;Cold&lt;/b&gt; ischemia time&gt; 30 h Non-heart-beating donor</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Bioavailability</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Composite Endpoints - Frequency of treatment failure</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Double-Blind, Double-Dummy, Efficacy/Safety, LCP-Tacro versus Prograf, Prevention Rejection, De Novo Adult Kidney Transplant</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - De Novo Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood platelets </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Transaminases </BiomarkerName><BiomarkerName> Triglycerides</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>42 Months</TrialDuration><NumberOfSites>89</NumberOfSites><ContactNames><Name>Alan Glicklich</Name><Name>Dr Terence Kee Yi Shern</Name><Name>Dr Vathsala Anatharaman</Name><Name>Ronald Guido</Name></ContactNames></Trial><Trial Id="69163"><Indications><Indication>Autoimmune hemolytic anemia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>B-lymphocyte antigen CD20 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Chimeric monoclonal antibody</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Roche Holding AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Assistance Publique Hopitaux de Paris</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2016-01-08T00:00:00Z</DateEnd><DateStart>2011-03-03T00:00:00Z</DateStart><Identifiers><Identifier>2008-008255-42</Identifier><Identifier>NCT01181154</Identifier><Identifier>P080704</Identifier><Identifier>RAHIA</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>rituximab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>32</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>immunosuppressive drugs Any other associated cause congenital or acquired hemolytic anemia (except thalassemia trait or heterozygous sickle cell anemia) Negative DAT or DAT positive with isolated anti-C3d pattern related to the presence of a monoclonal Ig M with &lt;b&gt;cold&lt;/b&gt; agglutinin properties Positive HIV test and/or hepatitis virus C infection and/or positive hepatitis B virus surface antigen (HbsAg) Neutrophils count&amp;lt; 1000/mm3 at inclusion Impaired renal function as indicated by a serum creatinine level&gt; 2 mg/</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anemia - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Anemia - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Anemia - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Anemia - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)</EndpointIndex><EndpointIndex>Anemia - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Anemia - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Anemia - Assessment of Therapy Related Outcomes - Assessment of cumulative treatment</EndpointIndex><EndpointIndex>Anemia - Assessment of Transfusions - Assessment of red blood cell transfusions</EndpointIndex><EndpointIndex>Anemia - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Splenectomy</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of Transfusions - Assessment of red blood cell transfusions</EndpointIndex><EndpointIndex>Idiopathic thrombocytopenic purpura - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Therapy Related Outcomes - Assessment of number of transfusions</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>RAHIA: Rituximab in Autoimmune Hemolytic Anemia</TitleDisplay><PatientSegmentTerms><PatientSegment>Anemia - Subjects with Hemolytic Anemia - Subjects with autoimmune hemolytic anemia</PatientSegment><PatientSegment>Thrombocytopenia - Subjects with Immune (Idiopathic) Thrombocytopenia - Subjects with autoimmune thrombocytopenia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2015-01-08T00:00:00Z</PrimaryCompletionDate><TrialDuration>58 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Marc MICHEL, MD</Name></ContactNames></Trial><Trial Id="68905"><Indications><Indication>Breast tumor</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Cell cycle inhibitor</Action><Action>Microtubule inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Natural product</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Auckland City Hospital</Company></CompaniesSponsor><DateChangeLast>2010-08-06T00:00:00Z</DateChangeLast><DateStart>1995-09-30T00:00:00Z</DateStart><IndicationsAdverse><Indication>Allergy</Indication><Indication>Anemia</Indication><Indication>Death</Indication><Indication>Diarrhea</Indication><Indication>Edema</Indication><Indication>Emesis</Indication><Indication>Hypersensitivity</Indication><Indication>Infectious disease</Indication><Indication>Leukopenia</Indication><Indication>Nausea</Indication><Indication>Neutropenia</Indication><Indication>Thrombocytopenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>docetaxel alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>527</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>This open-label, randomized, phase III trial was to evaluate the safety and efficacy of docetaxel in patients with unresectable locally advanced or metastatic breast cancer [ 745828 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>An open-label, randomized, phase III trial to evaluate the safety and efficacy of docetaxel in patients with unresectable locally advanced or metastatic breast cancer</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="6849"><Indications><Indication>Neuropathic pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CACNA2D calcium channel subunit modulator</Action><Action>GABA A receptor alpha-2 subunit stimulator</Action><Action>GABA A receptor delta subunit stimulator</Action><Action>GABA receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticonvulsant agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Pfizer Inc</Company></CompaniesSponsor><Countries><Country>US</Country><Country>China</Country><Country>Hong Kong</Country><Country>India</Country><Country>Chile</Country><Country>Czech Republic</Country><Country>Japan</Country><Country>Russian Federation</Country><Country>Philippines</Country></Countries><DateChangeLast>2016-11-21T00:00:00Z</DateChangeLast><DateEnd>2011-02-28T00:00:00Z</DateEnd><DateStart>2007-01-31T00:00:00Z</DateStart><Identifiers><Identifier>A0081107</Identifier><Identifier>JapicCTI-101173</Identifier><Identifier>NCT00407745</Identifier></Identifiers><IndicationsAdverse><Indication>Dizziness</Indication><Indication>Drowsiness</Indication><Indication>Edema</Indication><Indication>Fatigue</Indication><Indication>Insomnia</Indication><Indication>Vision disorder</Indication><Indication>Xerostomia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>pregabalin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>220</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to evaluate if pregabalin relieves nerve pain associated with spinal cord injury, compared with placebo. This study would also evaluate the safety of pregabalin in this patient population.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Brief Pain Inventory[BPI]</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment by Neuropathic Pain Symptom Inventory (NPSI)</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Quantitative sensory testing</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Daily Pain Rating Scale (DPRS)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>49 Months</TrialDuration><NumberOfSites>64</NumberOfSites><ContactNames><Name>Pfizer Call Center</Name><Name>Pfizer Japan Inc.</Name></ContactNames></Trial><Trial Id="6844"><Indications><Indication>Bipolar disorder</Indication><Indication>Insomnia</Indication><Indication>Schizophrenia</Indication></Indications><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2018-09-21T00:00:00Z</DateChangeLast><DateEnd>2008-06-30T00:00:00Z</DateEnd><DateStart>2006-08-31T00:00:00Z</DateStart><Identifiers><Identifier>6199-CL-0008</Identifier><Identifier>JapicCTI-060330</Identifier><Identifier>NCT00374777</Identifier></Identifiers><IndicationsAdverse><Indication>Constipation</Indication><Indication>Depression</Indication><Indication>Diarrhea</Indication><Indication>Dizziness</Indication><Indication>Drowsiness</Indication><Indication>Eczema</Indication><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Rhinopharyngitis</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>nitrazepam alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>zolpidem (controlled-release, insomnia), Sanofi alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>450</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> &gt;/= 45 min per night within 4 weeks before the start of the run-in period according to the health check sheet Patients who had a washout period before the start of the run-in period, when given antihistamine (H1 blocker only, including combination &lt;b&gt;cold&lt;/b&gt; remedy, except for eye-drops, nose drops or external medicine), hypnotics, or anxiolytic or antidepressant drugs for sleep Patients aged between 20 and 65 years when their informed consent was obtained Patients who had an ability to fill in the sleep</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bipolar disorder - Anthropometric Assessments</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Cardiac Function - Assessment of blood pressure</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Laboratory/Diagnostic Measures - Assessment of hematological parameters</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Sleep</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Sleep - Assessment of mean wake time</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Sleep - Assessment of night awakenings</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Sleep - Assessment of total sleep time</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of adverse events</EndpointIndex><EndpointIndex>Bipolar disorder - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of early morning awakening</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of number of awakenings</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of sleep onset latency (SOL)</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of total sleep time (TST)</EndpointIndex><EndpointIndex>Insomnia - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of adverse events(AEs)/side effects</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of discontinuations due to adverse events</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of neuropsychiatric adverse events</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Sleep</EndpointIndex><EndpointIndex>Schizophrenia - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Schizophrenia - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>A Double-Blind, Group-Comparison, Phase III Study With Zolpidem MR Using Placebo and Nitrazepam in Insomnia Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Insomnia - Subjects with comorbid conditions</PatientSegment><PatientSegment>Insomnia - Subjects with comorbid conditions - Subjects co-morbid with mood disorders</PatientSegment><PatientSegment>Schizophrenia - Subjects with Other Neuro-psychiatric Diseases/Disorders - Subjects with other psychotic disorders</PatientSegment><PatientSegment>Schizophrenia - Subjects with comorbid conditions - Subjects with mood disorders</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2008-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Astellas Pharma Inc.</Name><Name>Use Central Contact</Name></ContactNames></Trial><Trial Id="67877"><Indications><Indication>Cystic fibrosis</Indication><Indication>Sinusitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Genentech Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Pennsylvania State University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2015-06-30T00:00:00Z</DateEnd><DateStart>2013-07-31T00:00:00Z</DateStart><Identifiers><Identifier>IRB#33344</Identifier><Identifier>NCT01155752</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dornase alfa alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>12</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Other</Reason></ReasonForTrialDiscontinuation><Teaser>The hypothesis is that the intranasal use of Pulmozyme will decrease the severity of sinusitis in cystic fibrosis (CF) and lead to an improved quality of life.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cystic fibrosis - Assessment of compliance/adherence</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Cystic fibrosis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by quality of life (short form-36 and chronic respiratory questionnaire)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Pulmozyme in Cystic Fibrosis With Sinusitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Cystic fibrosis - Subjects with Diagnosis of Cystic Fibrosis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2014-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Cathy Mende, NP</Name><Name>Timothy Craig</Name><Name>Timothy Craig, DO</Name></ContactNames></Trial><Trial Id="67378"><Indications><Indication>Respiratory disorder</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Leukotriene D4 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation systemic</Technology><Technology>Daily dosing</Technology><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>University of Aberdeen</Company><Company>University of Leicester</Company></CompaniesCollaborator><CompaniesSponsor><Company>Queen Mary University of London</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2019-06-26T00:00:00Z</DateChangeLast><DateEnd>2014-02-28T00:00:00Z</DateEnd><DateStart>2010-11-30T00:00:00Z</DateStart><Identifiers><Identifier>08/43/03</Identifier><Identifier>2009-015626-11</Identifier><Identifier>NCT01142505</Identifier><Identifier>WAIT</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>montelukast sodium alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1358</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The patients would receive 4 mg po, qd granules of montelukast or mannitol for 10 days given alone or with &lt;b&gt;cold&lt;/b&gt; or warm food from the onset of a &lt;b&gt;cold&lt;/b&gt; or wheezing attack....given montelukast and 50% would be given dummy medication. Parents would start the trial medication whenever their child develops a &lt;b&gt;cold&lt;/b&gt;, and stop the medication when wheeze resolve. Parents would also be able to give the trial medication for wheeze</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Asthma - Assessment of Asthma Symptoms/Symptoms Score</EndpointIndex><EndpointIndex>Asthma - Assessment of Exacerbations</EndpointIndex><EndpointIndex>Asthma - Assessment of Therapy Related Outcomes - Efficacy</EndpointIndex><EndpointIndex>Asthma - Assessment of Wheeze</EndpointIndex><EndpointIndex>Asthma - Assessment of hospitalization</EndpointIndex><EndpointIndex>Asthma - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex><EndpointIndex>Asthma - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>WAIT: Wheeze and Intermittent Treatment</TitleDisplay><PatientSegmentTerms><PatientSegment>Asthma - Subjects with Symptomatic Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>39 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jonathan Grigg</Name></ContactNames></Trial><Trial Id="66158"><Indications><Indication>Raynauds disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>PDE 5 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action><Action>Muscle relaxant</Action><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Daily dosing</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Army Research and Referral hospital</Company><Company>Postgraduate Institute of Medical Education and Research</Company></CompaniesCollaborator><CompaniesSponsor><Company>Sanjay Gandhi Postgraduate Institute of Medical Sciences</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2018-12-21T00:00:00Z</DateChangeLast><DateEnd>2010-05-01T00:00:00Z</DateEnd><DateStart>2009-11-30T00:00:00Z</DateStart><Identifiers><Identifier>B22:A15:PGI/DM/EC/40/7.11.2007</Identifier><Identifier>NCT01117298</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tadalafil alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>66</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>between the ages of 18 and 60 years will be selected for the study if they have a clinical diagnosis of Raynauds phenomenon secondary to systemic sclerosis (scleroderma) despite being on vasodilator therapy. Raynauds phenomenon is defined as a history of &lt;b&gt;cold&lt;/b&gt; sensitivity associated with color changes of cyanosis or pallor, as well as a history of at least four attacks per week during 2 week pre-trial period even with treatment with other vasodilators. The diagnosis of scleroderma is defined by the American</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Biomarkers - Assessment of other biomarkers</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Functional Disability/Physical Function - Assessment by Raynaud Condition Score (RCS)</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Vascular Endothelial Function</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Vascular Endothelial Function - Assessment of flow mediated dilatation</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Wound Healing - Assessment of ulcer healing</EndpointIndex><EndpointIndex>Peripheral vascular disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Peripheral vascular disease - Patient Reported Outcomes/Quality of Life Assessments - Quality of life(Non-specific)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynauds Phenomenon in Scleroderma</TitleDisplay><PatientSegmentTerms><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - Subjects with raynaud's disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Aman Sharma</Name><Name>Darshan S Bhakuni, MD</Name><Name>Darshan Singh Bhakuni</Name><Name>Parasar Ghosh</Name></ContactNames></Trial><Trial Id="65812"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-09-24T00:00:00Z</DateChangeLast><DateEnd>2010-12-31T00:00:00Z</DateEnd><DateStart>2010-03-31T00:00:00Z</DateStart><Identifiers><Identifier>LAIV</Identifier><Identifier>MI-CP208</Identifier><Identifier>NCT01091246</Identifier></Identifiers><InterventionsControlDisplay><Intervention>FluMist alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>MEDI-8662 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2312</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of this study was to demonstrate the immunological noninferiority of Q/LAIV compared to FluMist in children 2 to 17 years of age by comparing the strain-specific post-dose geometric mean titers (GMTs) of hemagglutination inhibition (HAI) antibodies.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Bioequivalence</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of hospitalization - Assessment of Hospitalization Rates</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>LAIV: A Study to Evaluate the Immunogenicity Composed of Four Vaccine Strains in a Live Influenza Vaccine in Children (LAIV)</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anti-plasminogen activator inhibitor 1 antibodies</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>110</NumberOfSites><ContactNames><Name>Judith Falloon</Name></ContactNames></Trial><Trial Id="65706"><Indications><Indication>Familial cold autoinflammatory syndrome</Indication><Indication>Inflammatory disease</Indication><Indication>Muckle Wells syndrome</Indication><Indication>Urticaria</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin G1 agonist</Action><Action>Interleukin-1 beta ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action><Action>Cardioprotectant</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>DNA technology</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intra-articular formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2017-10-03T00:00:00Z</DateChangeLast><DateEnd>2012-05-31T00:00:00Z</DateEnd><DateStart>2010-08-31T00:00:00Z</DateStart><Identifiers><Identifier>2015-003491-69</Identifier><Identifier>CACZ885DCA01</Identifier><Identifier>NCT01105507</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>canakinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>4</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>any assessment is performed for patients&amp;lt; 18 years of age Patients with a diagnosis of CAPS: familial &lt;b&gt;cold&lt;/b&gt;-induced urticaria (FCAS/FCU), muckle-wells syndrome (MWS) or chronic infantile neurological cutaneous and articular syndrome (NOMID...Familial &lt;b&gt;Cold&lt;/b&gt; Autoinflammatory Syndrome (FCAS)/Familial &lt;b&gt;Cold&lt;/b&gt; Urticaria (FCU); Muckle-Wells Syndrome (MWS); Neonatal-Onset Multisystem Inflammatory Disease (NOMID)/Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA). To</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other genetic disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other genetic disease - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Urticaria - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Urticaria - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Urticaria - Assessment of Therapy Related Outcomes - Assessment of other efficacy parameters</EndpointIndex><EndpointIndex>Urticaria - Other Protocol Specified Outcomes</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada</TitleDisplay><PatientSegmentTerms><PatientSegment>Other genetic disease - Subjects with specific disease</PatientSegment><PatientSegment>Urticaria - Subjects with Cold Contact Urticaria (CCU)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Serum amyloid A protein 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-05-12T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="65310"><Indications><Indication>Urinary incontinence</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Acetylcholine receptor antagonist</Action><Action>p130Cas associated protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Antiarrhythmic agent</Action><Action>Antidepressant</Action><Action>Neuromuscular blocking agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Drying</Technology><Technology>Formulation powder</Technology><Technology>Intradermal formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Peptide</Technology><Technology>Toxin</Technology></Technologies><CompaniesCollaborator><Company>Ethica Clinical Research Inc</Company></CompaniesCollaborator><CompaniesSponsor><Company>Sunnybrook Health Sciences Centre</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2018-12-19T00:00:00Z</DateChangeLast><DateEnd>2009-04-30T00:00:00Z</DateEnd><DateStart>2006-10-31T00:00:00Z</DateStart><Identifiers><Identifier>0922006</Identifier><Identifier>NCT01091727</Identifier></Identifiers><IndicationsAdverse><Indication>Back pain</Indication><Indication>Common cold</Indication><Indication>Depression</Indication><Indication>Emesis</Indication><Indication>Headache</Indication><Indication>Hematuria</Indication><Indication>Insomnia</Indication><Indication>Muscle spasm</Indication><Indication>Muscle weakness</Indication><Indication>Nausea</Indication><Indication>Urinary tract infection</Indication><Indication>Vertigo</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>onabotulinumtoxinA alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>57</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>associated with an augment in detrusor pressure of &gt; 102 cm H2O. This was deemed possibly treatment related. Urinary tract infection (57 and 55% of patients), headache (21 and 17%), nausea with or without vomiting (21 and 7%), sweating (18 and 0%), common &lt;b&gt;cold&lt;/b&gt; (14 and 7%), muscle spasms (14 and 7%), muscle weakness (11 and 0%), depression (11 and 0%), dizziness (7 and 3%), hematuria (7 and 7%), insomnia (7 and 0%) and back pain (7 and 3%) were some of the AEs observed in &gt;/= 5% of patients in the Botox and</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of Therapy Related Outcomes - Efficacy</EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of Urodynamics</EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of Urodynamics - Change from baseline in incontinence episodes</EndpointIndex><EndpointIndex>Multiple sclerosis - Assessment of Urodynamics - Change from baseline in micturition or catheterization frequency</EndpointIndex><EndpointIndex>Multiple sclerosis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Multiple sclerosis - Patient Reported Outcomes/Quality of Life Assessments - International Consultation on Incontinence Questionnaire-Lower Urinary Tract Symptoms Quality of life (ICIQ-LUTSqol) questionnaire</EndpointIndex><EndpointIndex>Multiple sclerosis - Patient Reported Outcomes/Quality of Life Assessments - Urinary Incontinence Quality of Life Scale (I-QOL)</EndpointIndex><EndpointIndex>Urinary incontinence - Assessment of Incontinence Using Voiding Diary - Assessment of filling symptoms</EndpointIndex><EndpointIndex>Urinary incontinence - Assessment of Urodynamics - Assessment of cystometric outcome</EndpointIndex><EndpointIndex>Urinary incontinence - Patient Reported Outcomes/Quality of Life Assessments - Dowell-Bryant incontinence cost index(DBICI)</EndpointIndex><EndpointIndex>Urinary incontinence - Patient Reported Outcomes/Quality of Life Assessments - Incontinence quality of life(I-QoL)</EndpointIndex><EndpointIndex>Urinary incontinence - Patient Reported Outcomes/Quality of Life Assessments - International consultation on incontinence questionnaire (ICIQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity</TitleDisplay><PatientSegmentTerms><PatientSegment>Multiple sclerosis - Subjects with Symptomatic Disease - Subjects with urinary bladder dysfunction</PatientSegment><PatientSegment>Multiple sclerosis - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Urinary incontinence - Subjects at risk of developing disease - Subjects with history of neurological disorders</PatientSegment><PatientSegment>Urinary incontinence - Subjects with History of/Scheduled for drug Therapy</PatientSegment><PatientSegment>Urinary incontinence - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Urinary incontinence - Subjects with Urge Incontinence/Overactive Bladder - Subjects with neurogenic urge incontinence</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Sender Herschorn</Name></ContactNames></Trial><Trial Id="65141"><Indications><Indication>Uveitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-17 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>South Korea</Country><Country>Austria</Country><Country>Turkey</Country><Country>Taiwan</Country><Country>Hong Kong</Country><Country>Germany</Country><Country>Tunisia</Country><Country>Spain</Country><Country>US</Country><Country>Jordan</Country><Country>Singapore</Country><Country>Israel</Country><Country>Egypt</Country><Country>Greece</Country><Country>France</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2011-01-31T00:00:00Z</DateEnd><DateStart>2010-03-31T00:00:00Z</DateStart><Identifiers><Identifier>2009-013901-33</Identifier><Identifier>CAIN457C2303E1</Identifier><Identifier>NCT01093846</Identifier><Identifier>SHIELD</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>secukinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>59</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Lack of Efficacy</Reason></ReasonForTrialDiscontinuation><Teaser>procedures Any medical or psychiatric condition which, in the investigator's opinion would preclude the participant from adhering to the protocol or completing the study per protocol Active systemic infections during the last 2 weeks (exception: common &lt;b&gt;cold&lt;/b&gt;) prior Visit 16 that in the opinion of the study investigator or sponsor that would be a contraindication to additional treatment with AIN-457 Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Uveitis - Assessment of Medication Use</EndpointIndex><EndpointIndex>Uveitis - Assessment of Ocular Inflammation - Assessment of anterior chamber cells</EndpointIndex><EndpointIndex>Uveitis - Assessment of Ocular Inflammation - Assessment of vitreous haze</EndpointIndex><EndpointIndex>Uveitis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Uveitis - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Uveitis - Assessment of Visual Function - Assessment of visual acuity(VA)</EndpointIndex><EndpointIndex>Uveitis - Patient Reported Outcomes/Quality of Life Assessments - Assessment of quality of life</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SHIELD: A 38 Week Extension Study to CAIN457C2303</TitleDisplay><PatientSegmentTerms><PatientSegment>Uveitis - Subjects with History of/Scheduled for Therapy</PatientSegment><PatientSegment>Uveitis - Subjects with Intermediate Uveitis</PatientSegment><PatientSegment>Uveitis - Subjects with Posterior Uveitis</PatientSegment><PatientSegment>Uveitis - Subjects with specific disease - Subjects with Panuveitis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>26</NumberOfSites><ContactNames><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="64874"><Indications><Indication>Keratosis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Fungicide</Action><Action>Photosensitizer</Action><Action>Systemic dermatological antifungal product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Dermatological formulation</Technology><Technology>Patch formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>photonamic GmbH &amp; Co KG</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2018-07-14T00:00:00Z</DateChangeLast><DateEnd>2007-11-30T00:00:00Z</DateEnd><DateStart>2006-03-31T00:00:00Z</DateStart><Identifiers><Identifier>AK 04</Identifier><Identifier>EudraCT No. 2005-003556-36</Identifier><Identifier>NCT00308867</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Alacare alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>349</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>interfere with response evaluation of study treatment Skin sun sensitivity type V or VI according to Fitzpatrick Known intolerance to one or more of the ingredients of the study medication Known adverse reactions to cryosurgery (including &lt;b&gt;cold&lt;/b&gt; urticaria and &lt;b&gt;cold&lt;/b&gt; intolerance) Dementia or psychic condition that might interfere with the ability to understand the study and thus give a written informed consent Simultaneous participation in another clinical study or participation in another clinical study</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Actinic keratosis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Actinic keratosis - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Actinic keratosis - Assessment of adverse events</EndpointIndex><EndpointIndex>Actinic keratosis - Clinical Assessments - Complete clearance of actinic keratoses</EndpointIndex><EndpointIndex>Actinic keratosis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PDP-506A-PDT Versus Placebo-PDT and Cryosurgery for the Treatment of AK</TitleDisplay><PatientSegmentTerms><PatientSegment>Actinic keratosis - Subjects with clinically visible actinic keratosis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>20 Months</TrialDuration><NumberOfSites>26</NumberOfSites><ContactNames><Name>Rolf-Marcus Szeimies, Professor MD</Name></ContactNames></Trial><Trial Id="64636"><Indications><Indication>Atrophy</Indication><Indication>Fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2018-12-13T00:00:00Z</DateChangeLast><DateEnd>2012-06-01T00:00:00Z</DateEnd><DateStart>2009-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2009-011473-33</Identifier><Identifier>CERTITEM</Identifier><Identifier>CRAD001AFR10</Identifier><Identifier>NCT01079143</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including Corticosteroids , basiliximab , ciclosporin, Novartis , enteric-coated mycophenolate sodium, Novartis , everolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>194</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Recipient of a primary or secondary deceased or living (related or not) donor kidney transplant and who requires basiliximab induction therapy &lt;b&gt;Cold&lt;/b&gt; ischemia time&amp;lt; 30 h Women of child-bearing age, even those with a history of infertility, must have had a negative pregnancy test during the 7 days before screening or at the time of screening, and must use a recognized and reliable method of contraception</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Protocol Specified Other Endpoints - Degree of inflammation and fibrosis in renal biopsies</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>CERTITEM: Progression of Renal Interstitial Fibrosis/Tubular Atrophy (IF/TA) According to Epithelial-Mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - De Novo Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Urinary protein/Creatinine ratio</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>23</NumberOfSites><ContactNames><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="62655"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Elastase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antioxidant agent</Action><Action>Expectorant</Action><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Edmond Pharma</Company></CompaniesSponsor><Countries><Country>Slovakia</Country><Country>Italy</Country><Country>Czech Republic</Country><Country>Poland</Country><Country>France</Country><Country>Romania</Country><Country>Denmark</Country><Country>Bulgaria</Country><Country>UK</Country><Country>Belgium</Country></Countries><DateChangeLast>2018-02-22T00:00:00Z</DateChangeLast><DateEnd>2015-09-30T00:00:00Z</DateEnd><DateStart>2009-08-31T00:00:00Z</DateStart><Identifiers><Identifier>2008-008192-34</Identifier><Identifier>ERD-01-08/EP</Identifier><Identifier>NCT01032304</Identifier><Identifier>RESTORE</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>erdosteine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>492</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The aim of the study was to evaluate the effect of erdosteine , compared to placebo, on exacerbation rate over a 12-month treatment period in patients with moderate to severe COPD. Moreover, the effects of erdosteine on pulmonary function parameters, clinical symptoms, quality of life, exercise performance, disease-related costs and the long-term safety of erdosteine would be assessed.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Disease Progression - Severity of symptoms/symptom scores (SS)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation rate/frequency/number</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment of quality of life</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>RESTORE: The Efficacy and Safety of Erdosteine in Chronic Obstructive Pulmonary Disease (COPD)</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with disease related complications</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>8-Epi-prostaglandin F2 alpha </BiomarkerName><BiomarkerName> Six-minute walk distance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>73 Months</TrialDuration><NumberOfSites>49</NumberOfSites><ContactNames><Name>Medical Department</Name></ContactNames></Trial><Trial Id="62127"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action><Action>Glucocorticoid receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Bronchodilator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Argentina</Country><Country>South Africa</Country><Country>Australia</Country><Country>Italy</Country><Country>Sweden</Country><Country>Spain</Country><Country>Germany</Country><Country>Peru</Country><Country>Chile</Country><Country>Denmark</Country><Country>US</Country><Country>UK</Country><Country>Mexico</Country><Country>Canada</Country><Country>Netherlands</Country></Countries><DateChangeLast>2019-06-07T00:00:00Z</DateChangeLast><DateEnd>2011-10-17T00:00:00Z</DateEnd><DateStart>2009-09-25T00:00:00Z</DateStart><Identifiers><Identifier>102970</Identifier><Identifier>2009-013064-40</Identifier><Identifier>HZC102970</Identifier><Identifier>NCT01017952</Identifier></Identifiers><InterventionsControlDisplay><Intervention>vilanterol alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>fluticasone furoate + vilanterol trifenatate (oral inhalant, asthma/COPD), GlaxoSmithKline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1635</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Main objective of the trial was to evaluate safety and efficacy of fluticasone furoate + GW-642444 (FF/GW-642444) 50 microg/25 microg qd and FF/GW-642444 100 microg/25 microg qd and FF/GW-642444 200 microg/25 microg qd versus GW-642444 25 microg qd on the annual rate of moderate and severe exacerbations in subjects with COPD over a 52 week treatment period. This study would evaluate the contribution of the ICS on reducing the rate of exacerbations when used in combination with a fixed dose of the</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation rate/frequency/number</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of time to first exacerbation</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change in pre bronchodilator FEV1</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of use of Rescue Medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate Annual Rate of Exacerbations and Safety of Three Dosage Strengths of Fluticasone Furoate (FF)/GW-642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 4/Very Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with History of Treatment</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Symptomatic Disease - Subjects with dyspnea</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with disease related complications - Subjects with acute exacerbation of COPD/Infections</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Eosinophils </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-10-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>185</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial><Trial Id="61703"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Beta 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Beta 2 adrenoceptor agonist</Action><Action>Glucocorticoid receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Bronchodilator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Inhalant formulation</Technology><Technology>Oral formulation</Technology><Technology>Powder formulation inhalant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesSponsor><Company>Glaxo Group Research Ltd</Company><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><Countries><Country>Netherlands</Country><Country>Mexico</Country><Country>Canada</Country><Country>Argentina</Country><Country>US</Country><Country>South Africa</Country><Country>Sweden</Country><Country>Italy</Country><Country>UK</Country><Country>Germany</Country><Country>Peru</Country><Country>Chile</Country><Country>Estonia</Country><Country>Australia</Country><Country>Philippines</Country></Countries><DateChangeLast>2019-06-06T00:00:00Z</DateChangeLast><DateEnd>2011-10-31T00:00:00Z</DateEnd><DateStart>2009-09-25T00:00:00Z</DateStart><Identifiers><Identifier>102871</Identifier><Identifier>HZC102871</Identifier><Identifier>NCT01009463</Identifier></Identifiers><IndicationsAdverse><Indication>Back pain</Indication><Indication>Bronchitis</Indication><Indication>Candida infection</Indication><Indication>Chronic obstructive pulmonary disease</Indication><Indication>Headache</Indication><Indication>Pneumonia</Indication><Indication>Rhinopharyngitis</Indication><Indication>Sinusitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>vilanterol alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>fluticasone furoate + vilanterol trifenatate (oral inhalant, asthma/COPD), GlaxoSmithKline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1626</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to assess the efficacy and safety of three strengths of the fluticasone furoate + GW-642444 inhalation powder in patient with chronic obstructive pulmonary disease (COPD). Main objective of the trial was to evaluate safety and efficacy of FF/GW-642444 50/25 microg qd and FF/GW-642444 100/25 microg qd and FF/GW-642444 200/25 microg qd versus GW-642444 25 microg qd on the annual rate of moderate and severe exacerbations in patients with COPD over a 52 week treatment</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation rate/frequency/number</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation severity - moderate</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of exacerbation severity - severe</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations - Assessment of time to first exacerbation</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Forced Expiratory Volume in One Second (FEV1) - Change in pre bronchodilator FEV1</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of use of Rescue Medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW-642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 2/Moderate COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 4/Very Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with History of Treatment</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Symptomatic Disease - Subjects with dyspnea</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with disease related complications - Subjects with acute exacerbation of COPD/Infections</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Eosinophils </BiomarkerName><BiomarkerName> Forced expiratory volume</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-10-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>25 Months</TrialDuration><NumberOfSites>193</NumberOfSites><ContactNames><Name>Anthony De Soyza</Name><Name>GSK Clinical Trials</Name><Name>Giuseppe Mazza</Name><Name>Miguel E Trevino</Name><Name>Neil D Levine</Name><Name>Paul M Friedman</Name><Name>Peter M Calverley</Name><Name>Yasser Ahmed</Name></ContactNames></Trial><Trial Id="61265"><Indications><Indication>Insomnia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>GABA A receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Hypnotic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2019-02-07T00:00:00Z</DateChangeLast><DateEnd>2007-07-05T00:00:00Z</DateEnd><DateStart>2006-03-31T00:00:00Z</DateStart><Identifiers><Identifier>6199-CL-0006</Identifier><Identifier>JapicCTI-184447</Identifier><Identifier>JapicCTI-R140535</Identifier><Identifier>NCT00999219</Identifier></Identifiers><IndicationsAdverse><Indication>Amnesia</Indication><Indication>Atrial fibrillation</Indication><Indication>Drowsiness</Indication><Indication>Emesis</Indication><Indication>Erythema</Indication><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Rhinopharyngitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>zolpidem (controlled-release, insomnia), Sanofi alone</Intervention><Intervention>zolpidem (immediate-release, insomnia), Sanofi alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>55</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> &amp;lt; 30 Patient considered able to undertake a washout period before start of the screening examination, period 1 administration, and period 2 administration, where medication in question is an antihistamine (H1 blocker only, including combination &lt;b&gt;cold&lt;/b&gt; remedies, not including eye-drops, nasal or topical preparations), an hypnotic, or an anxiolytic or antidepressant drug used for hypnotic effect Patients who had an ability to fill in the sleep check sheet It does not matter whether the patients are</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Insomnia - Assessment of Laboratory/Diagnostic Measures - Assessment of electrophysiological recordings</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of number of awakenings</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment of wake time after sleep onset (WASO)</EndpointIndex><EndpointIndex>Insomnia - Assessment of Sleep - Assessment with sleep questionnaires</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study of FK1-99B to Compare Efficacy With Zolpidem by Polysomnography in Patients With Insomnia</TitleDisplay><PatientSegmentTerms><PatientSegment>Insomnia - Subjects with Chronic Insomnia</PatientSegment><PatientSegment>Insomnia - Subjects with Primary Insomnia</PatientSegment><PatientSegment>Insomnia - Subjects with Sleep Maintenance Insomnia - Subjects with middle insomnia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>4</NumberOfSites><ContactNames><Name>Use Central Contact</Name></ContactNames></Trial><Trial Id="61112"><Indications><Indication>Uveitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-17 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>Brazil</Country><Country>Israel</Country><Country>Saudi Arabia</Country><Country>US</Country><Country>Spain</Country><Country>Italy</Country><Country>Hungary</Country><Country>Austria</Country><Country>Jordan</Country><Country>Turkey</Country><Country>Egypt</Country><Country>Taiwan</Country><Country>Hong Kong</Country><Country>France</Country><Country>Singapore</Country><Country>Greece</Country><Country>Switzerland</Country><Country>South Korea</Country><Country>India</Country><Country>Tunisia</Country></Countries><DateChangeLast>2018-06-09T00:00:00Z</DateChangeLast><DateEnd>2010-07-31T00:00:00Z</DateEnd><DateStart>2009-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2009-011237-27</Identifier><Identifier>CAIN457C2303</Identifier><Identifier>CTRI/2009/091/000874</Identifier><Identifier>NCT00995709</Identifier><Identifier>SHIELD</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>secukinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>118</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>intravenously or subcutaneously within 3 months prior to screening and no prior treatment with AIN-457 Any prior treatment with systemic alkylating agents (cyclophosphamide, chlorambucil) Active systemic infections during the last 2 weeks (exception: common &lt;b&gt;cold&lt;/b&gt;) Underlying metabolic, hematological, renal, hepatic, infectious or gastrointestinal conditions which in the opinion of the investigator immunocompromises the patient and/or places the patient at an unacceptable risk for participation in an immunomodulatory</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Macular edema - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Macular edema - Assessment of Visual Function - Assessment of visual acuity(VA)</EndpointIndex><EndpointIndex>Macular edema - Assessment of adverse events</EndpointIndex><EndpointIndex>Macular edema - Patient Reported Outcomes/Quality of Life Assessments - Visual function questionnaire(VFQ)</EndpointIndex><EndpointIndex>Uveitis - Assessment of Medication Use</EndpointIndex><EndpointIndex>Uveitis - Assessment of Ocular Inflammation - Assessment of anterior chamber cells</EndpointIndex><EndpointIndex>Uveitis - Assessment of Ocular Inflammation - Assessment of vitreous haze</EndpointIndex><EndpointIndex>Uveitis - Assessment of Underlying Systemic Disease</EndpointIndex><EndpointIndex>Uveitis - Assessment of Visual Function - Assessment of visual acuity(VA)</EndpointIndex><EndpointIndex>Uveitis - Assessment of adverse events</EndpointIndex><EndpointIndex>Uveitis - Patient Reported Outcomes/Quality of Life Assessments - Visual function questionnaire(VFQ)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SHIELD: Phase III Study in Refractory Behcet's Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Macular edema - Subjects at risk of developing disease - Subjects with history of uveitis</PatientSegment><PatientSegment>Uveitis - Subjects Contraindicated for Steroid Therapy</PatientSegment><PatientSegment>Uveitis - Subjects with Acute Uveitis</PatientSegment><PatientSegment>Uveitis - Subjects with History of/Scheduled for Therapy - Subjects with history/scheduled for immunosuppressants</PatientSegment><PatientSegment>Uveitis - Subjects with Intermediate Uveitis</PatientSegment><PatientSegment>Uveitis - Subjects with Non-Infectious Uveitis - Subjects with autoimmune disorder associated uveitis</PatientSegment><PatientSegment>Uveitis - Subjects with Posterior Uveitis</PatientSegment><PatientSegment>Uveitis - Subjects with Recurrent Uveitis</PatientSegment><PatientSegment>Uveitis - Subjects with specific disease - Subjects with Panuveitis</PatientSegment><PatientSegment>Uveitis - Subjects with specific disease - Subjects with retinal vasculitis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anterior chamber </BiomarkerName><BiomarkerName> Interleukin-17A </BiomarkerName><BiomarkerName> Macula retinae </BiomarkerName><BiomarkerName> Visual acuity</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>60</NumberOfSites><ContactNames><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="60891"><Indications><Indication>Cryopyrin associated periodic syndrome</Indication><Indication>Familial cold autoinflammatory syndrome</Indication><Indication>Inflammatory disease</Indication><Indication>Muckle Wells syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin G1 agonist</Action><Action>Interleukin-1 beta ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action><Action>Cardioprotectant</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>DNA technology</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intra-articular formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2019-02-19T00:00:00Z</DateChangeLast><DateEnd>2012-02-29T00:00:00Z</DateEnd><DateStart>2009-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2015-003490-15</Identifier><Identifier>CACZ885D2308</Identifier><Identifier>JapicCTI-090930</Identifier><Identifier>NCT00991146</Identifier></Identifiers><IndicationsAdverse><Indication>Acne</Indication><Indication>Bronchitis</Indication><Indication>Conjunctivitis</Indication><Indication>Cough</Indication><Indication>Diarrhea</Indication><Indication>Epstein Barr virus infection</Indication><Indication>Gastroenteritis</Indication><Indication>Hypertension</Indication><Indication>Nervous system development disorder</Indication><Indication>Pain</Indication><Indication>Parvovirus infection</Indication><Indication>Pharyngitis</Indication><Indication>Pneumonia</Indication><Indication>Rhinitis</Indication><Indication>Rhinopharyngitis</Indication><Indication>Rhinorrhea</Indication><Indication>Stomatitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>canakinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>19</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The study was to assess the efficacy and safety of canakinumab in Japanese patients with cryopyrin-associated periodic syndromes (CAPS). This study would allow access for Japanese patients to a new potentially efficacious treatment for CAPS patients with a convenient dosing regimen. The objectives of this study were to assess the presence of protective antibody levels following immunization with non-live vaccines, proportion of patients with vaccination-associated reactions and the safety if</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other genetic disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase</TitleDisplay><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Serum amyloid A protein 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2012-02-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>28 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Novartis</Name><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="60606"><Indications><Indication>Iron overload</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Ferritin inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Antiviral</Action><Action>Blood system agent</Action><Action>Fungicide</Action><Action>Iron chelator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Daily dosing</Technology><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Novartis AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Children's Hospital of Los Angeles</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-25T00:00:00Z</DateChangeLast><DateEnd>2010-12-31T00:00:00Z</DateEnd><DateStart>2009-04-30T00:00:00Z</DateStart><Identifiers><Identifier>CICL670AUS30T</Identifier><Identifier>NCT00981370</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>deferasirox alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Operational Issues</Reason></ReasonForTrialDiscontinuation><Teaser>secondary objective(s) were to: Determine if the magnitude of endothelial-dependant vasodilation was related to the degree of iron overload. Determine if the degree of change in cardiac beat to beat variability in response to hypoxic exposure or to &lt;b&gt;cold&lt;/b&gt; exposure ('&lt;b&gt;cold&lt;/b&gt;-face-test') was related the magnitude of iron overload. The primary measure of iron overload would be MRI determination of liver iron concentration.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anemia - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Anemia - Assessment of Metabolic Parameters</EndpointIndex><EndpointIndex>Anemia - Assessment of Survival</EndpointIndex><EndpointIndex>Anemia - Assessment of iron status - Assessment of iron overload</EndpointIndex><EndpointIndex>Anemia - Hematological Assessments - Assessment of hemoglobin status</EndpointIndex><EndpointIndex>Anemia - Hematological Assessments - Assessment of reticulocyte count</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Clinical Importance of Treating Iron Overload in Sickle Cell Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Anemia - Subjects with Hemolytic Anemia</PatientSegment><PatientSegment>Anemia - Subjects with Sickle Cell Anemia</PatientSegment><PatientSegment>Anemia - Subjects with Thalassemia - Subjects with beta thalassemia major/cooley's anemia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>20 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Thomas D. Coates, M.D.</Name></ContactNames></Trial><Trial Id="59385"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>AstraZeneca plc</Company><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2010-03-31T00:00:00Z</DateEnd><DateStart>2009-08-31T00:00:00Z</DateStart><Identifiers><Identifier>MI-CP206</Identifier><Identifier>MI-CP206</Identifier><Identifier>NCT00952705</Identifier></Identifiers><IndicationsAdverse><Indication>Cough</Indication><Indication>Fever</Indication><Indication>Myalgia</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>FluMist alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>MEDI-8662 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1800</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>0.2 ml into a single nostril. Each dose contained 10(7.0 +/- 0.5) fluorescent focus units (FFU) of each of four &lt;b&gt;cold&lt;/b&gt;-adapted, temperature-sensitive, attenuated, 6: 2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A...III: participants would receive FluMist -B/Victoria intranasally using a BD Accuspray device. A total volume of 0.2 ml would be administered intranasally (approximately 0.1 ml into each nostril). Each dose contained 10(7.0 +/- 0.5 FFU) of each of three &lt;b&gt;cold&lt;/b&gt;-adapted, temperature-sensitive</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>MI-CP206: A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI-8662) in Adults 18 to 49 Years of Age</TitleDisplay><PrimaryCompletionDate type="Actual">2010-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>7 Months</TrialDuration><NumberOfSites>18</NumberOfSites><ContactNames><Name>Anita Chaudhary</Name><Name>Anne Cutter</Name><Name>Donald Brandon</Name><Name>Jill Bergers</Name><Name>Joseph Sliman, M.D., MPH</Name><Name>Karina Arencibia</Name><Name>Laurence Chu</Name><Name>Lorraine Boggs</Name><Name>Matthew Davis</Name><Name>Stephen Bowman</Name></ContactNames></Trial><Trial Id="58607"><Indications><Indication>Raynauds disease</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>MediQuest Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-07-14T00:00:00Z</DateChangeLast><DateEnd>2010-07-31T00:00:00Z</DateEnd><DateStart>2009-06-30T00:00:00Z</DateStart><Identifiers><Identifier>09-001</Identifier><Identifier>NCT00934427</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>MQX-503 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>for 1 day before certain planned &lt;b&gt;cold&lt;/b&gt; exposures, once just before same planned &lt;b&gt;cold&lt;/b&gt; exposures, and, if needed, right after the start of symptoms during same planned &lt;b&gt;cold&lt;/b&gt; exposures....Raynaud's events during a typical winter day Must be willing to apply creams to fingers Must be willing to undergo &lt;b&gt;cold&lt;/b&gt; temperature exposure Must be willing and able to stop certain medications Must be willing to use effective contraception, if applicable</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions - Vascular disease related outcomes</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Cardiovascular Events - Time to cardiovascular event</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Functional Disability/Physical Function - Assessment by Raynaud Condition Score (RCS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Somatic Pain - Patients with claudication pain</PatientSegment><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - Subjects with raynaud's disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2010-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>13 Months</TrialDuration><NumberOfSites>11</NumberOfSites><ContactNames><Name>Jeff Gregory, MD</Name></ContactNames></Trial><Trial Id="58128"><Indications><Indication>Amyloidosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Amyloid protein deposition inhibitor</Action><Action>Transthyretin modulator</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>FoldRx Pharmaceuticals Inc</Company><Company>Pfizer Inc</Company></CompaniesSponsor><Countries><Country>Argentina</Country><Country>Germany</Country><Country>US</Country><Country>Portugal</Country><Country>France</Country><Country>Sweden</Country><Country>Italy</Country><Country>Brazil</Country></Countries><DateChangeLast>2019-03-06T00:00:00Z</DateChangeLast><DateEnd>2021-12-31T00:00:00Z</DateEnd><DateStart>2009-08-05T00:00:00Z</DateStart><Identifiers><Identifier>2009-011535-12</Identifier><Identifier>B3461023</Identifier><Identifier>FX1A-303</Identifier><Identifier>NCT00925002</Identifier></Identifiers><IndicationsAdverse><Indication>Angina</Indication><Indication>Cardiac failure</Indication><Indication>Headache</Indication><Indication>Influenza virus infection</Indication><Indication>Sepsis</Indication><Indication>Skin burns</Indication><Indication>Transient ischemic attack</Indication><Indication>Upper respiratory tract infection</Indication><Indication>Urinary tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>tafamidis alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>93</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>, pooled results were presented from three studies ( NCT00409175 , NCT00791492 and NCT00925002). There were no new safety issues or side effects of Fx-1006A were observed in the long-term evaluation of 71 patients. Urinary tract infections (28.2%); &lt;b&gt;cold&lt;/b&gt; (nasopharyngitis, 25.4%); influenza (23.9%); diarrhea (22.5%); headache and pain in an extremity (both 19.7%); back pain (16.9%); upper respiratory tract infection (15.5%); depression and thermal burn (both 14.1%); upper abdominal pain, anxiety, death</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other musculoskeletal disease - Anthropometric Assessments</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TitleDisplay>Safety and Efficacy Evaluation of FX-1006A in Subjects With Transthyretin Amyloidosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Other musculoskeletal disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Total body mass </BiomarkerName><BiomarkerName> Transthyretin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2021-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>148 Months</TrialDuration><NumberOfSites>13</NumberOfSites><ContactNames><Name>Pfizer CT.gov Call Center</Name></ContactNames></Trial><Trial Id="57108"><Indications><Indication>Raynauds disease</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Small molecule therapeutic</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>MediQuest Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2013-09-10T00:00:00Z</DateChangeLast><DateEnd>2005-09-30T00:00:00Z</DateEnd><DateStart>2004-11-30T00:00:00Z</DateStart><Identifiers><Identifier>MQT 03-001</Identifier><Identifier>NCT00253331</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>MQX-503 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>36</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>finger blood flow and skin temperature in the fingers of patients with moderate to severe Raynaud's phenomenon, follwoing exposure to &lt;b&gt;cold&lt;/b&gt; temperatures. Blood flow is determined by scanning laser Doppler equipment and skin temperature is measured using attached thermistor probes. Following baseline measurements, the study gel is applied, the hand is placed in a &lt;b&gt;cold&lt;/b&gt; chamber, and then blood flow and skin temperature are monitored for the next 2 h. Each patient will receive multiple doses on different</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Hemodynamic Measurements - Assessment of blood flow to return cold exposure.</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Hemodynamic Measurements - Time required for skin temperature to return after cold exposure</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Vascular Indices or Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Lab Study of MQX-503 in Treatment of Raynaud's</TitleDisplay><PatientSegmentTerms><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - Subjects with raynaud's disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>10 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Carin Dugowson, MD, MPH</Name><Name>Laura K Hummers, MD</Name></ContactNames></Trial><Trial Id="57022"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor mu agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Endo Health Solutions Inc</Company></CompaniesSponsor><DateChangeLast>2013-12-02T00:00:00Z</DateChangeLast><DateEnd>2004-03-31T00:00:00Z</DateEnd><DateStart>2003-06-30T00:00:00Z</DateStart><Identifiers><Identifier>EN3202-028</Identifier><Identifier>NCT00911287</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>oxymorphone ER, Endo alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>129</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>test (females only) History of or active asthma or emphysema Clinically significant hepatic impairment Received any of the following medications within 48 hours prior to dosing: Dextromethorphan-containing medications (over-the-counter [OTC] cough and &lt;b&gt;cold&lt;/b&gt; preparations, such as Vicks Formula 44) St. John's Wort&gt; 1000 mg/day Received monoamine oxidase inhibitor (MAOI) drugs within 2 weeks prior to dosing Are not stabilized on the following medications for at least 4 weeks prior to dosing: Tricyclic antidepressant</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Brief Pain Inventory[BPI]</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2004-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Study Director</Name></ContactNames></Trial><Trial Id="5521"><Indications><Indication>Raynauds disease</Indication><Indication>Vascular disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Rho associated protein kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Vasodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Johns Hopkins University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-07-03T00:00:00Z</DateChangeLast><DateEnd>2012-03-31T00:00:00Z</DateEnd><DateStart>2007-04-30T00:00:00Z</DateStart><Identifiers><Identifier>NA_00002801</Identifier><Identifier>NCT00498615</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>fasudil alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>17</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> a new vasodilator called fasudil , a rho-kinase inhibitor. The study hypothesized that fasudil would prevent vasoconstriction of digital and cutaneous arteries during a standard laboratory based &lt;b&gt;cold&lt;/b&gt; exposure and would therefore improve digital blood flow and skin temperature recovery time following &lt;b&gt;cold&lt;/b&gt; challenge.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Cardiovascular Events - Time to cardiovascular event</EndpointIndex><EndpointIndex>Peripheral vascular disease - Imaging/Radiological Assessments - doppler</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Rho-Kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon</TitleDisplay><PatientSegmentTerms><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - Subjects with raynaud's disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>59 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Fredrick M Wigley, M.D.</Name><Name>Fredrick Wigley</Name></ContactNames></Trial><Trial Id="5411"><Indications><Indication>Insulin dependent diabetes</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Insulin ligand</Action><Action>Insulin receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Human insulin intermediate acting product</Action><Action>Hypoglycemic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Peptide</Technology><Technology>Powder formulation inhalant</Technology></Technologies><CompaniesSponsor><Company>Pfizer Inc</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>US</Country></Countries><DateChangeLast>2014-09-30T00:00:00Z</DateChangeLast><DateEnd>2000-09-30T00:00:00Z</DateEnd><DateStart>1999-09-30T00:00:00Z</DateStart><Identifiers><Identifier>217-106</Identifier><Identifier>NCT00424437</Identifier></Identifiers><IndicationsAdverse><Indication>Aphasia</Indication><Indication>Coma</Indication><Indication>Confusion</Indication><Indication>Cough</Indication><Indication>Dizziness</Indication><Indication>Headache</Indication><Indication>Hyperglycemia</Indication><Indication>Hypoglycemia</Indication><Indication>Hypothermia</Indication><Indication>Nausea</Indication><Indication>Pharyngitis</Indication><Indication>Respiratory tract infection</Indication><Indication>Rhinitis</Indication><Indication>Seizure disorder</Indication><Indication>Tremor</Indication><Indication>Unconsciousness</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>Variable regimens including NPH insulin , regular insulin , sc insulin (regular + NPH insulin)</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including Exubera + Ultralente , NPH insulin , Ultralente , insulin (inhaled), Pfizer , regular insulin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>320</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this study was to determine, in patients with type 1 diabetes mellitus, whether glycemic control could be achieved at least as effectively with an insulin regimen involving pre-meal inhaled insulin ( Exubera ) plus a single bedtime ultralente injection as with a conventional sc insulin regimen involving two to three mixed regular/NPH insulin injections per day. The study also aimed to determine the tolerability and safety of Exubera therapy and its effects after 6 months, if any, on</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Blood Glucose Levels - Assessment of postprandial plasma glucose (PPPG)</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of HbA1c Levels</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Hypoglycemic Episodes</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Insulin Dose</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Glycemic Control Analysis - Assessment of blood glucose</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment of patient satisfaction</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A 6-month clinical trial assessing efficacy and safety of inhaled insulin in type 1 diabetes mellitus</TitleDisplay><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Lipids </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>12 Months</TrialDuration><NumberOfSites>36</NumberOfSites><ContactNames><Name>Pfizer Call Center</Name></ContactNames></Trial><Trial Id="53913"><Indications><Indication>Acute lymphoblastic leukemia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Abl tyrosine kinase inhibitor</Action><Action>Bcr protein inhibitor</Action><Action>Kit tyrosine kinase inhibitor</Action><Action>PDGF receptor antagonist</Action><Action>Signal transduction inhibitor</Action><Action>Topoisomerase II inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action><Action>Fibrosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology><Technology>Systemic formulation unspecified</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>St Jude Children's Research Hospital</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-12-21T00:00:00Z</DateChangeLast><DateEnd>2020-11-30T00:00:00Z</DateEnd><DateStart>2000-07-08T00:00:00Z</DateStart><Identifiers><Identifier>F32CA141762</Identifier><Identifier>NCT00137111</Identifier><Identifier>P30CA021765</Identifier><Identifier>R37CA036401</Identifier><Identifier>TOTXV</Identifier><Identifier>Total XV</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>methotrexate alone</Intervention><Intervention>Variable regimens including 6-Mercaptopurine , L-asparaginase , anthracycline , cyclophosphamide , cytarabine , daunorubicin , dexamethasone , doxorubicin , etoposide phosphate , imatinib , leucovorin , methotrexate , prednisone , vincristine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>501</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The primary objective was to estimate the overall event-free survival of children at least one year of age at diagnosis who are treated with risk-directed therapy and to monitor the molecular remission induction rate. The secondary objectives were: To determine if CNS irradiation can be safely omitted in the context of the systemic therapy used in the protocol. To identify whether prolonged (24 h) iv infusions of HDMTX produce greater methotrexate polyglutamate (MTXPG) accumulation than short (4</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Leukemia - Assessment of Cardiovascular Events</EndpointIndex><EndpointIndex>Leukemia - Assessment of Disease Progression - Assessment of risk for disease progression</EndpointIndex><EndpointIndex>Leukemia - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Leukemia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Leukemia - Assessment of Laboratory/Diagnostic Measures - Neurological function assessment</EndpointIndex><EndpointIndex>Leukemia - Assessment of Markers of Tumor Growth and Progression - Assessment of prognostic markers</EndpointIndex><EndpointIndex>Leukemia - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Leukemia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Leukemia - Assessment of Response Rates (RR) - Assessment of antibody response</EndpointIndex><EndpointIndex>Leukemia - Assessment of Response Rates (RR) - Assessment of minimal residual disease</EndpointIndex><EndpointIndex>Leukemia - Assessment of Response Rates (RR) - Assessment of radiological response</EndpointIndex><EndpointIndex>Leukemia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Leukemia - Assessment of Safety and Tolerability - Treatment emergent adverse events (TEAEs)</EndpointIndex><EndpointIndex>Leukemia - Assessment of Survival - Assessment of event free survival (EFS)</EndpointIndex><EndpointIndex>Leukemia - Assessment of adverse events</EndpointIndex><EndpointIndex>Leukemia - Hematological Assessments</EndpointIndex><EndpointIndex>Leukemia - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Leukemia - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Leukemia - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Leukemia - Protocol Specified Other Endpoints - Assessment of Antileukemia Activity/Anti-Tumor Activity</EndpointIndex><EndpointIndex>Leukemia - Protocol Specified Other Endpoints - Assessment of Clinical Efficacy</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Laboratory/Diagnostic Measures - Assessment of hematology/biochemistry</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Mortality/Death Rates - Assessment of treatment-related mortality/non-relapse mortality</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Remission</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Safety and Tolerability - Assessment of infections</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Survival - Assessment of Recurrence/Relapse Free Survival</EndpointIndex><EndpointIndex>Stem cell transplantation - Assessment of Survival - Assessment of event free survival (EFS)</EndpointIndex><EndpointIndex>Stem cell transplantation - Protocol Specified Other Endpoints - Assessment of disease activity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia</TitleDisplay><PatientSegmentTerms><PatientSegment>Leukemia - Pediatric Leukemia Subjects</PatientSegment><PatientSegment>Leukemia - Subjects with Acute Leukemia Unspecified Type</PatientSegment><PatientSegment>Leukemia - Subjects with Acute Lymphocytic Leukemia (ALL)</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with H/O Hematological Malignancies Indicated for SCT</PatientSegment><PatientSegment>Stem cell transplantation - Subjects with History of/Indicated for Hematopoietic Stem Cell Transplantation(HSCT)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Albumin </BiomarkerName><BiomarkerName> Body Mass Index </BiomarkerName><BiomarkerName> Caspase-1 </BiomarkerName><BiomarkerName> Hydrocortisone </BiomarkerName><BiomarkerName> L-asparaginase </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Lipoproteins </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> NACHT, LRR and PYD domains-containing protein 3 </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>244 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Ching-Hon Pui, M.D.</Name></ContactNames></Trial><Trial Id="53895"><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-08-05T00:00:00Z</DateChangeLast><DateEnd>2005-02-28T00:00:00Z</DateEnd><DateStart>2004-07-31T00:00:00Z</DateStart><Identifiers><Identifier>MI-CP112</Identifier><Identifier>NCT00192335</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Abscess</Indication><Indication>Cough</Indication><Indication>Diarrhea</Indication><Indication>Fever</Indication><Indication>Nasal congestion</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>890</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of this study was to demonstrate equivalent immunogeniticity of CAIV-T / FluMist . The secondary objective of this study was to assess the safety and tolerability of CAIV-T / FluMist .</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Bioequivalence</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of anti-influenza antibodies</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Immune Response - Assessment of seroprotection/seroconversion rate</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers only</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FluMist in Healthy Participants</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Kunitz-type protease inhibitor 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>7 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Luis Angles, MD</Name></ContactNames></Trial><Trial Id="53894"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Wyeth</Company></CompaniesCollaborator><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><DateChangeLast>2017-12-02T00:00:00Z</DateChangeLast><DateEnd>2002-11-01T00:00:00Z</DateEnd><DateStart>2002-03-31T00:00:00Z</DateStart><Identifiers><Identifier>D153-P504</Identifier><Identifier>NCT00192400</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2160</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study is to determine the efficacy of the liquid formulation of CAIV-T against culture confirmed influenza illness in healthy children aged at least 6 months and &amp;lt; 36 months.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Incidence of Laboratory Confirmed Influenza</EndpointIndex><EndpointIndex>Influenza virus infection - Incidence of Laboratory Confirmed Influenza</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children</TitleDisplay><PatientSegmentTerms><PatientSegment>Influenza Vaccine - Children</PatientSegment><PatientSegment>Influenza Vaccine - Subjects with Prior Other Vaccination - Subjects with Prior Influenza Vaccination</PatientSegment><PatientSegment>Influenza virus infection - Children</PatientSegment><PatientSegment>Influenza virus infection - Subjects with Prior Other Vaccination - Subjects with Prior Influenza Vaccination</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>7 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Robert Walker, MD</Name></ContactNames></Trial><Trial Id="5292"><Indications><Indication>Diabetic neuropathy</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Dihydropyrimidinase related protein 2 modulator</Action><Action>Sodium channel modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticonvulsant agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Formulation powder</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>UCB BIOSCIENCES GmbH</Company><Company>UCB SA</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>Belgium</Country><Country>Germany</Country><Country>Hungary</Country><Country>Italy</Country><Country>Austria</Country><Country>Romania</Country><Country>Spain</Country><Country>Finland</Country><Country>Bulgaria</Country><Country>Poland</Country><Country>France</Country><Country>Serbia</Country><Country>Russian Federation</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2011-01-31T00:00:00Z</DateEnd><DateStart>2004-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2004-000551-42</Identifier><Identifier>NCT00546351</Identifier><Identifier>SP746</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>lacosamide alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>621</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of this trial was to assess the tolerability and safety of long-term lacosamide administration in subjects with painful distal diabetic neuropathy. The secondary objective was to evaluate the efficacy of long-term use of lacosamide in this indication. Trial sub-study: A double-blind, randomized withdrawal of lacosamide in subjects with painful diabetic neuropathy-subtrial to SP746. The primary objective of this subtrial was to demonstrate the efficacy of lacosamide in subjects</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Pain - Assessment of Pain Intensity</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Diabetic complication - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Diabetic complication - Imaging/Radiological Assessments - Assessment by echocardiography</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Likert scale</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Diabetic complication - Patient Reported Outcomes/Quality of Life Assessments - Neuropathic pain scale score</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Adverse Events</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Imaging/Radiological Assessments - Assessment by echocardiography</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Likert scale</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Non-insulin dependent diabetes - Patient Reported Outcomes/Quality of Life Assessments - Neuropathic pain scale score</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Pain During Activity</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Neuropathic pain scale score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy</TitleDisplay><PatientSegmentTerms><PatientSegment>Diabetic complication - Subjects with Diabetic Neuropathy</PatientSegment><PatientSegment>Non-insulin dependent diabetes - Subjects with diabetic neuropathy</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain - Subjects with diabetic neuropathy</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>80 Months</TrialDuration><NumberOfSites>65</NumberOfSites><ContactNames><Name>UCB Clinical Trial Call Center</Name></ContactNames></Trial><Trial Id="51993"><Indications><Indication>Breast tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA helicase inhibitor</Action><Action>Topoisomerase II inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Cell cycle inhibitor</Action><Action>DNA intercalator</Action><Action>Microtubule inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Natural product</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Fonden til Fremme af Eksperimentel Cancerforskning</Company><Company>Sanofi SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>Danish Breast Cancer Cooperative Group</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2018-11-20T00:00:00Z</DateChangeLast><DateEnd>2013-01-31T00:00:00Z</DateEnd><DateStart>2008-06-30T00:00:00Z</DateStart><Identifiers><Identifier>2007-003126-15</Identifier><Identifier>DBCG 07-READ</Identifier><Identifier>NCT00689156</Identifier><Identifier>READ</Identifier></Identifiers><IndicationsAdverse><Indication>Arthralgia</Indication><Indication>Edema</Indication><Indication>Emesis</Indication><Indication>Fatigue</Indication><Indication>Myalgia</Indication><Indication>Nausea</Indication><Indication>Peripheral neuropathy</Indication><Indication>Stomatitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Variable regimens including cyclophosphamide , docetaxel , docetaxel + cyclosphosphamide , epirubicin , epirubicin + docetaxel + cyclosphosphamide</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2015</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The Danish Breast Cancer Cooperative Group (DBCG) designed this study to clarify if recurrence-free and overall life expectancy is longer after docetaxel and cyclophosphamide compared to epirubicin and cyclophosphamide followed by docetaxel in patients with TOP2A (Topoisomerase [DNA] II Alpha [170 kD]) normal and operable breast cancer.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Disease Free Survival (DFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>READ: Epirubicin or Not in Patients With TOP2A (Topoisomerase [DNA] II Alpha [170 kD]) Normal Early Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Others - Subjects with node positive breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Early Stage Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Hormone Receptor Negative Breast Cancer - Estrogen receptor negative (ER-) breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Hormone Receptor Negative Breast Cancer - Progesterone receptor negative (PR-) breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Locally Advanced Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Resectable/Operable Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage II Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>DNA topoisomerase 2-alpha</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>55 Months</TrialDuration><NumberOfSites>13</NumberOfSites><ContactNames><Name>Bent Ejlertsen, M.D.</Name><Name>Henning T. Mouridsen, M.D.</Name></ContactNames></Trial><Trial Id="51387"><Indications><Indication>Adenocarcinoma</Indication><Indication>Breast tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Epidermal growth factor receptor antagonist</Action><Action>Erbb2 tyrosine kinase receptor inhibitor</Action><Action>Erbb4 tyrosine kinase receptor inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer protein kinase inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Puma Biotechnology Inc</Company><Company>Wyeth Pharmaceuticals</Company></CompaniesSponsor><Countries><Country>Romania</Country><Country>Poland</Country><Country>Turkey</Country><Country>Lebanon</Country><Country>Chile</Country><Country>Germany</Country><Country>Sweden</Country><Country>Israel</Country><Country>South Korea</Country><Country>New Zealand</Country><Country>Greece</Country><Country>Colombia</Country><Country>Hong Kong</Country><Country>China</Country><Country>Denmark</Country><Country>UK</Country><Country>Jordan</Country><Country>Portugal</Country><Country>Czech Republic</Country><Country>Taiwan</Country><Country>Bulgaria</Country><Country>Bahamas</Country><Country>France</Country><Country>Mexico</Country><Country>Brazil</Country><Country>Italy</Country><Country>Belgium</Country><Country>Malaysia</Country><Country>Malta</Country><Country>Singapore</Country><Country>Slovakia</Country><Country>Croatia</Country><Country>Hungary</Country><Country>Peru</Country><Country>US</Country><Country>Argentina</Country><Country>Saudi Arabia</Country><Country>Serbia</Country><Country>Switzerland</Country><Country>Canada</Country><Country>Spain</Country><Country>Australia</Country><Country>Japan</Country><Country>Netherlands</Country><Country>Lithuania</Country></Countries><DateChangeLast>2019-06-07T00:00:00Z</DateChangeLast><DateEnd>2020-11-30T00:00:00Z</DateEnd><DateStart>2009-07-09T00:00:00Z</DateStart><Identifiers><Identifier>2008-007345-31</Identifier><Identifier>3144A2-3004</Identifier><Identifier>3144A2-3004 / B1891004</Identifier><Identifier>3144A2-3004(B1891004)</Identifier><Identifier>3144A2-3004-WW</Identifier><Identifier>7006</Identifier><Identifier>B1891004</Identifier><Identifier>ExteNET</Identifier><Identifier>JapicCTI-101217</Identifier><Identifier>NCT00878709</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Appetite loss</Indication><Indication>Arthralgia</Indication><Indication>Cerebral edema</Indication><Indication>Diarrhea</Indication><Indication>Dizziness</Indication><Indication>Dyspepsia</Indication><Indication>Emesis</Indication><Indication>Epistaxis</Indication><Indication>Fatigue</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Hepatotoxicity drug-induced</Indication><Indication>Influenza virus infection</Indication><Indication>Jaundice</Indication><Indication>Liver disease</Indication><Indication>Muscle spasm</Indication><Indication>Nail disease</Indication><Indication>Nausea</Indication><Indication>Paronychia</Indication><Indication>Rhinopharyngitis</Indication><Indication>Skin rash</Indication><Indication>Stomach tumor</Indication><Indication>Stomatitis</Indication><Indication>Urinary tract infection</Indication><Indication>Weight loss</Indication><Indication>Xerosis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>neratinib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2840</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The purpose of this multicenter, randomized, double-blind, placebo-controlled, phase III trial was to investigate whether neratinib could further reduce the risk of recurrence from previously diagnosed HER-2 positive breast cancer after adjuvant treatment with trastuzumab [ 1665435 ], [ 1228385 ], [ 1782156 ], [ 1782157 ], [ 1790152 ], [ 1797854 ], [ 1918107 ], [ 1945729 ], [ 1945624 ], [ 1961588 ], [ 1989379 ], [ 2069325 ], [ 2102197 ], [ 2102199 ], [ 2130663 ], [ 2130860 ], [ 2158805 ]. Main</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Disease Free Survival (DFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Asian Ancestry</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>ExteNET: Study Evaluating the Effects of Neratinib After Adjuvant Trastuzumab in Women With Early Stage Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Others - Subjects with node positive breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Early Stage Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Locally Advanced Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage II Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer - TNM stage IIIA Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer - TNM stage IIIB Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer - TNM stage IIIC Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Alpha-amylase 1 </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Epidermal growth factor receptor </BiomarkerName><BiomarkerName> Estrogen receptor </BiomarkerName><BiomarkerName> HER2 </BiomarkerName><BiomarkerName> Left ventricular ejection fraction </BiomarkerName><BiomarkerName> Myc proto-oncogene protein </BiomarkerName><BiomarkerName> Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN </BiomarkerName><BiomarkerName> Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform </BiomarkerName><BiomarkerName> Progesterone receptor </BiomarkerName><BiomarkerName> QT interval </BiomarkerName><BiomarkerName> Receptor tyrosine-protein kinase erbB-3 </BiomarkerName><BiomarkerName> Receptor tyrosine-protein kinase erbB-4 </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Transaminases</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-08-21T00:00:00Z</PrimaryCompletionDate><TrialDuration>136 Months</TrialDuration><NumberOfSites>594</NumberOfSites><ContactNames><Name>Personal</Name><Name>Pfizer Japan Inc.</Name><Name>Puma</Name></ContactNames></Trial><Trial Id="49488"><Indications><Indication>Diabetic neuropathy</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>5-HT uptake inhibitor</Action><Action>Analgesic</Action><Action>Antidepressant</Action><Action>Anxiolytic</Action><Action>Norepinephrine uptake inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Daily dosing</Technology><Technology>Enteric coated formulation</Technology><Technology>Oral controlled release formulation</Technology><Technology>Oral formulation</Technology><Technology>Pellet</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Eli Lilly &amp; Co</Company></CompaniesSponsor><DateChangeLast>2010-09-21T00:00:00Z</DateChangeLast><DateStart>2003-11-30T00:00:00Z</DateStart><IndicationsAdverse><Indication>Appetite loss</Indication><Indication>Constipation</Indication><Indication>Drowsiness</Indication><Indication>Emesis</Indication><Indication>Hyperhidrosis</Indication><Indication>Nausea</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>duloxetine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>348</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>severity on the 11-point Likert scale (from the patient diary prior to randomization), and stable glycemic control Concomitant medication inclusions (chronic and episodic) were antacids, antiasthma agents, aminophylline, birth control medication, cough/&lt;b&gt;cold&lt;/b&gt; preparations (that did not contain dextromethorphan), diuretics, inhaled and topical steroids, hypoglycemics, insulin, laxatives, theophylline, anticoagulants, antibiotics, antidiarrheals, and antihistamines. Medications including angiotensin-converting</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A phase III, 12-week, multicenter, randomized, double-blind, placebo-controlled parallel study of duloxetine in patients with diabetic neuropathy</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="49419"><Indications><Indication>Periodontal disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Collagenase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Tetracycline</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Buccal formulation local</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>TOLMAR Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-02-08T00:00:00Z</DateChangeLast><DateStart>1997-03-21T00:00:00Z</DateStart><InterventionsPrimaryDisplay><Intervention>doxycycline (subgingival delivery: Atridox), Atrix alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>The drug was generally well tolerated. Side effects were similar to those of placebo. The most common side effects observed were headache, common &lt;b&gt;cold&lt;/b&gt;, gum discomfort, pain or soreness, toothache, and tooth sensitivity [ 327938 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A 9-month, randomized, double-blind, placebo-controlled, parallel-group, phase III study to evaluate the safety and efficacy of Atridox in patients with moderate to severe periodontal disease</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="47935"><Indications><Indication>Bladder cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>EGFR family tyrosine kinase receptor inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>National Cancer Institute of Canada</Company></CompaniesSponsor><Countries><Country>Canada</Country></Countries><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2012-01-01T00:00:00Z</DateEnd><DateStart>2006-04-30T00:00:00Z</DateStart><Identifiers><Identifier>BL11</Identifier><Identifier>CAN-NCIC-BL11</Identifier><Identifier>CDR0000486873</Identifier><Identifier>NCT00352079</Identifier></Identifiers><InterventionsControlDisplay><Intervention>BCG alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>BCG plus gefitinib</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>41</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Patient Enrollment Issues</Reason></ReasonForTrialDiscontinuation><Teaser>tumor(s) Carcinoma in situ (Tis) At least grade 2 tumor that invades the subepithelial connective tissue (T1) Has undergone TUR of all visible bladder lesions within the past 21 to 60 days with biopsy of the underlying bladder wall for all tumors and &lt;b&gt;cold&lt;/b&gt;-cup biopsy of all suspicious areas No metastatic disease as confirmed by negative radiology within the past 16 weeks, including the following: Chest x-ray Imaging of the upper urinary tract by one of the following methods: CT scan, MRI, or ultrasound</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Disease Relapse/Recurrence - Assessment of time to recurrence</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Bladder cancer - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Clinical Response - Assessment of Time-to-Treatment Failure (TTF)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Disease Relapse/Recurrence - Assessment of time to recurrence</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of adverse events</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Bladder cancer - Subjects with Histologic Grade 2 Bladder Cancer (G2)</PatientSegment><PatientSegment>Bladder cancer - Subjects with Histologic Grade 3 Bladder Cancer (G3)</PatientSegment><PatientSegment>Bladder cancer - Subjects with Superficial or Non-Muscle Invasive Bladder Cancer</PatientSegment><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>68 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Louis Lacombe, MD</Name></ContactNames></Trial><Trial Id="47928"><Indications><Indication>Premature labor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Progesterone receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Technologies><Technology>Intramuscular formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology><Technology>Sustained release formulation</Technology></Technologies><CompaniesCollaborator><Company>Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development</Company></CompaniesCollaborator><CompaniesSponsor><Company>The George Washington University Biostatistics Center</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2011-12-31T00:00:00Z</DateEnd><DateStart>2007-04-30T00:00:00Z</DateStart><Identifiers><Identifier>HD21410</Identifier><Identifier>HD27860</Identifier><Identifier>HD27869</Identifier><Identifier>HD27915</Identifier><Identifier>HD27917</Identifier><Identifier>HD34116</Identifier><Identifier>HD34136</Identifier><Identifier>HD34208</Identifier><Identifier>HD36801</Identifier><Identifier>HD36801 SCAN</Identifier><Identifier>HD40485</Identifier><Identifier>HD40500</Identifier><Identifier>HD40512</Identifier><Identifier>HD40544</Identifier><Identifier>HD40545</Identifier><Identifier>HD40560</Identifier><Identifier>NCT00439374</Identifier><Identifier>U10HD021410</Identifier><Identifier>U10HD027860</Identifier><Identifier>U10HD027869</Identifier><Identifier>U10HD027915</Identifier><Identifier>U10HD027917</Identifier><Identifier>U10HD034116</Identifier><Identifier>U10HD034136</Identifier><Identifier>U10HD034208</Identifier><Identifier>U10HD036801</Identifier><Identifier>U10HD040485</Identifier><Identifier>U10HD040500</Identifier><Identifier>U10HD040512</Identifier><Identifier>U10HD040544</Identifier><Identifier>U10HD040545</Identifier><Identifier>U10HD040560</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>hydroxyprogesterone caproate (long-acting, preterm birth prevention), Adeza alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>657</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Lack of Efficacy</Reason></ReasonForTrialDiscontinuation><Teaser>planned cervical cerclage Congenital Mullerian abnormality of the uterus Contraindication to intra-muscular injections Hypertension requiring medication Diabetes managed with insulin or oral hypoglycemic agents DES exposure Cervical surgery such as &lt;b&gt;cold&lt;/b&gt; knife conization Planned indicated preterm delivery Participation in another interventional study that influences age at delivery Participation in this trial in a previous pregnancy Prenatal care or delivery planned outside a MFMU Network center</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term></TermsPatientSelection><TitleDisplay>RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix</TitleDisplay><BiomarkerNames><BiomarkerName>Birth weight</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>56 Months</TrialDuration><NumberOfSites>14</NumberOfSites><ContactNames><Name>Menachem Miodovnik, MD</Name><Name>William Grobman, MD, MBA</Name></ContactNames></Trial><Trial Id="45807"><Indications><Indication>Neuropathy</Indication><Indication>Neurotoxicity drug-induced</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>5-HT 1a receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Apoptosis inhibitor</Action><Action>DNA synthesis inhibitor</Action><Action>Neuroprotectant</Action><Action>Nootropic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Sanofi SA</Company></CompaniesSponsor><DateChangeLast>2019-03-29T00:00:00Z</DateChangeLast><DateEnd>2004-05-31T00:00:00Z</DateEnd><DateStart>2002-07-31T00:00:00Z</DateStart><Identifiers><Identifier>EFC4972</Identifier><Identifier>NCT00272051</Identifier><Identifier>SR57746A</Identifier><Identifier>XENOX</Identifier></Identifiers><IndicationsAdverse><Indication>Anxiety disorder</Indication><Indication>Diarrhea</Indication><Indication>Insomnia</Indication><Indication>Tinnitus</Indication><Indication>Vertigo</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Variable regimens including 5-fluorouracil , folinic acid , oxaliplatin , xaliproden</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>620</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> not reveal any differences. Diabetic compared to non-diabetic patients, no differences was observed between the two groups in terms of acute oxaliplatin-induced neurological symptoms including laryngeal dysthesia (p = 0.707), jaw pain (p = 0.743), &lt;b&gt;cold&lt;/b&gt;-induced dysthesia (p = 0.600) or muscle pain (p =  0.506). Moreover, there was no difference observed between the two groups in parameters of the highest grade of paresthesia (p = 0.498), incidence of long-term oxaliplatin-induced paresthesia (p = </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Organ Function</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of clinical/pathological response</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Therapy Related Outcomes - Efficacy/feasibility Assessment</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>XENOX: XENOX – Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Other Chemotherapy Induced Adverse Events</PatientSegment><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Colon Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>22 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Gerard SAID</Name></ContactNames></Trial><Trial Id="4579"><Indications><Indication>Heart transplantation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Spain</Country><Country>Australia</Country><Country>Germany</Country><Country>Canada</Country><Country>Italy</Country><Country>Brazil</Country><Country>US</Country><Country>Austria</Country></Countries><DateChangeLast>2017-06-30T00:00:00Z</DateChangeLast><DateEnd>2007-01-08T00:00:00Z</DateEnd><DateStart>2004-08-09T00:00:00Z</DateStart><Identifiers><Identifier>2004-000541-38</Identifier><Identifier>CRAD001A2403</Identifier><Identifier>NCT00098007</Identifier><Identifier>RAD/Certican</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ciclosporin, Novartis plus everolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>199</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Patients with donor hearts &gt; 60 years of age and/or with a &lt;b&gt;cold&lt;/b&gt; ischemia time of more than 6 h and/or donor hearts which have obvious coronary disease or are known to have heart disease at time of transplant Patients who are recipients of multiple solid organ transplants, or who are previously received transplanted</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Dose Comparison</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR) - AGR associated with hemodynamic compromise (HDC)</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR) - Incidence/number of AGR episodes</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Graft Loss/Graft Failure - Incidence of graft loss</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Safety and Tolerability - Withdrawal/discontinuation of the drug due to toxicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study of Safety, Tolerability and Efficacy of Certican in de Novo Heart Transplant (Tx) Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Heart transplantation - Heart Transplant Recipients</PatientSegment><PatientSegment>Heart transplantation - Subjects with History of/on Currently on Heart Transplant Therapy</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-01-08T00:00:00Z</PrimaryCompletionDate><TrialDuration>29 Months</TrialDuration><NumberOfSites>28</NumberOfSites></Trial><Trial Id="45479"><Indications><Indication>Influenza virus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Nasal systemic formulation</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesSponsor><Company>MedImmune LLC</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2017-08-04T00:00:00Z</DateChangeLast><DateEnd>2006-12-01T00:00:00Z</DateEnd><DateStart>2006-06-30T00:00:00Z</DateStart><Identifiers><Identifier>MI-CP134</Identifier><Identifier>NCT00325481</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>FluMist alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>300</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study was designed to assess the safety of a bivalent vaccine of two new influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine ( FluMist ) containing them.</Teaser><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex><EndpointIndex>Influenza virus infection - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Study To Evaluate the Safety of Bivalent Vaccine</TitleDisplay><PrimaryCompletionDate/><TrialDuration>5 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Maria Allende, M.D.</Name></ContactNames></Trial><Trial Id="44938"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Astellas Pharma Europe BV</Company></CompaniesCollaborator><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>Belgium</Country><Country>Netherlands</Country><Country>France</Country><Country>Germany</Country><Country>Switzerland</Country><Country>UK</Country><Country>Spain</Country></Countries><DateChangeLast>2019-02-07T00:00:00Z</DateChangeLast><DateEnd>2007-08-31T00:00:00Z</DateEnd><DateStart>2004-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2004-000520-32</Identifier><Identifier>FG-506-02-42</Identifier><Identifier>JapicCTI-184472</Identifier><Identifier>JapicCTI-R140562</Identifier><Identifier>NCT00296309</Identifier><Identifier>SENIOR</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including Simulect , mycophenolate mofetil , tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>267</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Patient has an immunological high risk &lt;b&gt;Cold&lt;/b&gt; ischemia time &gt; 30 h Patient has significant liver disease Patient is allergic or intolerant to study medication Patient or donor is known to be HIV positive Patient with malignancy or history of malignancy Patient has significant, uncontrolled concomitant</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Steroid resistant AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Untreated AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Chronic Graft Rejection (CGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Creatinine Clearance</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Delayed Graft Function (DGF)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Dysfunction</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles - Assessment of Total Cholesterol</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles - LDL-C (Low-density lipoprotein cholesterol)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles - Triglyceride levels (TG)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of use of Rescue Medication - Need for antidiabetic agents</EndpointIndex><EndpointIndex>Kidney transplantation - Glycemic Control Analysis - Assessment of blood glucose</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications - Hyperglycemia</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SENIOR: Comparing Efficacy and Safety of Tacrolimus and MMF With/Without Induction in the Elderly Following Kidney Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Antibody Compatible Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Subjects Awaiting Renal Transplant</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2006-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>34 Months</TrialDuration><NumberOfSites>34</NumberOfSites><ContactNames><Name>Medical Physician</Name></ContactNames></Trial><Trial Id="44935"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Immunosuppressant</Action><Action>Protein synthesis inhibitor</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug coating</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Pfizer Inc</Company><Company>Sanofi Genzyme</Company></CompaniesCollaborator><CompaniesSponsor><Company>Astellas Pharma Inc</Company><Company>Australian Government Department of Health and Ageing</Company><Company>Fujisawa GmbH</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>Poland</Country><Country>Spain</Country><Country>Austria</Country><Country>France</Country><Country>Czech Republic</Country><Country>Netherlands</Country><Country>Sweden</Country><Country>Romania</Country><Country>Hungary</Country><Country>Belgium</Country><Country>Australia</Country><Country>Italy</Country><Country>Germany</Country></Countries><DateChangeLast>2019-02-07T00:00:00Z</DateChangeLast><DateEnd>2006-07-31T00:00:00Z</DateEnd><DateStart>2004-10-31T00:00:00Z</DateStart><Identifiers><Identifier>2004-000457-34</Identifier><Identifier>ACTRN12611001224910</Identifier><Identifier>FG-506-02-40</Identifier><Identifier>JapicCTI-184471</Identifier><Identifier>JapicCTI-R140561</Identifier><Identifier>NCT00296361</Identifier><Identifier>RESTORE</Identifier></Identifiers><InterventionsControlDisplay><Intervention>mycophenolate mofetil plus tacrolimus</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>sirolimus plus tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>634</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Patient has a high immunological risk, defined as a PRA grade &gt; 50% in the previous 6 months and / or having a previous graft survival&amp;lt; 1 year due to immunological reason Patient is receiving a graft from a non-heart-beating donor &lt;b&gt;Cold&lt;/b&gt; ischemia time of the donor kidney &gt; 30 h Patient has significant liver disease, defined as having during the past 30 days continuously elevated AST (SGOT) and/or ALT (SGPT) levels greater than 2 times the upper value of the normal range of the investigational</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Clinically-confirmed AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Freedom from acute rejection</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Incidence/number of AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Time to AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Bone Marrow - Leucopenia</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Creatinine Clearance</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Liver Functions - Serum glutamic oxaloacetic transaminase (SGOT)/Aspartate aminotransferase (AST)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Liver Functions - Serum glutamic-pyruvic transaminase (SGPT)/Alanine aminotransferase (ALT)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Hyperlipidemia/dyslipidemia</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles - Assessment of Total Cholesterol</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles - HDL-C (High-density lipoprotein cholesterol)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles - LDL-C (Low-density lipoprotein cholesterol)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of use of Rescue Medication - Need for antidiabetic agents</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of use of Rescue Medication - Need for lipid lowering drugs</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections - CMV infection</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications - Hyperkalaemia</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications - New onset/post transplant diabetes mellitus</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>RESTORE: To Compare the Efficacy and Safety of a Therapy of Tacrolimus With Sirolimus or MMF in Kidney Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Renal re-transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Subjects Awaiting Renal Transplant</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> C-reactive protein </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Total protein </BiomarkerName><BiomarkerName> Triglycerides </BiomarkerName><BiomarkerName> Waist circumference</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2006-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>59</NumberOfSites><ContactNames><Name>Medical Physician</Name></ContactNames></Trial><Trial Id="44746"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company><Company>Novartis Pharma KK</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2018-08-13T00:00:00Z</DateChangeLast><DateEnd>2012-05-31T00:00:00Z</DateEnd><DateStart>2008-02-29T00:00:00Z</DateStart><Identifiers><Identifier>A1202</Identifier><Identifier>A1202E1</Identifier><Identifier>A1202E1</Identifier><Identifier>CRAD001A1202</Identifier><Identifier>CRAD001A1202E1</Identifier><Identifier>JapicCTI-080593</Identifier><Identifier>JapicCTI-090710</Identifier><Identifier>NCT00658320</Identifier><Identifier>NCT00856466</Identifier></Identifiers><IndicationsAdverse><Indication>Acne</Indication><Indication>Constipation</Indication><Indication>Cytomegalovirus infection</Indication><Indication>Diarrhea</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Hyperlipidemia</Indication><Indication>Hypertension</Indication><Indication>Hyperuricemia</Indication><Indication>Insomnia</Indication><Indication>Iron deficiency anemia</Indication><Indication>Renal disease</Indication><Indication>Rhinopharyngitis</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Variable regimens including ciclosporin, Novartis , everolimus , everolimus + Neoral , mycophenolate mofetil , mycophenolate mofetil + Neoral</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>122</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> prior to randomization are acceptable, otherwise these tests should be performed within two weeks prior to randomization Recipients of organs from donors who test positive for Hepatitis B surface antigen, HCV or HIV are excluded Donor organ with a &lt;b&gt;cold&lt;/b&gt; ischemia time&gt; 24 h Donor age &gt; 65 years Patients with platelet count&amp;lt; 100,000/mm at baseline before transplantation Patients with an absolute neutrophil count of&amp;lt; 1500/mm3 or white blood cell count of &amp;lt; 4500/mm3 at baseline before transplantation</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Untreated AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR) - Calculated GFR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR) - GFR calculated using MDRD Study formula</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR) - GFR calculated using Nankivell formula</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure - Incidence/proportion of patients with graft loss</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Dose-adjusted trough concentration (C0/Dose)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Urinary Protein Excretion/Proteinuria</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Kidney transplantation - Composite Endpoints - Frequency of treatment failure</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Antibody Incompatible Renal Transplant (AiT) Recipients - HLA antibody incompatible (HLAi) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>51 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Novartis</Name><Name>Novartis Pharma KK</Name></ContactNames></Trial><Trial Id="4434"><Indications><Indication>Cardiovascular disease</Indication><Indication>Heart disease</Indication><Indication>Raynauds disease</Indication><Indication>Vascular disease</Indication></Indications><CompaniesSponsor><Company>National Heart Lung and Blood Institute</Company></CompaniesSponsor><DateChangeLast>2016-04-16T00:00:00Z</DateChangeLast><DateStart>1992-09-30T00:00:00Z</DateStart><Identifiers><Identifier>73</Identifier><Identifier>NCT00000530</Identifier><Identifier>RTS</Identifier></Identifiers><IndicationsAdverse><Indication>Edema</Indication><Indication>Headache</Indication><Indication>Tachycardia</Indication><Indication>Vertigo</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>nifedipine (once-daily controlled-release), Pfizer alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>313</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>the &lt;b&gt;cold&lt;/b&gt; season months of November through February in 1993 and 1994 (cohort 1) and 200 were enrolled during the 1994 and 1995 &lt;b&gt;cold&lt;/b&gt; season months (cohort 2) [ 1152064 ]....Patients completed at least 75% of the required 1-month basline record of attacks No contraindications to the study treatments Patients who reported at least two attacks on an average day during the previous &lt;b&gt;cold&lt;/b&gt; season</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Peripheral vascular disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>RTS: Raynaud's Treatment Study (RTS)</TitleDisplay><PatientSegmentTerms><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - Subjects with raynaud's disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites><ContactNames><Name>Bruce Thompson</Name></ContactNames></Trial><Trial Id="44232"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Astellas Pharma Inc</Company></CompaniesSponsor><Countries><Country>Hungary</Country><Country>Czech Republic</Country><Country>Poland</Country><Country>Slovakia</Country></Countries><DateChangeLast>2019-02-07T00:00:00Z</DateChangeLast><DateEnd>2004-08-31T00:00:00Z</DateEnd><DateStart>2003-02-28T00:00:00Z</DateStart><Identifiers><Identifier>DISTAMP</Identifier><Identifier>FG-506-02-CEE-01</Identifier><Identifier>JapicCTI-184504</Identifier><Identifier>JapicCTI-R140599</Identifier><Identifier>NCT00693381</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including methylprednisolone , mycophenolate mofetil , prednisone , tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>152</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>squamous cell carcinoma of the skin that has been treated successfully Patient has significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, or active peptic ulcer Patient is receiving a graft from a non-heart-beating donor &lt;b&gt;Cold&lt;/b&gt; ischemia time of the donor kidney&gt;/= 40 h</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Clinically-confirmed AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Freedom from acute rejection</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Incidence/number of AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Severity of AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Bone Marrow - Anemia</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Gastrointestinal adverse events</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections - CMV infection</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections - Urinary tract infections</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications - New onset/post transplant diabetes mellitus</EndpointIndex><EndpointIndex>Kidney transplantation - Post Transplant Malignancies</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>DISTAMP: Mycophenolate Mofetil (MMF) Discontinuation From a Tacrolimus/MMF/Steroid Triple Regimen After Kidney Transplantation</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Subjects Awaiting Renal Transplant</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2004-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>18 Months</TrialDuration><NumberOfSites>14</NumberOfSites><ContactNames><Name>Central Contact</Name></ContactNames></Trial><Trial Id="43935"><Indications><Indication>Metastatic colorectal cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Thymidylate synthase inhibitor</Action><Action>VEGF ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Anticancer antimetabolite</Action><Action>Anticancer monoclonal antibody</Action><Action>DNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Film coating</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Prodrug</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2007-01-01T00:00:00Z</DateEnd><DateStart>2004-04-30T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000330000</Identifier><Identifier>NCI-2012-02556</Identifier><Identifier>NCT00070122</Identifier><Identifier>S0303</Identifier><Identifier>U10CA032102</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including bevacizumab , capecitabine , fluorouracil , leucovorin calcium , oxaliplatin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2200</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>therapeutic anticoagulation Prophylactic anticoagulation of central venous lines allowed Low-dose prophylactic enoxaparin or heparin allowed No concurrent cimetidine No concurrent sorivudine or its related analogs (eg, brivudine) No concurrent use of a &lt;b&gt;cold&lt;/b&gt; cap or iced mouth rinses</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Biomarkers - Assessment of markers of DNA repair</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Clinical Response - Assessment of Time to Treatment Failure (TTF)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of growth factors</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of angiogenesis</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of toxicities</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of markers of drug resistance/metabolism</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by FACT-C TOI</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with Recurrent/Relapsed Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM Stage I/Dukes A Colorectal Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Charles Blanke</Name></ContactNames></Trial><Trial Id="43792"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><DateChangeLast>2017-04-01T00:00:00Z</DateChangeLast><DateStart>2001-05-31T00:00:00Z</DateStart><Identifiers><Identifier>CCHI621ADE01</Identifier><Identifier>NCT00228020</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Variable regimens including ciclosporin, Novartis , mycophenolate mofetil , prednisone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including basiliximab , ciclosporin, Novartis , mycophenolate mofetil , prednisone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>212</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Patients who are recipients of HLA-identical renal transplants. Patients whose donor kidney &lt;b&gt;cold&lt;/b&gt; ischemia time (CIT) is &gt; 36 h. Patients whose transplant kidney is obtained from a non-heart beating donor Other protocol-defined exclusion criteria may apply</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - First AGR episode</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Sub-clinical AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Clinical Response - Assessment of time to treatment failure (TTF)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Incidence of adverse events/Side Effects</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival - Survival Rates (Kaplan-Meier analysis)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Renal re-transplant recipients</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2006-01-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>0</NumberOfSites><ContactNames><Name>Novartis</Name></ContactNames></Trial><Trial Id="41370"><Indications><Indication>Neurotoxicity drug-induced</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>5-HT 1a receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Apoptosis inhibitor</Action><Action>DNA synthesis inhibitor</Action><Action>Neuroprotectant</Action><Action>Nootropic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Sanofi SA</Company></CompaniesSponsor><Countries><Country>Chile</Country><Country>Canada</Country><Country>Italy</Country><Country>Germany</Country><Country>US</Country><Country>Brazil</Country><Country>Argentina</Country><Country>UK</Country><Country>Australia</Country><Country>Hungary</Country><Country>Spain</Country><Country>Poland</Country><Country>Portugal</Country></Countries><DateChangeLast>2019-03-29T00:00:00Z</DateChangeLast><DateEnd>2009-10-31T00:00:00Z</DateEnd><DateStart>2005-12-31T00:00:00Z</DateStart><Identifiers><Identifier>EFC5505</Identifier><Identifier>EUDRACT : 2005-002570-30</Identifier><Identifier>NCT00305188</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including 5-fluorouracil , folinic acid , oxaliplatin , xaliproden</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>879</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> not reveal any differences. Diabetic compared to non-diabetic patients, no differences was observed between the two groups in terms of acute oxaliplatin-induced neurological symptoms including laryngeal dysthesia (p = 0.707), jaw pain (p = 0.743), &lt;b&gt;cold&lt;/b&gt;-induced dysthesia (p = 0.600) or muscle pain (p =  0.506). Moreover, there was no difference observed between the two groups in parameters of the highest grade of paresthesia (p = 0.498), incidence of long-term oxaliplatin-induced paresthesia (p = </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR) - Assessment of Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Organ Function</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Therapy Related Outcomes - Efficacy/feasibility Assessment</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Evaluation of the Efficacy of Xaliproden (SR-57746A) in Preventing the Neurotoxicity of Oxaliplatin/5FU/LV Chemotherapy</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Other Chemotherapy Induced Adverse Events</PatientSegment><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Colon Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>46 Months</TrialDuration><NumberOfSites>13</NumberOfSites><ContactNames><Name>Clinical Sciences &amp; Operations</Name></ContactNames></Trial><Trial Id="41217"><Indications><Indication>Kidney transplantation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Belgium</Country><Country>US</Country></Countries><DateChangeLast>2017-09-14T00:00:00Z</DateChangeLast><DateEnd>2007-03-31T00:00:00Z</DateEnd><DateStart>2000-06-30T00:00:00Z</DateStart><Identifiers><Identifier>CRAD001AB351</Identifier><Identifier>NCT00098241</Identifier><Identifier>RAD/Certican</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>everolimus alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>45</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> &lt;b&gt;Cold&lt;/b&gt; ischemia time &gt; 40 h Patients who are recipients of multiple solid organ transplants, including dual and en bloc kidneys, or who have previously received transplanted organs Patients with panel reactive T-cell antibodies of 50 % or higher at the last assessment before transplantation</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Composite Endpoints</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections - Incidence/rate of infections</EndpointIndex><EndpointIndex>Kidney transplantation - Protocol Specified Other Endpoints - Other Laboratory Parameters</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety And Efficacy of Certican in Pediatric De Novo Renal Transplant Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Antibody Incompatible Renal Transplant (AiT) Recipients - HLA antibody incompatible (HLAi) renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living related donor (LRD) - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living unrelated donor - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2007-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>81 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Novartis</Name></ContactNames></Trial><Trial Id="40943"><Indications><Indication>Heart transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Emulsion formulation</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Norway</Country><Country>UK</Country><Country>Taiwan</Country><Country>Spain</Country><Country>Belgium</Country><Country>Austria</Country><Country>US</Country><Country>Germany</Country><Country>New Zealand</Country><Country>France</Country><Country>Puerto Rico</Country><Country>Italy</Country><Country>Argentina</Country><Country>Australia</Country><Country>Canada</Country></Countries><DateChangeLast>2018-07-05T00:00:00Z</DateChangeLast><DateEnd>2011-07-31T00:00:00Z</DateEnd><DateStart>2006-01-31T00:00:00Z</DateStart><Identifiers><Identifier>-</Identifier><Identifier>2005-003413-32</Identifier><Identifier>CRAD001A2310</Identifier><Identifier>NCT00300274</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including ciclosporin, Novartis , everolimus , mycophenolate mofetil</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>721</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>melanoma skin lesions) Patients with a known hypersensitivity to similar drugs and to the components of the formulations Patients with donor greater than 65 years and/or with known donor coronary or heart disease at the time of transplant Donor heart &lt;b&gt;cold&lt;/b&gt; ischemic time &gt; 6 h Patients who are treated with drugs strong inducers or inhibitors of cytochrome P450 3A4. (See appendix 4) Patients who are unable to take oral medication by mouth (short- term NG administration allowed no longer than Day 5) Existence</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR) - AGR associated with hemodynamic compromise (HDC)</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Graft Loss/Graft Failure - Incidence of graft loss</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Heart transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Heart transplantation - Protocol Specified Other Endpoints - Loss to follow up</EndpointIndex><EndpointIndex>Heart transplantation - Protocol Specified Other Endpoints - Re-transplant</EndpointIndex><EndpointIndex>Renal failure - Assessment of Glomerular Filtration Rate (GFR) - Assessment of estimated glomerular filtration rate(eGFR)/creatinine clearance(CCr/CrCl/CLcr)</EndpointIndex><EndpointIndex>Renal failure - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Renal failure - Assessment of Organ Function - Cardiac assessment</EndpointIndex><EndpointIndex>Renal failure - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>-: Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection</TitleDisplay><PatientSegmentTerms><PatientSegment>Heart transplantation - Heart Transplant Recipients</PatientSegment><PatientSegment>Heart transplantation - Heart Transplant Recipients - Primary (First) Heart Transplant Recipients</PatientSegment><PatientSegment>Renal failure - Subjects with History/Scheduled for Other Transplantations</PatientSegment><PatientSegment>Renal failure - Subjects with Prerenal Causes for Acute Renal Failure(ARF) - Subjects with cardiopulmonary disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Carotid artery intima-media </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>66 Months</TrialDuration><NumberOfSites>66</NumberOfSites><ContactNames><Name>Novartis</Name></ContactNames></Trial><Trial Id="39802"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor mu agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Norepinephrine uptake inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral quick release formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Grunenthal GmbH</Company></CompaniesCollaborator><CompaniesSponsor><Company>Ortho-McNeil Janssen Scientific Affairs, LLC</Company></CompaniesSponsor><DateChangeLast>2018-05-09T00:00:00Z</DateChangeLast><DateEnd>2010-03-31T00:00:00Z</DateEnd><DateStart>2008-12-31T00:00:00Z</DateStart><Identifiers><Identifier>CR015040</Identifier><Identifier>KF5503/49</Identifier><Identifier>NCT00814580</Identifier><Identifier>R331333PAI3022</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>oxycodone IR alone</Intervention><Intervention>tapentadol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>382</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>least 3 days post-operatively. Patients who continue to meet all study criteria post-operatively would be randomized prior to PACU discharge and would be sent home with study medication (Visit 2). All patients would be prescribed a standard regimen of &lt;b&gt;cold&lt;/b&gt; pack application to the surgical shoulder. Patients would be instructed to take the first dose of study medication as their first oral analgesic when they have at least moderate pain (prior to discharge or at home). Patients would be reminded about</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR) - Rate of &gt;/=30% response</EndpointIndex><EndpointIndex>Pain - Assessment of Response Rates (RR) - Rate of &gt;/=50% response</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex><EndpointIndex>Pain - Health Economic Assessments - Assessment of Health Services Utilization</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Safety and Efficacy of Tapentadol Immediate Release (IR) and Oxycodone IR for Treatment of Acute Post-op Pain Following Elective Arthroscopic (Surgery Using a Thin Flexible Scope) Shoulder Surgery</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>0</NumberOfSites></Trial><Trial Id="39117"><Indications><Indication>Hypertension</Indication></Indications><ActionsPrimaryInterventionsControl><Action>ACE inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Angiotensin II receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Antihypertensive</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Antihypertensive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Takeda Europe R&amp;D Centre Ltd</Company><Company>Takeda Pharmaceutical Co Ltd</Company></CompaniesSponsor><Countries><Country>Russian Federation</Country><Country>Bulgaria</Country><Country>Slovakia</Country><Country>Finland</Country><Country>Estonia</Country><Country>Germany</Country><Country>Netherlands</Country><Country>Serbia</Country><Country>Sweden</Country><Country>Poland</Country></Countries><DateChangeLast>2017-03-07T00:00:00Z</DateChangeLast><DateEnd>2009-04-30T00:00:00Z</DateEnd><DateStart>2008-01-31T00:00:00Z</DateStart><Identifiers><Identifier>01-06-TL-491-020</Identifier><Identifier>2007-002583-10</Identifier><Identifier>NCT00760214</Identifier><Identifier>U1111-1113-8982</Identifier></Identifiers><InterventionsControlDisplay><Intervention>ramipril alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>azilsartan medoxomil potassium (hypertension), Takeda/ Arbor alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>885</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>that alter blood pressure, including: Tricyclic antidepressants Monoamine oxidase inhibitors Lithium Phosphodiesterase type 5 inhibitors Diet medications Amphetamines or their derivatives Chronically used (defined as more than 3 doses per week) common &lt;b&gt;cold&lt;/b&gt; medications or nonsteroidal anti-inflammatory, including aspirin greater than 300 mg/day or cyclooxygenase-2 inhibitors Systemic use of corticosteroids (topical or inhaled is acceptable) Thiazolidinediones Herbal medications Is hypersensitive to angiotensin</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Hypertension - Assessment of Diastolic Blood Pressure (DBP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Diastolic Blood Pressure (DBP) - DBP control rate</EndpointIndex><EndpointIndex>Hypertension - Assessment of Systolic Blood Pressure (SBP)</EndpointIndex><EndpointIndex>Hypertension - Assessment of Systolic Blood Pressure (SBP) - SBP control rate</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension</TitleDisplay><PatientSegmentTerms><PatientSegment>Hypertension - Subjects with Primary/Essential Hypertension</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Diastolic blood pressure </BiomarkerName><BiomarkerName> Systolic blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2009-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>16</NumberOfSites><ContactNames><Name>Medical Director</Name></ContactNames></Trial><Trial Id="386874"><Indications><Indication>Tooth disease</Indication></Indications><CompaniesSponsor><Company>Personal Products Co</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-07-03T00:00:00Z</DateChangeLast><DateEnd>2014-05-31T00:00:00Z</DateEnd><DateStart>2014-03-31T00:00:00Z</DateStart><Identifiers><Identifier>KOXDHY0009</Identifier><Identifier>NCT02113579</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Crest alone</Intervention><Intervention>mouth rinse 12027-033 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>375</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>process, complete a medical/dental history, and be evaluated for tactile sensitivity to Yeaple probe and response to a &lt;b&gt;cold&lt;/b&gt; air stimulus. Participants who qualify through screening would begin a run-in period that will last approximately 2 weeks. The...recession A minimum of two eligible teeth (premolars, canines and/or incisors) with a screening (-2 weeks baseline) and baseline &lt;b&gt;cold&lt;/b&gt; air stimulus Visual Analogue Scale (VAS) score of 40 to 80 mm on a 100 mm VAS scale, tactile sensitivity score between</Teaser><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity</TitleDisplay><PrimaryCompletionDate type="Actual">2014-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>2 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Michael Lynch</Name></ContactNames></Trial><Trial Id="386262"><Indications><Indication>Common cold</Indication><Indication>Nasal congestion</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Non-steroidal anti-inflammatory</Action><Action>Prostaglandin synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Drug combination</Technology><Technology>Formulation powder</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>AFT Pharmaceuticals Ltd</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2019-07-01T00:00:00Z</DateChangeLast><DateEnd>2017-03-17T00:00:00Z</DateEnd><DateStart>2015-11-10T00:00:00Z</DateStart><Identifiers><Identifier>2015-002385-23</Identifier><Identifier>AFT-MXCF-03</Identifier></Identifiers><InterventionsControlDisplay><Intervention>phenylephrine hydrochloride alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Maxiclear alone</Intervention><Intervention>acetaminophen and ibuprofen (oral formulation, pain), AFT Pharmaceuticals alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>275</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser> Male and/or female aged &gt;/= 18 years Presents &lt;b&gt;cold&lt;/b&gt; symptoms which began within 96 h of the study entry Has a minimum score of 2 from the list of the following URTI symptoms: runny nose, blocked nose, sore throat and cough For females: must be sterile or using adequate contraception Has a baseline NAR</Teaser><TrialCategories><Category>Medical device</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Other respiratory disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Respiratory tract infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A phase III clinical study to study the effects of different doses of phenylephrine hydrochloride in combination with paracetamol and/or ibuprofen, in people with blocked nose due to the common cold</TitleDisplay><BiomarkerNames><BiomarkerName>Specific airway conductance</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>16 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ioana Stanescu</Name></ContactNames></Trial><Trial Id="386022"><Indications><Indication>Adenocarcinoma</Indication><Indication>Anal tumor</Indication><Indication>Cervical dysplasia</Indication><Indication>Papillomavirus infection</Indication><Indication>Uterine cervix tumor</Indication><Indication>Vaginal cancer</Indication></Indications><ActionsSecondaryInterventionsControl><Action>Prophylactic vaccine</Action><Action>Protein subunit vaccine</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Prophylactic vaccine</Action><Action>Protein subunit vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antigen</Technology><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Nanoparticle formulation injectable</Technology><Technology>Protein recombinant</Technology><Technology>Suspension</Technology><Technology>Viral coat protein</Technology></Technologies><CompaniesSponsor><Company>MSD R&amp;D (China) Co Ltd</Company><Company>Merck &amp; Co Inc</Company><Company>Merck Sharp &amp; Dohme BV</Company><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-06-28T00:00:00Z</DateChangeLast><DateEnd>2027-02-01T00:00:00Z</DateEnd><DateStart>2019-06-30T00:00:00Z</DateStart><Identifiers><Identifier>CTR20190587</Identifier><Identifier>NCT03998254</Identifier><Identifier>V503-023</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Gardasil alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Gardasil 9 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>6000</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>This study will evaluate the efficacy, immunogenicity and safety of 9-valent human papillomavirus (9vHPV; V-503 ) vaccine in Chinese women 20 to 45 years of age. The safety and tolerability of the V-503 vaccine is evaluated. Using the qHPV vaccine as a control, whether the V-503 vaccine inoculated reduces the HPV 31, 33, 45, 52, and 58-related cervical intraepithelial neoplasia grade 2 or 3 (CIN 2/3) is observed in Phases I and II of the study). The incidence of adenocarcinoma and cervical cancer</Teaser><TrialCategories><Category>Biological</Category><Category>Dietary supplement</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immune Response</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immunogenicity/Seroprotection Status of Human Papillomavirus - Assessment of anti-human papillomavirus(subtype 11) antibody concentration</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immunogenicity/Seroprotection Status of Human Papillomavirus - Assessment of anti-human papillomavirus(subtype 16) antibody concentration</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immunogenicity/Seroprotection Status of Human Papillomavirus - Assessment of anti-human papillomavirus(subtype 18) antibody concentration</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immunogenicity/Seroprotection Status of Human Papillomavirus - Assessment of anti-human papillomavirus(subtype 31) antibody concentration</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immunogenicity/Seroprotection Status of Human Papillomavirus - Assessment of anti-human papillomavirus(subtype 33) antibody concentration</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immunogenicity/Seroprotection Status of Human Papillomavirus - Assessment of anti-human papillomavirus(subtype 45) antibody concentration</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immunogenicity/Seroprotection Status of Human Papillomavirus - Assessment of anti-human papillomavirus(subtype 52) antibody concentration</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immunogenicity/Seroprotection Status of Human Papillomavirus - Assessment of anti-human papillomavirus(subtype 58) antibody concentration</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Immunogenicity/Seroprotection Status of Human Papillomavirus - Assessment of anti-human papillomavirus(subtype 6) antibody concentration</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Morbidity</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessment of adverse events</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Assessments of Human Papillomavirus Infection - Assessment of frequency/incidence/persistence of human papillomavirus infection</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Clinical Assessments</EndpointIndex><EndpointIndex>Human Papillomavirus Vaccine - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Asian Ancestry</Term></TermsPatientSelection><TitleDisplay>Efficacy, Immunogenicity and Safety of V-503 in Chinese Women Aged 20 to 45 Years</TitleDisplay><PatientSegmentTerms><PatientSegment>Human Papillomavirus Vaccine - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anti-human papillomavirus type 11 antibodies </BiomarkerName><BiomarkerName> Anti-human papillomavirus type 16 antibodies </BiomarkerName><BiomarkerName> Anti-human papillomavirus type 18 antibodies </BiomarkerName><BiomarkerName> Anti-human papillomavirus type 31 antibodies </BiomarkerName><BiomarkerName> Anti-human papillomavirus type 33 antibodies </BiomarkerName><BiomarkerName> Anti-human papillomavirus type 45 antibodies </BiomarkerName><BiomarkerName> Anti-human papillomavirus type 52 antibodies </BiomarkerName><BiomarkerName> Anti-human papillomavirus type 58 antibodies </BiomarkerName><BiomarkerName> Anti-human papillomavirus type 6 antibodies</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2027-02-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>91 Months</TrialDuration><NumberOfSites>8</NumberOfSites><ContactNames><Name>Li Guohua</Name><Name>Li Honghua</Name><Name>Ma Xiang</Name><Name>Medical Director</Name><Name>Mo Zhaojun</Name><Name>Ren Sibiao</Name><Name>Shi Shaodong</Name><Name>Su Ruiping</Name><Name>Yin Peng</Name><Name>Zhao Wei</Name><Name>Zhu Xiaoping</Name></ContactNames></Trial><Trial Id="384911"><Indications><Indication>Cold agglutinin disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Complement C3 inhibitor</Action><Action>Complement cascade inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>PEGylated formulation</Technology><Technology>Peptide</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Apellis Pharmaceuticals Inc</Company></CompaniesSponsor><DateChangeLast>2019-06-19T00:00:00Z</DateChangeLast><InterventionsPrimaryDisplay><Intervention>APL-2 (subcutaneous), Apellis alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Planned</RecruitmentStatus><Teaser>Patients with &lt;b&gt;cold&lt;/b&gt; agglutinin disease (CAD)... This is a phase III trial of APL-2 in patients with &lt;b&gt;cold&lt;/b&gt; agglutinin disease (CAD) [ 2164236 ]. In June 2019, Apellis Pharmaceuticals Inc planned to commence this trial in early 2020 [ 2164236 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A Phase III trial of APL-2 in patients with cold agglutinin disease (CAD)</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="383733"><Indications><Indication>Cough</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>NK1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antidepressant</Action><Action>Antitussive</Action><Action>Anxiolytic</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>NeRRe Therapeutics Ltd</Company></CompaniesSponsor><DateChangeLast>2019-06-10T00:00:00Z</DateChangeLast><InterventionsPrimaryDisplay><Intervention>orvepitant alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Planned</RecruitmentStatus><Teaser>This is a phase III study of orvepitant for cough [ 2160349 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A phase III study of orvepitant for Cough</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="380991"><Indications><Indication>Bordetella pertussis infection</Indication><Indication>Clostridium tetani infection</Indication><Indication>Corynebacterium diphtheriae infection</Indication><Indication>Haemophilus influenzae infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Polysaccharide subunit vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Protein conjugated</Technology></Technologies><CompaniesSponsor><Company>Beijing Minhai Biotechnology Co Ltd</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-05-29T00:00:00Z</DateChangeLast><Identifiers><Identifier>2016L05247</Identifier><Identifier>CTR20182419</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Cell-free white-breaking Haemophilus influenzae type b vaccine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Haemophilus influenzae type b (Hib) vaccine (freeze-dried), Beijing Minhai Biotechnology alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1710</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>of cell-free white broken combination vaccine: 0.5 ml per dose, 0.5 ml per human dose, the cell-free pertussis vaccine titer will be not less than 4.0 IU, the diphtheria vaccine titer will be not less than 30 IU, broken. The vaccine efficacy of the &lt;b&gt;cold&lt;/b&gt; vaccine will be not less than 40 IU; Hemophilus influenzae type b conjugate vaccine: 0.5 ml per bottle, 0.5 ml per human dose, and no less than 10 microg of Hemophilus influenzae type b capsular polysaccharide. Intramuscular injection, vaccination </Teaser><TrialCategories><Category>Biological</Category><Category>Radiation therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Haemophilus Influenzae Type B Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibody concentration</EndpointIndex><EndpointIndex>Haemophilus Influenzae Type B Vaccine - Assessment of Safety and Tolerability - Adverse events/reactogenicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Adsorption of cell-free baibai broken freeze dry Haemophilus influenzae type b combined vaccine III</TitleDisplay><PatientSegmentTerms><PatientSegment>Haemophilus Influenzae Type B Vaccine - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>3</NumberOfSites><ContactNames><Name>Li Dahan</Name><Name>Li Guifan</Name><Name>Liang Shu</Name><Name>Liang Shuming, Bachelor of Medicine</Name><Name>Sun Guangwei</Name></ContactNames></Trial><Trial Id="38023"><Indications><Indication>Cryopyrin associated periodic syndrome</Indication><Indication>Familial cold autoinflammatory syndrome</Indication><Indication>Inflammatory disease</Indication><Indication>Muckle Wells syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin G1 agonist</Action><Action>Interleukin-1 beta ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action><Action>Cardioprotectant</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>DNA technology</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intra-articular formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company><Company>Novartis Farma SpA</Company><Company>Novartis Oncology</Company><Company>Novartis Pharma Services AG</Company></CompaniesSponsor><Countries><Country>Turkey</Country><Country>UK</Country><Country>India</Country><Country>France</Country><Country>US</Country><Country>Italy</Country><Country>Spain</Country><Country>Germany</Country><Country>Belgium</Country></Countries><DateChangeLast>2019-02-21T00:00:00Z</DateChangeLast><DateEnd>2010-04-30T00:00:00Z</DateEnd><DateStart>2008-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2007-004367-22</Identifier><Identifier>CACZ885D2306</Identifier><Identifier>NCT00685373</Identifier></Identifiers><IndicationsAdverse><Indication>Abscess</Indication><Indication>Arthralgia</Indication><Indication>Bronchitis</Indication><Indication>Cough</Indication><Indication>Diarrhea</Indication><Indication>Emesis</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Infectious disease</Indication><Indication>Rhinitis</Indication><Indication>Rhinopharyngitis</Indication><Indication>Spontaneous abortion</Indication><Indication>Tonsillitis</Indication><Indication>Upper respiratory tract infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>canakinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>166</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>required before any assessment is performed for patients&amp;nbsp;&amp;lt;18 years of age Diagnosis of familial &lt;b&gt;cold&lt;/b&gt; autoinflammatory syndrome, Muckle-Wells syndrome or Muckle-Wells syndrome with overlapping symptoms of neonatal onset multisystem inflammatory disease...studies or newly identified patients with the following cryopyrin-associated periodic syndromes (CAPS): familial &lt;b&gt;cold&lt;/b&gt; autoinflammatory syndrome, Muckle-Wells syndrome or Muckle-Wells syndrome with overlapping symptoms of neonatal onset multisystem</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Morbidity</EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other genetic disease - Assessment of adverse events</EndpointIndex><EndpointIndex>Other genetic disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other genetic disease - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Immune Response</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Morbidity</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Safety and Tolerability - Assessment of serious/treatment emergent adverse events</EndpointIndex><EndpointIndex>Other neurological disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other neurological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other neurological disease - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Urticaria - Assessment by Global Assessment Scales</EndpointIndex><EndpointIndex>Urticaria - Assessment by Urticarial Scores - Assessment by urticaria severity score</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Urticaria - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Urticaria - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Urticaria - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Urticaria - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Urticaria - Assessment of adverse events</EndpointIndex><EndpointIndex>Urticaria - Clinical Assessments</EndpointIndex><EndpointIndex>Urticaria - Other Protocol Specified Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of ACZ-885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Other genetic disease - Subjects with specific disease</PatientSegment><PatientSegment>Other neurological disease - Subjects with specific disease</PatientSegment><PatientSegment>Urticaria - Subjects with Cold Contact Urticaria (CCU)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Serum amyloid A protein 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2010-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>28</NumberOfSites></Trial><Trial Id="380205"><Indications><Indication>Paroxysmal nocturnal hemoglobinuria</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Complement C3 inhibitor</Action><Action>Complement cascade inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>PEGylated formulation</Technology><Technology>Peptide</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novotech Clinical Research (M) Sdn. Bhd</Company></CompaniesSponsor><Countries><Country>Malaysia</Country></Countries><DateChangeLast>2019-05-14T00:00:00Z</DateChangeLast><DateEnd>2020-07-01T00:00:00Z</DateEnd><DateStart>2019-07-01T00:00:00Z</DateStart><Identifiers><Identifier>47750</Identifier><Identifier>APL2-308</Identifier><Identifier>NMRR-19-863-47750</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>APL-2 (subcutaneous), Apellis alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>4</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>This is a phase III, randomized, multicenter, open-label, controlled study to evaluate the efficacy and safety of APL-2 in patients with paroxysmal nocturnal hemoglobinuria (PNH).</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anemia - Assessment of Fatigue</EndpointIndex><EndpointIndex>Anemia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Anemia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Anemia - Assessment of Transfusions - Assessment of red blood cell transfusions</EndpointIndex><EndpointIndex>Anemia - Clinical Assessments - Assessment of liver function</EndpointIndex><EndpointIndex>Anemia - Hematological Assessments - Assessment of hemoglobin response</EndpointIndex><EndpointIndex>Anemia - Hematological Assessments - Assessment of hemoglobin status</EndpointIndex><EndpointIndex>Anemia - Hematological Assessments - Assessment of reticulocyte count</EndpointIndex><EndpointIndex>Anemia - Patient Reported Outcomes/Quality of Life Assessments - EORTC QLQ-C30</EndpointIndex><EndpointIndex>Anemia - Patient Reported Outcomes/Quality of Life Assessments - Functional Assessment of Chronic Illness Therapy (FACIT)</EndpointIndex><EndpointIndex>Anemia - Patient Reported Outcomes/Quality of Life Assessments - Linear Analogue Self Assessment (LASA)</EndpointIndex><EndpointIndex>Anemia - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate the Efficacy and Safety of APL-2 in PNH Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Anemia - Subjects with Hemolytic Anemia - Subjects with paroxysmal nocturnal hemoglobinuria</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Erythrocytes </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Lactate dehydrogenase </BiomarkerName><BiomarkerName> Reticulocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Christine Chia Pek Imm</Name><Name>Dr Veena Selvaratnam</Name></ContactNames></Trial><Trial Id="379525"><Indications><Indication>Nasal congestion</Indication></Indications><CompaniesCollaborator><Company>Laboratório Daudt Oliveira Ltda</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hospital Sao Lucas da PUCRS</Company><Company>Synova Pesquisa Científica Ltda</Company></CompaniesSponsor><Countries><Country>Brazil</Country></Countries><DateChangeLast>2019-05-15T00:00:00Z</DateChangeLast><DateEnd>2019-12-01T00:00:00Z</DateEnd><DateStart>2019-07-01T00:00:00Z</DateStart><Identifiers><Identifier>07490419.4.1001.5481</Identifier><Identifier>3.214.163</Identifier><Identifier>RBR-8zgtmd</Identifier><Identifier>U1111-1230-6523</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Penetro alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>the corresponding number of the degree of symptoms of nasal congestion of that moment, which, 0 (excellent) and 10 (very bad). The participants with a diagnosis of moderate or severe nasal obstruction (ie, reaching, at least, VAS number 5) due to a &lt;b&gt;cold&lt;/b&gt; or flu and who present the symptoms started in the period between 24 and 48 h before this evaluation will continue in the study. The investigator shall confirm the medical history and any concomitant medication received by the participant within the</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by VAS scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Evaluation of efficacy and safety of Penetro solution for inhalation (eucalyptol, terpin monohydrate and menthol) over placebo in the treatment of acute nasal obstruction in 06 to 17 years-old children</TitleDisplay><PatientSegmentTerms><PatientSegment>Other otorhinolaryngological disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>5 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Carlos Sverdloff</Name><Name>Michele Espíndola</Name><Name>Mário Edvin Greters</Name></ContactNames></Trial><Trial Id="379387"><Indications><Indication>Common cold</Indication></Indications><CompaniesCollaborator><Company>Shanghai Kaibao Pharmaceutical Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>West China Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-05-14T00:00:00Z</DateChangeLast><DateEnd>2021-01-01T00:00:00Z</DateEnd><DateStart>2019-07-01T00:00:00Z</DateStart><Identifiers><Identifier>ChiCTR1900022951</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>tanreqing oral liquid alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>270</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>l and/or neutrophil differential count &amp;gt; 80% Other medicines (including &lt;b&gt;cold&lt;/b&gt;, antibiotics, antivirals and similar traditional Chinese medicines) that have been...common &lt;b&gt;cold&lt;/b&gt; according to western medicine Diagnosis of common &lt;b&gt;cold&lt;/b&gt; with wind-heat syndrome according to Traditional Chinese Medicine Aged between 18 and... The aim of this study is to evaluate the efficacy and safety of Tanreqing oral liquid for treating common &lt;b&gt;cold&lt;/b&gt; with wind-heat syndrome.</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Dietary supplement</Category><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Respiratory tract infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>The Efficacy and Safety of Tanreqing Oral Liquid for Treating Common Cold with Wind-heat Syndrome: A Multicenter, Phase III, Parallel-group, Double-blind, Single-dummy, Randomized, Placebo-Controlled Trial</TitleDisplay><PatientSegmentTerms><PatientSegment>Respiratory tract infection - Subjects with specific disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body temperature</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>18 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Bing Mao</Name><Name>Ruizhi Feng</Name></ContactNames></Trial><Trial Id="379250"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor mu agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>5-HT uptake inhibitor</Action><Action>Analgesic</Action><Action>Norepinephrine uptake inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug coating</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Dr. G. D. Pol Foundation Y.M.T. Dental, College and Hospital</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2019-05-10T00:00:00Z</DateChangeLast><DateStart>2019-05-06T00:00:00Z</DateStart><Identifiers><Identifier>CTRI/2019/05/018900</Identifier></Identifiers><InterventionsControlDisplay><Intervention>lignocaine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>tramadol hydrochloride alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>34</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>(ASA-I or ASA-II), aged between 18 to 65 years, who signed consent form Symptomatic irreversible pulpitis of the mandibular first or second molar The patients who have pain in a mandibular molar (visual analog scale &gt; 54) with prolonged response to &lt;b&gt;cold&lt;/b&gt; testing (lingering pain for &gt; 45 s) Absence of any periapical radiolucency on a periapical radiograph (except for a widened periodontal ligament of no more than 0.75 to 1 mm and no pain on percussion) Vital teeth with no history of previous root canal</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Post-operative Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs - Assessment of heart rate</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Pain by Visual Analog Scale (VAS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A comparison of the effectiveness of additional injections of opioid and anesthetic in emergency root canal treatment of adult lower teeth</TitleDisplay><PatientSegmentTerms><PatientSegment>Other mouth disease - Others - Healthy Subjects</PatientSegment><PatientSegment>Other mouth disease - Subjects with specific disease - Subjects with symptomatic irreversible pulpitis</PatientSegment><PatientSegment>Other mouth disease - Treatment Naive Subjects</PatientSegment><PatientSegment>Pain - Others - Healthy Subjects</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with dental pain</PatientSegment><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Heart rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr Aviraj Damrekar</Name><Name>Dr Ushaina Fanibunda</Name></ContactNames></Trial><Trial Id="376567"><Indications><Indication>Urticaria</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin E antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2019-06-13T00:00:00Z</DateChangeLast><DateEnd>2021-03-19T00:00:00Z</DateEnd><DateStart>2019-04-13T00:00:00Z</DateStart><Identifiers><Identifier>CQGE031C1301</Identifier><Identifier>JapicCTI-194705</Identifier><Identifier>NCT03907878</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ligelizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>65</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>similar chemical classes (ie, to murine, chimeric, or human antibodies) Subjects having a clearly defined, predominant trigger of their chronic urticaria (CU) (chronic inducible urticaria (CINDU)) including urticaria factitia (symptomatic dermographism), &lt;b&gt;cold&lt;/b&gt;-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact-urticaria Diseases, other than chronic urticaria, with urticarial or angioedema symptoms such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis </Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Urticaria - Assessment by Urticarial Scores - Assessment by Urticaria Activity Score (UAS)</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms - Assessment of number of hives</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms - Assessment of pruritus(itch) severity</EndpointIndex><EndpointIndex>Urticaria - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Urticaria - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Urticaria - Assessment of adverse events</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Dermatology Life Quality Index (DLQI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines</TitleDisplay><PatientSegmentTerms><PatientSegment>Urticaria - Subjects with Chronic Urticaria - Patiets with chronic spontaneous urticaria</PatientSegment><PatientSegment>Urticaria - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2021-03-11T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>9</NumberOfSites><ContactNames><Name>Novartis Pharma Ltd.</Name><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="376294"><Indications><Indication>Spondylarthritis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-17 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company><Company>Novartis Pharma GmbH Germany</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2019-06-07T00:00:00Z</DateChangeLast><DateEnd>2022-06-22T00:00:00Z</DateEnd><DateStart>2019-05-28T00:00:00Z</DateStart><Identifiers><Identifier>2018-003882-32</Identifier><Identifier>AScalate</Identifier><Identifier>CAIN457HDE01</Identifier><Identifier>NCT03906136</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Standard-of-care alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>adalimumab biosimilar alone</Intervention><Intervention>secukinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>300</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser> phosphatase or serum bilirubin History of renal trauma, glomerulonephritis, or patients with one kidney only, or a serum creatinine level exceeding 1.8 mg/dl (159.12 micromol/l) Active systemic infections during the last 2 weeks (exception: common &lt;b&gt;cold&lt;/b&gt;) prior to randomization History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis (TB) infection as defined by a positive QuantiFERON TB-Gold test. Patients with a positive test may participate in the study if further </Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment by Global Assessment Scales - Visual analogue scales (VAS) for local and general pain/overall disease activity</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Functional Disability/Physical Function - Bath ankylosing spondylitis functional index (BASFI)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C reactive protein (CRP)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Pain - Nocturnal spinal pain (assessed by VAS)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Pain - Spinal pain/Back pain (assessed by VAS)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Spinal Mobility - Bath ankylosing spondylitis metrology index (BASMI)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Spinal Mobility - Cervical rotation (Cervical mobility)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Spinal Mobility - Chest expansion (Thoracic mobility)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Spinal Mobility - Lateral spinal flexion (Lumbar mobility)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Spinal Mobility - Modified schober's test (Lumbar mobility)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Spinal Mobility - Occiput-to-wall distance (Cervical mobility)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Spinal Mobility - Tragus-to-wall distance (Cervical mobility)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Spinal Stiffness - Morning stiffness (assessed by VAS)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Assessment of Therapy Related Outcomes - Response to therapy</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Hematological Assessments - Erythrocyte sedimentation rate (ESR)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Patient Reported Outcomes/Quality of Life Assessments - Ankylosing spondylitis disease activity score (ASDAS)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Patient Reported Outcomes/Quality of Life Assessments - Ankylosing spondylitis quality of life questionnaires (ASQoL)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Patient Reported Outcomes/Quality of Life Assessments - Patient Global Assessment of Disease Activity</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Physician Global Assessment of Disease Activity - Overall disease activity (VAS)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Response to Therapy (ASAS criteria) - Assessments in Ankylosing Spondylitis (ASAS) 40</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Response to Therapy (ASAS criteria) - Percentages of patients achieving ASAS20</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Response to Therapy (ASAS criteria) - Percentages of patients achieving ASAS40</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Response to Therapy (BASDAI criteria)</EndpointIndex><EndpointIndex>Ankylosing spondylitis - Response to Therapy (BASDAI criteria) - Percentage of patients achieving BASDAI 50</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>AScalate: Treat-to-target in Axial Spondyloarthritis</TitleDisplay><PatientSegmentTerms><PatientSegment>Ankylosing spondylitis - Spondyloarthropathy - Active spondyloarthropathy</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with History of Use of Ankylosing Spondylitis Medications - NSAIDs</PatientSegment><PatientSegment>Ankylosing spondylitis - Subjects with Treatment Resistant Disease - Subjects with NSAID resistant disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Erythrocyte sedimentation rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2021-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Medizinischer Infoservice (MCC)</Name><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="376218"><Indications><Indication>Nose disease</Indication><Indication>Respiratory disorder</Indication></Indications><CompaniesCollaborator><Company>Laboratório Daudt Oliveira Ltda</Company></CompaniesCollaborator><CompaniesSponsor><Company>CAEP</Company><Company>Synova Pesquisa Científica Ltda</Company></CompaniesSponsor><Countries><Country>Brazil</Country></Countries><DateChangeLast>2019-04-10T00:00:00Z</DateChangeLast><DateStart>2019-07-01T00:00:00Z</DateStart><Identifiers><Identifier>05906119.7.1001.8098</Identifier><Identifier>3.168.467</Identifier><Identifier>RBR-8zzfzn</Identifier><Identifier>U1111-1229-4946</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Penetro alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>190</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>or severe nasal obstruction (ie, reaching, at least, VAS number 5) due to a &lt;b&gt;cold&lt;/b&gt; or flu and who present the symptoms started in the period between 24 and 48 h before...Penetro) at previous time Total obstruction of one nostril by other etiologies that are not related to &lt;b&gt;cold&lt;/b&gt; or flu, or for a period&amp;lt; 24 h and &amp;gt; 48 h after the onset...nasal obstruction (ie, at least number 5 of VAS - Visual Analogue Scale) due to &lt;b&gt;cold&lt;/b&gt; or flu and who present symptoms within 24 to 48 h after the onset of these symptoms</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Evaluation of Efficacy and Safety of Penetro Solution for Inhalation (Eucalyptol, Terpin Monohydrate and Menthol) over Placebo in the Treatment of Acute Nasal Obstruction in Adults</TitleDisplay><PatientSegmentTerms><PatientSegment>Other otorhinolaryngological disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Carlos Sverdloff</Name><Name>Jose Pedrazzoli Junior</Name><Name>Mario Edvin Greters</Name><Name>Michele Espíndola</Name></ContactNames></Trial><Trial Id="373836"><Indications><Indication>Respiratory tract infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Phosphoinositide 3-kinase inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR complex 2 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action><Action>Neuroprotectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>resTORbio Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-05-13T00:00:00Z</DateChangeLast><DateStart>2019-12-31T00:00:00Z</DateStart><Identifiers><Identifier>PROTECTOR 2</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dactolisib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1600</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Planned</RecruitmentStatus><Teaser>Patients will be randomized in 1 : 1 ratio to RTB-101 10 mg qd or matching placebo 16 weeks during winter &lt;b&gt;cold&lt;/b&gt; and flu season [ 2130891 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PROTECTOR 2: A randomized, double-blinded, placebo-controlled, phase III trial of RTB-101 for the respiratory tract infections (RTIs)</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="370238"><Indications><Indication>Respiratory tract infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Adjuvant</Action><Action>Immunostimulant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Rectal formulation</Technology><Technology>Rectal formulation systemic</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>NPO Petrovax Pharm LLC</Company></CompaniesSponsor><Countries><Country>Russian Federation</Country></Countries><DateChangeLast>2019-05-02T00:00:00Z</DateChangeLast><DateEnd>2019-03-31T00:00:00Z</DateEnd><DateStart>2018-11-07T00:00:00Z</DateStart><Identifiers><Identifier>NCT03840135</Identifier><Identifier>POARVI/PHIII_2017</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Polyoxidonium alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>172</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Male and female patients aged 1 to 12 years Diagnosis of acute respiratory viral infection [International Classification of Diseases (10-th revision) codes: Acute nasopharyngitis (common &lt;b&gt;cold&lt;/b&gt;), J02 Acute pharyngitis, J02.9 Acute pharyngitis, unspecified, J04 Acute laryngitis and tracheitis, J04.0 Acute laryngitis, J04.1 Acute tracheitis, J04.2 Acute laryngotracheitis, J06 Acute upper respiratory infections of multiple and unspecified sites</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Respiratory tract infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Viral infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1 to 12 Years With ARI</TitleDisplay><PatientSegmentTerms><PatientSegment>Other otorhinolaryngological disease - Subjects with specific disease - Subjects with otorhinolaryngological infection/inflammation</PatientSegment><PatientSegment>Respiratory tract infection - Subjects with specific disease</PatientSegment><PatientSegment>Viral infection - Subjects with specific disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body temperature</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>4 Months</TrialDuration><NumberOfSites>15</NumberOfSites><ContactNames><Name>Contact</Name><Name>Elvira Mukhametshina</Name></ContactNames></Trial><Trial Id="370080"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA gyrase inhibitor</Action><Action>Topoisomerase IV inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Bacterial nucleic acid synthesis inhibitor</Action><Action>Systemic dermatological antibacterial product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Institute for Health Research (NIHR)</Company></CompaniesCollaborator><CompaniesSponsor><Company>Imperial College London</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2019-02-22T00:00:00Z</DateChangeLast><DateEnd>2018-02-22T00:00:00Z</DateEnd><DateStart>2013-10-17T00:00:00Z</DateStart><Identifiers><Identifier>2012-002198-72</Identifier><Identifier>Targeted retreatment of COPD exacerbations</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ciprofloxacin hydrochloride alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>231</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Main objective of the trial: the principal research question was whether an extra course of antibiotics, given 2 weeks after an exacerbation (flare up) of chronic obstructive pulmonary disease, could prevent repeat exacerbations in those patients who have not fully recovered from the first exacerbation. Secondary objectives of the trial were to assess: Whether patients recovery from the first exacerbation was faster with the antibiotic treatment than with placebo The effects of the antibiotic</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Cough</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Dyspnea</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Exacerbations</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of C-reactive protein (CRP)/high sensitivity C-reactive protein (hs-CRP)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Laboratory/Diagnostic Measures - Estimation of antibodies</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Pulmonary Function</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Sputum</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Therapy Related Outcomes - Efficacy</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of adverse events</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of hospitalization - Readmission/time to readmission</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - COPD Assessment Test(CAT)Score</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Changes in St Georges Respiratory Questionnaire (SGRQ)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Protocol Specified Other Endpoints - Diary card data</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Targeted retreatment of COPD exacerbations: Targeted Retreatment With Antibiotics Following Exacerbations of Chronic Obstructive Pulmonary Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>52 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Nabila Youssouf</Name></ContactNames></Trial><Trial Id="369470"><Indications><Indication>Staphylococcus aureus infection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Isoleucyl tRNA synthetase inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Isoleucyl tRNA synthetase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Antibacterial</Action><Action>Bacterial protein synthesis inhibitor</Action><Action>RNA synthesis inhibitor</Action><Action>Topical dermatological antibacterial product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Cell wall synthesis modulator</Action><Action>RNA synthesis inhibitor</Action><Action>Topical dermatological antibacterial product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Antibiotic</Technology><Technology>Dermatological formulation</Technology><Technology>Drug combination</Technology><Technology>Emulsion dermatological</Technology><Technology>Nasal formulation local</Technology><Technology>Natural product</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Helperby Therapeutics Ltd</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2019-02-08T00:00:00Z</DateChangeLast><DateEnd>2010-06-10T00:00:00Z</DateEnd><DateStart>2010-02-02T00:00:00Z</DateStart><Identifiers><Identifier>2009-017398-39</Identifier><Identifier>HT-04</Identifier></Identifiers><InterventionsControlDisplay><Intervention>mupirocin alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>mupirocin + neomycin + HT-61 (fixed dose combination, staphylococcus aureus infection/MRSA), Cadila alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>56</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Not Reported</Reason></ReasonForTrialDiscontinuation><Teaser>eg, infected eczema Carriage of either methicillin sensitive or resistant staphylococcus aureas in the throat or skin/wound lesion Abnormal pathology of nasal passages Any clinically significant allergy or drug intolerance Active hay fever, on-going &lt;b&gt;cold&lt;/b&gt;/flu symptoms, including rhinitis Use of antibiotics for 4 weeks prior to the study drug application or use of concomitant systemic or topical antibiotics Any medical history or renal insufficiency or hepatic disorder Any history of history of pet ownership</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Staphylococcus aureus infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Randomized, double-blind, vehicle-controlled dosing frequency study of HT-61 1% gel applied to the anterior nares plus chlorhexidine body and hair washes in subjects with nasal carriage of staphylococcus aureus and comparison with mupirocin</TitleDisplay><PatientSegmentTerms><PatientSegment>Staphylococcus aureus infection - Others - Healthy Subjects</PatientSegment><PatientSegment>Staphylococcus aureus infection - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>4 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="36881"><Indications><Indication>Crohns disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>TNF alpha ligand inhibitor</Action><Action>TNF binding agent</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action><Action>Antiviral</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Chimeric monoclonal antibody</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intra-articular formulation</Technology><Technology>Intravenous formulation</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company><Company>Schering-Plough Corp</Company></CompaniesSponsor><DateChangeLast>2019-01-26T00:00:00Z</DateChangeLast><DateEnd>2005-01-31T00:00:00Z</DateEnd><DateStart>2003-11-30T00:00:00Z</DateStart><Identifiers><Identifier>NCT00796250</Identifier><Identifier>P02732</Identifier></Identifiers><InterventionsControlDisplay><Intervention>prednisolone alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>infliximab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>9</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Terminated</RecruitmentStatus><ReasonForTrialDiscontinuation><Reason>Patient Enrollment Issues</Reason></ReasonForTrialDiscontinuation><Teaser>appropriate screening tests, Thorax Rx, tuberculin test Presence of severe infections such as hepatitis, pneumonia, pyelonephritis within the past 3 months before the enrolment. Less severe infections, such as those in charge of the upper respiratory tract (&lt;b&gt;cold&lt;/b&gt; syndrome), are not considered exclusion criteria as well as the uncomplicated urinary tract infections, contracted during the previous 3 months before study inclusion Ongoing infections due to CMV, pneumocystis carinii, atypical mycobacterium. Proved</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Crohns disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Crohns disease - Assessment of Remission - Crohn's disease activity index (CDAI) score &lt; 150</EndpointIndex><EndpointIndex>Crohns disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Crohns disease - Assessment of Safety and Tolerability - Drug related adverse event</EndpointIndex><EndpointIndex>Crohns disease - Crohn's Disease Activity Assessed by Indices/Scores - Crohn's disease activity index (CDAI) score</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease</TitleDisplay><PatientSegmentTerms><PatientSegment>Crohns disease - Subjects with H/O Treatment with Crohns Disease Medication</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2005-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>0</NumberOfSites></Trial><Trial Id="368461"><Indications><Indication>Dental caries</Indication></Indications><CompaniesSponsor><Company>Manipal College of Dental Sciences</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2019-02-01T00:00:00Z</DateChangeLast><DateStart>2019-01-20T00:00:00Z</DateStart><Identifiers><Identifier>CTRI/2019/01/017167</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>sodium hypochlorite alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>96</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser> lesion radiographically reaching close to the pulp (inner quarter of dentine ie, &gt;75%) will be asked to participate. The tooth must not hurt spontaneously before treatment is initiated (Ricucci et al., 2014) Mild symptoms of thermal sensitivity to &lt;b&gt;cold&lt;/b&gt; stimuli when provoked will be included</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other mouth disease - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Other mouth disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Treatment of deep cavity with a debriding solution</TitleDisplay><PatientSegmentTerms><PatientSegment>Other mouth disease - Subjects with specific disease - Subjects with Dental Caries</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Matrix metalloproteinase-9</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Vasudev Ballal</Name></ContactNames></Trial><Trial Id="363379"><Indications><Indication>Common cold</Indication></Indications><CompaniesSponsor><Company>Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University</Company><Company>Gansu Qizheng Industrial Group Co Ltd</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-12-18T00:00:00Z</DateChangeLast><DateEnd>2020-12-31T00:00:00Z</DateEnd><DateStart>2018-01-01T00:00:00Z</DateStart><Identifiers><Identifier>ChiCTR1800019836</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Cuitang alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>220</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>common &lt;b&gt;cold&lt;/b&gt; Body temperature (under axilla) 37.5 to 39.0degC at the time of consultation The course of &lt;b&gt;cold&lt;/b&gt; is within 48 h TCM syndrome differentiation is wind-&lt;b&gt;cold&lt;/b&gt; and internal heat syndrome Aged 18 to 65 years old Those... Objectives of study: To evaluate the efficacy and safety of Cuitang granules in the treatment of common &lt;b&gt;cold&lt;/b&gt;.</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Respiratory tract infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Phase III Study for Cui-Tang Granules in the Treatment of Common Cold</TitleDisplay><BiomarkerNames><BiomarkerName>Body temperature</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>36 Months</TrialDuration><NumberOfSites>7</NumberOfSites><ContactNames><Name>Lunju Chen</Name><Name>Qingquan Liu</Name></ContactNames></Trial><Trial Id="363137"><Indications><Indication>Pruritus</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>NK1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Menlo Therapeutics Inc</Company></CompaniesSponsor><DateChangeLast>2018-12-12T00:00:00Z</DateChangeLast><InterventionsPrimaryDisplay><Intervention>serlopitant alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Planned</RecruitmentStatus><Teaser>This is a phase III clinical trial of serlopitant for the treatment of pruritus associated with psoriasis[ 2102863 ]. In December 2018, Menlo Therapeutics Inc planned to start this trial in 2019 [ 2102863 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A phase III clinical trial of serlopitant for the treatment of pruritus associated with psoriasis</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="362550"><Indications><Indication>Autoimmune hemolytic anemia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Syk tyrosine kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiarteriosclerotic</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action><Action>B-lymphocyte inhibitor</Action><Action>Macrophage inhibitor</Action><Action>Platelet aggregation modulator</Action><Action>Synergist</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Rigel Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>Georgia</Country><Country>US</Country></Countries><DateChangeLast>2019-06-17T00:00:00Z</DateChangeLast><DateEnd>2021-09-30T00:00:00Z</DateEnd><DateStart>2019-04-01T00:00:00Z</DateStart><Identifiers><Identifier>C-935788-057</Identifier><Identifier>NCT03764618</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>fostamatinib disodium alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Subject with other types of AIHA (eg, &lt;b&gt;cold&lt;/b&gt; antibody AIHA, &lt;b&gt;cold&lt;/b&gt; agglutinin syndrome, mixed type AIHA, or paroxysmal &lt;b&gt;cold&lt;/b&gt; hemoglobinuria) Subject has AIHA secondary to autoimmune disease, including systemic lupus erythematosus (SLE), or lymphoid malignancy if the underlying disease is not stable or is not well-controlled on current</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anemia - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Anemia - Hematological Assessments - Assessment of hemoglobin response</EndpointIndex><EndpointIndex>Anemia - Hematological Assessments - Assessment of hemoglobin status</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA</TitleDisplay><PatientSegmentTerms><PatientSegment>Anemia - Subjects with Hemolytic Anemia - Subjects with autoimmune hemolytic anemia</PatientSegment><PatientSegment>Anemia - Subjects with History of/Scheduled for Disease Specific Therapy</PatientSegment><PatientSegment>Anemia - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Hemoglobin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Amir Salam, MD</Name><Name>Elene Dolmazashvili</Name><Name>Hieu Nguyen Crouch</Name><Name>Irina Murakhovskaya, MD</Name><Name>Irine Datikashvili-David, MD</Name><Name>Magdana Betaneli, MD</Name><Name>Mamia Zodelava, MD</Name><Name>Michael Boxer, MD</Name><Name>Richy Agajanian, MD</Name></ContactNames></Trial><Trial Id="361769"><Indications><Indication>Renal injury</Indication></Indications><CompaniesSponsor><Company>Rajaie Cardiovascular Medical and Research Center</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2018-12-03T00:00:00Z</DateChangeLast><DateEnd>2019-12-31T00:00:00Z</DateEnd><DateStart>2018-11-01T00:00:00Z</DateStart><Identifiers><Identifier>INTERVENTION-01</Identifier><Identifier>NCT03755700</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>N-acetylcysteine plus vitamin E</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1000</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>used to assign a patient in either group): investigator will use simple randomization for assigning each patients in a group. The patients, physicians and outcome assessors will be blinded throughout the trial until the opening of the randomization &lt;b&gt;cold&lt;/b&gt;. All patients will be entered into three group and they will be given normal saline 0.9%, vitamin E, NAC, and the placebos of both regimens. These drugs will be given in addition to the routine hydration therapy which will be given to all patients.</Teaser><TrialCategories><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Renal failure - Assessment of Cardiovascular Events - Assessment of major adverse cardiac and cerebral events(MACCE)</EndpointIndex><EndpointIndex>Renal failure - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Renal failure - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Renal failure - Assessment of Organ Function - Pulmonary assessment</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Function - Assessment of creatinine level</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Replacement Therapy(RRT)</EndpointIndex><EndpointIndex>Renal failure - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Renal failure - Hematological Assessments</EndpointIndex><EndpointIndex>Renal failure - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Renal failure - Protocol Specified Other Endpoints - Length of stay in hospital /ICU</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Vitamin E and N-acetylcysteine for Preventing Contrast-Induced Acute Kidney Injury After Coronary Artery Catheterization</TitleDisplay><PatientSegmentTerms><PatientSegment>Renal failure - Subjects with Acute Renal Failure(ARF) - Subjects in risk(R) category</PatientSegment><PatientSegment>Renal failure - Subjects with Glomerular Disorder</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Bahram Mohebbi</Name><Name>Majid Maleki</Name><Name>Majid Maleki, MD</Name><Name>Yousef Rezaei</Name></ContactNames></Trial><Trial Id="360879"><Indications><Indication>Head and neck tumor</Indication><Indication>Neuropathic pain</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anticonvulsant agent</Action><Action>GABA modulator</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>AZ Groeninge Hospital</Company><Company>Anglia Ruskin University</Company><Company>KU Leuven R&amp;D</Company></CompaniesCollaborator><CompaniesSponsor><Company>Universitair Ziekenhuis Gent</Company></CompaniesSponsor><Countries><Country>Belgium</Country></Countries><DateChangeLast>2019-02-07T00:00:00Z</DateChangeLast><DateEnd>2022-01-07T00:00:00Z</DateEnd><DateStart>2019-03-01T00:00:00Z</DateStart><Identifiers><Identifier>AZGS2017112</Identifier><Identifier>NCT03747562</Identifier><Identifier>stREnGTH</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>gabapentin alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>105</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>A multicentre, phase III, double-blind, randomized controlled trial to study the efficacy and safety of gabapentin to reduce the need for strong opioid use in the treatment of radiation-induced pain in head and neck cancer (HNCA) patients undergoing a curative 7-week radio(chemo)therapy course with curative intent. The investigators aim of this study is to establish if addition of gabapentin is more effective in reducing the need to start (or dosage-increase) a strong opioid for HNCA pain than a</Teaser><TrialCategories><Category>Medical device</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Anthropometric Assessments</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Fatigue</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Pain</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Pain - Assesment of Brief Pain Inventory Short-Form (BPI-SF)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Sleep</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of adverse events</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of hospitalization</EndpointIndex><EndpointIndex>Cancer supportive care - Clinical Assessments</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-HN35</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Satisfaction Scale</EndpointIndex><EndpointIndex>Cancer supportive care - Protocol Specified Other Endpoints - Assessment of Other Treatment or Procedure Related Outcomes</EndpointIndex><EndpointIndex>Head and neck tumor - Anthropometric Assessments</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Fatigue</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Radiation Induced Toxicity - Assessment of radiation induced mucositis</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of compliance/adherence</EndpointIndex><EndpointIndex>Head and neck tumor - Clinical Assessments</EndpointIndex><EndpointIndex>Head and neck tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Head and neck tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Brief Pain Inventory (BPI)</EndpointIndex><EndpointIndex>Head and neck tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-C30</EndpointIndex><EndpointIndex>Head and neck tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EORTC QLQ-HN35</EndpointIndex><EndpointIndex>Head and neck tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Head and neck tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment of patient satisfaction</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>stREnGTH: Study of Efficacy and Safety of Gabapentin to Reduce the Need for Strong Opioid Use in Head and Neck Cancer Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Cancer/Treatment-related Pain</PatientSegment><PatientSegment>Cancer supportive care - Radiotherapy Related Adverse Events</PatientSegment><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment><PatientSegment>Cancer supportive care - Treatment Naive Subjects</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Laryngeal Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Locally Advanced Head and Neck Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Oral Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Pharyngeal Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Specific Histological Sub-type of HNC - Subjects with squamous cell carcinoma</PatientSegment><PatientSegment>Head and neck tumor - Subjects with TNM Stage I Head and Neck Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with TNM Stage II Head and Neck Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with TNM Stage III Head and Neck Cancer</PatientSegment><PatientSegment>Head and neck tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2021-01-07T00:00:00Z</PrimaryCompletionDate><TrialDuration>34 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Philip Debruyne</Name><Name>Philip Debruyne, MD, PhD, FRCP</Name><Name>Tom Boterberg, MD, PhD</Name></ContactNames></Trial><Trial Id="358283"><Indications><Indication>Gout</Indication><Indication>Hyperuricemia</Indication></Indications><CompaniesSponsor><Company>National Institute of Homoeopathy</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2018-11-01T00:00:00Z</DateChangeLast><DateStart>2018-11-01T00:00:00Z</DateStart><Identifiers><Identifier>CTRI/2018/10/016174</Identifier><Identifier>U1111-1221-8000</Identifier></Identifiers><InterventionsControlDisplay><Intervention>counselling and patient education alone</Intervention><Intervention>exercise and physiotherapy alone</Intervention><Intervention>hot or cold compress alone</Intervention><Intervention>individualized homeopathic medicine alone</Intervention><Intervention>lacto-vegetarian diet alone</Intervention><Intervention>lifestyle modification (LSM) alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Thalapsi bursa pastoris 6C alone</Intervention><Intervention>counselling and patient education alone</Intervention><Intervention>exercise and physiotherapy alone</Intervention><Intervention>hot or cold compress alone</Intervention><Intervention>lacto-vegetarian diet alone</Intervention><Intervention>lifestyle modification (LSM) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>mushroom, lentils, spinach, beans, peas etc, moderation of alcohol consumption, adequate fluids (2 l/day), hot or &lt;b&gt;cold&lt;/b&gt; compress over the affected joint, rest in bed and immobilisation of the affected joint in acute gout, moderate exercise in chronic...mushroom, lentils, spinach, beans, peas etc, moderation of alcohol consumption, adequate fluids (2 l/day), hot or &lt;b&gt;cold&lt;/b&gt; compress over the affected joint, rest in bed and immobilisation of the affected joint in acute gout, moderate exercise in chronic</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Bioequivalence</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Gout - Assessment of Urate/Uric Acid Levels - Change in serum uric acid levels</EndpointIndex><EndpointIndex>Gout - Patient Reported Outcomes/Quality of Life Assessments - Assessment of patient satisfaction</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Homeopathic treatment of increased uric acid</TitleDisplay><PatientSegmentTerms><PatientSegment>Gout - Hyperuricemic Subjects with Gout</PatientSegment><PatientSegment>Gout - Subjects with Acute Gout</PatientSegment><PatientSegment>Gout - Subjects with Chronic Gout</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Uric acid</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Koushik Bhar</Name><Name>Usha Ghelani Uchat</Name></ContactNames></Trial><Trial Id="357617"><Indications><Indication>Scleroderma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Acetylcholine receptor antagonist</Action><Action>p130Cas associated protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Antiarrhythmic agent</Action><Action>Antidepressant</Action><Action>Local anesthetic</Action><Action>Neuromuscular blocking agent</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Biological therapeutic</Technology><Technology>Dermatological formulation</Technology><Technology>Drying</Technology><Technology>Formulation powder</Technology><Technology>Intradermal formulation</Technology><Technology>Intramuscular formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Peptide</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Toxin</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Assistance Publique Hopitaux de Paris</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2018-11-15T00:00:00Z</DateChangeLast><DateEnd>2021-04-30T00:00:00Z</DateEnd><DateStart>2018-10-15T00:00:00Z</DateStart><Identifiers><Identifier>BRASS</Identifier><Identifier>NCT03717961</Identifier><Identifier>P170904J</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Variable regimens including lidocaine , nitrous oxide , oxygen , prilocaine</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including lidocaine , nitrous oxide , onabotulinumtoxinA , oxygen , prilocaine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>18 years and older Diagnosed with systemic sclerosis (EULAR/ACR 2013 criteria ; or Leroy and Metsger criteria) Symptoms of Raynaud's phenomenon affecting both hands (not necessarily to equal extents) Frequency of Raynaud's attacks &gt;/= 5/week during &lt;b&gt;cold&lt;/b&gt; weather Stable dose of phosphodiesterase inhibitors (sildenafil, tadalafil or vardenafil), endothelin antagonists, or calcium channel blockers defined as 1-month with no change in dose Ability to return/be available for follow-up evaluations Ability</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Functional Disability/Physical Function - Assessment by Raynaud Condition Score (RCS)</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Safety and Tolerability - Assessment of adverse effects</EndpointIndex><EndpointIndex>Peripheral vascular disease - Assessment of Wound Healing - Assessment of ulcer healing</EndpointIndex><EndpointIndex>Peripheral vascular disease - Clinical Assessments</EndpointIndex><EndpointIndex>Peripheral vascular disease - Patient Reported Outcomes/Quality of Life Assessments - Health assessment questionnaire (HAQ)</EndpointIndex><EndpointIndex>Peripheral vascular disease - Patient Reported Outcomes/Quality of Life Assessments - Pain scores</EndpointIndex><EndpointIndex>Peripheral vascular disease - Protocol Specified Other Endpoints - Duration of attacks</EndpointIndex><EndpointIndex>Peripheral vascular disease - Protocol Specified Other Endpoints - Frequency of attacks</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BRASS: Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis</TitleDisplay><PatientSegmentTerms><PatientSegment>Peripheral vascular disease - Subjects with comorbid conditions - Subjects with raynaud's disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2021-02-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Hervé MAILLARD, Dr</Name><Name>Jean Benoît MONFORT, Dr</Name><Name>Nathalie BENETON, Dr</Name><Name>Patricia SENET, Dr</Name><Name>Patricia Senet</Name><Name>Patricia Senet, Dr</Name><Name>Tullia DeRisi-PUGLIESE, Dr</Name></ContactNames></Trial><Trial Id="357572"><Indications><Indication>Hidradenitis suppurativa</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-17 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>NOVARTIS (SINGAPORE) PTE LTD</Company><Company>Novartis AG</Company><Company>Novartis Corporation (M) Sdn Bhd</Company><Company>Novartis Farmaceutica SA</Company><Company>Novartis India</Company><Company>Novartis Pharma AG</Company></CompaniesSponsor><Countries><Country>Brazil</Country><Country>Israel</Country><Country>Slovakia</Country><Country>Iceland</Country><Country>Jordan</Country><Country>Slovenia</Country><Country>Guatemala</Country><Country>Australia</Country><Country>Austria</Country><Country>Portugal</Country><Country>France</Country><Country>Italy</Country><Country>Philippines</Country><Country>Poland</Country><Country>South Africa</Country><Country>Turkey</Country><Country>Latvia</Country><Country>Mexico</Country><Country>Denmark</Country><Country>Singapore</Country><Country>Russian Federation</Country><Country>India</Country><Country>Egypt</Country><Country>Bulgaria</Country><Country>Lebanon</Country><Country>Lithuania</Country><Country>US</Country><Country>Japan</Country><Country>Saudi Arabia</Country><Country>Germany</Country><Country>Argentina</Country><Country>Belgium</Country><Country>Hungary</Country><Country>Croatia</Country><Country>Vietnam</Country><Country>Malaysia</Country><Country>Chile</Country><Country>South Korea</Country><Country>Canada</Country><Country>Spain</Country><Country>UK</Country><Country>Norway</Country><Country>Sweden</Country><Country>Greece</Country><Country>Netherlands</Country><Country>Finland</Country><Country>Romania</Country><Country>Colombia</Country><Country>Czech Republic</Country><Country>Switzerland</Country></Countries><DateChangeLast>2019-05-17T00:00:00Z</DateChangeLast><DateEnd>2022-05-13T00:00:00Z</DateEnd><DateStart>2019-02-25T00:00:00Z</DateStart><Identifiers><Identifier>2018-002062-39</Identifier><Identifier>44382</Identifier><Identifier>CAIN457M2302</Identifier><Identifier>CTRI/2019/02/017864</Identifier><Identifier>NCT03713632</Identifier><Identifier>NMRR-18-2963-44382</Identifier><Identifier>SUNRISE</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>secukinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>471</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>study) Previous exposure to secukinumab (AIN-457) or any other biologic drug directly targeting IL-17 A/F or the IL-17 receptor History of chronic or recurrent systemic infections or active systemic infections during the last 2 weeks (exception: common &lt;b&gt;cold&lt;/b&gt;) prior to randomization Evidence of tuberculosis infection as defined by a positive QuantiFERON TB-Gold test (QFT) at screening. Patients with a positive or indeterminate QFT test may participate in the study if a full tuberculosis work-up (according</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other dermatological disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other dermatological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SUNRISE: Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)</TitleDisplay><PatientSegmentTerms><PatientSegment>Other dermatological disease - Subjects with specific disease - Subjects with Hidradenitis Suppurativa</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2021-07-09T00:00:00Z</PrimaryCompletionDate><TrialDuration>38 Months</TrialDuration><NumberOfSites>71</NumberOfSites><ContactNames><Name>Dr GNarsimha Rao Netha</Name><Name>Dr Hazel Oon</Name><Name>Dr Jayesh Mukhi</Name><Name>Dr Kiran Godse</Name><Name>Dr Manjunath Shenoy</Name><Name>Dr Suganthi A/P Thevarajah</Name><Name>Dr Sunil Dogra</Name><Name>Dr. Choon Siew Eng</Name><Name>Dr. Tan Wooi Chiang</Name><Name>Information&amp;Communication Médicales</Name><Name>Medizinischer Infoservice (MCC)</Name><Name>Ms Neshaleni a/p Perakasam</Name><Name>Murugananthan K</Name><Name>Nisha Su Yien Subash Chandran</Name><Name>Novartis Pharmaceuticals</Name><Name>Public Information Desk</Name><Name>Veronique Schaaf</Name><Name>Yeo Yi Wei</Name></ContactNames></Trial><Trial Id="357317"><Indications><Indication>Alopecia drug-induced</Indication></Indications><CompaniesSponsor><Company>Peking University</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-03-22T00:00:00Z</DateChangeLast><DateEnd>2021-03-30T00:00:00Z</DateEnd><DateStart>2019-03-07T00:00:00Z</DateStart><Identifiers><Identifier>BCP-25</Identifier><Identifier>COHAIR</Identifier><Identifier>NCT03711877</Identifier></Identifiers><InterventionsControlDisplay><Intervention>chemical cold cap (Li Kang Tai) alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>scalp cooling system (DigniCap) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>256</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>to recieve either scalp cooling therapy using scalp cooling system (DigniCap) or &lt;b&gt;cold&lt;/b&gt; cap therapy (Li Kang Tai) used to prevent alopecia during chemotherapy regimen...used to calculate the sample size. According to the results of previous studies, the hair retention rate of the &lt;b&gt;cold&lt;/b&gt; cap group will be 67.7%, the hair retention...to compare the effect of scalp cooling system (DigniCap) and chemical &lt;b&gt;cold&lt;/b&gt; cap on preventing chemotherapy-induced alopecia in a group of breast cancer patients</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Anxiety by Protocol Specified Scales</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability - Assessment of treatment induced toxicity</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Hospital Anxiety and Depression Scale (HADS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Asian Ancestry</Term></TermsPatientSelection><TitleDisplay>COHAIR: Comparative Study of Scalp Cooling System and Chemical Cold Cap</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Stage I Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage II Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with invasive breast cancer</PatientSegment><PatientSegment>Cancer supportive care - Solid tumor subjects for supportive care</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2020-03-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>24 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Xinying Yu, Master</Name><Name>Yingping Dong, Bachelor</Name></ContactNames></Trial><Trial Id="357227"><Indications><Indication>Hidradenitis suppurativa</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-17 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Novartis Pharma Services AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Novartis AG</Company><Company>Novartis Healthcare Philippines, Inc</Company><Company>Novartis Pharma AG</Company></CompaniesSponsor><Countries><Country>India</Country><Country>Poland</Country><Country>France</Country><Country>Israel</Country><Country>Slovakia</Country><Country>Slovenia</Country><Country>Belgium</Country><Country>US</Country><Country>Russian Federation</Country><Country>Iceland</Country><Country>Malaysia</Country><Country>Saudi Arabia</Country><Country>Czech Republic</Country><Country>Denmark</Country><Country>Egypt</Country><Country>Portugal</Country><Country>South Korea</Country><Country>UK</Country><Country>Canada</Country><Country>Chile</Country><Country>Argentina</Country><Country>Guatemala</Country><Country>Australia</Country><Country>Brazil</Country><Country>Colombia</Country><Country>Sweden</Country><Country>Vietnam</Country><Country>Croatia</Country><Country>Lebanon</Country><Country>Mexico</Country><Country>Romania</Country><Country>Italy</Country><Country>Germany</Country><Country>Lithuania</Country><Country>South Africa</Country><Country>Spain</Country><Country>Hungary</Country><Country>Japan</Country><Country>Latvia</Country><Country>Philippines</Country><Country>Singapore</Country><Country>Bulgaria</Country><Country>Jordan</Country><Country>Netherlands</Country><Country>Taiwan</Country><Country>Austria</Country><Country>Switzerland</Country><Country>Greece</Country><Country>Turkey</Country><Country>Finland</Country><Country>Norway</Country></Countries><DateChangeLast>2019-06-12T00:00:00Z</DateChangeLast><DateEnd>2022-04-20T00:00:00Z</DateEnd><DateStart>2019-01-31T00:00:00Z</DateStart><Identifiers><Identifier>2018-002063-26</Identifier><Identifier>CAIN457M2301</Identifier><Identifier>CTRI/2019/03/018045</Identifier><Identifier>JapicCTI-194673</Identifier><Identifier>NCT03713619</Identifier><Identifier>PHRR190430-002114</Identifier><Identifier>SUNSHINE</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>secukinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>471</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>constituents Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL-17 A/F or the IL-17 receptor History of chronic or recurrent systemic infections or active systemic infections during the last 2 weeks (exception: common &lt;b&gt;cold&lt;/b&gt;) prior to randomization Evidence of tuberculosis infection as defined by a positive QuantiFERON TB-Gold test (QFT) at screening. Patients with a positive or indeterminate QFT test may participate in the study if a full tuberculosis work-up (according</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other dermatological disease - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Other dermatological disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other dermatological disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other dermatological disease - Assessment of pain</EndpointIndex><EndpointIndex>Other dermatological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SUNSHINE: This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)</TitleDisplay><PatientSegmentTerms><PatientSegment>Other dermatological disease - Subjects with specific disease - Subjects with Hidradenitis Suppurativa</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2021-06-16T00:00:00Z</PrimaryCompletionDate><TrialDuration>38 Months</TrialDuration><NumberOfSites>117</NumberOfSites><ContactNames><Name>Anna Liza Calingasin</Name><Name>Dr Nandini AS</Name><Name>Dr Nanjundaswamy</Name><Name>Dr Ramesh Bhat M</Name><Name>Dr Rohit Batra</Name><Name>Dr Suneel Vartak</Name><Name>Jenifer Otoday-Agustin, MD</Name><Name>Lily Lyralin Laconico Tumalad, MD</Name><Name>Medizinischer Infoservice (MCC)</Name><Name>Murugananthan K</Name><Name>Novartis Pharma Ltd.</Name><Name>Novartis Pharmaceuticals</Name><Name>Shari Daffodil Francisco</Name><Name>Victoria Patino-Guillano, Dermatologist</Name></ContactNames></Trial><Trial Id="35620"><Indications><Indication>Depression</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Alpha 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>CNS modulator</Action><Action>Dopamine uptake modulator</Action><Action>Psychomodulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral controlled release formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Janssen Pharmaceuticals Inc</Company><Company>Janssen-Ortho Inc (Canada)</Company></CompaniesSponsor><DateChangeLast>2013-12-24T00:00:00Z</DateChangeLast><DateEnd>2006-04-30T00:00:00Z</DateEnd><DateStart>2005-06-30T00:00:00Z</DateStart><Identifiers><Identifier>CR006073</Identifier><Identifier>NCT00246233</Identifier></Identifiers><IndicationsAdverse><Indication>Anxiety disorder</Indication><Indication>Appetite loss</Indication><Indication>Common cold</Indication><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Insomnia</Indication><Indication>Nausea</Indication><Indication>Xerostomia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>methylphenidate hydrochloride (oral controlled-release, OROS), ALZA alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>145</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to evaluate the effects of the addition of Concerta ( methylphenidate hydrochloride , a central nervous system (CNS) stimulant) or placebo in adult outpatients with Major Depressive Disorder who are currently being treated with oral antidepressant medication (selective serotonin reuptake inhibitors or selective norepinephine reuptake inhibitors). The general symptoms of depression were evaluated, as measured by the Montgomery Asberg Depression Rating Score (MADRS) on</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Depression - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Depression - Assessment of Clinical Symptoms - Assessment of sexual dysfunction</EndpointIndex><EndpointIndex>Depression - Assessment of Depression Severity by Specific Criteria - Assessment by Hamilton Depression Rating Scale (HDRS)</EndpointIndex><EndpointIndex>Depression - Assessment of Depression Severity by Specific Criteria - Assessment by Montgomery-Asberg Depression Scale (MADRS)</EndpointIndex><EndpointIndex>Depression - Assessment of Fatigue</EndpointIndex><EndpointIndex>Depression - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Depression - Assessment of Laboratory/Diagnostic Measures - Assessment of biochemical parameters</EndpointIndex><EndpointIndex>Depression - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Depression - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Depression - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Depression - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Depression - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Depression - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Depression - Assessment of adverse events</EndpointIndex><EndpointIndex>Depression - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Depression - Protocol Specified Other Endpoints - Assessment of treatment adherence</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Concerta (Methylphenidate Hydrochloride) as Add-on Therapy in the Treatment of Adult Major Depressive Disorder</TitleDisplay><PatientSegmentTerms><PatientSegment>Depression - Subjects with Major Depressive Disorder</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Total cholesterol </BiomarkerName><BiomarkerName> Triglycerides</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>10 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Janssen-Ortho Inc. Clinical Trial</Name></ContactNames></Trial><Trial Id="35618"><Indications><Indication>Metastatic colorectal cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Thymidylate synthase inhibitor</Action><Action>VEGF ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Anticancer antimetabolite</Action><Action>Anticancer monoclonal antibody</Action><Action>DNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Film coating</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Prodrug</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>National Cancer Institute</Company></CompaniesCollaborator><CompaniesSponsor><Company>Prologue Research International Inc.</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2013-12-02T00:00:00Z</DateChangeLast><DateEnd>2011-02-28T00:00:00Z</DateEnd><DateStart>2003-05-31T00:00:00Z</DateStart><Identifiers><Identifier>CDR0000304771</Identifier><Identifier>NCT00062426</Identifier><Identifier>PROLOGUE-SANOFI-ARD5099</Identifier><Identifier>SANOFI-ARD5099</Identifier><Identifier>TREE Study</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Emesis</Indication><Indication>Nausea</Indication><Indication>Neutropenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Variable regimens including bevacizumab , capecitabine , fluorouracil , leucovorin , oxaliplatin , oxaliplatin + capecitabine , oxaliplatin + leucovorin + fluorouracil</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>375</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>radiotherapy unless for the control of bone pain Surgery: Recovered from prior surgery No prior organ allografts Other: More than 4 weeks since prior investigational drugs No concurrent iced mouth rinses for the prevention of stomatitis No concurrent &lt;b&gt;cold&lt;/b&gt; cap alopecia prevention No concurrent pyridoxine No concurrent sorivudine or chemically-related analogues (eg, brivudine) No concurrent chronic aspirin, nonsteroidal anti-inflammatory drugs, or warfarin</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Clinical Response - Assessment of Time to Treatment Failure (TTF)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of toxicities</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TREE Study: Oxaliplatin and Bevacizumab (Avastin) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with Colon Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Recurrent/Relapsed Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>93 Months</TrialDuration><NumberOfSites>52</NumberOfSites><ContactNames><Name>Lauri Welles</Name><Name>Richard Gams</Name></ContactNames></Trial><Trial Id="355555"><Indications><Indication>Cough</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>P2X3 purinoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anti-inflammatory</Action><Action>Antitussive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2019-06-28T00:00:00Z</DateChangeLast><DateEnd>2020-10-06T00:00:00Z</DateEnd><DateStart>2018-10-31T00:00:00Z</DateStart><Identifiers><Identifier>184154</Identifier><Identifier>7264-038</Identifier><Identifier>MK-7264-00</Identifier><Identifier>MK-7264-038</Identifier><Identifier>NCT03696108</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>gefapixant alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>160</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The primary objective of this study is to evaluate the number of adverse events (AEs)and discontinuation due to AEs through up to 52 weeks of treatment with gefapixant ( MK-7264 ) in Japanese adult participants with refractory or unexplained chronic cough.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other respiratory disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough</TitleDisplay><PatientSegmentTerms><PatientSegment>Other respiratory disease - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Other respiratory disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2020-10-06T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>39</NumberOfSites><ContactNames><Name>MSD Corporation</Name><Name>Medical Director</Name><Name>Study Coordinator</Name><Name>Toll Free Number</Name></ContactNames></Trial><Trial Id="354899"><Indications><Indication>Anesthesia</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Analgesic</Action><Action>Local anesthetic</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intrathecal formulation</Technology><Technology>Rectal formulation</Technology><Technology>Rectal formulation local</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>University Hospital of Besancon</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2020-03-31T00:00:00Z</DateEnd><DateStart>2018-10-05T00:00:00Z</DateStart><Identifiers><Identifier>AxiRopiDexa</Identifier><Identifier>NCT03688269</Identifier><Identifier>P/2018/384</Identifier></Identifiers><InterventionsControlDisplay><Intervention>ropivacaine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>dexamethasone plus ropivacaine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>110</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This trial aims in the determination of the minimal effective concentration (EC90) of ropivacaine in axillary brachial plexus block with intravenous dexamethasone or saline injection.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Quantitative sensory testing</EndpointIndex><EndpointIndex>Pain - Assessment of Post-operative Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability - Assessment of postoperative complications</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of efficacy</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of procedural outcomes</EndpointIndex><EndpointIndex>Pain - Neurological Assessments</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Pain - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>AxiRopiDexa: Minimal Effective Concentration (EC90) of Ropivacaine</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2019-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Francis BERTHIER</Name><Name>Lucie VETTORETTI</Name></ContactNames></Trial><Trial Id="354538"><Indications><Indication>Common cold</Indication></Indications><CompaniesSponsor><Company>Policlinico Hospital</Company></CompaniesSponsor><Countries><Country>Italy</Country></Countries><DateChangeLast>2019-03-22T00:00:00Z</DateChangeLast><DateEnd>2018-03-31T00:00:00Z</DateEnd><DateStart>2015-12-31T00:00:00Z</DateStart><Identifiers><Identifier>NCT03683108</Identifier><Identifier>VIRNEO</Identifier><Identifier>VIRNEO1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>carboxymethyl-beta-glucan plus resveratrol</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Consecutive outpatient infants (0 to 6 months) with common &lt;b&gt;cold&lt;/b&gt; symptoms were enrolled, and randomly divided into two arms: Arm 1 (Experimental; resveratrol and... enrollment, after 48 h and after 7 and 30 days. Common &lt;b&gt;cold&lt;/b&gt; symptoms were specifically evaluated according to CARIFS Scale. Nasal swabs for human rhinovirus... Common &lt;b&gt;cold&lt;/b&gt; syndrome</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Respiratory tract infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term></TermsPatientSelection><TitleDisplay>VIRNEO: Efficacy and Safety of Resveratrol and Carboxymethyl-Beta-Glucan in Treatment of Upper Airways Disease in Infancy</TitleDisplay><PatientSegmentTerms><PatientSegment>Respiratory tract infection - Others - Healthy Subjects</PatientSegment><PatientSegment>Respiratory tract infection - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2018-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>27 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Maria Elisabetta Baldassarre</Name></ContactNames></Trial><Trial Id="354025"><Indications><Indication>Prurigo nodularis</Indication><Indication>Pruritus</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>NK1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Menlo Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>Poland</Country><Country>Europe</Country><Country>Austria</Country><Country>Germany</Country></Countries><DateChangeLast>2019-06-20T00:00:00Z</DateChangeLast><DateEnd>2020-02-29T00:00:00Z</DateEnd><DateStart>2018-08-29T00:00:00Z</DateStart><Identifiers><Identifier>2017-004210-25</Identifier><Identifier>MTI-106</Identifier><Identifier>NCT03677401</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>serlopitant alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This was a study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis [ 2018036 ], [ 2059242 ], [ 2080354 ], [ 2102863 ], [ 2110760 ], [ 2124070 ]. The safety objective was to assess the safety and tolerability of repeated oral doses of serlopitant in adults with prurigo nodularis. As of December 2017, Menlo Therapeutics Inc planned to initiate this study in the second quarter of 2018 [ 2018036 ], [ 2020314 ]. In August 2018</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pruritus - Assessment of Clinical Symptoms - Assessment of pruritus/itch/scratch score</EndpointIndex><EndpointIndex>Pruritus - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pruritus - Patient Reported Outcomes/Quality of Life Assessments - Numeric rating scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis</TitleDisplay><PatientSegmentTerms><PatientSegment>Pruritus - Subjects with Prurigo Nodularis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2020-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>18 Months</TrialDuration><NumberOfSites>41</NumberOfSites><ContactNames><Name>Chief Medical Officer</Name><Name>Franz Josef Legat, MD</Name><Name>Investigator Principal</Name><Name>Jacek Szepietowski, MD, Ph.D</Name><Name>Menlo Study Director</Name><Name>Principal Investigator</Name><Name>Sonja Stander, MD</Name></ContactNames></Trial><Trial Id="353244"><Indications><Indication>Respiratory tract infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Phosphoinositide 3-kinase inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR complex 2 inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action><Action>Neuroprotectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>PureTech Health Plc</Company><Company>resTORbio Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-05-13T00:00:00Z</DateChangeLast><DateStart>2019-05-09T00:00:00Z</DateStart><Identifiers><Identifier>PROTECTOR 1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>dactolisib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1000</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>Patients would be randomized in 1 : 1 ratio to RTB-101 10 mg qd or matching placebo 16 weeks during winter &lt;b&gt;cold&lt;/b&gt; and flu season [ 2130891 ], [ 2150081 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PROTECTOR 1: A pivotal, randomized, double-blinded, placebo-controlled, phase III trial of RTB-101 for the respiratory tract infections (RTIs)</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="352257"><Indications><Indication>Adenocarcinoma</Indication><Indication>Metastatic colorectal cancer</Indication><Indication>Peripheral neuropathy</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Superoxide dismutase stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Antioxidant agent</Action><Action>Chemoprotectant</Action><Action>DNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Solasia Pharma KK</Company></CompaniesCollaborator><CompaniesSponsor><Company>PledPharma AB</Company></CompaniesSponsor><Countries><Country>France</Country><Country>Germany</Country><Country>Italy</Country><Country>Spain</Country><Country>Hong Kong</Country><Country>Belgium</Country><Country>US</Country><Country>Europe</Country><Country>Japan</Country><Country>Czech Republic</Country><Country>Taiwan</Country><Country>Asia</Country><Country>UK</Country><Country>South Korea</Country></Countries><DateChangeLast>2019-05-14T00:00:00Z</DateChangeLast><DateEnd>2022-09-30T00:00:00Z</DateEnd><DateStart>2018-10-01T00:00:00Z</DateStart><Identifiers><Identifier>2017-004754-42</Identifier><Identifier>JapicCTI-184186</Identifier><Identifier>NCT03654729</Identifier><Identifier>POLAR-M</Identifier><Identifier>PP06490</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including calmangafodipir , fluorouracil , folinic acid , oxaliplatin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>420</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>placebo with respect to the proportion of patients with moderate or severe chronic CIPN [ 2108463 ], [ 2109779 ], [ 2111461 ]. Secondary objectives of the trial: Efficacy: Proportion of patients with mild, moderate or severe chronic CIPN. to touching &lt;b&gt;cold&lt;/b&gt; items. Cumulative dose of oxaliplatin during chemotherapy. Vibration sensitivity on the lateral malleolus. Worst pain in hands or feet. Functional impairment (non-dominant hand). Sustained efficacy on prevention of CIPN during LTFU. Safety: Overall</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Pain</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Response Rates (RR) - Assessment of Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability - Assessment of neurotoxicity</EndpointIndex><EndpointIndex>Cancer supportive care - Assessment of Safety and Tolerability - Assessment of treatment induced toxicity</EndpointIndex><EndpointIndex>Cancer supportive care - Clinical Assessments</EndpointIndex><EndpointIndex>Cancer supportive care - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Cancer supportive care - Protocol Specified Other Endpoints - Assessment of Other Treatment or Procedure Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>POLAR-M: Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Cancer supportive care - Treatment Naive Subjects</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Colon Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer - Subjects with rectal adenocarcinoma</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with specific disease - Subjects with colon adenocarcinoma</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2019-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>105</NumberOfSites><ContactNames><Name>Andreas Polychronis, MBBCh, MRCP, PhD, FRCP</Name><Name>Antonio C Sanchez Ruiz, MD, PhD</Name><Name>Antonio Cubillo Gracian, PhD</Name><Name>Bernhard Heinrich, MD</Name><Name>Cheng-Yao Lin</Name><Name>Cheryl Palmer, MA (Cantab) BM BCh (Oxon), MRC</Name><Name>Chief Medical Officer</Name><Name>Claus Bolling, MD</Name><Name>David Crockett, MD</Name><Name>David Paez, PhD, MSc</Name><Name>David Watkins, MB, BS</Name><Name>Debra M Prow, MD</Name><Name>Eiji Oki, MD</Name><Name>Elodie Gonne, MD</Name><Name>Enno Moorahrend, MD</Name><Name>Eugen Kubala, MD</Name><Name>Gopalakrishnan Srinivasan, MD</Name><Name>Guglielmo Nasti, MD</Name><Name>Gunnar Folprecht, PhD</Name><Name>Ichiro Takemasa, PhD, MD</Name><Name>James D'Olimpio, MD</Name><Name>Jaw-Yuan Wang</Name><Name>Jean Philippe Metges, MD</Name><Name>Jonathan Bleeker, MD</Name><Name>Jonathan Ticku, MD</Name><Name>Judith Raimbourg, MD</Name><Name>Julien Forestier, MD</Name><Name>Ka-On Lam, MBBS (HK), FRCR, FHKCR, FHKAM</Name><Name>Kai-Keen Shiu, MRCP, PhD</Name><Name>Katerina Jirsová, MD</Name><Name>Kei Muro, MD</Name><Name>Ken Kato</Name><Name>Kensei Yamaguchi, MD</Name><Name>Kentaro Yamazaki</Name><Name>Lee Kwen-Wook</Name><Name>Lionel D'hondt, MD, PhD</Name><Name>Louis Marie Dourthe, MD</Name><Name>Lucas Wong, MD, FACP</Name><Name>Marc Van den Eynde, MD</Name><Name>Maria Banzi, MD</Name><Name>Martin Šmákal, MUDr</Name><Name>Meinolf Karthaus, MD</Name><Name>Michal Vocka, MD</Name><Name>Michelle Cunnell, MD</Name><Name>Myriam Paris, MD</Name><Name>Naotoshi Sugimoto, MD</Name><Name>Nicklas Westerholm</Name><Name>Oh S Yong</Name><Name>Peter Kurniala, MD</Name><Name>Petr Rychlik, MD</Name><Name>Petra Holeckova, MUDr, MBA, PhD</Name><Name>Pieter Vandecandelaere, MD</Name><Name>Pieter-Jan Cuyle, MD, PhD</Name><Name>Pilar García Alfonso, MD, PhD</Name><Name>Prof. Per Pfeiffer</Name><Name>Raffaella Longarini, MD</Name><Name>Sameer Desai, MD</Name><Name>Sang-Cheul Oh</Name><Name>Sang-Hee Cho</Name><Name>Sanjay Goel, MD</Name><Name>Sebastian Serra, MD</Name><Name>Silvia Brugnatelli, MD</Name><Name>Stefan Carlsson, MD</Name><Name>Stefano de Santis, MD, PhD</Name><Name>Steven Hager, BS, DO</Name><Name>Tae-You Kim</Name><Name>Takeshi Kato, MD</Name><Name>Taroh Satoh, MD</Name><Name>Thomas Göhler, MD</Name><Name>Thomas Stanton, MD</Name><Name>Tomohiro Nishina</Name><Name>Vicente Alonso-Orduña, PhD</Name><Name>Yoichiro Yoshida, MD</Name><Name>Yoshiki Horie</Name><Name>Yoshito Komatsu</Name><Name>Yu-Min Yeh, MD</Name><Name>Zang D Young</Name></ContactNames></Trial><Trial Id="352125"><Indications><Indication>Perennial allergic rhinitis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Systemic formulation unspecified</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hanlim Pharmaceutical Co Ltd</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2019-05-31T00:00:00Z</DateChangeLast><DateEnd>2017-10-16T00:00:00Z</DateEnd><DateStart>2017-02-07T00:00:00Z</DateStart><Identifiers><Identifier>HL_HL151_301</Identifier><Identifier>KCT0003974</Identifier><Identifier>NCT03655210</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>HL-151 alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>272</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>sinusitis within 4 weeks of Visit 1 Patients who initiated immunotherapy or changes in dosage within 4 weeks of Visit 1 Patients who experienced use of long-acting antihistamines Patients with upper respiratory tract infections including the common &lt;b&gt;cold&lt;/b&gt;, and systemic infections within 2 weeks of Visit 1 Subjects with comorbidities that may interrupt the treatment of cancers or clinical significant disorders of the kidney, liver, psychiatric system, cardiovascular system, respiratory system, endocrine</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of nasal itching</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of sneezing</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Assessment of instantaneous total nasal symptom score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Total Nasal Symptom Score - Assessment of reflective total nasal symptom score</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of other end points</EndpointIndex><EndpointIndex>Allergic rhinitis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>To Evaluate the Efficacy and Safety of HL-151 Versus Placebo in Perennial Allergic Rhinitis Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Perennial Allergic Rhinitis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2017-02-20T00:00:00Z</PrimaryCompletionDate><TrialDuration>8 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Chae-Seo Rhee</Name></ContactNames></Trial><Trial Id="351342"><Indications><Indication>Acne vulgaris</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Retinoic acid receptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Topical anti-acne product</Action></ActionsSecondaryInterventionsControl><Technologies><Technology>Dermatological formulation</Technology><Technology>Dermatological gel formulation</Technology><Technology>Emulsion dermatological</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>catawba pharmaceuticals</Company></CompaniesCollaborator><CompaniesSponsor><Company>ALEOR DERMACEUTICALS LIMITED</Company></CompaniesSponsor><Countries><Country>India</Country><Country>Belize</Country><Country>US</Country></Countries><DateChangeLast>2019-04-27T00:00:00Z</DateChangeLast><DateEnd>2019-02-16T00:00:00Z</DateEnd><DateStart>2018-09-17T00:00:00Z</DateStart><Identifiers><Identifier>ADPG 1807</Identifier><Identifier>NCT03650361</Identifier></Identifiers><InterventionsControlDisplay><Intervention>adapalene alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>adapalene gel (Aleor Dermaceuticals Limited, India) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>755</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> from study participation. In addition, subjects who have any malignancy of the skin of the facial area will be excluded Subjects who engage in activities that involve excessive or prolonged exposure to sunlight or weather extremes, such as wind or &lt;b&gt;cold&lt;/b&gt; Subjects who consume excessive amounts of alcohol (greater than two drinks per day) or use drugs of abuse (including, but not limited to cannabinoids, cocaine and barbiturates) Subjects who have participated in an investigational drug study (ie, subjects</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Bioequivalence</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Acne vulgaris - Assessment of Lesion Count and Characteristics - Change in inflammatory lesion counts</EndpointIndex><EndpointIndex>Acne vulgaris - Assessment of Lesion Count and Characteristics - Change in noninflammatory lesion counts</EndpointIndex><EndpointIndex>Acne vulgaris - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Acne vulgaris - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Acne vulgaris - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Acne vulgaris - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris</TitleDisplay><PatientSegmentTerms><PatientSegment>Acne vulgaris - Others - Healthy Subjects</PatientSegment><PatientSegment>Acne vulgaris - Subjects by disease severity</PatientSegment><PatientSegment>Acne vulgaris - Subjects with Inflammatory Lesions - Subjects with nodules/nodulocystic lesions</PatientSegment><PatientSegment>Acne vulgaris - Subjects with Inflammatory Lesions - Subjects with papules</PatientSegment><PatientSegment>Acne vulgaris - Subjects with Inflammatory Lesions - Subjects with pustules</PatientSegment><PatientSegment>Acne vulgaris - Subjects with Non-inflammatory Lesions - Subjects with open/closed comedones</PatientSegment><PatientSegment>Acne vulgaris - Subjects with specific disease - Subjects with Facial Acne Vulgaris</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2019-02-16T00:00:00Z</PrimaryCompletionDate><TrialDuration>5 Months</TrialDuration><NumberOfSites>11</NumberOfSites><ContactNames><Name>Catawba Research</Name><Name>Venkata. K. R. CH. Hemanth Varma. P</Name></ContactNames></Trial><Trial Id="349261"><Indications><Indication>Prostate tumor</Indication></Indications><CompaniesCollaborator><Company>Advanced Nuclear Medicine Ingredients SA</Company><Company>GIE NANCYCLOTEP</Company></CompaniesCollaborator><CompaniesSponsor><Company>Central Hospital, Nancy, France</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2018-10-12T00:00:00Z</DateChangeLast><DateEnd>2020-05-01T00:00:00Z</DateEnd><DateStart>2019-02-01T00:00:00Z</DateStart><Identifiers><Identifier>2017-003620-69</Identifier><Identifier>NCT03623425</Identifier><Identifier>PSS2017/ANMI-OLIVIER/VS</Identifier><Identifier>TEPGALCHOL</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>18F-Fluorocholine alone</Intervention><Intervention>68Ga-PSMA-11, Central Hospital, Nancy, France alone</Intervention><Intervention>positron emission tomography imaging (PEG) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>46</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser> The aim of this study is to demonstrate the superiority of 68Ga-PSMA-11, prepared from a room temperature radiolabel kit containing PSMA-11 (PSMA-11 Sterile &lt;b&gt;Cold&lt;/b&gt; Kit) and gallium 68 obtained from a 68Ge / 68Ga generator on 18F-Fluorocholine (18F-FCH) in identifying prostate cancer recurrence after radical treatment sites. So, patients will be evaluated with the current workup at Central Hospital, Nancy and </Teaser><TrialCategories><Category>Diagnostic</Category><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Diagnosis</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Laboratory/Diagnostic Measures - Assessments by radiography/imaging</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Prostate tumor - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TEPGALCHOL: Comparison of PET With 68GA-PSMA-11 and 18F-Fluorocholine for Recurrence in Men With Prostate Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Prostate tumor - Subjects With Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Recurrent/Relapsed Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Treatment Resistant Disease - Subjects with Rising PSA levels</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Prostate-specific antigen </BiomarkerName><BiomarkerName> Standardized uptake value</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-05-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Pierre OLIVIER, MD, PhD</Name><Name>Pierre OLIVIER, MD,PhD</Name><Name>Véronique ROCH, MSc</Name></ContactNames></Trial><Trial Id="349254"><Indications><Indication>Anesthesia</Indication><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intrathecal formulation</Technology><Technology>Rectal formulation</Technology><Technology>Rectal formulation local</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Hospices Civils De Lyon</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2019-04-09T00:00:00Z</DateChangeLast><DateEnd>2019-08-31T00:00:00Z</DateEnd><DateStart>2018-02-07T00:00:00Z</DateStart><Identifiers><Identifier>2016-005213-53</Identifier><Identifier>69HCL16_0798</Identifier><Identifier>NCT03620136</Identifier><Identifier>SALIA</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>adductor channel block alone</Intervention><Intervention>locoregional analgesia alone</Intervention><Intervention>periarticular local infiltration therapy alone</Intervention><Intervention>ropivacaine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>thigh. It will be used echogenic needle adapted to the morphotype of each patient, of varying length from 50 to 100 mm. A single injection of 20 ml of ropivacaine 2 mg/ml, the efficacy of which will be checked before spinal anesthesia is performed by a &lt;b&gt;cold&lt;/b&gt; test. Knee analgesia will be supplemented by per-operative infiltration of 50 ml of ropivacaine 2 mg/ml at the posterior capsule, once the surfaces joints prepared to accommodate the prosthesis and by two placebo infiltrations of 50 ml each of physiological</Teaser><TrialCategories><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment by Global Assessment Scales - Visual analogue scales (VAS) for local and general pain/overall disease activity</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Other Measures of Pain Quality</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Assessment of adverse events</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other musculoskeletal disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex><EndpointIndex>Pain - Assessment of Morbidity - Assessment of block-related complications</EndpointIndex><EndpointIndex>Pain - Assessment of Pain During Activity</EndpointIndex><EndpointIndex>Pain - Assessment of Pain at Rest</EndpointIndex><EndpointIndex>Pain - Assessment of Post-operative Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Assessment of other outcomes associated with anesthetic use</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability - Assessment of postoperative complications</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment of patient satisfaction</EndpointIndex><EndpointIndex>Pain - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SALIA: Comparison of Two Techniques of Locoregional Analgesia in Total Knee Prosthesis Surgery: Block to the Adductor Channel Versus Peri-articular Local Infiltrations</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2019-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>18 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Caroline Macabeo</Name><Name>Caroline Macabeo, MD</Name><Name>Caroline Pic</Name></ContactNames></Trial><Trial Id="347966"><Indications><Indication>Common cold</Indication><Indication>Enterovirus infection</Indication><Indication>Rhinovirus infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antiviral</Action><Action>Unspecified drug target</Action><Action>Viral replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Oral controlled release formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Romark Laboratories LC</Company></CompaniesSponsor><Countries><Country>Puerto Rico</Country><Country>US</Country></Countries><DateChangeLast>2019-04-09T00:00:00Z</DateChangeLast><DateEnd>2018-12-11T00:00:00Z</DateEnd><DateStart>2018-09-11T00:00:00Z</DateStart><Identifiers><Identifier>NCT03605862</Identifier><Identifier>RM08-3005</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>nitazoxanide (controlled-release, viral infections), Romark alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1765</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The multicenter, randomized, double-blind, placebo-controlled trial was to evaluate efficacy and safety of nitazoxanide in the treatment of colds due to enterovirus/rhinovirus infection.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Enterovirus 71 infection - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Enterovirus 71 infection - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Enterovirus 71 infection - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Respiratory tract infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection</TitleDisplay><PatientSegmentTerms><PatientSegment>Enterovirus 71 infection - Subjects with Enterovirus 71 Infection</PatientSegment><PatientSegment>Respiratory tract infection - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2018-12-11T00:00:00Z</PrimaryCompletionDate><TrialDuration>3 Months</TrialDuration><NumberOfSites>45</NumberOfSites><ContactNames><Name>Jean-Francois Rossignol, M.D., Ph.D</Name></ContactNames></Trial><Trial Id="346861"><Indications><Indication>Neuropathic pain</Indication><Indication>Spinal cord injury</Indication></Indications><CompaniesSponsor><Company>Burke Medical Research Institute</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-01-24T00:00:00Z</DateChangeLast><DateEnd>2019-12-31T00:00:00Z</DateEnd><DateStart>2016-07-31T00:00:00Z</DateStart><Identifiers><Identifier>BRC527</Identifier><Identifier>NCT03592394</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Gear VR alone</Intervention><Intervention>distractive immersive virtual reality training alone</Intervention><Intervention>somatic immersive virtual reality training alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The investigators hypothesis is that spinal cord injury (SCI) patients using immersive immersive virtual reality (IVR) training will show improved reduction of neuropathic pain that will outlast the training sessions and transfers into daily life. The investigators will believe that IVR neurorehabilitation exploits the idea of inducing activation in action observation, motor imagery, and processing systems, which in turn, should activate downstream cortical areas involved in movement and motor</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Functional Disability/Physical Function - Assessment of daily activity/Work disability</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of motor function</EndpointIndex><EndpointIndex>Other neurological disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other neurological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other neurological disease - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Pain - Assessment of Brain Structure and Function</EndpointIndex><EndpointIndex>Pain - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Pain - Assessment of Depression Severity by Specific Criteria - Assessment by Beck Depression Inventory (BDI)</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropathic Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of Feasibility</EndpointIndex><EndpointIndex>Pain - Clinical Assessments</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Spinal Cord Independence Measure (SCIM) score</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Neuropathic pain scale score</EndpointIndex><EndpointIndex>Pain - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Virtual Reality for Chronic Neuropathic Pain</TitleDisplay><PatientSegmentTerms><PatientSegment>Other neurological disease - Subjects with specific disease - Subjects with spinal cord disease</PatientSegment><PatientSegment>Other neurological disease - Subjects with specific disease - Subjects with spinal cord injury</PatientSegment><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Motor evoked potential </BiomarkerName><BiomarkerName> Muscle strength</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>41 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Kathleen Friel, PhD</Name></ContactNames></Trial><Trial Id="346658"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-17 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company><Company>Novartis Pharma AG</Company></CompaniesSponsor><Countries><Country>Germany</Country><Country>US</Country></Countries><DateChangeLast>2019-02-04T00:00:00Z</DateChangeLast><DateEnd>2020-06-22T00:00:00Z</DateEnd><DateStart>2018-12-20T00:00:00Z</DateStart><Identifiers><Identifier>2018-000518-39</Identifier><Identifier>CAIN457A2325</Identifier><Identifier>MATURE</Identifier><Identifier>NCT03589885</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>secukinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>(176.8 micromol/l) Total white blood cell (WBC) count&amp;lt; 2,500/microl, or platelets &amp;lt; 100,000/microl or neutrophils &amp;lt; 1,500/microl or hemoglobin &amp;lt; 8.5 g/dl at Screening Active systemic infections during the last 2 weeks (exception: common &lt;b&gt;cold&lt;/b&gt;) prior to randomization or any infection that reoccurs on a regular basis History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis (TB) infection as defined by a positive central laboratory test result at screening</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Psoriasis - Assessment of adverse events</EndpointIndex><EndpointIndex>Psoriasis - Changes in Characteristics of Skin/Lesion - Assessment of scaling</EndpointIndex><EndpointIndex>Psoriasis - Changes in Characteristics of Skin/Lesion - Change in size/area of skin lesion</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-50 response</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-75 response</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-75 to 100 response</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Dermatology Life Quality Index (DLQI)</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Assessment of treatment satisfaction</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Self-administered self-injection assessment questionnaire(SIAQ) score</EndpointIndex><EndpointIndex>Psoriasis - Physician Global Assessment of Disease Activity - Assessment by Investigator/Physician Global Assessment (PGA) Scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>MATURE: Study of Efficacy and Safety of Secukinumab 2 ml Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with Moderate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment><PatientSegment>Psoriasis - Subjects with Severe Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Psoriasis - Subjects with specific disease - Subjects with Chronic Plaque Psoriasis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2019-09-26T00:00:00Z</PrimaryCompletionDate><TrialDuration>18 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Medizinischer Infoservice (MCC)</Name><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="345602"><Indications><Indication>Urticaria</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Immunoglobulin E antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin E antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Novartis Pharma AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>NOVARTIS (SINGAPORE) PTE LTD</Company><Company>Novartis AG</Company><Company>Novartis Corporation (M) Sdn Bhd</Company><Company>Novartis India</Company></CompaniesSponsor><Countries><Country>Bulgaria</Country><Country>India</Country><Country>Singapore</Country><Country>Canada</Country><Country>Germany</Country><Country>US</Country><Country>Oman</Country><Country>Russian Federation</Country><Country>France</Country><Country>Denmark</Country><Country>Brazil</Country><Country>South Africa</Country><Country>Czech Republic</Country><Country>Austria</Country><Country>Malaysia</Country><Country>Thailand</Country><Country>Spain</Country><Country>South Korea</Country><Country>Morocco</Country><Country>Poland</Country><Country>Colombia</Country><Country>Argentina</Country><Country>Guatemala</Country><Country>Peru</Country><Country>Greece</Country><Country>Sweden</Country><Country>Hungary</Country><Country>Turkey</Country></Countries><DateChangeLast>2019-07-01T00:00:00Z</DateChangeLast><DateEnd>2021-04-30T00:00:00Z</DateEnd><DateStart>2018-10-17T00:00:00Z</DateStart><Identifiers><Identifier>2018-000839-28</Identifier><Identifier>42331</Identifier><Identifier>CQGE031C2302</Identifier><Identifier>CTRI/2018/12/016719</Identifier><Identifier>NCT03580369</Identifier><Identifier>NMRR-18-1440-42331</Identifier><Identifier>P/329/2017</Identifier><Identifier>PEARL 1</Identifier></Identifiers><InterventionsControlDisplay><Intervention>omalizumab alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>ligelizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1050</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> chemical classes (ie, to murine, chimeric or human antibodies) Subjects having a clearly defined cause of their chronic urticaria, other than CSU. This includes, but is not limited to, the following: symptomatic dermographism (urticaria factitia), &lt;b&gt;cold&lt;/b&gt;, heat, solar, pressure, delayed pressure, aquagenic, cholinergic or contact-urticaria Diseases, other than chronic urticaria, with urticarial or angioedema symptoms such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Urticaria - Assessment by Urticarial Scores - Assessment by Urticaria Activity Score (UAS)</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms - Assessment of angioedema</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms - Assessment of pruritus(itch) severity</EndpointIndex><EndpointIndex>Urticaria - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Urticaria - Assessment of adverse events</EndpointIndex><EndpointIndex>Urticaria - Clinical Assessments</EndpointIndex><EndpointIndex>Urticaria - Other Protocol Specified Outcomes</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments - Angioedema activity score(AAS)</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Dermatology Life Quality Index (DLQI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PEARL 1: A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines</TitleDisplay><PatientSegmentTerms><PatientSegment>Urticaria - Subjects with Chronic Urticaria - Patiets with chronic spontaneous urticaria</PatientSegment><PatientSegment>Urticaria - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2020-05-04T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>124</NumberOfSites><ContactNames><Name>Clinical Trial Information Desk</Name><Name>Dr Abhiskek De</Name><Name>Dr Anne Goh</Name><Name>Dr Kiran Godse</Name><Name>Dr Neena Khanna</Name><Name>Dr Suganthi A/P Thevarajah</Name><Name>Dr T K Sumathy</Name><Name>Dr Tang Jyh Jong</Name><Name>Dr Teja Kulkarni</Name><Name>Dr Vinitha Panicker</Name><Name>Lee Haur Yueh</Name><Name>Medical Information</Name><Name>Medical information</Name><Name>Medizinischer Infoservice (MCC)</Name><Name>Murugananthan K</Name><Name>Nisha Su Yien Subash Chandran</Name><Name>Novartis Pharmaceuticals</Name><Name>Tee Shang-Ian</Name><Name>WONG WAN YING</Name></ContactNames></Trial><Trial Id="345592"><Indications><Indication>Urticaria</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Immunoglobulin E antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin E antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company><Company>Novartis Farmaceutica SA</Company><Company>Novartis Healthcare Philippines, Inc</Company><Company>Novartis Pharma AG</Company></CompaniesSponsor><Countries><Country>Romania</Country><Country>Lebanon</Country><Country>Australia</Country><Country>India</Country><Country>Italy</Country><Country>Finland</Country><Country>Estonia</Country><Country>France</Country><Country>Philippines</Country><Country>Vietnam</Country><Country>Spain</Country><Country>Netherlands</Country><Country>Russian Federation</Country><Country>Taiwan</Country><Country>Austria</Country><Country>Brazil</Country><Country>US</Country><Country>Argentina</Country><Country>Chile</Country><Country>Germany</Country><Country>Belgium</Country><Country>Mexico</Country><Country>Portugal</Country><Country>Israel</Country><Country>Poland</Country><Country>Tunisia</Country><Country>Slovakia</Country><Country>Egypt</Country><Country>Norway</Country><Country>Japan</Country></Countries><DateChangeLast>2019-06-17T00:00:00Z</DateChangeLast><DateEnd>2021-04-30T00:00:00Z</DateEnd><DateStart>2018-10-20T00:00:00Z</DateStart><Identifiers><Identifier>2018-000840-24</Identifier><Identifier>2018-CT0456</Identifier><Identifier>CQGE031C2303</Identifier><Identifier>CTRI/2018/12/016674</Identifier><Identifier>JapicCTI-184148</Identifier><Identifier>NCT03580356</Identifier><Identifier>P/329/2017</Identifier><Identifier>PEARL 2</Identifier><Identifier>PHRR190115-002037</Identifier></Identifiers><InterventionsControlDisplay><Intervention>omalizumab alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>ligelizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1050</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>similar chemical classes (ie, to murine, chimeric/human antibodies) Subjects having a clearly defined cause of their chronic urticaria, other than CSU. This includes, but is not limited to, the following: Symptomatic dermographism (urticaria factitia), &lt;b&gt;cold&lt;/b&gt;, heat, solar, pressure, delayed pressure, aquagenic, cholinergic or contact-urticaria Diseases, other than chronic urticaria, with urticarial/angioedema symptoms such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria </Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Urticaria - Assessment by Urticarial Scores - Assessment by Urticaria Activity Score (UAS)</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms - Assessment of angioedema</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms - Assessment of number of hives</EndpointIndex><EndpointIndex>Urticaria - Assessment of Clinical Symptoms - Assessment of pruritus(itch) severity</EndpointIndex><EndpointIndex>Urticaria - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Urticaria - Assessment of adverse events</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments - Angioedema activity score(AAS)</EndpointIndex><EndpointIndex>Urticaria - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Dermatology Life Quality Index (DLQI)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PEARL 2: A Phase III Study Of Efficacy and Safety Of Ligelizumab in the Treatment Of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines</TitleDisplay><PatientSegmentTerms><PatientSegment>Urticaria - Subjects with Chronic Urticaria - Patiets with chronic spontaneous urticaria</PatientSegment><PatientSegment>Urticaria - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2020-05-04T00:00:00Z</PrimaryCompletionDate><TrialDuration>30 Months</TrialDuration><NumberOfSites>182</NumberOfSites><ContactNames><Name>Anna Liza Calingasin</Name><Name>Clinical Trial Information Desk</Name><Name>DRA information desk</Name><Name>Dr Ishad Aggarwal</Name><Name>Dr Nandini AS</Name><Name>Dr Radha Shaha</Name><Name>Dr Rajesh Dutt Mehta</Name><Name>Dr Ramesh Bhat</Name><Name>Dr Subhash Chandra Bharija</Name><Name>Dr Suneel Vartak</Name><Name>Information&amp;Communication Médicales</Name><Name>Ma. Lourdes Anna M. Nebrida-Idea, MD</Name><Name>Maria Deanna Ramiscal, MD</Name><Name>Medical Information Service</Name><Name>Michelle Joy De Vera, MD</Name><Name>Murugananthan K</Name><Name>Novartis Pharma K. K.</Name><Name>Novartis Pharmaceuticals</Name><Name>Shari Daffodil Francisco</Name><Name>Trial Monitoring Organization (TMo)</Name><Name>Vermen Verallo-Rowell, MD</Name></ContactNames></Trial><Trial Id="34252"><Indications><Indication>Depression</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>5-HT uptake inhibitor</Action><Action>Analgesic</Action><Action>Antidepressant</Action><Action>Anxiolytic</Action><Action>Norepinephrine uptake inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Daily dosing</Technology><Technology>Enteric coated formulation</Technology><Technology>Oral controlled release formulation</Technology><Technology>Oral formulation</Technology><Technology>Pellet</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Boehringer Ingelheim Corp</Company></CompaniesCollaborator><CompaniesSponsor><Company>Eli Lilly &amp; Co</Company><Company>Eli Lilly &amp; Co Ltd</Company></CompaniesSponsor><Countries><Country>Sweden</Country><Country>France</Country><Country>Italy</Country><Country>Germany</Country><Country>Russian Federation</Country><Country>US</Country></Countries><DateChangeLast>2018-11-16T00:00:00Z</DateChangeLast><DateEnd>2008-01-31T00:00:00Z</DateEnd><DateStart>2005-03-31T00:00:00Z</DateStart><Identifiers><Identifier>2004-000167-95</Identifier><Identifier>8606</Identifier><Identifier>F1J-MC-HMDI</Identifier><Identifier>NCT00105989</Identifier><Identifier>Protocol F1J-MC-HMDI</Identifier></Identifiers><IndicationsAdverse><Indication>Back pain</Indication><Indication>Common cold</Indication><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Hyperhidrosis</Indication><Indication>Influenza virus infection</Indication><Indication>Insomnia</Indication><Indication>Nausea</Indication><Indication>Vertigo</Indication><Indication>Xerostomia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>duloxetine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>514</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>those occurring in at least 5% of patients in any treatment group) were insomnia, headache, fatigue, dizziness, common &lt;b&gt;cold&lt;/b&gt;, flu and back pain. Incidence of any of these adverse events were similar between duloxetine and placebo-treated patients. The...common &lt;b&gt;cold&lt;/b&gt; and excessive sweating; and in maintenance phase were headache, back pain and common &lt;b&gt;cold&lt;/b&gt; [ 969989 ], [ 970048 ]. In the open-label treatment phase, the percentage of patients showing treatment-emergent adverse events (TEAE</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Depression - Anthropometric Assessments</EndpointIndex><EndpointIndex>Depression - Assessment of Clinical Symptoms - Assessment of sexual dysfunction</EndpointIndex><EndpointIndex>Depression - Assessment of Depression Severity by Specific Criteria - Assessment by Hamilton Depression Rating Scale (HDRS)</EndpointIndex><EndpointIndex>Depression - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Depression - Assessment of Functional Disability/Physical Function - Assessment of disability</EndpointIndex><EndpointIndex>Depression - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Depression - Assessment of Laboratory/Diagnostic Measures - Assessment of hematological parameters</EndpointIndex><EndpointIndex>Depression - Assessment of Metabolic Parameters</EndpointIndex><EndpointIndex>Depression - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Depression - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Depression - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Depression - Assessment of Therapy Related Outcomes - Assessment of drop-out rate/withdrawal rate</EndpointIndex><EndpointIndex>Depression - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Depression - Assessment of adverse events</EndpointIndex><EndpointIndex>Depression - Assessment of pain</EndpointIndex><EndpointIndex>Depression - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Depression - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Patient Global Impression Scale (PGI)</EndpointIndex><EndpointIndex>Female sexual dysfunction - Assessment of Pain</EndpointIndex><EndpointIndex>Female sexual dysfunction - Assessment of Safety and Tolerability - Anthropometry/vital signs</EndpointIndex><EndpointIndex>Female sexual dysfunction - Assessment of Sexual Function - Assessment by Arizona Sexual Experiences Scale (ASEX)</EndpointIndex><EndpointIndex>Female sexual dysfunction - Assessment of Underlying Condition - Assessment of neuropsychiatric conditions</EndpointIndex><EndpointIndex>Female sexual dysfunction - Assessment of adverse events</EndpointIndex><EndpointIndex>Female sexual dysfunction - Health Economic Assessments - Assessment of direct cost</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder</TitleDisplay><PatientSegmentTerms><PatientSegment>Depression - Subjects with Major Depressive Disorder</PatientSegment><PatientSegment>Depression - Subjects with Relapse/Recurrent Depression</PatientSegment><PatientSegment>Female sexual dysfunction - Subjects with History of Neuropsychiatric Disorders</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Albumin </BiomarkerName><BiomarkerName> Bicarbonates </BiomarkerName><BiomarkerName> Bilirubin </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Hematocrit </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> High-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Low-density lipoprotein cholesterol </BiomarkerName><BiomarkerName> Thyroglobulin </BiomarkerName><BiomarkerName> Total protein </BiomarkerName><BiomarkerName> Uric acid </BiomarkerName><BiomarkerName> gamma-Glutamyltransferase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-01-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>34 Months</TrialDuration><NumberOfSites>34</NumberOfSites></Trial><Trial Id="341947"><Indications><Indication>Prurigo nodularis</Indication><Indication>Pruritus</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>NK1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Menlo Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-06-20T00:00:00Z</DateChangeLast><DateEnd>2020-03-31T00:00:00Z</DateEnd><DateStart>2018-05-02T00:00:00Z</DateStart><Identifiers><Identifier>MTI-105</Identifier><Identifier>NCT03546816</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>serlopitant alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>280</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The purpose of this phase III , multicenter, randomized, double-blind, placebo‑controlled trial was to study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis [ 2080354 ], [ 1984617 ], [ 2018036 ], [ 2102863 ], [ 2110760 ], [ 2124070 ]. As of December 2017, Menlo Therapeutics Inc planned to initiate this study in the second quarter of 2018 [ 1984617 ]. By May 2018, enrollment  was began [ 2032373 ], [ 2073258 ]. By December</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pruritus - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pruritus - Patient Reported Outcomes/Quality of Life Assessments - Numeric rating scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis</TitleDisplay><PatientSegmentTerms><PatientSegment>Pruritus - Subjects with Prurigo Nodularis</PatientSegment><PatientSegment>Pruritus - Subjects with Pruritus of Unknown Origin</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2020-02-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>47</NumberOfSites><ContactNames><Name>Menlo Study Director</Name><Name>Principal Investigator</Name><Name>Principle Investigator</Name></ContactNames></Trial><Trial Id="341237"><Indications><Indication>Atopic dermatitis</Indication><Indication>Prurigo nodularis</Indication><Indication>Pruritus</Indication><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>NK1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Menlo Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Germany</Country><Country>Poland</Country><Country>Austria</Country></Countries><DateChangeLast>2019-06-20T00:00:00Z</DateChangeLast><DateEnd>2021-05-31T00:00:00Z</DateEnd><DateStart>2018-03-15T00:00:00Z</DateStart><Identifiers><Identifier>2017-004211-40</Identifier><Identifier>MTI-107</Identifier><Identifier>NCT03540160</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>serlopitant alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>700</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The objective of this 52-week, multicenter, open-label study was to study the long-term safety of serlopitant in adults with pruritus associated with prurigo nodularis, atopic dermatitis, or psoriasis. The secondary objectives of this study are to assess the change in severity of pruritus in subjects with PN, AD, or psoriasis using the worst-itch numeric rating scale (WI-NRS); to assess the change in severity and extent of PN using the Investigator's Global Assessment of PN Stage (IGA PN-S), for</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pruritus - Assessment of Clinical Symptoms - Assessment of duration and severity of pruritus</EndpointIndex><EndpointIndex>Pruritus - Assessment of Clinical Symptoms - Assessment of pruritus/itch/scratch score</EndpointIndex><EndpointIndex>Pruritus - Assessment of Laboratory/Diagnostic Measures - Imaging Techniques</EndpointIndex><EndpointIndex>Pruritus - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pruritus - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pruritus - Assessment of adverse events</EndpointIndex><EndpointIndex>Pruritus - Investigator's Global Assessment (IGA)</EndpointIndex><EndpointIndex>Pruritus - Patient Reported Outcomes/Quality of Life Assessments - Numeric rating scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Study of the Long-Term Safety of Serlopitant for the Treatment of Pruritus (Itch)</TitleDisplay><PatientSegmentTerms><PatientSegment>Pruritus - Subjects with Pruritus Associated with Dermatological Disorders - Subjects with dermatitis/eczema</PatientSegment><PatientSegment>Pruritus - Subjects with Pruritus Associated with Dermatological Disorders - Subjects with psoriasis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> PR interval </BiomarkerName><BiomarkerName> QRS complex </BiomarkerName><BiomarkerName> QT interval </BiomarkerName><BiomarkerName> Respiratory frequency</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2021-05-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>38 Months</TrialDuration><NumberOfSites>80</NumberOfSites><ContactNames><Name>Investigator Principal</Name><Name>Menlo Study Director</Name><Name>Principal Investigator</Name></ContactNames></Trial><Trial Id="340740"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>IL-17 antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Interleukin 17A ligand inhibitor</Action><Action>Interleukin 17F ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>UCB SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>UCB Biopharma SPRL</Company></CompaniesSponsor><Countries><Country>France</Country><Country>Spain</Country><Country>Netherlands</Country><Country>Belgium</Country><Country>Germany</Country><Country>Australia</Country><Country>Canada</Country><Country>US</Country><Country>Turkey</Country><Country>UK</Country><Country>Poland</Country></Countries><DateChangeLast>2019-06-20T00:00:00Z</DateChangeLast><DateEnd>2020-08-31T00:00:00Z</DateEnd><DateStart>2018-06-13T00:00:00Z</DateStart><Identifiers><Identifier>2017-003784-35</Identifier><Identifier>BE RADIANT</Identifier><Identifier>NCT03536884</Identifier><Identifier>PS0015</Identifier></Identifiers><InterventionsControlDisplay><Intervention>secukinumab alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>bimekizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>743</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Subject has an active infection (except common &lt;b&gt;cold&lt;/b&gt;), a serious infection, or a history of opportunistic, recurrent or chronic infections Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection Subject has known tuberculosis (TB) infection, is at</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Psoriasis - Assessment of adverse events</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-75 response</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-75 to 100 response</EndpointIndex><EndpointIndex>Psoriasis - Physician Global Assessment of Disease Activity - Assessment by Investigator/Physician Global Assessment (PGA) Scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BE RADIANT: A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with Moderate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment><PatientSegment>Psoriasis - Subjects with Severe Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with specific disease - Subjects with Chronic Plaque Psoriasis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2019-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>71</NumberOfSites><ContactNames><Name>Clin Trial Reg &amp; Results Disclosure</Name><Name>UCB Cares</Name></ContactNames></Trial><Trial Id="340541"><Indications><Indication>Upper respiratory tract infection</Indication></Indications><CompaniesSponsor><Company>Yungjin Pharmaceutical Co Ltd</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2018-05-28T00:00:00Z</DateChangeLast><DateEnd>2016-06-05T00:00:00Z</DateEnd><DateStart>2013-07-31T00:00:00Z</DateStart><Identifiers><Identifier>KCT0002888</Identifier><Identifier>YJ9-301</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Dexibuprofen alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Propacetamol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>322</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Children of indistinct gender aged from 6 months to 14 years fever due to &lt;b&gt;cold&lt;/b&gt; (acute upper respiratory infection) (&gt;/= 38 degC) The applicant or who has a written consent of his / her parent (legal representative)</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Respiratory tract infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>Multi-center, Randomized, Double blind, Controlled Parallel-group Comparative Phase 3 Clinical trial to assess the efficacy and safety of Propacetamol Compared to Dexibuprofen in patients with Acute upper respiratory tract infection</TitleDisplay><PatientSegmentTerms><PatientSegment>Respiratory tract infection - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>34 Months</TrialDuration><NumberOfSites>7</NumberOfSites><ContactNames><Name>Jeong DaeChul</Name></ContactNames></Trial><Trial Id="340053"><Indications><Indication>Paroxysmal nocturnal hemoglobinuria</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Complement C3 inhibitor</Action><Action>Complement cascade inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>PEGylated formulation</Technology><Technology>Peptide</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Apellis Pharmaceuticals Inc</Company><Company>Novotech Clinical Research (M) Sdn. Bhd</Company></CompaniesSponsor><Countries><Country>Malaysia</Country><Country>US</Country></Countries><DateChangeLast>2018-10-12T00:00:00Z</DateChangeLast><DateEnd>2020-12-20T00:00:00Z</DateEnd><DateStart>2018-08-27T00:00:00Z</DateStart><Identifiers><Identifier>43730</Identifier><Identifier>APL2-307</Identifier><Identifier>NCT03531255</Identifier><Identifier>NMRR-18-2297-43730</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>APL-2 (subcutaneous), Apellis alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>109</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This is an open-label, non-randomized, multicenter, extension study for ongoing and planned phase Ib, phase II, and phase III studies with APL-2 in subjects with paroxysmal nocturnal hemoglobinuria (PNH).</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anemia - Assessment of Co-morbidity - Assessment of hematologic diseases/disorders</EndpointIndex><EndpointIndex>Anemia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Anemia - Assessment of adverse events</EndpointIndex><EndpointIndex>Anemia - Hematological Assessments - Assessment of hemoglobin response</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of APL-2 in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)</TitleDisplay><PatientSegmentTerms><PatientSegment>Anemia - Subjects with Hemolytic Anemia - Subjects with paroxysmal nocturnal hemoglobinuria</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Complement C3 </BiomarkerName><BiomarkerName> Complement hemolytic activity </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Lactate dehydrogenase </BiomarkerName><BiomarkerName> Reticulocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-12-20T00:00:00Z</PrimaryCompletionDate><TrialDuration>27 Months</TrialDuration><NumberOfSites>5</NumberOfSites><ContactNames><Name>Allen Papazian</Name><Name>Christine Chia Pek Imm</Name><Name>Dr Jameela Sathar</Name></ContactNames></Trial><Trial Id="338403"><Indications><Indication>Neuropathic pain</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Benzodiazepine receptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Benzodiazepine receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anxiolytic</Action><Action>General anesthetic</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anxiolytic</Action><Action>General anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Injectable formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Assistance Publique Hopitaux de Paris</Company><Company>Hôpital Ambroise Paré</Company><Company>INSERM</Company><Company>Raymond Poincare University Hospital</Company><Company>Recherche clinique Paris Descartes Necker Cochin Sainte Annne</Company></CompaniesCollaborator><CompaniesSponsor><Company>Recherche et enseignement en douleur, anesthesie reanimation</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2018-11-30T00:00:00Z</DateEnd><DateStart>2018-02-16T00:00:00Z</DateStart><Identifiers><Identifier>2017-003930-10</Identifier><Identifier>KEKU1</Identifier><Identifier>KEKU1</Identifier><Identifier>NCT03513822</Identifier><Identifier>PROTOCOLE PH-03-2018</Identifier><Identifier>REDAR</Identifier></Identifiers><InterventionsControlDisplay><Intervention>midazolam hydrochloride alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>ketamine plus midazolam hydrochloride</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>48</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>Main objective of this interventional, randomized, placebo-controlled clinical trial is to show improved clinical efficacy of ketamine in chronic pain in patients with an inflammatory component. Secondary objective of the trial is to explore the anti-inflammatory activity of ketamine through the kynurenine pathway.</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropathic Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Pain - Assessment of Pain - Assessment by Neuropathic Pain Symptom Inventory (NPSI)</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of adverse events</EndpointIndex><EndpointIndex>Pain - Clinical Assessments</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Hospital Anxiety and Depression Scale (HADS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>KEKU1: Ketamine's Efficiency in the Treatment of Chronic Pain: Kynurenin Pathway</TitleDisplay><PatientSegmentTerms><PatientSegment>Other neurological disease - Subjects with specific disease - Subjects with spinal cord injury</PatientSegment><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment><PatientSegment>Pain - Subjects with Somatic Pain - Subjects with trauma related pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Indoleamine 2,3-dioxygenase </BiomarkerName><BiomarkerName> Interleukin 1 </BiomarkerName><BiomarkerName> Interleukin-1 beta </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> Kynurenic acid </BiomarkerName><BiomarkerName> Kynurenine/Tryptophan ratio </BiomarkerName><BiomarkerName> L-kynurenine </BiomarkerName><BiomarkerName> Quinolinic acid </BiomarkerName><BiomarkerName> Serotonin </BiomarkerName><BiomarkerName> Tumor necrosis factor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>9 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Cyril QUEMENEUR, Resident</Name><Name>Didier Bouhassira, Md, PhD</Name><Name>Valeria Martinez, MD, PhD</Name><Name>Valeria Martinez, Md, Ph d</Name></ContactNames></Trial><Trial Id="338342"><Indications><Indication>Insulin dependent diabetes</Indication></Indications><CompaniesSponsor><Company>Next Gen Pharma India Pvt Ltd</Company><Company>Postgraduate Institute of Medical Education and Research</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2018-05-09T00:00:00Z</DateChangeLast><DateStart>2018-05-03T00:00:00Z</DateStart><Identifiers><Identifier>CTRI/2018/05/013581</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Vivomixx alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The study will consist of two treatment arms: Arm 1: patients will receive two capsules of placebo containing microcrystalline cellulose, daily with &lt;b&gt;cold&lt;/b&gt; water. Arm 2: patients will receive two capsules of probiotic preparation (Vivomixx capsules) every day (for 6 months) with &lt;b&gt;cold&lt;/b&gt; water. Vivomixx capsules contains the 'original De Simone formulation' (a mix of eight strains of bacteria, namely, L plantarum DSM 24730, L paracasei DSM 24733, L delbrueckii subsp bulgaricus DSM 24734, L acidophilus </Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Blood Glucose Levels - Assessment of glucose variability</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of C-peptide Levels</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Diabetes Autoantibody Levels - Assessment of islet antibodies (ICA, IAA, GADA, IA-2A)</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of HbA1c Levels</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of interleukin-10 (IL-10)</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Insulin Dose</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Insulin dependent diabetes - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Effect of oral probiotic intake on immune mechanisms in children with newly diagnosed type 1 diabetes mellitus</TitleDisplay><PatientSegmentTerms><PatientSegment>Insulin dependent diabetes - Subjects with Newly Diagnosed Type I Diabetes Mellitus</PatientSegment><PatientSegment>Insulin dependent diabetes - Subjects with Specified Duration of Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Anti-insulin antibodies </BiomarkerName><BiomarkerName> C-peptide </BiomarkerName><BiomarkerName> Glucose </BiomarkerName><BiomarkerName> Glutamate decarboxylase 2 </BiomarkerName><BiomarkerName> Hemoglobin A, glycosylated </BiomarkerName><BiomarkerName> Interleukin-10 </BiomarkerName><BiomarkerName> Receptor-type tyrosine-protein phosphatase-like N </BiomarkerName><BiomarkerName> Regulatory T-Lymphocytes </BiomarkerName><BiomarkerName> T-Helper Lymphocytes </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr Rakesh Kumar</Name><Name>Lokesh M N</Name></ContactNames></Trial><Trial Id="33690"><Indications><Indication>Alcoholism</Indication></Indications><CompaniesSponsor><Company>Yale University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-12-11T00:00:00Z</DateChangeLast><DateEnd>2015-07-31T00:00:00Z</DateEnd><DateStart>2001-10-31T00:00:00Z</DateStart><Identifiers><Identifier>HIC # 11637</Identifier><Identifier>NCT00338962</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>desipramine alone</Intervention><Intervention>paroxetine alone</Intervention><Intervention>Variable regimens including desipramine , naltrexone , paroxetine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>88</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to evaluate the efficacy of naltrexone in combination with an SSRI to reduce alcohol consumption in alcoholic subjects with comorbid PTSD and depression. The researchers hypothesis was that the combination of naltrexone and SSRI would exhibit a greater decrease in alcohol consumption than that seen with treatment with SSRI alone, or with a combination of another class of anti-depressant and naltrexone. The researchers also hypothesized that SSRI would be effective in</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Factorial Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Alcoholism - Assessment of Alcohol Consumption - Number of drinks per week</EndpointIndex><EndpointIndex>Alcoholism - Assessment of Co-morbidity - Assessment of symptoms of anxiety disorders</EndpointIndex><EndpointIndex>Alcoholism - Assessment of Co-morbidity - Assessment of symptoms of mood disorders</EndpointIndex><EndpointIndex>Alcoholism - Assessment of Psychiatric Symptoms</EndpointIndex><EndpointIndex>Alcoholism - Assessment of adverse events</EndpointIndex><EndpointIndex>Alcoholism - Assessment of craving</EndpointIndex><EndpointIndex>Alcoholism - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Alcoholism - Patient Reported Outcomes/Quality of Life Assessments - Assessment of quality of life (unspecified)</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Co-morbidity - Assessment of depression</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Co-morbidity - Assessment of substance use</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Symptoms of Post Traumatic Stress Disorder</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of adverse events</EndpointIndex><EndpointIndex>Anxiety disorder - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Anxiety disorder - Patient Reported Outcomes/Quality of Life Assessments - Assessment of quality of life(unspecified)</EndpointIndex><EndpointIndex>Depression - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Depression - Assessment of Co-morbidity - Assessment of anxiety disorder</EndpointIndex><EndpointIndex>Depression - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Depression - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Depression - Assessment of Substance Use/Abuse</EndpointIndex><EndpointIndex>Depression - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Naltrexone And SSRI in Alcoholics With Depression/PTSD</TitleDisplay><PatientSegmentTerms><PatientSegment>Alcoholism - Subjects with Hazardous Levels of Alcohol Consumption - Heavy drinkers</PatientSegment><PatientSegment>Alcoholism - Subjects with comorbid conditions - Subjects with anxiety disorders</PatientSegment><PatientSegment>Alcoholism - Subjects with comorbid conditions - Subjects with mood disorders</PatientSegment><PatientSegment>Alcoholism - Subjects with comorbid conditions - Subjects with other substance abuse disorders</PatientSegment><PatientSegment>Anxiety disorder - Subjects with Post Traumatic Stress Disorder</PatientSegment><PatientSegment>Depression - Subjects with Associated Neuropsychiatric Conditions</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2015-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>165 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ismene Petrakis</Name></ContactNames></Trial><Trial Id="336618"><Indications><Indication>Paroxysmal nocturnal hemoglobinuria</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Complement C5 factor inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Complement C3 inhibitor</Action><Action>Complement C5 factor inhibitor</Action><Action>Complement cascade inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Immunomodulator</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Immunomodulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>PEGylated formulation</Technology><Technology>Peptide</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Apellis Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>Russian Federation</Country><Country>France</Country><Country>Japan</Country><Country>Australia</Country><Country>US</Country><Country>Spain</Country><Country>Germany</Country><Country>Canada</Country></Countries><DateChangeLast>2019-07-02T00:00:00Z</DateChangeLast><DateEnd>2020-10-31T00:00:00Z</DateEnd><DateStart>2018-06-14T00:00:00Z</DateStart><Identifiers><Identifier>2017-004268-36</Identifier><Identifier>APL2-302</Identifier><Identifier>NCT03500549</Identifier><Identifier>PEGASUS</Identifier><Identifier>US IND Number: 123087</Identifier></Identifiers><InterventionsControlDisplay><Intervention>eculizumab alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>APL-2 (subcutaneous), Apellis alone</Intervention><Intervention>APL-2 (subcutaneous), Apellis plus eculizumab</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The purpose of this study was to evaluate the efficacy and safety of APL-2 in patients with paroxysmal nocturnal hemoglobinuria (PNH) [ 2049193 ], [ 2115815 ], [ 2118552 ], [ 2149578 ]. The primary objectives of this study were to establish the efficacy and safety of APL-2 compared to eculizumab in patients with PNH who continue to have Hb levels &amp;lt; 10.5 g/dl despite treatment with eculizumab. In June 2018, first patient was enroled [ 2049193 ], [ 2058804 ]. In May 2019, dosing was resumed</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anemia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Anemia - Hematological Assessments - Assessment of hemoglobin status</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PEGASUS: Study to Evaluate the Efficacy and Safety of APL-2 in Patients with PNH</TitleDisplay><PatientSegmentTerms><PatientSegment>Anemia - Subjects with Hemolytic Anemia - Subjects with paroxysmal nocturnal hemoglobinuria</PatientSegment><PatientSegment>Anemia - Subjects with History of/Scheduled for Disease Specific Therapy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Hemoglobin </BiomarkerName><BiomarkerName> Lactate dehydrogenase </BiomarkerName><BiomarkerName> Reticulocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>28 Months</TrialDuration><NumberOfSites>37</NumberOfSites><ContactNames><Name>Allen Papazian</Name><Name>European Project Operations</Name></ContactNames></Trial><Trial Id="336574"><Indications><Indication>Common cold</Indication><Indication>Cough</Indication><Indication>Fatigue</Indication><Indication>Headache</Indication><Indication>Nose disease</Indication><Indication>Rhinitis</Indication><Indication>Rhinorrhea</Indication><Indication>Sneezing</Indication></Indications><CompaniesSponsor><Company>Boiron</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2018-04-20T00:00:00Z</DateChangeLast><Identifiers><Identifier>2013-002785-39</Identifier><Identifier>BRN-C-2013-04</Identifier><Identifier>CORY</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Coryzalia (new form) alone</Intervention><Intervention>Coryzalia (old composition) alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>510</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>temperature &amp;gt; 38degC at inclusion Patient suffering from an ENT disorder other than common &lt;b&gt;cold&lt;/b&gt; or nasopharyngitis (eg, allergic rhinitis, sinusitis, etc) Patient with severe...responding positively to the question 'Do you think you have a &lt;b&gt;cold&lt;/b&gt;?'(Or 'do you think your child has a &lt;b&gt;cold&lt;/b&gt;?' If the question is asked to the parent) Patient able to follow the...obstruction, rhinorrhea, sneezing) every day between D1 and D5. Evolution of &lt;b&gt;cold&lt;/b&gt; symptoms (nasal obstruction, rhinorrhea, sneezing, irritation around the nostrils, tearing</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Respiratory tract infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>CORY: Study to evaluate the effectiveness and tolerance of the new orodispersible dosage form and the old composition of Coryzalia on the decrease of cold symptoms in children. Coryzalia is compared to a placebo</TitleDisplay><PatientSegmentTerms><PatientSegment>Respiratory tract infection - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Clinical operations department</Name></ContactNames></Trial><Trial Id="33631"><Indications><Indication>Kidney transplant rejection</Indication><Indication>Renal disease</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>General anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Inhalant formulation</Technology><Technology>Liquid formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesCollaborator><Company>Ministry of Health, France</Company></CompaniesCollaborator><CompaniesSponsor><Company>University Hospital, Bordeaux</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2018-07-11T00:00:00Z</DateChangeLast><DateEnd>2010-06-30T00:00:00Z</DateEnd><DateStart>2006-06-30T00:00:00Z</DateStart><Identifiers><Identifier>2003-048</Identifier><Identifier>9413-04</Identifier><Identifier>NCT00337051</Identifier><Identifier>SEVOREIN</Identifier></Identifiers><InterventionsControlDisplay><Intervention>propofol alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>sevoflurane alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>following transplantation) A tota; of 120 patients scheduled to undergo a renal allograft transplantation with transplants defined by either a &lt;b&gt;cold&lt;/b&gt; ischemia duration of more than 20h or a donor’s age older than 50 years or a donor cardiac arrest would... Age&amp;gt; 18 years Scheduled to undergo renal allograft transplantation Transplant : &lt;b&gt;cold&lt;/b&gt; ischemia duration&amp;gt; 20 h or donor age &amp;gt; 50 years or donor cardiac arrest ASA 2 to 3 Social security affiliation Informed consent signed</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Biomarkers - Assessment of N-acetyl-ß-D-glucosaminidase(NAG)</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Biomarkers - Assessment of cystatin</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Fluid Balance - Assessment of urinary output</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Survival</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of Transplantation</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of adverse events</EndpointIndex><EndpointIndex>End stage renal disease - Assessment of dialysis</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function - Serum cystatin C levels</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of dialysis - Incidence of dialysis</EndpointIndex><EndpointIndex>Renal failure - Assessment of Biomarkers - Assessment of N-acetyl-ß-D-glucosaminidase(NAG)</EndpointIndex><EndpointIndex>Renal failure - Assessment of Fluid Balance</EndpointIndex><EndpointIndex>Renal failure - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Renal failure - Assessment of Immune Function</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Function - Assessment of creatinine level</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Function - Serum cystatin C levels</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Replacement Therapy(RRT) - Assessment of filtration/dialysis</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Replacement Therapy(RRT) - Assessment of transplant</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Replacement Therapy(RRT) - Complications of renal replacement therapy(RRT)</EndpointIndex><EndpointIndex>Renal failure - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Renal failure - Assessment of Survival - Assessment of patient survival</EndpointIndex><EndpointIndex>Renal failure - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SEVOREIN: Renal Transplantation and Inhaled Anesthetic Sevoflurane</TitleDisplay><PatientSegmentTerms><PatientSegment>End stage renal disease - Kidney Transplant Subjects</PatientSegment><PatientSegment>Kidney transplantation - Subjects Awaiting Renal Transplant</PatientSegment><PatientSegment>Renal failure - Subjects with History/Scheduled for Other Transplantations</PatientSegment><PatientSegment>Renal failure - Subjects with History/Scheduled for Renal Replacement Therapy - Subjects with history/scheduled for renal transplantation</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2010-02-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>48 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Francois SZTARK, Pr</Name><Name>Paul PEREZ, Dr</Name></ContactNames></Trial><Trial Id="33629"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Angiotensin I receptor antagonist</Action><Action>Angiotensin II receptor antagonist</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antihypertensive</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Controlled release formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><DateChangeLast>2017-04-01T00:00:00Z</DateChangeLast><DateEnd>2005-06-30T00:00:00Z</DateEnd><DateStart>2002-10-31T00:00:00Z</DateStart><Identifiers><Identifier>CERL080A2405IT02</Identifier><Identifier>MYTHOS</Identifier><Identifier>NCT00308425</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>enteric-coated mycophenolate sodium, Novartis plus valsartan</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>119</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>Multi-organ recipients (eg, kidney and pancreas, double kidney) or previous transplant with any other organ Recipient of a kidney from a non-heart beating, from a cadaver donor aged more than 70 years, or with &lt;b&gt;cold&lt;/b&gt; ischemia time of more than 36 h Recipient who is HLA-identical to the donor Patients with a PRA level (past or current level) higher than 50% Patients with a known hypersensitivity to EC-MPS or other components of the formulation (eg, lactose) Patients with thrombocytopenia (&amp;lt; 75,000</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Incidence/number of AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Blood Pressure (BP) - Diastolic blood pressure (DBP)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Blood Pressure (BP) - Systolic blood pressure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Creatinine Clearance</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR) - GFR measured by iohexol clearance</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR) - Measured GFR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function - Fractional albumin clearance</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function - Urinary albumin excretion/albuminuria</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Survival</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles - Assessment of Total Cholesterol</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles - HDL-C (High-density lipoprotein cholesterol)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of lipid profiles - Triglyceride levels (TG)</EndpointIndex><EndpointIndex>Kidney transplantation - Composite Endpoints</EndpointIndex><EndpointIndex>Kidney transplantation - Glycemic Control Analysis - Assessment of blood glucose</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>MYTHOS: Safety and Efficacy of Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Valsartan in Patients With Kidney Transplants</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2005-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>32 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Novartis</Name></ContactNames></Trial><Trial Id="335420"><Indications><Indication>Cough</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Antitussive</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Controlled release formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hyundai Pharmaceutical</Company></CompaniesSponsor><Countries><Country>South Korea</Country></Countries><DateChangeLast>2018-11-22T00:00:00Z</DateChangeLast><DateEnd>2018-10-31T00:00:00Z</DateEnd><DateStart>2017-01-31T00:00:00Z</DateStart><Identifiers><Identifier>HOB-048</Identifier><Identifier>NCT03489837</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Levotuss CR alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>272</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this randomized, double-blind, multicenter, active-controlled, phase III study was to to evaluate the efficacy and safety of Levotuss CR tablet in comparison with Levotuss syrup in patients with cough due to acute or chronic bronchitis.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other respiratory disease - Clinical Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Phase III Study to Evaluate the Efficacy and Safety of HOB-048 CR Tablet in Comparison With HOB-048 Syrup in Patients With Cough Due to Acute or Chronic Bronchitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Other respiratory disease - Others - Healthy Subjects</PatientSegment><PatientSegment>Other respiratory disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2018-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="33531"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Controlled release formulation</Technology><Technology>Enteric coated formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><DateChangeLast>2013-12-02T00:00:00Z</DateChangeLast><DateEnd>2005-07-31T00:00:00Z</DateEnd><DateStart>2002-03-31T00:00:00Z</DateStart><Identifiers><Identifier>CERL080A2405IT01</Identifier><Identifier>NCT00239031</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including basiliximab , cyclosporine microemulsion , enteric-coated mycophenolate sodium, Novartis</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>117</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Male or female patients 55 to 75 years old, recipients of a primary kidney transplant from a cadaver donor Subjects in whom CsA-ME plus basiliximab is selected as basic immunosuppressive regimen &lt;b&gt;Cold&lt;/b&gt; ischemia time&amp;lt; 20 h Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrollment and must use an effective contraception during the trial and for 6 weeks following discontinuation of the study medication</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Incidence/number of AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Untreated AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Clinical Response - Assessment of incidence/frequency of treatment failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Creatinine Clearance - Creatinine clearance using Cockcroft-Gault formula</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Delayed Graft Function (DGF)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Creatinine</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Reduced-Dose Cyclosporine Microemulsion (CsA-ME) Compared to EC-MPS Plus Standard Dose CsA-ME in Eldery De Novo Renal Transplant Recipients Treated With Basiliximab and Short-Term Steroids</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2005-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>40 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Novartis</Name></ContactNames></Trial><Trial Id="33525"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cannabinoid receptor antagonist</Action><Action>Inosine monophosphate dehydrogenase inhibitor</Action><Action>PurH purine biosynthesis protein inhibitor</Action><Action>Sphingosine-1-phosphate receptor-1 modulator</Action><Action>Sphingosine-1-phosphate receptor-3 modulator</Action><Action>Sphingosine-1-phosphate receptor-4 modulator</Action><Action>Sphingosine-1-phosphate receptor-5 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antiviral</Action><Action>Immunomodulator</Action><Action>Immunosuppressant</Action><Action>Neuroprotectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Daily dosing</Technology><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Prodrug</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateStart>2003-04-30T00:00:00Z</DateStart><Identifiers><Identifier>CFTY7200124</Identifier><Identifier>CFTY720A0124</Identifier><Identifier>NCT00239785</Identifier></Identifiers><IndicationsAdverse><Indication>Bacterial infection</Indication><Indication>Dyspnea</Indication><Indication>Urinary tract infection</Indication><Indication>Viral infection</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>corticosteroids alone</Intervention><Intervention>Variable regimens including Group I , Group II , Group III , cyclosporine , fingolimod , mycophenolate mofetil</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>684</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Recipients of multi-organ transplantation or foreseen to receive a non-renal allograft during the study period Graft &lt;b&gt;cold&lt;/b&gt; ischemia time &gt; 40 h Panel-reactive antibodies (PRA) &gt; 50% Recipients of non-heart-beating or A-B-O incompatible or T-cell crossmatched positive transplants History of symptomatic bradycardia (syncope, cardiac arrest) or other specific cardiac conditions</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Incidence/number of AGR episodes</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Chronic Graft Rejection (CGR) - Chronic humoral rejection</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Creatinine Clearance</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Forced Expiratory Flow (FEF)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Forced Vital Capacity (FVC)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pulmonary Function - Carbon monoxide diffusing capacity (DLCO)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pulmonary Function - FEV1/FVC ratio</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pulmonary Function - Forced expiratory volume in the first second (FEV1)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function - Serum cystatin C levels</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Macular edema</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Urinary Protein Excretion/Proteinuria</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Urine (Urinalysis) - Urinary cystatin C levels</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of dialysis - Proportion of patients requiring permanent resumption of dialysis</EndpointIndex><EndpointIndex>Kidney transplantation - Composite Endpoints</EndpointIndex><EndpointIndex>Kidney transplantation - Hematological Assessments - Lymphocytes count</EndpointIndex><EndpointIndex>Kidney transplantation - Infections/Opportunistic Infections - CMV infection</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of FTY-720 in De Novo Adult Renal Transplant Recipients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Antibody Incompatible Renal Transplant (AiT) Recipients</PatientSegment><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Subjects Awaiting Renal Transplant</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Carbon monoxide diffusing capacity </BiomarkerName><BiomarkerName> Creatinine </BiomarkerName><BiomarkerName> Cystatin C </BiomarkerName><BiomarkerName> FEV / FVC ratio </BiomarkerName><BiomarkerName> Forced Vital Capacity </BiomarkerName><BiomarkerName> Forced expiratory flow </BiomarkerName><BiomarkerName> Forced expiratory volume </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Urinary protein</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2005-04-30T00:00:00Z</PrimaryCompletionDate><NumberOfSites>0</NumberOfSites><ContactNames><Name>Novartis</Name></ContactNames></Trial><Trial Id="335211"><Indications><Indication>Anesthesia</Indication><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Cyclooxygenase 2 inhibitor</Action><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Analgesic</Action><Action>Local anesthetic</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Local anesthetic</Action><Action>Non-steroidal anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug coating</Technology><Technology>Intramuscular formulation</Technology><Technology>Intrathecal formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Prodrug</Technology><Technology>Rectal formulation</Technology><Technology>Rectal formulation local</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Universiti Sains Malaysia</Company></CompaniesSponsor><Countries><Country>Malaysia</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2017-09-19T00:00:00Z</DateEnd><DateStart>2016-06-20T00:00:00Z</DateStart><Identifiers><Identifier>NCT03480165</Identifier><Identifier>USM/JEPEM/16010033</Identifier></Identifiers><InterventionsControlDisplay><Intervention>ropivacaine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including Lignocaine , Ringer's lactate solution , parecoxib , ropivacaine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>86</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> blockade would be graded as follows: Grade 0 = normal sensory response Grade 1 = reduced sensory perception (partial sensory blockade) Grade 2 = no sensation (complete sensory blockade). Sensory loss would be confirmed by the loss to &lt;b&gt;cold&lt;/b&gt; sensation using 10 ml &lt;b&gt;cold&lt;/b&gt; saline bottle and pinprick sensation using 23G needle in all dermatomes of the brachial plexus (Grade 2). Time zero would be defined as the time at which LA was completely injected. Sensory block success would be defined as complete pin-prick</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Pain - Assessment of Other Measures of Pain Quality</EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia - Level/Depth of block</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pain - Clinical Assessments - Assessment of hematological function</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>The Efficacy of 20 mg Parecoxib as an Adjunct to 0.75% Ropivacaine in Supraclavicular Brachial Plexus Block for Upper Limb Surgery (RCT)</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Others - Healthy Subjects</PatientSegment><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Arterial oxygen saturation </BiomarkerName><BiomarkerName> Blood pressure </BiomarkerName><BiomarkerName> Heart rate</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-09-19T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Vivekananda Gunasekaran, MBBS</Name></ContactNames></Trial><Trial Id="334184"><Indications><Indication>Anemia</Indication></Indications><CompaniesSponsor><Company>National Institute of Siddha</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2018-04-03T00:00:00Z</DateChangeLast><DateStart>2018-05-01T00:00:00Z</DateStart><Identifiers><Identifier>CTRI/2018/03/012850</Identifier></Identifiers><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser> Hb level&amp;lt; 13 in men &amp;lt; 12 in women Fatigue Shortness of breath Pale skin Brittle nails &lt;b&gt;Cold&lt;/b&gt; hands and feets Poor apetite</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Case Control</Term></TermsDesign><EndpointIndex><EndpointIndex>Anemia - Anthropometric Assessments</EndpointIndex><EndpointIndex>Anemia - Assessment of Risk Factors</EndpointIndex><EndpointIndex>Anemia - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Wrist circumference in anemia (low hemoglobin level patients)</TitleDisplay><PatientSegmentTerms><PatientSegment>Anemia - Subjects with Other Forms of Anemia</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Wrist</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr A Mariya Lourthu Gracy</Name><Name>Dr C J Christian</Name></ContactNames></Trial><Trial Id="334143"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Opioid receptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Analgesic</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Antitussive</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Oral sustained release formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Stereochemistry</Technology><Technology>Sustained release formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Society of Family Planning</Company></CompaniesCollaborator><CompaniesSponsor><Company>University of Pittsburgh</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-05-10T00:00:00Z</DateChangeLast><DateEnd>2019-06-30T00:00:00Z</DateEnd><DateStart>2018-07-28T00:00:00Z</DateStart><Identifiers><Identifier>DexMab</Identifier><Identifier>NCT03480009</Identifier><Identifier>PRO17090292</Identifier><Identifier>STUDY19020221</Identifier></Identifiers><InterventionsControlDisplay><Intervention>oxycodone (sustained release), Purdue alone</Intervention><Intervention>standard narcotic based therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>dextromethorphan hydrobromide (sustained release) alone</Intervention><Intervention>dextromethorphan hydrobromide (sustained release) plus oxycodone (sustained release), Purdue</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>156</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>This study evaluates dextromethorphan ( Delsym ) as a non-opioid adjunctive medication for pain control during medication abortion. This is double-blinded, four-arm, randomized, controlled trial enrolling 156 women over a period of 9 to 12 months. Investigators seek to test the efficacy and safety of dextromethorphan as a non-narcotic analgesic for medication abortion.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Likert scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>DexMab: Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Others - Healthy Subjects</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2019-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>11 Months</TrialDuration><NumberOfSites>3</NumberOfSites><ContactNames><Name>Principal Investigator, MD MPH</Name><Name>Study Sponsor-Investigator, MD</Name></ContactNames></Trial><Trial Id="334142"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>IL-17 antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>IL-23 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture technique</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immuno-oncology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>AbbVie Deutschland GmbH &amp; Co KG</Company><Company>AbbVie Inc</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>Italy</Country><Country>US</Country><Country>France</Country><Country>Germany</Country><Country>Australia</Country><Country>UK</Country><Country>Poland</Country><Country>Spain</Country><Country>Netherlands</Country></Countries><DateChangeLast>2019-03-18T00:00:00Z</DateChangeLast><DateEnd>2019-11-29T00:00:00Z</DateEnd><DateStart>2018-05-01T00:00:00Z</DateStart><Identifiers><Identifier>2017-004932-12</Identifier><Identifier>M16-766</Identifier><Identifier>NCT03478787</Identifier></Identifiers><InterventionsControlDisplay><Intervention>secukinumab alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>risankizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>281</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> to local country guidelines. The patient will not be eligible for randomization if latent tuberculosis is present and is untreated as per local guidelines Active systemic infection during the last 2 weeks prior to baseline visit (exception: common &lt;b&gt;cold&lt;/b&gt;) prior to baseline visit, as assessed by the investigator History of any documented active or suspected malignancy or history of any malignancy within the last five years except for successfully treated non-melanoma skin cancer (NMSC) or localized </Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment of Clinical Response - Assessment of erythema</EndpointIndex><EndpointIndex>Psoriasis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Psoriasis - Changes in Characteristics of Skin/Lesion - Assessment of induration</EndpointIndex><EndpointIndex>Psoriasis - Changes in Characteristics of Skin/Lesion - Assessment of scaling</EndpointIndex><EndpointIndex>Psoriasis - Changes in Characteristics of Skin/Lesion - Body surface area (BSA%) involvement</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-75 response</EndpointIndex><EndpointIndex>Psoriasis - Physician Global Assessment of Disease Activity - Assessment by Investigator/Physician Global Assessment (PGA) Scale</EndpointIndex><EndpointIndex>Psoriatic arthritis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Psoriatic arthritis - Assessment of Skin Disease Activity - Psoriasis area and severity index (PASI)score</EndpointIndex><EndpointIndex>Psoriatic arthritis - Physician Global Assessment of Disease Activity - Physician's global assessment (PGA) of psoriasis</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for systemic therapy</PatientSegment><PatientSegment>Psoriasis - Subjects with Moderate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Psoriatic Arthritis</PatientSegment><PatientSegment>Psoriasis - Subjects with Severe Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with specific disease - Subjects with Chronic Plaque Psoriasis</PatientSegment><PatientSegment>Psoriatic arthritis - Subjects with Diagnosis of Psoriasis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body surface area</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-11-29T00:00:00Z</PrimaryCompletionDate><TrialDuration>18 Months</TrialDuration><NumberOfSites>77</NumberOfSites><ContactNames><Name>AbbVie Inc</Name><Name>EU Clinical Trials Helpdesk</Name></ContactNames></Trial><Trial Id="333925"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Countries><Country>India</Country></Countries><DateChangeLast>2018-03-29T00:00:00Z</DateChangeLast><DateStart>2018-03-31T00:00:00Z</DateStart><Identifiers><Identifier>CTRI/2018/03/012712</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>bupivacaine, AstraZeneca alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The aim is to see the effect of erector spinae plane block for postoperative analgesia in reducing morphine requirement after breast surgery. Patient would be monitored postoperatively every 4 h on NRS Scale.</Teaser><TrialCategories><Category>Medical procedure</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Post-operative Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Procedural Analgesia/Anesthesia</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Numerical Analog Scale (NRS/NAS)</EndpointIndex><EndpointIndex>Pain - Physician Global Assessment of Disease Activity</EndpointIndex><EndpointIndex>Pain - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Use of nerve block for after surgery pain relief in breast surgery</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Post-Operative Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Gunjan Kumar</Name><Name>swati</Name></ContactNames></Trial><Trial Id="333334"><Indications><Indication>Candida infection</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Ergosterol synthesis inhibitor</Action><Action>Fungicide</Action><Action>Systemic dermatological antifungal product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Assiut University</Company></CompaniesSponsor><Countries><Country>Egypt</Country></Countries><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2019-04-01T00:00:00Z</DateEnd><DateStart>2018-04-01T00:00:00Z</DateStart><Identifiers><Identifier>KTVC</Identifier><Identifier>NCT03473418</Identifier></Identifiers><InterventionsControlDisplay><Intervention>terconazole alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>ketoconazole alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>69</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>will be used in the preparation of the in situ forming gels. Medicated in situ forming gels will be prepared on a weight basis using the modified &lt;b&gt;cold&lt;/b&gt; method. Vaginal preparations will be prepared in citro-phosphate buffer pH (power of hydrogen) 4.5. Characterization of ketoconazole vaginal in situ gel: Gelation temperature (Tgel) measurement 10 mm of &lt;b&gt;cold&lt;/b&gt; pluronic solution and a magnetic bar will be put into a beaker (25 ml) that will be placed in a low temperature water bath at room temperature. </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Candida infection - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Candida infection - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Candida infection - Assessment of Microbiological Response</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis</TitleDisplay><PatientSegmentTerms><PatientSegment>Candida infection - Others - Healthy Subjects</PatientSegment><PatientSegment>Candida infection - Subjects with Vulvovaginal Candidiasis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2018-10-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>12 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Mariana Noss Abdo</Name></ContactNames></Trial><Trial Id="33127"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Calcineurin inhibitor</Action><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action><Action>T-lymphocyte inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Macrolide</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><DateChangeLast>2014-12-03T00:00:00Z</DateChangeLast><DateEnd>2005-11-01T00:00:00Z</DateEnd><DateStart>2003-11-30T00:00:00Z</DateStart><Identifiers><Identifier>CRAD001AUS09</Identifier><Identifier>NCT00170833</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including basiliximab , everolimus , tacrolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Male or female patients between 18 and 65 years of age Male or female patients who are primary cadaveric, living unrelated or non-HLA identical living related donor renal transplant recipients The renal &lt;b&gt;cold&lt;/b&gt; ischemic time (CIT) must be&amp;lt; 30 h The age of the donor must be between 10 and 59 years and not meet UNOS expanded donor criteria</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Creatinine Clearance</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR) - Calculated GFR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR) - GFR calculated using Nankivell formula</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure - Incidence/proportion of patients with graft loss</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Renal Function</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability - Incidence of adverse events/Side Effects</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Creatinine</EndpointIndex><EndpointIndex>Kidney transplantation - Composite Endpoints</EndpointIndex><EndpointIndex>Kidney transplantation - Metabolic Disorders/Complications - New onset/post transplant diabetes mellitus</EndpointIndex><EndpointIndex>Renal failure - Assessment of Glomerular Filtration Rate (GFR) - Assessment of estimated glomerular filtration rate(eGFR)/creatinine clearance(CCr/CrCl/CLcr)</EndpointIndex><EndpointIndex>Renal failure - Assessment of Graft Survival</EndpointIndex><EndpointIndex>Renal failure - Assessment of Immune Function</EndpointIndex><EndpointIndex>Renal failure - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Renal failure - Assessment of Organ Function - Metabolic/endocrinal assessment</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Function - Assessment of creatinine level</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Replacement Therapy(RRT) - Assessment of transplant</EndpointIndex><EndpointIndex>Renal failure - Assessment of Renal Replacement Therapy(RRT) - Complications of renal replacement therapy(RRT)</EndpointIndex><EndpointIndex>Renal failure - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in De Novo Renal Transplant Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living related donor (LRD) - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living unrelated donor - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment><PatientSegment>Renal failure - Subjects with History/Scheduled for Renal Replacement Therapy - Subjects with history/scheduled for renal transplantation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2005-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Novartis</Name></ContactNames></Trial><Trial Id="33120"><Indications><Indication>Kidney transplant rejection</Indication></Indications><ActionsPrimaryInterventionsControl><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>IL-2 receptor alpha subunit inhibitor</Action><Action>mTOR complex 1 inhibitor</Action><Action>mTOR inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Anticonvulsant agent</Action><Action>Antiviral</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2019-06-06T00:00:00Z</DateChangeLast><DateEnd>2008-07-31T00:00:00Z</DateEnd><DateStart>2005-07-31T00:00:00Z</DateStart><Identifiers><Identifier>2005-000380-26</Identifier><Identifier>CERTES02</Identifier><Identifier>CRAD001A2419</Identifier><Identifier>CRAD001A2423</Identifier><Identifier>NCT00154284</Identifier><Identifier>NCT00170807</Identifier></Identifiers><InterventionsControlDisplay><Intervention>basiliximab plus everolimus</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including basiliximab , cyclosporine , everolimus</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>114</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Recipients of a first renal transplant from a primary cadaveric or non-HLA identical living related donor Renal &lt;b&gt;cold&lt;/b&gt; ischemic time&amp;lt; 36 h Age of donor&amp;lt; 65 years</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Biopsy-proven AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Acute Graft Rejection (AGR) - Clinically-confirmed AGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Chronic Allograft Nephropathy (CAN) - Biopsy-proven CAN/CAN determined by biopsy</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Chronic Graft Rejection (CGR) - Clinically-confirmed CGR</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Creatinine Clearance</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Glomerular Filtration Rate (GFR)</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Graft Loss/Graft Failure</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Kidney transplantation - Assessment of Serum Creatinine</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>CERTES02: Everolimus in a Cyclosporine Microemulsion-Free Regimen Compared to a Low-Dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Kidney transplantation - Deceased/Cadaveric Donor - Renal Transplant Recipients</PatientSegment><PatientSegment>Kidney transplantation - Living Donor - Renal Transplant Recipients - Living related donor (LRD) - renal transplant recipients</PatientSegment><PatientSegment>Kidney transplantation - Renal Transplant Recipients - Primary (first) renal transplant recipients</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Creatinine </BiomarkerName><BiomarkerName> Estimated glomerular filtration rate </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Urea </BiomarkerName><BiomarkerName> Urea nitrogen</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Novartis</Name></ContactNames></Trial><Trial Id="331058"><Indications><Indication>Cough</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>P2X3 purinoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anti-inflammatory</Action><Action>Antitussive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><Countries><Country>Canada</Country><Country>South Korea</Country><Country>Peru</Country><Country>Israel</Country><Country>Czech Republic</Country><Country>Japan</Country><Country>UK</Country><Country>France</Country><Country>Poland</Country><Country>US</Country><Country>Ukraine</Country><Country>Taiwan</Country><Country>Turkey</Country><Country>Argentina</Country><Country>Denmark</Country><Country>Hungary</Country><Country>Spain</Country></Countries><DateChangeLast>2019-05-30T00:00:00Z</DateChangeLast><DateEnd>2020-07-10T00:00:00Z</DateEnd><DateStart>2018-03-14T00:00:00Z</DateStart><Identifiers><Identifier>123007</Identifier><Identifier>184098</Identifier><Identifier>2017-000537-31</Identifier><Identifier>7264-027</Identifier><Identifier>JapicCTI-184098</Identifier><Identifier>MK-7264-027</Identifier><Identifier>MK-7264-027-02</Identifier><Identifier>NCT03449134</Identifier><Identifier>PN027</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>gefapixant alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>720</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The primary objective of this study is to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24 h period at week 12. Main objectives of the trial is to evaluate the safety and tolerability of MK-7264. Secondary objectives of the trial are: To evaluate the efficacy of MK-7264 in reducing cough frequency as measured while awake during a 24 h period. To evaluate the efficacy of MK-7264 based on the proportion of participants with a clinically significant</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other respiratory disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Phase III Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough</TitleDisplay><PatientSegmentTerms><PatientSegment>Other respiratory disease - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Other respiratory disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2020-07-10T00:00:00Z</PrimaryCompletionDate><TrialDuration>27 Months</TrialDuration><NumberOfSites>158</NumberOfSites><ContactNames><Name>Anyang si</Name><Name>Investigación Clínica</Name><Name>MSD Corporation</Name><Name>Medical Director</Name><Name>Petah-Tikva</Name><Name>Study Coordinator</Name></ContactNames></Trial><Trial Id="330845"><Indications><Indication>Cough</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>P2X3 purinoceptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Anti-inflammatory</Action><Action>Antitussive</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Merck Sharp &amp; Dohme Corp</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Ukraine</Country><Country>Hungary</Country><Country>Ireland</Country><Country>Israel</Country><Country>Guatemala</Country><Country>China</Country><Country>Malaysia</Country><Country>Italy</Country><Country>Turkey</Country><Country>Germany</Country><Country>Poland</Country><Country>Canada</Country><Country>Australia</Country><Country>UK</Country><Country>Czech Republic</Country><Country>Peru</Country><Country>Colombia</Country><Country>Denmark</Country><Country>New Zealand</Country><Country>South Africa</Country></Countries><DateChangeLast>2019-06-28T00:00:00Z</DateChangeLast><DateEnd>2021-01-08T00:00:00Z</DateEnd><DateStart>2018-03-15T00:00:00Z</DateStart><Identifiers><Identifier>123007</Identifier><Identifier>2017-003559-49</Identifier><Identifier>39380</Identifier><Identifier>7264-030</Identifier><Identifier>MK-7264-030</Identifier><Identifier>MK-7264-030-02</Identifier><Identifier>NCT03449147</Identifier><Identifier>NMRR-17-2854-39380</Identifier><Identifier>PN030</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>gefapixant alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1290</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The primary objective of this study is to evaluate the efficacy and safety of gefapixant (MK-7264) in reducing cough frequency as measured over a 24 h period. It is hypothesized that at least one dose of gefapixant is superior to placebo in reducing coughs per hour (over 24 h) at week 24. The secondary objectives of this trial are: To evaluate the efficacy of MK-7264 in reducing cough frequency as measured while awake during a 24 h period. To evaluate the ability of MK-7264 to provide a clinically</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other respiratory disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough</TitleDisplay><PatientSegmentTerms><PatientSegment>Other respiratory disease - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Other respiratory disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2021-01-08T00:00:00Z</PrimaryCompletionDate><TrialDuration>33 Months</TrialDuration><NumberOfSites>186</NumberOfSites><ContactNames><Name>DR Irfhan Ali Bin Hyder Ali</Name><Name>Dr Razul Md Nazri bin Md Kassim</Name><Name>Dr Umadevi A. Muthukumaru</Name><Name>Dr. Nurhayati Mohd Marzuki</Name><Name>Global Clinical Trial Operation</Name><Name>Medical Director</Name><Name>Ms Hong Lih Chun</Name><Name>Study Coordinator</Name><Name>Toll Free Number</Name></ContactNames></Trial><Trial Id="329863"><Indications><Indication>Nasal congestion</Indication><Indication>Upper respiratory tract infection</Indication></Indications><CompaniesCollaborator><Company>Johnson &amp; Johnson</Company></CompaniesCollaborator><CompaniesSponsor><Company>McNeil AB</Company></CompaniesSponsor><Countries><Country>Russian Federation</Country></Countries><DateChangeLast>2018-10-19T00:00:00Z</DateChangeLast><DateEnd>2018-05-02T00:00:00Z</DateEnd><DateStart>2018-02-26T00:00:00Z</DateStart><Identifiers><Identifier>CO-170117145845-URCT</Identifier><Identifier>NCT03439436</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Nasic alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>xylometazoline + dexpanthenol alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>140</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>rhinitis sicca, hyperthyroidism, porphyria, prostatic hyperplasia, glaucoma, previous surgical intervention on the meninges Are currently taking monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants Use of any analgesic, antipyretic or "&lt;b&gt;cold&lt;/b&gt; and flu" medication including non-prescription medication and/or herbal products within previous 8 hours, for naproxen containing products within previous 12 h Use of any nasal or oral decongestant including non-prescription medication and/or herbal</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Respiratory tract infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study to Compare Two Formulations of Xylometazoline/Dexpanthenol Nasal Spray for the Treatment of Nasal Congestion</TitleDisplay><PatientSegmentTerms><PatientSegment>Respiratory tract infection - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2018-05-02T00:00:00Z</PrimaryCompletionDate><TrialDuration>2 Months</TrialDuration><NumberOfSites>14</NumberOfSites><ContactNames><Name>Alison Hughes</Name><Name>Dmitry Lioznov, MD</Name><Name>Konstantin A Zakharov, MD</Name><Name>Tatiana E Morozova, MD</Name><Name>Vladimir Popov, MD</Name><Name>Zhanna M Sizova, MD</Name></ContactNames></Trial><Trial Id="329823"><Indications><Indication>Chronic obstructive pulmonary disease</Indication></Indications><CompaniesSponsor><Company>Henan University of Chinese Medicine</Company></CompaniesSponsor><DateChangeLast>2018-10-14T00:00:00Z</DateChangeLast><DateEnd>2019-12-31T00:00:00Z</DateEnd><DateStart>2018-03-01T00:00:00Z</DateStart><Identifiers><Identifier>NCT03428412</Identifier><Identifier>TCM FOR AECOPD</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Variable regimens including Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.) , Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.) , Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.)</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.) , Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.) , Traditional Chinese medicine , Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.)</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>378</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>Pharmaceutical Co., Ltd.), 10 g/packet, bid, for syndrome of external &lt;b&gt;cold&lt;/b&gt; and internal fluid in 14 treatment days. Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical...Pharmaceutical Co., Ltd.), 10g/packet, bid, for syndrome of external &lt;b&gt;cold&lt;/b&gt; and internal fluid in 14 treatment days. Placebo Qingrehuatan granule (Jiangyin Tian Jiang...40 and 80 years Syndrome differentiation meets criteria of syndrome of external &lt;b&gt;cold&lt;/b&gt; and internal fluid,syndrome of phlegm-heat congesting lung,or syndrome of phlegm-damp</Teaser><TrialCategories><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Dyspnea</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Mortality/Morbidity</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Therapy Related Outcomes - Assessment of treatment failure</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Therapy Related Outcomes - Cure rates/success rates</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of Ventilation/Perfusion</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of hospitalization - Assessment of duration of hospitalization</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Assessment of hospitalization - Readmission/time to readmission</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by SF-36/SF-12</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - COPD Assessment Test(CAT)Score</EndpointIndex><EndpointIndex>Chronic obstructive pulmonary disease - Patient Reported Outcomes/Quality of Life Assessments - Modified medical research council dyspnoea scale (MMRC)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Effects of Traditional Chinese Medicine on AECOPD Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 1/Mild COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 3/Severe COPD</PatientSegment><PatientSegment>Chronic obstructive pulmonary disease - Subjects with GOLD Stage 4/Very Severe COPD</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2019-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>Hailong Zhang, doctor</Name><Name>Jiansheng Li, doctor</Name></ContactNames></Trial><Trial Id="329214"><Indications><Indication>Pain</Indication><Indication>Throat disease</Indication></Indications><CompaniesCollaborator><Company>Janssen Pharmaceutica NV</Company></CompaniesCollaborator><CompaniesSponsor><Company>Johnson &amp; Johnson</Company></CompaniesSponsor><Countries><Country>Russian Federation</Country></Countries><DateChangeLast>2018-10-19T00:00:00Z</DateChangeLast><DateEnd>2018-04-21T00:00:00Z</DateEnd><DateStart>2018-02-02T00:00:00Z</DateStart><Identifiers><Identifier>129649CGH3001</Identifier><Identifier>CO-161004120104-URCT</Identifier><Identifier>NCT03432923</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>benzocaine lozenge alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>260</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>NSAIDs within 10 days) or antibiotics within 14 days up to first dose Use on any confectionery lozenge/tablet/gum or any products with demulcent properties within previous 2 h prior to first dose Use of any analgesic, oral anesthetics, antipyretic or "&lt;b&gt;cold&lt;/b&gt;" medication within previous 8 h, for naproxen containing products within previous 12 h prior to first dose Use of any antiseptics and/or oral rinses (eg, hexetidine, listerine, myramistin) within previous 2 h prior to first dose Participate in any </Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Respiratory tract infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study to Determine the Efficacy and Safety of a Benzocaine Lozenge for Treatment of Sore Throat</TitleDisplay><PatientSegmentTerms><PatientSegment>Other otorhinolaryngological disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2018-04-21T00:00:00Z</PrimaryCompletionDate><TrialDuration>2 Months</TrialDuration><NumberOfSites>20</NumberOfSites><ContactNames><Name>Steven Sacavage</Name></ContactNames></Trial><Trial Id="327737"><Indications><Indication>Cystic fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Biosimilar product</Technology><Technology>Inhalant formulation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>JHL Biotech Inc</Company></CompaniesSponsor><Countries><Country>Europe</Country></Countries><DateChangeLast>2019-01-02T00:00:00Z</DateChangeLast><InterventionsPrimaryDisplay><Intervention>dornase alfa biosimilar, JHL Biotech alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Planned</RecruitmentStatus><Teaser>The aim is to asess JHL-1922 for treatment of cystic fibrosis [ 2001770 ], [ 2106969 ]. In February 2018, the JHL Biotech (TW) planned to initiate in in 2018 [ 2001770 ]. In December 2018, JHL Biotech Inc expected this trial in Europe in 2019 [ 2106969 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A phase III trial of JHL-1922 for treatment of cystic fibrosis</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="327177"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Interleukin 17A ligand inhibitor</Action><Action>Interleukin 17F ligand inhibitor</Action><Action>TNF alpha ligand inhibitor</Action><Action>TNF binding agent</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Interleukin 17A ligand inhibitor</Action><Action>Interleukin 17F ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Analgesic</Action><Action>Anti-inflammatory</Action><Action>Cardioprotectant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>DNA technology</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>UCB SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>UCB Biopharma SPRL</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Russian Federation</Country><Country>Taiwan</Country><Country>Poland</Country><Country>Hungary</Country><Country>Germany</Country><Country>Czech Republic</Country><Country>Canada</Country><Country>South Korea</Country><Country>Australia</Country></Countries><DateChangeLast>2019-05-11T00:00:00Z</DateChangeLast><DateEnd>2020-03-31T00:00:00Z</DateEnd><DateStart>2018-01-26T00:00:00Z</DateStart><Identifiers><Identifier>2016-003392-22</Identifier><Identifier>BE SURE</Identifier><Identifier>NCT03412747</Identifier><Identifier>PS0008</Identifier></Identifiers><InterventionsControlDisplay><Intervention>adalimumab plus bimekizumab</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>bimekizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>480</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Subject has a known hypersensitivity to any excipients of bimekizumab or adalimumab Subject has an active infection (except common &lt;b&gt;cold&lt;/b&gt;), a serious infection, or a history of opportunistic or recurrent chronic infections Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection Subject has known tuberculosis (TB) infection, is at</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Psoriasis - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Psoriasis - Assessment of adverse events</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - Change in psoriasis area and severity index score (PASI)</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-75 response</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-75 to 100 response</EndpointIndex><EndpointIndex>Psoriasis - Physician Global Assessment of Disease Activity - Assessment by Investigator/Physician Global Assessment (PGA) Scale</EndpointIndex><EndpointIndex>Psoriasis - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BE SURE: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with Moderate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment><PatientSegment>Psoriasis - Subjects with Severe Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with specific disease - Subjects with Chronic Plaque Psoriasis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2019-02-07T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>71</NumberOfSites><ContactNames><Name>UCB Cares</Name></ContactNames></Trial><Trial Id="327039"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Interleukin 17A ligand inhibitor</Action><Action>Interleukin 17F ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>UCB SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>UCB Biopharma SPRL</Company></CompaniesSponsor><Countries><Country>UK</Country><Country>Hungary</Country><Country>Belgium</Country><Country>Canada</Country><Country>US</Country><Country>Germany</Country><Country>Australia</Country><Country>Poland</Country><Country>South Korea</Country><Country>Russian Federation</Country></Countries><DateChangeLast>2019-06-25T00:00:00Z</DateChangeLast><DateEnd>2020-01-31T00:00:00Z</DateEnd><DateStart>2018-02-05T00:00:00Z</DateStart><Identifiers><Identifier>2016-003426-16</Identifier><Identifier>BE READY</Identifier><Identifier>NCT03410992</Identifier><Identifier>PS0013</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>bimekizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>435</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Subject has an active infection (except common &lt;b&gt;cold&lt;/b&gt;), a recent serious infection, or a history of opportunistic, recurrent, or chronic infections Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection Subject has known tuberculosis (TB) infection</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment of Clinical Response</EndpointIndex><EndpointIndex>Psoriasis - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Psoriasis - Assessment of Safety and Tolerability - Interruption or discontinuation or withdrawal of study drug</EndpointIndex><EndpointIndex>Psoriasis - Assessment of adverse events</EndpointIndex><EndpointIndex>Psoriasis - Changes in Characteristics of Skin/Lesion - Assessment of scaling</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-75 response</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-75 to 100 response</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Psoriasis - Physician Global Assessment of Disease Activity - Assessment by Investigator/Physician Global Assessment (PGA) Scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BE READY: A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with Moderate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment><PatientSegment>Psoriasis - Subjects with Severe Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with specific disease - Subjects with Chronic Plaque Psoriasis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2018-12-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>72</NumberOfSites><ContactNames><Name>UCB Cares</Name></ContactNames></Trial><Trial Id="326312"><Indications><Indication>Throat disease</Indication></Indications><CompaniesSponsor><Company>Reckitt Benckiser Healthcare (UK) Ltd</Company></CompaniesSponsor><Countries><Country>UK</Country></Countries><DateChangeLast>2018-02-03T00:00:00Z</DateChangeLast><DateEnd>2011-02-25T00:00:00Z</DateEnd><DateStart>2010-09-10T00:00:00Z</DateStart><Identifiers><Identifier>2010-020985-94</Identifier><Identifier>TH1010</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Strepsils alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>200</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> pastille, spray, or any product with demulcent properties such as boiled sweets in the previous 2 h Those who have used any sore throat medication containing a local anaesthetic within the past 4 h Those who have used any analgesic, antipyretic or &lt;b&gt;cold&lt;/b&gt; medication (eg, decongestant, antihistamine, antitussive or throat lozenge) within the previous 8 h Those who have used a longer acting or slow release analgesic during the previous 24 h eg, piroxicam and naproxen Those taking antibiotics during the</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Area under concentration curve (AUC)</EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A randomized, double-blind, placebo-controlled, parallel-group, single-dose study of the efficacy of a flavoured variant of Strepsils Throat Lozenge in the relief of dry and irritated sore throat due to upper respiratory tract infection or environmental factors</TitleDisplay><PatientSegmentTerms><PatientSegment>Other otorhinolaryngological disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>5 Months</TrialDuration><NumberOfSites>1</NumberOfSites></Trial><Trial Id="32574"><Indications><Indication>Anxiety disorder</Indication><Indication>Generalized anxiety disorder</Indication><Indication>Social phobia</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>5-HT uptake inhibitor</Action><Action>Antidepressant</Action><Action>Anxiolytic</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>The National Institute of Mental Health</Company></CompaniesCollaborator><CompaniesSponsor><Company>Johns Hopkins University</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-08-07T00:00:00Z</DateChangeLast><DateEnd>2008-03-31T00:00:00Z</DateEnd><DateStart>2003-01-31T00:00:00Z</DateStart><Identifiers><Identifier>CAMS</Identifier><Identifier>DSIR 84-CTP</Identifier><Identifier>NCT00052078</Identifier><Identifier>U01 MH64089</Identifier></Identifiers><IndicationsAdverse><Indication>Fatigue</Indication><Indication>Insomnia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Cognitive behaviorl therapy alone</Intervention><Intervention>sertraline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>488</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>the sertraline group than in the placebo group. There was less insomnia, fatigue, sedation, and restlessness associated with cognitive behavioral therapy than with sertraline [ 1518226 ]. Common somatic complaints were headaches, stomachaches, head &lt;b&gt;cold&lt;/b&gt; or sniffles, sleeplessness, and feeling drowsy or too sleepy [ 1518325 ].</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Factorial Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Anxiety by Protocol Specified Scales</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of adverse events</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of the Symptoms of Anxiety Disorder</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>CAMS: Child and Adolescent Anxiety Disorders</TitleDisplay><PatientSegmentTerms><PatientSegment>Anxiety disorder - Subjects with Generalized Anxiety Disorder</PatientSegment><PatientSegment>Anxiety disorder - Subjects with Social Phobia</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate>2007-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>62 Months</TrialDuration><NumberOfSites>6</NumberOfSites></Trial><Trial Id="325564"><Indications><Indication>Ovary tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD95 modulator</Action><Action>TNF receptor modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer</Action><Action>Cell cycle inhibitor</Action><Action>Microtubule stabilizer</Action><Action>Vasoprotectant</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Adenovirus based gene therapy</Action><Action>Angiogenesis inhibitor</Action><Action>Anticancer</Action><Action>Apoptosis stimulator</Action><Action>Cell cycle inhibitor</Action><Action>Microtubule stabilizer</Action><Action>Vascular damaging agent</Action><Action>Vasoprotectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Natural product</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Virus recombinant</Technology></Technologies><CompaniesCollaborator><Company>Gynecologic Oncology Group</Company></CompaniesCollaborator><CompaniesSponsor><Company>VBL Therapeutics</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Israel</Country></Countries><DateChangeLast>2019-06-06T00:00:00Z</DateChangeLast><DateEnd>2023-06-30T00:00:00Z</DateEnd><DateStart>2017-12-19T00:00:00Z</DateStart><Identifiers><Identifier>NCT03398655</Identifier><Identifier>OVAL</Identifier><Identifier>VB-111-701/GOG-3018</Identifier></Identifiers><InterventionsControlDisplay><Intervention>chemotherapy alone</Intervention><Intervention>paclitaxel alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>chemotherapy alone</Intervention><Intervention>ofranergene obadenovec plus paclitaxel</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>400</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>with complete CA-125 GCIG response and radiological response [ 2131852 ]. In March 2019, results were presented, which demonstrated that recruitment of infiltrating T-cells into the tumor, turning it from '&lt;b&gt;cold&lt;/b&gt;' to 'hot'. This important finding suggests that VB-111 may be applied to other '&lt;b&gt;cold&lt;/b&gt;' tumors, in which checkpoint inhibitors show limited or no efficacy [ 2135904 ].</Teaser><TrialCategories><Category>Biological</Category><Category>Gene therapy</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of CA-125 level</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Mortality/Death Rates - Assessment of all cause mortality</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR) - Assessment of CA-125/serological response</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR) - Assessment of overall/objective response rate(ORR)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Ovary tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>OVAL: A Study of VB-111 Combined With Paclitaxel Versus Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Ovary tumor - Platinum-Resistant/Refractory Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Epithelial Tumor</PatientSegment><PatientSegment>Ovary tumor - Subjects with Recurrent or Persistent Ovarian Cancer</PatientSegment><PatientSegment>Ovary tumor - Subjects with gene variants - BRCA1_HUMAN_Mutation</PatientSegment><PatientSegment>Ovary tumor - Subjects with gene variants - BRCA2_HUMAN_Mutation</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Breast cancer type 1 susceptibility protein </BiomarkerName><BiomarkerName> CA-125 antigen </BiomarkerName><BiomarkerName> Cytotoxic T-Lymphocytes </BiomarkerName><BiomarkerName> Macrophages </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2022-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>66 Months</TrialDuration><NumberOfSites>26</NumberOfSites><ContactNames><Name>Adelya Yachnin, MD</Name><Name>Almog Chotiner</Name><Name>Amanda Struckhoff</Name><Name>Amnon Amit, MD</Name><Name>Ashley Haggerty, MD</Name><Name>Benjamin Marchello, MD</Name><Name>Cindy Miller</Name><Name>Claire Kostechka</Name><Name>Cynthia E Cruz</Name><Name>Dalia Sherizen</Name><Name>David Edelmann, MD</Name><Name>Elinor Dahari</Name><Name>Frederick Ueland, MD</Name><Name>Gina Norris</Name><Name>Heidi Heitkamp</Name><Name>James Barter, MD</Name><Name>Jasmine Hunt</Name><Name>Jeffrey Elder, MD</Name><Name>Joseph Lucci, MD</Name><Name>Joyce Barlin, MD</Name><Name>Kaelyn Kappeler</Name><Name>Kathy Wilkinson</Name><Name>Katrina Wade, MD</Name><Name>Kim Fredericks</Name><Name>Koji Matsuo, MD</Name><Name>Lavinia Dobrea</Name><Name>Linda Crossette</Name><Name>Lisa Barroilhet, MD</Name><Name>Lyudmila Kalnitskaya</Name><Name>Maria Grosse-Perdekamp, MD</Name><Name>Michael Callahan, MD</Name><Name>Michael G Teneriello, MD</Name><Name>Michelle Sedberry</Name><Name>Namita Khanna, MD</Name><Name>Nana Tchabo, MD</Name><Name>Nancy Ginder</Name><Name>Ora Rosengarten, MD</Name><Name>Richard Penson</Name><Name>Richard Penson, MD</Name><Name>Ronnie Shapira-Frommer, MD</Name><Name>Samuel Lentz, MD</Name><Name>Shar Ellixson</Name><Name>Shelly Morris, MD</Name><Name>Shulamit Fried</Name><Name>Sonia Robazetti</Name><Name>Stacey Worrell</Name><Name>Tali Lifshits-Gritzman</Name><Name>Tariq Mahmood, MD</Name><Name>Thomas Reid, MD</Name><Name>Thomas Woliver, MD</Name><Name>Wanda Caplinger</Name><Name>Zeno Ashai</Name></ContactNames></Trial><Trial Id="32522"><Indications><Indication>Generalized anxiety disorder</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>5-HT 1a receptor agonist</Action><Action>5-HT 1b receptor partial agonist</Action><Action>5-HT 1d receptor antagonist</Action><Action>5-HT 3 receptor antagonist</Action><Action>5-HT 7 receptor antagonist</Action><Action>Serotonin transporter inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>5-HT uptake inhibitor</Action><Action>Antidepressant</Action><Action>Antipsychotic</Action><Action>Anxiolytic</Action><Action>Nootropic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Daily dosing</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>H Lundbeck A/S</Company></CompaniesCollaborator><CompaniesSponsor><Company>Takeda Pharmaceutical Co Ltd</Company></CompaniesSponsor><Countries><Country>Estonia</Country><Country>Lithuania</Country><Country>Latvia</Country><Country>Russian Federation</Country><Country>Romania</Country><Country>Poland</Country><Country>Germany</Country><Country>Ukraine</Country></Countries><DateChangeLast>2018-12-15T00:00:00Z</DateChangeLast><DateEnd>2009-07-31T00:00:00Z</DateEnd><DateStart>2008-09-30T00:00:00Z</DateStart><Identifiers><Identifier>2008-001766-90</Identifier><Identifier>EudraCT: 2008-001766-90</Identifier><Identifier>LuAA21004_311</Identifier><Identifier>NCT00744627</Identifier><Identifier>U1111-1112-3487</Identifier></Identifiers><IndicationsAdverse><Indication>Dizziness</Indication><Indication>Headache</Indication><Indication>Nausea</Indication><Indication>Xerostomia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>vortioxetine hydrobromide alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>301</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>agents and Insulin Systemic steroids Antineoplastics Antiobesity agents Antidiarrheal agents (episodic use allowed) Antifungal agents (episodic topical use allowed) Antihistamines (episodic use of loratadine, desloratadine, cetirizine allowed) Cough/&lt;b&gt;cold&lt;/b&gt; agents (episodic use allowed but preparations containing pseudoephedrine and narcotics are not allowed) Diuretics (episodic use allowed) The subject has a significant risk of suicide according to the investigator's opinion or has a score &gt;/= 5 on item</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Anxiety by Protocol Specified Scales - Assessment by Hamilton Anxiety Rating Scale (HAM-A)</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Remission - Assessment of remission rate</EndpointIndex><EndpointIndex>Anxiety disorder - Assessment of Response Rates (RR) - Assessment of response rate</EndpointIndex><EndpointIndex>Anxiety disorder - Health Economic Assessments</EndpointIndex><EndpointIndex>Anxiety disorder - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Anxiety disorder - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Hospital Anxiety and Depression Scale (HADS)</EndpointIndex><EndpointIndex>Anxiety disorder - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Sheehan Disability Scale</EndpointIndex><EndpointIndex>Anxiety disorder - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Short Form Health Survey (SF-36)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of Vortioxetine (Lu-AA21004) for Treatment of Generalized Anxiety Disorder in Adults</TitleDisplay><PatientSegmentTerms><PatientSegment>Anxiety disorder - Subjects with Generalized Anxiety Disorder</PatientSegment><PatientSegment>Anxiety disorder - Subjects with Generalized Anxiety Disorder - Subjects with moderate to severe generalized anxiety disorder</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2009-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>36</NumberOfSites><ContactNames><Name>Medical Director Clinical Science</Name><Name>Medical Director, Clinical Science</Name></ContactNames></Trial><Trial Id="325056"><Indications><Indication>Agitation</Indication><Indication>Alzheimers disease</Indication><Indication>Dementia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cytochrome P450 2D6 inhibitor</Action><Action>NMDA receptor antagonist</Action><Action>Opioid receptor sigma agonist 1</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>5-HT uptake inhibitor</Action><Action>Analgesic</Action><Action>Anticancer</Action><Action>Antipsychotic</Action><Action>Antitussive</Action><Action>Norepinephrine uptake inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Avanir Pharmaceuticals Inc</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Hungary</Country><Country>Bulgaria</Country><Country>Australia</Country><Country>Italy</Country><Country>Czech Republic</Country><Country>South Africa</Country><Country>Poland</Country><Country>UK</Country><Country>Spain</Country></Countries><DateChangeLast>2019-06-07T00:00:00Z</DateChangeLast><DateEnd>2021-06-30T00:00:00Z</DateEnd><DateStart>2017-10-13T00:00:00Z</DateStart><Identifiers><Identifier>17-AVP-786-305</Identifier><Identifier>2017-001339-38</Identifier><Identifier>NCT03393520</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>deudextromethorphan hydrobromide + ultra-low dose quinidine sulfate (neurological/psychiatric disorders), Avanir alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>412</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This multicenter, randomized, double-blind, placebo-controlled, parallel-design study would be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in participants with dementia of the Alzheimers type [ 2133120 ]. Main objective of the trial: Efficacy, safety, and tolerability of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer's Type.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Alzheimers disease - Assessment of Caregiver Outcomes - Cohen mansfield agitation inventory (CMAI)</EndpointIndex><EndpointIndex>Alzheimers disease - Assessment of Dementia - Resource utilization in dementia (RUD)</EndpointIndex><EndpointIndex>Alzheimers disease - Assessment of Psychiatric Symptoms - Assessment by Neuropsychiatric Inventory (NPI)</EndpointIndex><EndpointIndex>Alzheimers disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Alzheimers disease - Cognitive, Global and Functional Assessments - Alzheimer's Disease Co-operative Study - Clinical Global Impression of Change (ADCS CGIC) score</EndpointIndex><EndpointIndex>Alzheimers disease - Cognitive, Global and Functional Assessments - Alzheimer's disease assessment scale - cognition (ADAS-cog)</EndpointIndex><EndpointIndex>Alzheimers disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment of European Quality of Life Questionnaire (EuroQol: EQ-5D)</EndpointIndex><EndpointIndex>Alzheimers disease - Patient Reported Outcomes/Quality of Life Assessments - Dementia Quality of Life (DemQoL) Scale</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Other neurological disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other neurological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6 DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type</TitleDisplay><PatientSegmentTerms><PatientSegment>Alzheimers disease - Subjects with Probable Diagnosis of Alzheimer's Disease</PatientSegment><PatientSegment>Other neurological disease - Subjects with specific disease - Subjects with Cognitive disorder</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2021-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>44 Months</TrialDuration><NumberOfSites>37</NumberOfSites><ContactNames><Name>Agitation Project Team</Name><Name>Caroline Mason</Name><Name>Fred Ledon</Name></ContactNames></Trial><Trial Id="32465"><Indications><Indication>Heparin induced thrombocytopenia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Factor IIa antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Coagulation inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesCollaborator><Company>Japan Medical Association</Company><Company>Mitsubishi Tanabe Pharma Corp</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hokkaido Cancer Center</Company><Company>Iwate Medical University Hospital</Company><Company>Japanese Ministry of Health, Labor and Welfare</Company><Company>Keio University</Company><Company>Kobe City Medical Center General Hospital</Company><Company>Kobe University Hospital</Company><Company>Kurume University</Company><Company>Kyoto Second Red Cross Hospital</Company><Company>Kyoto University Hospital</Company><Company>Mie University Hospital</Company><Company>Nagoya Daini Red Cross Hospital</Company><Company>Nagoya University Hospital</Company><Company>National Cardiovascular Center Research Institute</Company><Company>National Hospital Organization Hakodate National Hospital</Company><Company>National Hospital Organization Iwakuni Clinical Center</Company><Company>National Hospital Organization Nagoya Medical Center</Company><Company>National Hospital Organization, Tokyo Medical Center</Company><Company>Sakakibara Memorial Hospital</Company><Company>The University of Tokyo Hospital</Company><Company>Tokai University Hachioji Hospital</Company><Company>Yamaguchi Hospital</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2018-06-21T00:00:00Z</DateChangeLast><DateEnd>2006-09-30T00:00:00Z</DateEnd><DateStart>2005-06-30T00:00:00Z</DateStart><Identifiers><Identifier>ARG-HIT-CVD</Identifier><Identifier>ARG-HIT-CVD</Identifier><Identifier>JMA-IIA00001</Identifier><Identifier>NCT00198588</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>argatroban alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>8</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>thrombosis documented by appropriate imaging technique (ultrasound, angiography etc) or supported by clinical evidence such as a myocardial infarction, stroke, pulmonary embolism, or other clinical indications of vascular occlusion(absence of pulse, &lt;b&gt;cold&lt;/b&gt;, cyanotic extremities, etc) Patients with history of HIT/HITTS with positive test results (HIT antibody or platelet function test) could be enrolled without present thrombocytopenia Patients willing and able to give informed consent</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Co-morbidity</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Platelet Count</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Acute coronary syndrome - Assessment of Thrombotic/Thromboembolic Events</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Morbidity</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Platelet Count</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Thrombocytopenia - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Thrombosis - Assessment of Blood Coagulation</EndpointIndex><EndpointIndex>Thrombosis - Assessment of Blood Coagulation - Assessment of partial thromboplastin time(PTT)</EndpointIndex><EndpointIndex>Thrombosis - Assessment of Blood Coagulation - Assessment of platelet function/aggregation</EndpointIndex><EndpointIndex>Thrombosis - Assessment of Laboratory/Diagnostic Measures - Assessment of hematological parameters</EndpointIndex><EndpointIndex>Thrombosis - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Thrombosis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Thrombosis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Assessment of plasma drug concentrations</EndpointIndex><EndpointIndex>Thrombosis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Thrombosis - Assessment of Thrombotic/Thromboembolic Events - Assessment of recurrence of thrombotic/thromboembolic events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ARG-HIT-CVD: Efficacy and Safety Study of Argatroban to Treat Heparin-induced Thrombocytopenia</TitleDisplay><PatientSegmentTerms><PatientSegment>Acute coronary syndrome - Subjects with comorbid conditions</PatientSegment><PatientSegment>Coronary artery disease - Subjects with comorbid conditions</PatientSegment><PatientSegment>Thrombocytopenia - Subjects with Drug Induced Thrombocytopenia - Subjects with heparin induced thrombocytopenia</PatientSegment><PatientSegment>Thrombosis - Subjects on Prior/Concurrent Drug Therapies for Thrombosis - Subjects on prior/concurrent anticoagulants</PatientSegment><PatientSegment>Thrombosis - Subjects with Arterial Thrombosis</PatientSegment><PatientSegment>Thrombosis - Subjects with Venous Thrombosis</PatientSegment><PatientSegment>Thrombosis - Subjects with comorbid conditions</PatientSegment><PatientSegment>Thrombosis - Subjects with disease related complications</PatientSegment><PatientSegment>Thrombosis - Subjects with disease related complications - Subjects with arterial thrombus complications</PatientSegment><PatientSegment>Thrombosis - Subjects with disease related complications - Subjects with pulmonary embolism</PatientSegment><PatientSegment>Thrombosis - Subjects with disease related complications - Subjects with venous thrombus complications</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate>2006-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>15 Months</TrialDuration><NumberOfSites>20</NumberOfSites><ContactNames><Name>Haruko Yamamoto</Name><Name>Hitonobu TOMOIKE</Name></ContactNames></Trial><Trial Id="324244"><Indications><Indication>Common cold</Indication></Indications><CompaniesSponsor><Company>SS Pharmaceutical Co Ltd</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2018-03-16T00:00:00Z</DateChangeLast><DateStart>2017-10-21T00:00:00Z</DateStart><Identifiers><Identifier>JapicCTI-173748</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>ST-QT 200 alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Patients diagnosed with &lt;b&gt;cold&lt;/b&gt; syndrome Patients aged 15 years or older Patients who agreed to participate in the trial... The aim of this study is to investigate the efficacy and safety of ST-QT 200 in patients with &lt;b&gt;cold&lt;/b&gt; syndrome.</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Respiratory tract infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Phase III trial of ST-QT 200 for patients with cold syndrome</TitleDisplay><PatientSegmentTerms><PatientSegment>Respiratory tract infection - Others</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>SA Pharmaceutical Co., Ltd.</Name></ContactNames></Trial><Trial Id="323731"><Indications><Indication>Common cold</Indication></Indications><CompaniesSponsor><Company>Parul Institute of Ayurved</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2018-01-03T00:00:00Z</DateChangeLast><DateStart>2017-12-27T00:00:00Z</DateStart><Identifiers><Identifier>CTRI/2017/12/010932</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Patoladi syrup alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The present study is intended to evaluate the efficacy of Patoladi syrup in the treatment of Pratishyayain Kaumarabhritya. Hypothesis: if there is effect of Patoladi syrup in Pratishyaya.</Teaser><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other respiratory disease - Clinical Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TitleDisplay>Ayurvedic management of cold in children</TitleDisplay><PatientSegmentTerms><PatientSegment>Other respiratory disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood cells </BiomarkerName><BiomarkerName> Eosinophils</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr Sunil Changle</Name><Name>Shaheen Pinjari</Name></ContactNames></Trial><Trial Id="323102"><Indications><Indication>Agitation</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cytochrome P450 2D6 inhibitor</Action><Action>NMDA receptor antagonist</Action><Action>Opioid receptor sigma agonist 1</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>5-HT uptake inhibitor</Action><Action>Analgesic</Action><Action>Anticancer</Action><Action>Antipsychotic</Action><Action>Antitussive</Action><Action>Norepinephrine uptake inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug combination</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Otsuka Holdings Co Ltd</Company></CompaniesSponsor><Countries><Country>Europe</Country></Countries><DateChangeLast>2017-12-20T00:00:00Z</DateChangeLast><InterventionsPrimaryDisplay><Intervention>deudextromethorphan hydrobromide + ultra-low dose quinidine sulfate (neurological/psychiatric disorders), Avanir alone</Intervention></InterventionsPrimaryDisplay><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>This was a phase III study of AVP-786 for the treatment of agitation in subjects with alzheimer's disease [ 1992422 ].</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A phase III study of AVP-786 for the treatment of agitation in subjects with alzheimer's disease</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="322411"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>IL-12 receptor antagonist</Action><Action>IL-23 antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Interleukin 17A ligand inhibitor</Action><Action>Interleukin 17F ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell culture</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>UCB SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>UCB Biopharma SPRL</Company></CompaniesSponsor><Countries><Country>Belgium</Country><Country>Germany</Country><Country>Italy</Country><Country>Japan</Country><Country>Russian Federation</Country><Country>Hungary</Country><Country>UK</Country><Country>US</Country><Country>Australia</Country><Country>Poland</Country><Country>Canada</Country></Countries><DateChangeLast>2019-03-25T00:00:00Z</DateChangeLast><DateEnd>2020-01-31T00:00:00Z</DateEnd><DateStart>2017-12-06T00:00:00Z</DateStart><Identifiers><Identifier>2016-003425-42</Identifier><Identifier>BE VIVID</Identifier><Identifier>NCT03370133</Identifier><Identifier>PS0009</Identifier></Identifiers><InterventionsControlDisplay><Intervention>ustekinumab alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>bimekizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>570</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Subject has an active infection (except common &lt;b&gt;cold&lt;/b&gt;), a recent serious infection, or a history of opportunistic or recurrent chronic infections Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection Subject has known tuberculosis (TB) infection</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Psoriasis - Assessment of Safety and Tolerability - Interruption or discontinuation or withdrawal of study drug</EndpointIndex><EndpointIndex>Psoriasis - Assessment of adverse events</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-75 response</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-75 to 100 response</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Psoriasis - Physician Global Assessment of Disease Activity - Assessment by Investigator/Physician Global Assessment (PGA) Scale</EndpointIndex><EndpointIndex>Psoriasis - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>BE VIVID: A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with Moderate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Severe Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with specific disease - Subjects with Chronic Plaque Psoriasis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2019-01-08T00:00:00Z</PrimaryCompletionDate><TrialDuration>25 Months</TrialDuration><NumberOfSites>91</NumberOfSites><ContactNames><Name>Clin Trial Reg &amp; Results Disclosure</Name><Name>UCB Cares</Name></ContactNames></Trial><Trial Id="322363"><Indications><Indication>Seasonal allergic rhinitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin E antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Bronchodilator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company><Company>Novartis Pharma KK</Company></CompaniesSponsor><Countries><Country>Switzerland</Country><Country>Japan</Country></Countries><DateChangeLast>2019-03-26T00:00:00Z</DateChangeLast><DateEnd>2018-10-20T00:00:00Z</DateEnd><DateStart>2017-12-15T00:00:00Z</DateStart><Identifiers><Identifier>2017-002154-36</Identifier><Identifier>CIGE025F1301</Identifier><Identifier>JapicCTI-173813</Identifier><Identifier>NCT03369704</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>omalizumab alone</Intervention><Intervention>standard-of-care alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>337</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> itchy eye or watery eye) in at least one day, which is confirmed by patient e-diary (unless a symptom is clearly consider to take place due to other than Japanese cedar pollinosis/allergic rhinitis [eg, upper respiratory tract infection, or common &lt;b&gt;cold&lt;/b&gt;]) Body weight and serum total IgE level at screen epoch within the dosing table range; body weight of &gt;/= 20 to&amp;lt;/= 150 kg and serum total IgE levels of &gt;/= 30 to &amp;lt;/= 1500 IU/ml at a maximum</Teaser><TrialCategories><Category>Behavioral intervention</Category><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of immunoglobulin levels</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of nasal congestion</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of nasal itching</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of rhinorrhoea</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of sneezing</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Nasal Symptoms/Symptom scores - Assessment of symptom free days</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Ocular/Non Nasal Symptoms</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of use of Rescue Medication</EndpointIndex><EndpointIndex>Allergic rhinitis - Patient Reported Outcomes/Quality of Life Assessments - Japanese rhino-conjunctivitis QOL questionnaire JRQLQ</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent Patients</TitleDisplay><PatientSegmentTerms><PatientSegment>Allergic rhinitis - Subjects with Seasonal Allergic Rhinitis</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Immunoglobulin E</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-05-11T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>24</NumberOfSites><ContactNames><Name>Clinical trial Information Desk</Name><Name>Novartis Pharma K. K.</Name><Name>Novartis Pharmaceuticals</Name></ContactNames></Trial><Trial Id="322284"><Indications><Indication>Respiratory distress syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Deoxyribonuclease I stimulator</Action><Action>Deoxyribonuclease stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Mucolytic agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Biological therapeutic</Technology><Technology>Inhalant formulation</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Hopitaux Universitaires de Strasbourg</Company></CompaniesSponsor><Countries><Country>France</Country></Countries><DateChangeLast>2019-01-12T00:00:00Z</DateChangeLast><DateEnd>2021-10-01T00:00:00Z</DateEnd><DateStart>2019-03-01T00:00:00Z</DateStart><Identifiers><Identifier>6998</Identifier><Identifier>NCT03368092</Identifier><Identifier>TRAUMADORNASE</Identifier><Identifier>TRAUMADORNASE</Identifier><Identifier>TRAUMARDORNASE</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Aerogen solo alone</Intervention><Intervention>dornase alfa alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>500</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The aim of this study is to evaluate inhaled dornase alfa to reduce respiratory failure after severe trauma. The primary objective is to demonstrate a reduction in the incidence of moderate to severe acute respiratory distress syndrome (ARDS) in severe trauma patients during the first seven ICU days from 45% to 30% by providing aerosolized dornase alfa once during the first two consecutive ICU days and compared to equivalent provision of placebo (NaCl 0,9%). The secondary objectives are to</Teaser><TrialCategories><Category>Biological</Category><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Morbidity</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Other respiratory disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other respiratory disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other respiratory disease - Protocol Specified Other Endpoints - Length of hospital stay (LOS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>TRAUMADORNASE: Inhaled Dornase Alfa to Reduce Respiratory Failure After Severe Trauma</TitleDisplay><PatientSegmentTerms><PatientSegment>Other respiratory disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Arterial oxygen tension/inspiratory oxygen fraction ratio</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2021-10-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>31 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Julien POTTECHER, MD</Name></ContactNames></Trial><Trial Id="322066"><Indications><Indication>Pain</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Opioid receptor mu agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>5-HT uptake inhibitor</Action><Action>Analgesic</Action><Action>Norepinephrine uptake inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Drug coating</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Hørslev-Fonden</Company><Company>The Danish Ministry of Science, Technology and Innovation</Company></CompaniesCollaborator><CompaniesSponsor><Company>Rigshospitalet, Denmark</Company></CompaniesSponsor><Countries><Country>Denmark</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2014-12-01T00:00:00Z</DateEnd><DateStart>2009-02-02T00:00:00Z</DateStart><Identifiers><Identifier>H-B-2008-061</Identifier><Identifier>NCT03365817</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Morphine alone</Intervention><Intervention>fentanyl alone</Intervention><Intervention>methadone alone</Intervention><Intervention>oxycodone alone</Intervention><Intervention>tramadol hydrochloride alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>75</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this trial was to evaluate the effects of opioid dose reduction (morphine, oxycodone, metadone, fentanyl or tramadol ) in the treatment of chronic pain in adults. This study aimed at: Evaluating the feasibility of a opioid tapering off program to patients with chronic pain. Investigating the influence of opioid tapering off on cognitive function, pain, symptoms of opioid withdrawal, anxiety , depression, and health related quality of life. Investigating the prevalence of addiction</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Pain - Assessment of Fatigue</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Verbal Rating Scale [VRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Morbidity</EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Sleep</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of Feasibility</EndpointIndex><EndpointIndex>Pain - Assessment of Therapy Related Outcomes - Assessment of drop-out rate/withdrawal rate</EndpointIndex><EndpointIndex>Pain - Clinical Assessments - Assessment of learning efficiency</EndpointIndex><EndpointIndex>Pain - Clinical Assessments - Assessment of other neurological function</EndpointIndex><EndpointIndex>Pain - Neurological Assessments</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Hospital Anxiety and Depression Scale (HADS)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Likert scale</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by RAND-36 Health Survey</EndpointIndex><EndpointIndex>Pain - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Cognitive Function and Addiction Under Opioid Tapering</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects in need of Procedural Analgesia - Subjects with opiate dependence</PatientSegment><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2014-12-01T00:00:00Z</PrimaryCompletionDate><TrialDuration>70 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jette Højsted, MD</Name><Name>Per Sjøgren, DMSc</Name></ContactNames></Trial><Trial Id="321622"><Indications><Indication>Anesthesia</Indication><Indication>Epistaxis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Adrenergic receptor agonist</Action></ActionsPrimaryInterventionsControl><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action></ActionsSecondaryInterventionsControl><Technologies><Technology>Injectable formulation</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Postgraduate Institute of Medical Education and Research</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2017-12-13T00:00:00Z</DateChangeLast><DateStart>2018-12-01T00:00:00Z</DateStart><Identifiers><Identifier>CTRI/2017/11/010658</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Merocel nasal packing alone</Intervention><Intervention>epinephrine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>xylometazoline alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>110</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser> H/O cough and &lt;b&gt;cold&lt;/b&gt; in past 2 weeks Patients taking any oral decongestants, nonsteroidal inflammatory drugs(NSAIDS) or anti histamines H/O nasal deformity or nasal trauma H/O recurrent epistaxis, known allergy to used drugs Patients with dearanged liver function profile</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other hematological disease - Assessment of Hemorrhagic Complications</EndpointIndex><EndpointIndex>Other hematological disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other hematological disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other hematological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Comparison of xylometazoline (vasoconstrictor) nasal drops and epinephrine merocel nasal pack in reducing bleeding during nasal intubation</TitleDisplay><PatientSegmentTerms><PatientSegment>Other hematological disease - Subjects with History of/Undergoing Procedures/Surgery</PatientSegment><PatientSegment>Other hematological disease - Subjects with specific disease - Subjects with Epistaxis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Amarjyoti Hazarika</Name><Name>Sonam Patel</Name></ContactNames></Trial><Trial Id="321057"><Indications><Indication>Hypoglycemia</Indication></Indications><CompaniesSponsor><Company>Christian Medical College, Vellore, India</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2017-12-27T00:00:00Z</DateChangeLast><DateStart>2017-12-01T00:00:00Z</DateStart><Identifiers><Identifier>CTRI/2017/11/010645</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>colostrum alone</Intervention><Intervention>dextrose alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>600</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>The aim is to study the prophylactic effect of 40% oral dextrose gel on prevention of neonatal hypoglycemia in infants of diabetic mother and to formulate a scoring system to predict the responder and non responder to 40% oral dextrose gel</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other metabolic disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other metabolic disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Other metabolic disease - Assessment of Physical Examination - Assessment of growth</EndpointIndex><EndpointIndex>Other metabolic disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other metabolic disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other metabolic disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other metabolic disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term><Term>Infants (6-23 months)</Term></TermsPatientSelection><TitleDisplay>Prevention of low blood sugar by 40% oral dextrose gel in newborn infant of diabetic mother</TitleDisplay><PatientSegmentTerms><PatientSegment>Other metabolic disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Birth weight </BiomarkerName><BiomarkerName> Body temperature </BiomarkerName><BiomarkerName> C-peptide </BiomarkerName><BiomarkerName> Glucose</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Thanigainathan</Name></ContactNames></Trial><Trial Id="320180"><Indications><Indication>Cold agglutinin disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Complement C1s subcomponent inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology></Technologies><CompaniesSponsor><Company>Bioverativ Inc</Company></CompaniesSponsor><Countries><Country>Israel</Country><Country>Netherlands</Country><Country>Canada</Country><Country>US</Country><Country>Japan</Country><Country>Belgium</Country><Country>Spain</Country><Country>France</Country><Country>UK</Country><Country>Italy</Country><Country>Germany</Country><Country>Australia</Country><Country>Norway</Country><Country>Austria</Country></Countries><DateChangeLast>2019-06-25T00:00:00Z</DateChangeLast><DateEnd>2020-08-31T00:00:00Z</DateEnd><DateStart>2017-11-20T00:00:00Z</DateStart><Identifiers><Identifier>2017-003539-12</Identifier><Identifier>BIVV009-04</Identifier><Identifier>Cadenza</Identifier><Identifier>IND # 128,190</Identifier><Identifier>NCT03347422</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>sutimlimab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> &lt;b&gt;Cold&lt;/b&gt; agglutinin syndrome secondary to infection, rheumatologic disease, or active hematologic malignancy History of one or more blood transfusions within 6 months...C3d &lt;b&gt;Cold&lt;/b&gt; agglutinin titer&amp;gt;/= 64 at 4 degC Immunoglobulin G (IgG) DAT&amp;lt;/= 1+ No overt malignant disease Hemoglobin level&amp;lt;/= 10.0 g/dl...in hemoglobin (Hgb) level and avoidance of transfusion in patients with primary &lt;b&gt;cold&lt;/b&gt; agglutinin disease (CAD) without a recent history of blood transfusion. The</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anemia - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Anemia - Assessment of Fatigue</EndpointIndex><EndpointIndex>Anemia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Anemia - Assessment of Morbidity Rates</EndpointIndex><EndpointIndex>Anemia - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Anemia - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Anemia - Assessment of adverse events</EndpointIndex><EndpointIndex>Anemia - Assessment of pain</EndpointIndex><EndpointIndex>Anemia - Clinical Assessments - Assessment of liver function</EndpointIndex><EndpointIndex>Anemia - Hematological Assessments - Assessment of hemoglobin status</EndpointIndex><EndpointIndex>Anemia - Patient Reported Outcomes/Quality of Life Assessments - Functional Assessment of Chronic Illness Therapy (FACIT)</EndpointIndex><EndpointIndex>Anemia - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Cadenza: A Study to Assess the Efficacy and Safety of BIVV-009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion</TitleDisplay><PatientSegmentTerms><PatientSegment>Anemia - Subjects with Hemolytic Anemia - Subjects with cold agglutinin disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Bilirubin </BiomarkerName><BiomarkerName> Haptoglobin </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Lactate dehydrogenase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>33 Months</TrialDuration><NumberOfSites>58</NumberOfSites><ContactNames><Name>Adult Hematology Research</Name><Name>Anita Bøtter Brevik</Name><Name>Anne Morcombe</Name><Name>Antje van der Seylberg</Name><Name>Ashley Simpson</Name><Name>Aviv Avdi</Name><Name>Aziz Jiwajee</Name><Name>Bernard Silver, MD</Name><Name>Bioverativ Therapeutics Inc</Name><Name>Camelia Vladescu</Name><Name>Caroline De Man</Name><Name>Catherine Broome</Name><Name>Christine Duran</Name><Name>Cinzia Lamorgese</Name><Name>Clinical Trial Dept</Name><Name>Darshni Jhagroe</Name><Name>David Ivars</Name><Name>David Kuter, MD</Name><Name>Denous-Chataigner Paul</Name><Name>Dikla Varsano</Name><Name>Dr Alain Kento</Name><Name>Dr Alexander Roeth, MD</Name><Name>Dr Bernd Jilma, MD</Name><Name>Dr Cheze</Name><Name>Dr Corentin Orvain, MD</Name><Name>Dr Eros di Bona, MD</Name><Name>Dr Giuseppe Rossi, MD</Name><Name>Dr Henrik Hjort Hansen</Name><Name>Dr Ilya Kirgner, MD</Name><Name>Dr Jesus Martin Sanchez, MD</Name><Name>Dr Joan</Name><Name>Dr Joan Cid jcid@clinic.cat, +34 932 275 448</Name><Name>Dr Jose Luis Bueno, MD</Name><Name>Dr Ka Lung WU</Name><Name>Dr Lazareth, anne.lazareth@chu-lyon.fr</Name><Name>Dr Liesbeth Oosten, MD</Name><Name>Dr Luana Fianchi, MD</Name><Name>Dr Miguel Fernandez Zarzoso, MD</Name><Name>Dr Shlomo Bulvik, MD</Name><Name>Dr Thomas Illmer, MD</Name><Name>Dr Tor Henrik Anderson</Name><Name>Dr Wilma Barcellini, MD</Name><Name>Dr Yosef Kalish, MD</Name><Name>Dr. Catherine Broome</Name><Name>Dr. Chakra Chaulagain</Name><Name>Dr. Darla Liles</Name><Name>Dr. Eliot Williams</Name><Name>Dr. Ilene Weitz</Name><Name>Dr. Irina Murakhovskaya</Name><Name>Dr. J. Eric Russell</Name><Name>Dr. Joseph E. Kiss</Name><Name>Dr. Josephine Vos</Name><Name>Dr. Katerina Pavenski</Name><Name>Dr. Michael Boxer</Name><Name>Dr. Morey Blinder</Name><Name>Dr. Patricia Pelletier</Name><Name>Dr. Richy Agajanian</Name><Name>Ela Shai</Name><Name>Eric Parsons</Name><Name>Giulia Milesi</Name><Name>Irwindeep Sandhu</Name><Name>Irwindeep Sandhu, 780-407-1584 Ext. 5</Name><Name>Isabel Salcedo</Name><Name>Jean M Connors, MD</Name><Name>Jill Pannecoucke</Name><Name>Jordan Driscoll, Research Coordinator</Name><Name>Jude C Jonassaint, Program Manager</Name><Name>Judy Ann Moore</Name><Name>Kerritt Saintal</Name><Name>Kike Ibikunle</Name><Name>Kristin Eikevåg</Name><Name>Laura Lissandrini</Name><Name>Lauran Tindall</Name><Name>Liem Nguyen, Study Coordinator</Name><Name>Marika Picardi</Name><Name>Marina Pfetsch</Name><Name>Mary Kelty</Name><Name>Micheleine Uhe</Name><Name>Mr. Girard Emanuel</Name><Name>Mrs. Cecile Francoise</Name><Name>Mrs. Laetitia Languille</Name><Name>Nicole Preising</Name><Name>Pr Daan Dierick</Name><Name>Pr Daan Dierickx daan.dierickx@uzleuven.be</Name><Name>Pr Geir Tjonnfjord</Name><Name>Pr Michel</Name><Name>Prof Dr Hubert Schrezenmeier, MD</Name><Name>Robert G. Lerner, MD</Name><Name>Rocio Roncel</Name><Name>Sandra Pepin</Name><Name>Sarah Ely</Name><Name>Seah Lim, MD</Name><Name>Sharon Berbick</Name><Name>Simona Deplano</Name><Name>Stacey Kimbell</Name><Name>Tiffanie Moore</Name><Name>Turid Neverdal Almvik</Name><Name>Victoria Nam-Amnath</Name><Name>Willemien Benckhuijsen</Name></ContactNames></Trial><Trial Id="320060"><Indications><Indication>Cold agglutinin disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Complement C1s subcomponent inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology></Technologies><CompaniesSponsor><Company>Bioverativ Inc</Company></CompaniesSponsor><Countries><Country>Australia</Country><Country>Poland</Country><Country>Denmark</Country><Country>Hungary</Country><Country>Belgium</Country><Country>Austria</Country><Country>US</Country><Country>Italy</Country><Country>France</Country><Country>UK</Country><Country>Switzerland</Country><Country>Spain</Country><Country>Israel</Country><Country>Japan</Country><Country>Canada</Country><Country>Norway</Country><Country>Netherlands</Country><Country>Germany</Country></Countries><DateChangeLast>2019-02-20T00:00:00Z</DateChangeLast><DateEnd>2020-06-30T00:00:00Z</DateEnd><DateStart>2017-11-20T00:00:00Z</DateStart><Identifiers><Identifier>128,190</Identifier><Identifier>2017-003538-10</Identifier><Identifier>BIVV009-03</Identifier><Identifier>Cardinal</Identifier><Identifier>NCT03347396</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>sutimlimab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> &lt;b&gt;Cold&lt;/b&gt; agglutinin syndrome secondary to infection, rheumatologic disease, or active hematologic malignancy Clinically relevant infection of any kind within the...C3d &lt;b&gt;Cold&lt;/b&gt; agglutinin titer&amp;gt;/= 64 at 4degC Immunoglobulin G (IgG) DAT&amp;lt;/= 1+ No overt malignant disease History of at least one documented blood transfusion within 6...obviate the need for blood transfusion during treatment in participants with primary &lt;b&gt;cold&lt;/b&gt; agglutinin disease (CAD) who have a recent history of blood transfusion</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Anemia - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Anemia - Assessment of Fatigue</EndpointIndex><EndpointIndex>Anemia - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Anemia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Anemia - Assessment of Safety and Tolerability - Assessment of serious adverse events</EndpointIndex><EndpointIndex>Anemia - Assessment of Safety and Tolerability - Assessment of side-effects/complications</EndpointIndex><EndpointIndex>Anemia - Assessment of Therapy Related Outcomes - Assessment of number of transfusions</EndpointIndex><EndpointIndex>Anemia - Assessment of Transfusions</EndpointIndex><EndpointIndex>Anemia - Assessment of adverse events</EndpointIndex><EndpointIndex>Anemia - Clinical Assessments - Assessment of liver function</EndpointIndex><EndpointIndex>Anemia - Hematological Assessments - Assessment of hemoglobin response</EndpointIndex><EndpointIndex>Anemia - Hematological Assessments - Assessment of hemoglobin status</EndpointIndex><EndpointIndex>Anemia - Patient Reported Outcomes/Quality of Life Assessments - Functional Assessment of Chronic Illness Therapy (FACIT)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Cardinal: A Study to Assess the Efficacy and Safety of BIVV-009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion</TitleDisplay><PatientSegmentTerms><PatientSegment>Anemia - Subjects with Hemolytic Anemia - Subjects with cold agglutinin disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Bilirubin </BiomarkerName><BiomarkerName> Haptoglobin </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Lactate dehydrogenase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2020-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>31 Months</TrialDuration><NumberOfSites>55</NumberOfSites><ContactNames><Name>Clinical Trial Dept</Name><Name>David Kuter</Name><Name>Dr Alain Kentos</Name><Name>Dr Alexander Roeth, MD</Name><Name>Dr Bernd Jilma, MD</Name><Name>Dr Cheze</Name><Name>Dr Eros di Bona, MD</Name><Name>Dr Henrik Hjort Hansen</Name><Name>Dr Ilya Kirgner, MD</Name><Name>Dr Jesus Martin Sanchez, MD</Name><Name>Dr Joan Cid</Name><Name>Dr Jose Luis Bueno, MD</Name><Name>Dr Ka Lung WU</Name><Name>Dr Miguel Fernandez Zarzoso</Name><Name>Dr Shlomo Bulvik, MD</Name><Name>Dr Thomas Illmer, MD</Name><Name>Dr Tor Henrik Anderson</Name><Name>Dr Wilma Barcellini, MD</Name><Name>Dr Yosef Kalish, MD</Name><Name>Dr. A. Peters</Name><Name>Dr. Catherine Broome</Name><Name>Dr. Darla Liles</Name><Name>Dr. Irina Murakhovskaya</Name><Name>Dr. Joseph E. Kiss</Name><Name>Dr. Lazareth</Name><Name>Dr. Richy Agajanian</Name><Name>Pr Geir Tjonnfjord</Name><Name>Pr Michel</Name><Name>Robert G. Lerner, MD</Name></ContactNames></Trial><Trial Id="319854"><Indications><Indication>Colorectal tumor</Indication><Indication>Peripheral neuropathy</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Superoxide dismutase stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer alkylating agent</Action><Action>Antioxidant agent</Action><Action>Chemoprotectant</Action><Action>DNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>PledPharma AB</Company></CompaniesSponsor><Countries><Country>France</Country><Country>Japan</Country><Country>US</Country><Country>Europe</Country><Country>Spain</Country><Country>Germany</Country><Country>Asia</Country><Country>Belgium</Country></Countries><DateChangeLast>2019-05-14T00:00:00Z</DateChangeLast><DateEnd>2021-09-01T00:00:00Z</DateEnd><DateStart>2018-08-09T00:00:00Z</DateStart><Identifiers><Identifier>2017-004707-43</Identifier><Identifier>JapicCTI-184187</Identifier><Identifier>POLAR-A</Identifier><Identifier>PP06489</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Variable regimens including calmangafodipir , fluorouracil , folinic acid , oxaliplatin</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>280</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>oxaliplatin , fluorouracil, folinic acid) as adjuvant chemotherapy. Secondary objectives of the study would be: To compare PledOx versus placebo: Efficacy: The proportion of patients with mild, moderate or severe chronic CIPN. The sensitivity to touching &lt;b&gt;cold&lt;/b&gt; items. The cumulative dose of oxaliplatin during chemotherapy. The vibration sensitivity on the lateral malleolus. The worst pain in hands or feet. The functional impairment (in the non-dominant hand). The sustained efficacy on prevention of CIPN during</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Disease Free Survival (DFS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Colorectal tumor - Health Economic Assessments</EndpointIndex><EndpointIndex>Colorectal tumor - Health Economic Assessments - Assessment of indirect cost</EndpointIndex><EndpointIndex>Colorectal tumor - Health Economic Assessments - Health care resource utilization</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by EQ-5D</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity questionnaire (FACT/GOG-Ntx)</EndpointIndex><EndpointIndex>Colorectal tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Numeric Rating Scale for Pain</EndpointIndex><EndpointIndex>Colorectal tumor - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Pain - Assessment of Functional Disability/Physical Function</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Pain - Health Economic Assessments</EndpointIndex><EndpointIndex>Pain - Health Economic Assessments - Assessment of indirect cost</EndpointIndex><EndpointIndex>Pain - Health Economic Assessments - Health care resource utilization</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Euro Quality of Life (EQ-5D) Questionnaire</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Functional Assessment of Cancer Therapy (FACT)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment of Pain by Visual Analog Scale (VAS)</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Neuropathic pain scale score</EndpointIndex><EndpointIndex>Pain - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>POLAR-A: A Phase III, double-blind, multicenter, placebo-controlled study of a new drug, PledOx used on top of standard therapy to prevent damages to nerves of the peripheral nervous system, induced by chemotherapy, in the adjuvant treatment of patients with Stage III or high-risk Stage II cancer of the large intestine</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with TNM stage II/Dukes B Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage III/Dukes C Colorectal Cancer</PatientSegment><PatientSegment>Pain - Subjects with Neuropathic Pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><TrialDuration>36 Months</TrialDuration><NumberOfSites>6</NumberOfSites><ContactNames><Name>Chief Medical Officer</Name><Name>Nicklas Westerholm</Name><Name>PledPharma AB</Name></ContactNames></Trial><Trial Id="31781"><Indications><Indication>Muckle Wells syndrome</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Immunoglobulin G1 agonist</Action><Action>Interleukin-1 beta ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Anticancer monoclonal antibody</Action><Action>Cardioprotectant</Action><Action>Immunosuppressant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>DNA technology</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intra-articular formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody human</Technology><Technology>Protein recombinant</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Novartis AG</Company></CompaniesSponsor><Countries><Country>France</Country><Country>Spain</Country><Country>US</Country><Country>Germany</Country><Country>UK</Country><Country>India</Country></Countries><DateChangeLast>2019-02-05T00:00:00Z</DateChangeLast><DateStart>2007-04-30T00:00:00Z</DateStart><Identifiers><Identifier>2006-005455-15</Identifier><Identifier>CACZ885D2304</Identifier><Identifier>NCT00465985</Identifier><Identifier>REMITTER</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Glaucoma</Indication><Indication>Headache</Indication><Indication>Influenza virus infection</Indication><Indication>Nausea</Indication><Indication>Rhinopharyngitis</Indication><Indication>Sepsis</Indication><Indication>Upper respiratory tract infection</Indication><Indication>Urinary tract infection</Indication><Indication>Vertigo</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>canakinumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>35</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This study was designed to provide efficacy and safety data for ACZ-885 administered as an injection sc in patients with Muckle-Wells syndrome. Main objective of the trial was to assess efficacy (% of patients who relapse) of ACZ-885 compared with placebo in Part II as determined by the Physician's global assessment of autoinflammatory disease activity, assessment of skin disease and inflammation markers (C-reactive protein [CRP] and/or serum amyloid A [SAA]). Secondary objectives of the trial</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Other genetic disease - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Other genetic disease - Developmental Assessment by Protocol Specified Scales</EndpointIndex><EndpointIndex>Other genetic disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other genetic disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>REMITTER: Efficacy, Safety, and Tolerability of ACZ-885 in Patients With Muckle-Wells Syndrome</TitleDisplay><PatientSegmentTerms><PatientSegment>Other genetic disease - Subjects with gene variants - NLRP3_HUMAN_Mutation</PatientSegment><PatientSegment>Other genetic disease - Subjects with specific disease</PatientSegment><PatientSegment>Other genetic disease - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>C-reactive protein </BiomarkerName><BiomarkerName> Interleukin-1 beta </BiomarkerName><BiomarkerName> Interleukin-6 </BiomarkerName><BiomarkerName> NACHT, LRR and PYD domains-containing protein 3 </BiomarkerName><BiomarkerName> Serum amyloid A protein 1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-10-31T00:00:00Z</PrimaryCompletionDate><NumberOfSites>12</NumberOfSites></Trial><Trial Id="315200"><Indications><Indication>Pain</Indication><Indication>Tooth disease</Indication></Indications><CompaniesSponsor><Company>University of Michigan</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-12T00:00:00Z</DateChangeLast><DateEnd>2019-07-31T00:00:00Z</DateEnd><DateStart>2017-09-28T00:00:00Z</DateStart><Identifiers><Identifier>HUM00111890</Identifier><Identifier>NCT03304184</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Biodentine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Males and females age 18 to 64 Chief complaint associated with pain from &lt;b&gt;cold&lt;/b&gt; or hot Chronic sensitivity associated with supragingival lesions Pain not associated with decay Fluent in English and able to read English at a sixth grade level Pulpal response&amp;lt; 40 via pulp tester Active salivary flow from palpation of parotid </Teaser><TrialCategories><Category>Borderline product</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other mouth disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other mouth disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Underlying Conditions</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Health Related Quality of Life (HRQOL)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>The Role of Biodentine in Class V Dental Lesions on Oral Health Related Quality of Life</TitleDisplay><PatientSegmentTerms><PatientSegment>Other mouth disease - Subjects with specific disease</PatientSegment><PatientSegment>Pain - Subjects with Chronic Pain</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with dental pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2019-07-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Elizabeth Van Tubergen</Name><Name>Elizabeth Van Tubergen, DDS, PhD</Name></ContactNames></Trial><Trial Id="314445"><Indications><Indication>Diarrhea</Indication></Indications><CompaniesSponsor><Company>Sabzevar University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-10-06T00:00:00Z</DateChangeLast><DateStart>2017-02-19T00:00:00Z</DateStart><Identifiers><Identifier>IR.MEDSAB.REC.1395.143</Identifier><Identifier>IRCT2017071935178N1</Identifier></Identifiers><InterventionsControlDisplay><Intervention>standard oral rehydration therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>KidiLact alone</Intervention><Intervention>PediLact alone</Intervention><Intervention>standard oral rehydration therapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>100</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>clinical presentation will be given to parents). They will be going to be divided into two 50 patients groups (6 month to 2 years old and 2 to 5 years old). PediLact (oral drops which contain 15 cc in a bottle with 10[9] microorganism) plus ORS (1 l &lt;b&gt;cold&lt;/b&gt; boiled water)) randomly will be prescribed to 25 patients of 6 month to 2 year old's group, 10 drops daily till 5 day and KidiLact (1 g of 10[9] microorganism) plus ORS randomly will be prescribed to 25 patients of 2 year to 5 year old's group, 1 suchet</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Diarrhea - Assessment of Diarrhoea - Assessment of duration of diarrhoea</EndpointIndex><EndpointIndex>Diarrhea - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Diarrhea - Assessment of adverse events</EndpointIndex><EndpointIndex>Diarrhea - Clinical Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TitleDisplay>Efficacy of Synbiotics (KididLact and PediLact) in the treatment of acute diarrhea</TitleDisplay><PatientSegmentTerms><PatientSegment>Diarrhea - Subjects with Acute Diarrhoea</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Mitra Aldaghi</Name><Name>Zohre Nazemi</Name></ContactNames></Trial><Trial Id="31400"><Indications><Indication>Uterine cervix tumor</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action><Action>Cell cycle inhibitor</Action><Action>DNA synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Eli Lilly &amp; Co</Company></CompaniesSponsor><Countries><Country>Mexico</Country><Country>Bosnia and Herzegovina</Country><Country>Thailand</Country><Country>Pakistan</Country><Country>Argentina</Country><Country>Peru</Country><Country>India</Country></Countries><DateChangeLast>2018-07-16T00:00:00Z</DateChangeLast><DateEnd>2008-04-30T00:00:00Z</DateEnd><DateStart>2002-05-31T00:00:00Z</DateStart><Identifiers><Identifier>4015</Identifier><Identifier>B9E-MC-JHQS</Identifier><Identifier>NCT00191100</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>cisplatin plus gemcitabine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>515</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> Impairment such as hearing loss from prior cisplatin therapy Damage to nerves such as being unable to distinguish hot and &lt;b&gt;cold&lt;/b&gt; to touch Used other experimental medication in past 30 days Lab test results are not within the limits required for this study Pregnancy or breast-feeding or possibility of becoming pregnant during this study and not using an approved method of birth</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Papillomavirus infection - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Papillomavirus infection - Assessment of Mortality/Death Rates - Assessment of all cause mortality</EndpointIndex><EndpointIndex>Papillomavirus infection - Assessment of Tumor Response</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Clinical Response - Assessment of Time-to-Treatment Failure (TTF)</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Response Rates (RR) - Assessment of time to tumor response</EndpointIndex><EndpointIndex>Uterine cervix tumor - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Comparative Study of Gemcitabine, Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix</TitleDisplay><PatientSegmentTerms><PatientSegment>Papillomavirus infection - Subjects with Cervical Cancer</PatientSegment><PatientSegment>Uterine cervix tumor - Subjects with Locally Advanced Cervical Cancer (Stage IIB - IVA)</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Hemoglobin</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2008-04-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>71 Months</TrialDuration><NumberOfSites>7</NumberOfSites></Trial><Trial Id="313160"><Indications><Indication>Rosacea</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Nuclear factor kappa B modulator</Action><Action>PPAR gene modulator</Action></ActionsPrimaryInterventionsControl><ActionsSecondaryInterventionsControl><Action>Anti-inflammatory</Action><Action>Antibacterial</Action><Action>Cytokine synthesis inhibitor</Action><Action>Topical dermatological antibacterial product</Action></ActionsSecondaryInterventionsControl><Technologies><Technology>Dermatological formulation</Technology><Technology>Dermatological gel formulation</Technology><Technology>Emulsion dermatological</Technology><Technology>Small molecule therapeutic</Technology></Technologies><CompaniesSponsor><Company>Actavis Inc</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2017-06-22T00:00:00Z</DateEnd><DateStart>2016-07-19T00:00:00Z</DateStart><Identifiers><Identifier>ACTA/AZEL/2015</Identifier><Identifier>NCT03287791</Identifier></Identifiers><InterventionsControlDisplay><Intervention>azelaic acid alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>azelaic acid alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>978</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>or illicit drugs, or had a condition that could compromise the subjects ability to comply with study requirements Subjects who were engaged in activities that involved excessive or prolonged exposure to sunlight or weather extremes, such as wind or &lt;b&gt;cold&lt;/b&gt; A subject who had any clinically significant condition or situation, other than the condition being studied that, in the opinion of the Investigator, could have interfered with the study evaluations or optimal participation in the study A subject who</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Bioequivalence</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other dermatological disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other dermatological disease - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea Foam in Patients With Rosacea</TitleDisplay><PatientSegmentTerms><PatientSegment>Other dermatological disease - Others - Healthy Subjects</PatientSegment><PatientSegment>Other dermatological disease - Subjects with specific disease - Subjects with Erythema</PatientSegment><PatientSegment>Other dermatological disease - Subjects with specific disease - Subjects with Rosacea</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2017-06-22T00:00:00Z</PrimaryCompletionDate><TrialDuration>11 Months</TrialDuration><NumberOfSites>26</NumberOfSites><ContactNames><Name>Shree Cooper, Msc</Name></ContactNames></Trial><Trial Id="312482"><Indications><Indication>Common cold</Indication><Indication>Pharyngitis</Indication><Indication>Throat disease</Indication></Indications><CompaniesCollaborator><Company>MONİTÖR MEDİKAL ARAŞTIRMA VE DANIŞMANLIK TİCARET LİMİTED ŞİRKETİ</Company></CompaniesCollaborator><CompaniesSponsor><Company>Bosnalijek Pharmaceutical &amp; Chemical Industry Joint Stock Co</Company></CompaniesSponsor><Countries><Country>Bosnia and Herzegovina</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2018-12-31T00:00:00Z</DateEnd><DateStart>2016-10-31T00:00:00Z</DateStart><Identifiers><Identifier>BOS_CS_01</Identifier><Identifier>NCT03282045</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Pharyngal Oromucosal Spray alone</Intervention><Intervention>Tantum Verde Spray alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Lysobact Complete Sprsy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>320</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser> Patients with acute tonsillo-pharyngitis symptoms in common &lt;b&gt;cold&lt;/b&gt; and by using a scale-based symptom Tonsillo-Pharyngitis Assessment (TPA) as an objective finding of pharyngeal infection, with a score of &gt;/= 5 Patients who will be treated only on a symptomatic treatment basis, and with a prescribed a oropharyngeal</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other otorhinolaryngological disease - Patient Reported Outcomes/Quality of Life Assessments - Assessment by VAS scale</EndpointIndex><EndpointIndex>Respiratory tract infection - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Efficacy and Safety of the Lysobact Complete Spray, Tantum Verde and Pharyngal Oromucosal Spray in the Treatment of Acute Sore Throat</TitleDisplay><PatientSegmentTerms><PatientSegment>Other otorhinolaryngological disease - Subjects with specific disease</PatientSegment><PatientSegment>Respiratory tract infection - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2018-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>B. MURAT OZDEMIR</Name><Name>OZGUN ENVER, MD</Name><Name>Zorica Novaković</Name></ContactNames></Trial><Trial Id="309621"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsControl><Action>Heme oxygenase 1 modulator</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>IL-23 antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Enteric coated formulation</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Subcutaneous formulation</Technology><Technology>Sustained release formulation</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>AbbVie Deutschland GmbH &amp; Co KG</Company><Company>AbbVie Inc</Company></CompaniesSponsor><Countries><Country>Germany</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2018-07-06T00:00:00Z</DateEnd><DateStart>2017-08-22T00:00:00Z</DateStart><Identifiers><Identifier>2016-003718-28</Identifier><Identifier>M16-178</Identifier><Identifier>NCT03255382</Identifier></Identifiers><InterventionsControlDisplay><Intervention>dimethyl fumarate + ethyl hydrogen fumarate calcium + ethyl hydrogen fumarate magnesium + ethyl hydrogen fumarate zinc alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>risankizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>120</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>received systemic therapy for psoriasis, whether biologic or non-biologic or photochemotherapy (eg, PUVA therapy, any UV-therapy or baneotherapy associated with UV-sensitizing agent) Active systemic infection during the last 2 weeks (exception: common &lt;b&gt;cold&lt;/b&gt;) prior to screening Any documented active or suspected malignancy or history of malignancy within five years prior to screening, except appropriately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix Subject</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment by Global Assessment Scales - Patient's global assessment (PaGA)</EndpointIndex><EndpointIndex>Psoriasis - Assessment of Biopsy/Cytology/Histology - Thickness of epidermis/dermis</EndpointIndex><EndpointIndex>Psoriasis - Assessment of Clinical Response - Assessment of erythema</EndpointIndex><EndpointIndex>Psoriasis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Psoriasis - Changes in Characteristics of Skin/Lesion - Assessment of induration</EndpointIndex><EndpointIndex>Psoriasis - Changes in Characteristics of Skin/Lesion - Assessment of scaling</EndpointIndex><EndpointIndex>Psoriasis - Changes in Characteristics of Skin/Lesion - Body surface area (BSA%) involvement</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by Other Scales - Palmoplantar pustular psoriasis area and severity indices (PPPASI)</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - Change in psoriasis area and severity index score (PASI)</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-50 response</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-75 response</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-75 to 100 response</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Dermatology Life Quality Index (DLQI)</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Hospital Anxiety and Depression Scale (HADS)</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by SF-36/SF-12</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by patient benefit index(PBI)</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by psoriatic symptom assessment(PSA)</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - EuroQol-5D (EQ-5D)</EndpointIndex><EndpointIndex>Psoriasis - Physician Global Assessment of Disease Activity - Assessment by Investigator/Physician Global Assessment (PGA) Scale</EndpointIndex><EndpointIndex>Psoriasis - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study to Assess the Efficacy of Risankizumab Compared to Fumaderm in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naive to and Candidates for Systemic Therapy</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with History of/Scheduled for Therapy - Subjects with history of/scheduled for systemic therapy</PatientSegment><PatientSegment>Psoriasis - Subjects with Moderate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment><PatientSegment>Psoriasis - Subjects with Psoriatic Arthritis</PatientSegment><PatientSegment>Psoriasis - Subjects with Severe Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with specific disease - Subjects with Chronic Plaque Psoriasis</PatientSegment><PatientSegment>Psoriasis - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Body surface area</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2018-07-06T00:00:00Z</PrimaryCompletionDate><TrialDuration>10 Months</TrialDuration><NumberOfSites>24</NumberOfSites><ContactNames><Name>AbbVie Inc</Name><Name>EU Clinical Trials Helpdesk</Name></ContactNames></Trial><Trial Id="304847"><Indications><Indication>Dysmenorrhea</Indication></Indications><CompaniesCollaborator><Company>Babol University of Medical Sciences</Company></CompaniesCollaborator><CompaniesSponsor><Company>University Of Mysore</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2017-07-31T00:00:00Z</DateChangeLast><DateStart>2010-03-20T00:00:00Z</DateStart><Identifiers><Identifier>31 Ph.D/2009-10</Identifier><Identifier>IRCT2016022326724N1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>cumin alone</Intervention><Intervention>dill seeds alone</Intervention><Intervention>ginger alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The study is a comparative clinical trial to evaulate the effect of dill seeds, ginger and cumin on dysmenorrhea. It will be conducted on 30 primary dysmenorrheic subjects that have inclusion conditions for entering the study.</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Fatigue</EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]</EndpointIndex><EndpointIndex>Pain - Assessment of Migraine/Other Headaches</EndpointIndex><EndpointIndex>Pain - Assessment of Pain</EndpointIndex><EndpointIndex>Pain - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pain - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Effect of herbs on dysmenorrhea</TitleDisplay><PatientSegmentTerms><PatientSegment>Pain - Subjects with Visceral Pain - Subjects with dysmenorrhoea</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Muscle stiffness</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr. Khyrunnisa Begum</Name><Name>Shabnam Omidvar</Name></ContactNames></Trial><Trial Id="30459"><Indications><Indication>Herpes simplex virus infection</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA polymerase inhibitor</Action><Action>Thymidine kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Viral replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Buccal formulation local</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Onxeo SA</Company></CompaniesSponsor><Countries><Country>Poland</Country><Country>Germany</Country><Country>France</Country><Country>US</Country><Country>Australia</Country><Country>UK</Country><Country>Czech Republic</Country></Countries><DateChangeLast>2018-11-17T00:00:00Z</DateChangeLast><DateEnd>2009-08-31T00:00:00Z</DateEnd><DateStart>2007-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2006-005788-24</Identifier><Identifier>BA2005/21/02</Identifier><Identifier>LIP</Identifier><Identifier>NCT00769314</Identifier></Identifiers><IndicationsAdverse><Indication>Dizziness</Indication><Indication>Erythema</Indication><Indication>Headache</Indication><Indication>Pain</Indication><Indication>Skin rash</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>aciclovir (buccal, Lauriad), Onxeo alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1727</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>outside the lips (eg, nose, chin, etc) Abnormal perioral skin condition that might affect the normal course of &lt;b&gt;cold&lt;/b&gt; sores (eg, eczema, psoriasis) Oral diseases whose prodromal symptoms may mimick those of herpes labialis, including recurrent oral...Lauriad 50 mg muco-adhesive buccal tablet (MBT) versus a single-dose of matching placebo on the primary vesicular lesion of &lt;b&gt;cold&lt;/b&gt; sore. Secondary objectives of the trial: To compare the efficacy of acyclovir Lauriad 50 mg muco-adhesive buccal tablet versus</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Herpesvirus infection - Assessment of Herpetic Lesions - Healing</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>LIP: Phase III Clinical Study for the Treatment of Cold Sore</TitleDisplay><PatientSegmentTerms><PatientSegment>Herpesvirus infection - Subjects with Herpes Simplex Virus Infections</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2008-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>27 Months</TrialDuration><NumberOfSites>53</NumberOfSites><ContactNames><Name>David Baker</Name><Name>Fiona Bisshop</Name><Name>Frederic Cambazard</Name><Name>Jana Asterova</Name><Name>Mark Bloch</Name><Name>Maurice Archuleta</Name><Name>Neil Bodsworth</Name><Name>Olivier Chosidow</Name><Name>Roger Cady</Name><Name>Thomas Bieber</Name><Name>Viktor Aster</Name></ContactNames></Trial><Trial Id="303658"><Indications><Indication>Common cold</Indication><Indication>Hypertension</Indication></Indications><CompaniesSponsor><Company>Arak University of Medical Sciences and Health Services</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-08-21T00:00:00Z</DateChangeLast><DateStart>2017-07-06T00:00:00Z</DateStart><Identifiers><Identifier>IR.ARAKMU.REC.1395.140</Identifier><Identifier>IRCT2017060413366N8</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>diphenhydramine alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>110</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>be a clinical trial conducted on children (n = 110) at the age of 2 to 18 years, suffering from common &lt;b&gt;cold&lt;/b&gt;, refered to Amir Kabir Hospital. In this study after obtaining informed consent from the children blood pressure will be recorded and then... The purpose of study is assessing the effect of antihistamines (diphenhydramine) on blood pressure in children with common &lt;b&gt;cold&lt;/b&gt;.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>Diphenhydramine Effect on Blood Pressure in Children with Common Colds</TitleDisplay><PatientSegmentTerms><PatientSegment>Respiratory tract infection - Subjects with specific disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Blood pressure</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr. Parsa Yousefichaijan</Name><Name>Parsa Yousefichaijan</Name></ContactNames></Trial><Trial Id="30360"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD11a antagonist</Action><Action>Complement cascade inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Merck Serono SA</Company></CompaniesCollaborator><CompaniesSponsor><Company>Genentech Inc</Company><Company>XOMA Corp</Company></CompaniesSponsor><DateChangeLast>2008-10-21T00:00:00Z</DateChangeLast><DateStart>2002-10-02T00:00:00Z</DateStart><IndicationsAdverse><Indication>Chill</Indication><Indication>Common cold</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Muscle weakness</Indication><Indication>Nausea</Indication><Indication>Pain</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>efalizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>339</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>The objective of the study was to evaluate the efficacy and safety of long-term, continuous Raptiva therapy in patients with psoriasis [ 459967 ], [ 902994 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A phase III, open-label, multicenter trial to evaluate the safety and efficacy of Raptiva in patients with psoriasis</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="303349"><Indications><Indication>Peanut hypersensitivity</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Allergen</Action><Action>Anti-inflammatory</Action><Action>Immunomodulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Peptide</Technology></Technologies><CompaniesSponsor><Company>Aimmune Therapeutics Inc</Company></CompaniesSponsor><Countries><Country>France</Country><Country>Sweden</Country><Country>Ireland</Country><Country>Italy</Country><Country>Germany</Country><Country>Spain</Country><Country>UK</Country></Countries><DateChangeLast>2019-07-02T00:00:00Z</DateChangeLast><DateEnd>2019-02-15T00:00:00Z</DateEnd><DateStart>2017-06-12T00:00:00Z</DateStart><Identifiers><Identifier>2016-005004-26</Identifier><Identifier>ARC010</Identifier><Identifier>ARTEMIS</Identifier><Identifier>NCT03201003</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>AR-101, Aimmune Therapeutics alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>175</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser> symptoms of dysphagia or recurrent gastrointestinal symptoms of undiagnosed etiology History of a mast cell disorder, including mastocytosis, urticaria pigmentosa, chronic idiopathic or chronic physical urticaria beyond simple dermatographism (eg, &lt;b&gt;cold&lt;/b&gt; urticaria, cholinergic urticaria), and hereditary or idiopathic angioedema Any other condition that, in the opinion of the Investigator, precludes participation for reasons of safety History of chronic disease (other than asthma, atopic dermatitis,</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other immune disease - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Other immune disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other immune disease - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Other immune disease - Assessment of Safety and Tolerability - Assessment of serious adverse events(SAEs)</EndpointIndex><EndpointIndex>Other immune disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Preschool Children (2-5 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term></TermsPatientSelection><TitleDisplay>ARTEMIS: Peanut Allergy In Children</TitleDisplay><PatientSegmentTerms><PatientSegment>Other immune disease - Subjects with specific disease - Subjects with food allergy</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Eosinophils </BiomarkerName><BiomarkerName> Immunoglobulin E </BiomarkerName><BiomarkerName> Immunoglobulin G </BiomarkerName><BiomarkerName> Ribonucleic acid</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2019-02-15T00:00:00Z</PrimaryCompletionDate><TrialDuration>20 Months</TrialDuration><NumberOfSites>22</NumberOfSites><ContactNames><Name>Kate McKeown</Name><Name>Prof. Montserrat Fernández-Rivas, MD, PhD</Name><Name>Professor du Toit</Name><Name>Regulatory Affairs</Name></ContactNames></Trial><Trial Id="302139"><Indications><Indication>Anesthesia</Indication><Indication>Pain</Indication><Indication>Pulpitis</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Local anesthetic</Action><Action>Unspecified drug target</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation dermatological</Technology><Technology>Dermatological formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral gel formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Suspension</Technology><Technology>Transdermal formulation</Technology></Technologies><CompaniesSponsor><Company>Tabriz University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-06-23T00:00:00Z</DateChangeLast><DateStart>2016-08-05T00:00:00Z</DateStart><Identifiers><Identifier>IR.TBZMED.REC.1395.413</Identifier><Identifier>IRCT2016053028173N2</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>root canal therapy alone</Intervention><Intervention>Variable regimens including betamethasone LA , dexamethasone (cortone) , epinephrine , lidocaine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>213</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>anti-anxiety in the past 2 weeks No medical history No contraindication for prescribing cortisone Teeth with at least dilated periodontal ligament in periapical radiography No dental implants in studied dental quadrant; approved vitality with pulp tests and &lt;b&gt;cold&lt;/b&gt; spray Teeth with clinically diagnosed as irreversible pulpitis with response to electric pulp tester Longitudinal and magnified response (10 s) Moderate to severe pain after the removal of the ice test cotton ball</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>The Effect of local Injection of Cortone on Pain preception after Root Canal treatment of teeth with Irreversible Pulpitis</TitleDisplay><PatientSegmentTerms><PatientSegment>Other mouth disease - Subjects with specific disease - Subjects with asymptomatic irreversible pulpitis</PatientSegment><PatientSegment>Other mouth disease - Subjects with specific disease - Subjects with symptomatic irreversible pulpitis</PatientSegment><PatientSegment>Pain - Subjects with Moderate to Severe Pain</PatientSegment><PatientSegment>Pain - Subjects with Other Types of Pain - Subjects with dental pain</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr. Hamid Reza Yavari</Name><Name>Helen Jamlou</Name></ContactNames></Trial><Trial Id="301479"><Indications><Indication>Influenza virus infection</Indication></Indications><CompaniesCollaborator><Company>Ministry of Agriculture Forestry and Fisheries (Japan)</Company></CompaniesCollaborator><CompaniesSponsor><Company>Hokkaido Information University</Company><Company>Local Independent Administrative Agency Hokkaido Research Organization</Company></CompaniesSponsor><Countries><Country>Japan</Country></Countries><DateChangeLast>2018-05-21T00:00:00Z</DateChangeLast><DateEnd>2015-02-19T00:00:00Z</DateEnd><DateStart>2014-09-22T00:00:00Z</DateStart><Identifiers><Identifier>UMIN000015209</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>grifola frondosa extract alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>80</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The aim of this study was to evaluate the immune function and antibody producing ability for influenza vaccines by continuous ingestion of 6.825g per day of dehydrated grifola frondosa extracts for 12 weeks and to investigate its efficacy.</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Immune Response</EndpointIndex><EndpointIndex>Influenza Vaccine - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Influenza Vaccine - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Visual Analog Scale (VAS)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Anti-influenza effects of Grifola frondosa extracts</TitleDisplay><BiomarkerNames><BiomarkerName>Immunoglobulin G </BiomarkerName><BiomarkerName> Immunoglobulin M </BiomarkerName><BiomarkerName> Interleukin-12 </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Natural killer cells</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>4 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dir. Prof. Jun Nishihira, M.D.</Name><Name>Prof. Jun Nishihira, M.D.</Name></ContactNames></Trial><Trial Id="301415"><Indications><Indication>Infectious disease</Indication></Indications><CompaniesSponsor><Company>Tehran University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-06-19T00:00:00Z</DateChangeLast><DateStart>2016-12-05T00:00:00Z</DateStart><Identifiers><Identifier>IR.TUMS.VCR.REC.1395.1232</Identifier><Identifier>IRCT2016111530899N1</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>chlorhexidine alone</Intervention><Intervention>chlorhexidine plus alone</Intervention><Intervention>hypoclean alone</Intervention><Intervention>sodium hypochlorite alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>40</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> Premolar teeth with single root and single canal Necrotic teeth confirmed with no response to &lt;b&gt;cold&lt;/b&gt; test Tooth that is sensitive to percussion and palpation</Teaser><TrialCategories><Category>Medical device</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other infectious disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other mouth disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other mouth disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TitleDisplay>Comparison of antibacterial effect of intra canal irrigators (sodium hypochlorite, hypoclean, CHX and CHX pluse) in teeth with primary endodontic infection</TitleDisplay><PatientSegmentTerms><PatientSegment>Other infectious disease - Subjects with specific disease</PatientSegment><PatientSegment>Other mouth disease - Subjects with specific disease - Subjects with Endodontic Infection</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Dr. Sedighe Khedmat</Name><Name>Nooshin Fakhari</Name></ContactNames></Trial><Trial Id="30098"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD11a antagonist</Action><Action>Complement cascade inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Genentech Inc</Company><Company>XOMA Corp</Company></CompaniesSponsor><DateChangeLast>2008-11-06T00:00:00Z</DateChangeLast><DateStart>1999-12-20T00:00:00Z</DateStart><Identifiers><Identifier>ACD2059g</Identifier></Identifiers><IndicationsAdverse><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Hypothermia</Indication><Indication>Nausea</Indication><Indication>Pain</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>efalizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>597</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The study was designed to evaluate the safety and efficacy of Xanelim in patients with moderate-to-severe plaque psoriasis [ 351205 ], [ 385394 ], [ 413287 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A phase III, double-blind, randomized, placebo-controlled study to evaluate the safety and effectiveness of Xanelim in patients with moderate-to-severe plaque psoriasis</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>0</NumberOfSites></Trial><Trial Id="30097"><Indications><Indication>Psoriasis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD11a antagonist</Action><Action>Complement cascade inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Immunosuppressant</Action><Action>Systemic antipsoriatic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>Genentech Inc</Company><Company>XOMA Corp</Company></CompaniesSponsor><Countries><Country>US</Country><Country>Canada</Country></Countries><DateChangeLast>2014-02-18T00:00:00Z</DateChangeLast><DateStart>1999-12-20T00:00:00Z</DateStart><Identifiers><Identifier>ACD2058g</Identifier></Identifiers><IndicationsAdverse><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Hypothermia</Indication><Indication>Nausea</Indication><Indication>Pain</Indication><Indication>Thrombocytopenia</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>efalizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>498</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>The study was designed to evaluate the safety and efficacy of Xanelim in patients with moderate-to-severe plaque psoriasis [ 351205 ], [ 385394 ], [ 410649 ], [ 413287 ].</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Psoriasis - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Psoriasis - Changes in Characteristics of Skin/Lesion</EndpointIndex><EndpointIndex>Psoriasis - Changes in Characteristics of Skin/Lesion - Body surface area (BSA%) involvement</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response</EndpointIndex><EndpointIndex>Psoriasis - Disease Severity Assessment by PASI Scores/Response - PASI-75 to 100 response</EndpointIndex><EndpointIndex>Psoriasis - Patient Reported Outcomes/Quality of Life Assessments - Assessment by itch severity scale(ISS)</EndpointIndex><EndpointIndex>Psoriasis - Physician Global Assessment of Disease Activity - Assessment by Investigator/Physician Global Assessment (PGA) Scale</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A phase III, double-blind, randomized, placebo-controlled study to evaluate the safety and effectiveness of Xanelim in patients with moderate-to-severe plaque psoriasis</TitleDisplay><PatientSegmentTerms><PatientSegment>Psoriasis - Subjects with Moderate Psoriasis</PatientSegment><PatientSegment>Psoriasis - Subjects with Severe Psoriasis</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>2</NumberOfSites></Trial><Trial Id="300609"><Indications><Indication>Tooth disease</Indication></Indications><CompaniesSponsor><Company>Aga khan University</Company></CompaniesSponsor><Countries><Country>Pakistan</Country></Countries><DateChangeLast>2018-10-13T00:00:00Z</DateChangeLast><DateEnd>2018-12-20T00:00:00Z</DateEnd><DateStart>2017-05-03T00:00:00Z</DateStart><Identifiers><Identifier>4714-SUR-ERC-17</Identifier><Identifier>NCT03177109</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Acclean alone</Intervention><Intervention>Colgate Sensitive Pro-Relief alone</Intervention><Intervention>Seal and Protect, Dentsply alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The aim of the present single-center, randomized control study is to evaluate the efficacy of three common professionally applied desensitizing agents in the reduction of dentine hypersensitivity over a period of 4 weeks.</Teaser><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Factorial Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other mouth disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other mouth disease - Protocol Specified Other Endpoints</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Comparison of Different Desensitizers in Reducing Dentinal Hypersensitivity</TitleDisplay><PatientSegmentTerms><PatientSegment>Other mouth disease - Subjects with specific disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2018-12-20T00:00:00Z</PrimaryCompletionDate><TrialDuration>19 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Muhammad Hasan Hameed</Name><Name>Muhammad Hasan Hameed, BDS</Name><Name>Robia Ghafoor, BDS,FCPS</Name></ContactNames></Trial><Trial Id="299815"><Indications><Indication>Periodontal disease</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>DNA gyrase inhibitor</Action><Action>Topoisomerase IV inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Antibacterial</Action><Action>Antimicrobial</Action><Action>Bacterial nucleic acid synthesis inhibitor</Action><Action>Systemic dermatological antibacterial product</Action><Action>Tetracycline</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Antibiotic</Technology><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Granule</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Sri Venkateswara Dental</Company></CompaniesSponsor><Countries><Country>India</Country></Countries><DateChangeLast>2017-06-08T00:00:00Z</DateChangeLast><DateStart>2017-07-02T00:00:00Z</DateStart><Identifiers><Identifier>CTRI/2017/05/008660</Identifier></Identifiers><InterventionsControlDisplay><Intervention>endodontic therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>chlorhexidine alone</Intervention><Intervention>Variable regimens including chlorhexidine , ciprofloxacin hydrochloride , metronidazole , minocycline</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser> Clinical and radiographic diagnosis of a combined endodontic periodontal lesion Probing pocket depth (PPD) &gt;/= 6 mm Wide base pocket Pulpal necrosis as confirmed by negative response to &lt;b&gt;cold&lt;/b&gt; and electric pulp test Radiographic alveolar bone destruction without apical communication</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other mouth disease - Assessment of Safety and Tolerability - Assessment of bleeding</EndpointIndex><EndpointIndex>Other mouth disease - Clinical Assessments</EndpointIndex><EndpointIndex>Other mouth disease - Clinical Assessments - Assessment of probing pocket depth</EndpointIndex><EndpointIndex>Other mouth disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Other mouth disease - Protocol Specified Other Endpoints</EndpointIndex><EndpointIndex>Other mouth disease - Protocol Specified Other Endpoints - Assessment of treatment adherence</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Effect of pulpal medicine on periodontal healing</TitleDisplay><PatientSegmentTerms><PatientSegment>Other mouth disease - Subjects with specific disease - Subjects with Periodontal Disease</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Shanmuga Priya</Name></ContactNames></Trial><Trial Id="299604"><Indications><Indication>Allergic rhinitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Histamine H1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Topical antipruritic product</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Oral liquid formulation</Technology><Technology>Oral suspension formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Kermanshah University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-08-10T00:00:00Z</DateChangeLast><DateStart>2017-05-13T00:00:00Z</DateStart><Identifiers><Identifier>IRCT2017042433622N1</Identifier><Identifier>KUMS.REC.1395.716</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>budesonide plus fexofenadine</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>20</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser> People suffering from infectious diseases or common &lt;b&gt;cold&lt;/b&gt; and patients taking drugs other than drugs that must consume according to the research plan, during performance of the project will be excluded In addition, patients who have a fungal, viral or bacterial disease during the study and patients who do</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of Laboratory/Diagnostic Measures</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Effect of fexofenadine and budesonide on the level of transcription factors: GATA-3، ROR-gamma-t and FOXP3 in allergic rhinitis patients</TitleDisplay><BiomarkerNames><BiomarkerName>Forkhead box protein P3 </BiomarkerName><BiomarkerName> Nuclear receptor ROR-gamma </BiomarkerName><BiomarkerName> Trans-acting T-cell specific transcription factor GATA-3</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ali Gorgin Karaji</Name><Name>Dr. Seyed Hamid Reza Mortazavi</Name><Name>Elham Bagherinia</Name></ContactNames></Trial><Trial Id="29955"><Indications><Indication>Pulmonary fibrosis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>IL-4 receptor antagonist</Action><Action>Interferon gamma ligand</Action><Action>TGF beta receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Antibacterial</Action><Action>Anticancer hormone</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Antiparasitic</Action><Action>Collagen synthesis modulator</Action><Action>Fibrosuppressant</Action><Action>Fungicide</Action><Action>RNA synthesis inhibitor</Action><Action>Topical antipruritic product</Action><Action>Viral replication inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Peptide</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>InterMune Inc</Company><Company>University of Vienna</Company></CompaniesSponsor><Countries><Country>Austria</Country></Countries><DateChangeLast>2008-10-14T00:00:00Z</DateChangeLast><DateStart>1999-11-05T00:00:00Z</DateStart><IndicationsAdverse><Indication>Fever</Indication><Indication>Hypothermia</Indication><Indication>Myalgia</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>prednisolone alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Actimmune plus prednisolone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>18</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Status not specified</RecruitmentStatus><Teaser>This phase III, randomized, controlled study was designed to evaluate the efficacy of interferon gamma-1b plus an oral glucocorticoid (prednisolone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) who had not previously responded to glucocorticoids [ 346608 ].</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Active Control</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TitleDisplay>A phase III, randomized, controlled study to evaluate the efficacy of interferon gamma-1b plus an oral glucocorticoid (prednisolone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) who had not previously responded to glucocorticoids</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites></Trial><Trial Id="299207"><Indications><Indication>Hypothermia</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cyclooxygenase inhibitor</Action><Action>Oxidoreductase inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Analgesic</Action><Action>Non-steroidal anti-inflammatory</Action><Action>Prostaglandin synthesis inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Intramuscular formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Ardabil University of Medical Sciences</Company></CompaniesSponsor><Countries><Country>Iran</Country></Countries><DateChangeLast>2017-05-26T00:00:00Z</DateChangeLast><DateStart>2016-04-03T00:00:00Z</DateStart><Identifiers><Identifier>IR. ARUMS.REC.1394.68</Identifier><Identifier>IRCT2016080229162N1</Identifier></Identifiers><InterventionsControlDisplay><Intervention>pethidine alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>ketorolac alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>This randomized, double-blind clinical trial in the third phase and single-center study is designed to evaluate the effect of administration of intravenous (IV) ketorolac in comparison with pethidine on shivering, during the first minute following surgery in the recovery period.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term></TermsPatientSelection><TitleDisplay>Effect of ketorolac in incidence of post operative shivering</TitleDisplay><PrimaryCompletionDate/><NumberOfSites>1</NumberOfSites><ContactNames><Name>-</Name><Name>Dr. Ghodrat Akhavan Akbari</Name><Name>Neda Fathi</Name></ContactNames></Trial><Trial Id="298902"><Indications><Indication>Acute stress disorder</Indication><Indication>Cognitive disorder</Indication></Indications><CompaniesSponsor><Company>University College Cork</Company></CompaniesSponsor><Countries><Country>Ireland</Country></Countries><DateChangeLast>2018-10-16T00:00:00Z</DateChangeLast><DateEnd>2016-09-30T00:00:00Z</DateEnd><DateStart>2015-07-31T00:00:00Z</DateStart><Identifiers><Identifier>APC057</Identifier><Identifier>NCT03160066</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>Lactobacillus rhamnosus (JB-1) capsule alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>29</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>healthy male volunteers would be recruited in a randomized, single-blind, placebo-controlled, crossover trial. Study participation will involve a screening visit followed by a baseline cognitive test battery, EEG and stress visit (socially evaluated &lt;b&gt;cold&lt;/b&gt;-pressor test). These measures would be repeated after 4 weeks of daily probiotic (capsules containing 1 x 10[9] colony forming units of Lactobacillus rhamnosus (JB-1) would be given once per day for 4 weeks) and placebo capsules (corn starch, magnesium</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Single Blind</Term><Term>Placebo Control</Term><Term>Crossover Assignment</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Morbidity</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Neuropsychological Function</EndpointIndex><EndpointIndex>Other neurological disease - Assessment of Neuropsychological Function - Assessment of memory and learning</EndpointIndex><EndpointIndex>Other neurological disease - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Healthy volunteers accepted</Term><Term>Male</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TitleDisplay>The Effects of Lactobacillus Rhamnosus (JB-1) on Stress and Cognition</TitleDisplay><PatientSegmentTerms><PatientSegment>Other neurological disease - Others - Healthy Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Cytokines </BiomarkerName><BiomarkerName> Hydrocortisone </BiomarkerName><BiomarkerName> Toll-like receptors</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2016-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>14 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Ted Dinan, MD, PhD</Name></ContactNames></Trial></SearchResults></trialResultsOutput>